words,labels
Famotidine,I-Entity
-,O
associated,O
delirium,I-Entity
.,O
Famotidine,I-Entity
is,O
a,O
histamine,I-Entity
H2-receptor,I-Entity
antagonist,O
used,O
in,O
inpatient,O
settings,O
for,O
prevention,O
of,O
stress,I-Entity
ulcers,I-Entity
and,O
is,O
showing,O
increasing,O
popularity,O
because,O
of,O
its,O
low,O
cost,O
.,O
Although,I-Entity
all,O
of,O
the,O
currently,O
available,O
H2-receptor,I-Entity
antagonists,O
have,O
shown,O
the,O
propensity,O
to,O
cause,O
delirium,I-Entity
",",O
only,O
two,O
previously,O
reported,O
cases,O
have,O
been,O
associated,O
with,O
famotidine,I-Entity
.,O
The,I-Entity
authors,O
report,O
on,O
six,O
cases,O
of,O
famotidine,I-Entity
-,O
associated,O
delirium,I-Entity
in,O
hospitalized,O
patients,O
who,O
cleared,O
completely,O
upon,O
removal,O
of,O
famotidine,I-Entity
.,O
The,I-Entity
pharmacokinetics,O
of,O
famotidine,I-Entity
are,O
reviewed,O
",",O
with,O
no,O
change,O
in,O
its,O
metabolism,O
in,O
the,O
elderly,O
population,O
seen,O
.,O
The,I-Entity
implications,O
of,O
using,O
famotidine,I-Entity
in,O
elderly,O
persons,O
are,O
discussed,O
.,O
Indomethacin,I-Entity
induced,O
hypotension,I-Entity
in,O
sodium,I-Entity
and,O
volume,O
depleted,O
rats,O
.,O
After,I-Entity
a,O
single,O
oral,O
dose,O
of,O
4,O
mg,O
/,O
kg,O
indomethacin,I-Entity
(,O
IDM,I-Entity
),O
to,O
sodium,I-Entity
and,O
volume,O
depleted,O
rats,O
plasma,O
renin,O
activity,O
(,O
PRA,I-Entity
),O
and,O
systolic,O
blood,O
pressure,O
fell,I-Entity
significantly,O
within,O
four,O
hours,O
.,O
In,I-Entity
sodium,I-Entity
repleted,O
animals,O
indomethacin,I-Entity
did,O
not,O
change,O
systolic,O
blood,O
pressure,O
(,O
BP,I-Entity
),O
although,O
plasma,O
renin,O
activity,O
was,O
decreased,O
.,O
Thus,I-Entity
",",O
indomethacin,I-Entity
by,O
inhibition,O
of,O
prostaglandin,I-Entity
synthesis,O
may,O
diminish,O
the,O
blood,O
pressure,O
maintaining,O
effect,O
of,O
the,O
stimulated,O
renin,O
-,O
angiotensin,I-Entity
system,O
in,O
sodium,I-Entity
and,O
volume,O
depletion,O
.,O
Late,I-Entity
-,O
onset,O
scleroderma,I-Entity
renal,O
crisis,I-Entity
induced,O
by,O
tacrolimus,I-Entity
and,O
prednisolone,I-Entity
:,O
a,O
case,O
report,O
.,O
Scleroderma,I-Entity
renal,O
crisis,I-Entity
(,O
SRC,I-Entity
),O
is,O
a,O
rare,O
complication,O
of,O
systemic,O
sclerosis,I-Entity
(,O
SSc,I-Entity
),O
but,O
can,O
be,O
severe,O
enough,O
to,O
require,O
temporary,O
or,O
permanent,O
renal,O
replacement,O
therapy,O
.,O
Moderate,I-Entity
to,O
high,O
dose,O
corticosteroid,O
use,O
is,O
recognized,O
as,O
a,O
major,O
risk,O
factor,O
for,O
SRC,I-Entity
.,O
Furthermore,I-Entity
",",O
there,O
have,O
been,O
reports,O
of,O
thrombotic,I-Entity
microangiopathy,I-Entity
precipitated,O
by,O
cyclosporine,I-Entity
in,O
patients,O
with,O
SSc,I-Entity
.,O
In,I-Entity
this,O
article,O
",",O
we,O
report,O
a,O
patient,O
with,O
SRC,I-Entity
induced,O
by,O
tacrolimus,I-Entity
and,O
corticosteroids,I-Entity
.,O
The,I-Entity
aim,O
of,O
this,O
work,O
is,O
to,O
call,O
attention,O
to,O
the,O
risk,O
of,O
tacrolimus,I-Entity
use,O
in,O
patients,O
with,O
SSc,I-Entity
.,O
The,I-Entity
risk,O
and,O
associated,O
factors,O
of,O
methamphetamine,I-Entity
psychosis,I-Entity
in,O
methamphetamine,I-Entity
-,O
dependent,O
patients,O
in,O
Malaysia,I-Entity
.,O
The,I-Entity
objective,O
of,O
this,O
study,O
was,O
to,O
determine,O
the,O
risk,O
of,O
lifetime,O
and,O
current,O
methamphetamine,I-Entity
-,O
induced,O
psychosis,I-Entity
in,O
patients,O
with,O
methamphetamine,I-Entity
dependence,O
.,O
The,I-Entity
association,O
between,O
psychiatric,I-Entity
co,O
-,O
morbidity,O
and,O
methamphetamine,I-Entity
-,O
induced,O
psychosis,I-Entity
was,O
also,O
studied,O
.,O
Patients,I-Entity
with,O
the,O
diagnosis,O
of,O
methamphetamine,I-Entity
based,O
on,O
DSM,I-Entity
-,O
IV,I-Entity
were,O
interviewed,O
using,O
the,O
Mini,I-Entity
International,I-Entity
Neuropsychiatric,I-Entity
Interview,I-Entity
(,O
M.I.N.I.,I-Entity
),O
for,O
methamphetamine,I-Entity
-,O
induced,O
psychosis,I-Entity
and,O
other,O
Axis,I-Entity
I,I-Entity
psychiatric,I-Entity
disorders,I-Entity
.,O
Of,I-Entity
292,I-Entity
subjects,O
",",O
47.9%,O
of,O
the,O
subjects,O
had,O
a,O
past,O
history,O
of,O
psychotic,I-Entity
symptoms,O
and,O
13.0%,O
of,O
the,O
patients,O
were,O
having,O
current,O
psychotic,I-Entity
symptoms,O
.,O
Co,I-Entity
-,O
morbid,O
major,O
depressive,I-Entity
disorder,I-Entity
(,O
OR=7.18,O
",",O
95,O
CI=2.612,O
-,O
19.708,O
),O
",",O
bipolar,I-Entity
disorder,I-Entity
(,O
OR=13.807,O
",",O
95,O
CI=5.194,O
-,O
36.706,O
),O
",",O
antisocial,I-Entity
personality,O
disorder,I-Entity
(,O
OR=12.619,O
",",O
95,O
CI=6.702,O
-,O
23.759,O
),O
and,O
heavy,O
methamphetamine,I-Entity
uses,O
were,O
significantly,O
associated,O
with,O
lifetime,O
methamphetamine,I-Entity
-,O
induced,O
psychosis,I-Entity
after,O
adjusted,O
for,O
other,O
factors,O
.,O
Major,I-Entity
depressive,I-Entity
disorder,I-Entity
(,O
OR=2.870,I-Entity
",",O
CI=1.154,O
-,O
7.142,O
),O
and,O
antisocial,I-Entity
personality,O
disorder,I-Entity
(,O
OR=3.299,O
",",O
95,O
CI=1.375,I-Entity
-,O
7.914,O
),O
were,O
the,O
only,O
factors,O
associated,O
with,O
current,O
psychosis,I-Entity
.,O
CONCLUSION,I-Entity
:,O
There,I-Entity
was,O
a,O
high,O
risk,O
of,O
psychosis,I-Entity
in,O
patients,O
with,O
methamphetamine,I-Entity
dependence,O
.,O
It,I-Entity
was,O
associated,O
with,O
co,O
-,O
morbid,O
affective,O
disorder,I-Entity
",",O
antisocial,I-Entity
personality,O
",",O
and,O
heavy,O
methamphetamine,I-Entity
use,O
.,O
It,I-Entity
is,O
recommended,O
that,O
all,O
cases,O
of,O
methamphetamine,I-Entity
dependence,O
should,O
be,O
screened,O
for,O
psychotic,I-Entity
symptoms,O
.,O
motor,O
cortical,O
plasticity,I-Entity
in,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
:,O
clues,O
from,O
dyskinetic,I-Entity
patients,O
.,O
The,I-Entity
plasticity,I-Entity
of,O
primary,O
motor,O
cortex,O
(,O
M1,I-Entity
),O
in,O
patients,O
with,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
and,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
(,O
LIDs,I-Entity
),O
is,O
severely,O
impaired,I-Entity
.,O
This,I-Entity
study,O
demonstrates,O
that,O
the,O
deficient,O
sensorimotor,O
M1,I-Entity
plasticity,I-Entity
in,O
16,O
patients,O
with,O
LIDs,I-Entity
could,O
be,O
reinstated,O
by,O
a,O
single,O
session,O
of,O
real,O
inhibitory,O
cerebellar,O
stimulation,O
but,O
not,O
sham,I-Entity
stimulation,O
.,O
The,I-Entity
benefit,O
of,O
inhibitory,O
cerebellar,O
stimulation,O
on,O
LIDs,I-Entity
is,O
known,O
.,O
To,I-Entity
explore,O
whether,O
this,O
benefit,O
is,O
linked,O
to,O
the,O
restoration,O
of,O
sensorimotor,O
plasticity,I-Entity
of,O
M1,I-Entity
",",O
we,O
conducted,O
an,O
additional,O
study,O
looking,O
at,O
changes,O
in,O
LIDs,I-Entity
and,O
PAS,I-Entity
-,O
induced,O
plasticity,I-Entity
after,O
10,O
sessions,O
of,O
either,O
bilateral,O
",",O
real,O
inhibitory,O
cerebellar,O
stimulation,O
or,O
sham,I-Entity
stimulation,O
.,O
These,I-Entity
results,O
suggest,O
that,O
alterations,I-Entity
in,O
cerebellar,O
sensory,O
processing,O
function,O
",",O
occurring,O
secondary,O
to,O
abnormal,I-Entity
basal,O
ganglia,I-Entity
signals,O
reaching,O
it,O
",",O
may,O
be,O
an,O
important,O
element,O
contributing,O
to,O
the,O
maladaptive,I-Entity
sensorimotor,O
plasticity,I-Entity
of,O
M1,I-Entity
and,O
the,O
emergence,O
of,O
abnormal,I-Entity
involuntary,O
movements,O
.,O
The,I-Entity
function,O
of,O
P2X3,I-Entity
receptor,O
and,O
NK1,I-Entity
receptor,O
antagonists,O
on,O
cyclophosphamide,I-Entity
-,O
induced,O
cystitis,I-Entity
in,O
rats,O
.,O
The,I-Entity
purpose,O
of,O
the,O
study,O
is,O
to,O
explore,O
the,O
function,O
of,O
P2X3,I-Entity
and,O
NK1,I-Entity
receptors,O
antagonists,O
on,O
cyclophosphamide,I-Entity
(,O
CYP)-induced,I-Entity
cystitis,I-Entity
in,O
rats,O
.,O
injected,O
with,O
CYP,I-Entity
(,O
150,I-Entity
mg,O
/,O
kg,O
),O
;,O
and,O
the,O
rats,O
in,O
the,O
intervention,O
group,O
were,O
i.p,O
.,O
injected,O
with,O
CYP,I-Entity
with,O
subsequently,O
perfusion,O
of,O
bladder,I-Entity
with,O
P2X3,I-Entity
and,O
NK1,I-Entity
receptors,O
',O
antagonists,O
",",O
Suramin,I-Entity
and,O
GR,I-Entity
82334,I-Entity
.,O
Spontaneous,I-Entity
pain,I-Entity
behaviors,O
following,O
the,O
administration,O
of,O
CYP,I-Entity
were,O
observed,O
.,O
RESULTS,I-Entity
:,O
Cyclophosphamide,I-Entity
treatment,O
increased,O
the,O
spontaneous,O
pain,I-Entity
behaviors,O
scores,O
.,O
Histological,I-Entity
changes,O
evident,O
in,O
model,O
and,O
intervention,O
groups,O
rats,O
',O
bladder,I-Entity
included,O
edema,I-Entity
",",O
vasodilation,O
",",O
and,O
infiltration,I-Entity
of,O
inflammatory,O
cells,O
.,O
In,I-Entity
CYP,I-Entity
-,O
induced,O
cystitis,I-Entity
",",O
the,O
expression,O
of,O
P2X3,I-Entity
and,O
NK1,I-Entity
receptors,O
increased,O
in,O
urothelium,I-Entity
and/or,O
suburothelium,I-Entity
.,O
Acute,I-Entity
hepatitis,I-Entity
associated,O
with,O
clopidogrel,I-Entity
:,O
a,O
case,O
report,O
and,O
review,O
of,O
the,O
literature,O
.,O
Drug,I-Entity
-,O
induced,O
hepatotoxicity,I-Entity
is,O
a,O
common,O
cause,O
of,O
acute,O
hepatitis,I-Entity
",",O
and,O
the,O
recognition,O
of,O
the,O
responsible,O
drug,O
may,O
be,O
difficult,O
.,O
We,I-Entity
describe,O
a,O
case,O
of,O
clopidogrel,I-Entity
-,O
related,O
acute,O
hepatitis,I-Entity
.,O
Reports,I-Entity
about,O
cases,O
of,O
hepatotoxicity,I-Entity
due,O
to,O
clopidogrel,I-Entity
are,O
increasing,O
in,O
the,O
last,O
few,O
years,O
",",O
after,O
the,O
increased,O
use,O
of,O
this,O
drug,O
.,O
In,I-Entity
conclusion,O
",",O
we,O
believe,O
that,O
physicians,O
should,O
carefully,O
consider,O
the,O
risk,O
of,O
drug,O
-,O
induced,O
hepatic,B-Entity
injury,I-Entity
when,O
clopidogrel,I-Entity
is,O
prescribed,O
.,O
Bortezomib,I-Entity
and,O
dexamethasone,I-Entity
as,O
salvage,O
therapy,O
in,O
patients,O
with,O
relapsed,O
/,O
refractory,O
multiple,O
myeloma,I-Entity
:,O
analysis,O
of,O
long,O
-,O
term,O
clinical,O
outcomes,O
.,O
Bortezomib,I-Entity
(,O
bort)-dexamethasone,I-Entity
(,O
dex,O
),O
is,O
an,O
effective,O
therapy,O
for,O
relapsed,O
/,O
refractory,O
(,O
R,I-Entity
/,O
R,I-Entity
),O
multiple,O
myeloma,I-Entity
(,O
MM,I-Entity
),O
.,O
This,I-Entity
retrospective,O
study,O
investigated,O
the,O
combination,O
of,O
bort,O
(,O
1.3,O
mg,O
/,O
m(2,O
),O
on,O
days,O
1,O
",",O
4,O
",",O
8,O
",",O
and,O
11,O
every,O
3,O
weeks,O
),O
and,O
dex,O
(,O
20,O
mg,O
on,O
the,O
day,O
of,O
and,O
the,O
day,O
after,O
bort,O
),O
as,O
salvage,O
treatment,O
in,O
85,O
patients,O
with,O
R,I-Entity
/,O
R,I-Entity
MM,I-Entity
after,O
prior,O
autologous,O
stem,O
cell,O
transplantation,O
or,O
conventional,O
chemotherapy,O
.,O
Eighty,I-Entity
-,O
seven,O
percent,O
of,O
the,O
patients,O
had,O
received,O
immunomodulatory,O
drugs,O
included,O
in,O
some,O
line,O
of,O
therapy,O
before,O
bort,O
-,O
dex,O
.,O
The,I-Entity
median,O
number,O
of,O
bort,O
-,O
dex,O
cycles,O
was,O
6,O
",",O
up,O
to,O
a,O
maximum,O
of,O
12,O
cycles,O
.,O
The,I-Entity
most,O
relevant,O
adverse,O
event,O
was,O
peripheral,O
neuropathy,I-Entity
",",O
which,O
occurred,O
in,O
78,O
%,O
of,O
the,O
patients,O
(,O
grade,O
II,I-Entity
",",O
38,O
%,O
;,O
grade,O
III,I-Entity
",",O
21,O
%,O
),O
and,O
led,O
to,O
treatment,O
discontinuation,O
in,O
6,O
%,O
.,O
Prolonged,I-Entity
PFS,I-Entity
and,O
OS,I-Entity
were,O
observed,O
in,O
patients,O
achieving,O
CR,I-Entity
and,O
receiving,O
bort,O
-,O
dex,O
a,O
single,O
line,O
of,O
prior,O
therapy,O
.,O
Bort,I-Entity
-,O
dex,O
was,O
an,O
effective,O
salvage,O
treatment,O
for,O
MM,I-Entity
patients,O
",",O
particularly,O
for,O
those,O
in,O
first,O
relapse,O
.,O
Pubertal,I-Entity
exposure,O
to,O
Bisphenol,I-Entity
A,I-Entity
increases,O
anxiety,I-Entity
-,O
like,O
behavior,O
and,O
decreases,O
acetylcholinesterase,O
activity,O
of,O
hippocampus,O
in,O
adult,O
male,O
mice,O
.,O
The,I-Entity
negative,O
effects,O
of,O
Bisphenol,I-Entity
A,I-Entity
(,O
BPA,I-Entity
),O
on,O
neurodevelopment,I-Entity
and,O
behaviors,O
have,O
been,O
well,O
established,O
.,O
Acetylcholinesterase,I-Entity
(,O
AChE,I-Entity
),O
is,O
a,O
regulatory,O
enzyme,O
which,O
is,O
involved,O
in,O
anxiety,I-Entity
-,O
like,O
behavior,O
.,O
This,I-Entity
study,O
investigated,O
behavioral,O
phenotypes,O
and,O
AChE,I-Entity
activity,O
in,O
male,O
mice,O
following,O
BPA,I-Entity
exposure,O
during,O
puberty,O
.,O
On,I-Entity
postnatal,O
day,O
(,O
PND,I-Entity
),O
35,O
",",O
male,O
mice,O
were,O
exposed,O
to,O
50,O
mg,O
BPA,I-Entity
/,O
kg,O
diet,O
per,O
day,O
for,O
a,O
period,O
of,O
35,O
days,O
.,O
Results,I-Entity
from,O
our,O
behavioral,O
phenotyping,I-Entity
indicated,O
that,O
anxiety,I-Entity
-,O
like,O
behavior,O
was,O
increased,O
in,O
mice,O
exposed,O
to,O
BPA,I-Entity
.,O
AChE,I-Entity
activity,O
was,O
significantly,O
decreased,O
in,O
the,O
hippocampus,O
of,O
mice,O
with,O
BPA,I-Entity
compared,O
to,O
control,O
mice,O
",",O
whereas,O
no,O
difference,O
was,O
found,O
in,O
the,O
prefrontal,O
cortex,O
",",O
hypothalamus,I-Entity
and,O
cerebellum,O
.,O
Our,I-Entity
findings,O
showed,O
that,O
pubertal,O
BPA,I-Entity
exposure,O
increased,O
anxiety,I-Entity
-,O
like,O
behavior,O
",",O
which,O
may,O
be,O
associated,O
with,O
decreased,O
AChE,I-Entity
activity,O
of,O
the,O
hippocampus,O
in,O
adult,O
male,O
mice,O
.,O
Further,I-Entity
studies,O
are,O
necessary,O
to,O
investigate,O
the,O
cholinergic,O
signaling,O
of,O
the,O
hippocampus,O
in,O
PBE,I-Entity
induced,O
anxiety,I-Entity
-,O
like,O
behaviors,O
.,O
Biochemical,I-Entity
effects,O
of,O
Solidago,I-Entity
virgaurea,I-Entity
extract,O
on,O
experimental,O
cardiotoxicity,I-Entity
.,O
Cardiovascular,I-Entity
diseases,I-Entity
(,O
CVDs,I-Entity
),O
are,O
the,O
major,O
health,O
problem,O
of,O
advanced,O
as,O
well,O
as,O
developing,O
countries,O
of,O
the,O
world,O
.,O
The,I-Entity
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
the,O
protective,O
effect,O
of,O
the,O
Solidago,I-Entity
virgaurea,I-Entity
extract,O
on,O
isoproterenol,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
in,O
rats,O
.,O
The,I-Entity
subcutaneous,O
injection,O
of,O
isoproterenol,I-Entity
(,O
30,O
mg,O
/,O
kg,O
),O
into,O
rats,O
twice,O
at,O
an,O
interval,O
of,O
24,O
h,O
",",O
for,O
two,O
consecutive,O
days,O
",",O
led,O
to,O
a,O
significant,O
increase,O
in,O
serum,O
lactate,I-Entity
dehydrogenase,O
",",O
creatine,I-Entity
phosphokinase,O
",",O
alanine,I-Entity
transaminase,O
",",O
aspartate,I-Entity
transaminase,O
",",O
and,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
activities,O
",",O
total,O
cholesterol,I-Entity
",",O
triglycerides,I-Entity
",",O
free,O
serum,O
fatty,B-Entity
acid,O
",",O
cardiac,O
tissue,O
malondialdehyde,I-Entity
(,O
MDA,I-Entity
),O
",",O
and,O
nitric,I-Entity
oxide,I-Entity
levels,O
and,O
a,O
significant,O
decrease,O
in,O
levels,O
of,O
glutathione,I-Entity
and,O
superoxide,I-Entity
dismutase,O
in,O
cardiac,O
tissue,O
as,O
compared,O
to,O
the,O
normal,O
control,O
group,O
(,O
P,I-Entity
<,O
0.05,O
),O
.,O
Pretreatment,I-Entity
with,O
S.,I-Entity
virgaurea,I-Entity
extract,O
for,O
5,O
weeks,O
at,O
a,O
dose,O
of,O
250,O
mg,O
/,O
kg,O
followed,O
by,O
isoproterenol,I-Entity
injection,O
significantly,O
prevented,O
the,O
observed,O
alterations,I-Entity
.,O
Captopril,I-Entity
(,O
50,O
mg,O
/,O
kg,O
/,O
day,O
",",O
given,O
orally,O
),O
",",O
an,O
inhibitor,O
of,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
used,O
as,O
a,O
standard,O
cardioprotective,O
drug,O
",",O
was,O
used,O
as,O
a,O
positive,O
control,O
in,O
this,O
study,O
.,O
The,I-Entity
data,O
of,O
the,O
present,O
study,O
suggest,O
that,O
S.,I-Entity
virgaurea,I-Entity
extract,O
exerts,I-Entity
its,O
protective,O
effect,O
by,O
decreasing,O
MDA,I-Entity
level,O
and,O
increasing,O
the,O
antioxidant,O
status,O
in,O
isoproterenol,I-Entity
-,O
treated,O
rats,O
.,O
"""""""""",O
Real,I-Entity
-,O
world,O
"""""""""",O
data,O
on,O
the,O
efficacy,O
and,O
safety,O
of,O
lenalidomide,I-Entity
and,O
dexamethasone,I-Entity
in,O
patients,O
with,O
relapsed,O
/,O
refractory,O
multiple,O
myeloma,I-Entity
who,O
were,O
treated,O
according,O
to,O
the,O
standard,O
clinical,O
practice,O
:,O
a,O
study,O
of,O
the,O
Greek,I-Entity
Myeloma,I-Entity
Study,I-Entity
Group,I-Entity
.,O
Lenalidomide,I-Entity
and,O
dexamethasone,I-Entity
(,O
RD,I-Entity
),O
is,O
a,O
standard,O
of,O
care,O
for,O
relapsed,O
/,O
refractory,O
multiple,O
myeloma,I-Entity
(,O
RRMM,I-Entity
),O
",",O
but,O
there,O
is,O
limited,O
published,O
data,O
on,O
its,O
efficacy,O
and,O
safety,O
in,O
the,O
"""""""""",O
real,O
world,O
"""""""""",O
(,O
RW,I-Entity
),O
",",O
according,O
to,O
the,O
International,I-Entity
Society,I-Entity
of,O
Pharmacoeconomics,I-Entity
and,O
Outcomes,I-Entity
Research,I-Entity
definition,O
.,O
We,I-Entity
studied,O
212,O
RRMM,I-Entity
patients,O
who,O
received,O
RD,I-Entity
in,O
RW,I-Entity
.,O
Median,I-Entity
time,O
to,O
CR,I-Entity
when,O
RD,I-Entity
was,O
given,O
as,O
2nd,O
or,O
>,O
2(nd)-line,I-Entity
treatment,O
at,O
4,O
and,O
11,O
months,O
",",O
respectively,O
.,O
Quality,I-Entity
of,O
response,O
was,O
independent,O
of,O
previous,O
lines,O
of,O
therapies,O
or,O
previous,O
exposure,O
to,O
thalidomide,I-Entity
or,O
bortezomib,I-Entity
.,O
Median,I-Entity
duration,O
of,O
response,O
was,O
34.4,O
months,O
",",O
and,O
it,O
was,O
higher,O
in,O
patients,O
who,O
received,O
RD,I-Entity
until,O
progression,O
(,O
not,O
reached,O
versus,O
19,O
months,O
",",O
p,O
<,O
0.001,O
),O
.,O
Adverse,I-Entity
events,O
were,O
reported,O
in,O
68.9,O
%,O
of,O
patients,O
(,O
myelosuppression,I-Entity
in,O
49.4,O
%,O
),O
and,O
12.7,O
%,O
of,O
patients,O
needed,O
hospitalization,O
.,O
Peripheral,I-Entity
neuropathy,I-Entity
was,O
observed,O
only,O
in,O
2.5,O
%,O
of,O
patients,O
and,O
deep,O
vein,O
thrombosis,I-Entity
in,O
5.7,O
%,O
.,O
Performance,I-Entity
status,O
(,O
PS,I-Entity
),O
and,O
initial,O
lenalidomide,I-Entity
dose,O
predicted,O
for,O
treatment,O
discontinuation,O
.,O
Our,I-Entity
study,O
confirms,O
that,O
RD,I-Entity
is,O
effective,O
and,O
safe,O
in,O
RRMM,I-Entity
in,O
the,O
RW,I-Entity
;,O
it,O
produces,O
durable,O
responses,O
especially,O
in,O
patients,O
who,O
continue,O
on,O
treatment,O
till,O
progression,O
and,O
improves,O
humoral,O
immunity,O
even,O
in,O
patients,O
with,O
stable,O
disease,I-Entity
.,O
The,I-Entity
cytogenetic,O
action,O
of,O
ifosfamide,I-Entity
",",O
mesna,I-Entity
",",O
and,O
their,O
combination,O
on,O
peripheral,O
rabbit,I-Entity
lymphocytes,O
:,O
an,O
in,O
vivo,O
/,O
in,O
vitro,O
cytogenetic,O
study,O
.,O
Ifosfamide,I-Entity
(,O
IFO,I-Entity
),O
is,O
an,O
alkylating,B-Entity
nitrogen,I-Entity
mustard,I-Entity
",",O
administrated,O
as,O
an,O
antineoplasmic,O
agent,O
.,O
It,I-Entity
is,O
characterized,O
by,O
its,O
intense,O
urotoxic,I-Entity
action,O
",",O
leading,O
to,O
hemorrhagic,I-Entity
cystitis,I-Entity
.,O
This,I-Entity
side,O
effect,O
of,O
IFO,I-Entity
raises,O
the,O
requirement,O
for,O
the,O
co,O
-,O
administration,O
with,O
sodium,I-Entity
2-sulfanylethanesulfonate,B-Entity
(,O
Mesna,I-Entity
),O
aiming,O
to,O
avoid,O
or,O
minimize,O
this,O
effect,O
.,O
IFO,I-Entity
and,O
Mesna,I-Entity
were,O
administrated,O
separately,O
on,O
rabbit,I-Entity
's,I-Entity
lymphocytes,O
in,O
vivo,O
",",O
which,O
were,O
later,O
developed,O
in,O
vitro,O
.,O
Mesna,I-Entity
's,I-Entity
action,O
",",O
in,O
conjunction,O
with,O
IFO,I-Entity
reduces,O
the,O
frequency,O
of,O
SCEs,I-Entity
",",O
in,O
comparison,O
with,O
the,O
SCEs,I-Entity
recordings,O
obtained,O
when,O
IFO,I-Entity
is,O
administered,O
alone,O
.,O
In,I-Entity
addition,O
to,O
this,O
",",O
when,O
high,O
concentrations,O
of,O
Mesna,I-Entity
were,O
administered,O
alone,O
significant,O
reductions,O
of,O
the,O
PRI,I-Entity
were,O
noted,O
",",O
than,O
with,O
IFO,I-Entity
acting,O
at,O
the,O
same,O
concentration,O
on,O
the,O
lymphocytes,O
.,O
Mesna,I-Entity
significantly,O
reduces,O
IFO,I-Entity
's,I-Entity
genotoxicity,I-Entity
",",O
while,O
when,O
administered,O
in,O
high,O
concentrations,O
it,O
acts,O
in,O
an,O
inhibitory,O
fashion,O
on,O
the,O
cytostatic,O
action,O
of,O
the,O
drug,O
.,O
Risk,I-Entity
factors,O
and,O
predictors,O
of,O
levodopa,I-Entity
-,O
induced,O
dyskinesia,I-Entity
among,O
multiethnic,I-Entity
Malaysians,I-Entity
with,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
.,O
Chronic,I-Entity
pulsatile,O
levodopa,I-Entity
therapy,O
for,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
leads,O
to,O
the,O
development,O
of,O
motor,O
fluctuations,I-Entity
and,O
dyskinesia,I-Entity
.,O
We,I-Entity
studied,O
the,O
prevalence,O
and,O
predictors,O
of,O
levodopa,I-Entity
-,O
induced,O
dyskinesia,I-Entity
among,O
multiethnic,I-Entity
Malaysian,I-Entity
patients,O
with,O
PD,I-Entity
.,O
This,I-Entity
is,O
a,O
cross,O
-,O
sectional,O
study,O
involving,O
95,O
patients,O
with,O
PD,I-Entity
on,O
uninterrupted,O
levodopa,I-Entity
therapy,O
for,O
at,O
least,O
6,O
months,O
.,O
The,I-Entity
predictors,O
of,O
dyskinesia,I-Entity
were,O
determined,O
using,O
multivariate,O
logistic,O
regression,O
analysis,O
.,O
Dyskinesia,I-Entity
was,O
present,O
in,O
44%,O
(,O
n,O
=,O
42,O
),O
with,O
median,O
levodopa,I-Entity
therapy,O
of,O
3,O
years,O
.,O
Eighty,I-Entity
-,O
one,O
percent,O
of,O
patients,O
with,O
dyskinesia,I-Entity
had,O
clinical,O
fluctuations,I-Entity
.,O
Patients,I-Entity
with,O
dyskinesia,I-Entity
had,O
lower,O
onset,O
age,O
(,O
p,O
<,O
0.001,O
),O
",",O
longer,O
duration,O
of,O
levodopa,I-Entity
therapy,O
(,O
p,O
<,O
0.001,O
),O
",",O
higher,O
total,O
daily,O
levodopa,I-Entity
dose,O
(,O
p,O
<,O
0.001,O
),O
",",O
and,O
higher,O
total,O
UPDRS,I-Entity
scores,O
(,O
p,O
=,O
0.005,O
),O
than,O
patients,O
without,O
dyskinesia,I-Entity
.,O
The,I-Entity
three,O
significant,O
predictors,O
of,O
dyskinesia,I-Entity
were,O
duration,O
of,O
levodopa,I-Entity
therapy,O
",",O
onset,O
age,O
",",O
and,O
total,O
daily,O
levodopa,I-Entity
dose,O
.,O
The,I-Entity
prevalence,O
of,O
levodopa,I-Entity
-,O
induced,O
dyskinesia,I-Entity
in,O
our,O
patients,O
was,O
44%,O
.,O
The,I-Entity
most,O
significant,O
predictors,O
were,O
duration,O
of,O
levodopa,I-Entity
therapy,O
",",O
total,O
daily,O
levodopa,I-Entity
dose,O
",",O
and,O
onset,O
age,O
.,O
An,I-Entity
unexpected,O
diagnosis,O
in,O
a,O
renal,O
-,O
transplant,O
patient,O
with,O
proteinuria,I-Entity
treated,O
with,O
everolimus,I-Entity
:,O
AL,I-Entity
amyloidosis,I-Entity
.,O
Proteinuria,I-Entity
is,O
an,O
expected,O
complication,O
in,O
transplant,O
patients,O
treated,O
with,O
mammalian,O
target,O
of,O
rapamycin,I-Entity
inhibitors,O
(,O
mTOR,I-Entity
-,O
i,O
),O
.,O
However,I-Entity
",",O
clinical,O
suspicion,O
should,O
always,O
be,O
supported,O
by,O
histological,O
evidence,O
in,O
order,O
to,O
investigate,O
potential,O
alternate,O
diagnoses,O
such,O
as,O
acute,O
or,O
chronic,O
rejection,I-Entity
",",O
interstitial,O
fibrosis,I-Entity
and,O
tubular,O
atrophy,I-Entity
",",O
or,O
recurrent,O
or,O
de,O
novo,O
glomerulopathy,I-Entity
.,O
In,I-Entity
this,O
case,O
we,O
report,O
the,O
unexpected,O
diagnosis,O
of,O
amyloidosis,I-Entity
in,O
a,O
renal,O
-,O
transplant,O
patient,O
with,O
pre,O
-,O
transplant,O
monoclonal,O
gammapathy,I-Entity
of,O
undetermined,O
significance,O
who,O
developed,O
proteinuria,I-Entity
after,O
conversion,O
from,O
tacrolimus,I-Entity
to,O
everolimus,I-Entity
.,O
An,I-Entity
investigation,O
of,O
the,O
pattern,O
of,O
kidney,O
injury,I-Entity
in,O
HIV,I-Entity
-,O
positive,O
persons,O
exposed,O
to,O
tenofovir,I-Entity
disoproxil,I-Entity
fumarate,I-Entity
:,O
an,O
examination,O
of,O
a,O
large,O
population,O
database,O
(,O
MHRA,I-Entity
database,O
),O
.,O
The,I-Entity
potential,O
for,O
tenofovir,I-Entity
to,O
cause,O
a,O
range,O
of,O
kidney,O
syndromes,I-Entity
has,O
been,O
established,O
from,O
mechanistic,O
and,O
randomised,O
clinical,O
trials,O
.,O
We,I-Entity
undertook,O
a,O
descriptive,O
analysis,O
of,O
Yellow,I-Entity
Card,I-Entity
records,I-Entity
of,O
407,O
HIV,I-Entity
-,O
positive,O
persons,O
taking,O
tenofovir,I-Entity
disoproxil,I-Entity
fumarate,I-Entity
(,O
TDF,I-Entity
),O
as,O
part,O
of,O
their,O
antiretroviral,O
therapy,O
regimen,I-Entity
and,O
submitted,O
to,O
the,O
Medicines,I-Entity
and,O
Healthcare,I-Entity
Products,I-Entity
Regulatory,I-Entity
Agency,I-Entity
(,O
MHRA,I-Entity
),O
with,O
suspected,O
kidney,O
adverse,O
effects,O
.,O
Reports,I-Entity
that,O
satisfy,O
defined,O
criteria,O
were,O
classified,O
as,O
acute,O
kidney,O
injury,I-Entity
",",O
kidney,O
tubular,O
dysfunction,I-Entity
and,O
Fanconi,I-Entity
syndrome,I-Entity
.,O
Of,I-Entity
the,O
407,O
Yellow,I-Entity
Card,I-Entity
records,I-Entity
analysed,O
",",O
106,I-Entity
satisfied,O
criteria,O
for,O
TDF,I-Entity
-,O
related,O
kidney,O
disease,I-Entity
",",O
of,O
which,O
53,I-Entity
(,O
50%,O
),O
had,O
features,O
of,O
kidney,O
tubular,O
dysfunction,I-Entity
",",O
35,O
(,O
33%,O
),O
were,O
found,O
to,O
have,O
features,O
of,O
glomerular,O
dysfunction,I-Entity
and,O
18,O
(,O
17%,O
),O
had,O
Fanconi,I-Entity
syndrome,I-Entity
.,O
The,I-Entity
median,O
TDF,I-Entity
exposure,O
was,O
316,I-Entity
days,O
(,O
interquartile,O
range,O
120,I-Entity
-,O
740,O
),O
.,O
The,I-Entity
incidence,O
of,O
hospitalisation,O
for,O
TDF,I-Entity
kidney,O
adverse,O
effects,O
was,O
high,O
",",O
particularly,O
amongst,O
patients,O
with,O
features,O
of,O
Fanconi,I-Entity
syndrome,I-Entity
.,O
Cessation,I-Entity
of,O
TDF,I-Entity
was,O
associated,O
with,O
complete,O
restoration,O
of,O
kidney,O
function,O
in,O
up,O
half,O
of,O
the,O
patients,O
in,O
this,O
report,O
.,O
Incidence,I-Entity
of,O
postoperative,O
delirium,I-Entity
is,O
high,O
even,O
in,O
a,O
population,O
without,O
known,O
risk,O
factors,O
.,O
Postoperative,I-Entity
delirium,I-Entity
is,O
a,O
recognized,O
complication,O
in,O
populations,O
at,O
risk,O
.,O
The,I-Entity
aim,O
of,O
this,O
study,O
is,O
to,O
assess,O
the,O
prevalence,O
of,O
early,O
postoperative,O
delirium,I-Entity
in,O
a,O
population,O
without,O
known,O
risk,O
factors,O
admitted,O
to,O
the,O
ICU,I-Entity
for,O
postoperative,O
monitoring,O
after,O
elective,O
major,O
surgery,O
.,O
Exclusion,I-Entity
criteria,O
were,O
any,O
preexisting,O
predisposing,O
factor,O
for,O
delirium,I-Entity
or,O
other,O
potentially,O
confounding,I-Entity
neurological,O
dysfunctions,I-Entity
.,O
Patients,I-Entity
were,O
assessed,O
daily,O
using,O
the,O
confusion,I-Entity
assessment,O
method,O
for,O
the,O
ICU,I-Entity
scale,O
for,O
3,O
days,O
after,O
the,O
surgical,O
procedure,O
.,O
Early,I-Entity
postoperative,O
delirium,I-Entity
incidence,O
risk,O
factors,O
were,O
then,O
assessed,O
through,O
three,O
different,O
multiple,O
regression,O
models,O
.,O
According,I-Entity
to,O
the,O
confusion,I-Entity
assessment,O
method,O
for,O
the,O
ICU,I-Entity
scale,O
",",O
28,O
%,O
of,O
patients,O
were,O
diagnosed,O
with,O
early,O
postoperative,O
delirium,I-Entity
.,O
The,I-Entity
use,O
of,O
thiopentone,I-Entity
was,O
significantly,O
associated,O
with,O
an,O
eight,O
-,O
fold,O
-,O
higher,O
risk,O
for,O
delirium,I-Entity
compared,O
to,O
propofol,I-Entity
(,O
57.1%,O
CONCLUSION,I-Entity
:,O
In,I-Entity
this,O
study,O
early,O
postoperative,O
delirium,I-Entity
was,O
found,O
to,O
be,O
a,O
very,O
common,O
complication,O
after,O
major,O
surgery,O
",",O
even,O
in,O
a,O
population,O
without,O
known,O
risk,O
factors,O
.,O
Thiopentone,I-Entity
was,O
independently,O
associated,O
with,O
an,O
increase,O
in,O
its,O
relative,O
risk,O
.,O
A,I-Entity
single,O
neurotoxic,I-Entity
dose,O
of,O
methamphetamine,I-Entity
induces,O
a,O
long,O
-,O
lasting,O
depressive,I-Entity
-,O
like,O
behaviour,O
in,O
mice,O
.,O
Methamphetamine,I-Entity
(,O
METH,I-Entity
),O
triggers,O
a,O
disruption,I-Entity
of,O
the,O
monoaminergic,O
system,O
and,O
METH,I-Entity
abuse,I-Entity
leads,O
to,O
negative,O
emotional,I-Entity
states,O
including,O
depressive,I-Entity
symptoms,O
during,O
drug,O
withdrawal,O
.,O
However,I-Entity
",",O
it,O
is,O
currently,O
unknown,O
if,O
the,O
acute,O
toxic,I-Entity
dosage,O
of,O
METH,I-Entity
also,O
causes,O
a,O
long,O
-,O
lasting,O
depressive,I-Entity
phenotype,O
and,O
persistent,O
monoaminergic,O
deficits,I-Entity
.,O
Thus,I-Entity
",",O
we,O
now,O
assessed,O
the,O
depressive,I-Entity
-,O
like,O
behaviour,O
in,O
mice,O
at,O
early,O
and,O
long,O
-,O
term,O
periods,O
following,O
a,O
single,O
high,O
METH,I-Entity
dose,O
(,O
30,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
.,O
METH,I-Entity
did,O
not,O
alter,O
the,O
motor,O
function,O
and,O
procedural,O
memory,O
of,O
mice,O
as,O
assessed,O
by,O
swimming,O
speed,O
and,O
escape,O
latency,O
to,O
find,O
the,O
platform,O
in,O
a,O
cued,O
version,O
of,O
the,O
water,O
maze,O
task,O
.,O
However,I-Entity
",",O
METH,I-Entity
significantly,O
increased,O
the,O
immobility,I-Entity
time,O
in,O
the,O
tail,O
suspension,O
test,O
at,O
3,O
and,O
49,I-Entity
days,O
post,O
-,O
administration,O
.,O
This,I-Entity
depressive,I-Entity
-,O
like,O
profile,O
induced,O
by,O
METH,I-Entity
was,O
accompanied,O
by,O
a,O
marked,O
depletion,O
of,O
frontostriatal,O
dopaminergic,O
and,O
serotonergic,I-Entity
neurotransmission,O
",",O
indicated,O
by,O
a,O
reduction,O
in,O
the,O
levels,O
of,O
dopamine,I-Entity
",",O
DOPAC,I-Entity
and,O
HVA,I-Entity
",",O
tyrosine,I-Entity
hydroxylase,O
and,O
serotonin,I-Entity
",",O
observed,O
at,O
both,O
3,O
and,O
49,I-Entity
days,O
post,O
-,O
administration,O
.,O
In,I-Entity
parallel,I-Entity
",",O
another,O
neurochemical,O
feature,O
of,O
depression,I-Entity
--,O
astroglial,I-Entity
dysfunction,I-Entity
--,O
was,O
unaffected,O
in,O
the,O
cortex,O
and,O
the,O
striatal,O
levels,O
of,O
the,O
astrocytic,I-Entity
protein,O
marker,O
",",O
glial,O
fibrillary,O
acidic,O
protein,O
",",O
were,O
only,O
transiently,O
increased,O
at,O
3,O
days,O
.,O
These,I-Entity
findings,O
demonstrate,O
for,O
the,O
first,O
time,O
that,O
a,O
single,O
high,O
dose,O
of,O
METH,I-Entity
induces,O
long,O
-,O
lasting,O
depressive,I-Entity
-,O
like,O
behaviour,O
in,O
mice,O
associated,O
with,O
a,O
persistent,O
disruption,I-Entity
of,O
frontostriatal,O
dopaminergic,O
and,O
serotonergic,I-Entity
homoeostasis,I-Entity
.,O
Linezolid,I-Entity
-,O
induced,O
optic,O
neuropathy,I-Entity
.,O
We,I-Entity
describe,O
a,O
case,O
of,O
progressive,O
loss,I-Entity
of,O
vision,O
associated,O
with,O
linezolid,I-Entity
therapy,O
.,O
A,I-Entity
45-year,O
-,O
old,O
male,O
patient,O
who,O
was,O
on,O
treatment,O
with,O
multiple,O
second,O
-,O
line,O
anti,O
-,O
tuberculous,I-Entity
drugs,O
including,O
linezolid,I-Entity
and,O
ethambutol,I-Entity
for,O
extensively,O
drug,O
-,O
resistant,O
tuberculosis,I-Entity
(,O
XDR,I-Entity
-,O
TB,I-Entity
),O
presented,O
to,O
us,O
with,O
painless,I-Entity
progressive,O
loss,I-Entity
of,O
vision,O
in,O
both,O
eyes,O
.,O
Color,I-Entity
vision,O
was,O
defective,I-Entity
and,O
fundus,O
examination,O
revealed,O
optic,O
disc,O
edema,I-Entity
in,O
both,O
eyes,O
.,O
Ethambutol,I-Entity
-,O
induced,O
toxic,I-Entity
optic,O
neuropathy,I-Entity
was,O
suspected,O
and,O
tablet,O
ethambutol,I-Entity
was,O
withdrawn,O
.,O
Deterioration,I-Entity
of,O
vision,O
occurred,O
despite,O
withdrawal,O
of,O
ethambutol,I-Entity
.,O
Discontinuation,I-Entity
of,O
linezolid,I-Entity
resulted,O
in,O
marked,O
improvement,O
of,O
vision,O
.,O
Our,I-Entity
report,O
emphasizes,O
the,O
need,O
for,O
monitoring,O
of,O
visual,O
function,O
in,O
patients,O
on,O
long,O
-,O
term,O
linezolid,I-Entity
treatment,O
.,O
Resuscitation,I-Entity
with,O
lipid,O
",",O
epinephrine,I-Entity
",",O
or,O
both,O
in,O
levobupivacaine,I-Entity
-,O
induced,O
cardiac,O
toxicity,I-Entity
in,O
newborn,O
piglets,O
.,O
The,I-Entity
optimal,O
dosing,O
regimens,I-Entity
of,O
lipid,O
emulsion,I-Entity
",",O
epinephrine,I-Entity
",",O
or,O
both,O
are,O
not,O
yet,O
determined,O
in,O
neonates,O
in,O
cases,O
of,O
local,O
anaesthetic,O
systemic,O
toxicity,I-Entity
(,O
LAST,I-Entity
),O
.,O
Newborn,I-Entity
piglets,O
received,O
levobupivacaine,I-Entity
until,O
cardiovascular,O
collapse,I-Entity
occurred,O
.,O
Standard,I-Entity
cardiopulmonary,O
resuscitation,O
was,O
started,O
and,O
electrocardiogram,O
(,O
ECG,I-Entity
),O
was,O
monitored,O
for,O
ventricular,O
tachycardia,I-Entity
",",O
fibrillation,I-Entity
",",O
or,O
QRS,I-Entity
prolongation,O
.,O
Piglets,I-Entity
were,O
then,O
randomly,O
allocated,O
to,O
four,O
groups,O
:,O
control,O
(,O
saline,O
),O
",",O
Intralipid,I-Entity
(,O
),O
alone,O
",",O
epinephrine,I-Entity
alone,O
",",O
or,O
a,O
combination,O
of,O
Intralipd,I-Entity
plus,O
epinephrine,I-Entity
.,O
The,I-Entity
number,O
of,O
ECG,I-Entity
abnormalities,I-Entity
was,O
zero,O
in,O
the,O
Intralipid,I-Entity
only,O
group,O
",",O
but,O
14,O
and,O
17,O
",",O
respectively,O
",",O
in,O
the,O
epinephrine,I-Entity
and,O
epinephrine,I-Entity
plus,O
lipid,O
groups,O
(,O
P<0.05,I-Entity
),O
.,O
Lipid,I-Entity
emulsion,I-Entity
with,O
or,O
without,O
epinephrine,I-Entity
",",O
or,O
epinephrine,I-Entity
alone,O
were,O
equally,O
effective,O
in,O
achieving,O
a,O
return,O
to,O
spontaneous,O
circulation,O
in,O
this,O
model,O
of,O
LAST,I-Entity
.,O
Epinephrine,I-Entity
alone,O
or,O
in,O
combination,O
with,O
lipid,O
was,O
associated,O
with,O
an,O
increased,O
number,O
of,O
ECG,I-Entity
abnormalities,I-Entity
compared,O
with,O
lipid,O
emulsion,I-Entity
alone,O
.,O
Incidence,I-Entity
of,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
type,O
II,I-Entity
and,O
postoperative,O
recovery,O
of,O
platelet,O
count,O
in,O
liver,I-Entity
graft,O
recipients,O
:,O
a,O
retrospective,O
cohort,O
analysis,O
.,O
Thrombocytopenia,I-Entity
in,O
patients,O
with,O
end,O
-,O
stage,O
liver,I-Entity
disease,I-Entity
is,O
a,O
common,O
disorder,I-Entity
caused,O
mainly,O
by,O
portal,O
hypertension,I-Entity
",",O
low,O
levels,O
of,O
thrombopoetin,I-Entity
",",O
and,O
endotoxemia,I-Entity
.,O
The,I-Entity
impact,O
of,O
immune,O
-,O
mediated,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
type,O
II,I-Entity
(,O
HIT,I-Entity
type,O
II,I-Entity
),O
as,O
a,O
cause,O
of,O
thrombocytopenia,I-Entity
after,O
liver,I-Entity
transplantation,O
is,O
not,O
yet,O
understood,O
",",O
with,O
few,O
literature,O
citations,O
reporting,O
contradictory,O
results,O
.,O
The,I-Entity
aim,O
of,O
our,O
study,O
was,O
to,O
demonstrate,O
the,O
perioperative,O
course,O
of,O
thrombocytopenia,I-Entity
after,O
liver,I-Entity
transplantation,O
and,O
determine,O
the,O
occurrence,O
of,O
clinical,O
HIT,I-Entity
type,O
II,I-Entity
.,O
We,I-Entity
retrospectively,O
evaluated,O
the,O
medical,O
records,I-Entity
of,O
205,I-Entity
consecutive,O
adult,O
patients,O
who,O
underwent,O
full,O
-,O
size,O
liver,I-Entity
transplantation,O
between,O
January,I-Entity
2006,O
and,O
December,I-Entity
2010,O
due,O
to,O
end,O
-,O
stage,O
or,O
malignant,I-Entity
liver,I-Entity
disease,I-Entity
.,O
Preoperative,I-Entity
platelet,O
count,O
",",O
postoperative,O
course,O
of,O
platelets,O
",",O
and,O
clinical,O
signs,O
of,O
HIT,I-Entity
type,O
II,I-Entity
were,O
analyzed,O
.,O
A,I-Entity
total,O
of,O
155,I-Entity
(,O
75.6%,O
),O
of,O
205,I-Entity
patients,O
had,O
thrombocytopenia,I-Entity
before,O
transplantation,O
",",O
significantly,O
influenced,O
by,O
Model,I-Entity
of,O
End,I-Entity
-,O
Stage,I-Entity
Liver,I-Entity
Disease,I-Entity
score,O
and,O
liver,I-Entity
cirrhosis,I-Entity
.,O
The,I-Entity
platelet,O
count,O
exceeded,O
"100,000/uL",O
in,O
most,O
of,O
the,O
patients,O
(,O
n,O
=,O
193,I-Entity
),O
at,O
a,O
medium,O
of,O
7,O
d.,O
Regarding,I-Entity
HIT,I-Entity
II,I-Entity
",",O
there,O
were,O
four,O
(,O
1.95%,O
),O
patients,O
with,O
a,O
background,O
of,O
HIT,I-Entity
type,O
II,I-Entity
.,O
The,I-Entity
incidence,O
of,O
HIT,I-Entity
in,O
patients,O
with,O
end,O
-,O
stage,O
hepatic,B-Entity
failure,I-Entity
is,O
",",O
with,O
about,O
1.95%,O
",",O
rare,O
.,O
For,I-Entity
further,O
reduction,O
of,O
HIT,I-Entity
type,O
II,I-Entity
",",O
the,O
use,O
of,O
intravenous,O
heparin,I-Entity
should,O
be,O
avoided,O
and,O
the,O
prophylactic,O
anticoagulation,O
should,O
be,O
performed,O
with,O
low,O
-,O
molecular,O
-,O
weight,O
heparin,I-Entity
after,O
normalization,O
of,O
platelet,O
count,O
.,O
Takotsubo,I-Entity
syndrome,I-Entity
(,O
or,O
apical,O
ballooning,I-Entity
syndrome,I-Entity
),O
secondary,O
to,O
Zolmitriptan,I-Entity
.,O
Takotsubo,I-Entity
syndrome,I-Entity
(,O
TS,I-Entity
),O
",",O
also,O
known,O
as,O
broken,I-Entity
heart,O
syndrome,I-Entity
",",O
is,O
characterized,O
by,O
left,O
ventricle,O
apical,O
ballooning,I-Entity
with,O
elevated,O
cardiac,O
biomarkers,O
and,O
electrocardiographic,O
changes,O
suggestive,O
of,O
an,O
acute,O
coronary,O
syndrome,I-Entity
(,O
ie,O
",",O
ST,I-Entity
-,O
segment,O
elevation,O
",",O
T,I-Entity
wave,O
inversions,I-Entity
",",O
and,O
pathologic,O
Q,I-Entity
waves,O
),O
.,O
We,I-Entity
report,O
a,O
case,O
of,O
54-year,O
-,O
old,O
woman,O
with,O
medical,O
history,O
of,O
mitral,O
valve,O
prolapse,I-Entity
and,O
migraines,I-Entity
",",O
who,O
was,O
admitted,O
to,O
the,O
hospital,O
for,O
substernal,O
chest,O
pain,I-Entity
and,O
electrocardiogram,O
demonstrated,O
1/2,O
mm,O
ST,I-Entity
-,O
segment,O
elevation,O
in,O
leads,O
II,I-Entity
",",O
III,I-Entity
",",O
aVF,I-Entity
",",O
V5,I-Entity
",",O
and,O
V6,I-Entity
and,O
positive,O
troponin,I-Entity
I.,I-Entity
Emergent,I-Entity
coronary,O
angiogram,O
revealed,O
normal,O
coronary,O
arteries,O
with,O
moderately,O
reduced,O
left,O
ventricular,O
ejection,O
fraction,O
with,O
wall,O
motion,O
abnormalities,I-Entity
consistent,O
with,O
TS,I-Entity
.,O
Detailed,I-Entity
history,O
obtained,O
retrospectively,O
revealed,O
that,O
the,O
patient,O
took,O
zolmitriptan,I-Entity
sparingly,O
only,O
when,O
she,O
had,O
migraines,I-Entity
.,O
But,I-Entity
before,O
this,O
event,O
",",O
she,O
was,O
taking,O
zolmitriptan,I-Entity
2,O
-,O
3,O
times,O
daily,O
for,O
several,O
days,O
because,O
of,O
a,O
persistent,O
migraine,I-Entity
headache,I-Entity
.,O
There,I-Entity
was,O
no,O
evidence,O
of,O
any,O
recent,O
stress,I-Entity
or,O
status,O
migrainosus,I-Entity
.,O
Extensive,I-Entity
literature,O
search,O
revealed,O
multiple,O
cases,O
of,O
coronary,O
artery,I-Entity
vasospasm,I-Entity
secondary,O
to,O
zolmitriptan,I-Entity
",",O
but,O
none,O
of,O
the,O
cases,O
were,O
associated,O
with,O
TS,I-Entity
.,O
Depression,I-Entity
",",O
impulsiveness,I-Entity
",",O
sleep,O
",",O
and,O
memory,O
in,O
past,O
and,O
present,O
polydrug,O
users,O
of,O
"3,4-methylenedioxymethamphetamine",B-Entity
(,O
MDMA,I-Entity
",",O
ecstasy,I-Entity
),O
.,O
RATIONALE,I-Entity
:,O
Ecstasy,I-Entity
(,O
"3,4-methylenedioxymethamphetamine",B-Entity
",",O
MDMA,I-Entity
),O
is,O
a,O
worldwide,O
recreational,O
drug,O
of,O
abuse,I-Entity
.,O
The,I-Entity
present,O
study,O
aimed,O
to,O
be,O
the,O
largest,O
to,O
date,O
in,O
sample,O
size,O
and,O
5HT,I-Entity
-,O
related,O
behaviors,O
;,O
the,O
first,O
to,O
compare,O
present,O
ecstasy,I-Entity
users,O
with,O
past,O
users,O
after,O
an,O
abstinence,O
of,O
4,O
or,O
more,O
years,O
",",O
and,O
the,O
first,O
to,O
include,O
robust,O
controls,O
for,O
other,O
recreational,O
substances,O
.,O
A,I-Entity
sample,O
of,O
997,I-Entity
participants,O
(,O
52,O
%,O
male,O
),O
was,O
recruited,O
to,O
four,O
control,O
groups,O
(,O
non,O
-,O
drug,O
(,O
ND,I-Entity
),O
",",O
alcohol,I-Entity
/,O
nicotine,I-Entity
(,O
AN,I-Entity
),O
",",O
cannabis,I-Entity
/,O
alcohol,I-Entity
/,O
nicotine,I-Entity
(,O
CAN,I-Entity
),O
",",O
non,O
-,O
ecstasy,I-Entity
polydrug,O
(,O
PD,I-Entity
),O
),O
",",O
and,O
two,O
ecstasy,I-Entity
polydrug,O
groups,O
(,O
present,O
(,O
MDMA,I-Entity
),O
and,O
past,O
users,O
(,O
EX,I-Entity
-,O
MDMA,I-Entity
),O
.,O
Participants,I-Entity
completed,O
a,O
drug,O
history,O
questionnaire,O
",",O
Beck,I-Entity
Depression,I-Entity
Inventory,I-Entity
",",O
Barratt,I-Entity
Impulsiveness,I-Entity
Scale,I-Entity
",",O
Pittsburgh,I-Entity
Sleep,I-Entity
Quality,I-Entity
Index,I-Entity
",",O
and,O
Wechsler,I-Entity
Memory,I-Entity
Scale,I-Entity
-,O
Revised,I-Entity
which,O
",",O
in,O
total,O
",",O
provided,O
13,O
psychometric,O
measures,O
.,O
While,I-Entity
the,O
CAN,I-Entity
and,O
PD,I-Entity
groups,O
tended,O
to,O
record,O
greater,O
deficits,I-Entity
than,O
the,O
non,O
-,O
drug,O
controls,O
",",O
the,O
MDMA,I-Entity
and,O
EX,I-Entity
-,O
MDMA,I-Entity
groups,O
recorded,O
greater,O
deficits,I-Entity
than,O
all,O
the,O
control,O
groups,O
on,O
ten,O
of,O
the,O
13,O
psychometric,O
measures,O
.,O
Strikingly,I-Entity
",",O
despite,O
prolonged,O
abstinence,O
(,O
mean,O
",",O
4.98,O
;,O
range,O
",",O
4,O
-,O
9,O
years,O
),O
",",O
past,O
ecstasy,I-Entity
users,O
showed,O
few,O
signs,O
of,O
recovery,O
.,O
Compared,I-Entity
with,O
present,O
ecstasy,I-Entity
users,O
",",O
the,O
past,O
users,O
showed,O
no,O
change,O
for,O
ten,O
measures,O
",",O
increased,O
impairment,I-Entity
for,O
two,O
measures,O
",",O
and,O
improvement,O
on,O
just,O
one,O
measure,O
.,O
Given,I-Entity
this,O
record,O
of,O
impaired,I-Entity
memory,O
and,O
clinically,O
significant,O
levels,O
of,O
depression,I-Entity
",",O
impulsiveness,I-Entity
",",O
and,O
sleep,O
disturbance,I-Entity
",",O
the,O
prognosis,O
for,O
the,O
current,O
generation,O
of,O
ecstasy,I-Entity
users,O
is,O
a,O
major,O
cause,O
for,O
concern,O
.,O
Association,I-Entity
of,O
common,O
genetic,O
variants,O
of,O
HOMER1,I-Entity
gene,O
with,O
levodopa,I-Entity
adverse,O
effects,O
in,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
patients,O
.,O
Levodopa,I-Entity
is,O
the,O
most,O
effective,O
symptomatic,O
therapy,O
for,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
",",O
but,O
its,O
chronic,O
use,O
could,O
lead,O
to,O
chronic,O
adverse,O
outcomes,O
",",O
such,O
as,O
motor,O
fluctuations,I-Entity
",",O
dyskinesia,I-Entity
and,O
visual,O
hallucinations,I-Entity
.,O
HOMER1,I-Entity
is,O
a,O
protein,O
with,O
pivotal,O
function,O
in,O
glutamate,I-Entity
transmission,O
",",O
which,O
has,O
been,O
related,O
to,O
the,O
pathogenesis,O
of,O
these,O
complications,O
.,O
This,I-Entity
study,O
investigates,O
whether,O
polymorphisms,I-Entity
in,O
the,O
HOMER1,I-Entity
gene,O
promoter,O
region,O
are,O
associated,O
with,O
the,O
occurrence,O
of,O
the,O
chronic,O
complications,O
of,O
levodopa,I-Entity
therapy,O
.,O
A,I-Entity
total,O
of,O
205,I-Entity
patients,O
with,O
idiopathic,I-Entity
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
were,O
investigated,O
.,O
The,I-Entity
rs4704559,I-Entity
G,I-Entity
allele,I-Entity
was,O
associated,O
with,O
a,O
lower,O
prevalence,O
of,O
dyskinesia,I-Entity
(,O
prevalence,O
ratio,O
(,O
PR)=0.615,I-Entity
",",O
95%,O
confidence,O
interval,O
(,O
CI,I-Entity
),O
0.426,O
-,O
0.887,O
",",O
P=0.009,I-Entity
),O
and,O
visual,O
hallucinations,I-Entity
(,O
PR=0.515,I-Entity
",",O
95%,O
CI,I-Entity
0.295,O
-,O
0.899,O
",",O
P=0.020,I-Entity
),O
.,O
Our,I-Entity
data,O
suggest,O
that,O
HOMER1,I-Entity
rs4704559,I-Entity
G,I-Entity
allele,I-Entity
has,O
a,O
protective,O
role,O
for,O
the,O
development,O
of,O
levodopa,I-Entity
adverse,O
effects,O
.,O
Crocin,I-Entity
improves,O
lipid,O
dysregulation,I-Entity
in,O
subacute,O
diazinon,I-Entity
exposure,O
through,O
ERK1/2,O
pathway,O
in,O
rat,O
liver,I-Entity
.,O
Diazinon,I-Entity
Yis,I-Entity
one,O
of,O
the,O
most,O
broadly,O
used,O
organophosphorus,I-Entity
insecticides,I-Entity
in,O
agriculture,O
.,O
It,I-Entity
has,O
been,O
shown,O
that,O
exposure,O
to,O
diazinon,I-Entity
may,O
interfere,I-Entity
with,O
lipid,O
metabolism,O
.,O
Moreover,I-Entity
",",O
the,O
hypolipidemic,I-Entity
effect,O
of,O
crocin,I-Entity
has,O
been,O
established,O
.,O
The,I-Entity
aim,O
of,O
this,O
study,O
was,O
to,O
evaluate,O
changes,O
in,O
the,O
regulation,O
of,O
lipid,O
metabolism,O
",",O
ERK,I-Entity
and,O
LDLr,I-Entity
expression,O
in,O
the,O
liver,I-Entity
of,O
rats,O
exposed,O
to,O
subacute,O
diazinon,I-Entity
.,O
Furthermore,I-Entity
ameliorating,O
effect,O
of,O
crocin,I-Entity
on,O
diazinon,I-Entity
induced,O
disturbed,I-Entity
cholesterol,I-Entity
homeostasis,I-Entity
was,O
studied,O
.,O
24,O
Rats,I-Entity
were,O
divided,O
into,O
4,O
groups,O
and,O
received,O
following,O
treatments,O
for,O
4,O
weeks,O
;,O
Corn,I-Entity
oil,O
(,O
control,O
),O
",",O
diazinon,I-Entity
(,O
15mg,I-Entity
/,O
kg,O
per,O
day,O
",",O
orally,O
),O
and,O
crocin,I-Entity
(,O
12.5,O
and,O
25mg,I-Entity
/,O
kg,O
per,O
day,O
",",O
intraperitoneally,O
),O
in,O
combination,O
with,O
diazinon,I-Entity
(,O
15,O
mg,O
/,O
kg,O
),O
.,O
The,I-Entity
levels,O
of,O
cholesterol,I-Entity
",",O
triglyceride,I-Entity
and,O
LDL,I-Entity
in,O
blood,O
of,O
rats,O
were,O
analyzed,O
.,O
RESULTS,I-Entity
:,O
Our,I-Entity
data,O
showed,O
that,O
subacute,O
exposure,O
to,O
diazinon,I-Entity
significantly,O
increased,O
concentrations,O
of,O
cholesterol,I-Entity
",",O
triglyceride,I-Entity
and,O
LDL,I-Entity
.,O
Moreover,I-Entity
diazinon,I-Entity
decreased,O
ERK1/2,O
protein,O
phosphorylation,O
and,O
LDLr,I-Entity
transcript,O
.,O
Crocin,I-Entity
reduced,O
inhibition,O
of,O
ERK,I-Entity
activation,O
and,O
diazinon,I-Entity
-,O
induced,O
hyperlipemia,I-Entity
and,O
increased,O
levels,O
of,O
LDLr,I-Entity
transcript,O
.,O
Crocin,I-Entity
may,O
be,O
considered,O
as,O
a,O
novel,O
protective,O
agent,O
in,O
diazinon,I-Entity
-,O
induced,O
hyperlipemia,I-Entity
through,O
modulating,O
of,O
ERK,I-Entity
pathway,O
and,O
increase,O
of,O
LDLr,I-Entity
expression,O
.,O
GEM,I-Entity
-,O
P,I-Entity
chemotherapy,O
is,O
active,O
in,O
the,O
treatment,O
of,O
relapsed,O
Hodgkin,I-Entity
lymphoma,I-Entity
.,O
Hodgkin,I-Entity
lymphoma,I-Entity
(,O
HL,I-Entity
),O
is,O
a,O
relatively,O
chemosensitive,O
malignancy,I-Entity
.,O
Regimens,I-Entity
commonly,O
used,O
often,O
require,O
inpatient,O
administration,O
and,O
can,O
be,O
difficult,O
to,O
deliver,O
due,O
to,O
toxicity,I-Entity
.,O
Gemcitabine,I-Entity
and,O
cisplatin,I-Entity
have,O
activity,O
in,O
HL,I-Entity
",",O
non,O
-,O
overlapping,O
toxicity,I-Entity
with,O
first,O
-,O
line,O
chemotherapeutics,O
",",O
and,O
may,O
be,O
delivered,O
in,O
an,O
outpatient,I-Entity
setting,O
.,O
In,I-Entity
this,O
retrospective,O
single,O
-,O
centre,O
analysis,O
",",O
patients,O
with,O
relapsed,O
or,O
refractory,O
HL,I-Entity
treated,O
with,O
gemcitabine,I-Entity
"1,000",I-Entity
mg,O
/,O
m(2,O
),O
day,O
(,O
D)1,I-Entity
",",O
D8,I-Entity
and,O
D15,I-Entity
;,O
methylprednisolone,I-Entity
"1,000",I-Entity
mg,O
D1,I-Entity
-,O
5,O
;,O
and,O
cisplatin,I-Entity
100,O
mg,O
/,O
m(2,O
),O
D15,I-Entity
",",O
every,O
28,O
days,O
(,O
GEM,I-Entity
-,O
P,I-Entity
),O
were,O
included,O
.,O
Demographic,I-Entity
",",O
survival,O
",",O
response,O
and,O
toxicity,I-Entity
data,O
were,O
recorded,O
.,O
One,I-Entity
hundred,O
and,O
twenty,O
-,O
two,O
cycles,O
of,O
GEM,I-Entity
-,O
P,I-Entity
were,O
administered,O
in,O
total,O
(,O
median,O
3,O
cycles,O
;,O
range,O
1,O
-,O
6,O
),O
.,O
patients,O
received,O
GEM,I-Entity
-,O
P,I-Entity
as,O
second,O
-,O
line,O
treatment,O
and,O
11/41,O
(,O
27,O
%,O
),O
as,O
third,O
-,O
line,O
therapy,O
.,O
Overall,I-Entity
response,O
rate,O
(,O
ORR,I-Entity
),O
to,O
GEM,I-Entity
-,O
P,I-Entity
in,O
the,O
entire,O
cohort,O
was,O
80,O
%,O
(,O
complete,O
response,O
(,O
CR,I-Entity
),O
37,I-Entity
%,O
",",O
partial,O
response,O
44,I-Entity
%,O
),O
with,O
14/15,O
CR,I-Entity
confirmed,O
as,O
a,O
metabolic,O
CR,I-Entity
on,O
PET,I-Entity
and,O
ORR,I-Entity
of,O
85,O
%,O
in,O
the,O
20,O
second,O
-,O
line,O
patients,O
.,O
3/4,O
toxicities,I-Entity
were,O
haematological,O
:,O
neutropenia,I-Entity
54,I-Entity
%,O
and,O
thrombocytopenia,I-Entity
51,I-Entity
%,O
.,O
Median,I-Entity
follow,O
-,O
up,O
from,O
the,O
start,O
of,O
GEM,I-Entity
-,O
P,I-Entity
was,O
4.5,O
years,O
.,O
Following,I-Entity
GEM,I-Entity
-,O
P,I-Entity
",",O
5-year,O
progression,O
-,O
free,O
survival,O
was,O
46,I-Entity
%,O
(,O
95,O
%,O
confidence,O
interval,O
(,O
CI,I-Entity
),O
",",O
30,O
-,O
62,O
%,O
),O
and,O
5-year,O
overall,O
survival,O
was,O
59,I-Entity
%,O
(,O
95,O
%,O
CI,I-Entity
",",O
43,O
-,O
74,I-Entity
%,O
),O
.,O
GEM,I-Entity
-,O
P,I-Entity
is,O
a,O
salvage,O
chemotherapy,O
with,O
relatively,O
high,O
response,O
rates,O
",",O
leading,O
to,O
successful,O
transplantation,O
in,O
appropriate,O
patients,O
",",O
in,O
the,O
treatment,O
of,O
relapsed,O
or,O
refractory,O
HL,I-Entity
.,O
Basal,I-Entity
functioning,O
of,O
the,O
hypothalamic,O
-,O
pituitary,O
-,O
adrenal,O
(,O
HPA,I-Entity
),O
axis,O
and,O
psychological,O
distress,I-Entity
in,O
recreational,O
ecstasy,I-Entity
polydrug,O
users,O
.,O
RATIONALE,I-Entity
:,O
Ecstasy,I-Entity
(,O
MDMA,I-Entity
),O
is,O
a,O
psychostimulant,O
drug,O
which,O
is,O
increasingly,O
associated,O
with,O
psychobiological,O
dysfunction,I-Entity
.,O
The,I-Entity
current,O
study,O
is,O
the,O
first,O
to,O
explore,O
the,O
effects,O
of,O
ecstasy,I-Entity
-,O
polydrug,O
use,O
on,O
psychological,O
distress,I-Entity
and,O
basal,O
functioning,O
of,O
the,O
HPA,I-Entity
axis,O
through,O
assessing,O
the,O
secretion,O
of,O
cortisol,I-Entity
across,O
the,O
diurnal,O
period,O
.,O
METHOD,I-Entity
:,O
Seventy,I-Entity
-,O
six,O
participants,O
(,O
21,O
nonusers,O
",",O
29,O
light,O
ecstasy,I-Entity
-,O
polydrug,O
users,O
",",O
26,O
heavy,O
ecstasy,I-Entity
-,O
polydrug,O
users,O
),O
completed,O
a,O
substance,O
use,O
inventory,O
and,O
measures,O
of,O
psychological,O
distress,I-Entity
at,O
baseline,O
",",O
then,O
two,O
consecutive,O
days,O
of,O
cortisol,I-Entity
sampling,O
(,O
on,O
awakening,O
",",O
30,O
min,O
post,O
awakening,O
",",O
between,O
1400,O
and,O
1600,O
hours,O
and,O
pre,O
bedtime,O
),O
.,O
Both,I-Entity
user,O
groups,O
exhibited,O
significantly,O
greater,O
levels,O
of,O
anxiety,I-Entity
and,O
depression,I-Entity
than,O
nonusers,O
.,O
On,I-Entity
day,O
1,O
",",O
all,O
participants,O
exhibited,O
a,O
typical,O
cortisol,I-Entity
profile,O
",",O
though,O
light,O
users,O
had,O
significantly,O
elevated,O
levels,O
pre,O
-,O
bed,O
.,O
On,I-Entity
day,O
2,O
",",O
heavy,O
users,O
demonstrated,O
elevated,O
levels,O
upon,O
awakening,O
and,O
all,O
ecstasy,I-Entity
-,O
polydrug,O
users,O
demonstrated,O
elevated,O
pre,O
-,O
bed,O
levels,O
compared,O
to,O
non,O
-,O
users,O
.,O
Significant,I-Entity
between,O
group,O
differences,O
were,O
also,O
observed,O
in,O
afternoon,O
cortisol,I-Entity
levels,O
and,O
in,O
overall,O
cortisol,I-Entity
secretion,O
across,O
the,O
day,O
.,O
The,I-Entity
increases,O
in,O
anxiety,I-Entity
and,O
depression,I-Entity
are,O
in,O
line,O
with,O
previous,O
observations,O
in,O
recreational,O
ecstasy,I-Entity
-,O
polydrug,O
users,O
.,O
Dysregulated,I-Entity
diurnal,O
cortisol,I-Entity
may,O
be,O
indicative,O
of,O
inappropriate,O
anticipation,O
of,O
forthcoming,O
demands,O
and,O
hypersecretion,I-Entity
may,O
lead,O
to,O
the,O
increased,O
psychological,O
and,O
physical,O
morbidity,O
associated,O
with,O
heavy,O
recreational,O
use,O
of,O
ecstasy,I-Entity
.,O
Ifosfamide,I-Entity
related,O
encephalopathy,I-Entity
:,O
the,O
need,O
for,O
a,O
timely,O
EEG,I-Entity
evaluation,O
.,O
Ifosfamide,I-Entity
is,O
an,O
alkylating,B-Entity
agent,O
useful,O
in,O
the,O
treatment,O
of,O
a,O
wide,O
range,O
of,O
cancers,I-Entity
including,O
sarcomas,I-Entity
",",O
lymphoma,I-Entity
",",O
gynecologic,O
and,O
testicular,O
cancers,I-Entity
.,O
Encephalopathy,I-Entity
has,O
been,O
reported,O
in,O
10,O
-,O
40%,O
of,O
patients,O
receiving,O
high,O
-,O
dose,O
IV,I-Entity
ifosfamide,I-Entity
.,O
OBJECTIVE,I-Entity
:,O
To,I-Entity
highlight,O
the,O
role,O
of,O
electroencephalogram,O
(,O
EEG,I-Entity
),O
in,O
the,O
early,O
detection,O
and,O
management,O
of,O
ifosfamide,I-Entity
related,O
encephalopathy,I-Entity
.,O
Retrospective,I-Entity
chart,O
review,O
including,O
clinical,O
data,O
and,O
EEG,I-Entity
recordings,O
was,O
done,O
on,O
five,O
patients,O
",",O
admitted,O
to,O
MD,I-Entity
Anderson,I-Entity
Cancer,I-Entity
Center,I-Entity
between,O
years,O
2009,O
and,O
2012,O
",",O
who,O
developed,O
ifosfamide,I-Entity
related,O
acute,O
encephalopathy,I-Entity
.,O
All,I-Entity
five,O
patients,O
experienced,O
symptoms,O
of,O
encephalopathy,I-Entity
soon,O
after,O
(,O
within,O
12,O
h-2,O
days,O
),O
receiving,O
ifosfamide,I-Entity
.,O
Two,I-Entity
patients,O
developed,O
generalized,O
convulsions,I-Entity
while,O
one,O
patient,O
developed,O
continuous,O
non,O
-,O
convulsive,I-Entity
status,O
epilepticus,I-Entity
(,O
NCSE,I-Entity
),O
that,O
required,O
ICU,I-Entity
admission,O
and,O
intubation,O
.,O
CONCLUSIONS,I-Entity
:,O
Severity,I-Entity
of,O
ifosfamide,I-Entity
related,O
encephalopathy,I-Entity
correlates,O
with,O
EEG,I-Entity
changes,O
.,O
We,I-Entity
suggest,O
a,O
timely,O
EEG,I-Entity
evaluation,O
for,O
patients,O
receiving,O
ifosfamide,I-Entity
who,O
develop,O
features,O
of,O
encephalopathy,I-Entity
.,O
Incidence,I-Entity
of,O
contrast,O
-,O
induced,O
nephropathy,I-Entity
in,O
hospitalised,O
patients,O
with,O
cancer,I-Entity
.,O
OBJECTIVES,I-Entity
:,O
To,I-Entity
determine,O
the,O
frequency,O
of,O
and,O
possible,O
factors,O
related,O
to,O
contrast,O
-,O
induced,O
nephropathy,I-Entity
(,O
CIN,I-Entity
),O
in,O
hospitalised,O
patients,O
with,O
cancer,I-Entity
.,O
Patients,I-Entity
with,O
risk,O
factors,O
for,O
acute,O
renal,O
failure,I-Entity
were,O
excluded,O
.,O
Blood,I-Entity
samples,O
were,O
examined,O
the,O
day,O
before,O
contrast,O
-,O
enhanced,O
computed,O
tomography,O
(,O
CT,I-Entity
),O
and,O
serially,O
for,O
3,O
days,O
thereafter,O
.,O
CIN,I-Entity
was,O
defined,O
as,O
an,O
increase,O
in,O
serum,O
creatinine,I-Entity
(,O
Cr,I-Entity
),O
of,O
0.5,O
mg,O
/,O
dl,O
or,O
more,O
",",O
or,O
elevation,O
of,O
Cr,I-Entity
to,O
25,O
%,O
over,O
baseline,O
.,O
CIN,I-Entity
was,O
significantly,O
more,O
after,O
treatment,O
with,O
bevacizumab,I-Entity
/,O
irinotecan,I-Entity
(,O
P,I-Entity
=,O
0.021,O
),O
and,O
in,O
patients,O
with,O
hypertension,I-Entity
(,O
P,I-Entity
=,O
0.044,O
),O
.,O
CIN,I-Entity
developed,O
4.5-times,O
more,O
frequently,O
in,O
patients,O
with,O
cancer,I-Entity
who,O
had,O
undergone,O
recent,O
chemotherapy,O
.,O
Hypertension,I-Entity
and,O
the,O
combination,O
of,O
bevacizumab,I-Entity
/,O
irinotecan,I-Entity
may,O
be,O
additional,O
risk,O
factors,O
for,O
CIN,I-Entity
development,O
.,O
Contrast,I-Entity
-,O
induced,O
nephropathy,I-Entity
(,O
CIN,I-Entity
),O
is,O
a,O
concern,O
for,O
oncological,O
patients,O
undergoing,O
CT,I-Entity
.,O
.,O
Hypertension,I-Entity
and,O
treatment,O
with,O
bevacizumab,I-Entity
appear,O
to,O
be,O
additional,O
risk,O
factors,O
.,O
Syndrome,I-Entity
of,O
inappropriate,O
antidiuretic,I-Entity
hormone,I-Entity
secretion,O
associated,O
with,O
desvenlafaxine,I-Entity
.,O
OBJECTIVE,I-Entity
:,O
To,I-Entity
report,O
a,O
case,O
of,O
syndrome,I-Entity
of,O
inappropriate,O
anti,O
-,O
diuretic,I-Entity
hormone,I-Entity
(,O
SIADH,I-Entity
),O
secretion,O
associated,O
with,O
desvenlafaxine,I-Entity
.,O
A,I-Entity
57-year,O
old,O
female,O
with,O
hyponatraemia,I-Entity
.,O
Her,I-Entity
medications,O
included,O
desvenlafaxine,I-Entity
",",O
and,O
symptoms,O
included,O
nausea,I-Entity
",",O
anxiety,I-Entity
and,O
confusion,I-Entity
.,O
The,I-Entity
serum,O
sodium,I-Entity
at,O
this,O
time,O
was,O
120,I-Entity
mmol,O
/,O
L,I-Entity
",",O
serum,O
osmolality,O
was,O
263,O
mosmol,I-Entity
/,O
kg,O
",",O
urine,I-Entity
osmolality,O
410,O
mosmol,I-Entity
/,O
kg,O
and,O
urine,I-Entity
sodium,I-Entity
63,O
mmol,O
/,O
L,I-Entity
",",O
consistent,O
with,O
a,O
diagnosis,O
of,O
SIADH,I-Entity
.,O
Desvenlafaxine,I-Entity
was,O
ceased,O
and,O
fluid,O
restriction,O
implemented,O
.,O
After,I-Entity
4,O
days,O
the,O
sodium,I-Entity
increased,O
to,O
128,O
mmol,O
/,O
L,I-Entity
and,O
fluid,O
restriction,O
was,O
relaxed,O
.,O
During,I-Entity
her,O
further,O
3,O
weeks,O
inpatient,O
admission,O
the,O
serum,O
sodium,I-Entity
ranged,O
from,O
134,I-Entity
to,O
137,O
mmol,O
/,O
L,I-Entity
during,O
treatment,O
with,O
mirtazapine,I-Entity
.,O
SIADH,I-Entity
has,O
been,O
widely,O
reported,O
with,O
a,O
range,O
of,O
antidepressants,I-Entity
.,O
This,I-Entity
case,O
report,O
suggests,O
that,O
desvenlafaxine,I-Entity
might,O
cause,O
clinically,O
significant,O
hyponatremia,I-Entity
.,O
Clinicians,I-Entity
should,O
be,O
aware,O
of,O
the,O
potential,O
for,O
antidepressants,I-Entity
to,O
cause,O
hyponatremia,I-Entity
",",O
and,O
take,O
appropriate,O
corrective,O
action,O
where,O
necessary,O
.,O
Oxidative,I-Entity
stress,I-Entity
on,O
cardiotoxicity,I-Entity
after,O
treatment,O
with,O
single,O
and,O
multiple,O
doses,O
of,O
doxorubicin,I-Entity
.,O
The,I-Entity
mechanism,O
of,O
doxorubicin,I-Entity
(,O
DOX)-induced,I-Entity
cardiotoxicity,I-Entity
remains,O
controversial,O
.,O
Wistar,I-Entity
rats,O
(,O
n,O
=,O
66,I-Entity
),O
received,O
DOX,I-Entity
injections,O
intraperitoneally,O
and,O
were,O
randomly,O
assigned,O
to,O
2,O
experimental,O
protocols,O
:,O
(,O
1,O
),O
rats,O
were,O
killed,O
before,O
(,O
-24,O
h,O
",",O
n,O
=,O
8),O
and,O
24,O
h,O
after,O
(,O
+,O
24,O
h,O
",",O
n,O
=,O
8),O
a,O
single,O
dose,O
of,O
DOX,I-Entity
(,O
4,O
mg,O
/,O
kg,O
body,O
weight,O
),O
to,O
determine,O
the,O
DOX,I-Entity
acute,O
effect,O
and,O
(,O
2,O
),O
rats,O
(,O
n,O
=,O
58,O
),O
received,O
4,O
injections,O
of,O
DOX,I-Entity
(,O
4,O
mg,O
/,O
kg,O
body,O
weight,O
/,O
week,O
),O
and,O
were,O
killed,O
before,O
the,O
first,O
injection,O
(,O
M0,I-Entity
),O
and,O
1,O
week,O
after,O
each,O
injection,O
(,O
M1,I-Entity
",",O
M2,I-Entity
",",O
M3,I-Entity
",",O
and,O
M4,I-Entity
),O
to,O
determine,O
the,O
chronological,O
effects,O
.,O
Single,I-Entity
dose,O
of,O
DOX,I-Entity
was,O
associated,O
with,O
increased,O
cardiac,O
disarrangement,O
",",O
necrosis,I-Entity
",",O
and,O
DNA,I-Entity
damage,O
(,O
strand,O
breaks,I-Entity
(,O
SBs,I-Entity
),O
and,O
oxidized,O
pyrimidines,I-Entity
),O
and,O
decreased,O
TAP,I-Entity
.,O
The,I-Entity
chronological,O
study,O
showed,O
an,O
effect,O
of,O
a,O
cumulative,O
dose,O
on,O
body,O
weight,O
(,O
R,I-Entity
=,O
-0.99,O
",",O
p,O
=,O
0.011,O
),O
",",O
necrosis,I-Entity
(,O
R,I-Entity
=,O
1.00,O
",",O
p,O
=,O
0.004,O
),O
",",O
TAP,I-Entity
(,O
DNA,I-Entity
SBs,I-Entity
damage,O
was,O
negatively,O
associated,O
with,O
TAP,I-Entity
(,O
R,I-Entity
=,O
-0.98,O
",",O
p,O
=,O
0.018,O
),O
",",O
and,O
necrosis,I-Entity
Our,I-Entity
results,O
suggest,O
that,O
oxidative,O
damage,O
is,O
associated,O
with,O
acute,O
cardiotoxicity,I-Entity
induced,O
by,O
a,O
single,O
dose,O
of,O
DOX,I-Entity
only,O
.,O
Increased,I-Entity
resistance,O
to,O
the,O
oxidative,O
stress,I-Entity
is,O
plausible,O
for,O
the,O
multiple,O
dose,O
of,O
DOX,I-Entity
.,O
Thus,I-Entity
",",O
different,O
mechanisms,O
may,O
be,O
involved,O
in,O
acute,O
toxicity,I-Entity
versus,O
chronic,O
toxicity,I-Entity
.,O
Tacrolimus,I-Entity
-,O
related,O
seizure,I-Entity
after,O
pediatric,O
liver,I-Entity
transplantation,O
--,O
a,O
single,O
-,O
center,O
experience,O
.,O
To,I-Entity
identify,O
the,O
risk,O
factors,O
for,O
new,O
-,O
onset,O
seizures,I-Entity
after,O
pediatric,O
LT,I-Entity
and,O
to,O
assess,O
their,O
clinical,O
implications,O
and,O
long,O
-,O
term,O
prognosis,O
.,O
Patients,I-Entity
were,O
divided,O
into,O
seizures,I-Entity
group,O
and,O
a,O
non,O
-,O
seizures,I-Entity
group,O
.,O
Seizures,I-Entity
occurred,O
in,O
four,O
children,O
",",O
an,O
incidence,O
of,O
14.8%,O
.,O
All,I-Entity
exhibited,O
generalized,O
tonic,I-Entity
-,O
clonic,I-Entity
seizures,I-Entity
within,O
the,O
first,O
two,O
wk,O
after,O
LT,I-Entity
.,O
Univariate,I-Entity
analysis,O
showed,O
that,O
the,O
risk,O
factors,O
associated,O
with,O
seizures,I-Entity
after,O
pediatric,O
LT,I-Entity
included,O
gender,O
",",O
pediatric,O
end,O
-,O
stage,O
liver,I-Entity
disease,I-Entity
score,O
before,O
surgery,O
",",O
Child,I-Entity
-,O
Pugh,I-Entity
score,O
before,O
surgery,O
",",O
serum,O
total,O
bilirubin,I-Entity
after,O
surgery,O
",",O
and,O
trough,O
TAC,I-Entity
level,O
.,O
Multivariate,I-Entity
analysis,O
showed,O
that,O
trough,O
TAC,I-Entity
level,O
was,O
the,O
only,O
independent,O
risk,O
factor,O
associated,O
with,O
the,O
seizures,I-Entity
.,O
All,I-Entity
children,O
who,O
experienced,O
seizures,I-Entity
survived,O
with,O
good,O
graft,O
function,O
and,O
remained,O
seizure,I-Entity
-,O
free,O
without,O
anti,O
-,O
epileptic,I-Entity
drugs,O
over,O
a,O
mean,O
follow,O
-,O
up,O
period,O
of,O
33.7,O
+,O
14.6,O
months,O
.,O
High,I-Entity
trough,O
TAC,I-Entity
level,O
was,O
the,O
predominant,O
factor,O
that,O
contributed,O
to,O
seizures,I-Entity
in,O
the,O
early,O
post,O
-,O
operative,O
period,O
after,O
pediatric,O
LT,I-Entity
.,O
High,I-Entity
PELD,I-Entity
and,O
Child,I-Entity
-,O
Pugh,I-Entity
scores,O
before,O
LT,I-Entity
and,O
high,O
post,O
-,O
operative,O
serum,O
Tbil,I-Entity
may,O
be,O
contributory,O
risk,O
factors,O
for,O
TAC,I-Entity
-,O
related,O
seizures,I-Entity
.,O
The,I-Entity
flavonoid,O
apigenin,I-Entity
delays,O
forgetting,O
of,O
passive,O
avoidance,I-Entity
conditioning,O
in,O
rats,O
.,O
The,I-Entity
present,O
experiments,O
were,O
performed,O
to,O
study,O
the,O
effect,O
of,O
the,O
flavonoid,O
apigenin,I-Entity
(,O
20,O
mg,O
/,O
kg,O
intraperitoneally,O
(,O
i.p,O
.,O
),O
",",O
1,O
h,O
before,O
acquisition,O
),O
",",O
on,O
24,O
h,O
retention,O
performance,O
and,O
forgetting,O
of,O
a,O
step,O
-,O
through,O
passive,O
avoidance,I-Entity
task,O
",",O
in,O
young,O
male,O
Wistar,I-Entity
rats,O
.,O
There,I-Entity
were,O
no,O
differences,O
between,O
saline-,O
and,O
apigenin,I-Entity
-,O
treated,O
groups,O
in,O
the,O
24,O
h,O
retention,O
trial,O
.,O
Furthermore,I-Entity
",",O
apigenin,I-Entity
did,O
not,O
prevent,O
the,O
amnesia,I-Entity
induced,O
by,O
scopolamine,I-Entity
(,O
1mg,I-Entity
/,O
kg,O
",",O
i.p,O
.,O
The,I-Entity
saline-,O
and,O
apigenin,I-Entity
-,O
treated,O
rats,O
that,O
did,O
not,O
step,O
through,O
into,O
the,O
dark,O
compartment,O
during,O
the,O
cut,O
-,O
off,O
time,O
(,O
540,O
s,O
),O
were,O
retested,O
weekly,O
for,O
up,O
to,O
eight,O
weeks,O
.,O
In,I-Entity
the,O
saline,O
treated,O
group,O
",",O
the,O
first,O
significant,O
decline,O
in,O
passive,O
avoidance,I-Entity
response,O
was,O
observed,O
at,O
four,O
weeks,O
",",O
and,O
complete,O
memory,O
loss,I-Entity
was,O
found,O
five,O
weeks,O
after,O
the,O
acquisition,O
of,O
the,O
passive,O
avoidance,I-Entity
task,O
.,O
At,I-Entity
the,O
end,O
of,O
the,O
experimental,O
period,O
",",O
60%,O
of,O
the,O
animals,O
treated,O
with,O
apigenin,I-Entity
still,O
did,O
not,O
step,O
through,O
.,O
These,I-Entity
data,O
suggest,O
that,O
1,O
),O
apigenin,I-Entity
delays,O
the,O
long,O
-,O
term,O
forgetting,O
but,O
did,O
not,O
modulate,O
the,O
24,O
h,O
retention,O
of,O
fear,I-Entity
memory,O
and,O
2,O
),O
the,O
obtained,O
beneficial,O
effect,O
of,O
apigenin,I-Entity
on,O
the,O
passive,O
avoidance,I-Entity
conditioning,O
is,O
mediated,O
by,O
mechanisms,O
that,O
do,O
not,O
implicate,O
its,O
action,O
on,O
the,O
muscarinic,O
cholinergic,O
system,O
.,O
Cholecystokinin,I-Entity
-,O
octapeptide,I-Entity
restored,O
morphine,I-Entity
-,O
induced,O
hippocampal,O
long,O
-,O
term,O
potentiation,O
impairment,I-Entity
in,O
rats,O
.,O
Cholecystokinin,I-Entity
-,O
octapeptide,I-Entity
(,O
CCK-8,I-Entity
),O
",",O
which,O
is,O
a,O
typical,O
brain,O
-,O
gut,O
peptide,I-Entity
",",O
exerts,I-Entity
a,O
wide,O
range,O
of,O
biological,O
activities,O
on,O
the,O
central,O
nervous,I-Entity
system,O
.,O
We,I-Entity
have,O
previously,O
reported,O
that,O
CCK-8,I-Entity
significantly,O
alleviated,O
morphine,I-Entity
-,O
induced,O
amnesia,I-Entity
and,O
reversed,O
spine,O
density,O
decreases,O
in,O
the,O
CA1,I-Entity
region,O
of,O
the,O
hippocampus,O
in,O
morphine,I-Entity
-,O
treated,O
animals,O
.,O
Here,I-Entity
",",O
we,O
investigated,O
the,O
effects,O
of,O
CCK-8,I-Entity
on,O
long,O
-,O
term,O
potentiation,O
(,O
LTP,I-Entity
),O
in,O
the,O
lateral,O
perforant,O
path,O
(,O
LPP)-granule,I-Entity
cell,O
synapse,O
of,O
rat,O
dentate,O
gyrus,I-Entity
(,O
DG,I-Entity
),O
in,O
acute,O
saline,O
or,O
morphine,I-Entity
-,O
treated,O
rats,O
.,O
Acute,I-Entity
morphine,I-Entity
treatment,O
significantly,O
attenuated,O
hippocampal,O
LTP,I-Entity
and,O
CCK-8,I-Entity
(,O
1ug,O
",",O
i.c.v,O
.,O
),O
restored,O
the,O
amplitude,O
of,O
PS,I-Entity
that,O
was,O
attenuated,O
by,O
morphine,I-Entity
injection,O
.,O
Furthermore,I-Entity
",",O
microinjection,O
of,O
CCK-8,I-Entity
(,O
0.1,O
and,O
1ug,O
",",O
i.c.v,O
.,O
),O
also,O
significantly,O
augmented,O
hippocampal,O
LTP,I-Entity
in,O
saline,O
-,O
treated,O
(,O
1ml,I-Entity
/,O
kg,O
",",O
s.c,O
.,O
),O
rats,O
.,O
Pre,I-Entity
-,O
treatment,O
of,O
the,O
CCK2,I-Entity
receptor,O
antagonist,O
"L-365,260",I-Entity
(,O
10ug,O
",",O
i.c.v,O
),O
reversed,O
the,O
effects,O
of,O
CCK-8,I-Entity
",",O
but,O
the,O
CCK1,I-Entity
receptor,O
antagonist,O
"L-364,718",I-Entity
(,O
10ug,O
",",O
The,I-Entity
present,O
results,O
demonstrate,O
that,O
CCK-8,I-Entity
attenuates,O
the,O
effect,O
of,O
morphine,I-Entity
on,O
hippocampal,O
LTP,I-Entity
through,O
CCK2,I-Entity
receptors,O
and,O
suggest,O
an,O
ameliorative,O
function,O
of,O
CCK-8,I-Entity
on,O
morphine,I-Entity
-,O
induced,O
memory,O
impairment,I-Entity
.,O
Glial,I-Entity
activation,O
and,O
post,O
-,O
synaptic,O
neurotoxicity,I-Entity
:,O
the,O
key,O
events,O
in,O
Streptozotocin,I-Entity
(,O
ICV,I-Entity
),O
induced,O
memory,O
impairment,I-Entity
in,O
rats,O
.,O
In,I-Entity
the,O
present,O
study,O
the,O
role,O
of,O
glial,O
activation,O
and,O
post,O
synaptic,O
toxicity,I-Entity
in,O
ICV,I-Entity
Streptozotocin,I-Entity
(,O
STZ,I-Entity
),O
induced,O
memory,O
impaired,I-Entity
rats,O
was,O
explored,O
.,O
In,I-Entity
experiment,O
set,O
up,O
1,O
:,O
Memory,I-Entity
deficit,I-Entity
was,O
found,O
in,O
Morris,I-Entity
water,O
maze,O
test,O
on,O
14,O
-,O
16,O
days,O
after,O
STZ,I-Entity
(,O
ICV,I-Entity
;,O
3mg,I-Entity
/,O
Kg,I-Entity
),O
administration,O
.,O
STZ,I-Entity
causes,O
increased,O
expression,O
of,O
GFAP,I-Entity
",",O
CD11b,I-Entity
and,O
TNF,I-Entity
-,O
a,O
indicating,O
glial,O
activation,O
and,O
neuroinflammation,I-Entity
.,O
STZ,I-Entity
also,O
significantly,O
increased,O
the,O
level,O
of,O
ROS,I-Entity
",",O
nitrite,I-Entity
",",O
Ca(2,I-Entity
+,O
),O
and,O
reduced,O
the,O
mitochondrial,O
activity,O
in,O
synaptosomal,O
preparation,O
illustrating,O
free,O
radical,O
generation,O
and,O
excitotoxicity,I-Entity
.,O
Increased,I-Entity
expression,O
and,O
activity,O
of,O
Caspase-3,O
was,O
also,O
observed,O
in,O
STZ,I-Entity
treated,O
rat,O
which,O
specify,O
apoptotic,O
cell,O
death,I-Entity
in,O
hippocampus,O
and,O
cortex,O
.,O
STZ,I-Entity
treatment,O
showed,O
decrease,O
expression,O
of,O
post,O
synaptic,O
markers,O
CaMKIIa,I-Entity
and,O
PSD-95,I-Entity
",",O
while,O
",",O
expression,O
of,O
pre,O
synaptic,O
markers,O
(,O
synaptophysin,I-Entity
and,O
SNAP-25,I-Entity
),O
remains,O
unaltered,O
indicating,O
selective,O
post,O
synaptic,O
neurotoxicity,I-Entity
.,O
Oral,I-Entity
treatment,O
with,O
Memantine,I-Entity
(,O
10mg,I-Entity
/,O
kg,O
),O
and,O
Ibuprofen,I-Entity
(,O
50,O
mg,O
/,O
kg,O
),O
daily,O
for,O
13,O
days,O
attenuated,O
STZ,I-Entity
induced,O
glial,O
activation,O
",",O
apoptotic,O
cell,O
death,I-Entity
and,O
post,O
synaptic,O
neurotoxicity,I-Entity
in,O
rat,O
brain,O
.,O
Further,I-Entity
",",O
in,O
experiment,O
set,O
up,O
2,O
:,O
where,O
memory,O
function,O
was,O
not,O
affected,O
i.e.,O
7,O
-,O
9,O
days,O
after,O
STZ,I-Entity
treatment,O
.,O
The,I-Entity
level,O
of,O
GFAP,I-Entity
",",O
CD11b,I-Entity
",",O
TNF,I-Entity
-,O
a,O
",",O
ROS,I-Entity
and,O
nitrite,I-Entity
levels,O
were,O
increased,O
.,O
On,I-Entity
the,O
other,O
hand,O
",",O
apoptotic,O
marker,O
",",O
synaptic,O
markers,O
",",O
mitochondrial,O
activity,O
and,O
Ca(2,I-Entity
+,O
),O
levels,O
remained,O
unaffected,O
.,O
Collective,I-Entity
data,O
indicates,O
that,O
neuroinflammatory,O
process,O
and,O
oxidative,O
stress,I-Entity
occurs,O
earlier,O
to,O
apoptosis,O
and,O
does,O
not,O
affect,O
memory,O
function,O
.,O
Present,I-Entity
study,O
clearly,O
suggests,O
that,O
glial,O
activation,O
and,O
post,O
synaptic,O
neurotoxicity,I-Entity
are,O
the,O
key,O
factors,O
in,O
STZ,I-Entity
induced,O
memory,O
impairment,I-Entity
and,O
neuronal,O
cell,O
death,I-Entity
.,O
Comparison,I-Entity
of,O
effects,O
of,O
isotonic,I-Entity
sodium,I-Entity
chloride,I-Entity
with,O
diltiazem,I-Entity
in,O
prevention,O
of,O
contrast,O
-,O
induced,O
nephropathy,I-Entity
.,O
INTRODUCTION,I-Entity
AND,I-Entity
OBJECTIVE,I-Entity
:,O
Contrast,I-Entity
-,O
induced,O
nephropathy,I-Entity
(,O
CIN,I-Entity
),O
significantly,O
increases,O
the,O
morbidity,O
and,O
mortality,O
of,O
patients,O
.,O
The,I-Entity
aim,O
of,O
this,O
study,O
is,O
to,O
investigate,O
and,O
compare,O
the,O
protective,O
effects,O
of,O
isotonic,I-Entity
sodium,I-Entity
chloride,I-Entity
with,O
sodium,I-Entity
bicarbonate,I-Entity
infusion,O
and,O
isotonic,I-Entity
sodium,I-Entity
chloride,I-Entity
infusion,O
with,O
diltiazem,I-Entity
",",O
a,O
calcium,I-Entity
channel,O
blocker,O
",",O
in,O
preventing,O
CIN,I-Entity
.,O
MATERIALS,I-Entity
AND,I-Entity
METHODS,I-Entity
:,O
Our,I-Entity
study,O
included,O
patients,O
who,O
were,O
administered,O
30,O
-,O
60,O
mL,I-Entity
of,O
iodinated,O
contrast,O
agent,O
for,O
percutaneous,O
coronary,O
angiography,O
(,O
PCAG,I-Entity
),O
",",O
all,O
with,O
creatinine,I-Entity
values,O
between,O
1.1,O
and,O
3.1,O
mg,O
/,O
dL.,I-Entity
Patients,I-Entity
were,O
divided,O
into,O
three,O
groups,O
and,O
each,O
group,O
had,O
20,O
patients,O
.,O
The,I-Entity
first,O
group,O
of,O
patients,O
was,O
administered,O
isotonic,I-Entity
sodium,I-Entity
chloride,I-Entity
;,O
the,O
second,O
group,O
was,O
administered,O
a,O
solution,O
that,O
of,O
5%,O
dextrose,I-Entity
and,O
sodium,I-Entity
bicarbonate,I-Entity
",",O
while,O
the,O
third,O
group,O
was,O
administered,O
isotonic,I-Entity
sodium,I-Entity
chloride,I-Entity
before,O
and,O
after,O
the,O
contrast,O
injection,O
.,O
The,I-Entity
third,O
group,O
received,O
an,O
additional,O
injection,O
of,O
diltiazem,I-Entity
the,O
day,O
before,O
and,O
first,O
2,O
days,O
after,O
the,O
contrast,O
injection,O
.,O
All,I-Entity
of,O
the,O
patients,O
',O
plasma,O
blood,O
urea,I-Entity
nitrogen,I-Entity
(,O
BUN,I-Entity
),O
and,O
creatinine,I-Entity
levels,O
were,O
measured,O
on,O
the,O
second,O
and,O
seventh,O
day,O
after,O
the,O
administration,O
of,O
intravenous,O
contrast,O
material,O
.,O
The,I-Entity
basal,O
creatinine,I-Entity
levels,O
were,O
similar,O
for,O
all,O
three,O
groups,O
(,O
p,O
>,O
0.05,O
),O
.,O
Among,I-Entity
a,O
total,O
of,O
60,O
patients,O
included,O
in,O
the,O
study,O
",",O
16,O
patients,O
developed,O
acute,O
renal,O
failure,I-Entity
(,O
ARF,I-Entity
),O
on,O
the,O
second,O
day,O
after,O
contrast,O
material,O
was,O
injected,O
(,O
26.6%,O
),O
.,O
The,I-Entity
number,O
of,O
patients,O
who,O
developed,O
ARF,I-Entity
on,O
the,O
second,O
day,O
after,O
the,O
injection,O
in,O
the,O
first,O
group,O
was,O
five,O
(,O
25%,O
),O
",",O
in,O
the,O
second,O
group,O
was,O
six,O
(,O
30%,O
),O
and,O
the,O
third,O
group,O
was,O
five,O
(,O
25%,O
),O
(,O
p,O
>,O
0.05,O
),O
.,O
CONCLUSION,I-Entity
:,O
There,I-Entity
was,O
no,O
significant,O
difference,O
between,O
isotonic,I-Entity
sodium,I-Entity
chloride,I-Entity
",",O
sodium,I-Entity
bicarbonate,I-Entity
and,O
isotonic,I-Entity
sodium,I-Entity
chloride,I-Entity
with,O
diltiazem,I-Entity
application,O
in,O
prevention,O
of,O
CIN,I-Entity
.,O
Neurocognitive,I-Entity
and,O
neuroradiologic,O
central,O
nervous,I-Entity
system,O
late,O
effects,O
in,O
children,O
treated,O
on,O
Pediatric,I-Entity
Oncology,I-Entity
Group,I-Entity
(,O
POG,I-Entity
),O
P9605,I-Entity
(,O
standard,O
risk,O
),O
and,O
P9201,I-Entity
(,O
lesser,O
risk,O
),O
acute,O
lymphoblastic,B-Entity
leukemia,I-Entity
protocols,O
(,O
ACCL0131,I-Entity
),O
:,O
a,O
methotrexate,I-Entity
consequence,O
?,O
Concerns,I-Entity
about,O
long,O
-,O
term,O
methotrexate,I-Entity
(,O
MTX,I-Entity
),O
neurotoxicity,I-Entity
in,O
the,O
1990s,O
led,O
to,O
modifications,O
in,O
intrathecal,O
(,O
IT,I-Entity
),O
therapy,O
",",O
leucovorin,I-Entity
rescue,O
",",O
and,O
frequency,O
of,O
systemic,O
MTX,I-Entity
administration,O
in,O
children,O
with,O
acute,O
lymphoblastic,B-Entity
leukemia,I-Entity
.,O
In,I-Entity
this,O
study,O
",",O
neurocognitive,O
outcomes,O
and,O
neuroradiologic,O
evidence,O
of,O
leukoencephalopathy,I-Entity
were,O
compared,O
in,O
children,O
treated,O
with,O
intense,O
central,O
nervous,I-Entity
system,O
(,O
CNS)-directed,I-Entity
therapy,O
(,O
P9605,I-Entity
),O
versus,O
those,O
receiving,O
fewer,O
CNS,I-Entity
-,O
directed,O
treatment,O
days,O
during,O
intensive,O
consolidation,O
(,O
P9201,I-Entity
),O
.,O
A,I-Entity
total,O
of,O
66,I-Entity
children,O
from,O
16,O
Pediatric,I-Entity
Oncology,I-Entity
Group,I-Entity
institutions,O
with,O
"""""""""",O
standard,O
-,O
risk,O
"""""""""",O
acute,O
lymphoblastic,B-Entity
leukemia,I-Entity
",",O
1.00,O
to,O
9.99,O
years,O
at,O
diagnosis,O
",",O
without,O
evidence,O
of,O
CNS,I-Entity
leukemia,I-Entity
at,O
diagnosis,O
were,O
enrolled,O
on,O
ACCL0131,I-Entity
:,O
28,O
from,O
P9201,I-Entity
and,O
38,O
from,O
P9605,I-Entity
.,O
Significantly,I-Entity
more,O
P9605,I-Entity
patients,O
developed,O
leukoencephalopathy,I-Entity
compared,O
with,O
P9201,I-Entity
patients,O
(,O
68%,O
",",O
95%,O
confidence,O
interval,O
49%-83%,O
vs.,O
22%,O
",",O
95%,O
confidence,O
interval,O
5%-44%,O
;,O
P=0.001,I-Entity
),O
identified,O
as,O
late,O
as,O
7.7,O
years,O
after,O
the,O
end,O
of,O
treatment,O
.,O
Children,I-Entity
on,O
both,O
studies,O
had,O
significant,O
attention,O
problems,O
",",O
but,O
P9605,I-Entity
children,O
scored,O
below,O
average,O
on,O
more,O
neurocognitive,O
measures,O
than,O
those,O
treated,O
on,O
P9201,I-Entity
(,O
82%,O
",",O
14/17,O
measures,O
vs.,O
24%,O
",",O
4/17,O
measures,O
),O
.,O
This,I-Entity
supports,O
ongoing,O
concerns,O
about,O
intensive,O
MTX,I-Entity
exposure,O
as,O
a,O
major,O
contributor,O
to,O
CNS,I-Entity
late,O
effects,O
.,O
Tranexamic,I-Entity
acid,O
overdosage,I-Entity
-,O
induced,O
generalized,O
seizure,I-Entity
in,O
renal,O
failure,I-Entity
.,O
We,I-Entity
report,O
a,O
45-year,O
-,O
old,O
lady,I-Entity
with,O
chronic,O
kidney,O
disease,I-Entity
stage,O
4,O
due,O
to,O
chronic,O
tubulointerstial,O
disease,I-Entity
.,O
She,I-Entity
was,O
admitted,O
to,O
our,O
center,O
for,O
severe,O
anemia,I-Entity
due,O
to,O
menorrhagia,I-Entity
and,O
deterioration,O
of,O
renal,O
function,O
.,O
Tranexamic,I-Entity
acid,O
(,O
TNA,I-Entity
),O
1,O
g,O
8-hourly,O
was,O
administered,O
to,O
her,O
to,O
control,O
bleeding,I-Entity
per,O
vaginum,I-Entity
.,O
Two,I-Entity
hours,O
after,O
the,O
sixth,O
dose,O
of,O
TNA,I-Entity
",",O
she,O
had,O
an,O
episode,O
of,O
generalized,O
tonic,I-Entity
clonic,I-Entity
convulsions,I-Entity
.,O
TNA,I-Entity
was,O
discontinued,O
.,O
Investigations,I-Entity
of,O
the,O
patient,O
revealed,O
no,O
biochemical,O
or,O
structural,O
central,O
nervous,I-Entity
system,O
abnormalities,I-Entity
that,O
could,O
have,O
provoked,O
the,O
convulsions,I-Entity
.,O
She,I-Entity
had,O
no,O
further,O
episodes,O
of,O
convulsion,I-Entity
till,O
dis,I-Entity
-,O
charge,O
and,O
during,O
the,O
two,O
months,O
of,O
follow,O
-,O
up,O
.,O
Thus,I-Entity
",",O
the,O
precipitating,O
cause,O
of,O
convulsions,I-Entity
was,O
believed,O
to,O
be,O
an,O
overdose,I-Entity
of,O
TNA,I-Entity
.,O
Pre,I-Entity
-,O
treatment,O
of,O
bupivacaine,I-Entity
-,O
induced,O
cardiovascular,O
depression,I-Entity
using,O
different,O
lipid,O
formulations,O
of,O
propofol,I-Entity
.,O
Pre,I-Entity
-,O
treatment,O
with,O
lipid,O
emulsions,O
has,O
been,O
shown,O
to,O
increase,O
lethal,O
doses,O
of,O
bupivacaine,I-Entity
",",O
and,O
the,O
lipid,O
content,O
of,O
propofol,I-Entity
may,O
alleviate,O
bupivacaine,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
The,I-Entity
aim,O
of,O
this,O
study,O
is,O
to,O
investigate,O
the,O
effects,O
of,O
propofol,I-Entity
in,O
intralipid,O
or,O
medialipid,O
emulsions,O
on,O
bupivacaine,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
Rats,I-Entity
were,O
anaesthetised,O
with,O
ketamine,I-Entity
and,O
were,O
given,O
0.5,O
mg,O
/,O
kg,O
/,O
min,O
propofol,I-Entity
in,O
intralipid,O
(,O
Group,I-Entity
P,I-Entity
),O
",",O
propofol,I-Entity
in,O
medialipid,O
(,O
Group,I-Entity
L,I-Entity
),O
",",O
or,O
saline,O
(,O
Group,I-Entity
C,I-Entity
),O
over,O
20,O
min,O
.,O
bupivacaine,I-Entity
0.5%,O
was,O
infused,O
.,O
We,I-Entity
recorded,O
time,O
to,O
first,O
dysrhythmia,I-Entity
occurrence,O
",",O
respective,O
times,O
to,O
25%,O
and,O
50%,O
reduction,O
of,O
the,O
heart,O
rate,O
(,O
HR,I-Entity
),O
and,O
mean,O
arterial,O
pressure,O
",",O
and,O
time,O
to,O
asystole,I-Entity
and,O
total,O
amount,O
of,O
bupivacaine,I-Entity
consumption,O
.,O
Blood,I-Entity
and,O
tissue,O
samples,O
were,O
collected,O
following,O
asystole,I-Entity
.,O
The,I-Entity
time,O
to,O
first,O
dysrhythmia,I-Entity
occurrence,O
",",O
time,O
to,O
25%,O
and,O
50%,O
reductions,O
in,O
HR,I-Entity
",",O
and,O
time,O
to,O
asystole,I-Entity
were,O
longer,O
in,O
Group,I-Entity
P,I-Entity
than,O
the,O
other,O
groups,O
.,O
The,I-Entity
cumulative,O
bupivacaine,I-Entity
dose,O
given,O
at,O
those,O
time,O
points,O
was,O
higher,O
in,O
Group,I-Entity
P.,I-Entity
Plasma,I-Entity
bupivacaine,I-Entity
levels,O
were,O
significantly,O
lower,O
in,O
Group,I-Entity
P,I-Entity
than,O
in,O
Group,I-Entity
C.,I-Entity
Bupivacaine,I-Entity
levels,O
in,O
the,O
brain,O
and,O
heart,O
were,O
significantly,O
lower,O
in,O
Group,I-Entity
P,I-Entity
and,O
Group,I-Entity
L,I-Entity
than,O
in,O
Group,I-Entity
C.,I-Entity
CONCLUSION,I-Entity
:,O
We,I-Entity
conclude,O
that,O
pre,O
-,O
treatment,O
with,O
propofol,I-Entity
in,O
intralipid,O
",",O
compared,O
with,O
propofol,I-Entity
in,O
medialipid,O
or,O
saline,O
",",O
delayed,O
the,O
onset,O
of,O
bupivacaine,I-Entity
-,O
induced,O
cardiotoxic,I-Entity
effects,O
as,O
well,O
as,O
reduced,O
plasma,O
bupivacaine,I-Entity
levels,O
.,O
Further,I-Entity
studies,O
are,O
needed,O
to,O
explore,O
tissue,O
bupivacaine,I-Entity
levels,O
of,O
propofol,I-Entity
in,O
medialipid,O
and,O
adapt,O
these,O
results,O
to,O
clinical,O
practice,O
.,O
Drug,I-Entity
-,O
Induced,I-Entity
Acute,I-Entity
Liver,I-Entity
Injury,I-Entity
Within,I-Entity
12,O
Hours,I-Entity
After,I-Entity
Fluvastatin,I-Entity
Therapy,I-Entity
.,O
Although,I-Entity
statins,I-Entity
are,O
generally,O
well,O
-,O
tolerated,O
drugs,O
",",O
recent,O
cases,O
of,O
drug,O
-,O
induced,O
liver,I-Entity
injury,I-Entity
associated,O
with,O
their,O
use,O
have,O
been,O
reported,O
.,O
A,I-Entity
52-year,O
-,O
old,O
Chinese,I-Entity
man,O
reported,O
with,O
liver,I-Entity
damage,O
",",O
which,O
appeared,O
12,O
hours,O
after,O
beginning,O
treatment,O
with,O
fluvastatin,I-Entity
.,O
Patient,I-Entity
presented,O
with,O
complaints,O
of,O
increasing,O
nausea,I-Entity
",",O
anorexia,I-Entity
",",O
and,O
upper,O
abdominal,O
pain,I-Entity
.,O
His,I-Entity
laboratory,O
values,O
showed,O
elevated,O
creatine,I-Entity
kinase,O
and,O
transaminases,O
.,O
The,I-Entity
liver,I-Entity
biochemistries,O
eventually,O
normalized,O
within,O
3,O
weeks,O
of,O
stopping,O
the,O
fluvastatin,I-Entity
.,O
Therefore,I-Entity
",",O
when,O
prescribing,O
statins,I-Entity
",",O
the,O
possibility,O
of,O
hepatic,B-Entity
damage,O
should,O
be,O
taken,O
into,O
account,O
.,O
Fluconazole,I-Entity
associated,O
agranulocytosis,I-Entity
and,O
thrombocytopenia,I-Entity
.,O
CASE,I-Entity
:,O
We,I-Entity
describe,O
a,O
second,O
case,O
of,O
fluconazole,I-Entity
associated,O
agranulocytosis,I-Entity
with,O
thrombocytopenia,I-Entity
and,O
recovery,O
upon,O
discontinuation,O
of,O
therapy,O
.,O
The,I-Entity
patient,O
began,O
to,O
have,O
changes,O
in,O
white,O
blood,O
cells,O
and,O
platelets,O
within,O
48,I-Entity
h,O
of,O
administration,O
of,O
fluconazole,I-Entity
and,O
began,O
to,O
recover,O
with,O
48,I-Entity
h,O
of,O
discontinuation,O
.,O
This,I-Entity
case,O
highlights,O
that,O
drug,O
-,O
induced,O
blood,O
dyscrasias,I-Entity
can,O
occur,O
unexpectedly,O
as,O
a,O
result,O
of,O
treatment,O
with,O
a,O
commonly,O
used,O
drug,O
thought,O
to,O
be,O
"""""""""",O
safe,O
"""""""""",O
.,O
According,I-Entity
to,O
Naranjo,I-Entity
's,I-Entity
algorithm,O
the,O
likelihood,O
that,O
our,O
patient,O
's,I-Entity
agranulocytosis,I-Entity
and,O
thrombocytopenia,I-Entity
occurred,O
as,O
a,O
result,O
of,O
therapy,O
with,O
fluconazole,I-Entity
is,O
probable,O
",",O
with,O
a,O
total,O
of,O
six,O
points,O
.,O
In,I-Entity
particular,O
the,O
temporal,O
relationship,O
of,O
bone,O
marrow,O
suppression,O
to,O
the,O
initiation,O
of,O
fluconazole,I-Entity
and,O
the,O
abatement,O
of,O
symptoms,O
that,O
rapidly,O
reversed,O
immediately,O
following,O
discontinuation,O
.,O
Two,I-Entity
-,O
dimensional,O
speckle,I-Entity
tracking,O
echocardiography,O
combined,O
with,O
high,O
-,O
sensitive,I-Entity
cardiac,O
troponin,I-Entity
T,I-Entity
in,O
early,O
detection,O
and,O
prediction,O
of,O
cardiotoxicity,I-Entity
during,O
epirubicine,I-Entity
-,O
based,O
chemotherapy,O
.,O
To,I-Entity
investigate,O
whether,O
alterations,I-Entity
of,O
myocardial,B-Entity
strain,O
and,O
high,O
-,O
sensitive,I-Entity
cardiac,O
troponin,I-Entity
T,I-Entity
(,O
cTnT,I-Entity
),O
could,O
predict,O
future,O
cardiac,O
dysfunction,I-Entity
in,O
patients,O
after,O
epirubicin,I-Entity
exposure,O
.,O
METHODS,I-Entity
:,O
Seventy,I-Entity
-,O
five,O
patients,O
with,O
non,O
-,O
Hodgkin,I-Entity
lymphoma,I-Entity
treated,O
with,O
epirubicin,I-Entity
were,O
studied,O
.,O
Cardiotoxicity,I-Entity
was,O
defined,O
as,O
a,O
reduction,O
of,O
the,O
LVEF,I-Entity
of,O
>,O
5%,O
to,O
<,O
55%,O
with,O
symptoms,O
of,O
heart,O
failure,I-Entity
or,O
an,O
asymptomatic,O
reduction,O
of,O
the,O
LVEF,I-Entity
of,O
>,O
RESULTS,I-Entity
:,O
Fourteen,I-Entity
patients,O
(,O
18.67%,O
),O
developed,O
cardiotoxicity,I-Entity
after,O
treatment,O
.,O
AUC,I-Entity
=,O
0.757,O
;,O
P,I-Entity
=,O
0.005,O
),O
from,O
baseline,O
to,O
the,O
third,O
cycle,O
of,O
chemotherapy,O
predicted,O
later,O
cardiotoxicity,I-Entity
.,O
The,I-Entity
decrease,O
in,O
GLS,I-Entity
remained,O
the,O
only,O
independent,O
predictor,O
of,O
cardiotoxicity,I-Entity
(,O
P,I-Entity
=,O
0.000,O
),O
.,O
GLS,I-Entity
combined,O
with,O
cTnT,I-Entity
may,O
provide,O
a,O
reliable,O
and,O
non,O
-,O
invasive,O
method,O
to,O
predict,O
cardiac,O
dysfunction,I-Entity
in,O
patients,O
receiving,O
anthracycline,I-Entity
-,O
based,O
chemotherapy,O
.,O
Prevention,I-Entity
of,O
etomidate,I-Entity
-,O
induced,O
myoclonus,I-Entity
:,O
which,O
is,O
superior,O
:,O
Fentanyl,I-Entity
",",O
midazolam,I-Entity
",",O
or,O
a,O
combination,O
?,O
In,I-Entity
this,O
retrospective,O
comparative,O
study,O
",",O
we,O
aimed,O
to,O
compare,O
the,O
effectiveness,O
of,O
fentanyl,I-Entity
",",O
midazolam,I-Entity
",",O
and,O
a,O
combination,O
of,O
fentanyl,I-Entity
and,O
midazolam,I-Entity
to,O
prevent,O
etomidate,I-Entity
-,O
induced,O
myoclonus,I-Entity
.,O
Depending,I-Entity
on,O
the,O
drugs,O
that,O
would,O
be,O
given,O
before,O
the,O
induction,O
of,O
anesthesia,O
with,O
etomidate,I-Entity
",",O
the,O
patients,O
were,O
separated,O
into,O
4,O
groups,O
:,O
no,O
pretreatment,O
(,O
Group,I-Entity
NP,I-Entity
),O
",",O
fentanyl,I-Entity
1,O
ug.kg-1,O
(,O
Group,I-Entity
F,I-Entity
),O
",",O
midazolam,I-Entity
0.03,O
mg.kg-1,O
(,O
Group,I-Entity
M,I-Entity
),O
",",O
and,O
midazolam,I-Entity
0.015,O
mg.kg-1,O
+,O
fentanyl,I-Entity
Patients,I-Entity
who,O
received,O
the,O
same,O
anesthetic,O
procedure,O
were,O
selected,O
:,O
2,O
minutes,O
after,O
intravenous,O
injections,O
of,O
the,O
pretreatment,O
drugs,O
",",O
anesthesia,O
is,O
induced,O
with,O
0.3,O
mg.kg-1,O
etomidate,I-Entity
injected,O
intravenously,O
over,O
a,O
period,O
of,O
20,O
-,O
30,O
seconds,O
.,O
Myoclonic,I-Entity
movements,O
are,O
evaluated,O
",",O
which,O
were,O
observed,O
and,O
graded,O
according,O
to,O
clinical,O
severity,O
during,O
the,O
2,O
minutes,O
after,O
etomidate,I-Entity
injection,O
.,O
The,I-Entity
severity,O
of,O
pain,I-Entity
due,O
to,O
etomidate,I-Entity
injection,O
",",O
mean,O
arterial,O
pressure,O
",",O
heart,O
rate,O
",",O
and,O
adverse,O
effects,O
were,O
also,O
evaluated,O
.,O
Study,I-Entity
results,O
showed,O
that,O
myoclonus,I-Entity
incidence,O
was,O
85%,O
",",O
40%,O
",",O
70%,O
",",O
and,O
25%,O
in,O
Group,I-Entity
NP,I-Entity
",",O
Group,I-Entity
F,I-Entity
",",O
Group,I-Entity
M,I-Entity
",",O
and,O
Group,I-Entity
FM,I-Entity
",",O
respectively,O
",",O
and,O
were,O
significantly,O
lower,O
in,O
Group,I-Entity
F,I-Entity
and,O
Group,I-Entity
FM,I-Entity
.,O
CONCLUSIONS,I-Entity
:,O
We,I-Entity
conclude,O
that,O
pretreatment,O
with,O
fentanyl,I-Entity
or,O
combination,O
of,O
fentanyl,I-Entity
and,O
midazolam,I-Entity
was,O
effective,O
in,O
preventing,O
etomidate,I-Entity
-,O
induced,O
myoclonus,I-Entity
.,O
Cholestatic,I-Entity
presentation,O
of,O
yellow,O
phosphorus,I-Entity
poisoning,I-Entity
.,O
Yellow,I-Entity
phosphorus,I-Entity
",",O
a,O
component,O
of,O
certain,O
pesticide,O
pastes,O
and,O
fireworks,I-Entity
",",O
is,O
well,O
known,O
to,O
cause,O
hepatotoxicity,I-Entity
.,O
Poisoning,I-Entity
with,O
yellow,O
phosphorus,I-Entity
classically,O
manifests,O
with,O
acute,O
hepatitis,I-Entity
leading,O
to,O
acute,O
liver,I-Entity
failure,I-Entity
which,O
may,O
need,O
liver,I-Entity
transplantation,O
.,O
We,I-Entity
present,O
a,O
case,O
of,O
yellow,O
phosphorus,I-Entity
poisoning,I-Entity
in,O
which,O
a,O
patient,O
presented,O
with,O
florid,I-Entity
clinical,O
features,O
of,O
cholestasis,I-Entity
highlighting,O
the,O
fact,O
that,O
cholestasis,I-Entity
can,O
rarely,O
be,O
a,O
presenting,O
feature,O
of,O
yellow,O
phosphorus,I-Entity
hepatotoxicity,I-Entity
.,O
Vasovagal,I-Entity
syncope,I-Entity
and,O
severe,O
bradycardia,I-Entity
following,O
intranasal,O
dexmedetomidine,I-Entity
for,O
pediatric,O
procedural,O
sedation,O
.,O
We,I-Entity
report,O
syncope,I-Entity
and,O
bradycardia,I-Entity
in,O
an,O
11-year,O
-,O
old,O
girl,O
following,O
administration,O
of,O
intranasal,O
dexmedetomidine,I-Entity
for,O
sedation,O
for,O
a,O
voiding,I-Entity
cystourethrogram,O
.,O
The,I-Entity
primary,O
abnormality,I-Entity
found,O
was,O
persistent,O
bradycardia,I-Entity
",",O
and,O
she,O
was,O
admitted,O
to,O
the,O
hospital,O
for,O
telemetric,O
observation,O
.,O
The,I-Entity
bradycardia,I-Entity
lasted,O
~2,O
h,O
",",O
and,O
further,O
cardiac,O
workup,O
revealed,O
no,O
underlying,O
abnormality,I-Entity
.,O
Paradoxical,I-Entity
severe,O
agitation,I-Entity
induced,O
by,O
add,O
-,O
on,O
high,O
-,O
doses,O
quetiapine,I-Entity
in,O
schizo,I-Entity
-,O
affective,O
disorder,I-Entity
.,O
We,I-Entity
report,O
the,O
case,O
of,O
a,O
35-year,O
-,O
old,O
patient,O
suffering,O
from,O
schizo,I-Entity
-,O
affective,O
disorder,I-Entity
since,O
the,O
age,O
of,O
19,O
years,O
",",O
treated,O
by,O
a,O
combination,O
of,O
first,O
-,O
generation,O
antipsychotics,O
",",O
zuclopenthixol,I-Entity
(,O
100,O
mg,O
/,O
day,O
),O
and,O
lithium,I-Entity
(,O
1200,O
mg,O
/,O
day,O
),O
(,O
serum,O
lithium=0.85,I-Entity
mEq,I-Entity
/,O
l,O
),O
.,O
This,I-Entity
patient,O
had,O
no,O
associated,O
personality,O
disorder,I-Entity
(,O
particularly,O
no,O
antisocial,I-Entity
disorder,I-Entity
),O
and,O
no,O
substance,O
abuse,I-Entity
disorder,I-Entity
.,O
Within,I-Entity
the,O
48,I-Entity
h,O
following,O
the,O
gradual,O
introduction,O
of,O
quetiapine,I-Entity
(,O
up,O
to,O
600,O
mg,O
/,O
day,O
),O
",",O
the,O
patient,O
presented,O
severe,O
agitation,I-Entity
without,O
an,O
environmental,O
explanation,O
",",O
contrasting,O
with,O
the,O
absence,O
of,O
a,O
history,O
of,O
aggressiveness,I-Entity
or,O
personality,O
disorder,I-Entity
.,O
The,I-Entity
diagnoses,O
of,O
manic,I-Entity
shift,O
and,O
akathisia,I-Entity
were,O
dismissed,O
.,O
The,I-Entity
withdrawal,O
and,O
the,O
gradual,O
reintroduction,O
of,O
quetiapine,I-Entity
2,O
weeks,O
later,O
",",O
which,O
led,O
to,O
another,O
severe,O
agitation,I-Entity
",",O
enabled,O
us,O
to,O
attribute,O
the,O
agitation,I-Entity
specifically,O
to,O
quetiapine,I-Entity
.,O
Antioxidant,I-Entity
effects,O
of,O
bovine,I-Entity
lactoferrin,I-Entity
on,O
dexamethasone,I-Entity
-,O
induced,O
hypertension,I-Entity
in,O
rat,O
.,O
Dexamethasone-,I-Entity
(,O
Dex-,I-Entity
),O
induced,O
hypertension,I-Entity
is,O
associated,O
with,O
enhanced,O
oxidative,O
stress,I-Entity
.,O
Lactoferrin,I-Entity
(,O
LF,I-Entity
),O
is,O
an,O
iron,I-Entity
-,O
binding,O
glycoprotein,O
with,O
antihypertensive,O
properties,O
.,O
In,I-Entity
this,O
study,O
",",O
we,O
investigated,O
the,O
effect,O
of,O
chronic,O
administration,O
of,O
LF,I-Entity
on,O
oxidative,O
stress,I-Entity
and,O
hypertension,I-Entity
upon,O
Dex,I-Entity
administration,O
.,O
Male,I-Entity
Wistar,I-Entity
rats,O
were,O
treated,O
by,O
Dex,I-Entity
(,O
30,O
u,O
In,I-Entity
a,O
prevention,O
study,O
",",O
rats,O
received,O
4,O
days,O
of,O
LF,I-Entity
treatment,O
followed,O
by,O
Dex,I-Entity
and,O
continued,O
during,O
the,O
test,O
period,O
.,O
Plasma,I-Entity
hydrogen,I-Entity
peroxide,I-Entity
(,O
H2O2,I-Entity
),O
concentration,O
and,O
ferric,I-Entity
reducing,O
antioxidant,O
power,O
(,O
FRAP,I-Entity
),O
value,O
were,O
determined,O
.,O
Dexamethasone,I-Entity
significantly,O
increased,O
SBP,I-Entity
and,O
plasma,O
H2O2,I-Entity
level,O
and,O
decreased,O
thymus,I-Entity
and,O
body,O
weights,O
.,O
LF,I-Entity
lowered,O
(,O
P,I-Entity
<,O
0.01,O
),O
and,O
dose,O
dependently,O
prevented,O
(,O
P,I-Entity
<,O
0.001,O
),O
Dex,I-Entity
-,O
induced,O
hypertension,I-Entity
.,O
LF,I-Entity
prevented,O
body,O
weight,O
loss,I-Entity
and,O
significantly,O
reduced,O
the,O
elevated,O
plasma,O
H2O2,I-Entity
and,O
increased,O
FRAP,I-Entity
values,O
.,O
Chronic,I-Entity
administration,O
of,O
LF,I-Entity
strongly,O
reduced,O
the,O
blood,O
pressure,O
and,O
production,O
of,O
ROS,I-Entity
and,O
improved,O
antioxidant,O
capacity,O
in,O
Dex,I-Entity
-,O
induced,O
hypertension,I-Entity
",",O
suggesting,O
the,O
role,O
of,O
inhibition,O
of,O
oxidative,O
stress,I-Entity
as,O
another,O
mechanism,O
of,O
antihypertensive,O
action,O
of,O
LF,I-Entity
.,O
The,I-Entity
association,O
between,O
tranexamic,I-Entity
acid,O
and,O
convulsive,I-Entity
seizures,I-Entity
after,O
cardiac,O
surgery,O
:,O
a,O
multivariate,O
analysis,O
in,O
11,O
529,O
patients,O
.,O
Because,I-Entity
of,O
a,O
lack,O
of,O
contemporary,O
data,O
regarding,O
seizures,I-Entity
after,O
cardiac,O
surgery,O
",",O
we,O
undertook,O
a,O
retrospective,O
analysis,O
of,O
prospectively,O
collected,O
data,O
from,O
11,O
529,O
patients,O
in,O
whom,O
cardiopulmonary,O
bypass,O
was,O
used,O
from,O
January,I-Entity
2004,O
to,O
December,I-Entity
2010,O
.,O
A,I-Entity
convulsive,I-Entity
seizure,I-Entity
was,O
defined,O
as,O
a,O
transient,O
episode,O
of,O
disturbed,I-Entity
brain,O
function,O
characterised,O
by,O
abnormal,I-Entity
involuntary,O
motor,O
movements,O
.,O
Multivariate,I-Entity
regression,O
analysis,O
was,O
performed,O
to,O
identify,O
independent,O
predictors,O
of,O
postoperative,O
seizures,I-Entity
.,O
A,I-Entity
total,O
of,O
100,O
(,O
0.9%,O
),O
patients,O
developed,O
postoperative,O
convulsive,I-Entity
seizures,I-Entity
.,O
Generalised,I-Entity
and,O
focal,O
seizures,I-Entity
were,O
identified,O
in,O
68,O
and,O
32,O
patients,O
",",O
respectively,O
.,O
),O
time,O
after,O
surgery,O
when,O
the,O
seizure,I-Entity
occurred,O
was,O
7,O
(,O
6,O
-,O
12,O
[,O
1,O
-,O
216,I-Entity
],O
),O
Independent,I-Entity
predictors,O
of,O
postoperative,O
seizures,I-Entity
included,O
age,O
",",O
female,O
sex,O
",",O
redo,O
cardiac,O
surgery,O
",",O
calcification,I-Entity
of,O
ascending,O
aorta,O
",",O
congestive,B-Entity
heart,O
failure,I-Entity
",",O
deep,O
hypothermic,I-Entity
circulatory,O
arrest,I-Entity
",",O
duration,O
of,O
aortic,O
cross,O
-,O
clamp,O
and,O
tranexamic,I-Entity
acid,O
.,O
When,I-Entity
tested,O
in,O
a,O
multivariate,O
regression,O
analysis,O
",",O
tranexamic,I-Entity
acid,O
was,O
a,O
strong,O
independent,O
predictor,O
of,O
seizures,I-Entity
(,O
OR,I-Entity
14.3,O
",",O
95%,O
Patients,I-Entity
with,O
convulsive,I-Entity
seizures,I-Entity
had,O
2.5,O
times,O
higher,O
in,O
-,O
hospital,O
mortality,O
rates,O
and,O
twice,O
the,O
length,O
of,O
hospital,O
stay,O
compared,O
with,O
patients,O
without,O
convulsive,I-Entity
seizures,I-Entity
.,O
h,O
in,O
patients,O
with,O
convulsive,I-Entity
seizures,I-Entity
compared,O
with,O
26,O
(,O
22,O
-,O
69,I-Entity
[,O
14,O
-,O
1080,O
],O
),O
h,O
in,O
patients,O
without,O
seizures,I-Entity
(,O
p,O
<,O
0.001,O
),O
.,O
Convulsive,I-Entity
seizures,I-Entity
are,O
a,O
serious,O
postoperative,O
complication,O
after,O
cardiac,O
surgery,O
.,O
As,I-Entity
tranexamic,I-Entity
acid,O
is,O
the,O
only,O
modifiable,O
factor,O
",",O
its,O
administration,O
",",O
particularly,O
in,O
doses,O
exceeding,O
80,O
mg.kg(-1,O
),O
",",O
should,O
be,O
weighed,O
against,O
the,O
risk,O
of,O
postoperative,O
seizures,I-Entity
.,O
Dysfunctional,I-Entity
overnight,O
memory,O
consolidation,O
in,O
ecstasy,I-Entity
users,O
.,O
Previous,I-Entity
studies,O
indicate,O
that,O
ecstasy,I-Entity
users,O
have,O
marked,O
and,O
persistent,O
neurocognitive,O
and,O
sleep,O
-,O
related,O
impairments,I-Entity
.,O
We,I-Entity
extend,O
past,O
research,O
by,O
examining,O
overnight,O
memory,O
consolidation,O
among,O
regular,O
ecstasy,I-Entity
users,O
(,O
n=12,O
),O
and,O
drug,O
naive,O
healthy,O
controls,O
(,O
n=26,O
),O
.,O
Ecstasy,I-Entity
users,O
demonstrated,O
impaired,I-Entity
overnight,O
memory,O
consolidation,O
",",O
a,O
finding,O
that,O
was,O
more,O
pronounced,O
following,O
associative,O
interference,I-Entity
.,O
Additionally,I-Entity
",",O
ecstasy,I-Entity
users,O
demonstrated,O
impairments,I-Entity
on,O
tasks,O
recruiting,O
frontostriatal,O
and,O
hippocampal,O
neural,O
circuitry,O
",",O
in,O
the,O
domains,O
of,O
proactive,O
interference,I-Entity
memory,O
",",O
long,O
-,O
term,O
memory,O
",",O
encoding,O
",",O
working,O
memory,O
and,O
complex,O
planning,O
.,O
We,I-Entity
suggest,O
that,O
ecstasy,I-Entity
-,O
associated,O
dysfunction,I-Entity
in,O
fronto,O
-,O
temporal,O
circuitry,O
may,O
underlie,O
overnight,O
consolidation,O
memory,O
impairments,I-Entity
in,O
regular,O
ecstasy,I-Entity
users,O
.,O
Normoammonemic,I-Entity
encephalopathy,I-Entity
:,O
solely,O
valproate,I-Entity
induced,O
or,O
multiple,O
mechanisms,O
?,O
A,I-Entity
77-year,O
-,O
old,O
woman,O
presented,O
with,O
subacute,O
onset,O
progressive,O
confusion,I-Entity
",",O
aggression,I-Entity
",",O
auditory,O
hallucinations,I-Entity
and,O
delusions,I-Entity
.,O
In,I-Entity
the,O
preceding,O
months,O
",",O
the,O
patient,O
had,O
a,O
number,O
of,O
admissions,O
with,O
transient,O
unilateral,O
hemiparesis,I-Entity
with,O
facial,O
droop,O
",",O
and,O
had,O
been,O
started,O
on,O
valproate,I-Entity
for,O
presumed,O
hemiplegic,I-Entity
migraine,I-Entity
.,O
Valproate,I-Entity
was,O
withdrawn,O
soon,O
after,O
admission,O
and,O
her,O
cognitive,O
abilities,O
have,O
gradually,O
improved,O
over,O
3,O
months,O
of,O
follow,O
-,O
up,O
.,O
Valproate,I-Entity
levels,O
taken,O
prior,O
to,O
withdrawal,O
were,O
subtherapeutic,O
and,O
the,O
patient,O
was,O
normoammonaemic,O
.,O
EEG,I-Entity
undertaken,O
during,O
inpatient,O
stay,O
showed,O
changes,O
consistent,O
with,O
encephalopathy,I-Entity
",",O
and,O
low,O
titre,O
N,I-Entity
-,O
methyl,I-Entity
-,O
D,I-Entity
-,O
aspartate,I-Entity
(,O
NMDA,I-Entity
),O
receptor,O
antibodies,O
were,O
present,O
in,O
this,O
patient,O
.,O
The,I-Entity
possible,O
aetiologies,O
of,O
valproate,I-Entity
-,O
induced,O
encephalopathy,I-Entity
and,O
NMDA,I-Entity
receptor,O
-,O
associated,O
encephalitis,I-Entity
present,O
a,O
diagnostic,O
dilemma,O
.,O
Cerebellar,I-Entity
and,O
oculomotor,O
dysfunction,I-Entity
induced,O
by,O
rapid,O
infusion,O
of,O
pethidine,I-Entity
.,O
Pethidine,I-Entity
is,O
an,O
opioid,O
that,O
gains,O
its,O
popularity,O
for,O
the,O
effective,O
pain,I-Entity
control,O
through,O
acting,O
on,O
the,O
opioid,O
-,O
receptors,O
.,O
However,I-Entity
",",O
rapid,O
pain,I-Entity
relief,O
sometimes,O
brings,O
about,O
unfavourable,O
side,O
effects,O
that,O
largely,O
limit,O
its,O
clinical,O
utility,O
.,O
Common,I-Entity
side,O
effects,O
include,O
nausea,I-Entity
",",O
vomiting,I-Entity
and,O
hypotension,I-Entity
.,O
In,I-Entity
patients,O
with,O
impaired,I-Entity
renal,O
and,O
liver,I-Entity
function,O
",",O
and,O
those,O
who,O
need,O
long,O
-,O
term,O
pain,I-Entity
control,O
",",O
pethidine,I-Entity
may,O
cause,O
excitatory,O
central,O
nervous,I-Entity
system,O
(,O
CNS,I-Entity
),O
effects,O
through,O
its,O
neurotoxic,I-Entity
metabolite,O
",",O
norpethidine,I-Entity
",",O
resulting,O
in,O
irritability,I-Entity
and,O
seizure,I-Entity
attack,O
.,O
On,I-Entity
the,O
contrary,O
",",O
though,O
not,O
clinically,O
apparent,O
",",O
pethidine,I-Entity
potentially,O
causes,O
inhibitory,O
impacts,O
on,O
the,O
CNS,I-Entity
and,O
impairs,I-Entity
normal,O
cerebellar,O
and,O
oculomotor,O
function,O
in,O
the,O
short,I-Entity
term,O
.,O
In,I-Entity
this,O
case,O
report,O
",",O
we,O
highlight,O
opioid,O
's,I-Entity
inhibitory,O
side,O
effects,O
on,O
the,O
cerebellar,O
structure,O
that,O
causes,O
dysmetria,I-Entity
",",O
dysarthria,I-Entity
",",O
reduced,O
smooth,O
pursuit,O
gain,O
and,O
decreased,O
saccadic,O
velocity,O
.,O
Baboon,I-Entity
syndrome,I-Entity
induced,O
by,O
ketoconazole,I-Entity
.,O
A,I-Entity
27-year,O
-,O
old,O
male,O
patient,O
presented,O
with,O
a,O
maculopapular,O
eruption,O
on,O
the,O
flexural,O
areas,O
and,O
buttocks,O
after,O
using,O
oral,O
ketoconazole,I-Entity
.,O
The,I-Entity
patient,O
was,O
diagnosed,O
with,O
drug,O
-,O
induced,O
baboon,I-Entity
syndrome,I-Entity
based,O
on,O
his,O
history,O
",",O
which,O
included,O
prior,O
sensitivity,O
to,O
topical,O
ketoconazole,I-Entity
",",O
a,O
physical,O
examination,O
",",O
and,O
histopathological,O
findings,O
.,O
Baboon,I-Entity
syndrome,I-Entity
is,O
a,O
drug-,I-Entity
or,O
contact,O
allergen,O
-,O
related,O
maculopapular,O
eruption,O
that,O
typically,O
involves,O
the,O
flexural,O
and,O
gluteal,I-Entity
areas,O
.,O
To,I-Entity
the,O
best,O
of,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
reported,O
case,O
of,O
ketoconazole,I-Entity
-,O
induced,O
baboon,I-Entity
syndrome,I-Entity
in,O
the,O
English,I-Entity
literature,O
.,O
A,I-Entity
Case,I-Entity
of,O
Sudden,I-Entity
Cardiac,I-Entity
Death,I-Entity
due,O
to,O
Pilsicainide,I-Entity
-,O
Induced,I-Entity
Torsades,I-Entity
de,O
Pointes,I-Entity
.,O
An,I-Entity
84-year,O
-,O
old,O
male,O
received,O
oral,O
pilsicainide,I-Entity
",",O
a,O
pure,O
sodium,I-Entity
channel,O
blocker,O
with,O
slow,O
recovery,O
kinetics,O
",",O
to,O
convert,O
his,O
paroxysmal,O
atrial,I-Entity
fibrillation,I-Entity
to,O
a,O
sinus,O
rhythm,O
;,O
the,O
patient,O
developed,O
sudden,I-Entity
cardiac,O
death,I-Entity
two,O
days,O
later,O
.,O
The,I-Entity
Holter,I-Entity
electrocardiogram,O
",",O
which,O
was,O
worn,O
by,O
chance,O
",",O
revealed,O
torsade,I-Entity
de,O
pointes,I-Entity
with,O
gradually,O
prolonged,O
QT,I-Entity
intervals,O
.,O
Although,I-Entity
the,O
patient,O
's,I-Entity
renal,O
function,O
was,O
not,O
highly,O
impaired,I-Entity
and,O
the,O
dose,O
of,O
pilsicainide,I-Entity
was,O
low,O
",",O
the,O
plasma,O
concentration,O
of,O
pilsicainide,I-Entity
may,O
have,O
been,O
high,O
",",O
which,O
can,O
produce,O
torsades,I-Entity
de,O
pointes,I-Entity
in,O
the,O
octogenarian,O
.,O
Although,I-Entity
the,O
oral,O
administration,O
of,O
class,O
IC,I-Entity
drugs,O
",",O
including,O
pilsicainide,I-Entity
",",O
is,O
effective,O
to,O
terminate,O
atrial,I-Entity
fibrillation,I-Entity
",",O
careful,O
consideration,O
must,O
be,O
taken,O
before,O
giving,O
these,O
drugs,O
to,O
octogenarians,O
.,O
All,I-Entity
-,O
trans,O
retinoic,I-Entity
acid,O
-,O
induced,O
inflammatory,O
myositis,I-Entity
in,O
a,O
patient,O
with,O
acute,O
promyelocytic,O
leukemia,I-Entity
.,O
All,I-Entity
-,O
trans,O
retinoic,I-Entity
acid,O
(,O
ATRA,I-Entity
),O
",",O
a,O
component,O
of,O
standard,O
therapy,O
for,O
acute,O
promyelocytic,O
leukemia,I-Entity
(,O
APL,I-Entity
),O
",",O
is,O
associated,O
with,O
potentially,O
serious,O
but,O
treatable,O
adverse,O
effects,O
involving,O
numerous,O
organ,O
systems,O
",",O
including,O
rare,O
skeletal,O
muscle,O
involvement,O
.,O
Only,I-Entity
a,O
handful,O
of,O
cases,O
of,O
ATRA,I-Entity
-,O
induced,O
myositis,I-Entity
in,O
children,O
have,O
been,O
reported,O
",",O
and,O
none,O
in,O
the,O
radiology,O
literature,O
.,O
We,I-Entity
present,O
such,O
a,O
case,O
in,O
a,O
15-year,O
-,O
old,O
boy,O
with,O
APL,I-Entity
",",O
where,O
recognition,O
of,O
imaging,O
findings,O
played,O
a,O
crucial,O
role,O
in,O
making,O
the,O
diagnosis,O
and,O
facilitated,O
prompt,O
",",O
effective,O
treatment,O
.,O
Tolerability,I-Entity
of,O
lomustine,I-Entity
in,O
combination,O
with,O
cyclophosphamide,I-Entity
in,O
dogs,O
with,O
lymphoma,I-Entity
.,O
This,I-Entity
retrospective,O
study,O
describes,O
toxicity,I-Entity
associated,O
with,O
a,O
protocol,O
of,O
lomustine,I-Entity
(,O
CCNU,I-Entity
),O
and,O
cyclophosphamide,I-Entity
(,O
CTX,I-Entity
),O
in,O
dogs,O
with,O
lymphoma,I-Entity
.,O
CCNU,I-Entity
was,O
administered,O
per,O
os,O
(,O
PO,I-Entity
),O
at,O
a,O
targeted,O
dosage,O
of,O
60,O
mg,O
/,O
m(2,O
),O
body,O
surface,O
area,O
on,O
day,O
0,O
",",O
CTX,I-Entity
was,O
administered,O
PO,I-Entity
at,O
a,O
targeted,O
dosage,O
of,O
250,O
mg,O
/,O
m(2,O
),O
divided,O
over,O
days,O
0,O
through,O
4,O
",",O
and,O
all,O
dogs,O
received,O
prophylactic,O
antibiotics,O
.,O
Neutropenia,I-Entity
was,O
the,O
principal,O
toxic,I-Entity
effect,O
",",O
and,O
the,O
overall,O
frequency,O
of,O
grade,O
4,O
neutropenia,I-Entity
after,O
the,O
first,O
treatment,O
of,O
CCNU,I-Entity
/,O
CTX,I-Entity
was,O
30%,O
(,O
95%,O
confidence,O
interval,O
",",O
19,O
-,O
43%,O
),O
.,O
The,I-Entity
mean,O
body,O
weight,O
of,O
dogs,O
with,O
grade,O
4,O
neutropenia,I-Entity
(,O
19.7,O
kg,O
+,O
13.4,O
kg,O
),O
was,O
significantly,O
less,O
than,O
the,O
mean,O
body,O
weight,O
of,O
dogs,O
that,O
did,O
not,O
develop,O
grade,O
4,O
neutropenia,I-Entity
(,O
31.7,O
kg,O
+,O
12.4,O
kg,O
;,O
P,I-Entity
=,O
.005,I-Entity
),O
.,O
One,I-Entity
dog,O
(,O
3%,O
),O
developed,O
hematologic,O
changes,O
suggestive,O
of,O
hepatotoxicity,I-Entity
.,O
No,I-Entity
dogs,O
had,O
evidence,O
of,O
either,O
renal,O
toxicity,I-Entity
or,O
hemorrhagic,I-Entity
cystitis,I-Entity
.,O
On,I-Entity
the,O
basis,O
of,O
the,O
findings,O
reported,O
herein,O
",",O
a,O
dose,O
of,O
60,O
mg,O
/,O
m(2,O
),O
of,O
CCNU,I-Entity
combined,O
with,O
250,O
mg,O
/,O
m(2,O
),O
of,O
CTX,I-Entity
(,O
divided,O
over,O
5,O
days,O
),O
4,O
wk,O
is,O
tolerable,O
in,O
tumor,I-Entity
-,O
bearing,O
dogs,O
.,O
Nelarabine,I-Entity
neurotoxicity,I-Entity
with,O
concurrent,O
intrathecal,O
chemotherapy,O
:,O
Severe,I-Entity
nelarabine,I-Entity
neurotoxicity,I-Entity
in,O
a,O
patient,O
who,O
received,O
concurrent,O
intrathecal,O
A,I-Entity
37-year,O
-,O
old,O
Caucasian,I-Entity
woman,O
with,O
a,O
history,O
of,O
T,I-Entity
-,O
cell,O
lymphoblastic,B-Entity
lymphoma,I-Entity
was,O
admitted,O
for,O
relapsed,O
disease,I-Entity
.,O
She,I-Entity
developed,O
relapsed,O
disease,I-Entity
10,O
months,O
later,O
with,O
leukemic,I-Entity
involvement,O
.,O
She,I-Entity
was,O
re,O
-,O
induced,O
with,O
nelarabine,I-Entity
1500,I-Entity
mg,O
/,O
m(2,O
),O
on,O
days,O
1,O
",",O
3,O
",",O
and,O
5,O
with,O
1,O
dose,O
of,O
IT,I-Entity
cytarabine,I-Entity
100,O
mg,O
on,O
day,O
2,O
as,O
central,O
nervous,I-Entity
system,O
(,O
CNS,I-Entity
),O
prophylaxis,O
.,O
At,I-Entity
the,O
time,O
of,O
treatment,O
",",O
she,O
was,O
on,O
continuous,O
renal,O
replacement,O
therapy,O
due,O
to,O
sequelae,O
of,O
tumor,I-Entity
lysis,O
syndrome,I-Entity
(,O
TLS,I-Entity
),O
.,O
She,I-Entity
received,O
a,O
second,O
cycle,O
of,O
nelarabine,I-Entity
without,O
additional,O
IT,I-Entity
prophylaxis,O
one,O
month,O
later,O
.,O
Predominantly,I-Entity
sensory,O
",",O
though,O
also,O
motor,O
and,O
autonomic,O
",",O
peripheral,O
neuropathy,I-Entity
started,O
in,O
her,O
feet,O
",",O
ascended,O
proximally,O
to,O
the,O
mid,O
-,O
thoracic,O
region,O
",",O
and,O
eventually,O
included,O
her,O
distal,O
upper,O
extremities,O
.,O
Nelarabine,I-Entity
was,O
felt,O
to,O
be,O
the,O
cause,O
of,O
her,O
symptoms,O
.,O
Her,I-Entity
neuropathy,I-Entity
stabilized,O
and,O
showed,O
slight,O
improvement,O
and,O
ultimately,O
received,O
an,O
unrelated,O
",",O
reduced,O
-,O
intensity,O
allogeneic,O
transplant,O
while,O
in,O
complete,O
remission,O
",",O
but,O
relapsed,O
disease,I-Entity
10,O
weeks,O
later,O
.,O
To,I-Entity
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
published,O
case,O
report,O
of,O
severe,O
neurotoxicity,I-Entity
caused,O
by,O
nelarabine,I-Entity
in,O
a,O
patient,O
who,O
received,O
concurrent,O
IT,I-Entity
chemotherapy,O
.,O
Valproate,I-Entity
-,O
induced,O
hyperammonemic,I-Entity
encephalopathy,I-Entity
in,O
a,O
renal,O
transplanted,O
patient,O
.,O
Neurological,I-Entity
complications,O
after,O
renal,O
transplantation,O
constitute,O
an,O
important,O
cause,O
of,O
morbidity,O
and,O
mortality,O
.,O
Valproate,I-Entity
-,O
induced,O
hyperammonemic,I-Entity
encephalopathy,I-Entity
is,O
an,O
uncommon,O
but,O
serious,O
effect,O
of,O
valproate,I-Entity
treatment,O
.,O
Here,I-Entity
",",O
we,O
describe,O
the,O
case,O
of,O
a,O
15-year,O
-,O
old,O
girl,O
who,O
was,O
on,O
a,O
long,O
-,O
term,O
therapy,O
with,O
valproate,I-Entity
due,O
to,O
epilepsy,I-Entity
and,O
revealed,O
impaired,I-Entity
consciousness,O
with,O
hyperammonemia,I-Entity
12,O
days,O
after,O
renal,O
transplantation,O
.,O
After,I-Entity
withdraw,O
of,O
valproate,I-Entity
",",O
patients,O
',O
symptoms,O
resolved,O
within,O
24,O
h.,O
Clinicians,I-Entity
should,O
increase,O
their,O
awareness,O
for,O
potential,O
complication,O
of,O
valproate,I-Entity
",",O
especially,O
in,O
transplanted,O
patients,O
.,O
Necrotising,I-Entity
fasciitis,I-Entity
after,O
bortezomib,I-Entity
and,O
dexamethasone,I-Entity
-,O
containing,O
regimen,I-Entity
in,O
an,O
elderly,O
patient,O
of,O
Waldenstrom,I-Entity
macroglobulinaemia,I-Entity
.,O
Bortezomib,I-Entity
and,O
high,O
-,O
dose,O
dexamethasone,I-Entity
-,O
containing,O
regimens,I-Entity
are,O
considered,O
to,O
be,O
generally,O
tolerable,O
with,O
few,O
severe,O
bacterial,O
infections,I-Entity
in,O
patients,O
with,O
B,I-Entity
-,O
cell,O
malignancies,I-Entity
.,O
We,I-Entity
report,O
a,O
case,O
of,O
a,O
76-year,O
-,O
old,O
man,O
with,O
Waldenstrom,I-Entity
macroglobulinaemia,I-Entity
who,O
suffered,O
necrotising,I-Entity
fasciitis,I-Entity
without,O
neutropenia,I-Entity
after,O
the,O
combination,O
treatment,O
with,O
bortezomib,I-Entity
",",O
high,O
-,O
dose,O
dexamethasone,I-Entity
and,O
rituximab,I-Entity
.,O
Physicians,I-Entity
should,O
recognise,O
the,O
possibility,O
of,O
fatal,O
bacterial,O
infections,I-Entity
related,O
to,O
bortezomib,I-Entity
plus,O
high,O
-,O
dose,O
dexamethasone,I-Entity
in,O
elderly,O
patients,O
",",O
and,O
we,O
believe,O
this,O
case,O
warrants,O
further,O
investigation,O
.,O
An,I-Entity
integrated,O
characterization,O
of,O
serological,O
",",O
pathological,O
",",O
and,O
functional,O
events,O
in,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
Many,I-Entity
efficacious,O
cancer,I-Entity
treatments,O
cause,O
significant,O
cardiac,O
morbidity,O
",",O
yet,O
biomarkers,O
or,O
functional,O
indices,O
of,O
early,O
damage,O
",",O
which,O
would,O
allow,O
monitoring,O
and,O
intervention,O
",",O
are,O
lacking,O
.,O
In,I-Entity
this,O
study,O
",",O
we,O
have,O
utilized,O
a,O
rat,O
model,O
of,O
progressive,O
doxorubicin,I-Entity
(,O
DOX)-induced,I-Entity
cardiomyopathy,I-Entity
",",O
applying,O
multiple,O
approaches,O
",",O
including,O
cardiac,O
magnetic,O
resonance,O
imaging,O
(,O
MRI,I-Entity
),O
",",O
to,O
provide,O
the,O
most,O
comprehensive,O
characterization,O
to,O
date,O
of,O
the,O
timecourse,O
of,O
serological,O
",",O
pathological,O
",",O
and,O
functional,O
events,O
underlying,O
this,O
toxicity,I-Entity
.,O
Hannover,I-Entity
Wistar,I-Entity
rats,O
were,O
dosed,O
with,O
1.25,O
mg,O
/,O
kg,O
DOX,I-Entity
weekly,O
for,O
8,O
weeks,O
followed,O
by,O
a,O
4,O
week,O
off,O
-,O
dosing,O
"""""""""",O
recovery,O
"""""""""",O
period,O
.,O
Electron,I-Entity
microscopy,O
of,O
the,O
myocardium,I-Entity
revealed,O
subcellular,O
degeneration,I-Entity
and,O
marked,O
mitochondrial,O
changes,O
after,O
a,O
single,O
dose,O
.,O
Histopathological,I-Entity
analysis,O
revealed,O
progressive,O
cardiomyocyte,O
degeneration,I-Entity
",",O
hypertrophy,I-Entity
/,O
cytomegaly,I-Entity
",",O
and,O
extensive,O
vacuolation,O
after,O
two,O
doses,O
.,O
Extensive,I-Entity
replacement,O
fibrosis,I-Entity
(,O
quantified,O
by,O
Sirius,I-Entity
red,O
staining,I-Entity
),O
developed,O
during,O
the,O
off,O
-,O
dosing,O
period,O
.,O
Functional,I-Entity
indices,O
assessed,O
by,O
cardiac,O
MRI,I-Entity
(,O
including,O
left,O
ventricular,O
ejection,O
fraction,O
(,O
LVEF,I-Entity
),O
",",O
cardiac,O
output,O
",",O
and,O
E,I-Entity
/,O
A,I-Entity
ratio,O
),O
declined,O
progressively,O
",",O
reaching,O
statistical,O
significance,O
after,O
two,O
doses,O
and,O
culminating,O
in,O
"""""""""",O
clinical,O
"""""""""",O
LV,I-Entity
dysfunction,I-Entity
by,O
12,O
weeks,O
.,O
Troponin,I-Entity
I,I-Entity
levels,O
positively,O
correlated,O
with,O
delayed,O
and,O
peak,O
gadolinium,I-Entity
contrast,O
enhancement,O
",",O
histopathological,O
grading,O
",",O
and,O
diastolic,I-Entity
dysfunction,I-Entity
.,O
In,I-Entity
summary,O
",",O
subcellular,O
cardiomyocyte,O
degeneration,I-Entity
was,O
the,O
earliest,O
marker,O
",",O
followed,O
by,O
progressive,O
functional,O
decline,O
and,O
histopathological,O
manifestations,O
.,O
However,I-Entity
",",O
all,O
indices,O
predated,O
"""""""""",O
clinical,O
"""""""""",O
LV,I-Entity
dysfunction,I-Entity
and,O
thus,O
warrant,O
further,O
evaluation,O
as,O
predictive,O
biomarkers,O
.,O
Intradermal,I-Entity
glutamate,I-Entity
and,O
capsaicin,I-Entity
injections,O
:,O
intra-,O
and,O
interindividual,O
variability,O
of,O
provoked,O
hyperalgesia,I-Entity
and,O
allodynia,I-Entity
.,O
Intradermal,I-Entity
injections,O
of,O
glutamate,I-Entity
and,O
capsaicin,I-Entity
are,O
attractive,O
to,O
use,O
in,O
human,O
experimental,O
pain,I-Entity
models,O
because,O
hyperalgesia,I-Entity
and,O
allodynia,I-Entity
mimic,O
isolated,O
aspects,O
of,O
clinical,O
pain,I-Entity
disorders,I-Entity
.,O
Twenty,I-Entity
healthy,O
male,O
volunteers,O
(,O
mean,O
age,O
24,O
years,O
;,O
range,O
18,O
-,O
38,O
years,O
),O
received,O
intradermal,O
injections,O
of,O
glutamate,I-Entity
and,O
capsaicin,I-Entity
in,O
the,O
volar,O
forearm,O
.,O
Magnitudes,I-Entity
of,O
secondary,O
pinprick,I-Entity
hyperalgesia,I-Entity
and,O
brush,O
-,O
evoked,O
allodynia,I-Entity
were,O
investigated,O
using,O
von,O
Frey,I-Entity
filaments,O
(,O
gauges,O
10,O
",",O
15,O
",",O
60,O
and,O
100,O
g,O
),O
and,O
brush,O
strokes,O
.,O
Areas,I-Entity
of,O
secondary,O
hyperalgesia,I-Entity
and,O
allodynia,I-Entity
were,O
quantified,O
immediately,O
after,O
injection,O
and,O
after,O
15,O
",",O
30,O
and,O
60,O
min,O
.,O
Secondary,I-Entity
pinprick,I-Entity
hyperalgesia,I-Entity
was,O
observed,O
as,O
a,O
marked,O
increase,O
in,O
the,O
visual,O
analogue,O
scale,O
(,O
VAS,I-Entity
),O
response,O
to,O
von,O
Frey,I-Entity
gauges,O
60,O
and,O
100,O
g,O
<,O
0.001,O
),O
after,O
glutamate,I-Entity
injection,O
.,O
For,I-Entity
capsaicin,I-Entity
",",O
secondary,O
pinprick,I-Entity
hyperalgesia,I-Entity
was,O
detected,O
with,O
all,O
von,O
Frey,I-Entity
gauges,O
(,O
P,I-Entity
<,O
0.001,O
),O
.,O
Glutamate,I-Entity
evoked,O
reproducible,O
VAS,I-Entity
response,O
to,O
all,O
von,O
Frey,I-Entity
gauges,O
(,O
ICC,I-Entity
>,O
0.60,O
),O
and,O
brush,O
strokes,O
(,O
ICC,I-Entity
>,O
0.83,O
),O
.,O
Capsaicin,I-Entity
injection,O
was,O
reproducible,O
for,O
secondary,O
hyperalgesia,I-Entity
(,O
ICC,I-Entity
>,O
0.70,O
),O
and,O
allodynia,I-Entity
Intra,I-Entity
-,O
individual,O
variability,O
was,O
generally,O
lower,O
for,O
the,O
VAS,I-Entity
response,O
to,O
von,O
Frey,I-Entity
and,O
brush,O
compared,O
with,O
areas,O
of,O
secondary,O
hyperalgesia,I-Entity
and,O
allodynia,I-Entity
.,O
In,I-Entity
conclusion,O
",",O
glutamate,I-Entity
and,O
capsaicin,I-Entity
yield,O
reproducible,O
hyperalgesic,I-Entity
and,O
allodynic,O
responses,O
",",O
and,O
the,O
present,O
model,O
is,O
well,O
suited,O
for,O
basic,O
research,O
",",O
as,O
well,O
as,O
for,O
assessing,O
the,O
modulation,O
of,O
central,O
phenomena,O
.,O
Ocular,I-Entity
-,O
specific,O
ER,I-Entity
stress,I-Entity
reduction,O
rescues,O
glaucoma,I-Entity
in,O
murine,O
glucocorticoid,O
-,O
induced,O
glaucoma,I-Entity
.,O
Administration,I-Entity
of,O
glucocorticoids,O
induces,O
ocular,O
hypertension,I-Entity
in,O
some,O
patients,O
.,O
If,I-Entity
untreated,O
",",O
these,O
patients,O
can,O
develop,O
a,O
secondary,O
glaucoma,I-Entity
that,O
resembles,O
primary,O
open,O
-,O
angle,O
glaucoma,I-Entity
(,O
POAG,I-Entity
),O
.,O
The,I-Entity
underlying,O
pathology,O
of,O
glucocorticoid,O
-,O
induced,O
glaucoma,I-Entity
is,O
not,O
fully,O
understood,O
",",O
due,O
in,O
part,O
to,O
lack,O
of,O
an,O
appropriate,O
animal,O
model,O
.,O
Here,I-Entity
",",O
we,O
developed,O
a,O
murine,O
model,O
of,O
glucocorticoid,O
-,O
induced,O
glaucoma,I-Entity
that,O
exhibits,O
glaucoma,I-Entity
features,O
that,O
are,O
observed,O
in,O
patients,O
.,O
Treatment,I-Entity
of,O
WT,I-Entity
mice,O
with,O
topical,O
ocular,O
0.1%,O
dexamethasone,I-Entity
led,O
to,O
elevation,O
of,O
intraocular,O
pressure,O
(,O
IOP,I-Entity
),O
",",O
functional,O
and,O
structural,O
loss,I-Entity
of,O
retinal,B-Entity
ganglion,I-Entity
cells,O
",",O
and,O
axonal,O
degeneration,I-Entity
",",O
resembling,O
glucocorticoid,O
-,O
induced,O
glaucoma,I-Entity
in,O
human,O
patients,O
.,O
Furthermore,I-Entity
",",O
dexamethasone,I-Entity
-,O
induced,O
ocular,O
hypertension,I-Entity
was,O
associated,O
with,O
chronic,O
ER,I-Entity
stress,I-Entity
of,O
the,O
trabecular,O
meshwork,O
(,O
TM,I-Entity
),O
.,O
Similar,I-Entity
to,O
patients,O
",",O
withdrawal,O
of,O
dexamethasone,I-Entity
treatment,O
reduced,O
elevated,O
IOP,I-Entity
and,O
ER,I-Entity
stress,I-Entity
in,O
this,O
animal,O
model,O
.,O
Dexamethasone,I-Entity
induced,O
the,O
transcriptional,O
factor,O
CHOP,I-Entity
",",O
a,O
marker,O
for,O
chronic,O
ER,I-Entity
stress,I-Entity
",",O
in,O
the,O
anterior,O
segment,O
tissues,O
",",O
and,O
Chop,I-Entity
deletion,I-Entity
reduced,O
ER,I-Entity
stress,I-Entity
in,O
these,O
tissues,O
and,O
prevented,O
dexamethasone,I-Entity
-,O
induced,O
ocular,O
hypertension,I-Entity
.,O
Furthermore,I-Entity
",",O
reduction,O
of,O
ER,I-Entity
stress,I-Entity
in,O
the,O
TM,I-Entity
with,O
sodium,I-Entity
4-phenylbutyrate,I-Entity
prevented,O
dexamethasone,I-Entity
-,O
induced,O
ocular,O
hypertension,I-Entity
in,O
WT,I-Entity
mice,O
.,O
Our,I-Entity
data,O
indicate,O
that,O
ER,I-Entity
stress,I-Entity
contributes,O
to,O
glucocorticoid,O
-,O
induced,O
ocular,O
hypertension,I-Entity
and,O
suggest,O
that,O
reducing,O
ER,I-Entity
stress,I-Entity
has,O
potential,O
as,O
a,O
therapeutic,O
strategy,O
for,O
treating,O
glucocorticoid,O
-,O
induced,O
glaucoma,I-Entity
.,O
Effects,I-Entity
of,O
ginsenosides,I-Entity
on,O
opioid,O
-,O
induced,O
hyperalgesia,I-Entity
in,O
mice,O
.,O
Opioid,I-Entity
-,O
induced,O
hyperalgesia,I-Entity
(,O
OIH,I-Entity
),O
is,O
characterized,O
by,O
nociceptive,B-Entity
sensitization,I-Entity
caused,O
by,O
the,O
cessation,O
of,O
chronic,O
opioid,O
use,O
.,O
OIH,I-Entity
can,O
limit,O
the,O
clinical,O
use,O
of,O
opioid,O
analgesics,O
and,O
complicate,O
withdrawal,O
from,O
opioid,O
addiction,I-Entity
.,O
In,I-Entity
this,O
study,O
",",O
we,O
investigated,O
the,O
effects,O
of,O
Re,I-Entity
",",O
Rg1,I-Entity
",",O
and,O
Rb1,I-Entity
ginsenosides,I-Entity
",",O
the,O
bioactive,O
components,O
of,O
ginseng,O
",",O
on,O
OIH,I-Entity
.,O
OIH,I-Entity
was,O
achieved,O
in,O
mice,O
after,O
subcutaneous,O
administration,O
of,O
morphine,I-Entity
for,O
7,O
consecutive,O
days,O
three,O
times,O
per,O
day,O
.,O
During,I-Entity
withdrawal,O
(,O
days,O
8,O
and,O
9,O
),O
",",O
these,O
mice,O
were,O
administered,O
Re,I-Entity
",",O
Rg1,I-Entity
",",O
or,O
Rb1,I-Entity
intragastrically,O
two,O
times,O
per,O
day,O
.,O
On,I-Entity
the,O
test,O
day,O
(,O
day,O
10,O
),O
",",O
mice,O
were,O
subjected,O
to,O
the,O
thermal,O
sensitivity,O
test,O
and,O
the,O
acetic,I-Entity
acid,O
-,O
induced,O
writhing,I-Entity
test,O
.,O
Re,I-Entity
(,O
300,O
mg,O
/,O
kg,O
),O
inhibited,O
OIH,I-Entity
in,O
both,O
the,O
thermal,O
sensitivity,O
test,O
and,O
the,O
acetic,I-Entity
acid,O
-,O
induced,O
writhing,I-Entity
test,O
.,O
However,I-Entity
",",O
the,O
Rg1,I-Entity
and,O
Rb1,I-Entity
ginsenosides,I-Entity
failed,O
to,O
prevent,O
OIH,I-Entity
in,O
either,O
test,O
.,O
Furthermore,I-Entity
",",O
Rg1,I-Entity
showed,O
a,O
tendency,O
to,O
aggravate,O
OIH,I-Entity
in,O
the,O
acetic,I-Entity
acid,O
-,O
induced,O
writhing,I-Entity
test,O
.,O
Our,I-Entity
data,O
suggested,O
that,O
the,O
ginsenoside,I-Entity
Re,I-Entity
",",O
but,O
not,O
Rg1,I-Entity
or,O
Rb1,I-Entity
",",O
may,O
contribute,O
toward,O
reversal,O
of,O
OIH,I-Entity
.,O
A,I-Entity
comparison,O
of,O
severe,O
hemodynamic,O
disturbances,I-Entity
between,O
dexmedetomidine,I-Entity
and,O
propofol,I-Entity
for,O
sedation,O
in,O
neurocritical,O
care,O
patients,O
.,O
Dexmedetomidine,I-Entity
and,O
propofol,I-Entity
are,O
commonly,O
used,O
sedatives,O
in,O
neurocritical,O
care,O
as,O
they,O
allow,O
for,O
frequent,O
neurologic,O
examinations,O
.,O
The,I-Entity
primary,O
objective,O
of,O
this,O
study,O
is,O
to,O
compare,O
the,O
prevalence,O
of,O
severe,O
hemodynamic,O
effects,O
in,O
neurocritical,O
care,O
patients,O
receiving,O
dexmedetomidine,I-Entity
and,O
propofol,I-Entity
.,O
INTERVENTIONS,I-Entity
:,O
Continuous,I-Entity
sedation,O
with,O
dexmedetomidine,I-Entity
or,O
propofol,I-Entity
.,O
A,I-Entity
total,O
of,O
342,O
patients,O
(,O
105,I-Entity
dexmedetomidine,I-Entity
and,O
237,I-Entity
propofol,I-Entity
),O
were,O
included,O
in,O
the,O
analysis,O
",",O
with,O
190,I-Entity
matched,O
(,O
95,O
in,O
each,O
group,O
),O
by,O
propensity,O
score,O
.,O
The,I-Entity
primary,O
outcome,O
of,O
this,O
study,O
was,O
a,O
composite,O
of,O
severe,O
hypotension,I-Entity
(,O
mean,O
arterial,O
pressure,O
<,O
60,O
mm,O
Hg,I-Entity
),O
and,O
bradycardia,I-Entity
(,O
heart,O
rate,O
<,O
50,O
beats,O
/,O
min,O
),O
during,O
sedative,O
infusion,O
.,O
When,I-Entity
analyzed,O
separately,O
",",O
no,O
differences,O
could,O
be,O
found,O
in,O
the,O
prevalence,O
of,O
severe,O
hypotension,I-Entity
or,O
bradycardia,I-Entity
in,O
either,O
the,O
unmatched,O
or,O
matched,O
cohorts,O
.,O
Severe,I-Entity
hypotension,I-Entity
and,O
bradycardia,I-Entity
occur,O
at,O
similar,O
prevalence,O
in,O
neurocritical,O
care,O
patients,O
who,O
receive,O
dexmedetomidine,I-Entity
or,O
propofol,I-Entity
.,O
Providers,I-Entity
should,O
similarly,O
consider,O
the,O
likelihood,O
of,O
hypotension,I-Entity
or,O
bradycardia,I-Entity
before,O
starting,O
either,O
sedative,O
.,O
Hydroxytyrosol,I-Entity
ameliorates,O
oxidative,O
stress,I-Entity
and,O
mitochondrial,O
dysfunction,I-Entity
in,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
in,O
rats,O
with,O
breast,O
cancer,I-Entity
.,O
Oxidative,I-Entity
stress,I-Entity
is,O
involved,O
in,O
several,O
processes,O
including,O
cancer,I-Entity
",",O
aging,I-Entity
and,O
cardiovascular,O
disease,I-Entity
",",O
and,O
has,O
been,O
shown,O
to,O
potentiate,O
the,O
therapeutic,O
effect,O
of,O
drugs,O
such,O
as,O
doxorubicin,I-Entity
.,O
Doxorubicin,I-Entity
causes,O
significant,O
cardiotoxicity,I-Entity
characterized,O
by,O
marked,O
increases,O
in,O
oxidative,O
stress,I-Entity
and,O
mitochondrial,O
dysfunction,I-Entity
.,O
Herein,I-Entity
",",O
we,O
investigate,O
whether,O
doxorubicin,I-Entity
-,O
associated,O
chronic,O
cardiac,O
toxicity,I-Entity
can,O
be,O
ameliorated,O
with,O
the,O
antioxidant,O
hydroxytyrosol,I-Entity
in,O
rats,O
with,O
breast,O
cancer,I-Entity
.,O
Thirty,I-Entity
-,O
six,O
rats,O
bearing,O
breast,O
tumors,I-Entity
induced,O
chemically,O
were,O
divided,O
into,O
4,O
groups,O
:,O
control,O
",",O
hydroxytyrosol,I-Entity
(,O
0.5mg,O
/,O
kg,O
",",O
5days,O
/,O
week,O
),O
",",O
doxorubicin,I-Entity
(,O
1mg,I-Entity
/,O
kg,O
/,O
week,O
),O
",",O
and,O
doxorubicin,I-Entity
plus,O
hydroxytyrosol,I-Entity
.,O
Cardiac,I-Entity
disturbances,I-Entity
at,O
the,O
cellular,O
and,O
mitochondrial,O
level,O
",",O
mitochondrial,O
electron,O
transport,O
chain,O
complexes,O
I,I-Entity
-,O
IV,I-Entity
and,O
apoptosis,O
-,O
inducing,O
factor,O
",",O
and,O
oxidative,O
stress,I-Entity
markers,O
have,O
been,O
analyzed,O
.,O
Hydroxytyrosol,I-Entity
improved,O
the,O
cardiac,O
disturbances,I-Entity
enhanced,O
by,O
doxorubicin,I-Entity
by,O
significantly,O
reducing,O
the,O
percentage,O
of,O
altered,O
mitochondria,O
and,O
oxidative,O
damage,O
.,O
These,I-Entity
results,O
suggest,O
that,O
hydroxytyrosol,I-Entity
improve,O
the,O
mitochondrial,O
electron,O
transport,O
chain,O
.,O
This,I-Entity
study,O
demonstrates,O
that,O
hydroxytyrosol,I-Entity
protect,O
rat,O
heart,O
damage,O
provoked,O
by,O
doxorubicin,I-Entity
decreasing,O
oxidative,O
damage,O
and,O
mitochondrial,O
alterations,I-Entity
.,O
Amiodarone,I-Entity
-,O
induced,O
myxoedema,I-Entity
coma,I-Entity
.,O
A,I-Entity
62-year,O
-,O
old,O
man,O
was,O
found,O
to,O
have,O
bradycardia,I-Entity
",",O
hypothermia,I-Entity
and,O
respiratory,O
failure,I-Entity
3,O
weeks,O
after,O
initiation,O
of,O
amiodarone,I-Entity
therapy,O
for,O
atrial,I-Entity
fibrillation,I-Entity
.,O
0.3,O
-,O
5,O
uIU,I-Entity
/,O
mL,I-Entity
),O
and,O
free,O
thyroxine,I-Entity
(,O
FT4,I-Entity
),O
was,O
<,O
0.2,O
ng,O
/,O
dL,I-Entity
(,O
nl,O
.,O
He,I-Entity
received,O
intravenous,O
fluids,O
",",O
vasopressor,I-Entity
therapy,O
and,O
stress,I-Entity
dose,O
steroids,I-Entity
;,O
he,O
was,O
intubated,O
and,O
admitted,O
to,O
the,O
intensive,O
care,O
unit,O
.,O
He,I-Entity
received,O
500,O
ug,I-Entity
of,O
intravenous,O
levothyroxine,I-Entity
in,O
the,O
first,O
18,O
h,O
of,O
therapy,O
",",O
and,O
150,I-Entity
ug,I-Entity
intravenous,O
daily,O
thereafter,O
.,O
The,I-Entity
patient,O
was,O
maintained,O
on,O
levothyroxine,I-Entity
175,I-Entity
(,O
g,O
POorally,I-Entity
daily,O
.,O
The,I-Entity
24,O
hour,O
excretion,O
of,O
iodine,I-Entity
was,O
3657,I-Entity
(,O
mcg,O
(,O
25,O
-,O
756,I-Entity
(,O
mcg,O
),O
.,O
The,I-Entity
only,O
two,O
cases,O
of,O
amiodarone,I-Entity
-,O
induced,O
myxoedema,I-Entity
coma,I-Entity
in,O
the,O
literature,O
report,O
patient,O
death,I-Entity
despite,O
supportive,O
therapy,O
and,O
thyroid,I-Entity
hormone,I-Entity
replacement,O
.,O
This,I-Entity
case,O
represents,O
the,O
most,O
thoroughly,O
investigated,O
case,O
of,O
amiodarone,I-Entity
-,O
induced,O
myxoedema,I-Entity
coma,I-Entity
with,O
a,O
history,O
significant,O
for,O
subclinical,O
thyroid,I-Entity
disease,I-Entity
.,O
Use,I-Entity
of,O
argatroban,I-Entity
and,O
catheter,O
-,O
directed,O
thrombolysis,I-Entity
with,O
alteplase,I-Entity
in,O
an,O
oncology,O
patient,O
with,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
with,O
thrombosis,I-Entity
.,O
The,I-Entity
case,O
of,O
an,O
oncology,O
patient,O
who,O
developed,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
with,O
thrombosis,I-Entity
(,O
HITT,I-Entity
),O
and,O
was,O
treated,O
with,O
argatroban,I-Entity
plus,O
catheter,O
-,O
directed,O
thrombolysis,I-Entity
(,O
CDT,I-Entity
),O
with,O
alteplase,I-Entity
is,O
presented,O
.,O
A,I-Entity
63-year,O
-,O
old,O
Caucasian,I-Entity
man,O
with,O
renal,O
amyloidosis,I-Entity
undergoing,O
peripheral,O
blood,O
stem,O
cell,O
collection,O
for,O
an,O
autologous,O
stem,O
cell,O
transplant,O
developed,O
extensive,O
bilateral,O
upper,O
-,O
extremity,O
deep,O
venous,O
thrombosis,I-Entity
(,O
DVT,I-Entity
),O
and,O
pulmonary,O
embolism,I-Entity
secondary,O
to,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
.,O
infusion,O
of,O
argatroban,I-Entity
was,O
initiated,O
",",O
and,O
the,O
patient,O
was,O
managed,O
on,O
the,O
general,O
medical,O
floor,O
.,O
After,I-Entity
one,O
week,O
of,O
therapy,O
",",O
he,O
was,O
transferred,O
to,O
the,O
intensive,O
care,O
unit,O
with,O
cardiopulmonary,O
compromise,O
related,O
to,O
superior,O
vena,O
cava,O
(,O
SVC,I-Entity
),O
syndrome,I-Entity
.,O
A,I-Entity
percutaneous,O
mechanical,O
thrombectomy,I-Entity
and,O
CDT,I-Entity
with,O
alteplase,I-Entity
were,O
attempted,O
",",O
but,O
the,O
procedure,O
was,O
aborted,O
due,O
to,O
epistaxis,I-Entity
.,O
The,I-Entity
epistaxis,I-Entity
resolved,O
the,O
next,O
day,O
",",O
and,O
the,O
patient,O
was,O
restarted,O
on,O
argatroban,I-Entity
.,O
Postthrombectomy,I-Entity
continuous,O
CDT,I-Entity
with,O
alteplase,I-Entity
was,O
commenced,O
while,O
argatroban,I-Entity
was,O
withheld,O
",",O
and,O
complete,O
patency,O
of,O
the,O
SVC,I-Entity
and,O
central,O
veins,O
was,O
achieved,O
after,O
three,O
days,O
of,O
therapy,O
.,O
Alteplase,I-Entity
was,O
discontinued,O
",",O
and,O
the,O
patient,O
was,O
reinitiated,O
on,O
argatroban,I-Entity
;,O
ultimately,O
",",O
he,O
was,O
transitioned,O
to,O
warfarin,I-Entity
for,O
long,O
-,O
term,O
anticoagulation,O
.,O
Although,I-Entity
the,O
patient,O
recovered,O
",",O
he,O
experienced,O
permanent,O
vision,O
and,O
hearing,O
loss,I-Entity
",",O
as,O
well,O
as,O
end,O
-,O
stage,O
renal,O
disease,I-Entity
.,O
A,I-Entity
63-year,O
-,O
old,O
man,O
with,O
renal,O
amyloidosis,I-Entity
and,O
SVC,I-Entity
syndrome,I-Entity
secondary,O
to,O
HITT,I-Entity
was,O
successfully,O
treated,O
with,O
argatroban,I-Entity
and,O
CDT,I-Entity
with,O
alteplase,I-Entity
.,O
Effects,I-Entity
of,O
dehydroepiandrosterone,I-Entity
in,O
amphetamine,I-Entity
-,O
induced,O
schizophrenia,I-Entity
models,O
in,O
mice,O
.,O
OBJECTIVE,I-Entity
:,O
To,I-Entity
examine,O
the,O
effects,O
of,O
dehydroepiandrosterone,I-Entity
(,O
DHEA,I-Entity
),O
on,O
animal,O
models,O
of,O
schizophrenia,I-Entity
.,O
METHODS,I-Entity
:,O
Seventy,I-Entity
Swiss,I-Entity
albino,O
female,O
mice,O
(,O
25,O
-,O
35,O
g,O
),O
were,O
divided,O
into,O
4,O
groups,O
:,O
amphetamine,I-Entity
-,O
free,O
(,O
control,O
),O
",",O
amphetamine,I-Entity
",",O
50,O
",",O
and,O
100,O
mg,O
/,O
kg,O
DHEA,I-Entity
.,O
The,I-Entity
DHEA,I-Entity
was,O
administered,O
intraperitoneally,O
(,O
ip,O
),O
for,O
5,O
days,O
.,O
Amphetamine,I-Entity
(,O
3,O
mg,O
/,O
kg,O
ip,O
),O
induced,O
hyper,O
locomotion,O
",",O
apomorphine,I-Entity
(,O
1.5,O
mg,O
/,O
kg,O
subcutaneously,O
[,O
sc,O
],O
),O
induced,O
climbing,O
",",O
and,O
haloperidol,I-Entity
(,O
1.5,O
mg,O
/,O
kg,O
sc,O
),O
induced,O
catalepsy,I-Entity
tests,O
were,O
used,O
as,O
animal,O
models,O
of,O
schizophrenia,I-Entity
.,O
Statistical,I-Entity
analysis,O
was,O
carried,O
out,O
using,O
Kruskal,I-Entity
-,O
Wallis,I-Entity
test,O
for,O
hyper,O
locomotion,O
",",O
and,O
one,O
-,O
way,O
ANOVA,I-Entity
for,O
climbing,O
and,O
catalepsy,I-Entity
tests,O
.,O
In,I-Entity
the,O
amphetamine,I-Entity
-,O
induced,O
locomotion,O
test,O
",",O
there,O
were,O
significant,O
increases,O
in,O
all,O
movements,O
compared,O
with,O
the,O
amphetamine,I-Entity
-,O
free,O
group,O
.,O
Both,I-Entity
DHEA,I-Entity
50,O
mg,O
/,O
kg,O
(,O
p<0.05,O
),O
",",O
and,O
100,O
mg,O
/,O
kg,O
(,O
p<0.01,O
),O
significantly,O
decreased,O
all,O
movements,O
compared,O
with,O
the,O
amphetamine,I-Entity
-,O
induced,O
locomotion,O
group,O
.,O
There,I-Entity
was,O
a,O
significant,O
difference,O
between,O
groups,O
in,O
the,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
test,O
(,O
p<0.05,O
),O
.,O
There,I-Entity
was,O
no,O
significant,O
difference,O
between,O
groups,O
in,O
terms,O
of,O
total,O
climbing,O
time,O
in,O
the,O
apomorphine,I-Entity
-,O
induced,O
climbing,O
test,O
(,O
p>0.05,O
),O
.,O
We,I-Entity
observed,O
that,O
DHEA,I-Entity
reduced,O
locomotor,O
activity,O
and,O
increased,O
catalepsy,I-Entity
at,O
both,O
doses,O
",",O
while,O
it,O
had,O
no,O
effect,O
on,O
climbing,O
behavior,O
.,O
We,I-Entity
suggest,O
that,O
DHEA,I-Entity
displays,O
typical,O
neuroleptic,O
-,O
like,O
effects,O
",",O
and,O
may,O
be,O
used,O
in,O
the,O
treatment,O
of,O
schizophrenia,I-Entity
.,O
Availability,I-Entity
of,O
human,O
induced,O
pluripotent,O
stem,O
cell,O
-,O
derived,O
cardiomyocytes,O
in,O
assessment,O
of,O
drug,O
potential,O
for,O
QT,I-Entity
prolongation,O
.,O
Field,I-Entity
potential,O
duration,O
(,O
FPD,I-Entity
),O
in,O
human,O
-,O
induced,O
pluripotent,O
stem,O
cell,O
-,O
derived,O
cardiomyocytes,O
(,O
hiPS,I-Entity
-,O
CMs,I-Entity
),O
",",O
which,O
can,O
express,O
QT,I-Entity
interval,O
in,O
an,O
electrocardiogram,O
",",O
is,O
reported,O
to,O
be,O
a,O
useful,O
tool,O
to,O
predict,O
K(+,I-Entity
),O
channel,O
and,O
Ca(2,I-Entity
+,O
),O
channel,O
blocker,O
effects,O
on,O
QT,I-Entity
interval,O
.,O
However,I-Entity
",",O
there,O
is,O
no,O
report,O
showing,O
that,O
this,O
technique,O
can,O
be,O
used,O
to,O
predict,O
multichannel,O
blocker,O
potential,O
for,O
QT,I-Entity
prolongation,O
.,O
The,I-Entity
aim,O
of,O
this,O
study,O
is,O
to,O
show,O
that,O
FPD,I-Entity
from,O
MEA,I-Entity
(,O
Multielectrode,I-Entity
array,O
),O
of,O
hiPS,I-Entity
-,O
CMs,I-Entity
can,O
detect,O
QT,I-Entity
prolongation,O
induced,O
by,O
multichannel,O
blockers,O
.,O
IKr,I-Entity
and,O
IKs,I-Entity
blockers,O
concentration,O
-,O
dependently,O
prolonged,O
corrected,O
FPD,I-Entity
(,O
FPDc,I-Entity
),O
",",O
whereas,O
Ca(2,I-Entity
+,O
),O
channel,O
blockers,O
concentration,O
-,O
dependently,O
shortened,O
FPDc,I-Entity
.,O
Also,I-Entity
",",O
the,O
multichannel,O
blockers,O
Amiodarone,I-Entity
",",O
Paroxetine,I-Entity
",",O
Terfenadine,I-Entity
and,O
Citalopram,I-Entity
prolonged,O
FPDc,I-Entity
in,O
a,O
concentration,O
dependent,O
manner,O
.,O
Finally,I-Entity
",",O
the,O
IKr,I-Entity
blockers,O
",",O
Terfenadine,I-Entity
and,O
Citalopram,I-Entity
",",O
which,O
are,O
reported,O
to,O
cause,O
Torsade,I-Entity
de,O
Pointes,I-Entity
(,O
TdP,I-Entity
),O
in,O
clinical,O
practice,O
",",O
produced,O
early,O
afterdepolarization,O
(,O
EAD,I-Entity
),O
.,O
This,I-Entity
study,O
also,O
shows,O
that,O
this,O
assay,O
can,O
help,O
detect,O
EAD,I-Entity
for,O
drugs,O
with,O
TdP,I-Entity
potential,O
.,O
Dermal,I-Entity
developmental,O
toxicity,I-Entity
of,O
N,I-Entity
-,O
phenylimide,I-Entity
herbicides,O
in,O
rats,O
.,O
BACKGROUND,I-Entity
:,O
S-53482,I-Entity
and,O
S-23121,I-Entity
are,O
N,I-Entity
-,O
phenylimide,I-Entity
herbicides,O
and,O
produced,O
embryolethality,O
",",O
teratogenicity,O
(,O
mainly,O
ventricular,O
septal,O
defects,O
and,O
wavy,I-Entity
ribs,O
),O
",",O
and,O
growth,O
retardation,I-Entity
in,O
rats,O
in,O
conventional,O
oral,O
developmental,O
toxicity,I-Entity
studies,O
.,O
Our,I-Entity
objective,O
in,O
this,O
study,O
was,O
to,O
investigate,O
whether,O
the,O
compounds,O
induce,O
developmental,O
toxicity,I-Entity
via,O
the,O
dermal,O
route,O
",",O
which,O
is,O
more,O
relevant,O
to,O
occupational,O
exposure,O
",",O
hence,O
better,O
addressing,O
human,O
health,O
risks,O
.,O
S-53482,I-Entity
was,O
administered,O
dermally,O
to,O
rats,O
at,O
30,O
",",O
100,O
",",O
and,O
300,O
mg,O
/,O
kg,O
during,O
organogenesis,O
",",O
and,O
S-23121,I-Entity
was,O
administered,O
at,O
200,O
",",O
400,O
",",O
and,O
800,O
mg,O
/,O
kg,O
(,O
the,O
maximum,O
applicable,O
dose,O
level,O
),O
.,O
RESULTS,I-Entity
:,O
Dermal,I-Entity
exposure,O
of,O
rats,O
to,O
S-53482,I-Entity
at,O
300,O
mg,O
/,O
kg,O
produced,O
patterns,O
of,O
developmental,O
toxicity,I-Entity
similar,O
to,O
those,O
resulting,O
from,O
oral,O
exposure,O
.,O
Toxicity,I-Entity
included,O
embryolethality,O
",",O
teratogenicity,O
",",O
and,O
growth,O
retardation,I-Entity
.,O
Dermal,I-Entity
administration,O
of,O
S-23121,I-Entity
at,O
800,O
mg,O
/,O
kg,O
resulted,O
in,O
an,O
increased,O
incidence,O
of,O
embryonic,O
death,I-Entity
and,O
ventricular,O
septal,O
defect,I-Entity
",",O
but,O
retarded,I-Entity
fetal,O
growth,O
was,O
not,O
observed,O
as,O
it,O
was,O
following,O
oral,O
exposure,O
to,O
S-23121,I-Entity
.,O
CONCLUSIONS,I-Entity
:,O
Based,I-Entity
on,O
the,O
results,O
",",O
S-53482,I-Entity
and,O
S-23121,I-Entity
were,O
teratogenic,O
when,O
administered,O
dermally,O
to,O
pregnant,I-Entity
rats,O
as,O
were,O
the,O
compounds,O
administered,O
orally,O
.,O
Rates,I-Entity
of,O
Renal,I-Entity
Toxicity,I-Entity
in,O
Cancer,I-Entity
Patients,I-Entity
Receiving,I-Entity
Cisplatin,I-Entity
With,I-Entity
and,O
Without,I-Entity
Mannitol,I-Entity
.,O
Cisplatin,I-Entity
is,O
a,O
widely,O
used,O
antineoplastic,O
.,O
One,I-Entity
of,O
the,O
major,O
complications,O
of,O
cisplatin,I-Entity
use,O
is,O
dose,O
-,O
limiting,O
nephrotoxicity,I-Entity
.,O
There,I-Entity
are,O
many,O
strategies,O
to,O
prevent,O
this,O
toxicity,I-Entity
",",O
including,O
the,O
use,O
of,O
mannitol,I-Entity
as,O
a,O
nephroprotectant,I-Entity
in,O
combination,O
with,O
hydration,O
.,O
OBJECTIVE,I-Entity
:,O
We,I-Entity
aimed,O
to,O
evaluate,O
the,O
rates,O
of,O
cisplatin,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
in,O
cancer,I-Entity
patients,O
receiving,O
single,O
-,O
agent,O
cisplatin,I-Entity
with,O
and,O
without,O
mannitol,I-Entity
.,O
This,I-Entity
single,O
-,O
center,O
retrospective,O
analysis,O
was,O
a,O
quasi,O
experiment,O
created,O
by,O
the,O
national,O
mannitol,I-Entity
shortage,O
.,O
Data,I-Entity
were,O
collected,O
on,O
adult,O
cancer,I-Entity
patients,O
receiving,O
single,O
-,O
agent,O
cisplatin,I-Entity
as,O
an,O
outpatient,I-Entity
from,O
January,I-Entity
2011,O
to,O
September,I-Entity
2012,O
.,O
The,I-Entity
primary,O
outcome,O
was,O
acute,O
kidney,O
injury,I-Entity
(,O
AKI,I-Entity
),O
.,O
We,I-Entity
evaluated,O
143,I-Entity
patients,O
who,O
received,O
single,O
-,O
agent,O
cisplatin,I-Entity
;,O
97.2%,O
of,O
patients,O
had,O
head,O
and,O
neck,O
cancer,I-Entity
as,O
their,O
primary,O
malignancy,I-Entity
.,O
Patients,I-Entity
who,O
did,O
not,O
receive,O
mannitol,I-Entity
were,O
more,O
likely,O
to,O
develop,O
nephrotoxicity,I-Entity
:,O
odds,O
ratio,O
[,O
OR,I-Entity
],O
=,O
2.646,O
(,O
95%,O
CI,I-Entity
=,O
1.008,I-Entity
",",O
6.944,O
;,O
P,I-Entity
=,O
0.048,O
),O
.,O
Patients,I-Entity
who,O
received,O
the,O
100,O
mg,O
/,O
m(2,O
),O
dosing,O
and,O
patients,O
who,O
had,O
a,O
history,O
of,O
hypertension,I-Entity
also,O
had,O
a,O
higher,O
likelihood,O
of,O
developing,O
nephrotoxicity,I-Entity
:,O
OR,I-Entity
=,O
11.494,O
(,O
95%,O
CI,I-Entity
=,O
4.149,O
",",O
32.258,O
;,O
CONCLUSIONS,I-Entity
:,O
When,I-Entity
limited,O
quantities,O
of,O
mannitol,I-Entity
are,O
available,O
",",O
it,O
should,O
preferentially,O
be,O
given,O
to,O
patients,O
at,O
particularly,O
high,O
risk,O
of,O
nephrotoxicity,I-Entity
.,O
Our,I-Entity
analysis,O
suggests,O
that,O
those,O
patients,O
receiving,O
the,O
dosing,O
schedule,O
of,O
100,O
mg,O
/,O
m(2,O
),O
cisplatin,I-Entity
every,O
3,O
weeks,O
and,O
those,O
with,O
hypertension,I-Entity
are,O
at,O
the,O
greatest,O
risk,O
of,O
nephrotoxicity,I-Entity
and,O
would,O
benefit,O
from,O
the,O
addition,O
of,O
mannitol,I-Entity
.,O
Metformin,I-Entity
protects,O
against,O
seizures,I-Entity
",",O
learning,O
and,O
memory,O
impairments,I-Entity
and,O
oxidative,O
damage,O
induced,O
by,O
pentylenetetrazole,I-Entity
-,O
induced,O
kindling,O
in,O
mice,O
.,O
Cognitive,I-Entity
impairment,I-Entity
",",O
the,O
most,O
common,O
and,O
severe,O
comorbidity,O
of,O
epilepsy,I-Entity
",",O
greatly,O
diminishes,O
the,O
quality,O
of,O
life,O
.,O
However,I-Entity
",",O
current,O
therapeutic,O
interventions,O
for,O
epilepsy,I-Entity
can,O
also,O
cause,O
untoward,O
cognitive,O
effects,O
.,O
Thus,I-Entity
",",O
there,O
is,O
an,O
urgent,O
need,O
for,O
new,O
kinds,O
of,O
agents,O
targeting,O
both,O
seizures,I-Entity
and,O
cognition,O
deficits,I-Entity
.,O
Oxidative,I-Entity
stress,I-Entity
is,O
considered,O
to,O
play,O
an,O
important,O
role,O
in,O
epileptogenesis,O
and,O
cognitive,O
deficits,I-Entity
",",O
and,O
antioxidants,O
have,O
a,O
putative,O
antiepileptic,O
potential,O
.,O
Metformin,I-Entity
",",O
the,O
most,O
commonly,O
prescribed,O
antidiabetic,I-Entity
oral,O
drug,O
",",O
has,O
antioxidant,O
properties,O
.,O
This,I-Entity
study,O
was,O
designed,O
to,O
evaluate,O
the,O
ameliorative,O
effects,O
of,O
metformin,I-Entity
on,O
seizures,I-Entity
",",O
cognitive,O
impairment,I-Entity
and,O
brain,O
oxidative,O
stress,I-Entity
markers,O
observed,O
in,O
pentylenetetrazole,I-Entity
-,O
induced,O
kindling,O
animals,O
.,O
Male,I-Entity
C57BL/6,I-Entity
mice,O
were,O
administered,O
with,O
subconvulsive,B-Entity
dose,O
of,O
pentylenetetrazole,I-Entity
(,O
37,I-Entity
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
every,O
other,O
day,O
for,O
14,O
injections,O
.,O
Metformin,I-Entity
was,O
injected,O
intraperitoneally,O
in,O
dose,O
of,O
200mg,I-Entity
/,O
kg,O
along,O
with,O
alternate,O
-,O
day,O
PTZ,I-Entity
.,O
We,I-Entity
found,O
that,O
metformin,I-Entity
suppressed,O
the,O
progression,O
of,O
kindling,O
",",O
ameliorated,O
the,O
cognitive,O
impairment,I-Entity
and,O
decreased,O
brain,O
oxidative,O
stress,I-Entity
.,O
Thus,I-Entity
the,O
present,O
study,O
concluded,O
that,O
metformin,I-Entity
may,O
be,O
a,O
potential,O
agent,O
for,O
the,O
treatment,O
of,O
epilepsy,I-Entity
as,O
well,O
as,O
a,O
protective,O
medicine,O
against,O
cognitive,O
impairment,I-Entity
induced,O
by,O
seizures,I-Entity
.,O
P53,I-Entity
inhibition,O
exacerbates,O
late,O
-,O
stage,O
anthracycline,I-Entity
cardiotoxicity,I-Entity
.,O
AIMS,I-Entity
:,O
Doxorubicin,I-Entity
(,O
DOX,I-Entity
),O
is,O
an,O
effective,O
anti,O
-,O
cancer,I-Entity
therapeutic,O
",",O
but,O
is,O
associated,O
with,O
both,O
acute,O
and,O
late,O
-,O
stage,O
cardiotoxicity,I-Entity
.,O
Children,I-Entity
are,O
particularly,O
sensitive,I-Entity
to,O
DOX,I-Entity
-,O
induced,O
heart,O
failure,I-Entity
.,O
Here,I-Entity
",",O
the,O
impact,O
of,O
p53,I-Entity
inhibition,O
on,O
acute,O
vs.,O
late,O
-,O
stage,O
DOX,I-Entity
cardiotoxicity,I-Entity
was,O
examined,O
in,O
a,O
juvenile,O
model,O
.,O
littermates,O
received,O
weekly,O
DOX,I-Entity
injections,O
for,O
5,O
weeks,O
(,O
25,O
mg,O
/,O
kg,O
cumulative,O
dose,O
),O
.,O
One,I-Entity
week,O
after,O
the,O
last,O
DOX,I-Entity
treatment,O
(,O
acute,O
stage,O
),O
",",O
MHC,I-Entity
-,O
CB7,I-Entity
mice,O
exhibited,O
improved,O
cardiac,O
function,O
and,O
lower,O
levels,O
of,O
cardiomyocyte,O
apoptosis,O
when,O
compared,O
with,O
the,O
NON,I-Entity
-,O
TXG,I-Entity
mice,O
.,O
Surprisingly,I-Entity
",",O
by,O
13,O
weeks,O
following,O
the,O
last,O
DOX,I-Entity
treatment,O
(,O
late,O
stage,O
),O
",",O
MHC,I-Entity
-,O
CB7,I-Entity
exhibited,O
a,O
progressive,O
decrease,O
in,O
cardiac,O
function,O
and,O
higher,O
rates,O
of,O
cardiomyocyte,O
apoptosis,O
when,O
compared,O
with,O
NON,I-Entity
-,O
TXG,I-Entity
mice,O
.,O
p53,I-Entity
inhibition,O
blocked,O
transient,O
DOX,I-Entity
-,O
induced,O
STAT3,I-Entity
activation,O
in,O
MHC,I-Entity
-,O
CB7,I-Entity
mice,O
",",O
which,O
was,O
associated,O
with,O
enhanced,O
induction,O
of,O
the,O
DNA,I-Entity
repair,O
proteins,O
Ku70,I-Entity
and,O
Ku80,I-Entity
.,O
Mice,I-Entity
with,O
cardiomyocyte,O
-,O
restricted,O
deletion,I-Entity
of,O
STAT3,I-Entity
exhibited,O
worse,O
cardiac,O
function,O
",",O
higher,O
levels,O
of,O
cardiomyocyte,O
apoptosis,O
",",O
and,O
a,O
greater,O
induction,O
of,O
Ku70,I-Entity
and,O
Ku80,I-Entity
in,O
response,O
to,O
DOX,I-Entity
treatment,O
during,O
the,O
acute,O
stage,O
when,O
compared,O
with,O
control,O
animals,O
.,O
CONCLUSION,I-Entity
:,O
These,I-Entity
data,O
support,O
a,O
model,O
wherein,O
a,O
p53-dependent,I-Entity
cardioprotective,O
pathway,O
",",O
mediated,O
via,O
STAT3,I-Entity
activation,O
",",O
mitigates,O
DOX,I-Entity
-,O
induced,O
myocardial,B-Entity
stress,I-Entity
during,O
drug,O
delivery,O
.,O
Furthermore,I-Entity
",",O
these,O
data,O
suggest,O
an,O
explanation,O
as,O
to,O
how,O
p53,I-Entity
inhibition,O
can,O
result,O
in,O
cardioprotection,O
during,O
drug,O
treatment,O
and,O
",",O
paradoxically,O
",",O
enhanced,O
cardiotoxicity,I-Entity
long,O
after,O
the,O
cessation,O
of,O
drug,O
treatment,O
.,O
Metronidazole,I-Entity
-,O
induced,O
encephalopathy,I-Entity
:,O
an,O
uncommon,O
scenario,O
.,O
Metronidazole,I-Entity
can,O
produce,O
neurological,O
complications,O
although,O
it,O
is,O
not,O
a,O
common,O
scenario,O
.,O
We,I-Entity
present,O
a,O
case,O
where,O
a,O
patient,O
developed,O
features,O
of,O
encephalopathy,I-Entity
following,O
prolonged,O
metronidazole,I-Entity
intake,O
.,O
The,I-Entity
diagnosis,O
of,O
metronidazole,I-Entity
toxicity,I-Entity
was,O
made,O
by,O
the,O
MRI,I-Entity
findings,O
and,O
supported,O
clinically,O
.,O
Aconitine,I-Entity
-,O
induced,O
Ca2,I-Entity
+,O
overload,I-Entity
causes,O
arrhythmia,I-Entity
and,O
triggers,O
apoptosis,O
through,O
p38,O
MAPK,I-Entity
signaling,O
pathway,O
in,O
rats,O
.,O
Aconitine,I-Entity
is,O
a,O
major,O
bioactive,O
diterpenoid,I-Entity
alkaloid,O
with,O
high,O
content,O
derived,O
from,O
herbal,O
aconitum,I-Entity
plants,O
.,O
Emerging,I-Entity
evidence,O
indicates,O
that,O
voltage,O
-,O
dependent,O
Na(+,I-Entity
),O
channels,O
have,O
pivotal,O
roles,O
in,O
the,O
cardiotoxicity,I-Entity
of,O
aconitine,I-Entity
.,O
However,I-Entity
",",O
no,O
reports,O
are,O
available,O
on,O
the,O
role,O
of,O
Ca(2,I-Entity
+,O
),O
in,O
aconitine,I-Entity
poisoning,I-Entity
.,O
In,I-Entity
this,O
study,O
",",O
we,O
explored,O
the,O
importance,O
of,O
pathological,O
Ca(2,I-Entity
+,O
),O
signaling,O
in,O
aconitine,I-Entity
poisoning,I-Entity
in,O
vitro,O
and,O
in,O
vivo,O
.,O
We,I-Entity
found,O
that,O
Ca(2,I-Entity
+,O
),O
overload,I-Entity
lead,O
to,O
accelerated,O
beating,O
rhythm,O
in,O
adult,O
rat,O
ventricular,O
myocytes,I-Entity
and,O
caused,O
arrhythmia,I-Entity
in,O
conscious,O
freely,O
moving,O
rats,O
.,O
To,I-Entity
investigate,O
effects,O
of,O
aconitine,I-Entity
on,O
myocardial,B-Entity
injury,I-Entity
",",O
we,O
performed,O
cytotoxicity,O
assay,O
in,O
neonatal,O
rat,O
ventricular,O
myocytes,I-Entity
(,O
NRVMs,I-Entity
),O
",",O
as,O
well,O
as,O
measured,O
lactate,I-Entity
dehydrogenase,O
level,O
in,O
the,O
culture,O
medium,O
of,O
NRVMs,I-Entity
and,O
activities,O
of,O
serum,O
cardiac,O
enzymes,O
in,O
rats,O
.,O
The,I-Entity
results,O
showed,O
that,O
aconitine,I-Entity
resulted,O
in,O
myocardial,B-Entity
injury,I-Entity
and,O
reduced,O
NRVMs,I-Entity
viability,O
dose,O
-,O
dependently,O
.,O
transferase,O
-,O
mediated,O
dUTP,I-Entity
-,O
biotin,O
nick,O
end,O
labeling,O
assay,O
.,O
The,I-Entity
results,O
showed,O
that,O
aconitine,I-Entity
stimulated,O
apoptosis,O
time,O
-,O
dependently,O
.,O
The,I-Entity
expression,O
analysis,O
of,O
Ca(2,I-Entity
+,O
),O
handling,O
proteins,O
demonstrated,O
that,O
aconitine,I-Entity
promoted,O
Ca(2,I-Entity
+,O
),O
overload,I-Entity
through,O
the,O
expression,O
regulation,O
of,O
Ca(2,I-Entity
+,O
),O
handling,O
proteins,O
.,O
Hence,I-Entity
",",O
our,O
results,O
suggest,O
that,O
aconitine,I-Entity
significantly,O
aggravates,O
Ca(2,I-Entity
+,O
),O
overload,I-Entity
and,O
causes,O
arrhythmia,I-Entity
and,O
finally,O
promotes,O
apoptotic,O
development,O
via,O
phosphorylation,O
of,O
P38,I-Entity
mitogen,O
-,O
activated,O
protein,O
kinase,O
.,O
Chronic,I-Entity
treatment,O
with,O
metformin,I-Entity
suppresses,O
toll,O
-,O
like,O
receptor,O
4,O
signaling,O
and,O
attenuates,O
left,O
ventricular,O
dysfunction,I-Entity
following,O
myocardial,B-Entity
infarction,I-Entity
.,O
Acute,I-Entity
treatment,O
with,O
metformin,I-Entity
has,O
a,O
protective,O
effect,O
in,O
myocardial,B-Entity
infarction,I-Entity
by,O
suppression,O
of,O
inflammatory,O
responses,O
due,O
to,O
activation,O
of,O
AMP,I-Entity
-,O
activated,O
protein,O
kinase,O
(,O
AMPK,I-Entity
),O
.,O
In,I-Entity
the,O
present,O
study,O
",",O
the,O
effect,O
of,O
chronic,O
pre,O
-,O
treatment,O
with,O
metformin,I-Entity
on,O
cardiac,O
dysfunction,I-Entity
and,O
toll,O
-,O
like,O
receptor,O
4,O
(,O
TLR4,I-Entity
),O
activities,O
following,O
myocardial,B-Entity
infarction,I-Entity
and,O
their,O
relation,O
with,O
AMPK,I-Entity
were,O
assessed,O
.,O
Male,I-Entity
Wistar,I-Entity
rats,O
were,O
randomly,O
assigned,O
to,O
one,O
of,O
5,O
groups,O
(,O
n=6,O
),O
:,O
normal,O
control,O
and,O
groups,O
were,O
injected,O
isoproterenol,I-Entity
after,O
chronic,O
pre,O
-,O
treatment,O
with,O
0,O
",",O
25,O
",",O
50,O
",",O
or,O
100mg,I-Entity
/,O
kg,O
of,O
metformin,I-Entity
twice,O
daily,O
for,O
14,O
days,O
.,O
Isoproterenol,I-Entity
(,O
100mg,I-Entity
/,O
kg,O
),O
was,O
injected,O
subcutaneously,O
on,O
the,O
13th,O
and,O
14th,O
days,O
to,O
induce,O
acute,O
myocardial,B-Entity
infarction,I-Entity
.,O
Isoproterenol,I-Entity
alone,O
decreased,O
left,O
ventricular,O
systolic,O
pressure,O
and,O
myocardial,B-Entity
contractility,O
indexed,O
as,O
LVdp,I-Entity
/,O
dtmax,I-Entity
and,O
LVdp,I-Entity
/,O
dtmin,O
.,O
The,I-Entity
left,O
ventricular,O
dysfunction,I-Entity
was,O
significantly,O
lower,O
in,O
the,O
groups,O
treated,O
with,O
25,O
and,O
50mg,I-Entity
/,O
kg,O
of,O
metformin,I-Entity
.,O
Metfromin,I-Entity
markedly,O
lowered,O
isoproterenol,I-Entity
-,O
induced,O
elevation,O
in,O
the,O
levels,O
of,O
TLR4,I-Entity
mRNA,I-Entity
",",O
myeloid,I-Entity
differentiation,O
protein,O
88,O
(,O
MyD88,I-Entity
),O
",",O
tumor,I-Entity
necrosis,I-Entity
factor,O
-,O
alpha,O
(,O
TNF,I-Entity
-,O
a,O
),O
",",O
and,O
interleukin,O
6,O
(,O
IL-6,I-Entity
),O
in,O
the,O
heart,O
tissues,O
.,O
kg,O
of,O
metformin,I-Entity
",",O
slightly,O
by,O
50mg,I-Entity
/,O
kg,O
",",O
but,O
not,O
by,O
100mg,I-Entity
Chronic,I-Entity
pre,O
-,O
treatment,O
with,O
metformin,I-Entity
reduces,O
post,O
-,O
myocardial,B-Entity
infarction,I-Entity
cardiac,O
dysfunction,I-Entity
and,O
suppresses,O
inflammatory,O
responses,O
",",O
possibly,O
through,O
inhibition,O
of,O
TLR4,I-Entity
activities,O
.,O
Neuroleptic,I-Entity
malignant,I-Entity
syndrome,I-Entity
induced,O
by,O
combination,O
therapy,O
with,O
tetrabenazine,I-Entity
and,O
tiapride,I-Entity
in,O
a,O
Japanese,I-Entity
patient,O
with,O
Huntington,I-Entity
's,I-Entity
disease,I-Entity
at,O
the,O
terminal,O
stage,O
of,O
recurrent,O
breast,O
cancer,I-Entity
.,O
We,I-Entity
herein,O
describe,O
the,O
case,O
of,O
an,O
81-year,O
-,O
old,O
Japanese,I-Entity
woman,O
with,O
neuroleptic,O
malignant,I-Entity
syndrome,I-Entity
that,O
occurred,O
36,O
days,O
after,O
the,O
initiation,O
of,O
combination,O
therapy,O
with,O
tiapride,I-Entity
(,O
75,O
mg,O
/,O
day,O
),O
and,O
tetrabenazine,I-Entity
(,O
12.5,O
mg,O
/,O
day,O
),O
for,O
Huntington,I-Entity
's,I-Entity
disease,I-Entity
.,O
The,I-Entity
patient,O
had,O
been,O
treated,O
with,O
tiapride,I-Entity
or,O
tetrabenazine,I-Entity
alone,O
without,O
any,O
adverse,O
effects,O
before,O
the,O
administration,O
of,O
the,O
combination,O
therapy,O
.,O
She,I-Entity
also,O
had,O
advanced,O
breast,O
cancer,I-Entity
when,O
the,O
combination,O
therapy,O
was,O
initiated,O
.,O
To,I-Entity
the,O
best,O
of,O
our,O
knowledge,O
",",O
the,O
occurrence,O
of,O
neuroleptic,O
malignant,I-Entity
syndrome,I-Entity
due,O
to,O
combination,O
therapy,O
with,O
tetrabenazine,I-Entity
and,O
tiapride,I-Entity
has,O
not,O
been,O
previously,O
reported,O
.,O
Tetrabenazine,I-Entity
should,O
be,O
administered,O
very,O
carefully,O
in,O
combination,O
with,O
other,O
neuroleptic,O
drugs,O
",",O
particularly,O
in,O
patients,O
with,O
a,O
worsening,O
general,O
condition,O
.,O
A,I-Entity
metoprolol,I-Entity
-,O
terbinafine,I-Entity
combination,O
induced,O
bradycardia,I-Entity
.,O
To,I-Entity
report,O
a,O
sinus,O
bradycardia,I-Entity
induced,O
by,O
metoprolol,I-Entity
and,O
terbinafine,I-Entity
drug,O
-,O
drug,O
interaction,O
and,O
its,O
management,O
.,O
A,I-Entity
63,O
year,O
-,O
old,O
Caucasian,I-Entity
man,O
on,O
metoprolol,I-Entity
200,O
mg,O
/,O
day,O
for,O
stable,O
coronary,O
artery,I-Entity
disease,I-Entity
was,O
prescribed,O
a,O
90-day,O
course,O
of,O
oral,O
terbinafine,I-Entity
250,O
mg,O
/,O
day,O
for,O
onychomycosis,I-Entity
.,O
On,I-Entity
the,O
49th,O
day,O
of,O
terbinafine,I-Entity
therapy,O
",",O
he,O
was,O
brought,O
to,O
the,O
emergency,O
room,O
for,O
a,O
decrease,O
of,O
his,O
global,O
health,O
status,O
",",O
confusion,I-Entity
and,O
falls,I-Entity
.,O
The,I-Entity
electrocardiogram,O
revealed,O
a,O
37,I-Entity
beats,O
/,O
min,O
sinus,O
bradycardia,I-Entity
.,O
A,I-Entity
score,O
of,O
7,O
on,O
the,O
Naranjo,I-Entity
adverse,O
drug,O
reaction,I-Entity
probability,O
scale,O
indicates,O
a,O
probable,O
relationship,O
between,O
the,O
patient,O
's,I-Entity
sinus,O
bradycardia,I-Entity
and,O
the,O
drug,O
interaction,O
between,O
metoprolol,I-Entity
and,O
terbinafine,I-Entity
.,O
The,I-Entity
heart,O
rate,O
ameliorated,O
first,O
with,O
a,O
decrease,O
in,O
the,O
dose,O
of,O
metoprolol,I-Entity
.,O
It,I-Entity
was,O
subsequently,O
changed,O
to,O
bisoprolol,I-Entity
and,O
the,O
heart,O
rate,O
remained,O
normal,O
.,O
By,I-Entity
inhibiting,O
the,O
cytochrome,O
P450,I-Entity
2D6,I-Entity
",",O
terbinafine,I-Entity
had,O
decreased,O
metoprolol,I-Entity
's,I-Entity
clearance,O
",",O
leading,O
in,O
metoprolol,I-Entity
accumulation,O
which,O
has,O
resulted,O
in,O
clinically,O
significant,O
sinus,O
bradycardia,I-Entity
.,O
Optochiasmatic,I-Entity
and,O
peripheral,O
neuropathy,I-Entity
due,O
to,O
ethambutol,I-Entity
overtreatment,I-Entity
.,O
Ethambutol,I-Entity
is,O
known,O
to,O
cause,O
optic,O
neuropathy,I-Entity
and,O
",",O
more,O
rarely,O
",",O
axonal,O
polyneuropathy,I-Entity
.,O
We,I-Entity
characterize,O
the,O
clinical,O
",",O
neurophysiological,O
",",O
and,O
neuroimaging,O
findings,O
in,O
a,O
72-year,O
-,O
old,O
man,O
who,O
developed,O
visual,O
loss,I-Entity
and,O
paresthesias,I-Entity
after,O
11,O
weeks,O
of,O
exposure,O
to,O
a,O
supratherapeutic,I-Entity
dose,O
of,O
ethambutol,I-Entity
.,O
This,I-Entity
case,O
demonstrates,O
the,O
selective,O
vulnerability,O
of,O
the,O
anterior,O
visual,O
pathways,O
and,O
peripheral,O
nerves,I-Entity
to,O
ethambutol,I-Entity
toxicity,I-Entity
.,O
Testosterone,I-Entity
ameliorates,O
streptozotocin,I-Entity
-,O
induced,O
memory,O
impairment,I-Entity
in,O
male,O
rats,O
.,O
AIM,I-Entity
:,O
To,I-Entity
study,O
the,O
effects,O
of,O
testosterone,I-Entity
on,O
streptozotocin,I-Entity
(,O
STZ)-induced,I-Entity
memory,O
impairment,I-Entity
in,O
male,O
rats,O
.,O
Adult,I-Entity
male,O
Wistar,I-Entity
rats,O
were,O
intracerebroventricularly,O
(,O
icv,O
),O
infused,O
with,O
STZ,I-Entity
(,O
750,O
ug,I-Entity
),O
on,O
d,O
1,O
and,O
d,O
3,O
",",O
and,O
a,O
passive,O
avoidance,I-Entity
task,O
was,O
assessed,O
2,O
weeks,O
after,O
the,O
first,O
injection,O
of,O
STZ,I-Entity
.,O
Testosterone,I-Entity
(,O
1,O
mg.kg(-1).d(-1,O
),O
",",O
sc,O
),O
",",O
the,O
androgen,I-Entity
receptor,O
antagonist,O
flutamide,I-Entity
(,O
10,O
mg.kg(-1).d(-1,O
),O
",",O
ip,O
),O
",",O
the,O
estrogen,I-Entity
receptor,O
antagonist,O
tamoxifen,I-Entity
(,O
1,O
mg.kg(-1).d(-1,O
),O
",",O
ip,O
),O
or,O
the,O
aromatase,O
inhibitor,O
letrozole,I-Entity
(,O
4,O
mg.kg(-1).d(-1,O
),O
",",O
ip,O
),O
were,O
administered,O
for,O
6,O
d,O
after,O
the,O
first,O
injection,O
of,O
STZ,I-Entity
.,O
STZ,I-Entity
administration,O
and,O
castration,I-Entity
markedly,O
decreased,O
both,O
STL1,I-Entity
(,O
the,O
short,I-Entity
memory,O
),O
and,O
STL2,I-Entity
(,O
the,O
long,O
memory,O
),O
in,O
passive,O
avoidance,I-Entity
tests,O
.,O
Testosterone,I-Entity
replacement,O
almost,O
restored,O
the,O
STL1,I-Entity
and,O
STL2,I-Entity
in,O
castrated,I-Entity
rats,O
",",O
and,O
significantly,O
prolonged,O
the,O
STL1,I-Entity
and,O
STL2,I-Entity
in,O
STZ,I-Entity
-,O
treated,O
rats,O
.,O
Administration,I-Entity
of,O
flutamide,I-Entity
",",O
letrozole,I-Entity
or,O
tamoxifen,I-Entity
significantly,O
impaired,I-Entity
the,O
memory,O
in,O
intact,O
rats,O
",",O
and,O
significantly,O
attenuated,O
the,O
testosterone,I-Entity
replacement,O
in,O
improving,O
STZ-,I-Entity
and,O
castration,I-Entity
-,O
induced,O
memory,O
impairment,I-Entity
.,O
Testosterone,I-Entity
administration,O
ameliorates,O
STZ-,I-Entity
and,O
castration,I-Entity
-,O
induced,O
memory,O
impairment,I-Entity
in,O
male,O
Wistar,I-Entity
rats,O
.,O
Behavioral,I-Entity
and,O
neurochemical,O
studies,O
in,O
mice,O
pretreated,O
with,O
garcinielliptone,I-Entity
FC,I-Entity
in,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
.,O
Garcinielliptone,I-Entity
FC,I-Entity
(,O
GFC,I-Entity
),O
isolated,O
from,O
hexanic,I-Entity
fraction,O
seed,O
extract,O
of,O
species,O
Platonia,I-Entity
insignis,I-Entity
Mart,I-Entity
.,O
It,I-Entity
is,O
widely,O
used,O
in,O
folk,O
medicine,O
to,O
treat,O
skin,O
diseases,I-Entity
in,O
both,O
humans,O
and,O
animals,O
as,O
well,O
as,O
the,O
seed,O
decoction,O
has,O
been,O
used,O
to,O
treat,O
diarrheas,I-Entity
and,O
inflammatory,O
diseases,I-Entity
.,O
However,I-Entity
",",O
there,O
is,O
no,O
research,O
on,O
GFC,I-Entity
effects,O
in,O
the,O
central,O
nervous,I-Entity
system,O
of,O
rodents,O
.,O
The,I-Entity
present,O
study,O
aimed,O
to,O
evaluate,O
the,O
GFC,I-Entity
effects,O
at,O
doses,O
of,O
25,O
",",O
50,O
or,O
75,O
mg,O
/,O
kg,O
on,O
seizure,I-Entity
parameters,O
to,O
determine,O
their,O
anticonvulsant,O
activity,O
and,O
its,O
effects,O
on,O
amino,I-Entity
acid,O
(,O
r,O
-,O
aminobutyric,I-Entity
acid,O
(,O
GABA,I-Entity
),O
",",O
glutamine,I-Entity
",",O
aspartate,I-Entity
and,O
glutathione,I-Entity
),O
levels,O
as,O
well,O
as,O
on,O
acetylcholinesterase,O
(,O
AChE,I-Entity
),O
activity,O
in,O
mice,O
hippocampus,O
after,O
seizures,I-Entity
.,O
GFC,I-Entity
produced,O
an,O
increased,O
latency,O
to,O
first,O
seizure,I-Entity
",",O
at,O
doses,O
25mg,I-Entity
/,O
kg,O
(,O
20.12,O
+,O
2.20,O
min,O
),O
",",O
50mg,I-Entity
/,O
kg,O
(,O
20.95,O
+,O
2.21,O
min,O
),O
or,O
75,O
mg,O
/,O
kg,O
(,O
23.43,O
+,O
1.99,O
min,O
),O
when,O
compared,O
with,O
seized,O
mice,O
.,O
In,I-Entity
addition,O
",",O
GABA,I-Entity
content,O
of,O
mice,O
hippocampus,O
treated,O
with,O
GFC75,I-Entity
plus,O
P400,I-Entity
showed,O
an,O
increase,O
of,O
46.90%,O
when,O
compared,O
with,O
seized,O
mice,O
.,O
In,I-Entity
aspartate,I-Entity
",",O
glutamine,I-Entity
and,O
glutamate,I-Entity
levels,O
detected,O
a,O
decrease,O
of,O
5.21%,O
",",O
13.55%,O
and,O
21.80%,O
",",O
respectively,O
in,O
mice,O
hippocampus,O
treated,O
with,O
GFC75,I-Entity
plus,O
P400,I-Entity
when,O
compared,O
with,O
seized,O
mice,O
.,O
The,I-Entity
results,O
indicate,O
that,O
GFC,I-Entity
can,O
exert,I-Entity
anticonvulsant,O
activity,O
and,O
reduce,O
the,O
frequency,O
of,O
installation,O
of,O
pilocarpine,I-Entity
-,O
induced,O
status,O
epilepticus,I-Entity
",",O
as,O
demonstrated,O
by,O
increase,O
in,O
latency,O
to,O
first,O
seizure,I-Entity
and,O
decrease,O
in,O
mortality,O
rate,O
of,O
animals,O
.,O
In,I-Entity
conclusion,O
",",O
our,O
data,O
suggest,O
that,O
GFC,I-Entity
may,O
influence,O
in,O
epileptogenesis,O
and,O
promote,O
anticonvulsant,O
actions,O
in,O
pilocarpine,I-Entity
model,O
by,O
modulating,O
the,O
GABA,I-Entity
and,O
glutamate,I-Entity
contents,O
and,O
of,O
AChE,I-Entity
activity,O
in,O
seized,O
mice,O
hippocampus,O
.,O
Standard,I-Entity
operating,O
procedures,O
for,O
antibiotic,O
therapy,O
and,O
the,O
occurrence,O
of,O
acute,O
kidney,O
injury,I-Entity
:,O
a,O
prospective,O
",",O
clinical,O
",",O
non,O
-,O
interventional,O
",",O
observational,O
study,O
.,O
Acute,I-Entity
kidney,O
injury,I-Entity
(,O
AKI,I-Entity
),O
occurs,O
in,O
7%,O
of,O
hospitalized,O
and,O
66%,O
of,O
Intensive,I-Entity
Care,I-Entity
Unit,I-Entity
(,O
ICU,I-Entity
),O
The,I-Entity
aim,O
of,O
this,O
study,O
was,O
to,O
investigate,O
",",O
whether,O
there,O
is,O
an,O
association,O
between,O
adherence,O
to,O
guidelines,O
(,O
standard,O
operating,O
procedures,O
(,O
SOP,I-Entity
),O
),O
for,O
potentially,O
nephrotoxic,I-Entity
antibiotics,O
and,O
the,O
occurrence,O
of,O
AKI,I-Entity
.,O
163,I-Entity
of,O
these,O
had,O
therapy,O
with,O
vancomycin,I-Entity
",",O
gentamicin,I-Entity
",",O
or,O
tobramycin,I-Entity
;,O
were,O
>,O
18,O
years,O
;,O
and,O
treated,O
in,O
the,O
ICU,I-Entity
for,O
>,O
24,O
hours,O
.,O
AKI,I-Entity
was,O
defined,O
according,O
to,O
RIFLE,I-Entity
criteria,O
.,O
Development,I-Entity
of,O
AKI,I-Entity
was,O
compared,O
between,O
groups,O
with,O
exact,O
Chi2-test,I-Entity
and,O
multivariate,O
logistic,O
regression,O
analysis,O
(,O
two,O
-,O
sided,O
P,I-Entity
<,O
0.05,O
),O
.,O
AKI,I-Entity
occurred,O
significantly,O
more,O
often,O
in,O
LAG,I-Entity
with,O
36%,O
versus,O
21%,O
in,O
HAG,I-Entity
(,O
P,I-Entity
=,O
0.035,O
),O
.,O
Basic,I-Entity
characteristics,O
were,O
comparable,O
",",O
except,O
an,O
increased,O
rate,O
of,O
soft,O
tissue,O
infections,I-Entity
in,O
LAG,I-Entity
.,O
Multivariate,I-Entity
analysis,O
revealed,O
an,O
odds,O
ratio,O
of,O
2.5-fold,O
for,O
LAG,I-Entity
to,O
develop,O
AKI,I-Entity
compared,O
with,O
HAG,I-Entity
(,O
95%,O
confidence,O
interval,O
1.195,O
to,O
5.124,O
",",O
P,I-Entity
=,O
0.039,O
),O
.,O
CONCLUSION,I-Entity
:,O
Low,I-Entity
adherence,O
to,O
SOPs,I-Entity
for,O
potentially,O
nephrotoxic,I-Entity
antibiotics,O
was,O
associated,O
with,O
a,O
higher,O
occurrence,O
of,O
AKI,I-Entity
.,O
Rhabdomyolysis,I-Entity
in,O
a,O
hepatitis,I-Entity
C,I-Entity
virus,O
infected,I-Entity
patient,O
treated,O
with,O
telaprevir,I-Entity
and,O
simvastatin,I-Entity
.,O
A,I-Entity
46-year,O
old,O
man,O
with,O
a,O
chronic,O
hepatitis,I-Entity
C,I-Entity
virus,O
infection,I-Entity
received,O
triple,O
therapy,O
with,O
ribavirin,I-Entity
",",O
pegylated,I-Entity
interferon,I-Entity
and,O
telaprevir,I-Entity
.,O
The,I-Entity
patient,O
also,O
received,O
simvastatin,I-Entity
.,O
One,I-Entity
month,O
after,O
starting,O
the,O
antiviral,O
therapy,O
",",O
the,O
patient,O
was,O
admitted,O
to,O
the,O
hospital,O
because,O
he,O
developed,O
rhabdomyolysis,I-Entity
.,O
At,I-Entity
admission,O
simvastatin,I-Entity
and,O
all,O
antiviral,O
drugs,O
were,O
discontinued,O
because,O
toxicity,I-Entity
due,O
to,O
a,O
drug,O
-,O
drug,O
interaction,O
was,O
suspected,O
.,O
The,I-Entity
creatine,I-Entity
kinase,O
peaked,O
at,O
"62,246",O
IU,I-Entity
/,O
L,I-Entity
and,O
the,O
patient,O
was,O
treated,O
with,O
intravenous,O
normal,O
saline,O
.,O
Fourteen,I-Entity
days,O
after,O
hospitalization,O
",",O
creatine,I-Entity
kinase,O
level,O
had,O
returned,O
to,O
230,O
IU,I-Entity
/,O
L,I-Entity
and,O
the,O
patient,O
was,O
discharged,O
.,O
Telaprevir,I-Entity
was,O
considered,O
the,O
probable,O
causative,O
agent,O
of,O
an,O
interaction,O
with,O
simvastatin,I-Entity
according,O
to,O
the,O
Drug,I-Entity
Interaction,I-Entity
Probability,I-Entity
Scale,I-Entity
.,O
The,I-Entity
interaction,O
is,O
due,O
to,O
inhibition,O
of,O
CYP3A4-mediated,I-Entity
simvastatin,I-Entity
clearance,O
.,O
Simvastatin,I-Entity
plasma,O
concentration,O
increased,O
30,O
times,O
in,O
this,O
patient,O
and,O
statin,I-Entity
induced,O
muscle,O
toxicity,I-Entity
is,O
related,O
to,O
the,O
concentration,O
of,O
the,O
statin,I-Entity
in,O
blood,O
.,O
In,I-Entity
conclusion,O
",",O
with,O
this,O
case,O
we,O
illustrate,O
that,O
telaprevir,I-Entity
as,O
well,O
as,O
statins,I-Entity
are,O
susceptible,O
to,O
clinical,O
relevant,O
drug,O
-,O
drug,O
interactions,O
.,O
Combination,I-Entity
of,O
bortezomib,I-Entity
",",O
thalidomide,I-Entity
",",O
and,O
dexamethasone,I-Entity
(,O
VTD,I-Entity
),O
as,O
a,O
consolidation,O
therapy,O
after,O
autologous,O
stem,O
cell,O
transplantation,O
for,O
symptomatic,O
multiple,O
myeloma,I-Entity
in,O
Japanese,I-Entity
patients,O
.,O
Consolidation,I-Entity
therapy,O
for,O
patients,O
with,O
multiple,O
myeloma,I-Entity
(,O
MM,I-Entity
),O
has,O
been,O
widely,O
adopted,O
to,O
improve,O
treatment,O
response,O
following,O
autologous,O
stem,O
cell,O
transplantation,O
.,O
In,I-Entity
this,O
study,O
",",O
we,O
retrospectively,O
analyzed,O
the,O
safety,O
and,O
efficacy,O
of,O
combination,O
regimen,I-Entity
of,O
bortezomib,I-Entity
",",O
thalidomide,I-Entity
",",O
and,O
dexamethasone,I-Entity
(,O
VTD,I-Entity
),O
as,O
consolidation,O
therapy,O
in,O
24,O
Japanese,I-Entity
patients,O
with,O
newly,O
diagnosed,O
MM,I-Entity
.,O
VTD,I-Entity
consisted,O
of,O
bortezomib,I-Entity
at,O
a,O
dose,O
of,O
1.3,O
mg,O
/,O
m(2,O
),O
and,O
dexamethasone,I-Entity
at,O
a,O
dose,O
of,O
40,O
mg,O
/,O
day,O
on,O
days,O
1,O
",",O
8,O
",",O
15,O
",",O
and,O
22,O
of,O
a,O
35-day,O
cycle,O
",",O
with,O
daily,O
oral,O
thalidomide,I-Entity
at,O
a,O
dose,O
of,O
100,O
mg,O
/,O
day,O
.,O
Grade,I-Entity
3,O
-,O
4,O
neutropenia,I-Entity
and,O
thrombocytopenia,I-Entity
were,O
documented,O
in,O
four,O
and,O
three,O
patients,O
(,O
17,O
and,O
13,O
%,O
),O
",",O
respectively,O
",",O
but,O
drug,O
dose,O
reduction,O
due,O
to,O
cytopenia,I-Entity
was,O
not,O
required,O
in,O
any,O
case,O
.,O
Peripheral,I-Entity
neuropathy,I-Entity
was,O
common,O
(,O
63,O
%,O
),O
",",O
but,O
severe,O
grade,O
3,O
-,O
4,O
peripheral,O
neuropathy,I-Entity
was,O
not,O
observed,O
.,O
Conversion,I-Entity
to,O
sirolimus,I-Entity
ameliorates,O
cyclosporine,I-Entity
-,O
induced,O
nephropathy,I-Entity
in,O
the,O
rat,O
:,O
focus,O
on,O
serum,O
",",O
urine,I-Entity
",",O
gene,O
",",O
and,O
protein,O
renal,O
expression,O
biomarkers,O
.,O
Protocols,I-Entity
of,O
conversion,O
from,O
cyclosporin,I-Entity
A,I-Entity
(,O
CsA,I-Entity
),O
to,O
sirolimus,I-Entity
(,O
SRL,I-Entity
),O
have,O
been,O
widely,O
used,O
in,O
immunotherapy,O
after,O
transplantation,O
to,O
prevent,O
CsA,I-Entity
-,O
induced,O
nephropathy,I-Entity
",",O
but,O
the,O
molecular,O
mechanisms,O
underlying,O
these,O
protocols,O
remain,O
nuclear,O
.,O
This,I-Entity
study,O
aimed,O
to,O
identify,O
the,O
molecular,O
pathways,O
and,O
putative,O
biomarkers,O
of,O
CsA,I-Entity
-,O
to,O
-,O
SRL,I-Entity
conversion,O
in,O
a,O
rat,O
model,O
.,O
Four,I-Entity
animal,O
groups,O
(,O
n,O
=,O
6,O
),O
were,O
tested,O
during,O
9,O
weeks,O
:,O
control,O
",",O
CsA,I-Entity
",",O
SRL,I-Entity
",",O
and,O
conversion,O
(,O
CsA,I-Entity
for,O
3,O
weeks,O
followed,O
by,O
SRL,I-Entity
for,O
6,O
weeks,O
),O
.,O
Renal,I-Entity
lesions,O
were,O
analyzed,O
in,O
hematoxylin,I-Entity
and,O
eosin,I-Entity
",",O
periodic,O
acid,O
-,O
Schiff,I-Entity
",",O
and,O
Masson,I-Entity
's,I-Entity
trichrome,I-Entity
stains,O
.,O
SRL,I-Entity
-,O
treated,O
rats,O
presented,O
proteinuria,I-Entity
and,O
NGAL,I-Entity
(,O
serum,O
and,O
urinary,O
),O
as,O
the,O
best,O
markers,O
of,O
renal,O
impairment,I-Entity
.,O
Short,I-Entity
CsA,I-Entity
treatment,O
presented,O
slight,O
or,O
even,O
absent,O
kidney,O
lesions,O
and,O
TGF,I-Entity
-,O
b,O
",",O
NF-,I-Entity
kb,O
",",O
mTOR,I-Entity
",",O
PCNA,I-Entity
",",O
TP53,I-Entity
",",O
KIM-1,I-Entity
",",O
and,O
CTGF,I-Entity
as,O
relevant,O
gene,O
and,O
protein,O
changes,O
.,O
Prolonged,I-Entity
CsA,I-Entity
exposure,O
aggravated,I-Entity
renal,O
damage,O
",",O
without,O
clear,O
changes,O
on,O
the,O
traditional,O
markers,O
",",O
but,O
with,O
changes,O
in,O
serums,O
TGF-,I-Entity
b,O
and,O
IL-7,O
",",O
TBARs,I-Entity
clearance,O
",",O
and,O
kidney,O
TGF,I-Entity
-,O
b,O
and,O
mTOR,I-Entity
.,O
Conversion,I-Entity
to,O
SRL,I-Entity
prevented,O
CsA,I-Entity
-,O
induced,O
renal,O
damage,O
evolution,O
(,O
absent,O
/,O
mild,O
grade,O
lesions,O
),O
",",O
while,O
NGAL,I-Entity
(,O
serum,O
versus,O
urine,I-Entity
),O
seems,O
to,O
be,O
a,O
feasible,O
biomarker,O
of,O
CsA,I-Entity
replacement,O
to,O
SRL,I-Entity
.,O
cisplatin,I-Entity
-,O
induced,O
acute,O
renal,O
injury,I-Entity
.,O
Cisplatin,I-Entity
treatment,O
has,O
been,O
adopted,O
in,O
some,O
chemotherapies,O
;,O
however,O
",",O
this,O
drug,O
can,O
induce,O
acute,O
kidney,O
injury,I-Entity
due,O
its,O
ability,O
to,O
negatively,O
affect,O
renal,O
function,O
",",O
augment,O
serum,O
levels,O
of,O
creatinine,I-Entity
and,O
urea,I-Entity
",",O
increase,O
the,O
acute,O
tubular,O
necrosis,I-Entity
score,O
and,O
up,O
-,O
regulate,O
cytokines,O
(,O
e.g.,O
",",O
IL-1b,I-Entity
and,O
TNF,I-Entity
-,O
a,O
),O
.,O
The,I-Entity
kinin,I-Entity
B2,I-Entity
receptor,O
has,O
been,O
associated,O
with,O
the,O
inflammation,I-Entity
process,O
",",O
as,O
well,O
as,O
the,O
regulation,O
of,O
cytokine,I-Entity
expression,O
",",O
and,O
its,O
deletion,I-Entity
resulted,O
in,O
an,O
improvement,O
in,O
the,O
diabetic,I-Entity
nephropathy,I-Entity
status,O
.,O
To,I-Entity
examine,O
the,O
role,O
of,O
the,O
kinin,I-Entity
B2,I-Entity
receptor,O
in,O
cisplatin,I-Entity
-,O
induced,O
acute,O
kidney,O
injury,I-Entity
",",O
kinin,I-Entity
B2,I-Entity
receptor,O
knockout,O
mice,O
were,O
challenged,O
with,O
cisplatin,I-Entity
.,O
Additionally,I-Entity
",",O
WT,I-Entity
mice,O
were,O
treated,O
with,O
a,O
B2,I-Entity
receptor,O
antagonist,O
after,O
cisplatin,I-Entity
administration,O
.,O
B2,I-Entity
receptor,O
-,O
deficient,O
mice,O
were,O
less,O
sensitive,I-Entity
to,O
this,O
drug,O
than,O
the,O
WT,I-Entity
mice,O
",",O
as,O
shown,O
by,O
reduced,O
weight,O
loss,I-Entity
",",O
better,O
preservation,O
of,O
kidney,O
function,O
",",O
down,O
regulation,O
of,O
inflammatory,O
cytokines,O
and,O
less,O
acute,O
tubular,O
necrosis,I-Entity
.,O
Moreover,I-Entity
",",O
treatment,O
with,O
the,O
kinin,I-Entity
B2,I-Entity
receptor,O
antagonist,O
effectively,O
reduced,O
the,O
levels,O
of,O
serum,O
creatinine,I-Entity
and,O
blood,O
urea,I-Entity
after,O
cisplatin,I-Entity
administration,O
.,O
Thus,I-Entity
",",O
our,O
data,O
suggest,O
that,O
the,O
kinin,I-Entity
B2,I-Entity
receptor,O
is,O
involved,O
in,O
cisplatin,I-Entity
-,O
induced,O
acute,O
kidney,O
injury,I-Entity
by,O
mediating,O
the,O
necrotic,I-Entity
process,O
and,O
the,O
expression,O
of,O
inflammatory,O
cytokines,O
",",O
thus,O
resulting,O
in,O
declined,O
renal,O
function,O
.,O
These,I-Entity
results,O
highlight,O
the,O
kinin,I-Entity
B2,I-Entity
receptor,O
antagonist,O
treatment,O
in,O
amelioration,O
of,O
nephrotoxicity,I-Entity
induced,O
by,O
cisplatin,I-Entity
therapy,O
.,O
Safety,I-Entity
and,O
efficacy,O
of,O
fluocinolone,I-Entity
acetonide,I-Entity
intravitreal,O
implant,O
(,O
0.59,O
mg,O
),O
in,O
birdshot,O
retinochoroidopathy,I-Entity
.,O
PURPOSE,I-Entity
:,O
To,I-Entity
report,O
the,O
treatment,O
outcomes,O
of,O
the,O
fluocinolone,I-Entity
acetonide,I-Entity
intravitreal,O
implant,O
(,O
0.59,O
mg,O
),O
in,O
patients,O
with,O
birdshot,O
retinochoroidopathy,I-Entity
whose,O
disease,I-Entity
is,O
refractory,O
or,O
intolerant,O
to,O
conventional,O
immunomodulatory,O
therapy,O
.,O
A,I-Entity
retrospective,O
case,O
series,O
involving,O
11,O
birdshot,O
retinochoroidopathy,I-Entity
patients,O
(,O
11,O
eyes,O
),O
.,O
Eleven,I-Entity
patients,O
(,O
11,O
eyes,O
),O
underwent,O
surgery,O
for,O
fluocinolone,I-Entity
acetonide,I-Entity
implant,O
(,O
0.59,O
mg,O
),O
.,O
Treatment,I-Entity
outcomes,O
of,O
interest,O
were,O
noted,O
at,O
baseline,O
",",O
before,O
fluocinolone,I-Entity
acetonide,I-Entity
implant,O
",",O
and,O
then,O
at,O
6,O
months,O
",",O
1,O
year,O
",",O
2,O
years,O
",",O
3,O
years,O
",",O
and,O
beyond,O
3,O
years,O
.,O
Disease,I-Entity
activity,O
markers,O
",",O
including,O
signs,O
of,O
ocular,O
inflammation,I-Entity
",",O
evidence,O
of,O
retinal,B-Entity
vasculitis,I-Entity
",",O
Swedish,I-Entity
interactive,O
threshold,O
algorithm,O
-,O
short,I-Entity
wavelength,O
automated,O
perimetry,O
Humphrey,I-Entity
visual,O
field,O
analysis,O
",",O
electroretinographic,O
parameters,O
",",O
and,O
optical,O
coherence,O
tomography,O
were,O
recorded,O
.,O
Data,I-Entity
on,O
occurrence,O
of,O
cataract,I-Entity
and,O
raised,O
intraocular,O
pressure,O
were,O
collected,O
in,O
all,O
eyes,O
.,O
RESULTS,I-Entity
:,O
Intraocular,I-Entity
inflammation,I-Entity
was,O
present,O
in,O
54.5,O
",",O
9.9,O
",",O
11.1,O
",",O
and,O
0%,O
of,O
patients,O
at,O
baseline,O
",",O
6,O
months,O
",",O
1,O
year,O
",",O
2,O
years,O
",",O
3,O
years,O
",",O
and,O
beyond,O
3,O
years,O
after,O
receiving,O
the,O
implant,O
",",O
respectively,O
.,O
Active,I-Entity
vasculitis,I-Entity
was,O
noted,O
in,O
36.3%,O
patients,O
at,O
baseline,O
and,O
0%,O
at,O
3,O
years,O
of,O
follow,O
-,O
up,O
.,O
More,I-Entity
than,O
20%,O
(,O
47.61,O
-,O
67.2%,O
),O
reduction,O
in,O
central,O
retinal,B-Entity
thickness,O
was,O
noted,O
in,O
all,O
patients,O
with,O
cystoid,O
macular,O
edema,I-Entity
at,O
6,O
months,O
",",O
1,O
year,O
",",O
2,O
years,O
",",O
and,O
3,O
years,O
postimplant,I-Entity
.,O
Adverse,I-Entity
events,O
included,O
increased,O
intraocular,O
pressure,O
(,O
54.5%,O
),O
and,O
cataract,I-Entity
formation,O
(,O
100%,O
),O
.,O
The,I-Entity
data,O
suggest,O
that,O
fluocinolone,I-Entity
acetonide,I-Entity
implant,O
(,O
0.59,O
mg,O
),O
helps,O
to,O
control,O
inflammation,I-Entity
in,O
otherwise,O
treatment,O
-,O
refractory,O
cases,O
of,O
birdshot,O
retinochoroidopathy,I-Entity
.,O
It,I-Entity
is,O
associated,O
with,O
significant,O
side,O
effects,O
of,O
cataract,I-Entity
and,O
ocular,O
hypertension,I-Entity
requiring,O
treatment,O
.,O
Optimal,I-Entity
precurarizing,O
dose,O
of,O
rocuronium,I-Entity
to,O
decrease,O
fasciculation,I-Entity
and,O
myalgia,I-Entity
following,O
succinylcholine,I-Entity
administration,O
.,O
Succinylcholine,I-Entity
commonly,O
produces,O
frequent,O
adverse,O
effects,O
",",O
including,O
muscle,O
fasciculation,I-Entity
and,O
myalgia,I-Entity
.,O
The,I-Entity
current,O
study,O
identified,O
the,O
optimal,O
dose,O
of,O
rocuronium,I-Entity
to,O
prevent,O
succinylcholine,I-Entity
-,O
induced,O
fasciculation,I-Entity
and,O
myalgia,I-Entity
and,O
evaluated,O
the,O
influence,O
of,O
rocuronium,I-Entity
on,O
the,O
speed,O
of,O
onset,O
produced,O
by,O
succinylcholine,I-Entity
.,O
/,O
kg,O
rocuronium,I-Entity
as,O
a,O
precurarizing,O
dose,O
.,O
All,I-Entity
patients,O
received,O
succinylcholine,I-Entity
1.5,O
mg,O
/,O
kg,O
at,O
2,O
minutes,O
after,O
the,O
precurarization,O
",",O
and,O
were,O
assessed,O
the,O
incidence,O
and,O
severity,O
of,O
fasciculations,I-Entity
",",O
while,O
myalgia,I-Entity
was,O
assessed,O
at,O
24,O
hours,O
after,O
surgery,O
.,O
The,I-Entity
incidence,O
and,O
severity,O
of,O
visible,O
muscle,O
fasciculation,I-Entity
was,O
significantly,O
less,O
with,O
increasing,O
the,O
amount,O
of,O
precurarizing,O
dose,O
of,O
rocuronium,I-Entity
(,O
P,I-Entity
<,O
0.001,O
),O
.,O
Those,I-Entity
of,O
myalgia,I-Entity
tend,O
to,O
decrease,O
according,O
to,O
increasing,O
the,O
amount,O
of,O
precurarizing,O
dose,O
of,O
rocuronium,I-Entity
",",O
but,O
there,O
was,O
no,O
significance,O
(,O
P,I-Entity
=,O
0.072,O
),O
.,O
The,I-Entity
onset,O
time,O
of,O
succinylcholine,I-Entity
was,O
significantly,O
longer,O
with,O
increasing,O
the,O
amount,O
of,O
precurarizing,O
dose,O
of,O
rocuronium,I-Entity
(,O
P,I-Entity
<,O
0.001,O
),O
.,O
Precurarization,I-Entity
with,O
0.04,O
mg,O
/,O
kg,O
rocuronium,I-Entity
was,O
the,O
optimal,O
dose,O
considering,O
the,O
reduction,O
in,O
the,O
incidence,O
and,O
severity,O
of,O
fasciculation,I-Entity
and,O
myalgia,I-Entity
with,O
acceptable,O
onset,O
time,O
",",O
and,O
the,O
safe,O
and,O
effective,O
precurarization,O
.,O
Absence,I-Entity
of,O
PKC,I-Entity
-,O
alpha,O
attenuates,O
lithium,I-Entity
-,O
induced,O
nephrogenic,I-Entity
diabetes,I-Entity
insipidus,I-Entity
.,O
Lithium,I-Entity
",",O
an,O
effective,O
antipsychotic,O
",",O
induces,O
nephrogenic,I-Entity
diabetes,I-Entity
insipidus,I-Entity
(,O
NDI,I-Entity
),O
in,O
40%,O
of,O
patients,O
.,O
The,I-Entity
decreased,O
capacity,O
to,O
concentrate,O
urine,I-Entity
is,O
likely,O
due,O
to,O
lithium,I-Entity
acutely,O
disrupting,I-Entity
the,O
cAMP,I-Entity
pathway,O
and,O
chronically,O
reducing,O
urea,I-Entity
transporter,O
(,O
UT,I-Entity
-,O
A1,I-Entity
),O
and,O
water,O
channel,O
(,O
AQP2,I-Entity
),O
expression,O
in,O
the,O
inner,O
medulla,O
.,O
Targeting,I-Entity
an,O
alternative,O
signaling,O
pathway,O
",",O
such,O
as,O
PKC,I-Entity
-,O
mediated,O
signaling,O
",",O
may,O
be,O
an,O
effective,O
method,O
of,O
treating,O
lithium,I-Entity
-,O
induced,O
polyuria,I-Entity
.,O
),O
controls,O
were,O
treated,O
with,O
lithium,I-Entity
for,O
0,O
",",O
3,O
or,O
5,O
days,O
.,O
Animals,I-Entity
were,O
also,O
treated,O
with,O
lithium,I-Entity
for,O
6,O
weeks,O
.,O
Lithium,I-Entity
-,O
treated,O
WT,I-Entity
mice,O
had,O
19-fold,O
increased,O
urine,I-Entity
output,O
whereas,O
treated,O
PKCa,I-Entity
KO,I-Entity
animals,O
had,O
a,O
4-fold,O
increase,O
in,O
output,O
.,O
AQP2,I-Entity
and,O
UT,I-Entity
-,O
A1,I-Entity
expression,O
was,O
lowered,O
in,O
6,O
week,O
lithium,I-Entity
-,O
treated,O
WT,I-Entity
animals,O
whereas,O
in,O
treated,O
PKCa,I-Entity
KO,I-Entity
mice,O
",",O
AQP2,I-Entity
was,O
only,O
reduced,O
by,O
2-fold,O
and,O
UT,I-Entity
-,O
A1,I-Entity
expression,O
was,O
unaffected,O
.,O
Urinary,I-Entity
sodium,I-Entity
",",O
potassium,I-Entity
and,O
calcium,I-Entity
were,O
elevated,O
in,O
lithium,I-Entity
-,O
fed,O
WT,I-Entity
but,O
not,O
in,O
lithium,I-Entity
-,O
fed,O
PKCa,I-Entity
KO,I-Entity
mice,O
.,O
Our,I-Entity
data,O
show,O
that,O
ablation,O
of,O
PKCa,I-Entity
preserves,O
AQP2,I-Entity
and,O
UT,I-Entity
-,O
A1,I-Entity
protein,O
expression,O
and,O
localization,O
in,O
lithium,I-Entity
-,O
induced,O
NDI,I-Entity
",",O
and,O
prevents,O
the,O
development,O
of,O
the,O
severe,O
polyuria,I-Entity
associated,O
with,O
lithium,I-Entity
therapy,O
.,O
Is,I-Entity
Dysguesia,I-Entity
Going,I-Entity
to,O
be,O
a,O
Rare,I-Entity
or,O
a,O
Common,I-Entity
Side,I-Entity
-,O
effect,O
of,O
Amlodipine,I-Entity
?,O
A,I-Entity
very,O
rare,O
side,O
-,O
effect,O
of,O
amlodipine,I-Entity
is,O
dysguesia,I-Entity
.,O
We,I-Entity
report,O
a,O
case,O
about,O
a,O
female,O
with,O
essential,O
hypertension,I-Entity
on,O
drug,O
treatment,O
with,O
amlodipine,I-Entity
developed,O
loss,I-Entity
of,O
taste,O
sensation,O
.,O
We,I-Entity
conclude,O
that,O
amlodipine,I-Entity
can,O
cause,O
dysguesia,I-Entity
.,O
Here,I-Entity
",",O
we,O
describe,O
the,O
clinical,O
presentation,O
and,O
review,O
the,O
relevant,O
literature,O
on,O
amlodipine,I-Entity
and,O
dysguesia,I-Entity
.,O
Rhabdomyolysis,I-Entity
in,O
association,O
with,O
simvastatin,I-Entity
and,O
dosage,O
increment,O
in,O
clarithromycin,I-Entity
.,O
Clarithromycin,I-Entity
is,O
the,O
most,O
documented,O
cytochrome,O
P450,I-Entity
3A4,I-Entity
(,O
CYP3A4,I-Entity
),O
inhibitor,O
to,O
cause,O
an,O
adverse,O
interaction,O
with,O
simvastatin,I-Entity
.,O
This,I-Entity
particular,O
case,O
is,O
of,O
interest,O
as,O
rhabdomyolysis,I-Entity
only,O
occurred,O
after,O
an,O
increase,O
in,O
the,O
dose,O
of,O
clarithromycin,I-Entity
.,O
The,I-Entity
patient,O
developed,O
raised,O
cardiac,O
biomarkers,O
without,O
any,O
obvious,O
cardiac,O
issues,O
",",O
a,O
phenomenon,O
that,O
has,O
been,O
linked,O
to,O
rhabdomyolysis,I-Entity
previously,O
.,O
To,I-Entity
date,O
",",O
there,O
has,O
been,O
no,O
reported,O
effect,O
of,O
rhabdomyolysis,I-Entity
on,O
the,O
structure,O
and,O
function,O
of,O
cardiac,O
muscle,O
.,O
Clinicians,I-Entity
need,O
to,O
be,O
aware,O
of,O
prescribing,O
concomitant,I-Entity
medications,O
that,O
increase,O
the,O
risk,O
of,O
myopathy,I-Entity
or,O
inhibit,O
the,O
CYP3A4,I-Entity
enzyme,O
.,O
Our,I-Entity
case,O
suggests,O
that,O
troponin,I-Entity
elevation,O
could,O
be,O
associated,O
with,O
statin,I-Entity
induced,O
rhabdomyolysis,I-Entity
",",O
which,O
may,O
warrant,O
further,O
studies,O
.,O
Val204Asp,I-Entity
),O
causes,O
loss,I-Entity
of,O
activity,O
and,O
prolonged,O
apnea,I-Entity
with,O
suxamethonium,I-Entity
.,O
Butyrylcholinesterase,I-Entity
deficiency,I-Entity
is,O
characterized,O
by,O
prolonged,O
apnea,I-Entity
after,O
the,O
use,O
of,O
muscle,O
relaxants,O
(,O
suxamethonium,I-Entity
or,O
mivacurium,I-Entity
),O
in,O
patients,O
who,O
have,O
mutations,O
in,O
the,O
BCHE,I-Entity
gene,O
.,O
Here,I-Entity
",",O
we,O
report,O
a,O
case,O
of,O
prolonged,O
neuromuscular,O
block,O
after,O
administration,O
of,O
suxamethonium,I-Entity
leading,O
to,O
the,O
discovery,O
of,O
a,O
novel,O
BCHE,I-Entity
variant,O
(,O
c.695T,O
>,O
A,I-Entity
",",O
p,O
.,O
Low,I-Entity
activity,O
of,O
patient,O
plasma,O
butyrylcholinesterase,O
with,O
butyrylthiocholine,I-Entity
(,O
BTC,I-Entity
),O
and,O
benzoylcholine,I-Entity
",",O
and,O
values,O
of,O
dibucaine,I-Entity
and,O
fluoride,I-Entity
numbers,O
fit,I-Entity
with,O
heterozygous,O
atypical,O
silent,O
genotype,O
.,O
BChE,I-Entity
displays,O
a,O
pure,O
Michaelian,I-Entity
behavior,O
with,O
BTC,I-Entity
as,O
the,O
substrate,O
.,O
Both,I-Entity
catalytic,O
parameters,O
Km,I-Entity
=,O
265,I-Entity
uM,I-Entity
for,O
BTC,I-Entity
",",O
two,O
times,O
higher,O
than,O
that,O
of,O
the,O
atypical,O
enzyme,O
",",O
and,O
a,O
low,O
Vmax,I-Entity
are,O
consistent,O
with,O
the,O
absence,O
of,O
activity,O
against,O
suxamethonium,I-Entity
.,O
Val204Asp,I-Entity
is,O
disruption,I-Entity
of,O
hydrogen,I-Entity
bonding,I-Entity
between,O
Gln223,I-Entity
and,O
Glu441,I-Entity
",",O
leading,O
Ser198,I-Entity
and,O
His438,I-Entity
to,O
move,O
away,O
from,O
each,O
other,O
with,O
subsequent,O
disruption,I-Entity
of,O
the,O
catalytic,O
triad,I-Entity
functionality,O
regardless,O
of,O
the,O
type,O
of,O
substrate,O
.,O
Delayed,I-Entity
anemia,I-Entity
after,O
treatment,O
with,O
injectable,O
artesunate,I-Entity
in,O
the,O
Democratic,I-Entity
Republic,I-Entity
of,O
the,O
Congo,I-Entity
:,O
a,O
manageable,O
issue,O
.,O
Cases,I-Entity
of,O
delayed,O
hemolytic,I-Entity
anemia,I-Entity
have,O
been,O
described,O
after,O
treatment,O
with,O
injectable,O
artesunate,I-Entity
",",O
the,O
current,O
World,I-Entity
Health,I-Entity
Organization,I-Entity
(,O
WHO)-recommended,I-Entity
first,O
-,O
line,O
drug,O
for,O
the,O
treatment,O
of,O
severe,O
malaria,I-Entity
.,O
>,O
5,O
years,O
of,O
age,O
),O
were,O
followed,O
-,O
up,O
after,O
treatment,O
with,O
injectable,O
artesunate,I-Entity
for,O
severe,O
malaria,I-Entity
in,O
hospitals,O
and,O
health,O
centers,O
of,O
the,O
Democratic,I-Entity
Republic,I-Entity
of,O
the,O
Congo,I-Entity
.,O
All,I-Entity
cases,O
of,O
delayed,O
anemia,I-Entity
were,O
clinically,O
manageable,O
and,O
resolved,O
within,O
one,O
month,O
.,O
Regulation,I-Entity
of,O
signal,O
transducer,O
and,O
activator,O
of,O
transcription,O
3,O
and,O
apoptotic,O
pathways,O
by,O
betaine,I-Entity
attenuates,O
isoproterenol,I-Entity
-,O
induced,O
acute,O
myocardial,B-Entity
injury,I-Entity
in,O
rats,O
.,O
The,I-Entity
present,O
study,O
was,O
designed,O
to,O
investigate,O
the,O
cardioprotective,O
effects,O
of,O
betaine,I-Entity
on,O
acute,O
myocardial,B-Entity
ischemia,I-Entity
induced,O
experimentally,O
in,O
rats,O
focusing,O
on,O
regulation,O
of,O
signal,O
transducer,O
and,O
activator,O
of,O
transcription,O
3,O
(,O
STAT3,I-Entity
),O
and,O
apoptotic,O
pathways,O
as,O
the,O
potential,O
mechanism,O
underlying,O
the,O
drug,O
effect,O
.,O
Male,I-Entity
Sprague,I-Entity
Dawley,I-Entity
rats,O
were,O
treated,O
with,O
betaine,I-Entity
(,O
100,O
",",O
200,O
",",O
and,O
400,O
mg,O
/,O
kg,O
),O
orally,O
for,O
40,O
days,O
.,O
Acute,I-Entity
myocardial,B-Entity
ischemic,I-Entity
injury,I-Entity
was,O
induced,O
in,O
rats,O
by,O
subcutaneous,O
injection,O
of,O
isoproterenol,I-Entity
(,O
85,O
mg,O
/,O
kg,O
),O
",",O
for,O
two,O
consecutive,O
days,O
.,O
Oral,I-Entity
administration,O
of,O
betaine,I-Entity
(,O
200,O
and,O
400,O
mg,O
/,O
kg,O
),O
significantly,O
reduced,O
the,O
level,O
of,O
cardiac,O
marker,O
enzyme,O
in,O
the,O
serum,O
and,O
prevented,O
left,O
ventricular,O
remodeling,O
.,O
Western,I-Entity
blot,O
analysis,O
showed,O
that,O
isoproterenol,I-Entity
-,O
induced,O
phosphorylation,O
of,O
STAT3,I-Entity
was,O
maintained,O
or,O
further,O
enhanced,O
by,O
betaine,I-Entity
treatment,O
in,O
myocardium,I-Entity
.,O
Furthermore,I-Entity
",",O
betaine,I-Entity
(,O
200,O
and,O
400,O
mg,O
/,O
kg,O
),O
treatment,O
increased,O
the,O
ventricular,O
expression,O
of,O
Bcl-2,I-Entity
and,O
reduced,O
the,O
level,O
of,O
Bax,I-Entity
",",O
therefore,O
causing,O
a,O
significant,O
increase,O
in,O
the,O
ratio,O
of,O
Bcl-2/Bax,I-Entity
.,O
The,I-Entity
protective,O
role,O
of,O
betaine,I-Entity
on,O
myocardial,B-Entity
damage,O
was,O
further,O
confirmed,O
by,O
histopathological,O
examination,O
.,O
In,I-Entity
summary,O
",",O
our,O
results,O
showed,O
that,O
betaine,I-Entity
pretreatment,O
attenuated,O
isoproterenol,I-Entity
-,O
induced,O
acute,O
myocardial,B-Entity
ischemia,I-Entity
via,O
the,O
regulation,O
of,O
STAT3,I-Entity
and,O
apoptotic,O
pathways,O
.,O
Quetiapine,I-Entity
-,O
induced,O
neutropenia,I-Entity
in,O
a,O
bipolar,I-Entity
patient,O
with,O
hepatocellular,O
carcinoma,I-Entity
.,O
OBJECTIVE,I-Entity
:,O
Quetiapine,I-Entity
is,O
a,O
dibenzothiazepine,I-Entity
derivative,O
",",O
similar,O
to,O
clozapine,I-Entity
",",O
which,O
has,O
the,O
highest,O
risk,O
of,O
causing,O
blood,O
dyscrasias,I-Entity
",",O
especially,O
neutropenia,I-Entity
.,O
There,I-Entity
are,O
some,O
case,O
reports,O
about,O
this,O
side,O
effect,O
of,O
quetiapine,I-Entity
",",O
but,O
possible,O
risk,O
factors,O
are,O
seldom,O
discussed,O
and,O
identified,O
.,O
A,I-Entity
case,O
of,O
a,O
patient,O
with,O
hepatocellular,O
carcinoma,I-Entity
that,O
developed,O
neutropenia,I-Entity
after,O
treatment,O
with,O
quetiapine,I-Entity
is,O
described,O
here,O
.,O
CASE,I-Entity
REPORT,I-Entity
:,O
A,I-Entity
62-year,O
-,O
old,O
Taiwanese,I-Entity
widow,I-Entity
with,O
bipolar,I-Entity
disorder,I-Entity
was,O
diagnosed,O
with,O
hepatocellular,O
carcinoma,I-Entity
at,O
age,O
60,O
.,O
She,I-Entity
developed,O
leucopenia,I-Entity
after,O
being,O
treated,O
with,O
quetiapine,I-Entity
.,O
After,I-Entity
quetiapine,I-Entity
was,O
discontinued,O
",",O
her,O
white,O
blood,O
cell,O
count,O
returned,O
to,O
normal,O
.,O
CONCLUSIONS,I-Entity
:,O
Although,I-Entity
neutropenia,I-Entity
is,O
not,O
a,O
common,O
side,O
effect,O
of,O
quetiapine,I-Entity
",",O
physicians,O
should,O
be,O
cautious,O
about,O
its,O
presentation,O
and,O
associated,O
risk,O
factors,O
.,O
Hepatic,I-Entity
dysfunction,I-Entity
may,O
be,O
one,O
of,O
the,O
possible,O
risk,O
factors,O
",",O
and,O
concomitant,I-Entity
fever,I-Entity
may,O
be,O
a,O
diagnostic,O
marker,O
for,O
adverse,O
reaction,I-Entity
to,O
quetiapine,I-Entity
.,O
Lateral,I-Entity
antebrachial,I-Entity
cutaneous,O
neuropathy,I-Entity
after,O
steroid,I-Entity
injection,O
at,O
lateral,O
epicondyle,I-Entity
.,O
This,I-Entity
report,O
aimed,O
to,O
present,O
a,O
case,O
of,O
lateral,O
antebrachial,I-Entity
cutaneous,O
neuropathy,I-Entity
(,O
LACNP,I-Entity
),O
that,O
occurred,O
after,O
a,O
steroid,I-Entity
injection,O
in,O
the,O
lateral,O
epicondyle,I-Entity
to,O
treat,O
lateral,O
epicondylitis,I-Entity
in,O
a,O
40-year,O
-,O
old,O
woman,O
.,O
A,I-Entity
40-year,O
-,O
old,O
woman,O
presented,O
with,O
decreased,O
sensation,O
and,O
paresthesia,I-Entity
over,O
her,O
right,O
lateral,O
forearm,O
;,O
the,O
paresthesia,I-Entity
had,O
occurred,O
after,O
a,O
steroid,I-Entity
injection,O
in,O
the,O
right,O
lateral,O
epicondyle,I-Entity
3,O
months,O
before,O
.,O
Her,I-Entity
sensation,O
of,O
light,O
touch,O
and,O
pain,I-Entity
was,O
diminished,O
over,O
the,O
lateral,O
side,O
of,O
the,O
right,O
forearm,O
and,O
wrist,O
area,O
.,O
This,I-Entity
report,O
describes,O
the,O
case,O
of,O
a,O
woman,O
with,O
LACNP,I-Entity
that,O
developed,O
after,O
a,O
steroid,I-Entity
injection,O
for,O
the,O
treatment,O
of,O
lateral,O
epicondylitis,I-Entity
.,O
Curcumin,I-Entity
prevents,O
maleate,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
:,O
relation,O
to,O
hemodynamic,O
alterations,I-Entity
",",O
oxidative,O
stress,I-Entity
",",O
mitochondrial,O
oxygen,I-Entity
consumption,O
and,O
activity,O
of,O
respiratory,O
complex,O
I.,I-Entity
The,I-Entity
potential,O
protective,O
effect,O
of,O
the,O
dietary,O
antioxidant,O
curcumin,I-Entity
(,O
120,I-Entity
mg,O
/,O
Kg,I-Entity
/,O
day,O
for,O
6,O
days,O
),O
against,O
the,O
renal,O
injury,I-Entity
induced,O
by,O
maleate,I-Entity
was,O
evaluated,O
.,O
Tubular,I-Entity
proteinuria,I-Entity
and,O
oxidative,O
stress,I-Entity
were,O
induced,O
by,O
a,O
single,O
injection,O
of,O
maleate,I-Entity
(,O
400,O
mg,O
/,O
kg,O
),O
in,O
rats,O
.,O
Maleate,I-Entity
-,O
induced,O
renal,O
injury,I-Entity
included,O
increase,O
in,O
renal,O
vascular,O
resistance,O
and,O
in,O
the,O
urinary,O
excretion,O
of,O
total,O
protein,O
",",O
glucose,O
",",O
sodium,I-Entity
",",O
neutrophil,O
gelatinase,O
-,O
associated,O
lipocalin,I-Entity
(,O
NGAL,I-Entity
),O
and,O
N,I-Entity
-,O
acetyl,I-Entity
b,O
-,O
D,I-Entity
-,O
glucosaminidase,I-Entity
(,O
NAG,I-Entity
),O
",",O
upregulation,O
of,O
kidney,O
injury,I-Entity
molecule,O
(,O
KIM)-1,I-Entity
",",O
decrease,O
in,O
renal,O
blood,O
flow,O
and,O
claudin-2,I-Entity
expression,O
besides,O
of,O
necrosis,I-Entity
and,O
apoptosis,O
of,O
tubular,O
cells,O
on,O
24,O
h.,O
Oxidative,I-Entity
stress,I-Entity
was,O
determined,O
by,O
measuring,O
the,O
oxidation,I-Entity
of,O
lipids,O
and,O
proteins,O
and,O
diminution,I-Entity
in,O
renal,O
Nrf2,I-Entity
levels,O
.,O
Maleate,I-Entity
induced,O
cell,O
damage,O
and,O
reactive,O
oxygen,I-Entity
species,O
(,O
ROS,I-Entity
),O
production,O
in,O
LLC,I-Entity
-,O
PK1,I-Entity
cells,O
in,O
culture,O
.,O
In,I-Entity
addition,O
",",O
maleate,I-Entity
treatment,O
reduced,O
oxygen,I-Entity
consumption,O
in,O
ADP,I-Entity
-,O
stimulated,O
mitochondria,O
and,O
diminished,O
respiratory,O
control,O
index,O
when,O
using,O
malate,I-Entity
/,O
glutamate,I-Entity
as,O
substrate,O
.,O
All,I-Entity
the,O
above,O
-,O
described,O
alterations,I-Entity
were,O
prevented,O
by,O
curcumin,I-Entity
.,O
It,I-Entity
is,O
concluded,O
that,O
curcumin,I-Entity
is,O
able,O
to,O
attenuate,O
in,O
vivo,O
maleate,I-Entity
-,O
induced,O
nephropathy,I-Entity
and,O
in,O
vitro,O
cell,O
damage,O
.,O
The,I-Entity
in,O
vivo,O
protection,O
was,O
associated,O
to,O
the,O
prevention,O
of,O
oxidative,O
stress,I-Entity
and,O
preservation,O
of,O
mitochondrial,O
oxygen,I-Entity
consumption,O
and,O
activity,O
of,O
respiratory,O
complex,O
I,I-Entity
",",O
and,O
the,O
in,O
vitro,O
protection,O
was,O
associated,O
to,O
the,O
prevention,O
of,O
ROS,I-Entity
production,O
.,O
Incidence,I-Entity
of,O
solid,O
tumours,I-Entity
among,O
pesticide,O
applicators,O
exposed,O
to,O
the,O
organophosphate,I-Entity
insecticide,O
diazinon,I-Entity
in,O
the,O
Agricultural,I-Entity
Health,I-Entity
Study,I-Entity
:,O
an,O
updated,O
analysis,O
.,O
OBJECTIVE,I-Entity
:,O
Diazinon,I-Entity
",",O
a,O
common,O
organophosphate,I-Entity
insecticide,O
with,O
genotoxic,I-Entity
properties,O
",",O
was,O
previously,O
associated,O
with,O
lung,O
cancer,I-Entity
in,O
the,O
Agricultural,I-Entity
Health,I-Entity
Study,I-Entity
(,O
AHS,I-Entity
),O
cohort,O
",",O
but,O
few,O
other,O
epidemiological,O
studies,O
have,O
examined,O
diazinon,I-Entity
-,O
associated,O
cancer,I-Entity
risk,O
.,O
We,I-Entity
used,O
updated,O
diazinon,I-Entity
exposure,O
and,O
cancer,I-Entity
incidence,O
information,O
to,O
evaluate,O
solid,O
tumour,I-Entity
risk,O
in,O
the,O
AHS,I-Entity
.,O
Male,I-Entity
pesticide,O
applicators,O
in,O
Iowa,I-Entity
and,O
North,I-Entity
Carolina,I-Entity
reported,O
lifetime,O
diazinon,I-Entity
use,O
at,O
enrolment,O
(,O
1993,O
-,O
1997,O
),O
and,O
follow,O
-,O
up,O
(,O
1998,O
-,O
2005,O
),O
;,O
cancer,I-Entity
incidence,O
was,O
assessed,O
through,O
2010(North,O
Carolina)/2011(Iowa,O
),O
.,O
Among,I-Entity
applicators,O
with,O
usage,O
information,O
sufficient,O
to,O
evaluate,O
exposure,O
-,O
response,O
patterns,O
",",O
we,O
used,O
Poisson,I-Entity
regression,O
to,O
estimate,O
adjusted,O
rate,O
ratios,O
(,O
RRs,I-Entity
),O
and,O
95%,O
CI,I-Entity
for,O
cancer,I-Entity
sites,O
with,O
>,O
10,O
exposed,O
cases,O
for,O
both,O
lifetime,O
(,O
LT,I-Entity
),O
exposure,O
days,O
and,O
intensity,O
-,O
weighted,O
(,O
IW,I-Entity
),O
lifetime,O
exposure,O
days,O
(,O
accounting,O
for,O
factors,O
impacting,I-Entity
exposure,O
),O
.,O
We,I-Entity
observed,O
elevated,O
lung,O
cancer,I-Entity
risks,O
(,O
N=283,I-Entity
),O
among,O
applicators,O
with,O
the,O
greatest,O
number,O
of,O
LT,I-Entity
(,O
RR=1.60,I-Entity
;,O
95%,O
CI,I-Entity
1.11,O
to,O
2.31,O
;,O
Ptrend=0.02,I-Entity
),O
and,O
IW,I-Entity
days,O
of,O
diazinon,I-Entity
use,O
(,O
RR=1.41,I-Entity
;,O
95%,O
CI,I-Entity
0.98,O
to,O
2.04,O
;,O
Ptrend=0.08,I-Entity
),O
.,O
Kidney,I-Entity
cancer,I-Entity
(,O
N=94,O
),O
risks,O
were,O
non,O
-,O
significantly,O
elevated,O
(,O
RRLT,I-Entity
days=1.77,O
;,O
95%,O
CI,I-Entity
0.90,O
to,O
3.51,O
;,O
Ptrend=0.09,I-Entity
;,O
RRIW,I-Entity
days,O
1.37,O
;,O
95%,O
CI,I-Entity
0.64,O
to,O
2.92,O
;,O
Ptrend=0.50,I-Entity
),O
",",O
as,O
were,O
risks,O
for,O
aggressive,I-Entity
prostate,O
cancer,I-Entity
(,O
N=656,O
),O
.,O
Our,I-Entity
updated,O
evaluation,O
of,O
diazinon,I-Entity
provides,O
additional,O
evidence,O
of,O
an,O
association,O
with,O
lung,O
cancer,I-Entity
risk,O
.,O
Newly,I-Entity
identified,O
links,O
to,O
kidney,O
cancer,I-Entity
and,O
associations,O
with,O
aggressive,I-Entity
prostate,O
cancer,I-Entity
require,O
further,O
evaluation,O
.,O
Associations,I-Entity
of,O
Ozone,I-Entity
and,O
PM2.5,I-Entity
Concentrations,I-Entity
With,I-Entity
Parkinson,I-Entity
's,I-Entity
Disease,I-Entity
Among,I-Entity
Participants,I-Entity
in,O
the,O
Agricultural,I-Entity
Health,I-Entity
Study,I-Entity
.,O
This,I-Entity
study,O
describes,O
associations,O
of,O
ozone,I-Entity
and,O
fine,O
particulate,I-Entity
matter,O
with,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
observed,O
among,O
farmers,O
in,O
North,I-Entity
Carolina,I-Entity
and,O
Iowa,I-Entity
.,O
:,O
We,I-Entity
used,O
logistic,O
regression,O
to,O
determine,O
the,O
associations,O
of,O
these,O
pollutants,I-Entity
with,O
self,O
-,O
reported,O
",",O
doctor,O
-,O
diagnosed,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
.,O
We,I-Entity
observed,O
positive,O
associations,O
of,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
with,O
ozone,I-Entity
(,O
odds,O
ratio,O
=,O
1.39,O
;,O
95%,O
CI,I-Entity
:,O
0.98,O
to,O
1.98,O
),O
and,O
fine,O
particulate,I-Entity
matter,O
(,O
odds,O
ratio,O
=,O
1.34,O
;,O
95%,O
CI,I-Entity
:,O
0.93,O
to,O
1.93,O
),O
in,O
North,I-Entity
Carolina,I-Entity
but,O
not,O
in,O
Iowa,I-Entity
.,O
The,I-Entity
plausibility,O
of,O
an,O
effect,O
of,O
ambient,O
concentrations,O
of,O
these,O
pollutants,I-Entity
on,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
risk,O
is,O
supported,O
by,O
experimental,O
data,O
demonstrating,O
damage,O
to,O
dopaminergic,O
neurons,O
at,O
relevant,O
concentrations,O
.,O
Low,I-Entity
functional,O
programming,O
of,O
renal,O
AT2R,I-Entity
mediates,O
the,O
developmental,O
origin,O
of,O
glomerulosclerosis,I-Entity
in,O
adult,O
offspring,O
induced,O
by,O
prenatal,O
caffeine,I-Entity
exposure,O
.,O
UNASSIGNED,I-Entity
:,O
Our,I-Entity
previous,O
study,O
has,O
indicated,O
that,O
prenatal,O
caffeine,I-Entity
exposure,O
(,O
PCE,I-Entity
),O
could,O
induce,O
intrauterine,O
growth,O
retardation,I-Entity
(,O
IUGR,I-Entity
),O
of,O
offspring,O
.,O
Recent,I-Entity
research,O
suggested,O
that,O
IUGR,I-Entity
is,O
a,O
risk,O
factor,O
for,O
glomerulosclerosis,I-Entity
.,O
However,I-Entity
",",O
whether,O
PCE,I-Entity
could,O
induce,O
glomerulosclerosis,I-Entity
and,O
its,O
underlying,O
mechanisms,O
remain,O
unknown,O
.,O
This,I-Entity
study,O
aimed,O
to,O
demonstrate,O
the,O
induction,O
to,O
glomerulosclerosis,I-Entity
in,O
adult,O
offspring,O
by,O
PCE,I-Entity
and,O
its,O
intrauterine,O
programming,O
mechanisms,O
.,O
A,I-Entity
rat,O
model,O
of,O
IUGR,I-Entity
was,O
established,O
by,O
PCE,I-Entity
",",O
male,O
fetuses,O
and,O
adult,O
offspring,O
at,O
the,O
age,O
of,O
postnatal,O
week,O
24,O
were,O
euthanized,O
.,O
The,I-Entity
results,O
revealed,O
that,O
the,O
adult,O
offspring,O
kidneys,I-Entity
in,O
the,O
PCE,I-Entity
group,O
exhibited,O
glomerulosclerosis,I-Entity
as,O
well,O
as,O
interstitial,O
fibrosis,I-Entity
",",O
accompanied,O
by,O
elevated,O
levels,O
of,O
serum,O
creatinine,I-Entity
and,O
urine,I-Entity
protein,O
.,O
Renal,I-Entity
angiotensin,I-Entity
II,I-Entity
receptor,O
type,O
2,O
(,O
AT2R,I-Entity
),O
gene,O
expression,O
in,O
adult,O
offspring,O
was,O
reduced,O
by,O
PCE,I-Entity
",",O
whereas,O
the,O
renal,O
angiotensin,I-Entity
II,I-Entity
receptor,O
type,O
1a,O
(,O
AT1aR)/AT2R,I-Entity
expression,O
ratio,O
was,O
increased,O
.,O
Moreover,I-Entity
",",O
AT2R,I-Entity
gene,O
and,O
protein,O
expressions,O
in,O
fetal,O
kidneys,I-Entity
were,O
inhibited,O
by,O
PCE,I-Entity
",",O
associated,O
with,O
the,O
repression,O
of,O
the,O
gene,O
expression,O
of,O
glial,O
-,O
cell,O
-,O
line,O
-,O
derived,O
neurotrophic,O
factor,O
(,O
GDNF)/tyrosine,I-Entity
kinase,O
receptor,O
(,O
c,O
-,O
Ret,I-Entity
),O
signaling,O
pathway,O
.,O
These,I-Entity
results,O
demonstrated,O
that,O
PCE,I-Entity
could,O
induce,O
dysplasia,I-Entity
of,O
fetal,O
kidneys,I-Entity
as,O
well,O
as,O
glomerulosclerosis,I-Entity
of,O
adult,O
offspring,O
",",O
and,O
the,O
low,O
functional,O
programming,O
of,O
renal,O
AT2R,I-Entity
might,O
mediate,O
the,O
developmental,O
origin,O
of,O
adult,O
glomerulosclerosis,I-Entity
.,O
"1,3-Butadiene",O
",",O
CML,I-Entity
and,O
the,O
t(9:22,I-Entity
),O
Epidemiological,I-Entity
studies,O
of,O
"1,3-butadiene",O
have,O
suggest,O
that,O
exposures,O
to,O
humans,O
are,O
associated,O
with,O
chronic,O
myeloid,I-Entity
leukemia,I-Entity
(,O
CML,I-Entity
),O
.,O
CML,I-Entity
has,O
a,O
well,O
-,O
documented,O
association,O
with,O
ionizing,O
radiation,O
",",O
but,O
reports,O
of,O
associations,O
with,O
chemical,O
exposures,O
have,O
been,O
questioned,O
.,O
Ionizing,I-Entity
radiation,O
is,O
capable,O
of,O
inducing,O
the,O
requisite,O
CML,I-Entity
-,O
associated,O
t(9:22,I-Entity
),O
translocation,O
(,O
Philadelphia,I-Entity
chromosome,O
),O
in,O
appropriate,O
cells,O
in,O
vitro,O
We,I-Entity
have,O
proposed,O
that,O
"1,3-butadiene",O
metabolites,O
be,O
so,O
tested,O
as,O
a,O
reality,O
check,O
on,O
the,O
epidemiological,O
reports,O
.,O
Conditions,I-Entity
that,O
will,O
be,O
required,O
for,O
studies,O
of,O
"1,3-butadiene",O
are,O
discussed,O
.,O
Cancer,I-Entity
incidence,O
and,O
metolachlor,I-Entity
use,O
in,O
the,O
Agricultural,I-Entity
Health,I-Entity
Study,I-Entity
:,O
Metolachlor,I-Entity
",",O
a,O
widely,O
used,O
herbicide,O
",",O
is,O
classified,O
as,O
a,O
Group,I-Entity
C,I-Entity
carcinogen,O
by,O
the,O
U.S.,I-Entity
Environmental,I-Entity
Protection,I-Entity
Agency,I-Entity
based,O
on,O
increased,O
liver,I-Entity
neoplasms,I-Entity
in,O
female,O
rats,O
.,O
Epidemiologic,I-Entity
studies,O
of,O
the,O
health,O
effects,O
of,O
metolachlor,I-Entity
have,O
been,O
limited,O
.,O
We,I-Entity
evaluated,O
cancer,I-Entity
incidence,O
through,O
2010/2011,O
(,O
NC,I-Entity
/,O
IA,I-Entity
),O
for,O
"49,616",O
applicators,O
",",O
53%,O
of,O
whom,O
reported,O
ever,O
using,O
metolachlor,I-Entity
.,O
We,I-Entity
used,O
Poisson,I-Entity
regression,O
to,O
evaluate,O
relations,O
between,O
two,O
metrics,O
of,O
metolachlor,I-Entity
use,O
(,O
lifetime,O
days,O
",",O
intensity,O
-,O
weighted,O
lifetime,O
days,O
),O
and,O
cancer,I-Entity
incidence,O
.,O
We,I-Entity
saw,O
no,O
association,O
between,O
metolachlor,I-Entity
use,O
and,O
incidence,O
of,O
all,O
cancers,I-Entity
combined,O
(,O
n,O
=,O
"5,701",O
with,O
a,O
5-year,O
lag,I-Entity
),O
or,O
most,O
site,O
-,O
specific,O
cancers,I-Entity
.,O
For,I-Entity
liver,I-Entity
cancer,I-Entity
",",O
in,O
analyses,O
restricted,O
to,O
exposed,O
workers,O
",",O
elevations,O
observed,O
at,O
higher,O
categories,O
of,O
use,O
were,O
not,O
statistically,O
significant,O
.,O
However,I-Entity
",",O
trends,O
for,O
both,O
lifetime,O
and,O
intensity,O
-,O
weighted,O
lifetime,O
days,O
of,O
metolachor,I-Entity
use,O
were,O
positive,O
and,O
statistically,O
significant,O
with,O
an,O
unexposed,O
reference,O
group,O
.,O
A,I-Entity
similar,O
pattern,O
was,O
observed,O
for,O
follicular,O
cell,O
lymphoma,I-Entity
",",O
but,O
no,O
other,O
lymphoma,I-Entity
subtypes,O
.,O
An,I-Entity
earlier,O
suggestion,O
of,O
increased,O
lung,O
cancer,I-Entity
risk,O
at,O
high,O
levels,O
of,O
metolachlor,I-Entity
use,O
in,O
this,O
cohort,O
was,O
not,O
confirmed,O
in,O
this,O
update,O
.,O
This,I-Entity
suggestion,O
of,O
an,O
association,O
between,O
metolachlor,I-Entity
and,O
liver,I-Entity
cancer,I-Entity
among,O
pesticide,O
applicators,O
is,O
a,O
novel,O
finding,O
and,O
echoes,I-Entity
observation,O
of,O
increased,O
liver,I-Entity
neoplasms,I-Entity
in,O
some,O
animal,O
studies,O
.,O
However,I-Entity
",",O
our,O
findings,O
for,O
both,O
liver,I-Entity
cancer,I-Entity
and,O
follicular,O
cell,O
lymphoma,I-Entity
warrant,O
follow,O
-,O
up,O
to,O
better,O
differentiate,O
effects,O
of,O
metolachlor,I-Entity
use,O
from,O
other,O
factors,O
.,O
Mechanisms,I-Entity
Underlying,I-Entity
Latent,I-Entity
Disease,I-Entity
Risk,I-Entity
Associated,I-Entity
with,O
Early,I-Entity
-,O
Life,I-Entity
Arsenic,I-Entity
Millions,I-Entity
of,O
individuals,O
worldwide,O
",",O
particularly,O
those,O
living,O
in,O
rural,O
and,O
developing,O
areas,O
",",O
are,O
exposed,O
to,O
harmful,O
levels,O
of,O
inorganic,O
arsenic,I-Entity
(,O
iAs,I-Entity
),O
in,O
their,O
drinking,I-Entity
water,O
.,O
Inorganic,I-Entity
As,I-Entity
exposure,O
during,O
key,O
developmental,O
periods,O
is,O
associated,O
with,O
a,O
variety,O
of,O
adverse,O
health,O
effects,O
including,O
those,O
that,O
are,O
evident,O
in,O
adulthood,O
.,O
There,I-Entity
is,O
considerable,O
interest,O
in,O
identifying,O
the,O
molecular,O
mechanisms,O
that,O
relate,O
early,O
-,O
life,O
iAs,I-Entity
exposure,O
to,O
the,O
development,O
of,O
these,O
latent,O
diseases,I-Entity
",",O
particularly,O
in,O
relationship,O
to,O
cancer,I-Entity
.,O
This,I-Entity
work,O
summarizes,O
research,O
on,O
the,O
molecular,O
mechanisms,O
that,O
underlie,O
the,O
increased,O
risk,O
of,O
cancer,I-Entity
development,O
in,O
adulthood,O
that,O
is,O
associated,O
with,O
early,O
-,O
life,O
iAs,I-Entity
exposure,O
.,O
DISCUSSION,I-Entity
:,O
Epigenetic,I-Entity
reprogramming,O
that,O
imparts,O
functional,O
changes,O
in,O
gene,O
expression,O
",",O
the,O
development,O
of,O
cancer,I-Entity
stem,O
cells,O
",",O
and,O
immunomodulation,O
are,O
plausible,O
underlying,O
mechanisms,O
by,O
which,O
early,O
-,O
life,O
iAs,I-Entity
exposure,O
elicits,O
latent,O
carcinogenic,I-Entity
effects,O
.,O
Evidence,I-Entity
is,O
mounting,O
that,O
relates,O
early,O
-,O
life,O
iAs,I-Entity
exposure,O
and,O
cancer,I-Entity
development,O
later,O
in,O
life,O
.,O
On,I-Entity
the,O
antiarrhythmic,O
activity,O
of,O
one,O
N,I-Entity
-,O
substituted,O
piperazine,I-Entity
derivative,O
of,O
trans-2-amino-3-hydroxy-1,B-Entity
",",O
2,O
",",O
3,O
",",O
4-tetrahydroanaphthalene,I-Entity
.,O
The,I-Entity
antiarrhythmic,O
activity,O
of,O
the,O
compound,O
"N-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)-piperazine",I-Entity
hydrochloride,I-Entity
",",O
referred,O
to,O
as,O
P11,I-Entity
",",O
is,O
studied,O
on,O
anaesthesized,O
cats,O
and,O
Wistar,I-Entity
albino,O
rats,O
",",O
as,O
well,O
as,O
on,O
non,O
-,O
anaesthesized,O
rabbits,I-Entity
.,O
Four,I-Entity
types,O
of,O
experimental,O
arrhythmia,I-Entity
are,O
used,O
--,O
with,O
BaCl2,I-Entity
",",O
with,O
chloroform,I-Entity
-,O
adrenaline,I-Entity
",",O
with,O
strophantine,I-Entity
G,I-Entity
and,O
with,O
aconitine,I-Entity
.,O
The,I-Entity
compound,O
P11,I-Entity
is,O
introduced,O
in,O
doses,O
of,O
0.25,O
and,O
0.50,O
mg,O
/,O
kg,O
intravenously,O
and,O
10,O
mg,O
/,O
kg,O
orally,O
.,O
The,I-Entity
compound,O
manifests,O
antiarrhythmic,O
activity,O
in,O
all,O
models,O
of,O
experimental,O
arrhythmia,I-Entity
used,O
",",O
causing,O
greatest,O
inhibition,O
on,O
the,O
arrhythmia,I-Entity
induced,O
by,O
chloroform,I-Entity
-,O
adrenaline,I-Entity
(,O
in,O
90,I-Entity
per,O
cent,O
),O
and,O
with,O
BaCl2,I-Entity
(,O
in,O
84,O
per,O
cent,O
),O
.,O
Experimental,I-Entity
progressive,O
muscular,O
dystrophy,I-Entity
and,O
its,O
treatment,O
with,O
high,O
doses,O
anabolizing,O
agents,O
.,O
We,I-Entity
are,O
still,O
a,O
long,O
way,O
from,O
discovering,O
an,O
unequivocal,O
pathogenetic,O
interpretation,O
of,O
progressive,O
muscular,O
dystrophy,I-Entity
in,O
man,O
.,O
Myopathy,I-Entity
due,O
to,O
lack,O
of,O
vitamin,B-Entity
E,I-Entity
and,O
myopathy,I-Entity
induced,O
by,O
certain,O
viruses,O
have,O
much,O
in,O
common,O
anatomically,O
and,O
pathologically,O
with,O
the,O
human,O
form,O
.,O
The,I-Entity
authors,O
induced,O
myodystrophy,I-Entity
in,O
the,O
rat,O
by,O
giving,O
it,O
a,O
diet,O
lacking,O
in,O
vitamin,B-Entity
E.,I-Entity
The,I-Entity
pharmacological,O
characteristics,O
of,O
vitamin,B-Entity
E,I-Entity
and,O
the,O
degenerative,B-Entity
changes,O
brought,O
about,O
by,O
its,O
deficiency,I-Entity
",",O
especially,O
in,O
the,O
muscles,O
",",O
are,O
illustrated,O
.,O
It,I-Entity
is,O
thus,O
confirmed,O
that,O
the,O
histological,O
characteristics,O
of,O
myopathic,I-Entity
rat,O
muscle,O
induced,O
experimentally,O
are,O
extraordinarily,O
similar,O
to,O
those,O
of,O
human,O
myopathy,I-Entity
as,O
confirmed,O
during,O
biopsies,O
performed,O
at,O
the,O
Orthopaedic,I-Entity
Traumatological,I-Entity
Centre,I-Entity
",",O
Florence,I-Entity
.,O
The,I-Entity
encouraging,O
results,O
obtained,O
in,O
various,O
authoratative,O
departments,O
in,O
myopathic,I-Entity
patients,O
by,O
using,O
anabolizing,O
steroids,I-Entity
have,O
encouraged,O
the,O
authors,O
to,O
investigate,O
the,O
beneficial,O
effects,O
of,O
one,O
anabolizing,O
agent,O
(,O
Dianabol,I-Entity
",",O
CIBA,I-Entity
),O
at,O
high,O
doses,O
in,O
rats,O
rendered,O
myopathic,I-Entity
by,O
a,O
diet,O
deficient,O
in,O
vitamin,B-Entity
E.,I-Entity
In,I-Entity
this,O
way,O
they,O
obtained,O
appreciable,O
changes,O
in,O
body,O
weight,O
(,O
increased,O
from,O
50,O
to,O
70,I-Entity
g,O
after,O
forty,O
days,O
at,O
a,O
dose,O
of,O
5,O
mg,O
per,O
day,O
of,O
anabolizing,O
agent,O
),O
",",O
but,O
most,O
of,O
all,O
they,O
found,O
histological,O
changes,O
due,O
to,O
"""""""""",O
regenerative,O
"""""""""",O
changes,O
in,O
the,O
muscle,O
tissue,O
",",O
which,O
however,O
maintained,O
its,O
myopathic,I-Entity
characteristics,O
in,O
the,O
control,O
animals,O
that,O
were,O
not,O
treated,O
with,O
the,O
anabolizing,O
agent,O
.,O
The,I-Entity
authors,O
conclude,O
by,O
affirming,O
the,O
undoubted,O
efficacy,O
of,O
the,O
anabolizing,O
steroids,I-Entity
in,O
experimental,O
myopathic,I-Entity
disease,I-Entity
",",O
but,O
they,O
have,O
reservations,O
as,O
to,O
the,O
transfer,O
of,O
the,O
results,O
into,O
the,O
human,O
field,O
",",O
where,O
high,O
dosage,O
can,O
not,O
be,O
carried,O
out,O
continuously,O
because,O
of,O
the,O
effects,O
of,O
the,O
drug,O
on,O
virility,I-Entity
;,O
because,O
the,O
tissue,O
injury,I-Entity
too,O
often,O
occurs,O
at,O
an,O
irreversible,O
stage,O
vis,O
-,O
a,O
-,O
vis,O
the,O
"""""""""",O
regeneration,O
"""""""""",O
of,O
the,O
muscle,O
tissue,O
;,O
and,O
finally,O
because,O
the,O
dystrophic,I-Entity
injurious,I-Entity
agent,O
is,O
certainly,O
not,O
the,O
lack,O
of,O
vitamin,B-Entity
E,I-Entity
but,O
something,O
as,O
yet,O
unknown,O
.,O
Fetal,I-Entity
risks,O
due,O
to,O
warfarin,I-Entity
therapy,O
during,O
pregnancy,I-Entity
.,O
Two,I-Entity
mothers,O
with,O
heart,O
valve,O
prosthesis,O
were,O
treated,O
with,O
warfarin,I-Entity
during,O
pregnancy,I-Entity
.,O
In,I-Entity
the,O
first,O
case,O
a,O
caesarean,O
section,O
was,O
done,O
one,O
week,O
after,O
replacement,O
of,O
warfarin,I-Entity
with,O
heparin,I-Entity
.,O
The,I-Entity
baby,O
died,O
of,O
cerebral,O
and,O
pulmonary,O
hemorrhage,I-Entity
.,O
The,I-Entity
baby,O
showed,O
warfarin,I-Entity
-,O
induced,O
embryopathy,I-Entity
with,O
nasal,O
hypoplasia,I-Entity
and,O
stippled,O
epiphyses,O
(,O
chondrodysplasia,I-Entity
punctata,I-Entity
),O
.,O
Nasal,I-Entity
hypoplasia,I-Entity
with,O
or,O
without,O
stippled,O
epiphyses,O
has,O
now,O
been,O
reported,O
in,O
11,O
infants,O
born,O
to,O
mothers,O
treated,O
with,O
warfarin,I-Entity
during,O
the,O
first,O
trimester,O
",",O
and,O
a,O
causal,O
association,O
is,O
probable,O
.,O
Isradipine,I-Entity
treatment,O
for,O
hypertension,I-Entity
in,O
general,O
practice,O
in,O
Hong,I-Entity
Kong,I-Entity
.,O
A,I-Entity
6-week,O
open,O
study,O
of,O
the,O
introduction,O
of,O
isradipine,I-Entity
treatment,O
was,O
conducted,O
in,O
general,O
practice,O
in,O
Hong,I-Entity
Kong,I-Entity
.,O
303,O
Chinese,I-Entity
patients,O
with,O
mild,O
to,O
moderate,O
hypertension,I-Entity
entered,O
the,O
study,O
.,O
The,I-Entity
main,O
side,O
-,O
effects,O
were,O
headache,I-Entity
",",O
dizziness,I-Entity
",",O
palpitation,O
and,O
flushing,I-Entity
and,O
these,O
were,O
not,O
more,O
frequent,O
than,O
reported,O
in,O
other,O
studies,O
with,O
isradipine,I-Entity
or,O
with,O
placebo,O
.,O
Similar,I-Entity
reductions,O
occurred,O
in,O
standing,O
blood,O
pressure,O
and,O
there,O
was,O
no,O
evidence,O
of,O
postural,O
hypotension,I-Entity
.,O
Tachyphylaxis,I-Entity
to,O
systemic,O
but,O
not,O
to,O
airway,O
responses,O
during,O
prolonged,O
therapy,O
with,O
high,O
dose,O
inhaled,O
salbutamol,I-Entity
in,O
asthmatics,I-Entity
.,O
High,I-Entity
doses,O
of,O
inhaled,O
salbutamol,I-Entity
produce,O
substantial,O
improvements,O
in,O
airway,O
response,O
in,O
patients,O
with,O
asthma,I-Entity
",",O
and,O
are,O
associated,O
with,O
dose,O
-,O
dependent,O
systemic,O
beta,O
-,O
adrenoceptor,O
responses,O
.,O
The,I-Entity
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
whether,O
tachyphylaxis,I-Entity
occurs,O
during,O
prolonged,O
treatment,O
with,O
high,O
dose,O
inhaled,O
salbutamol,I-Entity
.,O
Twelve,I-Entity
asthmatic,I-Entity
patients,O
(,O
FEV1,I-Entity
",",O
81,I-Entity
were,O
given,O
a,O
14-day,O
treatment,O
with,O
high,O
dose,O
inhaled,O
salbutamol,I-Entity
(,O
HDS,I-Entity
),O
",",O
"4,000",I-Entity
micrograms,O
daily,O
",",O
low,O
dose,O
inhaled,O
salbutamol,I-Entity
(,O
LDS,I-Entity
),O
",",O
800,O
micrograms,O
daily,O
",",O
or,O
placebo,O
(,O
PI,I-Entity
),O
by,O
metered,O
-,O
dose,O
inhaler,O
in,O
a,O
double,O
-,O
blind,O
",",O
randomized,O
crossover,O
design,O
.,O
During,I-Entity
the,O
14-day,O
run,O
-,O
in,O
and,O
during,O
washout,I-Entity
periods,O
",",O
inhaled,O
beta,O
-,O
agonists,I-Entity
were,O
withheld,O
and,O
ipratropium,I-Entity
bromide,I-Entity
was,O
substituted,O
for,O
rescue,O
purposes,O
.,O
chronotropic,O
(,O
HR,I-Entity
),O
",",O
tremor,I-Entity
",",O
and,O
metabolic,O
(,O
K,I-Entity
",",O
Glu,I-Entity
),O
responses,O
were,O
measured,O
at,O
each,O
step,O
(,O
from,O
100,O
to,O
"4,000",I-Entity
micrograms,O
),O
.,O
DRC,I-Entity
for,O
HR,I-Entity
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
K,I-Entity
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
and,O
Glu,I-Entity
(,O
p,O
less,O
than,O
0.005,O
),O
were,O
attenuated,O
after,O
treatment,O
with,O
HDS,I-Entity
compared,O
with,O
PI,I-Entity
.,O
There,I-Entity
were,O
also,O
differences,O
between,O
HDS,I-Entity
and,O
LDS,I-Entity
for,O
HR,I-Entity
(,O
p,O
less,O
than,O
0.001,O
),O
and,O
Glu,I-Entity
(,O
p,O
less,O
than,O
0.05,O
),O
responses,O
.,O
Frequency,I-Entity
and,O
severity,O
of,O
subjective,O
adverse,O
effects,O
were,O
also,O
reduced,O
after,O
HDS,I-Entity
:,O
tremor,I-Entity
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
palpitations,O
(,O
p,O
less,O
than,O
0.001).(ABSTRACT,O
TRUNCATED,I-Entity
AT,I-Entity
250,O
WORDS,I-Entity
),O
Increased,I-Entity
anxiogenic,O
effects,O
of,O
caffeine,I-Entity
in,O
panic,I-Entity
disorders,I-Entity
.,O
The,I-Entity
effects,O
of,O
oral,O
administration,O
of,O
caffeine,I-Entity
(,O
10,O
mg,O
/,O
kg,O
),O
on,O
behavioral,O
ratings,O
",",O
somatic,I-Entity
symptoms,O
",",O
blood,O
pressure,O
and,O
plasma,O
levels,O
of,O
3-methoxy-4-hydroxyphenethyleneglycol,B-Entity
(,O
MHPG,I-Entity
),O
and,O
cortisol,I-Entity
were,O
determined,O
in,O
17,O
healthy,O
subjects,O
and,O
21,O
patients,O
meeting,O
DSM,I-Entity
-,O
III,I-Entity
criteria,O
for,O
agoraphobia,I-Entity
with,O
panic,I-Entity
attacks,O
or,O
panic,I-Entity
disorder,I-Entity
.,O
Caffeine,I-Entity
produced,O
significantly,O
greater,O
increases,O
in,O
subject,O
-,O
rated,O
anxiety,I-Entity
",",O
nervousness,I-Entity
",",O
fear,I-Entity
",",O
nausea,I-Entity
",",O
palpitations,O
",",O
restlessness,I-Entity
",",O
and,O
tremors,I-Entity
in,O
the,O
patients,O
compared,O
with,O
healthy,O
subjects,O
.,O
In,I-Entity
the,O
patients,O
",",O
but,O
not,O
the,O
healthy,O
subjects,O
",",O
these,O
symptoms,O
were,O
significantly,O
correlated,O
with,O
plasma,O
caffeine,I-Entity
levels,O
.,O
Seventy,I-Entity
-,O
one,O
percent,O
of,O
the,O
patients,O
reported,O
that,O
the,O
behavioral,O
effects,O
of,O
caffeine,I-Entity
were,O
similar,O
to,O
those,O
experienced,O
during,O
panic,I-Entity
attacks,O
.,O
Caffeine,I-Entity
did,O
not,O
alter,O
plasma,O
MHPG,I-Entity
levels,O
in,O
either,O
the,O
healthy,O
subjects,O
or,O
patients,O
.,O
Caffeine,I-Entity
increased,O
plasma,O
cortisol,I-Entity
levels,O
equally,O
in,O
the,O
patient,O
and,O
healthy,O
groups,O
.,O
Because,I-Entity
caffeine,I-Entity
is,O
an,O
adenosine,I-Entity
receptor,O
antagonist,O
",",O
these,O
results,O
suggest,O
that,O
some,O
panic,I-Entity
disorder,I-Entity
patients,O
may,O
have,O
abnormalities,I-Entity
in,O
neuronal,O
systems,O
involving,O
adenosine,I-Entity
.,O
Patients,I-Entity
with,O
anxiety,I-Entity
disorders,I-Entity
may,O
benefit,O
by,O
avoiding,O
caffeine,I-Entity
-,O
containing,O
foods,O
and,O
beverages,O
.,O
intestinal,O
polypeptide,O
:,O
decrease,O
with,O
heart,O
failure,I-Entity
.,O
Myocardial,I-Entity
levels,O
of,O
VIP,I-Entity
were,O
assayed,O
before,O
and,O
after,O
the,O
development,O
of,O
heart,O
failure,I-Entity
in,O
two,O
canine,O
models,O
.,O
In,I-Entity
the,O
first,O
",",O
cobalt,I-Entity
cardiomyopathy,I-Entity
was,O
induced,O
in,O
eight,O
dogs,O
;,O
VIP,I-Entity
(,O
by,O
radioimmunoassay,O
),O
decreased,O
from,O
35,O
+,O
/-,O
In,I-Entity
six,O
dogs,O
with,O
doxorubicin,I-Entity
-,O
induced,O
heart,O
failure,I-Entity
",",O
VIP,I-Entity
decreased,O
from,O
31,O
+,O
/-,O
In,I-Entity
addition,O
",",O
VIP,I-Entity
content,O
of,O
left,O
ventricular,O
muscle,O
of,O
resected,O
failing,O
hearts,O
in,O
10,O
patients,O
receiving,O
a,O
heart,O
transplant,O
was,O
compared,O
with,O
the,O
papillary,I-Entity
muscles,O
in,O
14,O
patients,O
(,O
five,O
with,O
rheumatic,I-Entity
disease,I-Entity
",",O
nine,O
with,O
myxomatous,I-Entity
degeneration,I-Entity
),O
receiving,O
mitral,O
valve,O
prostheses,O
.,O
The,I-Entity
lowest,O
myocardial,B-Entity
VIP,I-Entity
concentration,O
was,O
found,O
in,O
the,O
hearts,O
of,O
patients,O
with,O
coronary,O
disease,I-Entity
(,O
one,O
patient,O
receiving,O
a,O
transplant,O
and,O
three,O
receiving,O
mitral,O
prostheses,O
),O
(,O
6.3,O
+,O
/-,O
The,I-Entity
hearts,O
without,O
coronary,O
artery,I-Entity
disease,I-Entity
(,O
average,O
ejection,O
fraction,O
of,O
this,O
group,O
62%,O
+,O
/-,O
7.9,O
pg,O
/,O
mg,O
protein,O
",",O
and,O
this,O
was,O
greater,O
than,O
in,O
hearts,O
of,O
the,O
patients,O
with,O
coronary,O
disease,I-Entity
and,O
the,O
hearts,O
of,O
patients,O
receiving,O
a,O
transplant,O
(,O
P,I-Entity
less,O
than,O
0.05,O
),O
.,O
Myocardial,I-Entity
catecholamines,I-Entity
were,O
also,O
determined,O
in,O
14,O
subjects,O
;,O
a,O
weak,O
correlation,O
(,O
r,O
=,O
0.57,O
",",O
P,I-Entity
less,O
than,O
0.05,O
),O
between,O
the,O
tissue,O
concentrations,O
of,O
VIP,I-Entity
and,O
norepinephrine,I-Entity
was,O
noted.(ABSTRACT,O
TRUNCATED,I-Entity
AT,I-Entity
250,O
WORDS,I-Entity
),O
Interstrain,I-Entity
variation,O
in,O
acute,O
toxic,I-Entity
response,O
to,O
caffeine,I-Entity
among,O
inbred,O
mice,O
.,O
Acute,I-Entity
toxic,I-Entity
dosage,O
-,O
dependent,O
behavioral,O
effects,O
of,O
caffeine,I-Entity
were,O
compared,O
in,O
adult,O
males,O
from,O
seven,O
inbred,O
mouse,O
strains,O
(,O
A,I-Entity
/,O
J,I-Entity
",",O
BALB,I-Entity
/,O
cJ,I-Entity
",",O
CBA,I-Entity
/,O
J,I-Entity
",",O
C3H,I-Entity
/,O
HeJ,I-Entity
",",O
C57BL/6J,I-Entity
",",O
DBA/2J,I-Entity
",",O
SWR,I-Entity
/,O
J,I-Entity
),O
.,O
C57BL/6J,I-Entity
",",O
chosen,O
as,O
a,O
"""""""""",O
prototypic,O
"""""""""",O
mouse,O
strain,O
",",O
was,O
used,O
to,O
determine,O
behavioral,O
responses,O
to,O
a,O
broad,O
range,O
(,O
5,O
-,O
500,O
mg,O
/,O
kg,O
),O
of,O
caffeine,I-Entity
doses,O
.,O
Five,I-Entity
phenotypic,O
characteristics,O
--,O
locomotor,O
activity,O
",",O
righting,O
ability,O
",",O
clonic,I-Entity
seizure,I-Entity
induction,O
",",O
stress,I-Entity
-,O
induced,O
lethality,O
",",O
death,I-Entity
without,O
external,O
stress,I-Entity
--,O
were,O
scored,O
at,O
various,O
caffeine,I-Entity
doses,O
in,O
drug,O
-,O
naive,O
animals,O
under,O
empirically,O
optimized,O
",",O
rigidly,I-Entity
constant,O
experimental,O
conditions,O
.,O
Mice,I-Entity
(,O
n,O
=,O
12,O
for,O
each,O
point,O
),O
received,O
single,O
IP,I-Entity
injections,O
of,O
a,O
fixed,O
volume,O
/,O
g,O
body,O
weight,O
of,O
physiological,O
saline,O
carrier,O
with,O
or,O
without,O
caffeine,I-Entity
in,O
doses,O
ranging,O
from,O
125,I-Entity
-,O
500,O
mg,O
/,O
kg,O
.,O
In,I-Entity
the,O
same,O
animals,O
the,O
occurrence,O
of,O
clonic,I-Entity
seizures,I-Entity
was,O
scored,O
as,O
to,O
time,O
of,O
onset,O
and,O
severity,O
for,O
20,O
min,O
after,O
drug,O
administration,O
.,O
When,I-Entity
these,O
proceeded,O
to,O
tonic,I-Entity
seizures,I-Entity
",",O
death,I-Entity
occurred,O
in,O
less,O
than,O
20,O
min,O
.,O
Animals,I-Entity
surviving,O
for,O
20,O
min,O
were,O
immediately,O
stressed,O
by,O
a,O
swim,O
test,O
in,O
25,O
degrees,O
C,I-Entity
water,O
",",O
and,O
death,I-Entity
-,O
producing,O
tonic,I-Entity
seizures,I-Entity
were,O
scored,O
for,O
2,O
min,O
.,O
In,I-Entity
other,O
animals,O
locomotor,O
activity,O
was,O
measured,O
15,O
or,O
60,O
min,O
after,O
caffeine,I-Entity
administration,O
.,O
By,I-Entity
any,O
single,O
behavioral,O
criterion,O
or,O
a,O
combination,O
of,O
these,O
criteria,O
",",O
marked,O
differences,O
in,O
response,O
to,O
toxic,I-Entity
caffeine,I-Entity
doses,O
were,O
observed,O
between,O
strains,O
.,O
These,I-Entity
results,O
indicate,O
that,O
behavioral,O
toxicity,I-Entity
testing,O
of,O
alkylxanthines,B-Entity
in,O
a,O
single,O
mouse,O
strain,O
may,O
be,O
misleading,O
and,O
suggest,O
that,O
toxic,I-Entity
responses,O
of,O
the,O
central,O
nervous,I-Entity
system,O
to,O
this,O
class,O
of,O
compounds,O
are,O
genetically,O
influenced,O
in,O
mammals,O
.,O
Invasive,I-Entity
carcinoma,I-Entity
of,O
the,O
renal,O
pelvis,O
following,O
cyclophosphamide,I-Entity
therapy,O
for,O
nonmalignant,O
disease,I-Entity
.,O
A,I-Entity
47-year,O
-,O
old,O
woman,O
with,O
right,O
hydroureteronephrosis,I-Entity
due,O
to,O
ureterovesical,O
junction,O
obstruction,I-Entity
had,O
gross,O
hematuria,I-Entity
after,O
being,O
treated,O
for,O
five,O
years,O
wtih,O
cyclophosphamide,I-Entity
for,O
cerebral,O
vasculitis,I-Entity
.,O
A,I-Entity
right,O
nephroureterectomy,I-Entity
was,O
required,O
for,O
control,O
of,O
bleeding,I-Entity
.,O
The,I-Entity
pathology,O
specimen,O
contained,O
clinically,O
occult,O
invasive,O
carcinoma,I-Entity
of,O
the,O
renal,O
pelvis,O
.,O
Although,I-Entity
the,O
ability,O
of,O
cyclophosphamide,I-Entity
to,O
cause,O
hemorrhagic,I-Entity
cystitis,I-Entity
and,O
urine,I-Entity
cytologic,O
abnormalities,I-Entity
indistinguishable,O
from,O
high,O
grade,O
carcinoma,I-Entity
is,O
well,O
known,O
",",O
it,O
is,O
less,O
widely,O
appreciated,O
that,O
it,O
is,O
also,O
associated,O
with,O
carcinoma,I-Entity
of,O
the,O
urinary,O
tract,O
.,O
Twenty,I-Entity
carcinomas,I-Entity
of,O
the,O
urinary,O
bladder,I-Entity
and,O
one,O
carcinoma,I-Entity
of,O
the,O
prostate,O
have,O
been,O
reported,O
in,O
association,O
with,O
its,O
use,O
.,O
The,I-Entity
present,O
case,O
is,O
the,O
first,O
carcinoma,I-Entity
of,O
the,O
renal,O
pelvis,O
reported,O
in,O
association,O
with,O
cyclophosphamide,I-Entity
treatment,O
.,O
It,I-Entity
is,O
the,O
third,O
urinary,O
tract,O
cancer,I-Entity
reported,O
in,O
association,O
with,O
cyclophosphamide,I-Entity
treatment,O
for,O
nonmalignant,O
disease,I-Entity
.,O
The,I-Entity
association,O
of,O
the,O
tumor,I-Entity
with,O
preexisting,O
hydroureteronephrosis,I-Entity
suggests,O
that,O
stasis,I-Entity
prolonged,O
and,O
intensified,O
exposure,O
of,O
upper,O
urinary,O
tract,O
epithelium,I-Entity
to,O
cyclophosphamide,I-Entity
.,O
Patients,I-Entity
who,O
are,O
candidates,O
for,O
long,O
-,O
term,O
cyclophosphamide,I-Entity
treatment,O
should,O
be,O
routinely,O
evaluated,O
for,O
obstructive,B-Entity
uropathy,I-Entity
.,O
Ascending,I-Entity
dose,O
tolerance,O
study,O
of,O
intramuscular,O
carbetocin,I-Entity
administered,O
after,O
normal,O
vaginal,O
birth,O
.,O
OBJECTIVE,I-Entity
:,O
To,I-Entity
determine,O
the,O
maximum,O
tolerated,O
dose,O
(,O
MTD,I-Entity
),O
of,O
carbetocin,I-Entity
(,O
a,O
long,O
-,O
acting,O
synthetic,O
analogue,O
of,O
oxytocin,I-Entity
),O
",",O
when,O
administered,O
immediately,O
after,O
vaginal,O
delivery,O
at,O
term,O
.,O
Carbetocin,I-Entity
was,O
given,O
as,O
an,O
intramuscular,O
injection,O
immediately,O
after,O
the,O
birth,O
of,O
the,O
infant,O
in,O
45,I-Entity
healthy,O
women,O
with,O
normal,O
singleton,I-Entity
pregnancies,O
who,O
delivered,O
vaginally,O
at,O
term,O
.,O
Dosage,I-Entity
groups,O
of,O
15,O
",",O
30,O
",",O
50,O
",",O
75,O
",",O
100,O
",",O
125,I-Entity
",",O
150,I-Entity
",",O
175,I-Entity
or,O
200,O
microg,O
carbetocin,I-Entity
were,O
assigned,O
to,O
blocks,O
of,O
three,O
women,O
according,O
to,O
the,O
continual,O
reassessment,O
method,O
(,O
CRM,I-Entity
),O
.,O
Recorded,I-Entity
were,O
dose,O
-,O
limiting,O
adverse,O
events,O
:,O
hyper-,I-Entity
or,O
hypotension,I-Entity
(,O
three,O
),O
",",O
severe,O
abdominal,O
pain,I-Entity
(,O
0,O
),O
",",O
vomiting,I-Entity
(,O
0,O
),O
and,O
retained,O
placenta,O
(,O
four,O
),O
.,O
Serious,I-Entity
adverse,O
events,O
occurred,O
in,O
seven,O
women,O
:,O
six,O
cases,O
with,O
blood,O
loss,I-Entity
>,O
or,O
=,O
1000,O
ml,O
",",O
four,O
cases,O
of,O
manual,O
placenta,O
removal,O
",",O
five,O
cases,O
of,O
additional,O
oxytocics,O
administration,O
and,O
five,O
cases,O
of,O
blood,O
transfusion,O
.,O
Maximum,I-Entity
blood,O
loss,I-Entity
was,O
greatest,O
at,O
the,O
upper,O
and,O
lower,O
dose,O
levels,O
",",O
and,O
lowest,O
in,O
the,O
70,I-Entity
-,O
125,I-Entity
microg,O
dose,O
range,O
.,O
Four,I-Entity
out,O
of,O
six,O
cases,O
with,O
blood,O
loss,I-Entity
>,O
or,O
=,O
1000,O
ml,O
occurred,O
in,O
the,O
200,O
microg,O
group,O
.,O
The,I-Entity
MTD,I-Entity
was,O
calculated,O
to,O
be,O
at,O
200,O
microg,O
carbetocin,I-Entity
.,O
A,I-Entity
pilot,O
study,O
to,O
assess,O
the,O
safety,O
of,O
dobutamine,I-Entity
stress,I-Entity
echocardiography,O
in,O
the,O
emergency,O
department,O
evaluation,O
of,O
cocaine,I-Entity
-,O
associated,O
chest,O
pain,I-Entity
.,O
STUDY,I-Entity
OBJECTIVE,I-Entity
:,O
Chest,I-Entity
pain,I-Entity
in,O
the,O
setting,O
of,O
cocaine,I-Entity
use,O
poses,O
a,O
diagnostic,O
dilemma,O
.,O
Dobutamine,I-Entity
stress,I-Entity
echocardiography,O
(,O
DSE,I-Entity
),O
is,O
a,O
widely,O
available,O
and,O
sensitive,I-Entity
test,O
for,O
evaluating,O
cardiac,O
ischemia,I-Entity
.,O
Because,I-Entity
of,O
the,O
theoretical,O
concern,O
regarding,O
administration,O
of,O
dobutamine,I-Entity
in,O
the,O
setting,O
of,O
cocaine,I-Entity
use,O
",",O
we,O
conducted,O
a,O
pilot,O
study,O
to,O
assess,O
the,O
safety,O
of,O
DSE,I-Entity
in,O
emergency,O
department,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
chest,O
pain,I-Entity
.,O
Patients,I-Entity
were,O
eligible,O
for,O
DSE,I-Entity
if,O
they,O
had,O
used,O
cocaine,I-Entity
within,O
24,O
hours,O
preceding,O
the,O
onset,O
of,O
chest,O
pain,I-Entity
and,O
had,O
a,O
normal,O
ECG,I-Entity
and,O
tropinin,O
I,I-Entity
level,O
.,O
Patients,I-Entity
exhibiting,O
signs,O
of,O
continuing,O
cocaine,I-Entity
toxicity,I-Entity
were,O
excluded,O
from,O
the,O
study,O
.,O
Two,I-Entity
patients,O
had,O
inadequate,O
resting,O
images,O
",",O
one,O
DSE,I-Entity
was,O
terminated,O
because,O
of,O
inferior,O
hypokinesis,I-Entity
",",O
another,O
DSE,I-Entity
was,O
terminated,O
because,O
of,O
a,O
rate,O
-,O
related,O
atrial,I-Entity
conduction,O
deficit,I-Entity
",",O
and,O
1,O
patient,O
did,O
not,O
reach,O
the,O
target,O
heart,O
rate,O
.,O
None,I-Entity
of,O
the,O
patients,O
experienced,O
signs,O
of,O
exaggerated,O
adrenergic,O
response,O
",",O
which,O
was,O
defined,O
as,O
a,O
systolic,O
blood,O
pressure,O
of,O
greater,O
than,O
200,O
mm,O
Hg,I-Entity
or,O
the,O
occurrence,O
of,O
tachydysrhythmias,I-Entity
(,O
excluding,O
sinus,O
tachycardia,I-Entity
),O
.,O
Further,I-Entity
suggesting,O
lack,O
of,O
exaggerated,O
adrenergic,O
response,O
",",O
13,O
(,O
65%,O
),O
of,O
20,O
patients,O
required,O
supplemental,O
atropine,I-Entity
to,O
reach,O
their,O
target,O
heart,O
rates,O
.,O
No,I-Entity
exaggerated,O
adrenergic,O
response,O
was,O
detected,O
when,O
dobutamine,I-Entity
was,O
administered,O
to,O
patients,O
with,O
cocaine,I-Entity
-,O
related,O
chest,O
pain,I-Entity
.,O
Amiodarone,I-Entity
-,O
induced,O
torsade,I-Entity
de,O
pointes,I-Entity
during,O
bladder,I-Entity
irrigation,O
:,O
an,O
unusual,O
presentation,O
--,O
a,O
case,O
report,O
.,O
The,I-Entity
authors,O
present,O
a,O
case,O
of,O
early,O
(,O
within,O
4,O
days,O
),O
development,O
of,O
torsade,I-Entity
de,O
pointes,I-Entity
(,O
TdP,I-Entity
),O
associated,O
with,O
oral,O
amiodarone,I-Entity
therapy,O
.,O
Consistent,I-Entity
with,O
other,O
reports,O
this,O
case,O
of,O
TdP,I-Entity
occurred,O
in,O
the,O
context,O
of,O
multiple,O
exacerbating,O
factors,O
including,O
hypokalemia,I-Entity
and,O
digoxin,I-Entity
excess,O
.,O
Transient,I-Entity
prolongation,O
of,O
the,O
QT,I-Entity
during,O
bladder,I-Entity
irrigation,O
prompted,O
the,O
episode,O
of,O
TdP.,I-Entity
It,I-Entity
is,O
well,O
known,O
that,O
bradycardia,I-Entity
exacerbates,O
acquired,O
TdP.,I-Entity
The,I-Entity
authors,O
speculate,O
that,O
the,O
increased,O
vagal,I-Entity
tone,O
during,O
bladder,I-Entity
irrigation,O
",",O
a,O
vagal,I-Entity
maneuver,O
",",O
in,O
the,O
context,O
of,O
amiodarone,I-Entity
therapy,O
resulted,O
in,O
amiodarone,I-Entity
-,O
induced,O
proarrhythmia,I-Entity
.,O
In,I-Entity
the,O
absence,O
of,O
amiodarone,I-Entity
therapy,O
",",O
a,O
second,O
bladder,I-Entity
irrigation,O
did,O
not,O
induce,O
TdP,I-Entity
despite,O
hypokalemia,I-Entity
and,O
hypomagnesemia,I-Entity
.,O
Acute,I-Entity
renal,O
insufficiency,I-Entity
after,O
high,O
-,O
dose,O
melphalan,I-Entity
in,O
patients,O
with,O
primary,O
systemic,O
amyloidosis,I-Entity
during,O
stem,O
cell,O
transplantation,O
.,O
Patients,I-Entity
with,O
primary,O
systemic,O
amyloidosis,I-Entity
(,O
AL,I-Entity
),O
have,O
a,O
poor,O
prognosis,O
.,O
High,I-Entity
-,O
dose,O
intravenous,O
melphalan,I-Entity
followed,O
by,O
peripheral,O
blood,O
stem,O
cell,O
transplant,O
(,O
PBSCT,I-Entity
),O
appears,O
to,O
be,O
the,O
most,O
promising,O
therapy,O
",",O
but,O
treatment,O
mortality,O
can,O
be,O
high,O
.,O
The,I-Entity
authors,O
have,O
noted,O
the,O
development,O
of,O
acute,O
renal,O
insufficiency,I-Entity
immediately,O
after,O
melphalan,I-Entity
conditioning,O
.,O
METHODS,I-Entity
:,O
Consecutive,I-Entity
AL,I-Entity
patients,O
who,O
underwent,O
PBSCT,I-Entity
were,O
studied,O
retrospectively,O
.,O
Acute,I-Entity
renal,O
insufficiency,I-Entity
(,O
ARI,I-Entity
),O
after,O
high,O
-,O
dose,O
melphalan,I-Entity
was,O
defined,O
by,O
a,O
minimum,O
increase,O
of,O
0.5,O
mg,O
/,O
dL,I-Entity
(,O
44,I-Entity
micromol,I-Entity
/,O
L,I-Entity
),O
in,O
the,O
serum,O
creatinine,I-Entity
level,O
that,O
is,O
greater,O
than,O
50%,O
of,O
baseline,O
immediately,O
after,O
conditioning,O
.,O
Of,I-Entity
the,O
80,O
patients,O
studied,O
",",O
ARI,I-Entity
developed,O
in,O
18.8%,O
of,O
the,O
patients,O
after,O
high,O
-,O
dose,O
melphalan,I-Entity
.,O
Univariate,I-Entity
analysis,O
identified,O
age,O
",",O
hypoalbuminemia,I-Entity
",",O
heavy,O
proteinuria,I-Entity
",",O
diuretic,I-Entity
use,O
",",O
and,O
urine,I-Entity
sediment,O
score,O
(,O
>,O
3,O
),O
as,O
risk,O
factors,O
.,O
Patients,I-Entity
who,O
had,O
ARI,I-Entity
after,O
high,O
-,O
dose,O
melphalan,I-Entity
underwent,O
dialysis,O
more,O
often,O
(,O
P,I-Entity
=,O
0.007,O
),O
",",O
and,O
had,O
a,O
worse,O
1-year,O
survival,O
(,O
P,I-Entity
=,O
0.03,O
),O
.,O
The,I-Entity
timing,O
of,O
renal,O
injury,I-Entity
strongly,O
suggests,O
melphalan,I-Entity
as,O
the,O
causative,O
agent,O
.,O
Ongoing,I-Entity
tubular,O
injury,I-Entity
may,O
be,O
a,O
prerequisite,O
for,O
renal,O
injury,I-Entity
by,O
melphalan,I-Entity
as,O
evidenced,O
by,O
the,O
active,O
urinary,O
sediment,O
.,O
Development,I-Entity
of,O
ARI,I-Entity
adversely,O
affected,O
the,O
outcome,O
after,O
PBSCT,I-Entity
.,O
Effective,I-Entity
preventive,O
measures,O
may,O
help,O
decrease,O
the,O
treatment,O
mortality,O
of,O
PBSCT,I-Entity
in,O
AL,I-Entity
patients,O
.,O
Impaired,I-Entity
fear,I-Entity
recognition,O
in,O
regular,O
recreational,O
cocaine,I-Entity
users,O
.,O
The,I-Entity
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
conduct,O
the,O
first,O
investigation,O
of,O
facial,O
expression,O
recognition,O
performance,O
in,O
recreational,O
cocaine,I-Entity
users,O
.,O
MATERIALS,I-Entity
AND,I-Entity
METHODS,I-Entity
:,O
Three,I-Entity
groups,O
",",O
comprised,O
of,O
21,O
cocaine,I-Entity
naive,O
participants,O
(,O
CN,I-Entity
),O
",",O
30,O
occasional,O
cocaine,I-Entity
(,O
OC,I-Entity
),O
",",O
and,O
48,I-Entity
regular,O
recreational,O
cocaine,I-Entity
(,O
RC,I-Entity
),O
users,O
",",O
were,O
compared,O
.,O
There,I-Entity
were,O
no,O
group,O
differences,O
in,O
psychopathology,I-Entity
or,O
"""""""""",O
eyes,O
task,O
"""""""""",O
performance,O
",",O
but,O
the,O
RC,I-Entity
group,O
",",O
who,O
otherwise,O
had,O
similar,O
illicit,O
substance,O
use,O
histories,O
to,O
the,O
OC,I-Entity
group,O
",",O
exhibited,O
impaired,I-Entity
fear,I-Entity
recognition,O
accuracy,O
compared,O
to,O
the,O
OC,I-Entity
and,O
CN,I-Entity
groups,O
.,O
The,I-Entity
selective,O
deficit,I-Entity
in,O
fear,I-Entity
recognition,O
accuracy,O
manifested,O
by,O
the,O
RC,I-Entity
group,O
can,O
not,O
be,O
explained,O
by,O
the,O
subacute,O
effects,O
of,O
cocaine,I-Entity
",",O
or,O
ecstasy,I-Entity
",",O
because,O
recent,O
and,O
less,O
recent,O
users,O
of,O
these,O
drugs,O
within,O
this,O
group,O
were,O
similarly,O
impaired,I-Entity
.,O
Possible,I-Entity
parallels,O
between,O
RC,I-Entity
users,O
and,O
psychopaths,I-Entity
with,O
respect,O
to,O
impaired,I-Entity
fear,I-Entity
recognition,O
",",O
amygdala,O
dysfunction,I-Entity
",",O
and,O
etiology,O
are,O
discussed,O
.,O
Corneal,I-Entity
ulcers,I-Entity
associated,O
with,O
aerosolized,O
crack,I-Entity
cocaine,I-Entity
use,O
.,O
We,I-Entity
report,O
4,O
cases,O
of,O
corneal,B-Entity
ulcers,I-Entity
associated,O
with,O
drug,O
abuse,I-Entity
.,O
The,I-Entity
pathogenesis,O
of,O
these,O
ulcers,I-Entity
and,O
management,O
of,O
these,O
patients,O
are,O
also,O
reviewed,O
.,O
METHODS,I-Entity
:,O
Review,I-Entity
of,O
all,O
cases,O
of,O
corneal,B-Entity
ulcers,I-Entity
associated,O
with,O
drug,O
abuse,I-Entity
seen,O
at,O
our,O
institution,O
from,O
July,I-Entity
2006,O
to,O
December,I-Entity
2006,O
.,O
RESULTS,I-Entity
:,O
Four,I-Entity
patients,O
with,O
corneal,B-Entity
ulcers,I-Entity
associated,O
with,O
crack,I-Entity
cocaine,I-Entity
use,O
were,O
reviewed,O
.,O
All,I-Entity
corneal,B-Entity
ulcers,I-Entity
were,O
cultured,O
",",O
and,O
the,O
patients,O
were,O
admitted,O
to,O
the,O
hospital,O
for,O
intensive,O
topical,O
antibiotic,O
treatment,O
.,O
Each,I-Entity
patient,O
received,O
comprehensive,O
health,O
care,O
",",O
including,O
medical,O
and,O
substance,O
abuse,I-Entity
consultations,O
.,O
The,I-Entity
infections,I-Entity
responded,O
to,O
antibiotic,O
treatment,O
.,O
Two,I-Entity
patients,O
needed,O
a,O
lateral,O
tarsorrhaphy,I-Entity
for,O
persistent,O
epithelial,O
defects,O
.,O
CONCLUSIONS,I-Entity
:,O
Aerosolized,I-Entity
crack,I-Entity
cocaine,I-Entity
use,O
can,O
be,O
associated,O
with,O
the,O
development,O
of,O
corneal,B-Entity
ulcers,I-Entity
.,O
Drug,I-Entity
abuse,I-Entity
provides,O
additional,O
challenges,O
for,O
management,O
.,O
Not,I-Entity
only,O
treatment,O
of,O
their,O
infections,I-Entity
but,O
also,O
the,O
overall,O
poor,O
health,O
of,O
the,O
patients,O
and,O
increased,O
risk,O
of,O
noncompliance,O
need,O
to,O
be,O
addressed,O
.,O
Comprehensive,I-Entity
care,O
may,O
provide,O
the,O
patient,O
the,O
opportunity,O
to,O
discontinue,O
their,O
substance,O
abuse,I-Entity
",",O
improve,O
their,O
overall,O
health,O
",",O
and,O
prevent,O
future,O
corneal,B-Entity
complications,O
.,O
Levetiracetam,I-Entity
as,O
an,O
adjunct,O
to,O
phenobarbital,I-Entity
treatment,O
in,O
cats,O
with,O
suspected,O
idiopathic,I-Entity
epilepsy,I-Entity
.,O
OBJECTIVE,I-Entity
:,O
To,I-Entity
assess,O
pharmacokinetics,O
",",O
efficacy,O
",",O
and,O
tolerability,O
of,O
oral,O
levetiracetam,I-Entity
administered,O
as,O
an,O
adjunct,O
to,O
phenobarbital,I-Entity
treatment,O
in,O
cats,O
with,O
poorly,O
controlled,O
suspected,O
idiopathic,I-Entity
epilepsy,I-Entity
.,O
ANIMALS,I-Entity
:,O
12,O
cats,O
suspected,O
to,O
have,O
idiopathic,I-Entity
epilepsy,I-Entity
that,O
was,O
poorly,O
controlled,O
with,O
phenobarbital,I-Entity
or,O
that,O
had,O
unacceptable,O
adverse,O
effects,O
when,O
treated,O
with,O
phenobarbital,I-Entity
.,O
Cats,I-Entity
were,O
treated,O
with,O
levetiracetam,I-Entity
(,O
20,O
mg,O
/,O
kg,O
[,O
9.1,O
mg,O
/,O
lb,O
],O
",",O
PO,I-Entity
",",O
q,O
8,O
h,O
),O
.,O
After,I-Entity
a,O
minimum,O
of,O
1,O
week,O
of,O
treatment,O
",",O
serum,O
levetiracetam,I-Entity
concentrations,O
were,O
measured,O
before,O
and,O
2,O
",",O
4,O
",",O
and,O
6,O
hours,O
after,O
drug,O
administration,O
",",O
and,O
maximum,O
and,O
minimum,O
serum,O
concentrations,O
and,O
elimination,O
half,O
-,O
life,O
were,O
calculated,O
.,O
Seizure,I-Entity
frequencies,O
before,O
and,O
after,O
initiation,O
of,O
levetiracetam,I-Entity
treatment,O
were,O
compared,O
",",O
and,O
adverse,O
effects,O
were,O
recorded,O
.,O
Median,I-Entity
maximum,O
serum,O
levetiracetam,I-Entity
concentration,O
was,O
25.5,O
microg,O
/,O
mL,I-Entity
",",O
median,O
minimum,O
serum,O
levetiracetam,I-Entity
concentration,O
was,O
8.3,O
microg,O
/,O
mL,I-Entity
",",O
and,O
median,O
elimination,O
half,O
-,O
life,O
was,O
2.9,O
hours,O
.,O
Median,I-Entity
seizure,I-Entity
frequency,O
prior,O
to,O
treatment,O
with,O
levetiracetam,I-Entity
(,O
2.1,O
seizures,I-Entity
/,O
mo,O
),O
was,O
significantly,O
higher,O
than,O
median,O
seizure,I-Entity
frequency,O
after,O
initiation,O
of,O
levetiracetam,I-Entity
treatment,O
(,O
0.42,O
seizures,I-Entity
/,O
mo,O
),O
",",O
and,O
7,O
of,O
10,O
cats,O
were,O
classified,O
as,O
having,O
responded,O
to,O
levetiracetam,I-Entity
treatment,O
(,O
ie,O
",",O
reduction,O
in,O
seizure,I-Entity
frequency,O
of,O
>,O
or=50%,O
),O
.,O
Two,I-Entity
cats,O
had,O
transient,O
lethargy,I-Entity
and,O
inappetence,I-Entity
.,O
Results,I-Entity
suggested,O
that,O
levetiracetam,I-Entity
is,O
well,O
tolerated,O
in,O
cats,O
and,O
may,O
be,O
useful,O
as,O
an,O
adjunct,O
to,O
phenobarbital,I-Entity
treatment,O
in,O
cats,O
with,O
idiopathic,I-Entity
epilepsy,I-Entity
.,O
Bilateral,I-Entity
haemorrhagic,I-Entity
infarction,I-Entity
of,O
the,O
globus,O
pallidus,O
after,O
cocaine,I-Entity
and,O
alcohol,I-Entity
intoxication,O
.,O
Cocaine,I-Entity
is,O
a,O
risk,O
factor,O
for,O
both,O
ischemic,I-Entity
and,O
haemorrhagic,I-Entity
stroke,O
.,O
We,I-Entity
present,O
the,O
case,O
of,O
a,O
31-year,O
-,O
old,O
man,O
with,O
bilateral,O
ischemia,I-Entity
of,O
the,O
globus,O
pallidus,O
after,O
excessive,O
alcohol,I-Entity
and,O
intranasal,O
cocaine,I-Entity
use,O
.,O
Drug,I-Entity
-,O
related,O
globus,O
pallidus,O
infarctions,I-Entity
are,O
most,O
often,O
associated,O
with,O
heroin,I-Entity
.,O
Bilateral,I-Entity
basal,O
ganglia,I-Entity
infarcts,I-Entity
after,O
the,O
use,O
of,O
cocaine,I-Entity
",",O
without,O
concurrent,O
heroin,I-Entity
use,O
",",O
have,O
never,O
been,O
reported,O
.,O
In,I-Entity
our,O
patient,O
",",O
transient,O
cardiac,O
arrhythmia,I-Entity
or,O
respiratory,O
dysfunction,I-Entity
related,O
to,O
cocaine,I-Entity
and/or,O
ethanol,I-Entity
use,O
were,O
the,O
most,O
likely,O
causes,O
of,O
cerebral,O
hypoperfusion,I-Entity
.,O
Acute,I-Entity
renal,O
failure,I-Entity
after,O
high,O
-,O
dose,O
methotrexate,I-Entity
therapy,O
in,O
a,O
patient,O
with,O
ileostomy,I-Entity
.,O
High,I-Entity
-,O
dose,O
methotrexate,I-Entity
(,O
HD,I-Entity
-,O
MTX,I-Entity
),O
is,O
an,O
important,O
treatment,O
for,O
Burkitt,I-Entity
lymphoma,I-Entity
",",O
but,O
can,O
cause,O
hepatic,B-Entity
and,O
renal,O
toxicity,I-Entity
when,O
its,O
clearance,O
is,O
delayed,O
.,O
We,I-Entity
report,O
a,O
case,O
of,O
acute,O
renal,O
failure,I-Entity
after,O
HD,I-Entity
-,O
MTX,I-Entity
therapy,O
in,O
a,O
patient,O
with,O
ileostomy,I-Entity
",",O
The,I-Entity
patient,O
was,O
a,O
3-year,O
-,O
old,O
boy,O
who,O
had,O
received,O
a,O
living,O
-,O
related,O
liver,I-Entity
transplantation,O
for,O
congenital,O
biliary,O
atresia,I-Entity
.,O
At,I-Entity
day,O
833,O
after,O
the,O
transplantation,O
",",O
he,O
was,O
diagnosed,O
with,O
PTLD,I-Entity
(,O
post,O
-,O
transplantation,O
lymphoproliferative,O
disorder,I-Entity
",",O
Burkitt,I-Entity
-,O
type,O
malignant,I-Entity
lymphoma,I-Entity
),O
.,O
Subsequent,I-Entity
HD,I-Entity
-,O
MTX,I-Entity
therapy,O
caused,O
acute,O
renal,O
failure,I-Entity
that,O
required,O
continuous,O
hemodialysis,O
.,O
We,I-Entity
supposed,O
that,O
intravascular,O
hypovolemia,I-Entity
due,O
to,O
substantial,O
drainage,O
from,O
the,O
ileostoma,I-Entity
caused,O
acute,O
prerenal,O
failure,I-Entity
.,O
After,I-Entity
recovery,O
of,O
his,O
renal,O
function,O
",",O
we,O
could,O
safely,O
treat,O
the,O
patient,O
with,O
HD,I-Entity
-,O
MTX,I-Entity
therapy,O
by,O
controlling,O
drainage,O
from,O
ileostoma,I-Entity
with,O
total,O
parenteral,O
nutrition,O
.,O
Antithrombotic,I-Entity
drug,O
use,O
",",O
cerebral,O
microbleeds,O
",",O
and,O
intracerebral,O
hemorrhage,I-Entity
:,O
a,O
systematic,O
review,O
of,O
published,O
and,O
unpublished,O
studies,O
.,O
BACKGROUND,I-Entity
AND,I-Entity
PURPOSE,I-Entity
:,O
Cerebral,I-Entity
microbleeds,O
(,O
MB,I-Entity
),O
are,O
potential,O
risk,O
factors,O
for,O
intracerebral,O
hemorrhage,I-Entity
(,O
ICH,I-Entity
),O
",",O
but,O
it,O
is,O
unclear,O
if,O
they,O
are,O
a,O
contraindication,I-Entity
to,O
using,O
antithrombotic,O
drugs,O
.,O
Insights,I-Entity
could,O
be,O
gained,O
by,O
pooling,O
data,O
on,O
MB,I-Entity
frequency,O
stratified,O
by,O
antithrombotic,O
use,O
in,O
cohorts,O
with,O
ICH,I-Entity
and,O
ischemic,I-Entity
stroke,O
(,O
IS)/transient,I-Entity
ischemic,I-Entity
attack,O
(,O
TIA,I-Entity
),O
.,O
:,O
We,I-Entity
performed,O
a,O
systematic,O
review,O
of,O
published,O
and,O
unpublished,O
data,O
from,O
cohorts,O
with,O
stroke,O
or,O
TIA,I-Entity
to,O
compare,O
the,O
presence,O
of,O
MB,I-Entity
in,O
:,O
(,O
1,O
),O
antithrombotic,O
users,O
vs,O
nonantithrombotic,O
users,O
with,O
ICH,I-Entity
;,O
(,O
2,O
),O
antithrombotic,O
users,O
vs,O
nonusers,O
with,O
IS,I-Entity
/,O
TIA,I-Entity
;,O
and,O
(,O
3,O
),O
ICH,I-Entity
vs,O
ischemic,I-Entity
events,O
stratified,O
by,O
antithrombotic,O
use,O
.,O
We,I-Entity
also,O
analyzed,O
published,O
and,O
unpublished,O
follow,O
-,O
up,O
data,O
to,O
determine,O
the,O
risk,O
of,O
ICH,I-Entity
in,O
antithrombotic,O
users,O
with,O
MB,I-Entity
.,O
In,I-Entity
a,O
pooled,O
analysis,O
of,O
1460,I-Entity
ICH,I-Entity
and,O
3817,I-Entity
IS,I-Entity
/,O
TIA,I-Entity
",",O
MB,I-Entity
were,O
more,O
frequent,O
in,O
ICH,I-Entity
vs,O
IS,I-Entity
/,O
TIA,I-Entity
in,O
all,O
treatment,O
groups,O
",",O
but,O
the,O
excess,O
increased,O
from,O
2.8,O
(,O
odds,O
ratio,O
;,O
range,O
",",O
2.3,O
-,O
3.5,O
),O
in,O
nonantithrombotic,O
users,O
to,O
5.7,O
(,O
range,O
",",O
3.4,O
-,O
9.7,O
),O
in,O
antiplatelet,O
users,O
and,O
8.0,O
(,O
range,O
",",O
3.5,O
-,O
17.8,O
),O
in,O
warfarin,I-Entity
users,O
(,O
P,I-Entity
difference=0.01,O
),O
.,O
There,I-Entity
was,O
also,O
an,O
excess,O
of,O
MB,I-Entity
in,O
warfarin,I-Entity
users,O
vs,O
nonusers,O
with,O
ICH,I-Entity
(,O
OR,I-Entity
",",O
2.7,O
;,O
95%,O
CI,I-Entity
",",O
1.6,O
-,O
4.4,O
;,O
P<0.001,I-Entity
),O
but,O
none,O
in,O
warfarin,I-Entity
users,O
with,O
IS,I-Entity
/,O
TIA,I-Entity
(,O
OR,I-Entity
",",O
1.3,O
;,O
95%,O
CI,I-Entity
",",O
0.9,O
-,O
1.7,O
;,O
P=0.33,I-Entity
;,O
P,I-Entity
difference=0.01,O
),O
.,O
There,I-Entity
was,O
a,O
smaller,O
excess,O
of,O
MB,I-Entity
in,O
antiplatelet,O
users,O
vs,O
nonusers,O
with,O
ICH,I-Entity
(,O
OR,I-Entity
",",O
1.7,O
;,O
95%,O
CI,I-Entity
",",O
1.3,O
-,O
2.3,O
;,O
P<0.001,I-Entity
),O
",",O
but,O
findings,O
were,O
similar,O
for,O
antiplatelet,O
users,O
with,O
IS,I-Entity
/,O
TIA,I-Entity
(,O
OR,I-Entity
",",O
1.4,O
;,O
95%,O
CI,I-Entity
",",O
1.2,O
-,O
1.7,O
;,O
P<0.001,I-Entity
;,O
P,I-Entity
difference=0.25,O
),O
.,O
In,I-Entity
pooled,O
follow,O
-,O
up,O
data,O
for,O
768,O
antithrombotic,O
users,O
",",O
presence,O
of,O
MB,I-Entity
at,O
baseline,O
was,O
associated,O
with,O
a,O
substantially,O
increased,O
risk,O
of,O
subsequent,O
ICH,I-Entity
(,O
OR,I-Entity
",",O
12.1,O
;,O
95%,O
CI,I-Entity
",",O
3.4,O
-,O
42.5,O
;,O
P<0.001,I-Entity
),O
.,O
The,I-Entity
excess,O
of,O
MB,I-Entity
in,O
warfarin,I-Entity
users,O
with,O
ICH,I-Entity
compared,O
to,O
other,O
groups,O
suggests,O
that,O
MB,I-Entity
increase,O
the,O
risk,O
of,O
warfarin,I-Entity
-,O
associated,O
ICH,I-Entity
.,O
Verapamil,I-Entity
stimulation,O
test,O
in,O
hyperprolactinemia,I-Entity
:,O
loss,I-Entity
of,O
prolactin,O
response,O
in,O
anatomic,O
or,O
functional,O
stalk,O
effect,O
.,O
Verapamil,I-Entity
stimulation,O
test,O
was,O
previously,O
investigated,O
as,O
a,O
tool,O
for,O
differential,O
diagnosis,O
of,O
hyperprolactinemia,I-Entity
",",O
but,O
with,O
conflicting,O
results,O
.,O
Macroprolactinemia,I-Entity
was,O
never,O
considered,O
in,O
those,O
previous,O
studies,O
.,O
Here,I-Entity
",",O
we,O
aimed,O
to,O
re,O
-,O
investigate,O
the,O
diagnostic,O
value,O
of,O
verapamil,I-Entity
in,O
a,O
population,O
who,O
were,O
all,O
screened,O
for,O
macroprolactinemia,I-Entity
.,O
Prolactin,I-Entity
responses,O
to,O
verapamil,I-Entity
in,O
65,O
female,O
patients,O
(,O
age,O
:,O
29.9,O
+,O
/-,O
8.1,O
years,O
),O
with,O
hyperprolactinemia,I-Entity
were,O
tested,O
in,O
a,O
descriptive,O
",",O
matched,O
case,O
-,O
control,O
study,O
.,O
METHODS,I-Entity
:,O
Verapamil,I-Entity
80,O
mg,O
",",O
p.o,O
.,O
Verapamil,I-Entity
responsiveness,O
was,O
determined,O
by,O
peak,O
percent,O
change,O
in,O
basal,O
prolactin,O
levels,O
(,O
PRL,I-Entity
),O
.,O
Verapamil,I-Entity
significantly,O
increased,O
PRL,I-Entity
levels,O
in,O
healthy,O
controls,O
(,O
N.,I-Entity
8,O
",",O
PRL,I-Entity
:,O
183%,O
),O
",",O
macroprolactinoma,I-Entity
(,O
N.,I-Entity
8,O
",",O
PRL,I-Entity
:,O
7%,O
),O
",",O
microprolactinoma,I-Entity
(,O
N.,I-Entity
19,O
",",O
PRL,I-Entity
:,O
21%,O
),O
",",O
macroprolactinemia,I-Entity
but,O
not,O
in,O
pseudoprolactinoma,I-Entity
(,O
N.,I-Entity
8,O
",",O
PRL,I-Entity
:,O
0.8%,O
),O
",",O
and,O
risperidone,I-Entity
-,O
induced,O
hyperprolactinemia,I-Entity
(,O
N.,I-Entity
7,O
",",O
ROC,I-Entity
curve,O
analysis,O
revealed,O
that,O
unresponsiveness,O
to,O
verapamil,I-Entity
defined,O
as,O
PRL,I-Entity
<,O
0.001,O
",",O
CI,I-Entity
:,O
0.768,O
-,O
0.942,O
),O
associated,O
with,O
pseudoprolactinoma,I-Entity
or,O
risperidone,I-Entity
-,O
induced,O
hyperprolactinemia,I-Entity
",",O
respectively,O
.,O
CONCLUSION,I-Entity
:,O
Verapamil,I-Entity
responsiveness,O
is,O
not,O
a,O
reliable,O
finding,O
for,O
the,O
differential,O
diagnosis,O
of,O
hyperprolactinemia,I-Entity
.,O
However,I-Entity
",",O
verapamil,I-Entity
unresponsiveness,O
discriminates,O
stalk,O
effect,O
(,O
i.e.,O
",",O
anatomically,O
or,O
functionally,O
inhibited,O
dopaminergic,O
tonus,I-Entity
),O
from,O
other,O
causes,O
of,O
hyperprolactinemia,I-Entity
with,O
varying,O
degrees,O
of,O
responsiveness,O
.,O
The,I-Entity
effect,O
of,O
clonidine,I-Entity
",",O
naphazoline,I-Entity
and,O
xylometazoline,I-Entity
on,O
analgesia,O
induced,O
by,O
morphine,I-Entity
",",O
codeine,I-Entity
",",O
fentanyl,I-Entity
and,O
pentazocine,I-Entity
",",O
and,O
on,O
cataleptic,I-Entity
effect,O
of,O
morphine,I-Entity
",",O
codine,I-Entity
and,O
fentanyl,I-Entity
was,O
studied,O
in,O
rats,O
.,O
The,I-Entity
biochemical,O
assays,O
on,O
the,O
influence,O
of,O
four,O
analgesics,O
on,O
the,O
brain,O
concentration,O
and,O
turnover,O
of,O
noradrenaline,I-Entity
(,O
NA,I-Entity
),O
were,O
also,O
performed,O
.,O
It,I-Entity
was,O
found,O
that,O
three,O
drugs,O
stimulating,O
central,O
NA,I-Entity
receptors,O
failed,O
to,O
affect,O
the,O
analgesic,O
ED50,I-Entity
of,O
all,O
antinociceptive,O
agents,O
and,O
they,O
enhanced,O
catalepsy,I-Entity
induced,O
by,O
morphine,I-Entity
and,O
fentanyl,I-Entity
.,O
Codeine,I-Entity
catalepsy,I-Entity
was,O
increased,O
by,O
clonidine,I-Entity
and,O
decreased,O
by,O
naphazoline,I-Entity
and,O
xylometazoline,I-Entity
.,O
The,I-Entity
brain,O
concentration,O
of,O
NA,I-Entity
was,O
not,O
changed,O
by,O
morphine,I-Entity
and,O
fentanyl,I-Entity
",",O
but,O
one,O
of,O
the,O
doses,O
of,O
codeine,I-Entity
(,O
45,I-Entity
mg,O
/,O
kg,O
),O
slightly,O
enhanced,O
it,O
.,O
Pentazocine,I-Entity
dose,O
-,O
dependently,O
decreased,O
the,O
brain,O
level,O
of,O
NA,I-Entity
.,O
The,I-Entity
rate,O
of,O
NA,I-Entity
turnover,O
was,O
not,O
altered,O
by,O
analgesics,O
except,O
for,O
the,O
higher,O
dose,O
of,O
fentanyl,I-Entity
(,O
0.2,O
mg,O
/,O
kg,O
),O
following,O
which,O
the,O
disappearance,I-Entity
of,O
NA,I-Entity
from,O
the,O
brain,O
was,O
diminished,O
.,O
It,I-Entity
is,O
suggested,O
that,O
in,O
rats,O
the,O
brain,O
NA,I-Entity
plays,O
a,O
less,O
important,O
function,O
than,O
the,O
other,O
monoamines,I-Entity
in,O
the,O
behavioural,O
activity,O
of,O
potent,O
analgesics,O
.,O
Modification,I-Entity
by,O
propranolol,I-Entity
of,O
cardiovascular,O
effects,O
of,O
induced,O
hypoglycaemia,I-Entity
.,O
The,I-Entity
cardiovascular,O
effects,O
of,O
hypoglycaemia,I-Entity
",",O
with,O
and,O
without,O
beta,O
-,O
blockade,O
",",O
were,O
compared,O
in,O
fourteen,O
healthy,O
men,O
.,O
Eight,I-Entity
received,O
insulin,I-Entity
alone,O
",",O
and,O
eight,O
",",O
including,O
two,O
of,O
the,O
original,O
insulin,I-Entity
-,O
only,O
group,O
",",O
were,O
given,O
propranolol,I-Entity
and,O
insulin,I-Entity
.,O
In,I-Entity
the,O
insulin,I-Entity
-,O
group,O
the,O
period,O
of,O
hypoglycaemia,I-Entity
was,O
associated,O
with,O
an,O
increase,O
in,O
heart,O
-,O
rate,O
and,O
a,O
fall,O
in,O
diastolic,I-Entity
blood,O
-,O
pressure,O
.,O
In,I-Entity
the,O
propranolol,I-Entity
-,O
insulin,I-Entity
group,O
there,O
was,O
a,O
significant,O
fall,O
in,O
heart,O
-,O
rate,O
in,O
most,O
subjects,O
and,O
an,O
increase,O
in,O
diastolic,I-Entity
pressure,O
.,O
/,O
T,I-Entity
changes,O
occurred,O
in,O
the,O
insulin,I-Entity
-,O
group,O
but,O
in,O
none,O
of,O
the,O
propranolol,I-Entity
-,O
insulin,I-Entity
group,O
.,O
Hypertension,I-Entity
in,O
diabetics,I-Entity
prone,O
to,O
hypoglycaemia,I-Entity
attacks,O
should,O
not,O
be,O
treated,O
with,O
beta,O
-,O
blockers,O
because,O
these,O
drugs,O
may,O
cause,O
a,O
sharp,O
rise,O
in,O
blood,O
-,O
pressure,O
in,O
such,O
patients,O
.,O
Prevention,I-Entity
and,O
treatment,O
of,O
endometrial,O
disease,I-Entity
in,O
climacteric,O
women,O
receiving,O
oestrogen,I-Entity
therapy,O
.,O
The,I-Entity
treatment,O
regimens,I-Entity
are,O
described,O
in,O
74,I-Entity
patients,O
with,O
endometrial,O
disease,I-Entity
among,O
850,O
climacteric,O
women,O
receiving,O
oestrogen,I-Entity
therapy,O
.,O
Cystic,I-Entity
hyperplasia,I-Entity
was,O
associated,O
with,O
unopposed,O
oestrogen,I-Entity
therapy,O
without,O
progestagen,I-Entity
.,O
Two,I-Entity
courses,O
of,O
21,O
days,O
of,O
5,O
mg,O
norethisterone,I-Entity
daily,O
caused,O
reversion,O
to,O
normal,O
in,O
all,O
57,I-Entity
cases,O
of,O
cystic,I-Entity
hyperplasia,I-Entity
and,O
6,O
of,O
the,O
8,O
cases,O
of,O
atypical,O
hyperplasia,I-Entity
.,O
4,O
cases,O
of,O
endometrial,O
carcinoma,I-Entity
referred,O
from,O
elsewhere,O
demonstrated,O
the,O
problems,O
of,O
inappropriate,O
and,O
unsupervised,O
unopposed,O
oestrogen,I-Entity
therapy,O
and,O
the,O
difficulty,O
in,O
distinguishing,O
severe,O
hyperplasia,I-Entity
from,O
malignancy,I-Entity
.,O
Cyclical,I-Entity
low,O
-,O
dose,O
oestrogen,I-Entity
therapy,O
with,O
7,O
-,O
-13,O
days,O
of,O
progestagen,I-Entity
does,O
not,O
seem,O
to,O
increase,O
the,O
risk,O
of,O
endometrial,O
hyperplasia,I-Entity
or,O
carcinoma,I-Entity
.,O
Pure,I-Entity
red,O
cell,O
aplasia,I-Entity
",",O
toxic,I-Entity
dermatitis,I-Entity
and,O
lymphadenopathy,I-Entity
in,O
a,O
patient,O
taking,O
diphenylhydantoin,I-Entity
.,O
A,I-Entity
patient,O
taking,O
diphenylhydantoin,I-Entity
for,O
3,O
weeks,O
developed,O
a,O
generalized,O
skin,O
rash,I-Entity
",",O
lymphadenopathy,I-Entity
and,O
pure,O
red,O
cell,O
aplasia,I-Entity
.,O
Skin,I-Entity
rash,I-Entity
is,O
a,O
well,O
-,O
known,O
complication,O
of,O
diphenylhydantoin,I-Entity
treatment,O
as,O
is,O
benign,O
and,O
malignant,I-Entity
lymphadenopathy,I-Entity
.,O
Pure,I-Entity
red,O
cell,O
aplasia,I-Entity
associated,O
with,O
diphenylhydantoin,I-Entity
medication,O
has,O
been,O
reported,O
in,O
3,O
patients,O
.,O
The,I-Entity
exact,O
mechanism,O
by,O
which,O
diphenylhydantoin,I-Entity
exerts,I-Entity
its,O
toxic,I-Entity
effects,O
is,O
not,O
known,O
.,O
In,I-Entity
this,O
patient,O
the,O
time,O
relation,O
between,O
the,O
ingestion,O
of,O
diphenylhydantoin,I-Entity
and,O
the,O
occurrence,O
of,O
the,O
skin,O
rash,I-Entity
",",O
lymphadenopathy,I-Entity
and,O
pure,O
red,O
cell,O
aplasia,I-Entity
is,O
very,O
suggestive,O
of,O
a,O
direct,O
connection,O
.,O
Continuous,I-Entity
infusion,O
tobramycin,I-Entity
combined,O
with,O
carbenicillin,I-Entity
for,O
infections,I-Entity
in,O
cancer,I-Entity
patients,O
.,O
The,I-Entity
cure,O
rate,O
of,O
infections,I-Entity
in,O
cancer,I-Entity
patients,O
is,O
adversely,O
affected,O
by,O
neutropenia,I-Entity
(,O
less,O
than,O
"1,000/mm3",O
),O
.,O
In,I-Entity
particular,O
",",O
patients,O
with,O
severe,O
neutropenia,I-Entity
(,O
less,O
than,O
100/mm3,O
),O
have,O
shown,O
a,O
poor,O
response,O
to,O
antibiotics,O
.,O
To,I-Entity
overcome,O
the,O
adverse,O
effects,O
of,O
neutropenia,I-Entity
",",O
tobramycin,I-Entity
was,O
given,O
by,O
continuous,O
infusion,O
and,O
combined,O
with,O
intermittent,O
carbenicillin,I-Entity
.,O
Tobramycin,I-Entity
was,O
given,O
to,O
a,O
total,O
daily,O
dose,O
of,O
300,O
mg,O
/,O
m2,O
and,O
carbenicillin,I-Entity
was,O
given,O
at,O
a,O
dose,O
of,O
5,O
gm,O
every,O
four,O
hours,O
.,O
There,I-Entity
were,O
125,I-Entity
infectious,O
episodes,O
in,O
116,I-Entity
cancer,I-Entity
patients,O
receiving,O
myelosuppressive,I-Entity
chemotherapy,O
.,O
Pneumonia,I-Entity
was,O
the,O
most,O
common,O
infection,I-Entity
and,O
61%,O
of,O
59,I-Entity
episodes,O
were,O
cured,O
.,O
Gram,I-Entity
-,O
negative,O
bacilli,I-Entity
were,O
the,O
most,O
common,O
causative,O
organisms,O
and,O
69%,O
of,O
these,O
infections,I-Entity
were,O
cured,O
.,O
The,I-Entity
most,O
common,O
pathogen,O
was,O
Klebsiella,I-Entity
pneumoniae,I-Entity
and,O
this,O
",",O
together,O
with,O
Escherichia,I-Entity
coli,I-Entity
and,O
Pseudomonas,I-Entity
aeruginosa,I-Entity
",",O
accounted,O
for,O
74%,O
of,O
all,O
gram,O
-,O
negative,O
bacillary,O
infections,I-Entity
.,O
Response,I-Entity
was,O
not,O
influenced,O
by,O
the,O
initial,O
neutrophil,O
count,O
",",O
with,O
a,O
62%,O
cure,O
rate,O
for,O
39,O
episodes,O
associated,O
with,O
severe,O
neutropenia,I-Entity
.,O
Azotemia,I-Entity
was,O
the,O
major,O
side,O
effect,O
recognized,O
",",O
and,O
it,O
occurred,O
in,O
11%,O
of,O
episodes,O
.,O
Major,I-Entity
azotemia,I-Entity
(,O
serum,O
creatinine,I-Entity
greater,O
than,O
2.5,O
mg,O
/,O
dl,O
or,O
BUN,I-Entity
greater,O
than,O
50,O
mg,O
/,O
dl,O
),O
occurred,O
in,O
only,O
2%,O
.,O
Azotemia,I-Entity
was,O
not,O
related,O
to,O
duration,O
of,O
therapy,O
or,O
serum,O
tobramycin,I-Entity
concentration,O
.,O
This,I-Entity
antibiotic,O
regimen,I-Entity
showed,O
both,O
therapeutic,O
efficacy,O
and,O
acceptable,O
renal,O
toxicity,I-Entity
for,O
these,O
patients,O
.,O
Recurrent,I-Entity
subarachnoid,O
hemorrhage,I-Entity
associated,O
with,O
aminocaproic,I-Entity
acid,O
therapy,O
and,O
acute,O
renal,O
artery,I-Entity
thrombosis,I-Entity
.,O
Epsilon,I-Entity
aminocaproic,I-Entity
acid,O
(,O
EACA,I-Entity
),O
has,O
been,O
used,O
to,O
prevent,O
rebleeding,O
in,O
patients,O
with,O
subarachnoid,O
hemorrhage,I-Entity
(,O
SAH,I-Entity
),O
.,O
Although,I-Entity
this,O
agent,O
does,O
decrease,O
the,O
frequency,O
of,O
rebleeding,O
",",O
several,O
reports,O
have,O
described,O
thrombotic,I-Entity
complications,O
of,O
EACA,I-Entity
therapy,O
.,O
These,I-Entity
complications,O
have,O
included,O
clinical,O
deterioration,O
and,O
intracranial,B-Entity
vascular,O
thrombosis,I-Entity
in,O
patients,O
with,O
SAH,I-Entity
",",O
arteriolar,O
and,O
capillary,O
fibrin,O
thrombi,I-Entity
in,O
patients,O
with,O
fibrinolytic,O
syndromes,I-Entity
treated,O
with,O
EACA,I-Entity
",",O
or,O
other,O
thromboembolic,I-Entity
phenomena,O
.,O
Since,I-Entity
intravascular,O
fibrin,O
thrombi,I-Entity
are,O
often,O
observed,O
in,O
patients,O
with,O
fibrinolytic,O
disorders,I-Entity
",",O
EACA,I-Entity
should,O
not,O
be,O
implicated,O
in,O
the,O
pathogenesis,O
of,O
fibrin,O
thrombi,I-Entity
in,O
patients,O
with,O
disseminated,O
intravascular,O
coagulation,I-Entity
or,O
other,O
"""""""""",O
consumption,O
coagulopathies,I-Entity
.,O
"""""""""",O
This,I-Entity
report,O
describes,O
subtotal,O
infarction,I-Entity
of,O
the,O
kidney,O
due,O
to,O
thrombosis,I-Entity
of,O
a,O
normal,O
renal,O
artery,I-Entity
.,O
This,I-Entity
occlusion,I-Entity
occurred,O
after,O
EACA,I-Entity
therapy,O
in,O
a,O
patient,O
with,O
SAH,I-Entity
and,O
histopathological,O
documentation,O
of,O
recurrent,O
SAH,I-Entity
.,O
The,I-Entity
corresponding,O
clinical,O
event,O
was,O
characterized,O
by,O
marked,O
hypertension,I-Entity
and,O
abrupt,O
neurological,O
deterioration,O
.,O
Long,I-Entity
-,O
term,O
propranolol,I-Entity
therapy,O
in,O
pregnancy,I-Entity
:,O
maternal,O
and,O
fetal,O
outcome,O
.,O
Propranolol,I-Entity
",",O
a,O
beta,O
-,O
adrenergic,O
blocking,I-Entity
agent,O
",",O
has,O
found,O
an,O
important,O
position,O
in,O
the,O
practice,O
of,O
medicine,O
.,O
Ten,I-Entity
patients,O
and,O
12,O
pregnancies,O
are,O
reported,O
where,O
chronic,O
propranolol,I-Entity
has,O
been,O
administered,O
.,O
Five,I-Entity
patients,O
with,O
serial,O
pregnancies,O
with,O
and,O
without,O
propranolol,I-Entity
therapy,O
are,O
also,O
examined,O
.,O
We,I-Entity
conclude,O
that,O
previously,O
reported,O
hypoglycemia,I-Entity
",",O
hyperbilirubinemia,I-Entity
",",O
polycythemia,I-Entity
",",O
neonatal,O
apnea,I-Entity
",",O
and,O
bradycardia,I-Entity
are,O
not,O
invariable,I-Entity
and,O
can,O
not,O
be,O
statistically,O
correlated,O
with,O
chronic,O
propranolol,I-Entity
therapy,O
.,O
Growth,I-Entity
retardation,I-Entity
",",O
however,O
",",O
appears,O
to,O
be,O
significant,O
in,O
both,O
of,O
our,O
series,O
.,O
Use,I-Entity
of,O
propranolol,I-Entity
in,O
the,O
treatment,O
of,O
idiopathic,I-Entity
orthostatic,B-Entity
hypotension,I-Entity
.,O
Five,I-Entity
patients,O
with,O
idiopathic,I-Entity
orthostatic,B-Entity
hypotension,I-Entity
who,O
had,O
physiologic,O
and,O
biochemical,O
evidence,O
of,O
severe,O
autonomic,O
dysfunction,I-Entity
were,O
included,O
in,O
the,O
study,O
.,O
They,I-Entity
all,O
exhibited,O
markedly,O
reduced,O
plasma,O
catecholamines,I-Entity
and,O
plasma,O
renin,O
activity,O
in,O
both,O
recumbent,O
and,O
upright,O
positions,O
and,O
had,O
marked,O
hypersensitivity,I-Entity
to,O
the,O
pressor,O
effects,O
of,O
infused,O
norepinephrine,I-Entity
.,O
Treatment,I-Entity
with,O
propanolol,I-Entity
administered,O
intravenously,O
(,O
1,O
-,O
5,O
mg,O
),O
produced,O
increases,O
in,O
supine,I-Entity
and,O
upright,O
blood,O
pressure,O
in,O
4,O
of,O
the,O
5,O
individuals,O
with,O
rises,O
ranging,O
from,O
11/6,O
to,O
22/11,O
mmHg,I-Entity
.,O
Chronic,I-Entity
oral,O
administration,O
of,O
propranolol,I-Entity
(,O
40,O
-,O
160,I-Entity
mg,O
/,O
day,O
),O
also,O
elevated,O
the,O
blood,O
pressures,O
of,O
these,O
individuals,O
with,O
increases,O
in,O
the,O
order,O
of,O
20,O
-,O
35/15,O
-,O
25,O
mmg,O
being,O
observed,O
.,O
In,I-Entity
1,O
patient,O
",",O
marked,O
hypertension,I-Entity
was,O
induced,O
by,O
propranolol,I-Entity
and,O
the,O
drug,O
had,O
to,O
be,O
withdrawn,O
.,O
Hemodynamic,I-Entity
measurements,O
in,O
1,O
of,O
the,O
patients,O
demonstrated,O
an,O
increase,O
in,O
total,O
peripheral,O
resistance,O
and,O
essentially,O
no,O
change,O
in,O
cardiac,O
output,O
following,O
propranolol,I-Entity
therapy,O
.,O
The,I-Entity
studies,O
suggest,O
that,O
propranolol,I-Entity
is,O
a,O
useful,O
drug,O
in,O
selected,O
patients,O
with,O
severe,O
idiopathic,I-Entity
orthostatic,B-Entity
hypotension,I-Entity
.,O
Total,I-Entity
intravenous,O
anesthesia,O
with,O
etomidate,I-Entity
.,O
An,I-Entity
investigation,O
was,O
undertaken,O
to,O
determine,O
the,O
dosage,O
of,O
etomidate,I-Entity
required,O
to,O
maintain,O
sleep,O
in,O
adults,O
undergoing,O
surgery,O
under,O
regional,O
local,O
anesthesia,O
.,O
Premedication,I-Entity
of,O
diazepam,I-Entity
10,O
mg,O
and,O
atropine,I-Entity
0.5,O
mg,O
was,O
given,O
",",O
and,O
sleep,O
was,O
induced,O
and,O
maintained,O
by,O
intermittent,O
intravenous,O
injections,O
of,O
etomidate,I-Entity
0.1/mg,O
/,O
kg,O
",",O
given,O
whenever,O
the,O
patient,O
would,O
open,O
his,O
eyes,O
on,O
request,O
.,O
A,I-Entity
mean,O
overall,O
dose,O
of,O
etomidate,I-Entity
17.4,O
microgram,O
/,O
kg,O
/,O
min,O
.,O
The,I-Entity
investigation,O
was,O
discontinued,O
after,O
18,O
patients,O
because,O
of,O
the,O
frequency,O
and,O
intensity,O
of,O
side,O
-,O
effects,O
",",O
particularly,O
pain,I-Entity
and,O
myoclonia,I-Entity
",",O
which,O
caused,O
the,O
technique,O
to,O
be,O
abandoned,O
in,O
two,O
cases,O
.,O
It,I-Entity
is,O
considered,O
unlikely,O
that,O
etomidate,I-Entity
will,O
prove,O
to,O
be,O
the,O
hypnotic,O
of,O
choice,O
for,O
a,O
totally,O
intravenous,O
anesthetic,O
technique,O
in,O
adults,O
because,O
of,O
the,O
high,O
incidence,O
of,O
myoclonia,I-Entity
after,O
prolonged,O
administration,O
.,O
A,I-Entity
method,O
for,O
the,O
measurement,O
of,O
tremor,I-Entity
",",O
and,O
a,O
comparison,O
of,O
the,O
effects,O
of,O
tocolytic,I-Entity
beta,O
-,O
mimetics,I-Entity
.,O
A,I-Entity
method,O
permitting,O
measurement,O
of,O
finger,O
tremor,I-Entity
as,O
a,O
displacement,O
-,O
time,O
curve,O
is,O
described,O
",",O
using,O
a,O
test,O
system,O
with,O
simple,O
amplitude,O
calibration,O
.,O
By,I-Entity
means,O
of,O
a,O
computer,O
program,O
",",O
periods,O
and,O
amplitudes,O
of,O
tremor,I-Entity
oscillations,I-Entity
were,O
calculated,O
and,O
classified,O
.,O
The,I-Entity
actions,O
of,O
fenoterol,I-Entity
-,O
hydrobromide,I-Entity
",",O
ritodrin,I-Entity
-,O
HCl,I-Entity
and,O
placebo,O
given,O
to,O
10,O
healthy,O
subjects,O
by,O
intravenous,O
infusion,O
in,O
a,O
double,O
-,O
blind,O
crossover,O
study,O
were,O
tested,O
by,O
this,O
method,O
.,O
At,I-Entity
therapeutic,O
doses,O
both,O
substances,O
raised,O
the,O
mean,O
tremor,I-Entity
amplitude,O
to,O
about,O
three,O
times,O
the,O
control,O
level,O
.,O
After,I-Entity
the,O
end,O
of,O
fenoterol,I-Entity
-,O
hydrobromide,I-Entity
infusion,O
",",O
tremor,I-Entity
amplitudes,O
decreased,O
significantly,O
faster,O
than,O
those,O
following,O
ritodrin,I-Entity
-,O
HCl,I-Entity
infusion,O
.,O
Bilateral,I-Entity
retinal,B-Entity
artery,I-Entity
and,O
choriocapillaris,I-Entity
occlusion,I-Entity
following,O
the,O
injection,O
of,O
long,O
-,O
acting,O
corticosteroid,O
suspensions,I-Entity
in,O
combination,O
with,O
other,O
drugs,O
:,O
I.,I-Entity
Clinical,I-Entity
studies,O
.,O
Two,I-Entity
well,O
-,O
documented,O
cases,O
of,O
bilateral,O
retinal,B-Entity
artery,I-Entity
and,O
choriocapillaris,I-Entity
occlusions,I-Entity
with,O
blindness,I-Entity
following,O
head,O
and,O
neck,O
soft,O
-,O
tissue,O
injection,O
with,O
methylprednisolone,I-Entity
acetate,I-Entity
in,O
combination,O
with,O
lidocaine,I-Entity
",",O
epinephrine,I-Entity
",",O
or,O
penicillin,I-Entity
are,O
reported,O
.,O
The,I-Entity
acute,O
observations,O
included,O
hazy,O
sensorium,I-Entity
",",O
superior,O
gaze,O
palsy,I-Entity
",",O
pupillary,I-Entity
abnormalities,I-Entity
",",O
and,O
conjunctival,O
hemorrhages,I-Entity
with,O
edema,I-Entity
.,O
Follow,I-Entity
-,O
up,O
changes,O
showed,O
marked,O
visual,O
loss,I-Entity
",",O
constricted,I-Entity
visual,O
fields,O
",",O
optic,O
nerve,O
pallor,I-Entity
",",O
vascular,O
attenuation,O
",",O
and,O
chorioretinal,O
atrophy,I-Entity
.,O
Cephalothin,I-Entity
-,O
induced,O
immune,O
hemolytic,I-Entity
anemia,I-Entity
.,O
A,I-Entity
patient,O
with,O
renal,O
disease,I-Entity
developed,O
Coombs,I-Entity
-,O
positive,O
hemolytic,I-Entity
anemia,I-Entity
while,O
receiving,O
cephalothin,I-Entity
therapy,O
.,O
An,I-Entity
anti,O
-,O
cephalothin,I-Entity
IgG,I-Entity
antibody,O
was,O
detected,O
in,O
the,O
patient,O
's,I-Entity
serum,O
and,O
in,O
the,O
eluates,I-Entity
from,O
her,O
erythrocytes,O
.,O
In,I-Entity
addition,O
",",O
nonimmunologic,O
binding,O
of,O
normal,O
and,O
patient,O
's,I-Entity
serum,O
proteins,O
to,O
her,O
own,O
and,O
cephalothin,I-Entity
-,O
coated,O
normal,O
red,O
cells,O
was,O
demonstrated,O
.,O
Skin,I-Entity
tests,O
and,O
in,O
vitro,O
lymphocyte,O
stimulation,O
revealed,O
that,O
the,O
patient,O
was,O
sensitized,I-Entity
to,O
cephalothin,I-Entity
and,O
also,O
to,O
ampicillin,I-Entity
.,O
Careful,I-Entity
investigation,O
of,O
drug,O
-,O
induced,O
hemolytic,I-Entity
anemias,I-Entity
reveals,O
the,O
complexity,O
of,O
the,O
immune,O
mechanisms,O
involved,O
.,O
Kaliuretic,I-Entity
effect,O
of,O
L,I-Entity
-,O
dopa,I-Entity
treatment,O
in,O
parkinsonian,I-Entity
patients,O
.,O
Hypokalemia,I-Entity
",",O
sometimes,O
severe,O
",",O
was,O
observed,O
in,O
some,O
L,I-Entity
-,O
dopa,I-Entity
-,O
treated,O
parkinsonian,I-Entity
patients,O
.,O
The,I-Entity
influence,O
of,O
L,I-Entity
-,O
dopa,I-Entity
on,O
the,O
renal,O
excretion,O
of,O
potassium,I-Entity
was,O
studied,O
in,O
3,O
patients,O
with,O
hypokalemia,I-Entity
and,O
in,O
5,O
normokalemic,O
patients,O
by,O
determination,O
of,O
renal,O
plasma,O
flow,O
",",O
glomerular,O
filtration,O
rate,O
",",O
plasma,O
concentration,O
of,O
potassium,I-Entity
and,O
sodium,I-Entity
as,O
well,O
as,O
urinary,O
excretion,O
of,O
potassium,I-Entity
",",O
sodium,I-Entity
and,O
aldosterone,I-Entity
.,O
L,I-Entity
-,O
Dopa,I-Entity
intake,O
was,O
found,O
to,O
cause,O
an,O
increased,O
excretion,O
of,O
potassium,I-Entity
",",O
and,O
sometimes,O
also,O
of,O
sodium,I-Entity
",",O
in,O
the,O
hypokalemic,I-Entity
but,O
not,O
in,O
the,O
normokalemic,O
patients,O
.,O
It,I-Entity
is,O
not,O
known,O
why,O
this,O
effect,O
occurred,O
in,O
some,O
individuals,O
but,O
not,O
in,O
others,O
",",O
but,O
our,O
results,O
indicate,O
a,O
correlation,O
between,O
aldosterone,I-Entity
production,O
and,O
this,O
renal,O
effect,O
of,O
L,I-Entity
-,O
dopa,I-Entity
.,O
Phenytoin,I-Entity
encephalopathy,I-Entity
as,O
probable,O
idiosyncratic,O
reaction,I-Entity
:,O
case,O
report,O
.,O
A,I-Entity
case,O
of,O
phenytoin,I-Entity
(,O
DPH,I-Entity
),O
encephalopathy,I-Entity
with,O
increasing,O
seizures,I-Entity
and,O
EEG,I-Entity
and,O
mental,O
changes,O
is,O
described,O
.,O
Despite,I-Entity
adequate,O
oral,O
dosage,O
of,O
DPH,I-Entity
(,O
5,O
mg,O
/,O
kg,O
/,O
daily,O
),O
the,O
plasma,O
level,O
was,O
very,O
low,O
(,O
2.8,O
microgramg,O
/,O
ml,O
),O
.,O
The,I-Entity
encephalopathy,I-Entity
was,O
probably,O
an,O
idiosyncratic,O
and,O
not,O
toxic,I-Entity
or,O
allergic,I-Entity
reaction,I-Entity
.,O
In,I-Entity
fact,O
the,O
concentration,O
of,O
free,O
DPH,I-Entity
was,O
normal,O
",",O
the,O
patient,O
presented,O
a,O
retarded,I-Entity
morbilliform,B-Entity
rash,I-Entity
during,O
DPH,I-Entity
treatment,O
",",O
the,O
protidogram,I-Entity
was,O
normal,O
",",O
and,O
an,O
intradermic,O
DPH,I-Entity
injection,O
had,O
no,O
local,O
effect,O
.,O
The,I-Entity
authors,O
conclude,O
that,O
in,O
a,O
patient,O
starting,O
DPH,I-Entity
treatment,O
an,O
unexpected,O
increase,O
in,O
seizures,I-Entity
",",O
with,O
EEG,I-Entity
and,O
mental,O
changes,O
occurring,O
simultaneously,O
",",O
should,O
alert,O
the,O
physician,O
to,O
the,O
possible,O
need,O
for,O
eliminating,O
DPH,I-Entity
from,O
the,O
therapeutic,O
regimen,I-Entity
",",O
even,O
if,O
plasma,O
concentrations,O
are,O
low,O
.,O
Effects,I-Entity
of,O
exercise,O
on,O
the,O
severity,O
of,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
.,O
The,I-Entity
effect,O
of,O
exercise,O
on,O
the,O
severity,O
of,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
was,O
studied,O
in,O
male,O
rats,O
.,O
The,I-Entity
exercise,O
-,O
isoproterenol,I-Entity
(,O
E-1,I-Entity
),O
and,O
exercise,O
control,O
(,O
EC,I-Entity
),O
groups,O
exercised,O
daily,O
for,O
thirty,O
days,O
on,O
a,O
treadmill,O
at,O
1,O
mph,O
",",O
2%,O
grade,O
while,O
animals,O
of,O
the,O
sedentary,O
-,O
isoproterenol,I-Entity
(,O
S,I-Entity
-,O
I,I-Entity
),O
group,O
remained,O
sedentary,O
.,O
Forty,I-Entity
-,O
eight,O
hours,O
after,O
the,O
final,O
exercise,O
period,O
",",O
S,I-Entity
-,O
I,I-Entity
and,O
E,I-Entity
-,O
I,I-Entity
animals,O
received,O
a,O
single,O
subcutaneous,O
injection,O
of,O
isoproterenol,I-Entity
(,O
250,O
mg,O
/,O
kg,O
body,O
weight,O
),O
.,O
Animals,I-Entity
of,O
the,O
S,I-Entity
-,O
I,I-Entity
group,O
exhibited,O
significantly,O
(,O
Pp,I-Entity
less,O
than,O
0.05,O
),O
greater,O
mortality,O
from,O
the,O
effects,O
of,O
isoproterenol,I-Entity
than,O
animals,O
of,O
the,O
E,I-Entity
-,O
I,I-Entity
group,O
.,O
Serum,I-Entity
CPK,I-Entity
activity,O
for,O
E,I-Entity
-,O
I,I-Entity
animals,O
was,O
significantly,O
(,O
p,O
less,O
than,O
0.05,O
),O
greater,O
than,O
for,O
animals,O
in,O
the,O
S,I-Entity
-,O
I,I-Entity
and,O
EC,I-Entity
groups,O
twenty,O
hours,O
following,O
isoproterenol,I-Entity
injection,O
.,O
No,I-Entity
statistically,O
significant,O
differences,O
were,O
observed,O
between,O
the,O
two,O
isoproterenol,I-Entity
treated,O
groups,O
for,O
severity,O
of,O
the,O
induced,O
lesions,O
",",O
changes,O
in,O
heart,O
weight,O
",",O
or,O
heart,O
weight,O
to,O
body,O
weight,O
ratios,O
.,O
The,I-Entity
results,O
indicated,O
that,O
exercise,O
reduced,O
the,O
mortality,O
associated,O
with,O
the,O
effects,O
of,O
large,O
dosages,O
of,O
isoproterenol,I-Entity
but,O
had,O
little,O
on,O
the,O
severity,O
of,O
the,O
infarction,I-Entity
.,O
Effect,I-Entity
of,O
D,I-Entity
-,O
Glucarates,I-Entity
on,O
basic,O
antibiotic,O
-,O
induced,O
renal,O
damage,O
in,O
rats,O
.,O
Dehydrated,I-Entity
rats,O
regularly,O
develop,O
acute,O
renal,O
failure,I-Entity
following,O
single,O
injection,O
of,O
aminoglycoside,I-Entity
antibiotics,O
combined,O
with,O
dextran,I-Entity
or,O
of,O
antibiotics,O
only,O
.,O
Oral,I-Entity
administration,O
of,O
"2,5-di",O
-,O
O,I-Entity
-,O
acetyl,I-Entity
-,O
D,I-Entity
-,O
"glucaro-1,4",I-Entity
-,O
"6,3-dilactone",I-Entity
protected,O
rats,O
against,O
renal,O
failure,I-Entity
induced,O
by,O
kanamycin,I-Entity
-,O
dextran,I-Entity
.,O
The,I-Entity
protective,O
effect,O
was,O
prevalent,O
among,O
D,I-Entity
-,O
glucarates,I-Entity
",",O
and,O
also,O
to,O
other,O
saccharic,I-Entity
acid,O
",",O
hexauronic,I-Entity
acids,O
and,O
hexaaldonic,B-Entity
acids,O
",",O
although,O
to,O
a,O
lesser,O
degree,O
",",O
but,O
not,O
to,O
a,O
hexaaldose,I-Entity
",",O
sugar,O
alcohols,I-Entity
",",O
substances,O
inthe,O
TCA,I-Entity
cycle,O
and,O
other,O
acidic,O
compounds,O
.,O
D,I-Entity
-,O
Glucarates,I-Entity
were,O
effective,O
against,O
renal,O
damage,O
induced,O
by,O
peptide,I-Entity
antibiotics,O
as,O
well,O
as,O
various,O
aminoglycoside,I-Entity
antibitocis,I-Entity
.,O
Dose,I-Entity
-,O
responses,O
were,O
observed,O
in,O
the,O
protective,O
effect,O
of,O
D,I-Entity
-,O
Glucarates,I-Entity
.,O
With,I-Entity
a,O
D,I-Entity
-,O
glucarate,I-Entity
of,O
a,O
fixed,O
size,O
of,O
dose,O
",",O
approximately,O
the,O
same,O
degree,O
of,O
protection,O
was,O
obtained,O
against,O
renal,O
damages,O
induced,O
by,O
different,O
basic,O
antibiotics,O
despite,O
large,O
disparities,I-Entity
in,O
administration,O
doses,O
of,O
different,O
antibiotics,O
.,O
D,I-Entity
-,O
Glucarates,I-Entity
had,O
the,O
ability,O
to,O
prevent,O
renal,O
damage,O
but,O
not,O
to,O
cure,O
it,O
.,O
Rats,I-Entity
excreted,O
acidic,O
urine,I-Entity
when,O
they,O
were,O
spared,O
from,O
renal,O
lesions,O
by,O
monosaccharides,O
.,O
The,I-Entity
reduction,O
effect,O
of,O
D,I-Entity
-,O
glucarates,I-Entity
against,O
nephrotoxicity,I-Entity
of,O
basic,O
antibiotics,O
was,O
discussed,O
.,O
Paraplegia,I-Entity
following,O
intrathecal,O
methotrexate,I-Entity
:,O
report,O
of,O
a,O
case,O
and,O
review,O
of,O
the,O
literature,O
.,O
A,I-Entity
patient,O
who,O
developed,O
paraplegia,I-Entity
following,O
the,O
intrathecal,O
instillation,O
of,O
methotrexate,I-Entity
is,O
discribed,O
.,O
The,I-Entity
following,O
factors,O
appear,O
to,O
predispose,O
to,O
the,O
development,O
of,O
this,O
complication,O
:,O
abnormal,I-Entity
cerebrospinal,O
dynamics,O
related,O
to,O
the,O
presence,O
of,O
central,O
nervous,I-Entity
system,O
leukemia,I-Entity
",",O
and,O
epidural,O
cerebrospinal,O
leakage,I-Entity
;,O
elevated,O
cerebrospinal,O
fluid,O
methothexate,I-Entity
concentration,O
related,O
to,O
abnormal,I-Entity
cerebrospinal,O
fluid,O
dynamics,O
and,O
to,O
inappropriately,I-Entity
high,O
methotrexate,I-Entity
doses,O
based,O
on,O
body,O
surface,O
area,O
calculations,O
in,O
older,O
children,O
and,O
adults,O
;,O
the,O
presence,O
of,O
neurotoxic,I-Entity
preservatives,I-Entity
in,O
commercially,O
available,O
methotrexate,I-Entity
preparations,O
and,O
diluents,B-Entity
;,O
and,O
the,O
use,O
of,O
methotrexate,I-Entity
diluents,B-Entity
of,O
unphysiologic,O
pH,I-Entity
",",O
ionic,O
content,O
and,O
osmolarity,O
.,O
The,I-Entity
role,O
of,O
methotrexate,I-Entity
contaminants,I-Entity
",",O
local,O
folate,I-Entity
deficiency,I-Entity
",",O
and,O
cranial,O
irradiation,I-Entity
in,O
the,O
pathogenesis,O
of,O
intrathecal,O
methotrexate,I-Entity
toxicity,I-Entity
is,O
unclear,O
.,O
The,I-Entity
incidence,O
of,O
neurotoxicity,I-Entity
may,O
be,O
reduced,O
by,O
employing,O
lower,O
doses,O
of,O
methotrexate,I-Entity
in,O
the,O
presence,O
of,O
central,O
nervous,I-Entity
system,O
leukemia,I-Entity
",",O
in,O
older,O
children,O
and,O
adults,O
",",O
and,O
in,O
the,O
presence,O
of,O
epidural,O
leakage,I-Entity
.,O
Only,I-Entity
preservative,I-Entity
-,O
free,O
methotrexate,I-Entity
in,O
Elliott,I-Entity
's,I-Entity
B,I-Entity
Solution,I-Entity
at,O
a,O
concentration,O
of,O
not,O
more,O
than,O
1,O
mg,O
/,O
ml,O
should,O
be,O
used,O
for,O
intrathecal,O
administration,O
.,O
Periodic,I-Entity
monitoring,O
of,O
cerebruspinal,B-Entity
fluid,O
methotrexate,I-Entity
levels,O
may,O
be,O
predictive,O
of,O
the,O
development,O
of,O
serious,O
neurotoxicity,I-Entity
.,O
Centrally,I-Entity
mediated,O
cardiovascular,O
effects,O
of,O
intracisternal,O
application,O
of,O
carbachol,I-Entity
in,O
anesthetized,O
rats,O
.,O
injection,O
of,O
carbachol,I-Entity
(,O
1,O
mug,O
),O
in,O
anesthetized,O
rats,O
was,O
analyzed,O
.,O
injection,O
of,O
guanethidine,I-Entity
(,O
5,O
mg,O
),O
",",O
hexamethonium,I-Entity
(,O
10,O
mg,O
),O
or,O
phentolamine,I-Entity
(,O
5,O
mg,O
),O
",",O
and,O
conversely,O
",",O
potentiated,O
by,O
i.v,O
.,O
desmethylimipramine,I-Entity
(,O
0.3,O
mg,O
),O
",",O
while,O
propranolol,I-Entity
(,O
0.5,O
mg,O
),O
i.v,O
.,O
selectively,O
inhibited,O
the,O
enlargement,I-Entity
of,O
pulse,O
pressure,O
and,O
the,O
tachycardia,I-Entity
following,O
i.c,O
.,O
carbachol,I-Entity
(,O
1,O
mug,O
),O
.,O
carbachol,I-Entity
(,O
1,O
mug,O
),O
was,O
almost,O
completely,O
blocked,O
by,O
i.c,O
.,O
atropine,I-Entity
(,O
3,O
mug,O
),O
or,O
hexamethonium,I-Entity
(,O
500,O
mug,O
),O
",",O
and,O
significantly,O
reduced,O
by,O
i.c,O
.,O
chlorpromazine,I-Entity
(,O
50,O
mug,O
),O
but,O
desmethylimipramine,I-Entity
(,O
30,O
mug,O
),O
.,O
carbachol,I-Entity
(,O
1,O
mug,O
),O
remained,O
unchanged,O
after,O
sectioning,O
of,O
the,O
bilateral,O
cervical,O
vagal,I-Entity
nerves,I-Entity
but,O
disappeared,O
after,O
sectioning,O
of,O
the,O
spinal,O
cord,O
(,O
C7-C8,I-Entity
),O
.,O
carbachol,I-Entity
ortral,O
and,O
peripheral,O
adrenergic,O
mechanisms,O
",",O
and,O
that,O
the,O
sympathetic,O
trunk,O
is,O
the,O
main,O
pathway,O
.,O
Hyperglycemic,I-Entity
effect,O
of,O
amino,I-Entity
compounds,O
structurally,O
related,O
to,O
caproate,I-Entity
in,O
rats,O
.,O
The,I-Entity
chronic,O
feeding,O
of,O
small,O
amounts,O
(,O
0.3,O
-,O
3%,O
of,O
diet,O
weight,O
),O
of,O
certain,O
amino,I-Entity
derivatives,O
of,O
caproate,I-Entity
resulted,O
in,O
hyperglycemia,I-Entity
",",O
an,O
elevated,O
glucose,O
tolerance,O
curve,O
and,O
",",O
occasionally,O
",",O
glucosuria,I-Entity
.,O
Effective,I-Entity
compounds,O
included,O
norleucine,I-Entity
",",O
norvaline,I-Entity
",",O
glutamate,I-Entity
",",O
epsilon,O
-,O
aminocaproate,I-Entity
",",O
methionine,I-Entity
",",O
and,O
leucine,I-Entity
.,O
Fatty,I-Entity
liver,I-Entity
induced,O
by,O
tetracycline,I-Entity
in,O
the,O
rat,O
.,O
Dose,I-Entity
-,O
response,O
relationships,O
",",O
biochemical,O
mechanisms,O
",",O
and,O
sex,O
differences,O
in,O
the,O
experimental,O
fatty,B-Entity
liver,I-Entity
induced,O
by,O
tetracycline,I-Entity
were,O
studied,O
in,O
the,O
intact,O
rat,O
and,O
with,O
the,O
isolated,O
perfused,O
rat,O
liver,I-Entity
in,O
vitro,O
.,O
In,I-Entity
the,O
intact,O
male,O
and,O
female,O
rat,O
",",O
no,O
direct,O
relationship,O
was,O
observed,O
between,O
dose,O
of,O
tetracycline,I-Entity
and,O
hepatic,B-Entity
accumulation,O
of,O
triglyceride,I-Entity
.,O
With,I-Entity
provision,O
of,O
adequate,O
oleic,O
acid,O
as,O
a,O
substrate,O
for,O
the,O
isolated,O
perfused,O
liver,I-Entity
",",O
a,O
direct,O
relationship,O
was,O
observed,O
between,O
dose,O
of,O
tetracycline,I-Entity
and,O
both,O
accumulation,O
of,O
triglyceride,I-Entity
in,O
the,O
liver,I-Entity
and,O
depression,I-Entity
of,O
output,O
of,O
triglyceride,I-Entity
by,O
livers,I-Entity
from,O
male,O
and,O
female,O
rats,O
.,O
Marked,I-Entity
differences,O
were,O
observed,O
between,O
female,O
and,O
male,O
rats,O
with,O
regard,O
to,O
base,O
line,O
(,O
control,O
),O
hepatic,B-Entity
concentration,O
of,O
triglyceride,I-Entity
and,O
output,O
of,O
triglyceride,I-Entity
.,O
Accumulation,I-Entity
of,O
hepatic,B-Entity
triglyceride,I-Entity
",",O
as,O
a,O
per,O
cent,O
of,O
control,O
values,O
",",O
in,O
response,O
to,O
graded,O
doses,O
of,O
tetracycline,I-Entity
",",O
did,O
not,O
differ,O
significantly,O
between,O
male,O
",",O
female,O
and,O
pregnant,I-Entity
rat,O
livers,I-Entity
.,O
However,I-Entity
",",O
livers,I-Entity
from,O
female,O
",",O
and,O
especially,O
pregnant,I-Entity
female,O
rats,O
",",O
were,O
strikingly,O
resistant,O
to,O
the,O
effects,O
of,O
tetracycline,I-Entity
on,O
depression,I-Entity
of,O
output,O
of,O
triglyceride,I-Entity
under,O
these,O
experimental,O
conditions,O
.,O
These,I-Entity
differences,O
between,O
the,O
sexes,O
could,O
not,O
be,O
related,O
to,O
altered,O
disposition,O
of,O
tetracycline,I-Entity
or,O
altered,O
uptake,O
of,O
oleic,O
acid,O
.,O
Depressed,I-Entity
hepatic,B-Entity
secretion,O
of,O
triglyceride,I-Entity
accounted,O
only,O
for,O
30,O
to,O
50%,O
of,O
accumulated,O
hepatic,B-Entity
triglyceride,I-Entity
",",O
indicating,O
that,O
additional,O
mechanisms,O
must,O
be,O
involved,O
in,O
the,O
production,O
of,O
the,O
triglyceride,I-Entity
-,O
rich,O
fatty,B-Entity
liver,I-Entity
in,O
response,O
to,O
tetracycline,I-Entity
.,O
Fatal,I-Entity
myeloencephalopathy,I-Entity
due,O
to,O
intrathecal,O
vincristine,I-Entity
administration,O
.,O
Vincristine,I-Entity
was,O
accidentally,O
given,O
intrathecally,O
to,O
a,O
child,O
with,O
leukaemia,I-Entity
",",O
producing,O
sensory,O
and,O
motor,O
dysfunction,I-Entity
followed,O
by,O
encephalopathy,I-Entity
and,O
death,I-Entity
.,O
Separate,I-Entity
times,O
for,O
administering,O
vincristine,I-Entity
and,O
intrathecal,O
therapy,O
is,O
recommended,O
.,O
Progesterone,I-Entity
potentiation,O
of,O
bupivacaine,I-Entity
arrhythmogenicity,I-Entity
in,O
pentobarbital,I-Entity
-,O
anesthetized,O
rats,O
and,O
beating,O
rat,O
heart,O
cell,O
cultures,O
.,O
The,I-Entity
effects,O
of,O
progesterone,I-Entity
treatment,O
on,O
bupivacaine,I-Entity
arrhythmogenicity,I-Entity
in,O
beating,O
rat,O
heart,O
myocyte,I-Entity
cultures,O
and,O
on,O
anesthetized,O
rats,O
were,O
determined,O
.,O
After,I-Entity
determining,O
the,O
bupivacaine,I-Entity
AD50,I-Entity
(,O
the,O
concentration,O
of,O
bupivacaine,I-Entity
that,O
caused,O
50%,O
of,O
all,O
beating,O
rat,O
heart,O
myocyte,I-Entity
cultures,O
to,O
become,O
arrhythmic,I-Entity
),O
",",O
we,O
determined,O
the,O
effect,O
of,O
1-hour,O
progesterone,I-Entity
HCl,I-Entity
exposure,O
on,O
myocyte,I-Entity
contractile,O
rhythm,O
.,O
Each,I-Entity
concentration,O
of,O
progesterone,I-Entity
(,O
6.25,O
",",O
12.5,O
",",O
25,O
",",O
and,O
50,O
micrograms,O
/,O
ml,O
),O
caused,O
a,O
significant,O
and,O
concentration,O
-,O
dependent,O
reduction,O
in,O
the,O
AD50,I-Entity
for,O
bupivacaine,I-Entity
.,O
Estradiol,I-Entity
treatment,O
also,O
increased,O
the,O
arrhythmogenicity,I-Entity
of,O
bupivacaine,I-Entity
in,O
myocyte,I-Entity
cultures,O
",",O
but,O
was,O
only,O
one,O
fourth,O
as,O
potent,O
as,O
progesterone,I-Entity
.,O
Neither,I-Entity
progesterone,I-Entity
nor,O
estradiol,I-Entity
effects,O
on,O
bupivacaine,I-Entity
arrhythmogenicity,I-Entity
were,O
potentiated,O
by,O
epinephrine,I-Entity
.,O
Chronic,I-Entity
progesterone,I-Entity
pretreatment,O
(,O
5,O
mg,O
/,O
kg,O
/,O
day,O
for,O
21,O
days,O
),O
caused,O
a,O
significant,O
increase,O
in,O
bupivacaine,I-Entity
arrhythmogenicity,I-Entity
in,O
intact,O
pentobarbital,I-Entity
-,O
anesthetized,O
rats,O
.,O
There,I-Entity
was,O
a,O
significant,O
decrease,O
in,O
the,O
time,O
to,O
onset,O
of,O
arrhythmia,I-Entity
as,O
compared,O
with,O
control,O
nonprogesterone,I-Entity
-,O
treated,O
rats,O
(,O
6.2,O
+,O
/-,O
The,I-Entity
results,O
of,O
this,O
study,O
indicate,O
that,O
progesterone,I-Entity
can,O
potentiate,O
bupivacaine,I-Entity
arrhythmogenicity,I-Entity
both,O
in,O
vivo,O
and,O
in,O
vitro,O
.,O
Potentiation,I-Entity
of,O
bupivacaine,I-Entity
arrhythmia,I-Entity
in,O
myocyte,I-Entity
cultures,O
suggests,O
that,O
this,O
effect,O
is,O
at,O
least,O
partly,O
mediated,O
at,O
the,O
myocyte,I-Entity
level,O
.,O
Acute,I-Entity
renal,O
failure,I-Entity
occurring,O
during,O
intravenous,O
desferrioxamine,I-Entity
therapy,O
:,O
recovery,O
after,O
haemodialysis,O
.,O
A,I-Entity
patient,O
with,O
transfusion,O
-,O
dependent,O
thalassemia,I-Entity
was,O
undergoing,O
home,O
intravenous,O
desferrioxamine,I-Entity
(,O
DFX,I-Entity
),O
treatment,O
by,O
means,O
of,O
a,O
totally,O
implanted,O
system,O
because,O
of,O
his,O
poor,O
compliance,O
with,O
the,O
nightly,O
subcutaneous,O
therapy,O
.,O
Due,I-Entity
to,O
an,O
accidental,O
malfunctioning,I-Entity
of,O
the,O
infusion,O
pump,O
",",O
the,O
patient,O
was,O
inadvertently,O
administered,O
a,O
toxic,I-Entity
dosage,O
of,O
the,O
drug,O
which,O
caused,O
renal,O
insufficiency,I-Entity
.,O
Given,I-Entity
the,O
progressive,O
deterioration,O
of,O
the,O
symptoms,O
and,O
of,O
the,O
laboratory,O
values,O
",",O
despite,O
adequate,O
medical,O
treatment,O
",",O
a,O
decision,O
was,O
made,O
to,O
introduce,O
haemodialytical,O
therapy,O
in,O
order,O
to,O
remove,O
the,O
drug,O
and,O
therapy,O
reduce,O
the,O
nephrotoxicity,I-Entity
.,O
From,I-Entity
the,O
results,O
obtained,O
",",O
haemodialysis,O
can,O
therefore,O
be,O
suggested,O
as,O
a,O
useful,O
therapy,O
in,O
rare,O
cases,O
of,O
progressive,O
acute,O
renal,O
failure,I-Entity
caused,O
by,O
desferrioxamine,I-Entity
.,O
Neuroleptic,I-Entity
-,O
associated,O
hyperprolactinemia,I-Entity
.,O
Can,I-Entity
it,O
be,O
treated,O
with,O
bromocriptine,I-Entity
?,O
Six,I-Entity
stable,O
psychiatric,I-Entity
outpatients,O
with,O
hyperprolactinemia,I-Entity
and,O
amenorrhea,I-Entity
/,O
oligomenorrhea,I-Entity
associated,O
with,O
their,O
neuroleptic,O
medications,O
were,O
treated,O
with,O
bromocriptine,I-Entity
.,O
Daily,I-Entity
dosages,O
of,O
5,O
-,O
10,O
mg,O
corrected,O
the,O
hyperprolactinemia,I-Entity
and,O
restored,O
menstruation,I-Entity
in,O
four,O
of,O
the,O
six,O
patients,O
.,O
One,I-Entity
woman,O
",",O
however,O
",",O
developed,O
worsened,O
psychiatric,I-Entity
symptoms,O
while,O
taking,O
bromocriptine,I-Entity
",",O
and,O
it,O
was,O
discontinued,O
.,O
Thus,I-Entity
",",O
three,O
of,O
six,O
patients,O
had,O
their,O
menstrual,O
irregularity,I-Entity
successfully,O
corrected,O
with,O
bromocriptine,I-Entity
.,O
This,I-Entity
suggests,O
that,O
bromocriptine,I-Entity
should,O
be,O
further,O
evaluated,O
as,O
potential,O
therapy,O
for,O
neuroleptic,O
-,O
associated,O
hyperprolactinemia,I-Entity
and,O
amenorrhea,I-Entity
/,O
galactorrhea,I-Entity
.,O
Ethacrynic,I-Entity
acid,O
-,O
induced,O
convulsions,I-Entity
and,O
brain,O
neurotransmitters,O
in,O
mice,O
.,O
Intracerebroventricular,I-Entity
injection,O
of,O
ethacrynic,O
acid,O
(,O
50%,O
convulsive,I-Entity
dose,O
;,O
50,O
micrograms,O
/,O
mouse,O
),O
accelerated,O
the,O
synthesis,O
/,O
turnover,O
of,O
5-hydroxytryptamine,I-Entity
(,O
5-HT,I-Entity
),O
but,O
suppressed,O
the,O
synthesis,O
of,O
gamma,I-Entity
-,O
aminobutyric,I-Entity
acid,O
and,O
acetylcholine,I-Entity
in,O
mouse,O
brain,O
.,O
These,I-Entity
effects,O
were,O
completely,O
antagonized,I-Entity
by,O
pretreatment,O
with,O
a,O
glutamate,I-Entity
/,O
N,I-Entity
-,O
methyl,I-Entity
-,O
D,I-Entity
-,O
aspartate,I-Entity
antagonist,O
",",O
aminophosphonovaleric,I-Entity
acid,O
.,O
In,I-Entity
ethacrynic,O
acid,O
-,O
induced,O
convulsions,I-Entity
",",O
these,O
neurotransmitter,O
systems,O
may,O
be,O
differentially,O
modulated,O
",",O
probably,O
through,O
activation,O
of,O
glutaminergic,O
neurons,O
in,O
the,O
brain,O
.,O
Pharmacology,I-Entity
of,O
gamma,I-Entity
-,O
aminobutyric,I-Entity
acidA,I-Entity
receptor,O
complex,O
after,O
the,O
in,O
vivo,O
administration,O
of,O
the,O
anxioselective,O
and,O
anticonvulsant,O
beta,O
-,O
carboline,I-Entity
derivative,O
abecarnil,I-Entity
.,O
In,I-Entity
rodents,O
",",O
the,O
effect,O
of,O
the,O
beta,O
-,O
carboline,I-Entity
derivative,O
isopropyl-6-,I-Entity
benzyloxy-4-methoxymethyl,B-Entity
-,O
beta,O
-,O
carboline-3-carboxylate,I-Entity
(,O
abecarrnil,I-Entity
),O
",",O
a,O
new,O
ligand,O
for,O
benzodiazepine,I-Entity
receptors,O
possessing,O
anxiolytic,O
and,O
anticonvulsant,O
properties,O
",",O
was,O
evaluated,O
on,O
the,O
function,O
of,O
central,O
gamma,I-Entity
-,O
aminobutyric,I-Entity
acid,O
(,O
GABA)A,I-Entity
receptor,O
complex,O
",",O
both,O
in,O
vitro,O
and,O
in,O
vivo,O
.,O
Added,I-Entity
in,O
vitro,O
to,O
rat,O
cortical,O
membrane,O
preparation,O
",",O
abecarnil,I-Entity
increased,O
[,O
3H]GABA,I-Entity
binding,O
",",O
enhanced,O
muscimol,I-Entity
-,O
stimulated,O
36Cl-,I-Entity
uptake,O
and,O
reduced,O
the,O
binding,O
of,O
t-[35S]butylbicyclophosphorothionate,B-Entity
(,O
[,O
35S]TBPS,I-Entity
),O
.,O
These,I-Entity
effects,O
were,O
similar,O
to,O
those,O
induced,O
by,O
diazepam,I-Entity
",",O
whereas,O
the,O
partial,O
agonist,I-Entity
Ro,I-Entity
16,O
-,O
6028,I-Entity
(,O
tert,O
-,O
"butyl-(S)-8-bromo-11,12,13,13a",B-Entity
-,O
tetrahydro-9-oxo-9H-,B-Entity
"imidazo[1,5-a]-pyrrolo-[2,1-c][1,4]benzodiazepine-1-carboxylate",B-Entity
),O
showed,O
very,O
weak,O
efficacy,O
in,O
these,O
biochemical,O
tests,O
.,O
injection,O
to,O
rats,O
",",O
abecarnil,I-Entity
and,O
diazepam,I-Entity
decreased,O
in,O
a,O
time,O
-,O
dependent,O
and,O
dose,O
-,O
related,O
(,O
0.25,O
-,O
20,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
manner,O
[,O
35S]TBPS,I-Entity
binding,O
measured,O
ex,O
vivo,O
in,O
the,O
cerebral,O
cortex,O
.,O
Moreover,I-Entity
",",O
both,O
drugs,O
at,O
the,O
dose,O
of,O
0.5,O
mg,O
/,O
kg,O
antagonized,I-Entity
completely,O
the,O
convulsant,I-Entity
activity,O
and,O
the,O
increase,O
of,O
[,O
35S]TBPS,I-Entity
binding,O
induced,O
by,O
isoniazide,I-Entity
(,O
350,I-Entity
mg,O
/,O
kg,O
s.c,O
.,O
),O
as,O
well,O
as,O
the,O
increase,O
of,O
[,O
35S]TBPS,I-Entity
binding,O
induced,O
by,O
foot,O
-,O
shock,I-Entity
stress,I-Entity
.,O
To,I-Entity
better,O
correlate,O
the,O
biochemical,O
and,O
the,O
pharmacological,O
effects,O
",",O
we,O
studied,O
the,O
action,O
of,O
abecarnil,I-Entity
on,O
[,O
35S]TBPS,I-Entity
binding,O
",",O
exploratory,O
motility,O
and,O
on,O
isoniazid,I-Entity
-,O
induced,O
biochemical,O
and,O
pharmacological,O
effects,O
in,O
mice,O
.,O
In,I-Entity
these,O
animals,O
",",O
abecarnil,I-Entity
produced,O
a,O
paralleled,O
dose,O
-,O
dependent,O
(,O
0.05,O
-,O
1,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
reduction,O
of,O
both,O
motor,O
behavior,O
and,O
cortical,O
[,O
35S]TBPS,I-Entity
binding,O
.,O
kg,O
of,O
this,O
beta,O
-,O
carboline,I-Entity
reduced,O
markedly,O
the,O
increase,O
of,O
[,O
35S]TBPS,I-Entity
binding,O
and,O
the,O
convulsions,I-Entity
induced,O
by,O
isoniazid,I-Entity
(,O
200,O
mg,O
/,O
kg,O
s.c.).(ABSTRACT,O
TRUNCATED,I-Entity
AT,I-Entity
250,O
WORDS,I-Entity
),O
Recurrent,I-Entity
myocardial,B-Entity
infarction,I-Entity
in,O
a,O
postpartum,O
patient,O
receiving,O
bromocriptine,I-Entity
.,O
Myocardial,I-Entity
infarction,I-Entity
in,O
puerperium,I-Entity
is,O
infrequently,O
reported,O
.,O
Spasm,I-Entity
",",O
coronary,O
dissection,O
",",O
or,O
atheromatous,I-Entity
etiology,O
has,O
been,O
described,O
.,O
Bromocriptine,I-Entity
has,O
been,O
implicated,O
in,O
several,O
previous,O
case,O
reports,O
of,O
myocardial,B-Entity
infarction,I-Entity
in,O
the,O
puerperium,I-Entity
.,O
Although,I-Entity
generally,O
regarded,O
as,O
"""""""""",O
safe,O
",",O
"""""""""",O
possible,O
serious,O
cardiac,O
effects,O
of,O
bromocriptine,I-Entity
should,O
be,O
acknowledged,O
.,O
Asterixis,I-Entity
induced,O
by,O
carbamazepine,I-Entity
therapy,O
.,O
There,I-Entity
are,O
very,O
few,O
reports,O
about,O
asterixis,I-Entity
as,O
a,O
side,O
effect,O
of,O
treatment,O
with,O
psychopharmacologic,O
agents,O
.,O
In,I-Entity
this,O
report,O
we,O
present,O
four,O
patients,O
treated,O
with,O
a,O
combination,O
of,O
different,O
psychotropic,I-Entity
drugs,O
",",O
in,O
whom,O
asterixis,I-Entity
was,O
triggered,O
either,O
by,O
adding,O
carbamazepine,I-Entity
(,O
CBZ,I-Entity
),O
to,O
a,O
treatment,O
regimen,I-Entity
",",O
or,O
by,O
increasing,O
its,O
dosage,O
.,O
Neither,I-Entity
dosage,O
nor,O
serum,O
levels,O
of,O
CBZ,I-Entity
were,O
in,O
a,O
higher,O
range,O
.,O
We,I-Entity
consider,O
asterixis,I-Entity
to,O
be,O
an,O
easily,O
overlooked,O
sign,O
of,O
neurotoxicity,I-Entity
",",O
which,O
may,O
occur,O
even,O
at,O
low,O
or,O
moderate,O
dosage,O
levels,O
",",O
if,O
certain,O
drugs,O
as,O
lithium,I-Entity
or,O
clozapine,I-Entity
are,O
used,O
in,O
combination,O
with,O
CBZ,I-Entity
.,O
Pharmacodynamics,I-Entity
of,O
the,O
hypotensive,I-Entity
effect,O
of,O
levodopa,I-Entity
in,O
parkinsonian,I-Entity
patients,O
.,O
levodopa,I-Entity
were,O
examined,O
in,O
parkinsonian,I-Entity
patients,O
with,O
stable,O
and,O
fluctuating,O
responses,O
to,O
levodopa,I-Entity
.,O
The,I-Entity
magnitude,O
of,O
the,O
hypotensive,I-Entity
effect,O
of,O
levodopa,I-Entity
was,O
concentration,O
dependent,O
and,O
was,O
fit,I-Entity
to,O
an,O
Emax,I-Entity
model,O
in,O
fluctuating,O
responders,O
.,O
Stable,I-Entity
responders,O
demonstrated,O
a,O
small,O
hypotensive,I-Entity
response,O
.,O
Baseline,I-Entity
blood,O
pressures,O
were,O
higher,O
in,O
fluctuating,O
patients,O
;,O
a,O
higher,O
baseline,O
blood,O
pressure,O
correlated,O
with,O
greater,O
hypotensive,I-Entity
effects,O
.,O
Antiparkinsonian,I-Entity
effects,O
of,O
levodopa,I-Entity
temporally,O
correlated,O
with,O
blood,O
pressure,O
changes,O
.,O
Phenylalanine,I-Entity
",",O
a,O
large,O
neutral,O
amino,I-Entity
acid,O
(,O
LNAA,I-Entity
),O
competing,O
with,O
levodopa,I-Entity
for,O
transport,O
across,O
the,O
blood,O
-,O
brain,O
barrier,O
",",O
reduced,O
the,O
hypotensive,I-Entity
and,O
antiparkinsonian,I-Entity
effects,O
of,O
levodopa,I-Entity
.,O
We,I-Entity
conclude,O
that,O
levodopa,I-Entity
has,O
a,O
central,O
hypotensive,I-Entity
action,O
that,O
parallels,O
the,O
motor,O
effects,O
in,O
fluctuating,O
patients,O
.,O
The,I-Entity
hypotensive,I-Entity
effect,O
appears,O
to,O
be,O
related,O
to,O
the,O
higher,O
baseline,O
blood,O
pressure,O
we,O
observed,O
in,O
fluctuating,O
patients,O
relative,O
to,O
stable,O
patients,O
.,O
Syndrome,I-Entity
of,O
inappropriate,O
secretion,O
of,O
antidiuretic,I-Entity
hormone,I-Entity
after,O
infusional,O
vincristine,I-Entity
.,O
A,I-Entity
77-year,O
-,O
old,O
woman,O
with,O
refractory,O
multiple,O
myeloma,I-Entity
was,O
treated,O
with,O
a,O
4-day,O
continuous,O
intravenous,O
infusion,O
of,O
vincristine,I-Entity
and,O
doxorubicin,I-Entity
and,O
4,O
days,O
of,O
oral,O
dexamethasone,I-Entity
.,O
Nine,I-Entity
days,O
after,O
her,O
second,O
cycle,O
she,O
presented,O
with,O
lethargy,I-Entity
and,O
weakness,I-Entity
associated,O
with,O
hyponatremia,I-Entity
.,O
Evaluation,I-Entity
revealed,O
the,O
syndrome,I-Entity
of,O
inappropriate,O
secretion,O
of,O
antidiuretic,I-Entity
hormone,I-Entity
",",O
which,O
was,O
attributed,O
to,O
the,O
vincristine,I-Entity
infusion,O
.,O
After,I-Entity
normal,O
serum,O
sodium,I-Entity
levels,O
returned,O
",",O
further,O
doxorubicin,I-Entity
and,O
dexamethasone,I-Entity
chemotherapy,O
without,O
vincristine,I-Entity
did,O
not,O
produce,O
this,O
complication,O
.,O
Heart,I-Entity
failure,I-Entity
:,O
to,O
digitalise,O
or,O
not,O
?,O
Despite,I-Entity
extensive,O
clinical,O
experience,O
the,O
role,O
of,O
digoxin,I-Entity
is,O
still,O
not,O
well,O
defined,O
.,O
In,I-Entity
patients,O
with,O
atrial,I-Entity
fibrillation,I-Entity
digoxin,I-Entity
is,O
beneficial,O
for,O
ventricular,O
rate,O
control,O
.,O
For,I-Entity
patients,O
in,O
sinus,O
rhythm,O
and,O
heart,O
failure,I-Entity
the,O
situation,O
is,O
less,O
clear,O
.,O
Digoxin,I-Entity
has,O
a,O
narrow,O
therapeutic,O
:,O
toxic,I-Entity
ratio,O
and,O
concentrations,O
are,O
affected,O
by,O
a,O
number,O
of,O
drugs,O
.,O
Also,I-Entity
",",O
digoxin,I-Entity
has,O
undesirable,I-Entity
effects,O
such,O
as,O
increasing,O
peripheral,O
resistance,O
and,O
myocardial,B-Entity
demands,O
",",O
and,O
causing,O
arrhythmias,I-Entity
.,O
More,I-Entity
convincing,O
evidence,O
is,O
required,O
showing,O
that,O
digoxin,I-Entity
improves,O
symptoms,O
or,O
exercise,O
capacity,O
.,O
Pooled,I-Entity
analysis,O
of,O
the,O
effects,O
of,O
other,O
inotropic,O
drugs,O
shows,O
an,O
excess,O
mortality,O
and,O
there,O
is,O
a,O
possibility,O
that,O
digoxin,I-Entity
may,O
increase,O
mortality,O
after,O
myocardial,B-Entity
infarction,I-Entity
(,O
MI,I-Entity
),O
.,O
Angiotensin,I-Entity
-,O
converting,O
enzyme,O
(,O
ACE,I-Entity
),O
inhibitors,O
should,O
be,O
used,O
first,O
as,O
they,O
are,O
safer,O
",",O
do,O
not,O
require,O
blood,O
level,O
monitoring,O
",",O
modify,O
progression,O
of,O
disease,I-Entity
",",O
relieve,O
symptoms,O
",",O
improve,O
exercise,O
tolerance,O
and,O
reduce,O
mortality,O
.,O
Caution,I-Entity
should,O
be,O
exercised,O
in,O
using,O
digoxin,I-Entity
until,O
large,O
mortality,O
trials,O
are,O
completed,O
showing,O
either,O
benefit,O
or,O
harm,O
.,O
Until,I-Entity
then,O
digoxin,I-Entity
should,O
be,O
considered,O
a,O
third,O
-,O
line,O
therapy,O
.,O
Intravascular,I-Entity
hemolysis,I-Entity
and,O
acute,O
renal,O
failure,I-Entity
following,O
intermittent,O
rifampin,I-Entity
therapy,O
.,O
Renal,I-Entity
failure,I-Entity
is,O
a,O
rare,O
complication,O
associated,O
with,O
the,O
use,O
of,O
rifampin,I-Entity
.,O
Intravascular,I-Entity
hemolysis,I-Entity
leading,O
to,O
acute,O
renal,O
failure,I-Entity
following,O
rifampin,I-Entity
therapy,O
is,O
extremely,O
rare,O
.,O
Two,I-Entity
patients,O
with,O
leprosy,I-Entity
who,O
developed,O
hemolysis,I-Entity
and,O
acute,O
renal,O
failure,I-Entity
following,O
rifampin,I-Entity
are,O
reported,O
.,O
Zidovudine,I-Entity
-,O
induced,O
hepatitis,I-Entity
.,O
A,I-Entity
case,O
of,O
acute,O
hepatitis,I-Entity
induced,O
by,O
zidovudine,I-Entity
in,O
a,O
38-year,O
-,O
old,O
patient,O
with,O
AIDS,I-Entity
is,O
presented,O
.,O
The,I-Entity
mechanism,O
whereby,O
the,O
hepatitis,I-Entity
was,O
induced,O
is,O
not,O
known,O
.,O
However,I-Entity
",",O
the,O
patient,O
tolerated,O
well,O
an,O
alternative,O
reverse,O
transcriptase,O
inhibitor,O
",",O
2'3,I-Entity
',O
dideoxyinosine,I-Entity
.,O
Physicians,I-Entity
caring,I-Entity
for,O
patients,O
with,O
AIDS,I-Entity
should,O
be,O
aware,O
of,O
this,O
hitherto,O
rarely,O
reported,O
complication,O
.,O
Thoracic,I-Entity
hematomyelia,I-Entity
secondary,O
to,O
coumadin,I-Entity
anticoagulant,O
therapy,O
:,O
a,O
case,O
report,O
.,O
A,I-Entity
case,O
of,O
thoracic,O
hematomyelia,I-Entity
secondary,O
to,O
anticoagulant,O
therapy,O
is,O
presented,O
.,O
Mania,I-Entity
associated,O
with,O
fluoxetine,I-Entity
treatment,O
in,O
adolescents,I-Entity
.,O
Fluoxetine,I-Entity
",",O
a,O
selective,O
serotonin,I-Entity
reuptake,O
inhibitor,O
",",O
is,O
gaining,O
increased,O
acceptance,O
in,O
the,O
treatment,O
of,O
adolescent,O
depression,I-Entity
.,O
Generally,I-Entity
safe,O
and,O
well,O
tolerated,O
by,O
adults,O
",",O
fluoxetine,I-Entity
has,O
been,O
reported,O
to,O
induce,O
mania,I-Entity
.,O
The,I-Entity
cases,O
of,O
five,O
depressed,I-Entity
adolescents,I-Entity
",",O
14,O
-,O
16,O
years,O
of,O
age,O
",",O
who,O
developed,O
mania,I-Entity
during,O
pharmacotherapy,O
with,O
fluoxetine,I-Entity
",",O
are,O
reported,O
here,O
.,O
Apparent,I-Entity
risk,O
factors,O
for,O
the,O
development,O
of,O
mania,I-Entity
or,O
hypomania,I-Entity
during,O
fluoxetine,I-Entity
pharmacotherapy,O
in,O
this,O
population,O
were,O
the,O
combination,O
of,O
attention,O
-,O
deficit,I-Entity
hyperactivity,I-Entity
disorder,I-Entity
and,O
affective,O
instability,O
;,O
major,O
depression,I-Entity
with,O
psychotic,I-Entity
features,O
;,O
a,O
family,O
history,O
of,O
affective,O
disorder,I-Entity
",",O
especially,O
bipolar,I-Entity
disorder,I-Entity
;,O
and,O
a,O
diagnosis,O
of,O
bipolar,I-Entity
disorder,I-Entity
.,O
Further,I-Entity
study,O
is,O
needed,O
to,O
determine,O
the,O
optimal,O
dosage,O
and,O
to,O
identify,O
risk,O
factors,O
that,O
increase,O
individual,O
vulnerability,O
to,O
fluoxetine,I-Entity
induced,O
mania,I-Entity
in,O
adolescents,I-Entity
.,O
Gemfibrozil,I-Entity
-,O
lovastatin,I-Entity
therapy,O
for,O
primary,O
hyperlipoproteinemias,I-Entity
.,O
The,I-Entity
specific,O
aim,O
of,O
this,O
retrospective,O
",",O
observational,O
study,O
was,O
to,O
assess,O
safety,O
and,O
efficacy,O
of,O
long,O
-,O
term,O
(,O
21,O
months,O
/,O
patient,O
),O
",",O
open,O
-,O
label,O
",",O
gemfibrozil,I-Entity
-,O
lovastatin,I-Entity
treatment,O
in,O
80,O
patients,O
with,O
primary,O
mixed,O
hyperlipidemia,I-Entity
(,O
68%,O
of,O
whom,O
had,O
atherosclerotic,I-Entity
vascular,O
disease,I-Entity
),O
.,O
Because,I-Entity
ideal,O
lipid,O
targets,O
were,O
not,O
reached,O
(,O
low,O
-,O
density,O
lipoprotein,O
(,O
LDL,I-Entity
),O
cholesterol,I-Entity
less,O
than,O
130,O
mg,O
/,O
dl,O
",",O
high,O
-,O
density,O
lipoprotein,O
(,O
HDL,I-Entity
),O
cholesterol,I-Entity
greater,O
than,O
35,O
mg,O
/,O
dl,O
",",O
or,O
total,O
cholesterol,I-Entity
/,O
HDL,I-Entity
cholesterol,I-Entity
less,O
than,O
4.5,O
mg,O
/,O
dl,O
),O
with,O
diet,O
plus,O
a,O
single,O
drug,O
",",O
gemfibrozil,I-Entity
(,O
1.2,O
g,O
/,O
day)-lovastatin,O
(,O
primarily,O
20,O
or,O
40,O
mg,O
),O
treatment,O
was,O
given,O
.,O
Follow,I-Entity
-,O
up,O
visits,O
were,O
scheduled,O
with,O
2-drug,O
therapy,O
every,O
6,O
to,O
8,O
weeks,O
",",O
an,O
average,O
of,O
10.3,O
visits,O
per,O
patient,O
",",O
with,O
741,I-Entity
batteries,O
of,O
6,O
liver,I-Entity
function,O
tests,O
and,O
714,O
creatine,I-Entity
phosphokinase,O
levels,O
measured,O
.,O
Of,I-Entity
the,O
714,O
creatine,I-Entity
phosphokinase,O
levels,O
",",O
9%,O
were,O
high,O
;,O
only,O
1,O
(,O
0.1%,O
),O
was,O
greater,O
than,O
or,O
equal,O
to,O
3,O
times,O
the,O
upper,O
normal,O
limit,O
.,O
With,I-Entity
2-drug,O
therapy,O
",",O
mean,O
total,O
cholesterol,I-Entity
decreased,O
22%,O
from,O
255,O
to,O
200,O
mg,O
/,O
dl,O
",",O
triglyceride,I-Entity
levels,O
decreased,O
35%,O
from,O
236,O
to,O
154,I-Entity
mg,O
/,O
dl,O
",",O
LDL,I-Entity
cholesterol,I-Entity
decreased,O
26%,O
from,O
176,I-Entity
to,O
131,O
mg,O
/,O
dl,O
",",O
and,O
the,O
total,O
cholesterol,I-Entity
/,O
HDL,I-Entity
cholesterol,I-Entity
ratio,O
decreased,O
24%,O
from,O
7.1,O
to,O
5.4,O
",",O
all,O
p,O
less,O
than,O
or,O
equal,O
to,O
0.0001,O
.,O
Myositis,I-Entity
",",O
attributable,O
to,O
the,O
drug,O
combination,O
and,O
symptomatic,O
enough,O
to,O
discontinue,O
it,O
",",O
occurred,O
in,O
3%,O
of,O
patients,O
",",O
and,O
in,O
1%,O
with,O
concurrent,O
high,O
creatine,I-Entity
phosphokinase,O
(,O
769,O
U,I-Entity
/,O
liter,O
),O
;,O
no,O
patients,O
had,O
rhabdomyolysis,I-Entity
or,O
myoglobinuria.(ABSTRACT,I-Entity
TRUNCATED,I-Entity
AT,I-Entity
250,O
WORDS,I-Entity
),O
Hepatocellular,I-Entity
carcinoma,I-Entity
in,O
Fanconi,I-Entity
's,I-Entity
anemia,I-Entity
treated,O
with,O
androgen,I-Entity
and,O
corticosteroid,O
.,O
The,I-Entity
case,O
of,O
an,O
11-year,O
-,O
old,O
boy,O
is,O
reported,O
who,O
was,O
known,O
to,O
have,O
Fanconi,I-Entity
's,I-Entity
anemia,I-Entity
for,O
3,O
years,O
and,O
was,O
treated,O
with,O
androgens,O
",",O
corticosteroids,I-Entity
and,O
transfusions,O
.,O
Two,I-Entity
weeks,O
before,O
his,O
death,I-Entity
he,O
was,O
readmitted,O
because,O
of,O
aplastic,B-Entity
crisis,I-Entity
with,O
septicemia,I-Entity
and,O
marked,O
abnormalities,I-Entity
in,O
liver,I-Entity
function,O
and,O
died,O
of,O
hemorrhagic,I-Entity
bronchopneumonia,I-Entity
.,O
At,I-Entity
autopsy,O
peliosis,I-Entity
and,O
multiple,O
hepatic,B-Entity
tumors,I-Entity
were,O
found,O
which,O
histologically,O
proved,O
to,O
be,O
well,O
-,O
differentiated,O
hepatocellular,O
carcinoma,I-Entity
.,O
This,I-Entity
case,O
contributes,O
to,O
the,O
previous,O
observations,O
that,O
non,O
-,O
metastasizing,O
hepatic,B-Entity
neoplasms,I-Entity
and,O
peliosis,I-Entity
can,O
develop,O
in,O
patients,O
with,O
androgen-,O
and,O
corticosteroid,O
-,O
treated,O
Fanconi,I-Entity
's,I-Entity
anemia,I-Entity
.,O
Chronic,I-Entity
lesion,I-Entity
of,O
rostral,O
ventrolateral,O
medulla,O
in,O
spontaneously,O
hypertensive,I-Entity
rats,O
.,O
We,I-Entity
studied,O
the,O
effects,O
of,O
chronic,O
selective,O
neuronal,O
lesion,I-Entity
of,O
rostral,O
ventrolateral,O
medulla,O
on,O
mean,O
arterial,O
pressure,O
",",O
heart,O
rate,O
",",O
and,O
neurogenic,I-Entity
tone,O
in,O
conscious,O
",",O
unrestrained,O
spontaneously,O
hypertensive,I-Entity
rats,O
.,O
N,I-Entity
-,O
methyl,I-Entity
-,O
D,I-Entity
-,O
aspartic,I-Entity
acid,O
.,O
The,I-Entity
restimulation,O
of,O
this,O
area,O
with,O
N,I-Entity
-,O
methyl,I-Entity
-,O
D,I-Entity
-,O
aspartic,I-Entity
acid,O
15,O
days,O
postlesion,I-Entity
failed,O
to,O
produce,O
a,O
pressor,O
response,O
.,O
The,I-Entity
ganglionic,O
blocker,O
trimethaphan,I-Entity
(,O
5,O
mg,O
/,O
kg,O
i.v,O
.,O
),O
The,I-Entity
trimethaphan,I-Entity
-,O
induced,O
hypotension,I-Entity
was,O
accompanied,O
by,O
a,O
significant,O
bradycardia,I-Entity
in,O
lesioned,O
rats,O
(,O
-32,O
13,O
beats,O
per,O
minute,O
),O
but,O
a,O
tachycardia,I-Entity
in,O
sham,I-Entity
rats,O
(,O
+,O
33,O
+,O
/-,O
Therefore,I-Entity
",",O
rostral,O
ventrolateral,O
medulla,O
neurons,O
appear,O
to,O
play,O
a,O
significant,O
role,O
in,O
maintaining,O
hypertension,I-Entity
in,O
conscious,O
spontaneously,O
hypertensive,I-Entity
rats,O
.,O
Spinal,I-Entity
or,O
suprabulbar,I-Entity
structures,O
could,O
be,O
responsible,O
for,O
the,O
gradual,O
recovery,O
of,O
the,O
hypertension,I-Entity
in,O
the,O
lesioned,O
rats,O
.,O
Damage,I-Entity
of,O
substantia,I-Entity
nigra,I-Entity
pars,O
reticulata,I-Entity
during,O
pilocarpine,I-Entity
-,O
induced,O
status,O
epilepticus,I-Entity
in,O
the,O
rat,O
:,O
immunohistochemical,O
study,O
of,O
neurons,O
",",O
astrocytes,I-Entity
and,O
serum,O
-,O
protein,O
extravasation,O
.,O
The,I-Entity
substantia,I-Entity
nigra,I-Entity
has,O
a,O
gating,O
function,O
controlling,O
the,O
spread,O
of,O
epileptic,I-Entity
seizure,I-Entity
activity,O
.,O
Additionally,I-Entity
",",O
in,O
models,O
of,O
prolonged,O
status,O
epilepticus,I-Entity
the,O
pars,O
reticulata,I-Entity
of,O
substantia,I-Entity
nigra,I-Entity
(,O
SNR,I-Entity
),O
suffers,O
from,O
a,O
massive,O
lesion,I-Entity
which,O
may,O
arise,O
from,O
a,O
massive,O
metabolic,O
derangement,I-Entity
and,O
hyperexcitation,I-Entity
developing,O
in,O
the,O
activated,O
SNR,I-Entity
.,O
In,I-Entity
this,O
study,O
",",O
status,O
epilepticus,I-Entity
was,O
induced,O
by,O
systemic,O
injection,O
of,O
pilocarpine,I-Entity
in,O
rats,O
.,O
Animals,I-Entity
surviving,O
20,O
",",O
30,O
",",O
40,O
",",O
60,O
min,O
",",O
2,O
",",O
3,O
",",O
6,O
hours,O
",",O
1,O
",",O
2,O
",",O
and,O
3,O
days,O
after,O
induction,O
of,O
status,O
epilepticus,I-Entity
were,O
perfusion,O
-,O
fixed,O
",",O
and,O
brains,O
processed,O
for,O
immunohistochemical,O
staining,I-Entity
of,O
SNR,I-Entity
.,O
Nissl,I-Entity
-,O
staining,I-Entity
and,O
antibodies,O
against,O
the,O
neuron,O
-,O
specific,O
calcium,I-Entity
-,O
binding,O
protein,O
",",O
parvalbumin,I-Entity
",",O
served,O
to,O
detect,O
neuronal,O
damage,O
in,O
SNR,I-Entity
.,O
Antibodies,I-Entity
against,O
the,O
astroglia,I-Entity
-,O
specific,O
cytoskeletal,O
protein,O
",",O
glial,O
fibrillary,O
acidic,O
protein,O
(,O
GFAP,I-Entity
),O
",",O
and,O
against,O
the,O
glial,O
calcium,I-Entity
-,O
binding,O
protein,O
",",O
S-100,I-Entity
protein,O
",",O
were,O
used,O
to,O
assess,O
the,O
status,O
of,O
astrocytes,I-Entity
.,O
Immunohistochemical,I-Entity
staining,I-Entity
for,O
serum,O
-,O
albumin,O
and,O
immunoglobulins,O
in,O
brain,O
tissue,O
was,O
taken,O
as,O
indicator,O
of,O
blood,O
-,O
brain,O
barrier,O
disturbances,I-Entity
and,O
vasogenic,O
edema,I-Entity
formation,O
.,O
Immunohistochemical,I-Entity
staining,I-Entity
indicated,O
loss,I-Entity
of,O
GFAP,I-Entity
-,O
staining,I-Entity
already,O
at,O
30,O
min,O
after,O
induction,O
of,O
seizures,I-Entity
in,O
an,O
oval,O
focus,O
situated,O
in,O
the,O
center,O
of,O
SNR,I-Entity
while,O
sparing,O
medial,O
and,O
lateral,O
aspects,O
.,O
By,I-Entity
2,O
hours,O
",",O
parvalbumin,I-Entity
-,O
staining,I-Entity
changed,O
in,O
the,O
central,O
SNR,I-Entity
indicating,O
neuronal,O
damage,O
",",O
and,O
Nissl,I-Entity
-,O
staining,I-Entity
visualized,O
some,O
neuronal,O
distortion,I-Entity
.,O
By,I-Entity
6,O
h,O
",",O
vasogenic,O
edema,I-Entity
covered,O
the,O
lesioned,O
SNR,I-Entity
.,O
In,I-Entity
a,O
further,O
group,O
of,O
animals,O
surviving,O
1,O
to,O
5,O
days,O
",",O
conventional,O
paraffin,I-Entity
-,O
sections,O
confirmed,O
the,O
neuronal,O
and,O
glial,O
damage,O
of,O
SNR,I-Entity
.,O
Both,I-Entity
cell,O
elements,O
may,O
suffer,O
in,O
common,O
from,O
metabolic,O
disturbance,I-Entity
and,O
neurotransmitter,O
dysfunction,I-Entity
as,O
occur,O
during,O
massive,O
status,O
epilepticus,I-Entity
.,O
Reduced,I-Entity
cardiotoxicity,I-Entity
of,O
doxorubicin,I-Entity
given,O
in,O
the,O
form,O
of,O
N-(2-hydroxypropyl)methacrylamide,I-Entity
conjugates,I-Entity
:,O
and,O
experimental,O
study,O
in,O
the,O
rat,O
.,O
A,I-Entity
rat,O
model,O
was,O
used,O
to,O
evaluate,O
the,O
general,O
acute,O
toxicity,I-Entity
and,O
the,O
late,O
cardiotoxicity,I-Entity
of,O
4,O
mg,O
/,O
kg,O
doxorubicin,I-Entity
(,O
DOX,I-Entity
),O
given,O
either,O
as,O
free,O
drug,O
or,O
in,O
the,O
form,O
of,O
three,O
N-(2-hydroxypropyl)methacrylamide,I-Entity
(,O
HPMA,I-Entity
),O
In,I-Entity
these,O
HPMA,I-Entity
copolymers,O
",",O
DOX,I-Entity
was,O
covalently,O
bound,O
via,O
peptide,I-Entity
linkages,O
that,O
were,O
either,O
non,O
-,O
biodegradable,O
(,O
Gly,I-Entity
-,O
Gly,I-Entity
),O
or,O
degradable,O
by,O
lysosomal,O
proteinases,O
(,O
Gly,I-Entity
-,O
Phe,I-Entity
-,O
Leu,I-Entity
-,O
Gly,I-Entity
),O
.,O
In,I-Entity
addition,O
",",O
one,O
biodegradable,O
conjugate,O
containing,O
galactosamine,I-Entity
was,O
used,O
;,O
this,O
residue,O
was,O
targeted,O
to,O
the,O
liver,I-Entity
.,O
administration,O
of,O
free,O
and,O
polymer,O
-,O
bound,O
DOX,I-Entity
",",O
all,O
animals,O
showed,O
a,O
transient,O
reduction,O
in,O
body,O
weight,O
.,O
However,I-Entity
",",O
the,O
maximal,O
reduction,O
in,O
body,O
weight,O
seen,O
in,O
animals,O
that,O
received,O
polymer,O
-,O
bound,O
DOX,I-Entity
(,O
4,O
mg,O
/,O
kg,O
),O
was,O
significantly,O
lower,O
than,O
that,O
observed,O
in,O
those,O
that,O
received,O
free,O
DOX,I-Entity
(,O
4,O
mg,O
/,O
kg,O
),O
or,O
a,O
mixture,O
of,O
the,O
unmodified,O
parent,O
HPMA,I-Entity
copolymer,I-Entity
and,O
free,O
DOX,I-Entity
(,O
4,O
mg,O
/,O
kg,O
;,O
P,I-Entity
less,O
than,O
0.01,O
),O
.,O
Throughout,I-Entity
the,O
study,O
(,O
20,O
weeks,O
),O
",",O
deaths,I-Entity
related,O
to,O
cardiotoxicity,I-Entity
were,O
observed,O
only,O
in,O
animals,O
that,O
received,O
either,O
free,O
DOX,I-Entity
or,O
the,O
mixture,O
of,O
HPMA,I-Entity
copolymer,I-Entity
and,O
free,O
DOX,I-Entity
;,O
in,O
these,O
cases,O
",",O
histological,O
investigations,O
revealed,O
marked,O
changes,O
in,O
the,O
heart,O
that,O
were,O
consistent,O
with,O
DOX,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
Sequential,I-Entity
measurements,O
of,O
cardiac,O
output,O
in,O
surviving,O
animals,O
that,O
received,O
either,O
free,O
DOX,I-Entity
or,O
the,O
mixture,O
of,O
HPMA,I-Entity
copolymer,I-Entity
and,O
free,O
DOX,I-Entity
showed,O
a,O
reduction,O
of,O
approximately,O
30%,O
in,O
function,O
beginning,O
at,O
the,O
4th,O
week,O
after,O
drug,O
administration,O
.,O
Animals,I-Entity
that,O
were,O
given,O
the,O
HPMA,I-Entity
copolymer,I-Entity
conjugates,I-Entity
containing,O
DOX,I-Entity
exhibited,O
no,O
significant,O
change,O
in,O
cardiac,O
output,O
throughout,O
the,O
study,O
(,O
P,I-Entity
less,O
than,O
0.05,O
),O
.,O
In,I-Entity
addition,O
",",O
no,O
significant,O
histological,O
change,O
was,O
observed,O
in,O
the,O
heart,O
of,O
animals,O
that,O
received,O
DOX,I-Entity
in,O
the,O
form,O
of,O
HPMA,I-Entity
copolymer,I-Entity
conjugates,I-Entity
and,O
were,O
killed,O
at,O
the,O
end,O
of,O
the,O
study,O
.,O
Topical,I-Entity
0.025%,O
capsaicin,I-Entity
in,O
chronic,O
post,O
-,O
herpetic,O
neuralgia,I-Entity
:,O
efficacy,O
",",O
predictors,O
of,O
response,O
and,O
long,O
-,O
term,O
course,O
.,O
In,I-Entity
order,O
to,O
evaluate,O
the,O
efficacy,O
",",O
time,O
-,O
course,O
of,O
action,O
and,O
predictors,O
of,O
response,O
to,O
topical,O
capsaicin,I-Entity
",",O
39,O
patients,O
with,O
chronic,O
post,O
-,O
herpetic,O
neuralgia,I-Entity
(,O
PHN,I-Entity
),O
",",O
median,O
duration,O
24,O
months,O
",",O
were,O
treated,O
with,O
0.025%,O
capsaicin,I-Entity
cream,O
for,O
8,O
weeks,O
.,O
During,I-Entity
therapy,O
the,O
patients,O
rated,O
their,O
pain,I-Entity
on,O
a,O
visual,O
analogue,O
scale,O
(,O
VAS,I-Entity
),O
and,O
a,O
verbal,O
outcome,O
scale,O
.,O
Nineteen,I-Entity
patients,O
(,O
48.7%,O
),O
substantially,O
improved,O
after,O
the,O
8-week,O
trial,O
;,O
5,O
(,O
12.8%,O
),O
discontinued,O
therapy,O
due,O
to,O
side,O
-,O
effects,O
such,O
as,O
intolerable,O
capsaicin,I-Entity
-,O
induced,O
burning,O
sensations,O
(,O
4,O
),O
or,O
mastitis,I-Entity
(,O
1,O
),O
;,O
15,O
(,O
38.5%,O
),O
reported,O
no,O
benefit,O
.,O
Treatment,I-Entity
effect,O
was,O
not,O
dependent,O
on,O
patient,O
's,I-Entity
age,O
",",O
duration,O
or,O
localization,O
of,O
PHN,I-Entity
(,O
trigeminal,I-Entity
involvement,O
was,O
excluded,O
),O
",",O
sensory,O
disturbance,I-Entity
or,O
pain,I-Entity
character,O
.,O
Treatment,I-Entity
response,O
was,O
not,O
correlated,O
with,O
the,O
incidence,O
",",O
time,O
-,O
course,O
or,O
severity,O
of,O
capsaicin,I-Entity
-,O
induced,O
burning,O
.,O
If,I-Entity
confirmed,O
in,O
controlled,O
trials,O
",",O
the,O
long,O
-,O
term,O
results,O
of,O
this,O
open,O
",",O
non,O
-,O
randomized,O
study,O
might,O
indicate,O
that,O
the,O
analgesic,O
effect,O
of,O
capsaicin,I-Entity
in,O
PHN,I-Entity
is,O
mediated,O
by,O
both,O
interference,I-Entity
with,O
neuropeptide,O
metabolism,O
and,O
morphological,O
changes,O
(,O
perhaps,O
degeneration,I-Entity
),O
of,O
nociceptive,B-Entity
afferents,O
.,O
Serotonin,I-Entity
reuptake,O
inhibitors,O
",",O
paranoia,I-Entity
",",O
and,O
the,O
ventral,O
basal,O
ganglia,I-Entity
.,O
Antidepressants,I-Entity
have,O
previously,O
been,O
associated,O
with,O
paranoid,I-Entity
reactions,O
in,O
psychiatric,I-Entity
patients,O
.,O
Five,I-Entity
cases,O
of,O
paranoid,I-Entity
exacerbation,O
with,O
the,O
serotonin,I-Entity
reuptake,O
inhibitors,O
fluoxetine,I-Entity
and,O
amitriptyline,I-Entity
are,O
reported,O
here,O
.,O
Elements,I-Entity
common,O
to,O
these,O
cases,O
included,O
a,O
history,O
of,O
paranoid,I-Entity
symptomatology,O
and,O
the,O
concomitant,I-Entity
occurrence,O
of,O
depressive,I-Entity
and,O
psychotic,I-Entity
symptoms,O
.,O
Complicated,I-Entity
depressive,I-Entity
disorders,I-Entity
(,O
including,O
atypicality,O
of,O
course,O
and,O
symptomatology,O
",",O
chronicity,O
",",O
psychosis,I-Entity
",",O
bipolarity,I-Entity
",",O
and,O
secondary,O
onset,O
in,O
the,O
course,O
of,O
a,O
primary,O
psychosis,I-Entity
),O
may,O
present,O
particular,O
vulnerability,O
to,O
paranoid,I-Entity
exacerbations,O
associated,O
with,O
serotonin,I-Entity
reuptake,O
inhibitors,O
.,O
Although,I-Entity
the,O
pharmacology,O
and,O
neurobiology,O
of,O
paranoia,I-Entity
remain,O
cryptic,O
",",O
several,O
mechanisms,O
",",O
including,O
5HT3,I-Entity
receptor,O
-,O
mediated,O
dopamine,I-Entity
release,O
",",O
beta,O
-,O
noradrenergic,I-Entity
receptor,O
downregulation,O
",",O
or,O
GABAB,I-Entity
receptor,O
upregulation,O
acting,O
in,O
the,O
vicinity,O
of,O
the,O
ventral,O
basal,O
ganglia,I-Entity
(,O
possibly,O
in,O
lateral,O
orbitofrontal,O
or,O
anterior,O
cingulate,O
circuits,O
),O
",",O
might,O
apply,O
to,O
this,O
phenomenon,O
.,O
These,I-Entity
cases,O
call,O
attention,O
to,O
possible,O
paranoid,I-Entity
exacerbations,O
with,O
serotonin,I-Entity
reuptake,O
blockers,O
in,O
select,O
patients,O
and,O
raise,O
neurobiological,O
considerations,O
regarding,O
paranoia,I-Entity
.,O
Five,I-Entity
cases,O
of,O
encephalitis,I-Entity
during,O
treatment,O
of,O
loiasis,I-Entity
with,O
diethylcarbamazine,I-Entity
.,O
Five,I-Entity
cases,O
of,O
encephalitis,I-Entity
following,O
treatment,O
with,O
diethylcarbamazine,I-Entity
(,O
DEC,I-Entity
),O
were,O
observed,O
in,O
Congolese,I-Entity
patients,O
with,O
Loa,I-Entity
loa,O
filariasis,I-Entity
.,O
The,I-Entity
notable,O
fact,O
was,O
that,O
this,O
complication,O
occurred,O
in,O
three,O
patients,O
hospitalized,O
before,O
treatment,O
began,O
",",O
with,O
whom,O
particularly,O
strict,O
therapeutic,O
precautions,O
were,O
taken,O
",",O
i.e.,O
",",O
initial,O
dose,O
less,O
than,O
10,O
mg,O
of,O
DEC,I-Entity
",",O
very,O
gradual,O
dose,O
increases,O
",",O
and,O
associated,O
anti,O
-,O
allergic,I-Entity
treatment,O
.,O
The,I-Entity
relationship,O
between,O
the,O
occurrence,O
of,O
encephalitis,I-Entity
and,O
the,O
decrease,O
in,O
microfilaremia,I-Entity
is,O
evident,O
.,O
Delirium,I-Entity
in,O
an,O
elderly,O
woman,O
possibly,O
associated,O
with,O
administration,O
of,O
misoprostol,I-Entity
.,O
Misoprostol,I-Entity
has,O
been,O
associated,O
with,O
adverse,O
reactions,O
",",O
including,O
gastrointestinal,B-Entity
symptoms,O
",",O
gynecologic,O
problems,O
",",O
and,O
headache,I-Entity
.,O
We,I-Entity
present,O
a,O
case,O
in,O
which,O
an,O
89-year,O
-,O
old,O
woman,O
in,O
a,O
long,O
-,O
term,O
care,O
facility,O
became,O
confused,I-Entity
after,O
the,O
initiation,O
of,O
misoprostol,I-Entity
therapy,O
.,O
Her,I-Entity
delirium,I-Entity
significantly,O
improved,O
after,O
misoprostol,I-Entity
was,O
discontinued,O
and,O
her,O
mental,O
status,O
returned,O
to,O
normal,O
within,O
a,O
week,O
.,O
Because,I-Entity
no,O
other,O
factors,O
related,O
to,O
this,O
patient,O
changed,O
significantly,O
",",O
the,O
delirium,I-Entity
experienced,O
by,O
this,O
patient,O
possibly,O
resulted,O
from,O
misoprostol,I-Entity
therapy,O
.,O
Hepatocellular,I-Entity
oxidant,O
stress,I-Entity
following,O
intestinal,O
ischemia,I-Entity
-,O
reperfusion,O
injury,I-Entity
.,O
Reperfusion,I-Entity
of,O
ischemic,I-Entity
intestine,O
results,O
in,O
acute,O
liver,I-Entity
dysfunction,I-Entity
characterized,O
by,O
hepatocellular,O
enzyme,O
release,O
into,O
plasma,O
",",O
reduction,O
in,O
bile,I-Entity
flow,O
rate,O
",",O
and,O
neutrophil,O
sequestration,O
within,O
the,O
liver,I-Entity
.,O
The,I-Entity
pathophysiology,O
underlying,O
this,O
acute,O
hepatic,B-Entity
injury,I-Entity
is,O
unknown,O
.,O
This,I-Entity
study,O
was,O
undertaken,O
to,O
determine,O
whether,O
oxidants,O
are,O
associated,O
with,O
the,O
hepatic,B-Entity
injury,I-Entity
and,O
to,O
determine,O
the,O
relative,O
value,O
of,O
several,O
indirect,O
methods,O
of,O
assessing,O
oxidant,O
exposure,O
in,O
vivo,O
.,O
Rats,I-Entity
were,O
subjected,O
to,O
a,O
standardized,O
intestinal,O
ischemia,I-Entity
-,O
reperfusion,O
injury,I-Entity
.,O
Hepatic,I-Entity
tissue,O
was,O
assayed,O
for,O
lipid,O
peroxidation,O
products,O
and,O
oxidized,O
and,O
reduced,O
glutathione,I-Entity
.,O
There,I-Entity
was,O
no,O
change,O
in,O
hepatic,B-Entity
tissue,O
total,O
glutathione,I-Entity
following,O
intestinal,O
ischemia,I-Entity
-,O
reperfusion,O
injury,I-Entity
.,O
Oxidized,I-Entity
glutathione,I-Entity
(,O
GSSG,I-Entity
),O
increased,O
significantly,O
following,O
30,O
and,O
60,O
min,O
of,O
reperfusion,O
.,O
An,I-Entity
increase,O
in,O
GSSG,I-Entity
within,O
hepatic,B-Entity
tissue,O
during,O
intestinal,O
reperfusion,O
suggests,O
exposure,O
of,O
hepatocytes,O
to,O
an,O
oxidant,O
stress,I-Entity
.,O
These,I-Entity
data,O
also,O
suggest,O
that,O
the,O
measurement,O
of,O
tissue,O
GSSG,I-Entity
may,O
be,O
a,O
more,O
sensitive,I-Entity
indicator,O
of,O
oxidant,O
stress,I-Entity
than,O
measurement,O
of,O
products,O
of,O
lipid,O
peroxidation,O
.,O
Diphenhydramine,I-Entity
prevents,O
the,O
haemodynamic,O
changes,O
of,O
cimetidine,I-Entity
in,O
ICU,I-Entity
patients,O
.,O
Cimetidine,I-Entity
",",O
a,O
histamine,I-Entity
2,O
(,O
H2,I-Entity
),O
antagonist,O
",",O
produces,O
a,O
decrease,O
in,O
arterial,O
pressure,O
due,O
to,O
vasodilatation,O
",",O
especially,O
in,O
critically,O
ill,O
patients,O
.,O
This,I-Entity
may,O
be,O
because,O
cimetidine,I-Entity
acts,O
as,O
a,O
histamine,I-Entity
agonist,I-Entity
.,O
We,I-Entity
",",O
therefore,O
",",O
investigated,O
the,O
effects,O
of,O
the,O
histamine,I-Entity
1(H1,O
),O
receptor,O
antagonist,O
",",O
diphenhydramine,I-Entity
",",O
on,O
the,O
haemodynamic,O
changes,O
observed,O
after,O
cimetidine,I-Entity
in,O
ICU,I-Entity
patients,O
.,O
In,I-Entity
a,O
random,O
fashion,O
",",O
they,O
received,O
cimetidine,I-Entity
200,O
mg,O
iv,O
on,O
one,O
day,O
",",O
and,O
on,O
the,O
other,O
",",O
a,O
pretreatment,O
of,O
diphenhydramine,I-Entity
40,O
mg,O
iv,O
with,O
cimetidine,I-Entity
200,O
mg,O
iv,O
.,O
11.4,O
mmHg,I-Entity
(,O
P,I-Entity
less,O
than,O
0.01,O
),O
two,O
minutes,O
after,O
cimetidine,I-Entity
.,O
We,I-Entity
conclude,O
that,O
an,O
H1,I-Entity
antagonist,O
may,O
be,O
useful,O
in,O
preventing,O
hypotension,I-Entity
caused,O
by,O
iv,O
cimetidine,I-Entity
",",O
since,O
the,O
vasodilating,O
activity,O
of,O
cimetidine,I-Entity
is,O
mediated,O
",",O
in,O
part,O
",",O
through,O
the,O
H1,I-Entity
receptor,O
.,O
Acute,I-Entity
renal,O
failure,I-Entity
due,O
to,O
rifampicin,I-Entity
.,O
A,I-Entity
23-year,O
-,O
old,O
male,O
patient,O
with,O
bacteriologically,O
proven,O
pulmonary,O
tuberculosis,I-Entity
was,O
treated,O
with,O
the,O
various,O
regimens,I-Entity
of,O
antituberculosis,I-Entity
drugs,O
for,O
nearly,O
15,O
months,O
.,O
Rifampicin,I-Entity
was,O
administered,O
thrice,O
as,O
one,O
of,O
the,O
3,O
-,O
4,O
drug,O
regimen,I-Entity
and,O
each,O
time,O
he,O
developed,O
untoward,O
side,O
effects,O
like,O
nausea,I-Entity
",",O
vomiting,I-Entity
and,O
fever,I-Entity
with,O
chills,I-Entity
and,O
rigors,O
.,O
Severe,I-Entity
polyneuropathy,I-Entity
and,O
motor,O
loss,I-Entity
after,O
intrathecal,O
thiotepa,I-Entity
combination,O
chemotherapy,O
:,O
Two,I-Entity
cases,O
of,O
severe,O
delayed,O
neurologic,O
toxicity,I-Entity
related,O
to,O
the,O
administration,O
of,O
intrathecal,O
(,O
IT,I-Entity
),O
combination,O
chemotherapy,O
including,O
thiotepa,I-Entity
(,O
TSPA,I-Entity
),O
are,O
presented,O
.,O
Both,I-Entity
cases,O
developed,O
axonal,O
neuropathy,I-Entity
with,O
motor,O
predominance,O
in,O
the,O
lower,O
extremities,O
1,O
and,O
6,O
months,O
after,O
IT,I-Entity
chemotherapy,O
was,O
administered,O
.,O
Neurologic,I-Entity
toxicities,I-Entity
have,O
been,O
described,O
with,O
IT,I-Entity
-,O
methotrexate,I-Entity
",",O
IT,I-Entity
-,O
cytosine,I-Entity
arabinoside,I-Entity
and,O
IT,I-Entity
-,O
TSPA,I-Entity
.,O
To,I-Entity
our,O
knowledge,O
",",O
however,O
",",O
axonal,O
neuropathy,I-Entity
In,I-Entity
spite,O
of,O
the,O
fact,O
that,O
TSPA,I-Entity
is,O
a,O
useful,O
IT,I-Entity
agent,O
",",O
its,O
combination,O
with,O
MTX,I-Entity
",",O
ara,O
-,O
C,I-Entity
and,O
radiotherapy,O
could,O
cause,O
severe,O
neurotoxicity,I-Entity
.,O
This,I-Entity
unexpected,O
complication,O
indicates,O
the,O
need,O
for,O
further,O
toxicology,I-Entity
research,O
on,O
IT,I-Entity
-,O
TSPA,I-Entity
.,O
Effects,I-Entity
of,O
cromakalim,I-Entity
and,O
pinacidil,I-Entity
on,O
large,O
epicardial,O
and,O
small,O
coronary,O
arteries,O
in,O
conscious,O
dogs,O
.,O
bolus,O
administration,O
of,O
cromakalim,I-Entity
(,O
1,O
-,O
10,O
micrograms,O
/,O
kg,O
),O
and,O
pinacidil,I-Entity
(,O
3,O
-,O
100,O
micrograms,O
/,O
kg,O
),O
on,O
large,O
(,O
circumflex,O
artery,I-Entity
),O
and,O
small,O
coronary,O
arteries,O
and,O
on,O
systemic,O
hemodynamics,O
were,O
investigated,O
in,O
chronically,O
instrumented,O
conscious,O
dogs,O
and,O
compared,O
to,O
those,O
of,O
nitroglycerin,I-Entity
(,O
0.03,O
-,O
10,O
micrograms,O
/,O
kg,O
),O
.,O
Nitroglycerin,I-Entity
",",O
up,O
to,O
0.3,O
micrograms,O
/,O
kg,O
",",O
selectively,O
increased,O
circumflex,O
artery,I-Entity
diameter,O
(,O
CxAD,I-Entity
),O
without,O
simultaneously,O
affecting,O
any,O
other,O
cardiac,O
or,O
systemic,O
hemodynamic,O
parameter,O
.,O
In,I-Entity
contrast,O
",",O
cromakalim,I-Entity
and,O
pinacidil,I-Entity
at,O
all,O
doses,O
and,O
nitroglycerin,I-Entity
at,O
doses,O
higher,O
than,O
0.3,O
micrograms,O
/,O
kg,O
simultaneously,O
and,O
dose,O
-,O
dependently,O
increased,O
CxAD,I-Entity
",",O
coronary,O
blood,O
flow,O
and,O
heart,O
rate,O
and,O
decreased,O
coronary,O
vascular,O
resistance,O
and,O
aortic,O
pressure,O
.,O
Cromakalim,I-Entity
was,O
approximately,O
8-,I-Entity
to,O
9.5-fold,O
more,O
potent,O
than,O
pinacidil,I-Entity
in,O
increasing,O
CxAD,I-Entity
.,O
Vasodilation,I-Entity
of,O
large,O
and,O
small,O
coronary,O
vessels,O
and,O
hypotension,I-Entity
induced,O
by,O
cromakalim,I-Entity
and,O
pinacidil,I-Entity
were,O
not,O
affected,O
by,O
prior,O
combined,O
beta,O
adrenergic,O
and,O
muscarinic,O
receptors,O
blockade,O
but,O
drug,O
-,O
induced,O
tachycardia,I-Entity
was,O
abolished,O
.,O
When,I-Entity
circumflex,O
artery,I-Entity
blood,O
flow,O
was,O
maintained,O
constant,O
",",O
the,O
increases,O
in,O
CxAD,I-Entity
induced,O
by,O
cromakalim,I-Entity
(,O
10,O
micrograms,O
/,O
kg,O
),O
",",O
pinacidil,I-Entity
(,O
30,O
micrograms,O
/,O
kg,O
),O
and,O
nitroglycerin,I-Entity
(,O
10,O
micrograms,O
/,O
kg,O
),O
were,O
reduced,O
by,O
68,O
+,O
/-,O
Thus,I-Entity
",",O
whereas,O
nitroglycerin,I-Entity
preferentially,O
and,O
flow,O
-,O
independently,O
dilates,O
large,O
coronary,O
arteries,O
",",O
cromakalim,I-Entity
and,O
pinacidil,I-Entity
dilate,O
both,O
large,O
and,O
small,O
coronary,O
arteries,O
and,O
this,O
effect,O
is,O
not,O
dependent,O
upon,O
the,O
simultaneous,O
beta,O
adrenoceptors,O
-,O
mediated,O
rise,O
in,O
myocardial,B-Entity
metabolic,O
demand,O
.,O
Finally,I-Entity
",",O
two,O
mechanisms,O
at,O
least,O
",",O
direct,O
vasodilation,O
and,O
flow,O
dependency,O
",",O
are,O
involved,O
in,O
the,O
cromakalim-,I-Entity
and,O
pinacidil,I-Entity
-,O
induced,O
increase,O
in,O
CxAD,I-Entity
.,O
Mefenamic,I-Entity
acid,O
-,O
induced,O
neutropenia,I-Entity
and,O
renal,O
failure,I-Entity
in,O
elderly,O
females,O
with,O
hypothyroidism,I-Entity
.,O
We,I-Entity
report,O
mefenamic,I-Entity
acid,O
-,O
induced,O
non,O
-,O
oliguric,I-Entity
renal,O
failure,I-Entity
and,O
severe,O
neutropenia,I-Entity
occurring,O
simultaneously,O
in,O
two,O
elderly,O
females,O
.,O
The,I-Entity
neutropenia,I-Entity
was,O
due,O
to,O
maturation,O
arrest,I-Entity
of,O
the,O
myeloid,I-Entity
series,O
in,O
one,O
patient,O
.,O
Both,I-Entity
patients,O
were,O
also,O
hypothyroid,I-Entity
",",O
but,O
it,O
is,O
not,O
clear,O
whether,O
this,O
was,O
a,O
predisposing,O
factor,O
to,O
the,O
development,O
of,O
these,O
adverse,O
reactions,O
.,O
However,I-Entity
",",O
it,O
would,O
seem,O
prudent,O
not,O
to,O
use,O
mefenamic,I-Entity
acid,O
in,O
hypothyroid,I-Entity
patients,O
until,O
the,O
hypothyroidism,I-Entity
has,O
been,O
corrected,O
.,O
Etiology,I-Entity
of,O
hypercalcemia,I-Entity
in,O
hemodialysis,O
patients,O
on,O
calcium,I-Entity
carbonate,I-Entity
therapy,O
.,O
Fourteen,I-Entity
of,O
39,O
dialysis,O
patients,O
(,O
36%,O
),O
became,O
hypercalcemic,B-Entity
after,O
switching,O
to,O
calcium,I-Entity
carbonate,I-Entity
as,O
their,O
principal,O
phosphate,I-Entity
binder,O
.,O
In,I-Entity
order,O
to,O
identify,O
risk,O
factors,O
associated,O
with,O
the,O
development,O
of,O
hypercalcemia,I-Entity
",",O
indirect,O
parameters,O
of,O
intestinal,O
calcium,I-Entity
reabsorption,O
and,O
bone,O
turnover,O
rate,O
in,O
these,O
14,O
patients,O
were,O
compared,O
with,O
results,O
in,O
14,O
eucalcemic,I-Entity
patients,O
matched,O
for,O
age,O
",",O
sex,O
",",O
length,O
of,O
time,O
on,O
dialysis,O
",",O
and,O
etiology,O
of,O
renal,O
disease,I-Entity
.,O
In,I-Entity
addition,O
to,O
experiencing,O
hypercalcemic,B-Entity
episodes,O
with,O
peak,O
calcium,I-Entity
values,O
of,O
2.7,O
to,O
3.8,O
mmol,O
/,O
L,I-Entity
(,O
10.7,O
to,O
15.0,O
mg,O
/,O
dL,I-Entity
),O
",",O
patients,O
in,O
the,O
hypercalcemic,B-Entity
group,O
exhibited,O
a,O
significant,O
increase,O
in,O
the,O
mean,O
calcium,I-Entity
concentration,O
obtained,O
during,O
6,O
months,O
before,O
the,O
switch,O
",",O
compared,O
with,O
the,O
mean,O
value,O
obtained,O
during,O
the,O
7,O
months,O
of,O
observation,O
after,O
the,O
switch,O
(,O
2.4,O
+,O
/-,O
In,I-Entity
contrast,O
",",O
eucalcemic,I-Entity
patients,O
exhibited,O
no,O
change,O
in,O
mean,O
calcium,I-Entity
values,O
over,O
the,O
same,O
time,O
period,O
(,O
2.3,O
+,O
/-,O
CaCO3,I-Entity
dosage,O
",",O
calculated,O
dietary,O
calcium,I-Entity
intake,O
",",O
and,O
circulating,O
levels,O
of,O
vitamin,B-Entity
D,I-Entity
metabolites,O
were,O
similar,O
in,O
both,O
groups,O
.,O
Physical,I-Entity
activity,O
index,O
and,O
predialysis,O
serum,O
bicarbonate,I-Entity
levels,O
also,O
were,O
similar,O
in,O
both,O
groups,O
.,O
Methyldopa,I-Entity
-,O
induced,O
hemolytic,I-Entity
anemia,I-Entity
in,O
a,O
15,O
year,O
old,O
presenting,O
as,O
near,O
-,O
syncope,I-Entity
.,O
Methyldopa,I-Entity
is,O
an,O
antihypertensive,O
medication,O
which,O
is,O
available,O
generically,O
and,O
under,O
the,O
trade,O
name,O
Aldomet,I-Entity
that,O
is,O
widely,O
prescribed,O
in,O
the,O
adult,O
population,O
and,O
infrequently,O
used,O
in,O
children,O
.,O
Methyldopa,I-Entity
causes,O
an,O
autoimmune,I-Entity
hemolytic,I-Entity
anemia,I-Entity
in,O
a,O
small,O
percentage,O
of,O
patients,O
who,O
take,O
the,O
drug,O
.,O
We,I-Entity
report,O
a,O
case,O
of,O
methyldopa,I-Entity
-,O
induced,O
hemolytic,I-Entity
anemia,I-Entity
in,O
a,O
15-year,O
-,O
old,O
boy,O
who,O
presented,O
to,O
the,O
emergency,O
department,O
with,O
near,O
-,O
syncope,I-Entity
.,O
The,I-Entity
boy,O
had,O
been,O
treated,O
with,O
intravenous,O
methyldopa,I-Entity
during,O
a,O
trauma,I-Entity
admission,O
seven,O
weeks,O
prior,O
to,O
presentation,O
.,O
Transfusion,I-Entity
and,O
corticosteroid,O
therapy,O
resulted,O
in,O
a,O
complete,O
recovery,O
of,O
the,O
patient,O
.,O
A,I-Entity
brief,O
review,O
of,O
autoimmune,I-Entity
and,O
drug,O
-,O
induced,O
hemolytic,I-Entity
anemias,I-Entity
is,O
provided,O
.,O
The,I-Entity
long,O
-,O
term,O
safety,O
of,O
danazol,I-Entity
in,O
women,O
with,O
hereditary,O
angioedema,I-Entity
.,O
Although,I-Entity
the,O
short,I-Entity
-,O
term,O
safety,O
(,O
less,O
than,O
or,O
equal,O
to,O
6,O
months,O
),O
of,O
danazol,I-Entity
has,O
been,O
established,O
in,O
a,O
variety,O
of,O
settings,O
",",O
no,O
information,O
exists,O
as,O
to,O
its,O
long,O
-,O
term,O
safety,O
.,O
We,I-Entity
therefore,O
investigated,O
the,O
long,O
-,O
term,O
safety,O
of,O
danazol,I-Entity
by,O
performing,O
a,O
retrospective,O
chart,O
review,O
of,O
60,O
female,O
patients,O
with,O
hereditary,O
angioedema,I-Entity
treated,O
with,O
danazol,I-Entity
for,O
a,O
continuous,O
period,O
of,O
6,O
months,O
or,O
longer,O
.,O
Menstrual,I-Entity
abnormalities,I-Entity
(,O
79%,O
),O
",",O
weight,O
gain,O
(,O
60%,O
),O
",",O
muscle,O
cramps,I-Entity
/,O
myalgias,I-Entity
(,O
40%,O
),O
",",O
and,O
transaminase,O
elevations,O
(,O
40%,O
),O
were,O
the,O
most,O
common,O
adverse,O
reactions,O
.,O
We,I-Entity
conclude,O
that,O
",",O
despite,O
a,O
relatively,O
high,O
incidence,O
of,O
adverse,O
reactions,O
",",O
danazol,I-Entity
has,O
proven,O
to,O
be,O
remarkably,O
safe,O
over,O
the,O
long,O
-,O
term,O
in,O
this,O
group,O
of,O
patients,O
.,O
Patient,I-Entity
tolerance,O
study,O
of,O
topical,O
chlorhexidine,I-Entity
diphosphanilate,I-Entity
:,O
a,O
new,O
topical,O
agent,O
for,O
burns,I-Entity
.,O
Effective,I-Entity
topical,O
antimicrobial,O
agents,O
decrease,O
infection,I-Entity
and,O
mortality,O
in,O
burn,O
patients,O
.,O
Chlorhexidine,I-Entity
phosphanilate,I-Entity
(,O
CHP,I-Entity
),O
",",O
a,O
new,O
broad,O
-,O
spectrum,O
antimicrobial,O
agent,O
",",O
has,O
been,O
evaluated,O
as,O
a,O
topical,O
burn,O
wound,O
dressing,O
in,O
cream,O
form,O
",",O
but,O
preliminary,O
clinical,O
trials,O
reported,O
that,O
it,O
was,O
painful,O
upon,O
application,O
.,O
This,I-Entity
study,O
compared,O
various,O
concentrations,O
of,O
CHP,I-Entity
to,O
determine,O
if,O
a,O
tolerable,O
concentration,O
could,O
be,O
identified,O
with,O
retention,O
of,O
antimicrobial,O
efficacy,O
.,O
Twenty,I-Entity
-,O
nine,O
burn,O
patients,O
",",O
each,O
with,O
two,O
similar,O
burns,I-Entity
which,O
could,O
be,O
separately,O
treated,O
",",O
were,O
given,O
pairs,O
of,O
treatments,O
at,O
successive,O
12-h,O
intervals,O
over,O
a,O
3-day,O
period,O
.,O
One,I-Entity
burn,O
site,O
was,O
treated,O
with,O
each,O
of,O
four,O
different,O
CHP,I-Entity
concentrations,O
",",O
from,O
0.25,O
per,O
cent,O
to,O
2,O
per,O
cent,O
",",O
their,O
vehicle,O
",",O
and,O
1,O
per,O
cent,O
silver,O
sulphadiazine,I-Entity
(,O
AgSD,I-Entity
),O
cream,O
",",O
an,O
antimicrobial,O
agent,O
frequently,O
used,O
for,O
topical,O
treatment,O
of,O
burn,O
wounds,O
.,O
The,I-Entity
other,O
site,O
was,O
always,O
treated,O
with,O
AgSD,I-Entity
cream,O
.,O
There,I-Entity
was,O
a,O
direct,O
relationship,O
between,O
CHP,I-Entity
concentration,O
and,O
patients,O
',O
ratings,O
of,O
pain,I-Entity
on,O
an,O
analogue,O
scale,O
.,O
The,I-Entity
0.25,O
per,O
cent,O
CHP,I-Entity
cream,O
was,O
closest,O
to,O
AgSD,I-Entity
in,O
pain,I-Entity
tolerance,O
;,O
however,O
",",O
none,O
of,O
the,O
treatments,O
differed,O
statistically,O
from,O
AgSD,I-Entity
or,O
from,O
each,O
other,O
.,O
In,I-Entity
addition,O
",",O
ease,O
of,O
application,O
of,O
CHP,I-Entity
creams,O
was,O
less,O
satisfactory,O
than,O
that,O
of,O
AgSD,I-Entity
.,O
It,I-Entity
was,O
concluded,O
that,O
formulations,O
at,O
or,O
below,O
0.5,O
per,O
cent,O
CHP,I-Entity
may,O
prove,O
acceptable,O
for,O
wound,O
care,O
",",O
but,O
the,O
vehicle,O
system,O
needs,O
pharmaceutical,O
improvement,O
to,O
render,O
it,O
more,O
tolerable,O
and,O
easier,O
to,O
use,O
.,O
Dose,I-Entity
-,O
dependent,O
neurotoxicity,I-Entity
of,O
high,O
-,O
dose,O
busulfan,I-Entity
in,O
children,O
:,O
a,O
clinical,O
and,O
pharmacological,O
study,O
.,O
Busulfan,I-Entity
is,O
known,O
to,O
be,O
neurotoxic,I-Entity
in,O
animals,O
and,O
humans,O
",",O
but,O
its,O
acute,O
neurotoxicity,I-Entity
remains,O
poorly,O
characterized,O
in,O
children,O
.,O
We,I-Entity
report,O
here,O
a,O
retrospective,O
study,O
of,O
123,O
children,O
(,O
median,O
age,O
",",O
6.5,O
years,O
),O
receiving,O
high,O
-,O
dose,O
busulfan,I-Entity
in,O
combined,O
chemotherapy,O
before,O
bone,O
marrow,O
transplantation,O
for,O
malignant,I-Entity
solid,O
tumors,I-Entity
",",O
brain,O
tumors,I-Entity
excluded,O
.,O
Busulfan,I-Entity
was,O
given,O
p.o,O
.,O
Ninety,I-Entity
-,O
six,O
patients,O
were,O
not,O
given,O
anticonvulsive,O
prophylaxis,O
;,O
7,O
(,O
7.5%,O
),O
developed,O
seizures,I-Entity
during,O
the,O
4,O
days,O
of,O
the,O
busulfan,I-Entity
course,O
or,O
within,O
24,O
h,O
after,O
the,O
last,O
dosing,O
.,O
When,I-Entity
the,O
total,O
busulfan,I-Entity
dose,O
was,O
taken,O
into,O
account,O
",",O
there,O
was,O
a,O
significant,O
difference,O
in,O
terms,O
of,O
neurotoxicity,I-Entity
incidence,O
among,O
patients,O
under,O
16,O
mg,O
/,O
kg,O
(,O
1,O
of,O
57,I-Entity
",",O
1.7%,O
),O
and,O
patients,O
under,O
600,O
mg,O
/,O
m2,O
(,O
6,O
of,O
39,O
",",O
15.4%,O
),O
(,O
P,I-Entity
less,O
than,O
0.02,O
),O
.,O
Twenty,I-Entity
-,O
seven,O
patients,O
were,O
given,O
a,O
600-mg,I-Entity
/,O
m2,O
busulfan,I-Entity
total,O
dose,O
with,O
continuous,O
i.v,O
.,O
infusion,O
of,O
clonazepam,I-Entity
;,O
none,O
had,O
any,O
neurological,O
symptoms,O
.,O
Busulfan,I-Entity
levels,O
were,O
measured,O
by,O
a,O
gas,O
chromatographic,O
-,O
mass,O
spectrometry,O
assay,O
in,O
the,O
plasma,O
and,O
cerebrospinal,O
fluid,O
of,O
9,O
children,O
without,O
central,O
nervous,I-Entity
system,O
disease,I-Entity
under,O
600,O
mg,O
/,O
m2,O
busulfan,I-Entity
with,O
clonazepam,I-Entity
:,O
busulfan,I-Entity
cerebrospinal,O
fluid,O
:,O
plasma,O
ratio,O
was,O
1.39,O
.,O
This,I-Entity
was,O
significantly,O
different,O
(,O
P,I-Entity
less,O
than,O
0.02,O
),O
from,O
the,O
cerebrospinal,O
fluid,O
:,O
plasma,O
ratio,O
previously,O
defined,O
in,O
children,O
receiving,O
a,O
16-mg,O
/,O
kg,O
total,O
dose,O
of,O
busulfan,I-Entity
.,O
This,I-Entity
study,O
shows,O
that,O
busulfan,I-Entity
neurotoxicity,I-Entity
is,O
dose,O
-,O
dependent,O
in,O
children,O
and,O
efficiently,O
prevented,O
by,O
clonazepam,I-Entity
.,O
A,I-Entity
busulfan,I-Entity
dose,O
calculated,O
on,O
the,O
basis,O
of,O
body,O
surface,O
area,O
",",O
resulting,O
in,O
higher,O
doses,O
in,O
young,O
children,O
",",O
was,O
followed,O
by,O
increased,O
neurotoxicity,I-Entity
",",O
close,O
to,O
neurotoxicity,I-Entity
incidence,O
observed,O
in,O
adults,O
.,O
Since,I-Entity
plasma,O
pharmacokinetic,O
studies,O
showed,O
a,O
faster,O
busulfan,I-Entity
clearance,O
in,O
children,O
than,O
in,O
adults,O
",",O
this,O
new,O
dose,O
may,O
approximate,O
more,O
closely,O
the,O
adult,O
systemic,O
exposure,O
obtained,O
after,O
the,O
usual,O
16-mg,O
/,O
kg,O
total,O
dose,O
",",O
with,O
potential,O
inferences,O
in,O
terms,O
of,O
anticancer,O
or,O
myeloablative,I-Entity
effects,O
.,O
The,I-Entity
busulfan,I-Entity
dose,O
in,O
children,O
and,O
infants,O
undergoing,O
bone,O
marrow,O
transplantation,O
should,O
be,O
reconsidered,O
on,O
the,O
basis,O
of,O
pharmacokinetic,O
studies,O
.,O
Histamine,I-Entity
antagonists,O
and,O
d,O
-,O
tubocurarine,I-Entity
-,O
induced,O
hypotension,I-Entity
in,O
cardiac,O
surgical,O
patients,O
.,O
Hemodynamic,I-Entity
effects,O
and,O
histamine,I-Entity
release,O
by,O
bolus,O
injection,O
of,O
0.35,O
mg,O
/,O
kg,O
of,O
d,O
-,O
tubocurarine,I-Entity
were,O
studied,O
in,O
24,O
patients,O
.,O
H1-,I-Entity
and,O
H2-histamine,B-Entity
antagonists,O
or,O
placebo,O
were,O
given,O
before,O
dosing,O
with,O
d,O
-,O
tubocurarine,I-Entity
in,O
a,O
randomized,O
double,O
-,O
blind,O
fashion,O
to,O
four,O
groups,O
:,O
group,O
1,O
-,O
-placebo,O
;,O
group,O
2,O
-,O
-cimetidine,I-Entity
",",O
4,O
mg,O
/,O
kg,O
",",O
plus,O
placebo,O
;,O
group,O
3,O
-,O
-chlorpheniramine,I-Entity
",",O
0.1,O
mg,O
/,O
kg,O
",",O
plus,O
placebo,O
;,O
and,O
group,O
4,O
-,O
-cimetidine,I-Entity
plus,O
chlorpheniramine,I-Entity
.,O
Histamine,I-Entity
release,O
occurred,O
in,O
most,O
patients,O
",",O
the,O
highest,O
level,O
2,O
minutes,O
after,O
d,O
-,O
tubocurarine,I-Entity
dosing,O
.,O
Group,I-Entity
1,O
had,O
a,O
moderate,O
negative,O
correlation,O
between,O
plasma,O
histamine,I-Entity
change,O
and,O
systemic,O
vascular,O
resistance,O
(,O
r,O
=,O
0.58,O
;,O
P,I-Entity
less,O
than,O
0.05,O
),O
not,O
present,O
in,O
group,O
4,O
.,O
These,I-Entity
data,O
demonstrate,O
that,O
the,O
hemodynamic,O
changes,O
associated,O
with,O
d,O
-,O
tubocurarine,I-Entity
dosing,O
are,O
only,O
partially,O
explained,O
by,O
histamine,I-Entity
release,O
.,O
Convulsant,I-Entity
effect,O
of,O
lindane,I-Entity
and,O
regional,O
brain,O
concentration,O
of,O
GABA,I-Entity
and,O
dopamine,I-Entity
.,O
Lindane,I-Entity
(,O
gamma,I-Entity
-,O
hexachlorocyclohexane,I-Entity
),O
is,O
an,O
organochlorine,I-Entity
insecticide,O
with,O
known,O
neurotoxic,I-Entity
effects,O
.,O
Its,I-Entity
mechanism,O
of,O
action,O
is,O
not,O
well,O
understood,O
although,O
it,O
has,O
been,O
proposed,O
that,O
lindane,I-Entity
acts,O
as,O
a,O
non,O
-,O
competitive,O
antagonist,O
at,O
the,O
gamma,I-Entity
-,O
aminobutyric,I-Entity
acid,O
(,O
GABA)-A,I-Entity
receptor,O
.,O
We,I-Entity
studied,O
the,O
effect,O
of,O
lindane,I-Entity
(,O
150,I-Entity
mg,O
/,O
kg,O
),O
on,O
the,O
GABAergic,I-Entity
and,O
dopaminergic,O
systems,O
by,O
measuring,O
the,O
concentration,O
of,O
GABA,I-Entity
",",O
dopamine,I-Entity
and,O
its,O
metabolites,O
in,O
7,O
brain,O
areas,O
at,O
the,O
onset,O
of,O
seizures,I-Entity
.,O
All,I-Entity
animals,O
suffered,O
tonic,I-Entity
convulsions,I-Entity
at,O
18.3,O
1.4,O
min,O
after,O
lindane,I-Entity
administration,O
.,O
The,I-Entity
concentration,O
of,O
GABA,I-Entity
was,O
only,O
slightly,O
but,O
significantly,O
decreased,O
in,O
the,O
colliculi,O
without,O
modifications,O
in,O
the,O
other,O
areas,O
.,O
The,I-Entity
concentration,O
of,O
dopamine,I-Entity
was,O
increased,O
in,O
the,O
mesencephalon,I-Entity
and,O
that,O
of,O
its,O
metabolite,O
DOPAC,I-Entity
was,O
also,O
increased,O
in,O
the,O
mesencephalon,I-Entity
and,O
the,O
striatum,O
.,O
Two,I-Entity
cases,O
of,O
propylthiouracil,I-Entity
-,O
associated,O
acute,O
hepatitis,I-Entity
",",O
one,O
case,O
of,O
fatal,O
methimazole,I-Entity
-,O
associated,O
hepatocellular,O
necrosis,I-Entity
and,O
one,O
case,O
of,O
propylthiouracil,I-Entity
-,O
associated,O
lupus,I-Entity
-,O
like,O
syndrome,I-Entity
are,O
described,O
.,O
It,I-Entity
is,O
concluded,O
that,O
in,O
most,O
circumstances,O
131I,I-Entity
is,O
the,O
therapy,O
of,O
choice,O
for,O
hyperthyroidism,I-Entity
.,O
Anticonvulsant,I-Entity
actions,O
of,O
MK-801,I-Entity
on,O
the,O
lithium,I-Entity
-,O
pilocarpine,I-Entity
model,O
of,O
status,O
epilepticus,I-Entity
in,O
rats,O
.,O
MK-801,I-Entity
",",O
a,O
noncompetitive,O
N,I-Entity
-,O
methyl,I-Entity
-,O
D,I-Entity
-,O
aspartate,I-Entity
(,O
NMDA,I-Entity
),O
receptor,O
antagonist,O
",",O
was,O
tested,O
for,O
anticonvulsant,O
effects,O
in,O
rats,O
using,O
two,O
seizure,I-Entity
models,O
",",O
coadministration,O
of,O
lithium,I-Entity
and,O
pilocarpine,I-Entity
and,O
administration,O
of,O
a,O
high,O
dose,O
of,O
pilocarpine,I-Entity
alone,O
.,O
First,I-Entity
",",O
pretreatment,O
with,O
MK-801,I-Entity
produced,O
an,O
effective,O
and,O
dose,O
-,O
dependent,O
anticonvulsant,O
action,O
with,O
the,O
lithium,I-Entity
-,O
pilocarpine,I-Entity
model,O
but,O
not,O
with,O
rats,O
treated,O
with,O
pilocarpine,I-Entity
alone,O
",",O
suggesting,O
that,O
different,O
biochemical,O
mechanisms,O
control,O
seizures,I-Entity
in,O
these,O
two,O
models,O
.,O
Second,I-Entity
",",O
the,O
anticonvulsant,O
effect,O
of,O
MK-801,I-Entity
in,O
the,O
lithium,I-Entity
-,O
pilocarpine,I-Entity
model,O
only,O
occurred,O
after,O
initial,O
periods,O
of,O
seizure,I-Entity
activity,O
.,O
This,I-Entity
observation,O
is,O
suggested,O
to,O
be,O
an,O
in,O
vivo,O
demonstration,O
of,O
the,O
conclusion,O
derived,O
from,O
in,O
vitro,O
experiments,O
that,O
MK-801,I-Entity
binding,O
requires,O
agonist,I-Entity
-,O
induced,O
opening,O
of,O
the,O
channel,O
sites,O
of,O
the,O
NMDA,I-Entity
receptor,O
.,O
Third,I-Entity
",",O
although,O
it,O
is,O
relatively,O
easy,O
to,O
block,O
seizures,I-Entity
induced,O
by,O
lithium,I-Entity
and,O
pilocarpine,I-Entity
by,O
administration,O
of,O
anticonvulsants,O
prior,O
to,O
pilocarpine,I-Entity
",",O
it,O
is,O
more,O
difficult,O
to,O
terminate,O
ongoing,O
status,O
epilepticus,I-Entity
and,O
block,O
the,O
lethality,O
of,O
the,O
seizures,I-Entity
.,O
Administration,I-Entity
of,O
MK-801,I-Entity
30,O
or,O
60,O
min,O
after,O
pilocarpine,I-Entity
",",O
i.e.,O
",",O
during,O
status,O
epilepticus,I-Entity
",",O
gradually,O
reduced,O
electrical,O
and,O
behavioral,O
seizure,I-Entity
activity,O
and,O
greatly,O
enhanced,O
the,O
survival,O
rate,O
.,O
These,I-Entity
results,O
suggest,O
that,O
activation,O
of,O
NMDA,I-Entity
receptors,O
plays,O
an,O
important,O
role,O
in,O
status,O
epilepticus,I-Entity
and,O
brain,O
damage,O
in,O
the,O
lithium,I-Entity
-,O
pilocarpine,I-Entity
model,O
.,O
This,I-Entity
was,O
further,O
supported,O
by,O
results,O
showing,O
that,O
nonconvulsive,O
doses,O
of,O
NMDA,I-Entity
and,O
pilocarpine,I-Entity
were,O
synergistic,O
",",O
resulting,O
in,O
status,O
epilepticus,I-Entity
and,O
subsequent,O
mortality,O
.,O
Nifedipine,I-Entity
induced,O
bradycardia,I-Entity
in,O
a,O
patient,O
with,O
autonomic,O
neuropathy,I-Entity
.,O
An,I-Entity
80,O
year,O
old,O
diabetic,I-Entity
male,O
with,O
evidence,O
of,O
peripheral,O
and,O
autonomic,O
neuropathy,I-Entity
was,O
admitted,O
with,O
chest,O
pain,I-Entity
.,O
He,I-Entity
was,O
found,O
to,O
have,O
atrial,I-Entity
flutter,I-Entity
at,O
a,O
ventricular,O
rate,O
of,O
70/min,O
which,O
slowed,O
down,O
to,O
30,O
-,O
40/min,O
when,O
nifedipine,I-Entity
(,O
60,O
mg,O
),O
in,O
3,O
divided,O
doses,O
",",O
during,O
which,O
he,O
was,O
paced,O
at,O
a,O
rate,O
of,O
70/min,O
.,O
This,I-Entity
is,O
inconsistent,O
with,O
the,O
well,O
-,O
established,O
finding,O
that,O
nifedipine,I-Entity
induces,O
tachycardia,I-Entity
in,O
normally,O
innervated,O
hearts,O
.,O
However,I-Entity
",",O
in,O
hearts,O
deprived,O
of,O
compensatory,O
sympathetic,O
drive,O
",",O
it,O
may,O
lead,O
to,O
bradycardia,I-Entity
.,O
The,I-Entity
effect,O
of,O
haloperidol,I-Entity
in,O
cocaine,I-Entity
and,O
amphetamine,I-Entity
intoxication,O
.,O
The,I-Entity
effectiveness,O
of,O
haloperidol,I-Entity
pretreatment,O
in,O
preventing,O
the,O
toxic,I-Entity
effects,O
of,O
high,O
doses,O
of,O
amphetamine,I-Entity
and,O
cocaine,I-Entity
was,O
studied,O
in,O
rats,O
.,O
injection,O
of,O
amphetamine,I-Entity
75,O
mg,O
/,O
kg,O
(,O
100%,O
death,I-Entity
rate,O
),O
or,O
cocaine,I-Entity
70,I-Entity
mg,O
/,O
kg,O
(,O
82%,O
death,I-Entity
rate,O
),O
.,O
Haloperidol,I-Entity
failed,O
to,O
prevent,O
amphetamine,I-Entity
-,O
induced,O
seizures,I-Entity
",",O
but,O
did,O
lower,O
the,O
mortality,O
rate,O
at,O
most,O
doses,O
tested,O
.,O
Haloperidol,I-Entity
decreased,O
the,O
incidence,O
of,O
cocaine,I-Entity
-,O
induced,O
seizures,I-Entity
at,O
the,O
two,O
highest,O
doses,O
",",O
but,O
the,O
lowering,O
of,O
the,O
mortality,O
rate,O
did,O
not,O
reach,O
statistical,O
significance,O
at,O
any,O
dose,O
.,O
These,I-Entity
data,O
suggest,O
a,O
protective,O
role,O
for,O
the,O
central,O
dopamine,I-Entity
blocker,O
haloperidol,I-Entity
against,O
death,I-Entity
from,O
high,O
-,O
dose,O
amphetamine,I-Entity
exposure,O
without,O
reducing,O
the,O
incidence,O
of,O
seizures,I-Entity
.,O
In,I-Entity
contrast,O
",",O
haloperidol,I-Entity
demonstrated,O
an,O
ability,O
to,O
reduce,O
cocaine,I-Entity
-,O
induced,O
seizures,I-Entity
without,O
significantly,O
reducing,O
mortality,O
.,O
Autoradiographic,I-Entity
evidence,O
of,O
estrogen,I-Entity
binding,O
sites,O
in,O
nuclei,O
of,O
diethylstilbesterol,I-Entity
induced,O
hamster,I-Entity
renal,O
carcinomas,I-Entity
.,O
Estrogen,I-Entity
binding,O
sites,O
were,O
demonstrated,O
by,O
autoradiography,O
in,O
one,O
transplantable,O
and,O
five,O
primary,O
diethylstilbesterol,I-Entity
induced,O
renal,O
carcinomas,I-Entity
in,O
three,O
hamsters,I-Entity
.,O
Radiolabelling,I-Entity
",",O
following,O
the,O
in,O
vivo,O
injection,O
of,O
3H-17,I-Entity
beta,O
estradiol,I-Entity
",",O
was,O
increased,O
only,O
over,O
the,O
nuclei,O
of,O
tumor,I-Entity
cells,O
;,O
stereologic,O
analysis,O
revealed,O
a,O
4.5-,O
to,O
6.7-times,O
higher,O
concentration,O
of,O
reduced,O
silver,O
grains,O
over,O
nuclei,O
than,O
cytoplasm,O
of,O
these,O
cells,O
.,O
Despite,I-Entity
rapid,O
tubular,O
excretion,O
of,O
estradiol,I-Entity
which,O
peaked,O
in,O
less,O
than,O
1,O
This,I-Entity
is,O
the,O
first,O
published,O
report,O
documenting,O
the,O
preferential,O
in,O
vivo,O
binding,O
of,O
estrogen,I-Entity
to,O
nuclei,O
of,O
cells,O
in,O
estrogen,I-Entity
induced,O
hamster,I-Entity
renal,O
carcinomas,I-Entity
.,O
Bradycardia,I-Entity
due,O
to,O
biperiden,I-Entity
.,O
In,I-Entity
a,O
38-year,O
-,O
old,O
male,O
patient,O
suffering,O
from,O
a,O
severe,O
postzosteric,O
trigeminal,I-Entity
neuralgia,I-Entity
",",O
intravenous,O
application,O
of,O
10,O
mg,O
biperiden,I-Entity
lactate,I-Entity
led,O
to,O
a,O
long,O
-,O
lasting,O
paradoxical,I-Entity
reaction,I-Entity
characterized,O
by,O
considerable,O
bradycardia,I-Entity
",",O
dysarthria,I-Entity
",",O
and,O
dysphagia,I-Entity
.,O
The,I-Entity
heart,O
rate,O
was,O
back,O
to,O
normal,O
within,O
12,O
hours,O
upon,O
administration,O
of,O
orciprenaline,I-Entity
under,O
cardiac,O
monitoring,O
in,O
an,O
intensive,O
care,O
unit,O
.,O
Bradycardia,I-Entity
induced,O
by,O
biperiden,I-Entity
is,O
attributed,O
to,O
the,O
speed,O
of,O
injection,O
and,O
to,O
a,O
dose,O
-,O
related,O
dual,O
effect,O
of,O
atropine,I-Entity
-,O
like,O
drugs,O
on,O
muscarine,I-Entity
receptors,O
.,O
Deliberate,I-Entity
hypotension,I-Entity
induced,O
by,O
labetalol,I-Entity
with,O
halothane,I-Entity
",",O
enflurane,I-Entity
or,O
isoflurane,I-Entity
for,O
middle,O
-,O
ear,O
surgery,O
.,O
The,I-Entity
feasibility,O
of,O
using,O
labetalol,I-Entity
",",O
an,O
alpha-,B-Entity
and,O
beta,O
-,O
adrenergic,O
blocking,I-Entity
agent,O
",",O
as,O
a,O
hypotensive,I-Entity
agent,O
in,O
combination,O
with,O
inhalation,O
anaesthetics,O
(,O
halothane,I-Entity
",",O
enflurane,I-Entity
or,O
isoflurane,I-Entity
),O
was,O
studied,O
in,O
23,O
adult,O
patients,O
undergoing,O
middle,O
-,O
ear,O
surgery,O
.,O
10,O
min,O
in,O
the,O
halothane,I-Entity
(,O
H,I-Entity
),O
group,O
",",O
from,O
79,I-Entity
+,O
/-,O
11,O
min,O
in,O
the,O
enflurane,I-Entity
(,O
E,I-Entity
),O
group,O
",",O
and,O
from,O
80,O
+,O
/-,O
15,O
min,O
in,O
the,O
isoflurane,I-Entity
(,O
I,I-Entity
),O
group,O
.,O
The,I-Entity
mean,O
H,I-Entity
concentration,O
during,O
hypotension,I-Entity
in,O
the,O
inspiratory,O
gas,O
was,O
0.7,O
+,O
/-,O
0.1,O
vol%,O
",",O
the,O
mean,O
E,I-Entity
concentration,O
1.6,O
+,O
/-,O
I,I-Entity
concentration,O
1.0,O
+,O
/-,O
In,I-Entity
addition,O
",",O
the,O
patients,O
received,O
fentanyl,I-Entity
and,O
d,O
-,O
tubocurarine,I-Entity
.,O
The,I-Entity
initial,O
dose,O
of,O
labetalol,I-Entity
for,O
lowering,O
blood,O
pressure,O
was,O
similar,O
",",O
0.52,O
-,O
0.59,O
mg,O
/,O
kg,O
",",O
in,O
all,O
the,O
groups,O
.,O
During,I-Entity
hypotension,I-Entity
",",O
the,O
heart,O
rate,O
was,O
stable,O
without,O
tachy-,I-Entity
or,O
bradycardia,I-Entity
.,O
The,I-Entity
operating,O
conditions,O
regarding,O
bleeding,I-Entity
were,O
estimated,O
in,O
a,O
double,O
-,O
blind,O
manner,O
",",O
and,O
did,O
not,O
differ,O
significantly,O
between,O
the,O
groups,O
.,O
During,I-Entity
hypotension,I-Entity
",",O
the,O
serum,O
creatinine,I-Entity
concentration,O
rose,O
significantly,O
in,O
all,O
groups,O
from,O
the,O
values,O
before,O
hypotension,I-Entity
and,O
returned,O
postoperatively,O
to,O
the,O
initial,O
level,O
in,O
the,O
other,O
groups,O
",",O
except,O
the,O
isoflurane,I-Entity
group,O
.,O
After,I-Entity
hypotension,I-Entity
there,O
was,O
no,O
rebound,O
phenomenon,O
in,O
either,O
blood,O
pressure,O
or,O
heart,O
rate,O
.,O
These,I-Entity
results,O
indicate,O
that,O
labetalol,I-Entity
induces,O
easily,O
adjustable,O
hypotension,I-Entity
without,O
compensatory,O
tachycardia,I-Entity
and,O
rebound,O
hypertension,I-Entity
.,O
Convulsion,I-Entity
following,O
intravenous,O
fluorescein,I-Entity
angiography,O
.,O
Tonic,I-Entity
-,O
clonic,I-Entity
seizures,I-Entity
followed,O
intravenous,O
fluorescein,I-Entity
injection,O
for,O
fundus,O
angiography,O
in,O
a,O
47-year,O
-,O
old,O
male,O
.,O
Despite,I-Entity
precautions,O
this,O
adverse,O
reaction,I-Entity
recurred,O
on,O
re,O
-,O
exposure,O
to,O
intravenous,O
fluorescein,I-Entity
.,O
Pharmacology,I-Entity
of,O
ACC-9653,I-Entity
(,O
phenytoin,I-Entity
prodrug,O
),O
.,O
ACC-9653,I-Entity
",",O
the,O
disodium,I-Entity
phosphate,I-Entity
ester,I-Entity
of,O
"3-hydroxymethyl-5,5-diphenylhydantoin",B-Entity
",",O
is,O
a,O
prodrug,O
of,O
phenytoin,I-Entity
with,O
advantageous,O
physicochemical,O
properties,O
.,O
ACC-9653,I-Entity
is,O
rapidly,O
converted,O
enzymatically,O
to,O
phenytoin,I-Entity
in,O
vivo,O
.,O
ACC-9653,I-Entity
and,O
phenytoin,I-Entity
sodium,I-Entity
have,O
equivalent,O
anticonvulsant,O
activity,O
against,O
seizures,I-Entity
induced,O
by,O
maximal,O
electroshock,O
(,O
MES,I-Entity
),O
in,O
mice,O
following,O
i.p,O
.,O
ACC-9653,I-Entity
and,O
8,O
mg,O
/,O
kg,O
for,O
i.v,O
.,O
phenytoin,I-Entity
sodium,I-Entity
.,O
ACC-9653,I-Entity
and,O
phenytoin,I-Entity
sodium,I-Entity
have,O
similar,O
antiarrhythmic,O
activity,O
against,O
ouabain,I-Entity
-,O
induced,O
ventricular,O
tachycardia,I-Entity
in,O
anesthetized,O
dogs,O
.,O
The,I-Entity
total,O
doses,O
of,O
ACC-9653,I-Entity
or,O
phenytoin,I-Entity
sodium,I-Entity
necessary,O
to,O
convert,O
the,O
arrhythmia,I-Entity
to,O
a,O
normal,O
sinus,O
rhythm,O
were,O
24,O
+,O
/-,O
Only,I-Entity
phenytoin,I-Entity
sodium,I-Entity
displayed,O
in,O
vitro,O
antiarrhythmic,O
activity,O
against,O
strophanthidin,I-Entity
-,O
induced,O
arrhythmias,I-Entity
in,O
guinea,I-Entity
pig,O
right,O
atria,O
.,O
In,I-Entity
anesthetized,O
dogs,O
",",O
a,O
high,O
dose,O
of,O
ACC-9653,I-Entity
(,O
31,O
mg,O
/,O
kg,O
),O
was,O
infused,O
over,O
15,O
",",O
20,O
",",O
and,O
30,O
min,O
and,O
the,O
responses,O
were,O
compared,O
to,O
an,O
equimolar,O
dose,O
of,O
phenytoin,I-Entity
sodium,I-Entity
(,O
21,O
mg,O
/,O
kg,O
),O
.,O
The,I-Entity
ACC-9653,I-Entity
and,O
phenytoin,I-Entity
sodium,I-Entity
treatments,O
produced,O
similar,O
marked,O
reductions,O
in,O
diastolic,I-Entity
blood,O
pressure,O
and,O
contractile,O
force,O
(,O
LVdP,I-Entity
/,O
dt,O
),O
.,O
The,I-Entity
maximum,O
effects,O
of,O
each,O
treatment,O
occurred,O
at,O
the,O
time,O
of,O
maximum,O
phenytoin,I-Entity
sodium,I-Entity
levels,O
.,O
Acute,I-Entity
toxicity,I-Entity
studies,O
of,O
ACC-9653,I-Entity
and,O
phenytoin,I-Entity
sodium,I-Entity
were,O
carried,O
out,O
in,O
mice,O
",",O
rats,O
",",O
rabbits,I-Entity
",",O
and,O
dogs,O
by,O
i.v,O
.,O
Importantly,I-Entity
",",O
the,O
local,O
irritation,I-Entity
of,O
ACC-9653,I-Entity
was,O
markedly,O
less,O
than,O
phenytoin,I-Entity
sodium,I-Entity
following,O
i.m,O
.,O
Phenytoin,I-Entity
induced,O
fatal,O
hepatic,B-Entity
injury,I-Entity
.,O
A,I-Entity
61,O
year,O
old,O
female,O
developed,O
fatal,O
hepatic,B-Entity
failure,I-Entity
after,O
phenytoin,I-Entity
administration,O
.,O
A,I-Entity
typical,O
multisystem,O
clinical,O
pattern,O
precedes,O
the,O
manifestations,O
of,O
hepatic,B-Entity
injury,I-Entity
.,O
The,I-Entity
hematologic,O
",",O
biochemical,O
and,O
pathologic,O
features,O
indicate,O
a,O
mixed,O
hepatocellular,O
damage,O
due,O
to,O
drug,O
hypersensitivity,I-Entity
.,O
In,I-Entity
a,O
patient,O
receiving,O
phenytoin,I-Entity
who,O
presents,O
a,O
viral,O
-,O
like,O
illness,I-Entity
",",O
early,O
recognition,O
and,O
discontinuation,O
of,O
the,O
drug,O
are,O
mandatory,O
.,O
Treatment,I-Entity
of,O
lethal,O
pertussis,I-Entity
vaccine,O
reaction,I-Entity
with,O
histamine,I-Entity
H1,I-Entity
antagonists,O
.,O
We,I-Entity
studied,O
mortality,O
after,O
pertussis,I-Entity
immunization,O
in,O
the,O
mouse,O
.,O
Without,I-Entity
treatment,O
",",O
73,O
of,O
92,O
animals,O
(,O
80%,O
),O
died,O
after,O
injection,O
of,O
bovine,I-Entity
serum,O
albumin,O
(,O
BSA,I-Entity
),O
on,O
day,O
+,O
7,O
of,O
pertussis,I-Entity
immunization,O
.,O
After,I-Entity
pretreatment,O
with,O
3,O
mg,O
of,O
cyproheptadine,I-Entity
",",O
2,O
mg,O
mianserin,I-Entity
",",O
or,O
2,O
mg,O
chlorpheniramine,I-Entity
",",O
only,O
5,O
of,O
105,I-Entity
animals,O
(,O
5%,O
),O
died,O
after,O
receiving,O
BSA,I-Entity
on,O
day,O
+,O
7,O
(,O
p,O
less,O
than,O
0.001,O
),O
.,O
Blockade,I-Entity
of,O
histamine,I-Entity
H1,I-Entity
receptors,O
may,O
reduce,O
mortality,O
in,O
pertussis,I-Entity
immunization,O
-,O
induced,O
encephalopathy,I-Entity
in,O
mice,O
.,O
Support,I-Entity
for,O
adrenaline,I-Entity
-,O
hypertension,I-Entity
hypothesis,O
:,O
18,O
hour,O
pressor,O
effect,O
after,O
6,O
hours,O
adrenaline,I-Entity
infusion,O
.,O
In,I-Entity
a,O
double,O
blind,O
",",O
crossover,O
study,O
6,O
h,O
infusions,O
of,O
adrenaline,I-Entity
(,O
15,O
ng,O
/,O
kg,O
/,O
min,O
;,O
1,O
ng,O
=,O
5.458,O
pmol,I-Entity
),O
",",O
noradrenaline,I-Entity
(,O
30,O
ng,O
/,O
kg,O
/,O
min,O
;,O
1,O
ng,O
=,O
5.911,I-Entity
pmol,I-Entity
),O
",",O
and,O
a,O
5%,O
dextrose,I-Entity
solution,O
(,O
5.4,O
ml,O
/,O
h,O
),O
",",O
were,O
given,O
to,O
ten,O
healthy,O
volunteers,O
in,O
random,O
order,O
2,O
weeks,O
apart,O
.,O
Adrenaline,I-Entity
",",O
but,O
not,O
noradrenaline,I-Entity
",",O
caused,O
a,O
delayed,O
and,O
protracted,O
pressor,O
effect,O
.,O
Over,I-Entity
the,O
total,O
postinfusion,O
period,O
systolic,O
and,O
diastolic,I-Entity
arterial,O
pressure,O
were,O
6,O
(,O
SEM,I-Entity
2)%,O
and,O
7,O
(,O
2)%,O
",",O
respectively,O
",",O
higher,O
than,O
after,O
dextrose,I-Entity
infusion,O
(,O
ANOVA,I-Entity
",",O
p,O
less,O
than,O
0.001,O
),O
.,O
Thus,I-Entity
",",O
"""""""""",O
stress,I-Entity
"""""""""",O
levels,O
of,O
adrenaline,I-Entity
(,O
230,O
pg,O
/,O
ml,O
),O
for,O
6,O
h,O
cause,O
a,O
delayed,O
and,O
protracted,O
pressor,O
effect,O
.,O
These,I-Entity
findings,O
are,O
strong,O
support,O
for,O
the,O
adrenaline,I-Entity
-,O
hypertension,I-Entity
hypothesis,O
in,O
man,O
.,O
Effect,I-Entity
of,O
alkylxanthines,B-Entity
on,O
gentamicin,I-Entity
-,O
induced,O
acute,O
renal,O
failure,I-Entity
in,O
the,O
rat,O
.,O
Adenosine,I-Entity
antagonists,O
have,O
been,O
previously,O
shown,O
to,O
be,O
of,O
benefit,O
in,O
some,O
ischaemic,I-Entity
and,O
nephrotoxic,I-Entity
models,O
of,O
acute,O
renal,O
failure,I-Entity
(,O
ARF,I-Entity
),O
.,O
In,I-Entity
the,O
present,O
study,O
",",O
the,O
effects,O
of,O
three,O
alkylxanthines,B-Entity
with,O
different,O
potencies,O
as,O
adenosine,I-Entity
antagonists,O
8-phenyltheophylline,I-Entity
",",O
theophylline,I-Entity
and,O
enprofylline,I-Entity
",",O
were,O
examined,O
in,O
rats,O
developing,O
acute,O
renal,O
failure,I-Entity
after,O
4,O
daily,O
injections,O
of,O
gentamicin,I-Entity
(,O
200,O
mg,O
kg-1,O
),O
.,O
Renal,I-Entity
function,O
was,O
assessed,O
by,O
biochemical,O
(,O
plasma,O
urea,I-Entity
and,O
creatinine,I-Entity
),O
",",O
functional,O
(,O
urine,I-Entity
analysis,O
and,O
[,O
3H]inulin,I-Entity
and,O
[,O
14C]p,I-Entity
-,O
aminohippuric,I-Entity
acid,O
clearances,O
),O
and,O
morphological,O
(,O
degree,O
of,O
necrosis,I-Entity
),O
indices,O
.,O
However,I-Entity
",",O
any,O
improvement,O
produced,O
by,O
drug,O
treatment,O
was,O
largely,O
a,O
result,O
of,O
a,O
beneficial,O
effect,O
exerted,O
by,O
its,O
vehicle,O
(,O
polyethylene,I-Entity
glycol,I-Entity
and,O
NaOH,I-Entity
),O
.,O
The,I-Entity
lack,O
of,O
any,O
consistent,O
protective,O
effect,O
noted,O
with,O
the,O
alkylxanthines,B-Entity
tested,O
in,O
the,O
present,O
study,O
indicates,O
that,O
adenosine,I-Entity
plays,O
little,O
",",O
if,O
any,O
",",O
pathophysiological,O
role,O
in,O
gentamicin,I-Entity
-,O
induced,O
ARF,I-Entity
.,O
Adverse,I-Entity
ocular,O
reactions,O
possibly,O
associated,O
with,O
isotretinoin,I-Entity
.,O
A,I-Entity
total,O
of,O
261,O
adverse,O
ocular,O
reactions,O
occurred,O
in,O
237,I-Entity
patients,O
who,O
received,O
isotretinoin,I-Entity
",",O
a,O
commonly,O
used,O
drug,O
in,O
the,O
treatment,O
of,O
severe,O
cystic,I-Entity
acne,I-Entity
.,O
Blepharoconjunctivitis,I-Entity
",",O
subjective,O
complaints,O
of,O
dry,O
eyes,O
",",O
blurred,I-Entity
vision,O
",",O
contact,O
lens,O
intolerance,O
",",O
and,O
photodermatitis,I-Entity
are,O
reversible,O
side,O
effects,O
.,O
More,I-Entity
serious,O
ocular,O
adverse,O
reactions,O
include,O
papilledema,I-Entity
",",O
pseudotumor,I-Entity
cerebri,O
",",O
and,O
white,O
or,O
gray,O
subepithelial,O
corneal,B-Entity
opacities,I-Entity
;,O
all,O
of,O
these,O
are,O
reversible,O
if,O
the,O
drug,O
is,O
discontinued,O
.,O
Isotretinoin,I-Entity
is,O
contraindicated,I-Entity
in,O
pregnancy,I-Entity
because,O
of,O
the,O
many,O
reported,O
congenital,O
abnormalities,I-Entity
after,O
maternal,O
use,O
(,O
including,O
microphthalmos,I-Entity
",",O
orbital,O
hypertelorism,I-Entity
",",O
and,O
optic,O
nerve,O
hypoplasia,I-Entity
),O
.,O
Procaterol,I-Entity
and,O
terbutaline,I-Entity
in,O
bronchial,O
asthma,I-Entity
.,O
Procaterol,I-Entity
",",O
a,O
new,O
beta-2,O
adrenoceptor,O
stimulant,O
",",O
was,O
studied,O
in,O
a,O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
",",O
cross,O
-,O
over,O
trial,O
in,O
patients,O
with,O
bronchial,O
asthma,I-Entity
.,O
Oral,I-Entity
procaterol,I-Entity
50,O
micrograms,O
b.d,O
.,O
",",O
procaterol,I-Entity
100,O
micrograms,O
b.d,O
.,O
terbutaline,I-Entity
5,O
mg,O
t.i.d,I-Entity
.,O
The,I-Entity
best,O
clinical,O
effect,O
was,O
found,O
with,O
terbutaline,I-Entity
.,O
Both,I-Entity
anti,O
-,O
asthmatic,I-Entity
and,O
tremorgenic,I-Entity
effects,O
of,O
procaterol,I-Entity
were,O
dose,O
-,O
related,O
.,O
Procaterol,I-Entity
appeared,O
effective,O
in,O
the,O
doses,O
tested,O
",",O
and,O
a,O
twice,O
daily,O
regimen,I-Entity
would,O
appear,O
to,O
be,O
suitable,O
with,O
this,O
drug,O
.,O
Subacute,I-Entity
effects,O
of,O
propranolol,I-Entity
and,O
B,I-Entity
24/76,O
on,O
isoproterenol,I-Entity
-,O
induced,O
rat,O
heart,O
hypertrophy,I-Entity
in,O
correlation,O
with,O
blood,O
pressure,O
.,O
24/76,O
i.e.,O
"1-(2,4-dichlorophenoxy)-3[2",I-Entity
-,O
"3,4-dimethoxyphenyl)ethanolamino]-prop",B-Entity
an-2-ol,I-Entity
",",O
which,O
is,O
characterized,O
by,O
beta,O
1-adrenoceptor,O
blocking,I-Entity
and,O
beta,O
2-adrenoceptor,O
stimulating,O
properties,O
with,O
propranolol,I-Entity
.,O
The,I-Entity
studies,O
were,O
performed,O
using,O
an,O
experimental,O
model,O
of,O
isoproterenol,I-Entity
-,O
induced,O
heart,O
hypertrophy,I-Entity
in,O
rats,O
.,O
A,I-Entity
correlation,O
of,O
the,O
blood,O
pressure,O
was,O
neither,O
found,O
in,O
the,O
development,O
nor,O
in,O
the,O
attempt,O
to,O
suppress,O
the,O
development,O
of,O
heart,O
hypertrophy,I-Entity
with,O
the,O
two,O
beta,O
-,O
receptor,O
blockers,O
.,O
Both,I-Entity
beta,O
-,O
blockers,O
influenced,O
the,O
development,O
of,O
hypertrophy,I-Entity
to,O
a,O
different,O
",",O
but,O
not,O
reproducible,O
extent,O
.,O
It,I-Entity
was,O
possible,O
to,O
suppress,O
the,O
increased,O
ornithine,I-Entity
decarboxylase,O
activity,O
with,O
both,O
beta,O
-,O
blockers,O
in,O
hypertrophied,I-Entity
hearts,O
",",O
but,O
there,O
was,O
no,O
effect,O
on,O
the,O
heart,O
mass,O
.,O
Neither,I-Entity
propranolol,I-Entity
nor,O
B,I-Entity
24/76,O
could,O
stop,O
the,O
changes,O
in,O
the,O
characteristic,O
myosin,I-Entity
isoenzyme,O
pattern,O
of,O
the,O
hypertrophied,I-Entity
rat,O
heart,O
.,O
Thus,I-Entity
",",O
the,O
investigations,O
did,O
not,O
provide,O
any,O
evidence,O
that,O
the,O
beta,O
-,O
receptor,O
blockers,O
propranolol,I-Entity
and,O
B,I-Entity
24/76,O
have,O
the,O
potency,O
to,O
prevent,O
isoproterenol,I-Entity
from,O
producing,O
heart,O
hypertrophy,I-Entity
.,O
Comparison,I-Entity
of,O
the,O
effect,O
of,O
oxitropium,I-Entity
bromide,I-Entity
and,O
of,O
slow,O
-,O
release,O
theophylline,I-Entity
on,O
nocturnal,O
asthma,I-Entity
.,O
The,I-Entity
effects,O
of,O
a,O
new,O
inhaled,O
antimuscarinic,O
drug,O
",",O
oxitropium,I-Entity
bromide,I-Entity
",",O
and,O
of,O
a,O
slow,O
-,O
release,O
theophylline,I-Entity
preparation,O
upon,O
nocturnal,O
asthma,I-Entity
were,O
compared,O
in,O
a,O
placebo,O
-,O
controlled,O
double,O
-,O
blind,O
study,O
.,O
Two,I-Entity
samples,O
were,O
studied,O
:,O
12,O
patients,O
received,O
oxitropium,I-Entity
at,O
600,O
micrograms,O
(,O
6,O
subjects,O
),O
or,O
at,O
400,O
micrograms,O
t.i.d,I-Entity
.,O
(,O
6,O
subjects,O
),O
whereas,O
11,O
received,O
theophylline,I-Entity
at,O
300,O
mg,O
b.i.d,O
.,O
No,I-Entity
significant,O
difference,O
was,O
noticed,O
between,O
results,O
obtained,O
with,O
either,O
active,O
drug,O
",",O
as,O
well,O
as,O
with,O
either,O
dosage,O
of,O
oxitropium,I-Entity
.,O
No,I-Entity
subject,O
reported,O
side,O
effects,O
of,O
oxitropium,I-Entity
",",O
as,O
compared,O
to,O
three,O
subjects,O
reporting,O
nausea,I-Entity
",",O
vomiting,I-Entity
and,O
tremors,I-Entity
after,O
theophylline,I-Entity
.,O
Oxitropium,I-Entity
proves,O
to,O
be,O
a,O
valuable,O
alternative,O
to,O
theophylline,I-Entity
in,O
nocturnal,O
asthma,I-Entity
",",O
since,O
it,O
is,O
equally,O
potent,O
",",O
safer,O
and,O
does,O
not,O
require,O
the,O
titration,O
of,O
dosage,O
.,O
Penicillin,I-Entity
anaphylaxis,I-Entity
.,O
A,I-Entity
case,O
of,O
oral,O
penicillin,I-Entity
anaphylaxis,I-Entity
is,O
described,O
",",O
and,O
the,O
terminology,O
",",O
occurrence,O
",",O
clinical,O
manifestations,O
",",O
pathogenesis,O
",",O
prevention,O
",",O
and,O
treatment,O
of,O
anaphylaxis,I-Entity
are,O
reviewed,O
.,O
Emergency,I-Entity
physicians,O
should,O
be,O
aware,O
of,O
oral,O
penicillin,I-Entity
anaphylaxis,I-Entity
in,O
order,O
to,O
prevent,O
its,O
occurrence,O
by,O
prescribing,O
the,O
antibiotic,O
judiciously,O
and,O
knowledgeably,O
and,O
to,O
offer,O
optimal,O
medical,O
therapy,O
once,O
this,O
life,O
-,O
threatening,I-Entity
reaction,I-Entity
has,O
begun,O
.,O
Reversible,I-Entity
valproic,B-Entity
acid,O
-,O
induced,O
dementia,I-Entity
:,O
a,O
case,O
report,O
.,O
Reversible,I-Entity
valproic,B-Entity
acid,O
-,O
induced,O
dementia,I-Entity
was,O
documented,O
in,O
a,O
21-year,O
-,O
old,O
man,O
with,O
epilepsy,I-Entity
who,O
had,O
a,O
3-year,O
history,O
of,O
insidious,I-Entity
progressive,O
decline,O
in,O
global,O
cognitive,O
abilities,O
documented,O
by,O
serial,O
neuropsychological,O
studies,O
.,O
Possible,I-Entity
pathophysiological,O
mechanisms,O
which,O
may,O
have,O
been,O
operative,O
in,O
this,O
case,O
include,O
:,O
a,O
direct,O
central,O
nervous,I-Entity
system,O
(,O
CNS,I-Entity
),O
toxic,I-Entity
effect,O
of,O
valproic,B-Entity
acid,O
;,O
a,O
paradoxical,I-Entity
epileptogenic,O
effect,O
secondary,O
to,O
the,O
drug,O
;,O
and,O
an,O
indirect,O
CNS,I-Entity
toxic,I-Entity
effect,O
mediated,O
through,O
valproic,B-Entity
acid,O
-,O
induced,O
hyperammonemia,I-Entity
.,O
Reversal,I-Entity
of,O
scopolamine,I-Entity
-,O
induced,O
amnesia,I-Entity
of,O
passive,O
avoidance,I-Entity
by,O
pre-,O
and,O
post,O
-,O
training,O
naloxone,I-Entity
.,O
In,I-Entity
a,O
series,O
of,O
five,O
experiments,O
",",O
the,O
modulating,O
role,O
of,O
naloxone,I-Entity
on,O
a,O
scopolamine,I-Entity
-,O
induced,O
retention,O
deficit,I-Entity
in,O
a,O
passive,O
avoidance,I-Entity
paradigm,O
was,O
investigated,O
in,O
mice,O
.,O
Scopolamine,I-Entity
",",O
but,O
not,O
methyl,I-Entity
scopolamine,I-Entity
(,O
1,O
and,O
3,O
mg,O
/,O
kg,O
),O
",",O
induced,O
an,O
amnesia,I-Entity
as,O
measured,O
by,O
latency,O
and,O
duration,O
parameters,O
.,O
Naloxone,I-Entity
(,O
0.3,O
",",O
1,O
",",O
3,O
",",O
and,O
10,O
mg,O
/,O
kg,O
),O
injected,O
prior,O
to,O
training,O
attenuated,O
the,O
retention,O
deficit,I-Entity
with,O
a,O
peak,O
of,O
activity,O
at,O
3,O
mg,O
/,O
kg,O
.,O
The,I-Entity
effect,O
of,O
naloxone,I-Entity
could,O
be,O
antagonized,I-Entity
with,O
morphine,I-Entity
(,O
1,O
",",O
3,O
",",O
and,O
10,O
mg,O
/,O
kg,O
),O
",",O
demonstrating,O
the,O
opioid,O
specificity,O
of,O
the,O
naloxone,I-Entity
effect,O
.,O
Post,I-Entity
-,O
training,O
administration,O
of,O
naloxone,I-Entity
(,O
3,O
mg,O
/,O
kg,O
),O
as,O
a,O
single,O
or,O
as,O
a,O
split,O
dose,O
also,O
attenuated,O
the,O
scopolamine,I-Entity
-,O
induced,O
amnesia,I-Entity
.,O
Control,I-Entity
experiments,O
indicated,O
that,O
neither,O
an,O
increase,O
in,O
pain,I-Entity
sensitivity,O
(,O
pre,O
-,O
training,O
naloxone,I-Entity
),O
nor,O
an,O
induced,O
aversive,I-Entity
state,O
(,O
post,O
-,O
training,O
naloxone,I-Entity
),O
appear,O
to,O
be,O
responsible,O
for,O
the,O
influence,O
of,O
naloxone,I-Entity
on,O
the,O
scopolamine,I-Entity
-,O
induced,O
retention,O
deficit,I-Entity
.,O
Electron,I-Entity
microscopic,O
investigations,O
of,O
the,O
cyclophosphamide,I-Entity
-,O
induced,O
lesions,O
of,O
the,O
urinary,O
bladder,I-Entity
of,O
the,O
rat,O
and,O
their,O
prevention,O
by,O
mesna,I-Entity
.,O
Fully,I-Entity
developed,O
cyclophosphamide,I-Entity
-,O
induced,O
cystitis,I-Entity
is,O
characterized,O
by,O
nearly,O
complete,O
detachment,O
of,O
the,O
urothelium,I-Entity
",",O
severe,O
submucosal,O
edema,I-Entity
owing,O
to,O
damage,O
to,O
the,O
microvascular,O
bed,O
and,O
focal,O
muscle,O
necroses,I-Entity
.,O
The,I-Entity
initial,O
response,O
to,O
the,O
primary,O
attack,O
by,O
the,O
cyclophosphamide,I-Entity
metabolites,O
seems,O
to,O
be,O
fragmentation,I-Entity
of,O
the,O
luminal,I-Entity
membrane,O
.,O
Subsequent,I-Entity
breaks,I-Entity
in,O
the,O
lateral,O
cell,O
membranes,O
of,O
the,O
superficial,O
cells,O
and,O
in,O
all,O
the,O
plasma,O
membranes,O
of,O
the,O
intermediate,O
and,O
basal,O
cells,O
",",O
intercellular,O
and,O
intracellular,O
edema,I-Entity
and,O
disintegration,I-Entity
of,O
the,O
desmosomes,I-Entity
and,O
hemidesmosomes,O
lead,O
to,O
progressive,O
degeneration,I-Entity
and,O
detachment,O
of,O
the,O
epithelial,O
cells,O
with,O
exposure,O
and,O
splitting,O
of,O
the,O
basal,O
membrane,O
.,O
These,I-Entity
changes,O
can,O
be,O
effectively,O
prevented,O
by,O
mesna,I-Entity
.,O
Increase,I-Entity
in,O
intragastric,O
pressure,O
during,O
suxamethonium,I-Entity
-,O
induced,O
muscle,O
fasciculations,I-Entity
in,O
children,O
:,O
inhibition,O
by,O
alfentanil,I-Entity
.,O
Changes,I-Entity
in,O
intragastric,O
pressure,O
after,O
the,O
administration,O
of,O
suxamethonium,I-Entity
1.5,O
mg,O
kg-1,O
i.v,O
.,O
were,O
studied,O
in,O
32,O
children,O
(,O
mean,O
age,O
6.9,O
yr,I-Entity
),O
pretreated,O
with,O
either,O
physiological,O
saline,O
or,O
alfentanil,I-Entity
50,O
micrograms,O
kg-1,O
.,O
Anaesthesia,I-Entity
was,O
induced,O
with,O
thiopentone,I-Entity
5,O
mg,O
kg-1,O
.,O
The,I-Entity
incidence,O
and,O
intensity,O
of,O
muscle,O
fasciculations,I-Entity
caused,O
by,O
suxamethonium,I-Entity
were,O
significantly,O
greater,O
in,O
the,O
control,O
than,O
in,O
the,O
alfentanil,I-Entity
group,O
.,O
The,I-Entity
intragastric,O
pressure,O
during,O
muscle,O
fasciculations,I-Entity
was,O
significantly,O
higher,O
in,O
the,O
control,O
group,O
(,O
16,O
+,O
/-,O
0.7,O
(,O
SEM,I-Entity
),O
cm,O
H2O,I-Entity
),O
than,O
in,O
the,O
alfentanil,I-Entity
group,O
(,O
7.7,O
+,O
/-,O
(,O
SEM,I-Entity
),O
cm,O
H2O,I-Entity
),O
.,O
The,I-Entity
increase,O
in,O
intragastric,O
pressure,O
was,O
directly,O
related,O
to,O
the,O
intensity,O
of,O
muscle,O
fasciculations,I-Entity
(,O
regression,O
line,O
:,O
y,O
=,O
0.5,O
+,O
4.78x,O
with,O
r,O
of,O
0.78,O
),O
.,O
It,I-Entity
is,O
concluded,O
that,O
intragastric,O
pressure,O
increases,O
significantly,O
during,O
muscle,O
fasciculations,I-Entity
caused,O
by,O
suxamethonium,I-Entity
in,O
healthy,O
children,O
.,O
Alfentanil,I-Entity
50,O
micrograms,O
kg-1,O
effectively,O
inhibits,O
the,O
incidence,O
and,O
intensity,O
of,O
suxamethonium,I-Entity
-,O
induced,O
muscle,O
fasciculations,I-Entity
;,O
moreover,O
",",O
intragastric,O
pressure,O
remains,O
at,O
its,O
control,O
value,O
.,O
Acute,I-Entity
insulin,I-Entity
treatment,O
normalizes,O
the,O
resistance,O
to,O
the,O
cardiotoxic,I-Entity
effect,O
of,O
isoproterenol,I-Entity
in,O
streptozotocin,I-Entity
diabetic,I-Entity
rats,O
.,O
A,I-Entity
morphometric,O
study,O
of,O
isoproterenol,I-Entity
induced,O
myocardial,B-Entity
fibrosis,I-Entity
.,O
The,I-Entity
acute,O
effect,O
of,O
insulin,I-Entity
treatment,O
on,O
the,O
earlier,O
reported,O
protective,O
effect,O
of,O
streptozotocin,I-Entity
diabetes,I-Entity
against,O
the,O
cardiotoxic,I-Entity
effect,O
of,O
high,O
doses,O
of,O
isoproterenol,I-Entity
(,O
ISO,I-Entity
),O
was,O
investigated,O
in,O
rats,O
.,O
Thirty,I-Entity
to,O
135,I-Entity
min,O
after,O
the,O
injection,O
of,O
crystalline,O
insulin,I-Entity
",",O
ISO,I-Entity
was,O
given,O
subcutaneously,O
and,O
when,O
ISO,I-Entity
induced,O
fibrosis,I-Entity
in,O
the,O
myocardium,I-Entity
was,O
morphometrically,O
analyzed,O
7,O
days,O
later,O
",",O
a,O
highly,O
significant,O
correlation,O
(,O
r,O
=,O
0.83,O
",",O
2,O
p,O
=,O
0.006,O
),O
to,O
the,O
slope,O
of,O
the,O
fall,O
in,O
blood,O
glucose,O
after,O
insulin,I-Entity
treatment,O
appeared,O
.,O
The,I-Entity
myocardial,B-Entity
content,O
of,O
catecholamines,I-Entity
was,O
estimated,O
in,O
these,O
8,O
day,O
diabetic,I-Entity
rats,O
.,O
The,I-Entity
norepinephrine,I-Entity
content,O
was,O
significantly,O
increased,O
while,O
epinephrine,I-Entity
remained,O
unchanged,O
.,O
An,I-Entity
enhanced,O
sympathetic,O
nervous,I-Entity
system,O
activity,O
with,O
a,O
consequent,O
down,O
regulation,O
of,O
the,O
myocardial,B-Entity
beta,O
-,O
adrenergic,O
receptors,O
could,O
",",O
therefore,O
",",O
explain,O
this,O
catecholamine,I-Entity
resistance,O
.,O
The,I-Entity
rapid,O
reversion,O
after,O
insulin,I-Entity
treatment,O
excludes,O
the,O
possibility,O
that,O
streptozotocin,I-Entity
in,O
itself,O
causes,O
the,O
ISO,I-Entity
resistance,O
and,O
points,O
towards,O
a,O
direct,O
insulin,I-Entity
effect,O
on,O
myocardial,B-Entity
catecholamine,I-Entity
sensitivity,O
in,O
diabetic,I-Entity
rats,O
.,O
The,I-Entity
phenomenon,O
described,O
might,O
elucidate,O
pathogenetic,O
mechanisms,O
behind,O
toxic,I-Entity
myocardial,B-Entity
cell,O
degeneration,I-Entity
and,O
may,O
possibly,O
have,O
relevance,O
for,O
acute,O
cardiovascular,O
complications,O
in,O
diabetic,I-Entity
patients,O
.,O
Differential,I-Entity
effects,O
of,O
non,O
-,O
steroidal,I-Entity
anti,O
-,O
inflammatory,O
drugs,O
on,O
seizures,I-Entity
produced,O
by,O
pilocarpine,I-Entity
in,O
rats,O
.,O
The,I-Entity
muscarinic,O
cholinergic,O
agonist,I-Entity
pilocarpine,I-Entity
induces,O
in,O
rats,O
seizures,I-Entity
and,O
status,O
epilepticus,I-Entity
followed,O
by,O
widespread,O
damage,O
to,O
the,O
forebrain,O
.,O
anti,O
-,O
inflammatory,O
drugs,O
",",O
sodium,I-Entity
salicylate,I-Entity
",",O
phenylbutazone,I-Entity
",",O
indomethacin,I-Entity
",",O
ibuprofen,I-Entity
and,O
mefenamic,I-Entity
acid,O
",",O
on,O
seizures,I-Entity
produced,O
by,O
pilocarpine,I-Entity
.,O
Pretreatment,I-Entity
of,O
rats,O
with,O
sodium,I-Entity
salicylate,I-Entity
",",O
ED50,I-Entity
103,O
mg,O
/,O
kg,O
(,O
60,O
-,O
174,I-Entity
),O
",",O
and,O
phenylbutazone,I-Entity
",",O
59,I-Entity
mg,O
/,O
kg,O
(,O
50,O
-,O
70,I-Entity
),O
converted,O
the,O
non,O
-,O
convulsant,I-Entity
dose,O
of,O
pilocarpine,I-Entity
",",O
200,O
mg,O
/,O
kg,O
",",O
to,O
a,O
convulsant,I-Entity
one,O
.,O
Indomethacin,I-Entity
",",O
1,O
-,O
10,O
mg,O
/,O
kg,O
",",O
and,O
ibuprofen,I-Entity
",",O
10,O
-,O
100,O
mg,O
/,O
kg,O
",",O
failed,O
to,O
modulate,O
seizures,I-Entity
produced,O
by,O
pilocarpine,I-Entity
.,O
Mefenamic,I-Entity
acid,O
",",O
26,O
(,O
22,O
-,O
30,O
),O
mg,O
/,O
kg,O
",",O
prevented,O
seizures,I-Entity
and,O
protected,O
rats,O
from,O
seizure,I-Entity
-,O
related,O
brain,O
damage,O
induced,O
by,O
pilocarpine,I-Entity
",",O
380,I-Entity
mg,O
/,O
kg,O
.,O
These,I-Entity
results,O
indicate,O
that,O
non,O
-,O
steroidal,I-Entity
anti,O
-,O
inflammatory,O
drugs,O
differentially,O
modulate,O
the,O
threshold,O
for,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
.,O
Acute,I-Entity
neurologic,O
dysfunction,I-Entity
after,O
high,O
-,O
dose,O
etoposide,I-Entity
therapy,O
for,O
malignant,I-Entity
glioma,I-Entity
.,O
Etoposide,I-Entity
(,O
VP-16,O
-,O
213,O
),O
has,O
been,O
used,O
in,O
the,O
treatment,O
of,O
many,O
solid,O
tumors,I-Entity
and,O
hematologic,O
malignancies,I-Entity
.,O
When,I-Entity
used,O
in,O
high,O
doses,O
and,O
in,O
conjunction,O
with,O
autologous,O
bone,O
marrow,O
transplantation,O
",",O
this,O
agent,O
has,O
activity,O
against,O
several,O
treatment,O
-,O
resistant,O
cancers,I-Entity
including,O
malignant,I-Entity
glioma,I-Entity
.,O
In,I-Entity
six,O
of,O
eight,O
patients,O
(,O
75%,O
),O
who,O
we,O
treated,O
for,O
recurrent,O
or,O
resistant,O
glioma,I-Entity
",",O
sudden,I-Entity
severe,O
neurologic,O
deterioration,O
occurred,O
.,O
This,I-Entity
developed,O
a,O
median,O
of,O
9,O
days,O
after,O
initiation,O
of,O
high,O
-,O
dose,O
etoposide,I-Entity
therapy,O
.,O
Significant,I-Entity
clinical,O
manifestations,O
have,O
included,O
confusion,I-Entity
",",O
papilledema,I-Entity
",",O
somnolence,I-Entity
",",O
exacerbation,O
of,O
motor,O
deficits,I-Entity
",",O
and,O
sharp,O
increase,O
in,O
seizure,I-Entity
activity,O
.,O
These,I-Entity
abnormalities,I-Entity
resolved,O
rapidly,O
after,O
initiation,O
of,O
high,O
-,O
dose,O
intravenous,O
dexamethasone,I-Entity
therapy,O
.,O
brain,O
scans,O
demonstrated,O
stability,O
in,O
tumor,I-Entity
size,O
and,O
peritumor,O
edema,I-Entity
when,O
compared,O
with,O
pretransplant,O
scans,O
.,O
This,I-Entity
complication,O
appears,O
to,O
represent,O
a,O
significant,O
new,O
toxicity,I-Entity
of,O
high,O
-,O
dose,O
etoposide,I-Entity
therapy,O
for,O
malignant,I-Entity
glioma,I-Entity
.,O
Progressive,I-Entity
bile,I-Entity
duct,O
injury,I-Entity
after,O
thiabendazole,I-Entity
administration,O
.,O
A,I-Entity
27-yr,O
-,O
old,O
man,O
developed,O
jaundice,I-Entity
2,O
wk,O
after,O
exposure,O
to,O
thiabendazole,I-Entity
.,O
Cholestasis,I-Entity
persisted,O
for,O
3,O
yr,I-Entity
",",O
at,O
which,O
time,O
a,O
liver,I-Entity
transplant,O
was,O
performed,O
.,O
Prominent,I-Entity
fibrosis,I-Entity
and,O
hepatocellular,O
regeneration,O
were,O
also,O
present,O
;,O
however,O
",",O
the,O
lobular,O
architecture,O
was,O
preserved,O
.,O
This,I-Entity
case,O
represents,O
an,O
example,O
of,O
"""""""""",O
idiosyncratic,O
"""""""""",O
drug,O
-,O
induced,O
liver,I-Entity
damage,O
in,O
which,O
the,O
primary,O
target,O
of,O
injury,I-Entity
is,O
the,O
bile,I-Entity
duct,O
.,O
An,I-Entity
autoimmune,I-Entity
pathogenesis,O
of,O
the,O
bile,I-Entity
duct,O
destruction,O
is,O
suggested,O
.,O
Differential,I-Entity
effects,O
of,O
"1,4-dihydropyridine",O
calcium,I-Entity
channel,O
blockers,O
:,O
therapeutic,O
implications,O
.,O
Increasing,I-Entity
recognition,O
of,O
the,O
importance,O
of,O
calcium,I-Entity
in,O
the,O
pathogenesis,O
of,O
cardiovascular,O
disease,I-Entity
has,O
stimulated,O
research,O
into,O
the,O
use,O
of,O
calcium,I-Entity
channel,O
blocking,I-Entity
agents,O
for,O
treatment,O
of,O
a,O
variety,O
of,O
cardiovascular,O
diseases,I-Entity
.,O
Clinical,I-Entity
applications,O
of,O
calcium,I-Entity
channel,O
blockers,O
parallel,I-Entity
their,O
tissue,O
selectivity,O
.,O
In,I-Entity
contrast,O
to,O
verapamil,I-Entity
and,O
diltiazem,I-Entity
",",O
which,O
are,O
roughly,O
equipotent,O
in,O
their,O
actions,O
on,O
the,O
heart,O
and,O
vascular,O
smooth,O
muscle,O
",",O
the,O
dihydropyridine,I-Entity
calcium,I-Entity
channel,O
blockers,O
are,O
a,O
group,O
of,O
potent,O
peripheral,O
vasodilator,O
agents,O
that,O
exert,I-Entity
minimal,O
electrophysiologic,O
effects,O
on,O
cardiac,O
nodal,O
or,O
conduction,O
tissue,O
.,O
As,I-Entity
the,O
first,O
dihydropyridine,I-Entity
available,O
for,O
use,O
in,O
the,O
United,I-Entity
States,I-Entity
",",O
nifedipine,I-Entity
controls,O
angina,I-Entity
and,O
hypertension,I-Entity
with,O
minimal,O
depression,I-Entity
of,O
cardiac,O
function,O
.,O
Additional,I-Entity
members,O
of,O
this,O
group,O
of,O
calcium,I-Entity
channel,O
blockers,O
have,O
been,O
studied,O
for,O
a,O
variety,O
of,O
indications,O
for,O
which,O
they,O
may,O
offer,O
advantages,O
over,O
current,O
therapy,O
.,O
Once,I-Entity
or,O
twice,O
daily,O
dosage,O
possible,O
with,O
nitrendipine,I-Entity
and,O
nisoldipine,I-Entity
offers,O
a,O
convenient,O
administration,O
schedule,O
",",O
which,O
encourages,O
patient,O
compliance,O
in,O
long,O
-,O
term,O
therapy,O
of,O
hypertension,I-Entity
.,O
The,I-Entity
coronary,O
vasodilating,O
properties,O
of,O
nisoldipine,I-Entity
have,O
led,O
to,O
the,O
investigation,O
of,O
this,O
agent,O
for,O
use,O
in,O
angina,I-Entity
.,O
Selectivity,I-Entity
for,O
the,O
cerebrovascular,O
bed,O
makes,O
nimodipine,I-Entity
potentially,O
useful,O
in,O
the,O
treatment,O
of,O
subarachnoid,O
hemorrhage,I-Entity
",",O
migraine,I-Entity
headache,I-Entity
",",O
dementia,I-Entity
",",O
and,O
stroke,O
.,O
In,I-Entity
general,O
",",O
the,O
dihydropyridine,I-Entity
calcium,I-Entity
channel,O
blockers,O
are,O
usually,O
well,O
tolerated,O
",",O
with,O
headache,I-Entity
",",O
facial,O
flushing,I-Entity
",",O
palpitations,O
",",O
edema,I-Entity
",",O
nausea,I-Entity
",",O
anorexia,I-Entity
",",O
and,O
dizziness,I-Entity
being,O
the,O
more,O
common,O
adverse,O
effects,O
.,O
The,I-Entity
enhancement,O
of,O
aminonucleoside,I-Entity
nephrosis,I-Entity
by,O
the,O
co,O
-,O
administration,O
of,O
protamine,I-Entity
.,O
An,I-Entity
experimental,O
model,O
of,O
focal,O
segmental,O
glomerular,O
sclerosis,I-Entity
(,O
FSGS,I-Entity
),O
was,O
developed,O
in,O
rats,O
by,O
the,O
combined,O
administration,O
of,O
puromycin,I-Entity
-,O
aminonucleoside,I-Entity
(,O
AMNS,I-Entity
),O
and,O
protamine,I-Entity
sulfate,O
(,O
PS,I-Entity
),O
.,O
Male,I-Entity
Sprague,I-Entity
-,O
Dawley,I-Entity
rats,O
",",O
uninephrectomized,O
three,O
weeks,O
before,O
",",O
received,O
daily,O
injections,O
of,O
subcutaneous,O
AMNS,I-Entity
(,O
1,O
mg/100,I-Entity
g,O
body,O
wt,O
),O
and,O
intravenous,O
PS,I-Entity
(,O
2,O
separated,O
doses,O
of,O
2.5,O
mg/100,I-Entity
g,O
body,O
wt,O
),O
for,O
four,O
days,O
.,O
They,I-Entity
developed,O
nephrotic,I-Entity
syndrome,I-Entity
and,O
finally,O
renal,O
failure,I-Entity
.,O
The,I-Entity
time,O
-,O
course,O
curve,O
of,O
creatinine,I-Entity
clearance,O
dropped,O
and,O
showed,O
significant,O
difference,O
(,O
P,I-Entity
less,O
than,O
0.01,O
),O
from,O
that,O
of,O
each,O
control,O
group,O
",",O
such,O
as,O
",",O
AMNS,I-Entity
alone,O
",",O
PS,I-Entity
alone,O
or,O
saline,O
injected,O
.,O
Their,I-Entity
glomeruli,O
showed,O
changes,O
of,O
progressive,O
FSGS,I-Entity
.,O
The,I-Entity
ultrastructural,O
studies,O
in,O
the,O
initial,O
stage,O
revealed,O
significant,O
lack,O
of,O
particles,O
of,O
perfused,O
ruthenium,I-Entity
red,O
on,O
the,O
lamina,I-Entity
rara,O
externa,I-Entity
and,O
marked,O
changes,O
in,O
epithelial,O
cell,O
cytoplasm,O
.,O
Therefore,I-Entity
",",O
it,O
is,O
suggested,O
that,O
the,O
administration,O
of,O
PS,I-Entity
enhances,O
the,O
toxicity,I-Entity
of,O
AMNS,I-Entity
on,O
the,O
glomerulus,I-Entity
and,O
readily,O
produces,O
progressive,O
FSGS,I-Entity
in,O
rats,O
resulting,O
in,O
the,O
end,O
-,O
stage,O
renal,O
disease,I-Entity
.,O
Theophylline,I-Entity
neurotoxicity,I-Entity
in,O
pregnant,I-Entity
rats,O
.,O
The,I-Entity
purpose,O
of,O
this,O
investigation,O
was,O
to,O
determine,O
whether,O
the,O
neurotoxicity,I-Entity
of,O
theophylline,I-Entity
is,O
altered,O
in,O
advanced,O
pregnancy,I-Entity
.,O
Sprague,I-Entity
-,O
Dawley,I-Entity
rats,O
that,O
were,O
20,O
days,O
pregnant,I-Entity
and,O
nonpregnant,O
rats,O
of,O
the,O
same,O
age,O
and,O
strain,O
received,O
infusions,O
of,O
aminophylline,I-Entity
until,O
onset,O
of,O
maximal,O
seizures,I-Entity
which,O
occurred,O
after,O
28,O
and,O
30,O
minutes,O
respectively,O
.,O
Theophylline,I-Entity
concentrations,O
at,O
this,O
endpoint,O
in,O
serum,O
(,O
total,O
),O
and,O
CSF,I-Entity
were,O
similar,O
but,O
serum,O
(,O
free,O
),O
and,O
brain,O
concentrations,O
were,O
slightly,O
different,O
in,O
pregnant,I-Entity
rats,O
.,O
Theophylline,I-Entity
serum,O
protein,O
binding,O
determined,O
by,O
equilibrium,O
dialysis,O
was,O
lower,O
in,O
pregnant,I-Entity
rats,O
.,O
Fetal,I-Entity
serum,O
concentrations,O
at,O
onset,O
of,O
seizures,I-Entity
in,O
the,O
mother,O
were,O
similar,O
to,O
maternal,O
brain,O
and,O
CSF,I-Entity
concentrations,O
and,O
correlated,O
significantly,O
with,O
the,O
former,O
.,O
It,I-Entity
is,O
concluded,O
that,O
advanced,O
pregnancy,I-Entity
has,O
a,O
negligible,O
effect,O
on,O
the,O
neurotoxic,I-Entity
response,O
to,O
theophylline,I-Entity
in,O
rats,O
.,O
Hyperkalemia,I-Entity
induced,O
by,O
indomethacin,I-Entity
and,O
naproxen,I-Entity
and,O
reversed,O
by,O
fludrocortisone,I-Entity
.,O
We,I-Entity
have,O
described,O
a,O
patient,O
with,O
severe,O
rheumatoid,O
arthritis,I-Entity
and,O
a,O
history,O
of,O
mefenamic,I-Entity
acid,O
nephropathy,I-Entity
in,O
whom,O
hyperkalemia,I-Entity
and,O
inappropriate,O
hypoaldosteronism,I-Entity
were,O
caused,O
by,O
both,O
indomethacin,I-Entity
and,O
naproxen,I-Entity
",",O
without,O
major,O
decline,O
in,O
renal,O
function,O
.,O
It,I-Entity
is,O
likely,O
that,O
preexisting,O
renal,O
disease,I-Entity
predisposed,O
this,O
patient,O
to,O
type,O
IV,I-Entity
renal,O
tubular,O
acidosis,I-Entity
with,O
prostaglandin,I-Entity
synthetase,O
inhibitors,O
.,O
Because,I-Entity
he,O
was,O
unable,O
to,O
discontinue,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drug,O
therapy,O
",",O
fludrocortisone,I-Entity
was,O
added,O
",",O
correcting,O
the,O
hyperkalemia,I-Entity
and,O
allowing,O
indomethacin,I-Entity
therapy,O
to,O
be,O
continued,O
safely,O
.,O
Hypotension,I-Entity
as,O
a,O
manifestation,O
of,O
cardiotoxicity,I-Entity
in,O
three,O
patients,O
receiving,O
cisplatin,I-Entity
and,O
5-fluorouracil,I-Entity
.,O
Cardiac,I-Entity
symptoms,O
",",O
including,O
hypotension,I-Entity
",",O
developed,O
in,O
three,O
patients,O
with,O
advanced,O
colorectal,B-Entity
carcinoma,I-Entity
while,O
being,O
treated,O
with,O
cisplatin,I-Entity
(,O
CDDP,I-Entity
),O
and,O
5-fluorouracil,I-Entity
(,O
5-FU,I-Entity
),O
.,O
In,I-Entity
two,O
patients,O
",",O
hypotension,I-Entity
was,O
associated,O
with,O
severe,O
left,O
ventricular,O
dysfunction,I-Entity
.,O
The,I-Entity
presentation,O
and,O
cardiac,O
evaluation,O
(,O
hemodynamic,O
",",O
echocardiographic,O
",",O
and,O
scintigraphic,O
),O
of,O
these,O
patients,O
suggest,O
new,O
manifestations,O
of,O
5-FU,I-Entity
cardiotoxicity,I-Entity
that,O
may,O
be,O
influenced,O
by,O
CDDP,I-Entity
.,O
Fatal,I-Entity
aplastic,B-Entity
anemia,I-Entity
in,O
a,O
patient,O
treated,O
with,O
carbamazepine,I-Entity
.,O
A,I-Entity
case,O
of,O
fatal,O
aplastic,B-Entity
anemia,I-Entity
due,O
to,O
carbamazepine,I-Entity
treatment,O
in,O
an,O
epileptic,I-Entity
woman,O
is,O
reported,O
.,O
Despite,I-Entity
concerns,O
of,O
fatal,O
bone,O
marrow,O
toxicity,I-Entity
due,O
to,O
carbamazepine,I-Entity
",",O
this,O
is,O
only,O
the,O
fourth,O
documented,O
and,O
published,O
report,O
.,O
Carbamazepine,I-Entity
is,O
a,O
safe,O
drug,O
",",O
but,O
physicians,O
and,O
patients,O
should,O
be,O
aware,O
of,O
the,O
exceedingly,O
rare,O
but,O
potentially,O
fatal,O
side,O
effects,O
",",O
better,O
prevented,O
by,O
clinical,O
than,O
by,O
laboratory,O
monitoring,O
.,O
Participation,I-Entity
of,O
a,O
bulbospinal,B-Entity
serotonergic,I-Entity
pathway,O
in,O
the,O
rat,O
brain,O
in,O
clonidine,I-Entity
-,O
induced,O
hypotension,I-Entity
and,O
bradycardia,I-Entity
.,O
The,I-Entity
effects,O
of,O
microinjection,O
of,O
clonidine,I-Entity
(,O
1,O
-,O
10,O
micrograms,O
in,O
1,O
microliter,O
),O
into,O
a,O
region,O
adjacent,O
to,O
the,O
ventrolateral,O
surface,O
of,O
the,O
medulla,O
oblongata,O
on,O
cardiovascular,O
function,O
were,O
assessed,O
in,O
urethane,I-Entity
-,O
anesthetized,O
rats,O
.,O
Intramedullary,I-Entity
administration,O
of,O
clonidine,I-Entity
",",O
but,O
not,O
saline,O
vehicle,O
",",O
caused,O
a,O
dose,O
-,O
dependent,O
decrease,O
in,O
both,O
the,O
mean,O
arterial,O
pressure,O
and,O
the,O
heart,O
rate,O
.,O
The,I-Entity
clonidine,I-Entity
-,O
induced,O
hypotension,I-Entity
was,O
antagonized,I-Entity
by,O
prior,O
spinal,O
transection,O
",",O
but,O
not,O
bilateral,O
vagotomy,I-Entity
.,O
On,I-Entity
the,O
other,O
hand,O
",",O
the,O
clonidine,I-Entity
-,O
induced,O
bradycardia,I-Entity
was,O
antagonized,I-Entity
by,O
prior,O
bilateral,O
vagotomy,I-Entity
",",O
but,O
not,O
spinal,O
transection,O
.,O
Furthermore,I-Entity
",",O
selective,O
destruction,O
of,O
the,O
spinal,O
5-HT,I-Entity
nerves,I-Entity
",",O
produced,O
by,O
bilateral,O
spinal,O
injection,O
of,O
"5,7-dihydroxytryptamine",I-Entity
",",O
reduced,O
the,O
magnitude,O
of,O
the,O
vasodepressor,I-Entity
or,O
the,O
bradycardiac,I-Entity
responses,O
to,O
clonidine,I-Entity
microinjected,O
into,O
the,O
area,O
near,O
the,O
ventrolateral,O
surface,O
of,O
the,O
medulla,O
oblongata,O
in,O
rats,O
.,O
The,I-Entity
data,O
indicate,O
that,O
a,O
bulbospinal,B-Entity
serotonergic,I-Entity
pathway,O
is,O
involved,O
in,O
development,O
of,O
clonidine,I-Entity
-,O
induced,O
hypotension,I-Entity
and,O
bradycardia,I-Entity
.,O
The,I-Entity
induced,O
hypotension,I-Entity
is,O
brought,O
about,O
by,O
a,O
decrease,O
in,O
sympathetic,O
efferent,O
activity,O
",",O
whereas,O
the,O
induced,O
bradycardia,I-Entity
was,O
due,O
to,O
an,O
increase,O
in,O
vagal,I-Entity
efferent,O
activity,O
.,O
Hypertension,I-Entity
in,O
neuroblastoma,I-Entity
induced,O
by,O
imipramine,I-Entity
.,O
Hypertension,I-Entity
is,O
a,O
well,O
-,O
known,O
finding,O
in,O
some,O
patients,O
with,O
neuroblastoma,I-Entity
.,O
However,I-Entity
",",O
it,O
has,O
not,O
previously,O
been,O
described,O
in,O
association,O
with,O
the,O
use,O
of,O
Imipramine,I-Entity
.,O
We,I-Entity
report,O
the,O
occurrence,O
of,O
severe,O
hypertension,I-Entity
(,O
blood,O
pressure,O
190/160,I-Entity
),O
in,O
a,O
4-year,O
-,O
old,O
girl,O
with,O
neuroblastoma,I-Entity
who,O
was,O
given,O
Imipramine,I-Entity
to,O
control,O
a,O
behavior,O
disorder,I-Entity
.,O
It,I-Entity
was,O
determined,O
later,O
that,O
this,O
patient,O
's,I-Entity
tumor,I-Entity
was,O
recurring,O
at,O
the,O
time,O
of,O
her,O
hypertensive,I-Entity
episode,O
.,O
Since,I-Entity
she,O
had,O
no,O
blood,O
pressure,O
elevation,O
at,O
initial,O
diagnosis,O
and,O
none,O
following,O
discontinuation,O
of,O
the,O
Imipramine,I-Entity
(,O
when,O
she,O
was,O
in,O
florid,I-Entity
relapse,O
),O
",",O
we,O
believe,O
that,O
this,O
drug,O
rather,O
than,O
her,O
underlying,O
disease,I-Entity
alone,O
caused,O
her,O
hypertension,I-Entity
.,O
The,I-Entity
mechanism,O
for,O
this,O
reaction,I-Entity
is,O
believed,O
to,O
be,O
increased,O
levels,O
of,O
vasoactive,O
catecholamines,I-Entity
due,O
to,O
interference,I-Entity
of,O
their,O
physiologic,O
inactivation,O
by,O
Imipramine,I-Entity
.,O
From,I-Entity
this,O
experience,O
",",O
we,O
urge,O
extreme,O
caution,O
in,O
the,O
use,O
of,O
tricyclic,O
antidepressants,I-Entity
in,O
children,O
with,O
active,O
neuroblastoma,I-Entity
.,O
Rechallenge,I-Entity
of,O
patients,O
who,O
developed,O
oral,O
candidiasis,I-Entity
or,O
hoarseness,I-Entity
with,O
beclomethasone,I-Entity
dipropionate,I-Entity
.,O
Of,I-Entity
158,I-Entity
asthmatic,I-Entity
patients,O
who,O
were,O
placed,O
on,O
inhaled,O
beclomethasone,I-Entity
",",O
15,O
(,O
9.5%,O
),O
developed,O
either,O
hoarseness,I-Entity
(,O
8),O
",",O
oral,O
thrush,I-Entity
(,O
6,O
),O
",",O
or,O
both,O
(,O
1,O
),O
.,O
When,I-Entity
their,O
adverse,O
reactions,O
subsided,O
",",O
seven,O
of,O
these,O
15,O
patients,O
were,O
rechallenged,O
with,O
inhaled,O
beclomethasone,I-Entity
.,O
These,I-Entity
included,O
five,O
cases,O
who,O
developed,O
hoarseness,I-Entity
and,O
three,O
who,O
developed,O
Candidiasis,I-Entity
.,O
Oral,I-Entity
thrush,I-Entity
did,O
not,O
recur,O
",",O
but,O
60%,O
(,O
3/5,O
),O
of,O
patients,O
with,O
hoarseness,I-Entity
had,O
recurrence,O
.,O
We,I-Entity
conclude,O
that,O
patients,O
may,O
be,O
restarted,O
on,O
inhaled,O
beclomethasone,I-Entity
when,O
clinically,O
indicated,O
;,O
however,O
",",O
because,O
of,O
the,O
high,O
recurrence,O
rate,O
",",O
patients,O
who,O
develop,O
hoarseness,I-Entity
should,O
not,O
be,O
re,O
-,O
challenged,O
.,O
Concomitant,I-Entity
use,O
of,O
oral,O
prednisone,I-Entity
and,O
topical,O
beclomethasone,I-Entity
may,O
increase,O
the,O
risk,O
of,O
developing,O
hoarseness,I-Entity
or,O
candidiasis,I-Entity
.,O
Cyclophosphamide,I-Entity
cardiotoxicity,I-Entity
:,O
an,O
analysis,O
of,O
dosing,O
as,O
a,O
risk,O
factor,O
.,O
Patients,I-Entity
who,O
undergo,O
bone,O
marrow,O
transplantation,O
are,O
generally,O
immunosuppressed,O
with,O
a,O
dose,O
of,O
cyclophosphamide,I-Entity
(,O
CYA,I-Entity
),O
which,O
is,O
usually,O
calculated,O
based,O
on,O
the,O
patient,O
's,I-Entity
weight,O
.,O
At,I-Entity
these,O
high,O
doses,O
of,O
CYA,I-Entity
",",O
serious,O
cardiotoxicity,I-Entity
may,O
occur,O
",",O
but,O
definitive,O
risk,O
factors,O
for,O
the,O
development,O
of,O
such,O
cardiotoxicity,I-Entity
have,O
not,O
been,O
described,O
.,O
Since,I-Entity
chemotherapeutic,O
agent,O
toxicity,I-Entity
generally,O
correlates,O
with,O
dose,O
per,O
body,O
surface,O
area,O
",",O
we,O
retrospectively,O
calculated,O
the,O
dose,O
of,O
CYA,I-Entity
in,O
patients,O
transplanted,O
at,O
our,O
institution,O
to,O
determine,O
whether,O
the,O
incidence,O
of,O
CYA,I-Entity
cardiotoxicity,I-Entity
correlated,O
with,O
the,O
dose,O
per,O
body,O
surface,O
area,O
.,O
Eighty,I-Entity
patients,O
who,O
were,O
to,O
receive,O
CYA,I-Entity
50,O
mg,O
/,O
kg,O
/,O
d,O
for,O
four,O
days,O
as,O
preparation,O
for,O
marrow,O
grafting,O
underwent,O
a,O
total,O
of,O
84,O
transplants,O
for,O
aplastic,B-Entity
anemia,I-Entity
",",O
Wiskott,I-Entity
-,O
Aldrich,I-Entity
syndrome,I-Entity
",",O
or,O
severe,O
combined,O
immunodeficiency,I-Entity
syndrome,I-Entity
.,O
Fourteen,I-Entity
of,O
84,O
(,O
17%,O
),O
patients,O
had,O
symptoms,O
and,O
signs,O
consistent,O
with,O
CYA,I-Entity
cardiotoxicity,I-Entity
within,O
ten,O
days,O
of,O
receiving,O
1,O
to,O
4,O
doses,O
of,O
CYA,I-Entity
.,O
Six,I-Entity
of,O
the,O
14,O
patients,O
died,O
with,O
congestive,B-Entity
heart,O
failure,I-Entity
.,O
The,I-Entity
dose,O
of,O
CYA,I-Entity
per,O
body,O
surface,O
area,O
was,O
calculated,O
for,O
all,O
patients,O
and,O
the,O
patients,O
were,O
divided,O
into,O
two,O
groups,O
based,O
on,O
daily,O
CYA,I-Entity
dose,O
:,O
Group,I-Entity
1,O
",",O
CYA,I-Entity
less,O
than,O
or,O
equal,O
to,O
1.55,O
g,O
/,O
m2/d,O
;,O
Group,I-Entity
2,O
",",O
CYA,I-Entity
greater,O
than,O
1.55,O
Cardiotoxicity,I-Entity
that,O
was,O
thought,O
to,O
be,O
related,O
to,O
CYA,I-Entity
occurred,O
in,O
1/32,O
(,O
3%,O
),O
of,O
patients,O
in,O
Group,I-Entity
1,O
and,O
in,O
13/52,O
(,O
25%,O
),O
patients,O
in,O
Group,I-Entity
2,O
(,O
P,I-Entity
less,O
than,O
0.025,O
),O
.,O
Congestive,I-Entity
heart,O
failure,I-Entity
caused,O
or,O
contributed,O
to,O
death,I-Entity
in,O
0/32,O
patients,O
in,O
Group,I-Entity
1,O
v,O
6/52,O
(,O
12%,O
),O
of,O
patients,O
in,O
Group,I-Entity
2,O
(,O
P,I-Entity
less,O
than,O
0.25,O
),O
.,O
We,I-Entity
conclude,O
that,O
the,O
CYA,I-Entity
cardiotoxicity,I-Entity
correlates,O
with,O
CYA,I-Entity
dosage,O
as,O
calculated,O
by,O
body,O
surface,O
area,O
",",O
and,O
that,O
patients,O
with,O
aplastic,B-Entity
anemia,I-Entity
and,O
immunodeficiencies,O
can,O
be,O
effectively,O
prepared,O
for,O
bone,O
marrow,O
grafting,O
at,O
a,O
CYA,I-Entity
dose,O
of,O
1.55,O
g,O
/,O
m2/d,O
for,O
four,O
days,O
with,O
a,O
lower,O
incidence,O
of,O
cardiotoxicity,I-Entity
than,O
patients,O
whose,O
CYA,I-Entity
dosage,O
is,O
calculated,O
based,O
on,O
weight,O
.,O
This,I-Entity
study,O
reaffirms,O
the,O
principle,O
that,O
drug,O
toxicity,I-Entity
correlates,O
with,O
dose,O
per,O
body,O
surface,O
area,O
.,O
Studies,I-Entity
of,O
risk,O
factors,O
for,O
aminoglycoside,I-Entity
nephrotoxicity,I-Entity
.,O
The,I-Entity
epidemiology,O
of,O
aminoglycoside,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
is,O
not,O
fully,O
understood,O
.,O
Experimental,I-Entity
studies,O
in,O
healthy,O
human,O
volunteers,O
indicate,O
aminoglycosides,I-Entity
cause,O
proximal,O
tubular,O
damage,O
in,O
most,O
patients,O
",",O
but,O
rarely,O
",",O
if,O
ever,O
",",O
cause,O
glomerular,O
or,O
tubular,O
dysfunction,I-Entity
.,O
Clinical,I-Entity
trials,O
of,O
aminoglycosides,I-Entity
in,O
seriously,O
ill,O
patients,O
indicate,O
that,O
the,O
relative,O
risk,O
for,O
developing,O
acute,O
renal,O
failure,I-Entity
during,O
therapy,O
ranges,O
from,O
8,O
to,O
10,O
and,O
that,O
the,O
attributable,O
risk,O
is,O
70%,O
to,O
80%,O
.,O
Further,I-Entity
analysis,O
of,O
these,O
data,O
suggests,O
that,O
the,O
duration,O
of,O
therapy,O
",",O
plasma,O
aminoglycoside,I-Entity
levels,O
",",O
liver,I-Entity
disease,I-Entity
",",O
advanced,O
age,O
",",O
high,O
initial,O
estimated,O
creatinine,I-Entity
clearance,O
and,O
",",O
possibly,O
",",O
female,O
gender,O
all,O
increase,O
the,O
risk,O
for,O
nephrotoxicity,I-Entity
.,O
Other,I-Entity
causes,O
of,O
acute,O
renal,O
failure,I-Entity
",",O
such,O
as,O
shock,I-Entity
",",O
appear,O
to,O
have,O
an,O
additive,O
effect,O
.,O
These,I-Entity
models,O
may,O
also,O
be,O
useful,O
in,O
developing,O
insights,O
into,O
the,O
pathophysiology,O
of,O
aminoglycoside,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
.,O
Flurothyl,I-Entity
seizure,I-Entity
thresholds,O
in,O
mice,O
treated,O
neonatally,O
with,O
a,O
single,O
injection,O
of,O
monosodium,I-Entity
glutamate,I-Entity
(,O
MSG,I-Entity
),O
:,O
evaluation,O
of,O
experimental,O
parameters,O
in,O
flurothyl,I-Entity
seizure,I-Entity
testing,O
.,O
Monosodium,I-Entity
glutamate,I-Entity
(,O
MSG,I-Entity
),O
administration,O
to,O
neonatal,O
rodents,O
produces,O
convulsions,I-Entity
and,O
results,O
in,O
numerous,O
biochemical,O
and,O
behavioral,O
deficits,I-Entity
.,O
These,I-Entity
studies,O
were,O
undertaken,O
to,O
determine,O
if,O
neonatal,O
administration,O
of,O
MSG,I-Entity
produced,O
permanent,O
alterations,I-Entity
in,O
seizure,I-Entity
susceptibility,O
",",O
since,O
previous,O
investigations,O
were,O
inconclusive,O
.,O
A,I-Entity
flurothyl,I-Entity
ether,I-Entity
seizure,I-Entity
screening,O
technique,O
was,O
used,O
to,O
evaluate,O
seizure,I-Entity
susceptibility,O
in,O
adult,O
mice,O
that,O
received,O
neonatal,O
injections,O
of,O
MSG,I-Entity
(,O
4,O
mg,O
/,O
g,O
and,O
1,O
mg,O
/,O
g,O
),O
.,O
MSG,I-Entity
treatment,O
resulted,O
in,O
significant,O
reductions,O
in,O
whole,O
brain,O
weight,O
but,O
did,O
not,O
alter,O
seizure,I-Entity
threshold,O
.,O
A,I-Entity
naloxone,I-Entity
(,O
5,O
mg,O
/,O
kg,O
),O
challenge,O
was,O
also,O
ineffective,O
in,O
altering,O
the,O
seizure,I-Entity
thresholds,O
of,O
either,O
control,O
of,O
MSG,I-Entity
-,O
treated,O
mice,O
.,O
Flurothyl,I-Entity
ether,I-Entity
produced,O
hypothermia,I-Entity
which,O
was,O
correlated,O
with,O
the,O
duration,O
of,O
flurothyl,I-Entity
exposure,O
;,O
however,O
",",O
the,O
relationship,O
of,O
hypothermia,I-Entity
to,O
seizure,I-Entity
induction,O
was,O
unclear,O
.,O
Flurothyl,I-Entity
seizure,I-Entity
testing,O
proved,O
to,O
be,O
a,O
rapid,O
and,O
reliable,O
technique,O
with,O
which,O
to,O
evaluate,O
seizure,I-Entity
susceptibility,O
.,O
Susceptibility,I-Entity
to,O
seizures,I-Entity
produced,O
by,O
pilocarpine,I-Entity
in,O
rats,O
after,O
microinjection,O
of,O
isoniazid,I-Entity
or,O
gamma,I-Entity
-,O
vinyl,I-Entity
-,O
GABA,I-Entity
into,O
the,O
substantia,I-Entity
nigra,I-Entity
.,O
Pilocarpine,I-Entity
",",O
given,O
intraperitoneally,O
to,O
rats,O
",",O
reproduces,O
the,O
neuropathological,O
sequelae,O
of,O
temporal,O
lobe,O
epilepsy,I-Entity
and,O
provides,O
a,O
relevant,O
animal,O
model,O
for,O
studying,O
mechanisms,O
of,O
buildup,O
of,O
convulsive,I-Entity
activity,O
and,O
pathways,O
operative,O
in,O
the,O
generalization,O
and,O
propagation,O
of,O
seizures,I-Entity
within,O
the,O
forebrain,O
.,O
In,I-Entity
the,O
present,O
study,O
",",O
the,O
effects,O
of,O
manipulating,O
the,O
activity,O
of,O
the,O
gamma,I-Entity
-,O
aminobutyric,I-Entity
acid,O
(,O
GABA)-mediated,I-Entity
synaptic,O
inhibition,O
within,O
the,O
substantia,I-Entity
nigra,I-Entity
on,O
seizures,I-Entity
produced,O
by,O
pilocarpine,I-Entity
in,O
rats,O
",",O
were,O
investigated,O
.,O
In,I-Entity
animals,O
pretreated,O
with,O
microinjections,O
of,O
isoniazid,I-Entity
",",O
150,I-Entity
micrograms,O
",",O
an,O
inhibitor,O
of,O
activity,O
of,O
the,O
GABA,I-Entity
-,O
synthesizing,O
enzyme,O
",",O
L,I-Entity
-,O
glutamic,I-Entity
acid,O
decarboxylase,O
",",O
into,O
the,O
substantia,I-Entity
nigra,I-Entity
pars,O
reticulata,I-Entity
(,O
SNR,I-Entity
),O
",",O
bilaterally,O
",",O
non,O
-,O
convulsant,I-Entity
doses,O
of,O
pilocarpine,I-Entity
",",O
100,O
and,O
200,O
mg,O
/,O
kg,O
",",O
resulted,O
in,O
severe,O
motor,O
limbic,O
seizures,I-Entity
and,O
status,O
epilepticus,I-Entity
.,O
Electroencephalographic,I-Entity
and,O
behavioral,O
monitoring,O
revealed,O
a,O
profound,O
reduction,O
of,O
the,O
threshold,O
for,O
pilocarpine,I-Entity
-,O
induced,O
convulsions,I-Entity
.,O
Morphological,I-Entity
analysis,O
of,O
frontal,O
forebrain,O
sections,O
with,O
light,O
microscopy,O
revealed,O
seizure,I-Entity
-,O
related,O
damage,O
to,O
the,O
hippocampal,O
formation,O
",",O
thalamus,I-Entity
",",O
amygdala,O
",",O
olfactory,O
cortex,O
",",O
substantia,I-Entity
nigra,I-Entity
and,O
neocortex,I-Entity
",",O
which,O
is,O
typically,O
observed,O
with,O
pilocarpine,I-Entity
in,O
doses,O
exceeding,O
350,I-Entity
mg,O
/,O
kg,O
.,O
Bilateral,I-Entity
intrastriatal,O
injections,O
of,O
isoniazid,I-Entity
did,O
not,O
augment,O
seizures,I-Entity
produced,O
by,O
pilocarpine,I-Entity
",",O
200,O
mg,O
/,O
kg,O
.,O
Application,I-Entity
of,O
an,O
irreversible,O
inhibitor,O
of,O
GABA,I-Entity
transaminase,O
",",O
gamma,I-Entity
-,O
vinyl,I-Entity
-,O
GABA,I-Entity
(,O
D,I-Entity
",",O
L-4-amino,B-Entity
-,O
hex-5-enoic,B-Entity
acid,O
),O
",",O
5,O
micrograms,O
",",O
into,O
the,O
SNR,I-Entity
",",O
bilaterally,O
",",O
suppressed,O
the,O
appearance,O
of,O
electrographic,O
and,O
behavioral,O
seizures,I-Entity
produced,O
by,O
pilocarpine,I-Entity
",",O
380,I-Entity
mg,O
/,O
kg,O
.,O
This,I-Entity
treatment,O
was,O
also,O
sufficient,O
to,O
protect,O
animals,O
from,O
the,O
occurrence,O
of,O
brain,O
damage,O
.,O
Microinjections,I-Entity
of,O
gamma,I-Entity
-,O
vinyl,I-Entity
-,O
GABA,I-Entity
",",O
5,O
micrograms,O
",",O
into,O
the,O
dorsal,O
striatum,O
",",O
bilaterally,O
",",O
failed,O
to,O
prevent,O
the,O
development,O
of,O
convulsions,I-Entity
produced,O
by,O
pilocarpine,I-Entity
",",O
380,I-Entity
mg,O
/,O
kg,O
.,O
The,I-Entity
results,O
demonstrate,O
that,O
the,O
threshold,O
for,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
in,O
rats,O
is,O
subjected,O
to,O
the,O
regulation,O
of,O
the,O
GABA,I-Entity
-,O
mediated,O
synaptic,O
inhibition,O
within,O
the,O
substantia,I-Entity
nigra,I-Entity
.,O
Non,I-Entity
-,O
invasive,O
detection,O
of,O
coronary,O
artery,I-Entity
disease,I-Entity
by,O
body,O
surface,O
electrocardiographic,O
mapping,O
after,O
dipyridamole,I-Entity
infusion,O
.,O
Electrocardiographic,I-Entity
changes,O
after,O
dipyridamole,I-Entity
infusion,O
(,O
0.568,O
mg,O
/,O
kg/4,O
min,O
),O
were,O
studied,O
in,O
41,O
patients,O
with,O
coronary,O
artery,I-Entity
disease,I-Entity
and,O
compared,O
with,O
those,O
after,O
submaximal,O
treadmill,O
exercise,O
by,O
use,O
of,O
the,O
body,O
surface,O
mapping,O
technique,O
.,O
Patients,I-Entity
were,O
divided,O
into,O
three,O
groups,O
;,O
19,O
patients,O
without,O
myocardial,B-Entity
infarction,I-Entity
(,O
non,O
-,O
MI,I-Entity
group,O
),O
",",O
14,O
with,O
anterior,O
infarction,I-Entity
(,O
ANT,I-Entity
-,O
MI,I-Entity
),O
and,O
eight,O
with,O
inferior,O
infarction,I-Entity
(,O
INF,I-Entity
-,O
MI,I-Entity
),O
.,O
After,I-Entity
dipyridamole,I-Entity
",",O
ischemic,I-Entity
ST,I-Entity
-,O
segment,O
depression,I-Entity
(,O
0.05,O
mV,I-Entity
or,O
more,O
),O
was,O
observed,O
in,O
84%,O
of,O
the,O
non,O
-,O
MI,I-Entity
group,O
",",O
29%,O
of,O
the,O
ANT,I-Entity
-,O
MI,I-Entity
group,O
",",O
63%,O
of,O
the,O
INF,I-Entity
-,O
MI,I-Entity
group,O
and,O
61%,O
of,O
the,O
total,O
population,O
.,O
Exercise,I-Entity
-,O
induced,O
ST,I-Entity
depression,I-Entity
was,O
observed,O
in,O
84%,O
of,O
the,O
non,O
-,O
MI,I-Entity
group,O
",",O
43%,O
of,O
the,O
ANT,I-Entity
-,O
MI,I-Entity
group,O
",",O
38%,O
of,O
the,O
INF,I-Entity
-,O
MI,I-Entity
group,O
and,O
61%,O
of,O
the,O
total,O
.,O
For,I-Entity
individual,O
patients,O
",",O
there,O
were,O
no,O
obvious,O
differences,O
between,O
the,O
body,O
surface,O
distribution,O
of,O
ST,I-Entity
depression,I-Entity
in,O
both,O
tests,O
.,O
The,I-Entity
increase,O
in,O
pressure,O
rate,O
product,O
after,O
dipyridamole,I-Entity
was,O
significantly,O
less,O
than,O
that,O
during,O
the,O
treadmill,O
exercise,O
.,O
The,I-Entity
data,O
suggest,O
that,O
the,O
dipyridamole,I-Entity
-,O
induced,O
myocardial,B-Entity
ischemia,I-Entity
is,O
caused,O
by,O
the,O
inhomogenous,O
distribution,O
of,O
myocardial,B-Entity
blood,O
flow,O
.,O
We,I-Entity
conclude,O
that,O
the,O
dipyridamole,I-Entity
ECG,I-Entity
test,O
is,O
as,O
useful,O
as,O
the,O
exercise,O
ECG,I-Entity
test,O
for,O
the,O
assessment,O
of,O
coronary,O
artery,I-Entity
disease,I-Entity
.,O
Bradycardia,I-Entity
after,O
high,O
-,O
dose,O
intravenous,O
methylprednisolone,I-Entity
therapy,O
.,O
In,I-Entity
5,O
consecutive,O
patients,O
with,O
rheumatoid,O
arthritis,I-Entity
who,O
received,O
intravenous,O
high,O
-,O
dose,O
methylprednisolone,I-Entity
(,O
MP,I-Entity
),O
therapy,O
(,O
1,O
g,O
daily,O
for,O
2,O
or,O
3,O
consecutive,O
days,O
),O
",",O
a,O
decline,O
in,O
pulse,O
rate,O
was,O
observed,O
",",O
most,O
pronounced,O
on,O
day,O
4,O
.,O
In,I-Entity
one,O
of,O
the,O
5,O
patients,O
the,O
bradycardia,I-Entity
was,O
associated,O
with,O
complaints,O
of,O
substernal,O
pressure,O
.,O
Electrocardiographic,I-Entity
registrations,O
showed,O
sinus,O
bradycardia,I-Entity
in,O
all,O
cases,O
.,O
Careful,I-Entity
observation,O
of,O
patients,O
receiving,O
high,O
-,O
dose,O
MP,I-Entity
is,O
recommended,O
.,O
High,I-Entity
-,O
dose,O
MP,I-Entity
may,O
be,O
contraindicated,I-Entity
in,O
patients,O
with,O
known,O
heart,O
disease,I-Entity
.,O
Two,I-Entity
cases,O
of,O
downbeat,O
nystagmus,I-Entity
and,O
oscillopsia,I-Entity
associated,O
with,O
carbamazepine,I-Entity
.,O
Downbeat,I-Entity
nystagmus,I-Entity
is,O
often,O
associated,O
with,O
structural,O
lesions,O
at,O
the,O
craniocervical,O
junction,O
",",O
but,O
has,O
occasionally,O
been,O
reported,O
as,O
a,O
manifestation,O
of,O
metabolic,O
imbalance,I-Entity
or,O
drug,O
intoxication,O
.,O
We,I-Entity
recorded,O
the,O
eye,O
movements,O
of,O
two,O
patients,O
with,O
reversible,O
downbeat,O
nystagmus,I-Entity
related,O
to,O
carbamazepine,I-Entity
therapy,O
.,O
The,I-Entity
nystagmus,I-Entity
of,O
both,O
patients,O
resolved,O
after,O
reduction,O
of,O
the,O
serum,O
carbamazepine,I-Entity
levels,O
.,O
In,I-Entity
patients,O
with,O
downbeat,O
nystagmus,I-Entity
who,O
are,O
taking,O
anticonvulsant,O
medications,O
",",O
consideration,O
should,O
be,O
given,O
to,O
reduction,O
in,O
dose,O
before,O
further,O
investigation,O
is,O
undertaken,O
.,O
Improvement,I-Entity
by,O
denopamine,I-Entity
(,O
TA-064,I-Entity
),O
of,O
pentobarbital,I-Entity
-,O
induced,O
cardiac,O
failure,I-Entity
in,O
the,O
dog,O
heart,O
-,O
lung,O
preparation,O
.,O
The,I-Entity
efficacy,O
of,O
denopamine,I-Entity
",",O
an,O
orally,O
active,O
beta,O
1-adrenoceptor,O
agonist,I-Entity
",",O
in,O
improving,O
cardiac,O
failure,I-Entity
was,O
assessed,O
in,O
dog,O
heart,O
-,O
lung,O
preparations,O
.,O
Cardiac,I-Entity
functions,O
depressed,I-Entity
by,O
pentobarbital,I-Entity
(,O
118,I-Entity
+,O
/-,O
SD,I-Entity
),O
such,O
that,O
cardiac,O
output,O
and,O
maximum,O
rate,O
of,O
rise,O
of,O
left,O
ventricular,O
pressure,O
(,O
LV,I-Entity
dP,I-Entity
/,O
dt,O
max,O
),O
had,O
been,O
reduced,O
by,O
about,O
35%,O
and,O
26%,O
of,O
the,O
respective,O
controls,O
were,O
improved,O
by,O
denopamine,I-Entity
(,O
10,O
-,O
300,O
micrograms,O
),O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
.,O
With,I-Entity
100,O
micrograms,O
denopamine,I-Entity
",",O
almost,O
complete,O
restoration,O
of,O
cardiac,O
performance,O
was,O
attained,O
",",O
associated,O
with,O
a,O
slight,O
increase,O
in,O
heart,O
rate,O
.,O
No,I-Entity
arrhythmias,I-Entity
were,O
induced,O
by,O
these,O
doses,O
of,O
denopamine,I-Entity
.,O
The,I-Entity
results,O
warrant,O
clinical,O
trials,O
of,O
denopamine,I-Entity
in,O
the,O
treatment,O
of,O
cardiac,O
failure,I-Entity
.,O
Clonazepam,I-Entity
monotherapy,O
for,O
epilepsy,I-Entity
in,O
childhood,O
.,O
Sixty,I-Entity
patients,O
(,O
age,O
-,O
range,O
one,O
month,O
to,O
14,O
years,O
),O
with,O
other,O
types,O
of,O
epilepsy,I-Entity
than,O
infantile,I-Entity
spasms,I-Entity
were,O
treated,O
with,O
clonazepam,I-Entity
.,O
Disappearance,I-Entity
of,O
seizures,I-Entity
and,O
normalization,O
of,O
abnormal,I-Entity
EEG,I-Entity
with,O
disappearance,I-Entity
of,O
seizures,I-Entity
were,O
recognized,O
in,O
77%,O
and,O
50%,O
",",O
respectively,O
.,O
Seizures,I-Entity
disappeared,O
in,O
71%,O
of,O
the,O
patients,O
with,O
generalized,O
seizures,I-Entity
and,O
89%,O
of,O
partial,O
seizures,I-Entity
.,O
The,I-Entity
incidence,O
of,O
side,O
effects,O
such,O
as,O
drowsiness,O
and,O
ataxia,I-Entity
was,O
only,O
5%,O
.,O
Postmarketing,I-Entity
study,O
of,O
timolol,I-Entity
-,O
hydrochlorothiazide,I-Entity
antihypertensive,O
therapy,O
.,O
A,I-Entity
postmarketing,O
surveillance,O
study,O
was,O
conducted,O
to,O
determine,O
the,O
safety,O
and,O
efficacy,O
of,O
a,O
fixed,O
-,O
ratio,O
combination,O
containing,O
10,O
mg,O
of,O
timolol,I-Entity
maleate,I-Entity
and,O
25,O
mg,O
of,O
hydrochlorothiazide,I-Entity
",",O
administered,O
twice,O
daily,O
for,O
one,O
month,O
to,O
hypertensive,I-Entity
patients,O
.,O
Mean,I-Entity
systolic,O
blood,O
pressure,O
decreased,O
25,O
mmHg,I-Entity
and,O
mean,O
diastolic,I-Entity
blood,O
pressure,O
declined,O
15,O
mmHg,I-Entity
after,O
one,O
month,O
of,O
timolol,I-Entity
-,O
hydrochlorothiazide,I-Entity
therapy,O
(,O
P,I-Entity
less,O
than,O
0.01,O
",",O
both,O
comparisons,O
),O
.,O
The,I-Entity
antihypertensive,O
effect,O
of,O
the,O
drug,O
was,O
greater,O
in,O
patients,O
with,O
more,O
severe,O
hypertension,I-Entity
.,O
Overall,I-Entity
",",O
"1,453",O
patients,O
experienced,O
a,O
total,O
of,O
"2,658",O
adverse,O
events,O
",",O
the,O
most,O
common,O
being,O
fatigue,I-Entity
",",O
dizziness,I-Entity
",",O
and,O
weakness,I-Entity
.,O
Salicylate,I-Entity
nephropathy,I-Entity
in,O
the,O
Gunn,I-Entity
rat,O
:,O
potential,O
role,O
of,O
prostaglandins,I-Entity
.,O
We,I-Entity
examined,O
the,O
potential,O
role,O
of,O
prostaglandins,I-Entity
in,O
the,O
development,O
of,O
analgesic,O
nephropathy,I-Entity
in,O
the,O
Gunn,I-Entity
strain,O
of,O
rat,O
.,O
The,I-Entity
homozygous,O
Gunn,I-Entity
rats,O
have,O
unconjugated,O
hyperbilirubinemia,I-Entity
due,O
to,O
the,O
absence,O
of,O
glucuronyl,I-Entity
transferase,O
",",O
leading,O
to,O
marked,O
bilirubin,I-Entity
deposition,O
in,O
renal,O
medulla,O
and,O
papilla,I-Entity
.,O
These,I-Entity
rats,O
are,O
also,O
highly,O
susceptible,O
to,O
develop,O
papillary,I-Entity
necrosis,I-Entity
with,O
analgesic,O
administration,O
.,O
Four,I-Entity
groups,O
of,O
rats,O
(,O
n,O
=,O
7,O
),O
were,O
studied,O
:,O
jj,O
and,O
jJ,I-Entity
rats,O
treated,O
either,O
with,O
aspirin,I-Entity
300,O
mg,O
/,O
kg,O
every,O
other,O
day,O
or,O
sham,I-Entity
-,O
treated,O
.,O
After,I-Entity
one,O
week,O
",",O
slices,O
of,O
cortex,O
",",O
outer,O
and,O
inner,O
medulla,O
from,O
one,O
kidney,O
were,O
incubated,O
in,O
buffer,O
and,O
prostaglandin,I-Entity
synthesis,O
was,O
determined,O
by,O
radioimmunoassay,O
.,O
A,I-Entity
marked,O
corticomedullary,O
gradient,O
of,O
prostaglandin,I-Entity
synthesis,O
was,O
observed,O
in,O
all,O
groups,O
.,O
PGE2,I-Entity
synthesis,O
was,O
significantly,O
higher,O
in,O
outer,O
medulla,O
",",O
but,O
not,O
cortex,O
or,O
inner,O
medulla,O
",",O
of,O
jj,O
(,O
38,O
+,O
/-,O
Aspirin,I-Entity
treatment,O
reduced,O
PGE2,I-Entity
synthesis,O
in,O
all,O
regions,O
",",O
but,O
outer,O
medullary,O
PGE2,I-Entity
remained,O
higher,O
in,O
jj,O
(,O
18,O
+,O
/-,O
PGF2,I-Entity
alpha,O
was,O
also,O
significantly,O
higher,O
in,O
the,O
outer,O
medulla,O
of,O
jj,O
rats,O
with,O
and,O
without,O
aspirin,I-Entity
administration,O
(,O
p,O
less,O
than,O
0.05,O
),O
.,O
The,I-Entity
changes,O
in,O
renal,O
prostaglandin,I-Entity
synthesis,O
were,O
accompanied,O
by,O
evidence,O
of,O
renal,O
damage,O
in,O
aspirin,I-Entity
-,O
treated,O
jj,O
but,O
not,O
jJ,I-Entity
rats,O
as,O
evidenced,O
by,O
:,O
increased,O
incidence,O
and,O
severity,O
of,O
hematuria,I-Entity
(,O
p,O
less,O
than,O
0.01,O
),O
;,O
increased,O
serum,O
creatinine,I-Entity
(,O
p,O
less,O
than,O
0.05,O
),O
;,O
and,O
increase,O
in,O
outer,O
medullary,O
histopathologic,O
lesions,O
(,O
p,O
less,O
than,O
0.005,O
compared,O
to,O
either,O
sham,I-Entity
-,O
treated,O
jj,O
or,O
aspirin,I-Entity
-,O
treated,O
jJ,I-Entity
),O
.,O
These,I-Entity
results,O
suggest,O
that,O
enhanced,O
prostaglandin,I-Entity
synthesis,O
contributes,O
to,O
maintenance,O
of,O
renal,O
function,O
and,O
morphological,O
integrity,O
",",O
and,O
that,O
inhibition,O
of,O
prostaglandin,I-Entity
synthesis,O
may,O
lead,O
to,O
pathological,O
renal,O
medullary,O
lesions,O
and,O
deterioration,O
of,O
renal,O
function,O
.,O
Prophylactic,I-Entity
lidocaine,I-Entity
in,O
the,O
early,O
phase,O
of,O
suspected,O
myocardial,B-Entity
infarction,I-Entity
.,O
Four,I-Entity
hundred,O
two,O
patients,O
with,O
suspected,O
myocardial,B-Entity
infarction,I-Entity
seen,O
within,O
6,O
hours,O
of,O
the,O
onset,O
of,O
symptoms,O
entered,O
a,O
double,O
-,O
blind,O
randomized,O
trial,O
of,O
lidocaine,I-Entity
vs,O
placebo,O
.,O
During,I-Entity
the,O
1,O
hour,O
after,O
administration,O
of,O
the,O
drug,O
the,O
incidence,O
of,O
ventricular,O
fibrillation,I-Entity
or,O
sustained,O
ventricular,O
tachycardia,I-Entity
among,O
the,O
204,I-Entity
patients,O
with,O
acute,O
myocardial,B-Entity
infarction,I-Entity
was,O
low,O
",",O
1.5%,O
.,O
Lidocaine,I-Entity
",",O
given,O
in,O
a,O
300,O
mg,O
dose,O
intramuscularly,O
followed,O
by,O
100,O
mg,O
intravenously,O
",",O
did,O
not,O
prevent,O
sustained,O
ventricular,O
tachycardia,I-Entity
",",O
although,O
there,O
was,O
a,O
significant,O
reduction,O
in,O
the,O
number,O
of,O
patients,O
with,O
warning,O
arrhythmias,I-Entity
between,O
15,O
and,O
45,I-Entity
minutes,O
after,O
the,O
administration,O
of,O
lidocaine,I-Entity
(,O
p,O
less,O
than,O
0.05,O
),O
.,O
The,I-Entity
average,O
plasma,O
lidocaine,I-Entity
level,O
10,O
minutes,O
after,O
administration,O
for,O
patients,O
without,O
a,O
myocardial,B-Entity
infarction,I-Entity
was,O
significantly,O
higher,O
than,O
that,O
for,O
patients,O
with,O
an,O
acute,O
infarction,I-Entity
.,O
The,I-Entity
mean,O
plasma,O
lidocaine,I-Entity
level,O
of,O
patients,O
on,O
beta,O
-,O
blocking,I-Entity
agents,O
was,O
no,O
different,O
from,O
that,O
in,O
patients,O
not,O
on,O
beta,O
blocking,I-Entity
agents,O
.,O
During,I-Entity
the,O
1-hour,O
study,O
period,O
",",O
the,O
incidence,O
of,O
central,O
nervous,I-Entity
system,O
side,O
effects,O
was,O
significantly,O
greater,O
in,O
the,O
lidocaine,I-Entity
group,O
",",O
hypotension,I-Entity
occurred,O
in,O
11,O
patients,O
",",O
nine,O
of,O
whom,O
had,O
received,O
lidocaine,I-Entity
",",O
and,O
four,O
patients,O
died,O
from,O
asystole,I-Entity
",",O
three,O
of,O
whom,O
had,O
had,O
lidocaine,I-Entity
.,O
We,I-Entity
can,O
not,O
advocate,O
the,O
administration,O
of,O
lidocaine,I-Entity
prophylactically,O
in,O
the,O
early,O
hours,O
of,O
suspected,O
myocardial,B-Entity
infarction,I-Entity
.,O
Evidence,I-Entity
for,O
a,O
cholinergic,O
role,O
in,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
.,O
Experiments,I-Entity
in,O
mice,O
tested,O
previous,O
evidence,O
that,O
activation,O
of,O
cholinergic,O
systems,O
promotes,O
catalepsy,I-Entity
and,O
that,O
cholinergic,O
mechanisms,O
need,O
to,O
be,O
intact,O
for,O
full,O
expression,O
of,O
neuroleptic,O
-,O
induced,O
catalepsy,I-Entity
.,O
Large,I-Entity
doses,O
of,O
the,O
cholinomimetic,I-Entity
",",O
pilocarpine,I-Entity
",",O
could,O
induce,O
catalepsy,I-Entity
when,O
peripheral,O
cholinergic,O
receptors,O
were,O
blocked,O
.,O
Low,I-Entity
doses,O
of,O
pilocarpine,I-Entity
caused,O
a,O
pronounced,O
enhancement,O
of,O
the,O
catalepsy,I-Entity
that,O
was,O
induced,O
by,O
the,O
dopaminergic,O
blocker,O
",",O
haloperidol,I-Entity
.,O
A,I-Entity
muscarinic,O
receptor,O
blocker,O
",",O
atropine,I-Entity
",",O
disrupted,I-Entity
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
.,O
Intracranial,I-Entity
injection,O
of,O
an,O
acetylcholine,I-Entity
-,O
synthesis,O
inhibitor,O
",",O
hemicholinium,I-Entity
",",O
prevented,O
the,O
catalepsy,I-Entity
that,O
is,O
usually,O
induced,O
by,O
haloperidol,I-Entity
.,O
These,I-Entity
findings,O
suggest,O
the,O
hypothesis,O
that,O
the,O
catalepsy,I-Entity
that,O
is,O
produced,O
by,O
neuroleptics,O
such,O
as,O
haloperidol,I-Entity
is,O
actually,O
mediated,O
by,O
intrinsic,O
central,O
cholinergic,O
systems,O
.,O
Alternatively,I-Entity
",",O
activation,O
of,O
central,O
cholinergic,O
systems,O
could,O
promote,O
catalepsy,I-Entity
by,O
suppression,O
of,O
dopaminergic,O
systems,O
.,O
Cardiovascular,I-Entity
dysfunction,I-Entity
and,O
hypersensitivity,I-Entity
to,O
sodium,I-Entity
pentobarbital,I-Entity
induced,O
by,O
chronic,O
barium,I-Entity
chloride,I-Entity
ingestion,O
.,O
Barium,I-Entity
-,O
supplemented,O
Long,I-Entity
-,O
Evans,I-Entity
hooded,O
rats,O
were,O
characterized,O
by,O
a,O
persistent,O
hypertension,I-Entity
that,O
was,O
evident,O
after,O
1,O
month,O
of,O
barium,I-Entity
(,O
100,O
micrograms,O
/,O
ml,O
mineral,O
fortified,O
water,O
),O
treatment,O
.,O
myocardial,B-Entity
excitability,I-Entity
",",O
contractility,O
",",O
and,O
metabolic,O
characteristics,O
at,O
16,O
months,O
revealed,O
other,O
significant,O
barium,I-Entity
-,O
induced,O
disturbances,I-Entity
within,O
the,O
cardiovascular,O
system,O
.,O
The,I-Entity
most,O
distinctive,O
aspect,O
of,O
the,O
barium,I-Entity
effect,O
was,O
a,O
demonstrated,O
hypersensitivity,I-Entity
of,O
the,O
cardiovascular,O
system,O
to,O
sodium,I-Entity
pentobarbital,I-Entity
.,O
Under,I-Entity
barbiturate,I-Entity
anesthesia,O
",",O
virtually,O
all,O
of,O
the,O
myocardial,B-Entity
contractile,O
indices,O
were,O
depressed,I-Entity
significantly,O
in,O
barium,I-Entity
-,O
exposed,O
rats,O
relative,O
to,O
the,O
corresponding,O
control,O
-,O
fed,O
rats,O
.,O
The,I-Entity
lack,O
of,O
a,O
similar,O
response,O
to,O
ketamine,I-Entity
and,O
xylazine,I-Entity
anesthesia,O
revealed,O
that,O
the,O
cardiovascular,O
actions,O
of,O
sodium,I-Entity
pentobarbital,I-Entity
in,O
barium,I-Entity
-,O
treated,O
rats,O
were,O
linked,O
specifically,O
to,O
this,O
anesthetic,O
",",O
and,O
were,O
not,O
representative,O
of,O
a,O
generalized,O
anesthetic,O
response,O
.,O
Other,I-Entity
myocardial,B-Entity
pathophysiologic,O
and,O
metabolic,O
changes,O
induced,O
by,O
barium,I-Entity
were,O
manifest,O
",",O
irrespective,O
of,O
the,O
anesthetic,O
employed,O
.,O
The,I-Entity
contractile,O
element,O
shortening,O
velocity,O
of,O
the,O
cardiac,O
muscle,O
fibers,O
was,O
significantly,O
slower,O
in,O
both,O
groups,O
of,O
barium,I-Entity
-,O
treated,O
rats,O
relative,O
to,O
the,O
control,O
groups,O
",",O
irrespective,O
of,O
the,O
anesthetic,O
regimen,I-Entity
.,O
Similarly,I-Entity
",",O
significant,O
disturbances,I-Entity
in,O
myocardial,B-Entity
energy,O
metabolism,O
were,O
detected,O
in,O
the,O
barium,I-Entity
-,O
exposed,O
rats,O
which,O
were,O
consistent,O
with,O
the,O
reduced,O
contractile,O
element,O
shortening,O
velocity,O
.,O
In,I-Entity
addition,O
",",O
the,O
excitability,I-Entity
of,O
the,O
cardiac,O
conduction,O
system,O
was,O
depressed,I-Entity
preferentially,O
in,O
the,O
atrioventricular,B-Entity
nodal,O
region,O
of,O
hearts,O
from,O
barium,I-Entity
-,O
exposed,O
rats,O
.,O
Overall,I-Entity
",",O
the,O
altered,O
cardiac,O
contractility,O
and,O
excitability,I-Entity
characteristics,O
",",O
the,O
myocardial,B-Entity
metabolic,O
disturbances,I-Entity
",",O
and,O
the,O
hypersensitivity,I-Entity
of,O
the,O
cardiovascular,O
system,O
to,O
sodium,I-Entity
pentobarbital,I-Entity
suggest,O
the,O
existence,O
of,O
a,O
heretofore,O
undescribed,O
cardiomyopathic,I-Entity
disorder,I-Entity
induced,O
by,O
chronic,O
barium,I-Entity
exposure,O
.,O
These,I-Entity
experimental,O
findings,O
represent,O
the,O
first,O
indication,O
that,O
life,O
-,O
long,O
barium,I-Entity
ingestion,O
may,O
have,O
significant,O
adverse,O
effects,O
on,O
the,O
mammalian,O
cardiovascular,O
system,O
.,O
Propranolol,I-Entity
antagonism,I-Entity
of,O
phenylpropanolamine,I-Entity
-,O
induced,O
hypertension,I-Entity
.,O
Phenylpropanolamine,I-Entity
(,O
PPA,I-Entity
),O
overdose,I-Entity
can,O
cause,O
severe,O
hypertension,I-Entity
",",O
intracerebral,O
hemorrhage,I-Entity
",",O
and,O
death,I-Entity
.,O
We,I-Entity
studied,O
the,O
efficacy,O
and,O
safety,O
of,O
propranolol,I-Entity
in,O
the,O
treatment,O
of,O
PPA,I-Entity
-,O
induced,O
hypertension,I-Entity
.,O
Subjects,I-Entity
received,O
propranolol,I-Entity
either,O
by,O
mouth,O
for,O
48,I-Entity
hours,O
before,O
PPA,I-Entity
or,O
as,O
a,O
rapid,O
intravenous,O
infusion,O
after,O
PPA,I-Entity
.,O
PPA,I-Entity
",",O
75,O
mg,O
alone,O
",",O
increased,O
blood,O
pressure,O
(,O
31,O
+,O
/-,O
5,O
mm,O
Hg,I-Entity
diastolic,I-Entity
),O
",",O
and,O
propranolol,I-Entity
pretreatment,O
antagonized,I-Entity
this,O
increase,O
(,O
12,O
+,O
/-,O
Intravenous,I-Entity
propranolol,I-Entity
after,O
PPA,I-Entity
also,O
decreased,O
blood,O
pressure,O
.,O
Left,I-Entity
ventricular,O
function,O
(,O
assessed,O
by,O
echocardiography,O
),O
showed,O
that,O
PPA,I-Entity
increased,O
the,O
stroke,O
volume,O
30%,O
(,O
from,O
62.5,O
+,O
/-,O
Intravenous,I-Entity
propranolol,I-Entity
reversed,O
these,O
effects,O
.,O
Systemic,I-Entity
vascular,O
resistance,O
was,O
increased,O
by,O
PPA,I-Entity
28%,O
(,O
from,O
1710,O
+,O
/-,O
sec,O
/,O
cm5,O
),O
and,O
was,O
further,O
increased,O
by,O
propranolol,I-Entity
22%,O
(,O
to,O
2660,I-Entity
+,O
/-,O
We,I-Entity
conclude,O
that,O
PPA,I-Entity
increases,O
blood,O
pressure,O
by,O
increasing,O
systemic,O
vascular,O
resistance,O
and,O
cardiac,O
output,O
",",O
and,O
that,O
propranolol,I-Entity
antagonizes,I-Entity
this,O
increase,O
by,O
reversing,O
the,O
effect,O
of,O
PPA,I-Entity
on,O
cardiac,O
output,O
.,O
That,I-Entity
propranolol,I-Entity
antagonizes,I-Entity
the,O
pressor,O
effect,O
of,O
PPA,I-Entity
is,O
in,O
contrast,O
to,O
the,O
interaction,O
in,O
which,O
propranolol,I-Entity
enhances,O
the,O
pressor,O
effect,O
of,O
norepinephrine,I-Entity
.,O
This,I-Entity
is,O
probably,O
because,O
PPA,I-Entity
has,O
less,O
beta,O
2,O
activity,O
than,O
does,O
norepinephrine,I-Entity
.,O
Mesangial,I-Entity
function,O
and,O
glomerular,O
sclerosis,I-Entity
in,O
rats,O
with,O
aminonucleoside,I-Entity
nephrosis,I-Entity
.,O
The,I-Entity
possible,O
relationship,O
between,O
mesangial,I-Entity
dysfunction,I-Entity
and,O
development,O
of,O
glomerular,O
sclerosis,I-Entity
was,O
studied,O
in,O
the,O
puromycin,I-Entity
aminonucleoside,I-Entity
(,O
PAN,I-Entity
),O
model,O
.,O
Five,I-Entity
male,O
Wistar,I-Entity
rats,O
received,O
repeated,O
subcutaneous,O
PAN,I-Entity
injections,O
;,O
five,O
controls,O
received,O
saline,O
only,O
.,O
After,I-Entity
4,O
weeks,O
the,O
PAN,I-Entity
rats,O
were,O
severely,O
proteinuric,O
(,O
190,I-Entity
+,O
/-,O
80,O
mg/24,O
hr,O
),O
",",O
and,O
all,O
rats,O
were,O
given,O
colloidal,O
carbon,I-Entity
(,O
CC,I-Entity
),O
intravenously,O
.,O
At,I-Entity
5,O
months,O
glomerular,O
sclerosis,I-Entity
was,O
found,O
in,O
7.6,O
+,O
/-,O
3.4%,O
of,O
the,O
glomeruli,O
of,O
PAN,I-Entity
rats,O
;,O
glomeruli,O
of,O
the,O
controls,O
were,O
normal,O
.,O
Glomeruli,I-Entity
of,O
PAN,I-Entity
rats,O
contained,O
significantly,O
more,O
CC,I-Entity
than,O
glomeruli,O
of,O
controls,O
.,O
Glomeruli,I-Entity
with,O
sclerosis,I-Entity
contained,O
significantly,O
more,O
CC,I-Entity
than,O
non,O
-,O
sclerotic,I-Entity
glomeruli,O
in,O
the,O
same,O
kidneys,I-Entity
.,O
Since,I-Entity
mesangial,I-Entity
CC,I-Entity
clearance,O
from,O
the,O
mesangium,I-Entity
did,O
not,O
change,O
during,O
chronic,O
PAN,I-Entity
treatment,O
",",O
we,O
conclude,O
that,O
this,O
preferential,O
CC,I-Entity
localization,O
within,O
the,O
lesions,O
is,O
caused,O
by,O
an,O
increased,O
CC,I-Entity
uptake,O
shortly,O
after,O
injection,O
in,O
apparent,O
vulnerable,O
areas,O
where,O
sclerosis,I-Entity
will,O
develop,O
subsequently,O
.,O
Cluster,I-Entity
analysis,O
showed,O
a,O
random,O
distribution,O
of,O
lesions,O
in,O
the,O
PAN,I-Entity
glomeruli,O
in,O
concordance,I-Entity
with,O
the,O
random,O
localization,O
of,O
mesangial,I-Entity
areas,O
with,O
dysfunction,I-Entity
in,O
this,O
model,O
.,O
Similar,I-Entity
to,O
the,O
remnant,O
kidney,O
model,O
in,O
PAN,I-Entity
nephrosis,I-Entity
the,O
development,O
of,O
glomerular,O
sclerosis,I-Entity
may,O
be,O
related,O
to,O
"""""""""",O
mesangial,I-Entity
overloading,I-Entity
.,O
"""""""""",O
Relationship,I-Entity
between,O
nicotine,I-Entity
-,O
induced,O
seizures,I-Entity
and,O
hippocampal,O
nicotinic,O
receptors,O
.,O
Using,I-Entity
mice,O
derived,O
from,O
a,O
classical,O
F2,I-Entity
and,O
backcross,I-Entity
genetic,O
design,O
",",O
a,O
relationship,O
between,O
nicotine,I-Entity
-,O
induced,O
seizures,I-Entity
and,O
alpha,O
-,O
bungarotoxin,I-Entity
nicotinic,O
receptor,O
concentration,O
was,O
found,O
.,O
Mice,I-Entity
sensitive,I-Entity
to,O
the,O
convulsant,I-Entity
effects,O
of,O
nicotine,I-Entity
had,O
greater,O
alpha,O
-,O
bungarotoxin,I-Entity
binding,O
in,O
the,O
hippocampus,O
than,O
seizure,I-Entity
insensitive,I-Entity
mice,O
.,O
The,I-Entity
binding,O
sites,O
from,O
seizure,I-Entity
sensitive,I-Entity
and,O
resistant,O
mice,O
were,O
equally,O
affected,O
by,O
treatment,O
with,O
dithiothreitol,I-Entity
",",O
trypsin,I-Entity
or,O
heat,O
.,O
Thus,I-Entity
it,O
appears,O
that,O
the,O
difference,O
between,O
seizure,I-Entity
sensitive,I-Entity
and,O
insensitive,I-Entity
animals,O
may,O
be,O
due,O
to,O
a,O
difference,O
in,O
hippocampal,O
nicotinic,O
receptor,O
concentration,O
as,O
measured,O
with,O
alpha,O
-,O
bungarotoxin,I-Entity
binding,O
.,O
The,I-Entity
role,O
of,O
p,O
-,O
aminophenol,I-Entity
in,O
acetaminophen,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
:,O
effect,O
of,O
bis(p,I-Entity
-,O
nitrophenyl,I-Entity
),O
phosphate,I-Entity
on,O
acetaminophen,I-Entity
and,O
p,O
-,O
aminophenol,I-Entity
nephrotoxicity,I-Entity
and,O
metabolism,O
in,O
Fischer,I-Entity
344,O
rats,O
.,O
Acetaminophen,I-Entity
(,O
APAP,I-Entity
),O
produces,O
proximal,O
tubular,O
necrosis,I-Entity
in,O
Fischer,I-Entity
344,O
(,O
F344,I-Entity
),O
rats,O
.,O
Recently,I-Entity
",",O
p,O
-,O
aminophenol,I-Entity
(,O
PAP,I-Entity
),O
",",O
a,O
known,O
potent,O
nephrotoxicant,I-Entity
",",O
was,O
identified,O
as,O
a,O
metabolite,O
of,O
APAP,I-Entity
in,O
F344,I-Entity
rats,O
.,O
The,I-Entity
purpose,O
of,O
this,O
study,O
was,O
to,O
determine,O
if,O
PAP,I-Entity
formation,O
is,O
a,O
requisite,O
step,O
in,O
APAP,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
.,O
Therefore,I-Entity
",",O
the,O
effect,O
of,O
bis(p,I-Entity
-,O
nitrophenyl,I-Entity
),O
phosphate,I-Entity
(,O
BNPP,I-Entity
),O
",",O
an,O
acylamidase,I-Entity
inhibitor,O
",",O
on,O
APAP,I-Entity
and,O
PAP,I-Entity
nephrotoxicity,I-Entity
and,O
metabolism,O
was,O
determined,O
.,O
BNPP,I-Entity
(,O
1,O
to,O
8,O
mM,I-Entity
),O
reduced,O
APAP,I-Entity
deacetylation,I-Entity
and,O
covalent,O
binding,O
in,O
F344,I-Entity
renal,O
cortical,O
homogenates,O
in,O
a,O
concentration,O
-,O
dependent,O
manner,O
.,O
Pretreatment,I-Entity
of,O
animals,O
with,O
BNPP,I-Entity
prior,O
to,O
APAP,I-Entity
or,O
PAP,I-Entity
administration,O
resulted,O
in,O
marked,O
reduction,O
of,O
APAP,I-Entity
(,O
900,O
mg,O
/,O
kg,O
),O
nephrotoxicity,I-Entity
but,O
not,O
PAP,I-Entity
nephrotoxicity,I-Entity
.,O
This,I-Entity
result,O
was,O
not,O
due,O
to,O
altered,O
disposition,O
of,O
either,O
APAP,I-Entity
or,O
acetylated,I-Entity
metabolites,O
in,O
plasma,O
or,O
renal,O
cortical,O
and,O
hepatic,B-Entity
tissue,O
.,O
Rather,I-Entity
",",O
BNPP,I-Entity
pretreatment,O
reduced,O
the,O
fraction,O
of,O
APAP,I-Entity
excreted,O
as,O
PAP,I-Entity
by,O
64,I-Entity
and,O
75%,O
after,O
APAP,I-Entity
doses,O
of,O
750,O
and,O
900,O
mg,O
/,O
kg,O
.,O
BNPP,I-Entity
did,O
not,O
alter,O
the,O
excretion,O
of,O
APAP,I-Entity
or,O
any,O
of,O
its,O
non,O
-,O
deacetylated,I-Entity
metabolites,O
nor,O
did,O
BNPP,I-Entity
alter,O
excretion,O
of,O
PAP,I-Entity
or,O
its,O
metabolites,O
after,O
PAP,I-Entity
doses,O
of,O
150,I-Entity
and,O
300,O
mg,O
/,O
kg,O
.,O
Therefore,I-Entity
",",O
the,O
BNPP,I-Entity
-,O
induced,O
reduction,O
in,O
APAP,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
appears,O
to,O
be,O
due,O
to,O
inhibition,O
of,O
APAP,I-Entity
deacetylation,I-Entity
.,O
It,I-Entity
is,O
concluded,O
that,O
PAP,I-Entity
formation,O
",",O
in,O
vivo,O
",",O
accounts,O
",",O
at,O
least,O
in,O
part,O
",",O
for,O
APAP,I-Entity
-,O
induced,O
renal,O
tubular,O
necrosis,I-Entity
.,O
Morphine,I-Entity
-,O
induced,O
seizures,I-Entity
in,O
newborn,O
infants,O
.,O
Two,I-Entity
neonates,O
suffered,O
from,O
generalized,O
seizures,I-Entity
during,O
the,O
course,O
of,O
intravenous,O
morphine,I-Entity
sulfate,O
for,O
post,O
-,O
operative,O
analgesia,O
.,O
They,I-Entity
received,O
morphine,I-Entity
in,O
doses,O
of,O
32,O
micrograms,O
/,O
kg,O
/,O
hr,O
and,O
40,O
micrograms,O
/,O
kg,O
/,O
hr,O
larger,O
than,O
a,O
group,O
of,O
10,O
neonates,O
who,O
received,O
6,O
-,O
24,O
micrograms,O
/,O
kg,O
/,O
hr,O
and,O
had,O
no,O
seizures,I-Entity
.,O
Plasma,I-Entity
concentrations,O
of,O
morphine,I-Entity
in,O
these,O
neonates,O
was,O
excessive,O
(,O
60,O
and,O
90,I-Entity
mg,O
/,O
ml,O
),O
.,O
Other,I-Entity
known,O
reasons,O
for,O
seizures,I-Entity
were,O
ruled,O
out,O
and,O
the,O
convulsions,I-Entity
stopped,O
a,O
few,O
hours,O
after,O
cessation,O
of,O
morphine,I-Entity
and,O
did,O
not,O
reoccur,O
in,O
the,O
subsequent,O
8,O
months,O
.,O
It,I-Entity
is,O
suggested,O
that,O
post,O
-,O
operative,O
intravenous,O
morphine,I-Entity
should,O
not,O
exceed,O
20,O
micrograms,O
/,O
kg,O
/,O
ml,O
in,O
neonates,O
.,O
Effect,I-Entity
of,O
vincristine,I-Entity
sulfate,O
on,O
Pseudomonas,I-Entity
infections,I-Entity
in,O
monkeys,O
.,O
Leukocytosis,I-Entity
was,O
observed,O
in,O
all,O
monkeys,O
.,O
Intravenous,I-Entity
or,O
intratracheal,O
inoculation,O
of,O
2.0,O
to,O
2.5,O
mg,O
of,O
vincristine,I-Entity
sulfate,O
was,O
followed,O
by,O
leukopenia,I-Entity
in,O
4,O
to,O
5,O
days,O
.,O
Pseudomonas,I-Entity
organisms,O
in,O
monkeys,O
given,O
vincristine,I-Entity
sulfate,O
4,O
days,O
previously,O
resulted,O
in,O
fatal,O
infection,I-Entity
in,O
11,O
of,O
14,O
monkeys,O
",",O
whereas,O
none,O
of,O
four,O
receiving,O
Pseudomonas,I-Entity
alone,O
died,O
.,O
These,I-Entity
studies,O
suggest,O
that,O
an,O
antimetabolite,O
-,O
induced,O
leukopenia,I-Entity
predisposes,O
to,O
severe,O
Pseudomonas,I-Entity
sepsis,I-Entity
and,O
that,O
such,O
monkeys,O
may,O
serve,O
as,O
a,O
biological,O
model,O
for,O
study,O
of,O
comparative,O
efficacy,O
of,O
antimicrobial,O
agents,O
.,O
Central,I-Entity
excitatory,O
actions,O
of,O
flurazepam,I-Entity
.,O
Toxic,I-Entity
actions,O
of,O
flurazepam,I-Entity
(,O
FZP,I-Entity
),O
were,O
studied,O
in,O
cats,O
",",O
mice,O
and,O
rats,O
.,O
High,I-Entity
doses,O
caused,O
an,O
apparent,O
central,O
excitation,O
",",O
most,O
clearly,O
seen,O
as,O
clonic,I-Entity
convulsions,I-Entity
",",O
superimposed,O
on,O
general,O
depression,I-Entity
.,O
Following,I-Entity
a,O
lethal,O
dose,O
",",O
death,I-Entity
was,O
always,O
associated,O
with,O
convulsions,I-Entity
.,O
Comparing,I-Entity
the,O
relative,O
sensitivity,O
to,O
central,O
depression,I-Entity
and,O
excitation,O
revealed,O
that,O
rats,O
were,O
least,O
likely,O
to,O
have,O
convulsions,I-Entity
at,O
doses,O
that,O
did,O
not,O
first,O
cause,O
loss,I-Entity
of,O
consciousness,O
",",O
while,O
cats,O
most,O
clearly,O
showed,O
marked,O
central,O
excitatory,O
actions,O
.,O
Signs,I-Entity
of,O
FZP,I-Entity
toxocity,I-Entity
in,O
cats,O
included,O
excessive,O
salivation,O
",",O
extreme,O
apprehensive,I-Entity
behavior,O
",",O
retching,I-Entity
",",O
muscle,O
tremors,I-Entity
and,O
convulsions,I-Entity
.,O
An,I-Entity
interaction,O
between,O
FZP,I-Entity
and,O
pentylenetetrazol,I-Entity
(,O
PTZ,I-Entity
),O
was,O
shown,O
by,O
pretreating,O
mice,O
with,O
FZP,I-Entity
before,O
PTZ,I-Entity
challenge,O
.,O
As,I-Entity
a,O
function,O
of,O
dose,O
",",O
FZP,I-Entity
first,O
protected,O
against,O
convulsions,I-Entity
and,O
death,I-Entity
.,O
At,I-Entity
higher,O
doses,O
",",O
however,O
",",O
convulsions,I-Entity
again,O
emerged,O
.,O
These,I-Entity
doses,O
of,O
FZP,I-Entity
were,O
lower,O
than,O
those,O
that,O
would,O
alone,O
cause,O
convulsions,I-Entity
.,O
These,I-Entity
results,O
may,O
be,O
relevant,O
to,O
the,O
use,O
of,O
FZP,I-Entity
in,O
clinical,O
situations,O
in,O
which,O
there,O
is,O
increased,O
neural,O
excitability,I-Entity
",",O
such,O
as,O
epilepsy,I-Entity
or,O
sedative,O
-,O
hypnotic,O
drug,O
withdrawal,O
.,O
We,I-Entity
compared,O
the,O
effects,O
of,O
single,O
doses,O
of,O
50,O
mg,O
atenolol,I-Entity
(,O
cardioselective,I-Entity
),O
",",O
40,O
mg,O
propranolol,I-Entity
(,O
nonselective,O
),O
",",O
and,O
placebo,O
on,O
both,O
exercise-,O
and,O
isoproterenol,I-Entity
-,O
induced,O
tachycardia,I-Entity
in,O
two,O
experiments,O
involving,O
nine,O
normal,O
subjects,O
.,O
7,O
bpm,I-Entity
after,O
atenolol,I-Entity
and,O
138,I-Entity
+,O
/-,O
6,O
bpm,I-Entity
after,O
propranolol,I-Entity
",",O
The,I-Entity
effects,O
on,O
isoproterenol,I-Entity
tachycardia,I-Entity
were,O
determined,O
before,O
and,O
after,O
atropine,I-Entity
(,O
0.04,O
mg,O
/,O
kg,O
IV,I-Entity
),O
.,O
Isoproterenol,I-Entity
sensitivity,O
was,O
determined,O
as,O
the,O
intravenous,O
dose,O
that,O
increased,O
heart,O
rate,O
by,O
25,O
bpm,I-Entity
(,O
CD25,I-Entity
),O
and,O
this,O
was,O
increased,O
from,O
1.8,O
+,O
/-,O
8.3,O
micrograms,O
after,O
propranolol,I-Entity
and,O
8.3,O
+,O
/-,O
1.7,O
micrograms,O
after,O
atenolol,I-Entity
.,O
After,I-Entity
atropine,I-Entity
the,O
CD25,I-Entity
was,O
unchanged,O
after,O
placebo,O
(,O
2.3,O
+,O
/-,O
0.3,O
micrograms,O
),O
and,O
atenolol,I-Entity
(,O
7.7,O
+,O
/-,O
1.3,O
micrograms,O
),O
;,O
it,O
was,O
reduced,O
after,O
propranolol,I-Entity
(,O
24.8,O
+,O
/-,O
5.0,O
micrograms,O
),O
",",O
but,O
remained,O
different,O
from,O
atenolol,I-Entity
.,O
This,I-Entity
change,O
with,O
propranolol,I-Entity
sensitivity,O
was,O
calculated,O
as,O
the,O
apparent,O
Ka,I-Entity
",",O
this,O
was,O
unchanged,O
by,O
atropine,I-Entity
(,O
11.7,O
+,O
/-,O
These,I-Entity
data,O
are,O
consistent,O
with,O
the,O
hypothesis,O
that,O
exercise,O
-,O
induced,O
tachycardia,I-Entity
results,O
largely,O
from,O
beta,O
1-receptor,O
activation,O
that,O
is,O
blocked,O
by,O
both,O
cardioselective,I-Entity
and,O
nonselective,O
drugs,O
",",O
whereas,O
isoproterenol,I-Entity
activates,O
both,O
beta,O
1-,I-Entity
and,O
beta,O
2-receptors,I-Entity
so,O
that,O
after,O
cardioselective,I-Entity
blockade,O
there,O
remains,O
a,O
beta,O
2-component,O
that,O
can,O
be,O
blocked,O
with,O
a,O
nonselective,O
drug,O
.,O
Hormones,I-Entity
and,O
risk,O
of,O
breast,O
cancer,I-Entity
.,O
It,I-Entity
was,O
hypothesized,O
that,O
progestins,I-Entity
could,O
equilibrate,O
the,O
effects,O
of,O
the,O
estrogenic,I-Entity
stimulation,O
on,O
the,O
mammary,O
and,O
endometrial,O
target,O
tissues,O
of,O
women,O
on,O
hormonal,O
replacement,O
therapy,O
.,O
The,I-Entity
treatment,O
schedule,O
consisted,O
of,O
conjugated,O
estrogens,I-Entity
(,O
Premarin,I-Entity
),O
1.25,O
mg,O
/,O
day,O
for,O
21,O
days,O
and,O
Medroxyprogesterone,I-Entity
acetate,I-Entity
10,O
mg,O
/,O
day,O
for,O
10,O
days,O
in,O
each,O
month,O
.,O
Mastodynia,I-Entity
was,O
reported,O
by,O
21,O
patients,O
",",O
and,O
physical,O
examination,O
revealed,O
a,O
light,O
increase,O
in,O
breast,O
firmness,I-Entity
in,O
12,O
women,O
and,O
a,O
moderate,O
increase,O
in,O
breast,O
nodularity,O
in,O
2,O
women,O
.,O
Themography,I-Entity
confirmed,O
the,O
existence,O
of,O
an,O
excessive,O
breast,O
stimulation,O
in,O
1,O
women,O
who,O
complained,O
of,O
moderate,O
mastodynia,I-Entity
and,O
in,O
5,O
of,O
the,O
7,O
women,O
who,O
complained,O
of,O
severe,O
mastodynia,I-Entity
.,O
Normalization,I-Entity
was,O
obtained,O
by,O
halving,O
the,O
estrogen,I-Entity
dose,O
.,O
Early,I-Entity
infections,I-Entity
in,O
kidney,O
",",O
heart,O
",",O
and,O
liver,I-Entity
transplant,O
recipients,O
on,O
cyclosporine,I-Entity
.,O
Eighty,I-Entity
-,O
one,O
renal,O
",",O
seventeen,O
heart,O
",",O
and,O
twenty,O
-,O
four,O
liver,I-Entity
transplant,O
patients,O
were,O
followed,O
for,O
infection,I-Entity
.,O
Seventeen,I-Entity
renal,O
patients,O
received,O
azathioprine,I-Entity
(,O
Aza,I-Entity
),O
and,O
prednisone,I-Entity
as,O
part,O
of,O
a,O
randomized,O
trial,O
of,O
immunosuppression,O
with,O
21,O
cyclosporine,I-Entity
-,O
and,O
-,O
prednisone,I-Entity
-,O
treated,O
renal,O
transplant,O
patients,O
.,O
All,I-Entity
others,O
received,O
cyclosporine,I-Entity
and,O
prednisone,I-Entity
.,O
The,I-Entity
randomized,O
Aza,I-Entity
patients,O
had,O
more,O
overall,O
infections,I-Entity
(,O
P,I-Entity
less,O
than,O
0.05,O
),O
and,O
more,O
nonviral,O
infections,I-Entity
(,O
P,I-Entity
less,O
than,O
0.02,O
),O
than,O
the,O
randomized,O
cyclosporine,I-Entity
patients,O
.,O
Heart,I-Entity
and,O
liver,I-Entity
patients,O
had,O
more,O
infections,I-Entity
than,O
cyclosporine,I-Entity
renal,O
patients,O
but,O
fewer,O
infections,I-Entity
than,O
the,O
Aza,I-Entity
renal,O
patients,O
.,O
There,I-Entity
were,O
no,O
infectious,O
deaths,I-Entity
in,O
renal,O
transplant,O
patients,O
on,O
cyclosporine,I-Entity
or,O
Aza,I-Entity
",",O
but,O
infection,I-Entity
played,O
a,O
major,O
role,O
in,O
3,O
out,O
of,O
6,O
cardiac,O
transplant,O
deaths,I-Entity
and,O
in,O
8,O
out,O
of,O
9,O
liver,I-Entity
transplant,O
deaths,I-Entity
.,O
Renal,I-Entity
patients,O
on,O
cyclosporine,I-Entity
had,O
the,O
fewest,O
bacteremias,I-Entity
.,O
Analysis,I-Entity
of,O
site,O
of,O
infection,I-Entity
showed,O
a,O
preponderance,O
of,O
abdominal,O
infections,I-Entity
in,O
liver,I-Entity
patients,O
",",O
intrathoracic,O
infections,I-Entity
in,O
heart,O
patients,O
",",O
and,O
urinary,O
tract,O
infections,I-Entity
in,O
renal,O
patients,O
.,O
Pulmonary,I-Entity
infections,I-Entity
were,O
less,O
common,O
in,O
cyclosporine,I-Entity
-,O
treated,O
renal,O
patients,O
than,O
in,O
Aza,I-Entity
-,O
treated,O
patients,O
(,O
P,I-Entity
less,O
than,O
0.05,O
),O
.,O
Aza,I-Entity
patients,O
had,O
significantly,O
more,O
staphylococcal,O
infections,I-Entity
than,O
all,O
other,O
transplant,O
groups,O
(,O
P,I-Entity
less,O
than,O
0.005,O
),O
",",O
and,O
systemic,O
fungal,O
infections,I-Entity
occurred,O
only,O
in,O
the,O
liver,I-Entity
transplant,O
group,O
.,O
Cytomegalovirus,I-Entity
(,O
CMV,I-Entity
),O
shedding,O
or,O
serological,O
rises,O
in,O
antibody,O
titer,O
",",O
or,O
both,O
occurred,O
in,O
78%,O
of,O
cyclosporine,I-Entity
patients,O
and,O
76%,O
of,O
Aza,I-Entity
patients,O
.,O
Of,I-Entity
the,O
cyclosporine,I-Entity
patients,O
",",O
15%,O
had,O
symptoms,O
related,O
to,O
CMV,I-Entity
infection,I-Entity
.,O
Serological,I-Entity
evidence,O
for,O
Epstein,I-Entity
Barr,I-Entity
Virus,I-Entity
infection,I-Entity
was,O
found,O
in,O
20%,O
of,O
65,O
cyclosporine,I-Entity
patients,O
studied,O
.,O
Three,I-Entity
had,O
associated,O
symptoms,O
",",O
and,O
one,O
developed,O
a,O
lymphoma,I-Entity
.,O
Structure,I-Entity
-,O
activity,O
and,O
dose,O
-,O
effect,O
relationships,O
of,O
the,O
antagonism,I-Entity
of,O
picrotoxin,I-Entity
-,O
induced,O
seizures,I-Entity
by,O
cholecystokinin,I-Entity
",",O
fragments,O
and,O
analogues,O
of,O
cholecystokinin,I-Entity
in,O
mice,O
.,O
Intraperitoneal,I-Entity
administration,O
of,O
cholecystokinin,I-Entity
octapeptide,I-Entity
sulphate,I-Entity
ester,I-Entity
(,O
CCK-8-SE,I-Entity
),O
and,O
nonsulphated,I-Entity
cholecystokinin,I-Entity
octapeptide,I-Entity
(,O
CCK-8-NS,I-Entity
),O
enhanced,O
the,O
latency,O
of,O
seizures,I-Entity
induced,O
by,O
picrotoxin,I-Entity
in,O
mice,O
.,O
The,I-Entity
analogues,O
CCK-8-SE,I-Entity
and,O
CCK-8-NS,I-Entity
(,O
dose,O
range,O
0.2,O
-,O
6.4,O
mumol,I-Entity
/,O
kg,O
),O
and,O
caerulein,I-Entity
dose,O
range,O
0.1,O
-,O
0.8,O
mumol,I-Entity
/,O
kg,O
),O
showed,O
bell,O
-,O
shaped,O
dose,O
-,O
effect,O
curves,O
",",O
with,O
the,O
greatest,O
maximum,O
inhibition,O
for,O
CCK-8-NS,I-Entity
.,O
The,I-Entity
peptide,I-Entity
CCK-5,I-Entity
-,O
8,O
had,O
weak,O
anticonvulsant,O
activity,O
in,O
comparison,O
to,O
the,O
octapeptides,I-Entity
",",O
3.2,O
mumol,I-Entity
/,O
kg,O
and,O
larger,O
doses,O
of,O
the,O
reference,O
drug,O
",",O
diazepam,I-Entity
",",O
totally,O
prevented,O
picrotoxin,I-Entity
-,O
induced,O
seizures,I-Entity
and,O
mortality,O
.,O
The,I-Entity
maximum,O
effect,O
of,O
the,O
peptides,I-Entity
tested,O
was,O
less,O
than,O
that,O
of,O
diazepam,I-Entity
.,O
Experiments,I-Entity
with,O
analogues,O
and,O
derivatives,O
of,O
CCK-5,I-Entity
-,O
8,O
demonstrated,O
that,O
the,O
effectiveness,O
of,O
the,O
beta,O
-,O
alanyl,I-Entity
derivatives,O
of,O
CCK-5,I-Entity
-,O
8,O
were,O
enhanced,O
and,O
that,O
they,O
were,O
equipotent,O
with,O
CCK-8-SE,I-Entity
.,O
Of,I-Entity
the,O
CCK-2,I-Entity
-,O
8,O
analogues,O
",",O
Ser(SO3H)7-Ac,I-Entity
-,O
CCK-2,I-Entity
-,O
8-SE,I-Entity
and,O
Thr(SO3H)7-Ac,I-Entity
-,O
CCK-2,I-Entity
-,O
8-SE,I-Entity
and,O
Hyp(SO3H)-Ac,I-Entity
-,O
CCK-2,I-Entity
-,O
8-SE,I-Entity
were,O
slightly,O
more,O
active,O
than,O
CCK-8-SE,I-Entity
.,O
Vasopressin,I-Entity
as,O
a,O
possible,O
contributor,O
to,O
hypertension,I-Entity
.,O
The,I-Entity
role,O
of,O
vasopressin,I-Entity
as,O
a,O
pressor,O
agent,O
to,O
the,O
hypertensive,I-Entity
process,O
was,O
examined,O
.,O
Vasopressin,I-Entity
plays,O
a,O
major,O
role,O
in,O
the,O
pathogenesis,O
of,O
DOCA,I-Entity
-,O
salt,O
hypertension,I-Entity
",",O
since,O
the,O
elevation,O
of,O
blood,O
pressure,O
was,O
not,O
substantial,O
in,O
the,O
rats,O
with,O
lithium,I-Entity
-,O
treated,O
diabetes,I-Entity
insipidus,I-Entity
after,O
DOCA,I-Entity
-,O
salt,O
treatment,O
.,O
Administration,I-Entity
of,O
DDAVP,I-Entity
which,O
has,O
antidiuretic,I-Entity
action,O
but,O
minimal,O
vasopressor,I-Entity
effect,O
failed,O
to,O
increase,O
blood,O
pressure,O
to,O
the,O
levels,O
observed,O
after,O
administration,O
of,O
AVP,I-Entity
.,O
Furthermore,I-Entity
",",O
the,O
pressor,O
action,O
of,O
vasopressin,I-Entity
appears,O
to,O
be,O
important,O
in,O
the,O
development,O
of,O
this,O
model,O
of,O
hypertension,I-Entity
",",O
since,O
the,O
enhanced,O
pressor,O
responsiveness,O
to,O
the,O
hormone,I-Entity
was,O
observed,O
in,O
the,O
initial,O
stage,O
of,O
hypertension,I-Entity
.,O
Increased,I-Entity
secretion,O
of,O
vasopressin,I-Entity
from,O
neurohypophysis,I-Entity
also,O
promotes,O
the,O
function,O
of,O
the,O
hormone,I-Entity
as,O
a,O
pathogenetic,O
factor,O
in,O
hypertension,I-Entity
.,O
An,I-Entity
unproportional,O
release,O
of,O
vasopressin,I-Entity
compared,O
to,O
plasma,O
osmolality,O
may,O
be,O
induced,O
by,O
the,O
absence,O
of,O
an,O
adjusting,O
control,O
of,O
angiotensin,I-Entity
II,I-Entity
forming,O
and,O
receptor,O
binding,O
capacity,O
for,O
sodium,I-Entity
balance,O
in,O
the,O
brain,O
.,O
However,I-Entity
",",O
the,O
role,O
of,O
vasopressin,I-Entity
remains,O
to,O
be,O
determined,O
in,O
human,O
essential,O
hypertension,I-Entity
.,O
Toxic,I-Entity
hepatitis,I-Entity
induced,O
by,O
disulfiram,I-Entity
in,O
a,O
non,O
-,O
alcoholic,I-Entity
.,O
A,I-Entity
reversible,O
toxic,I-Entity
liver,I-Entity
damage,O
was,O
observed,O
in,O
a,O
non,O
-,O
alcoholic,I-Entity
woman,O
treated,O
with,O
disulfiram,I-Entity
.,O
Atrial,I-Entity
thrombosis,I-Entity
involving,O
the,O
heart,O
of,O
F-344,I-Entity
rats,O
ingesting,O
quinacrine,I-Entity
hydrochloride,I-Entity
.,O
Quinacrine,I-Entity
hydrochloride,I-Entity
is,O
toxic,I-Entity
for,O
the,O
heart,O
of,O
F-344,I-Entity
rats,O
.,O
Rats,I-Entity
treated,O
with,O
500,O
ppm,O
quinacrine,I-Entity
hydrochloride,I-Entity
in,O
the,O
diet,O
all,O
developed,O
a,O
high,O
incidence,O
of,O
left,O
atrial,I-Entity
thrombosis,I-Entity
.,O
The,I-Entity
lesion,I-Entity
was,O
associated,O
with,O
cardiac,O
hypertrophy,I-Entity
and,O
dilatation,O
and,O
focal,O
myocardial,B-Entity
degeneration,I-Entity
.,O
Rats,I-Entity
died,O
from,O
cardiac,O
hypertrophy,I-Entity
with,O
severe,O
acute,O
and,O
chronic,O
congestion,I-Entity
of,O
the,O
lungs,O
",",O
liver,I-Entity
",",O
and,O
other,O
organs,O
.,O
Seventy,I-Entity
percent,O
of,O
rats,O
given,O
250,O
ppm,O
quinacrine,I-Entity
hydrochloride,I-Entity
and,O
"1,000",I-Entity
ppm,O
sodium,I-Entity
nitrite,I-Entity
simultaneously,O
in,O
the,O
diet,O
had,O
thrombosis,I-Entity
of,O
the,O
atria,O
of,O
the,O
heart,O
",",O
while,O
untreated,O
control,O
rats,O
in,O
this,O
laboratory,O
did,O
not,O
have,O
atrial,I-Entity
thrombosis,I-Entity
.,O
Sodium,I-Entity
nitrite,I-Entity
in,O
combination,O
with,O
quinacrine,I-Entity
hydrochloride,I-Entity
appeared,O
to,O
have,O
no,O
additional,O
effect,O
.,O
Alternating,I-Entity
sinus,O
rhythm,O
and,O
intermittent,O
sinoatrial,O
block,O
induced,O
by,O
propranolol,I-Entity
.,O
Alternating,I-Entity
sinus,O
rhythm,O
and,O
intermittent,O
sinoatrial,O
(,O
S,I-Entity
-,O
A,I-Entity
),O
block,O
was,O
observed,O
in,O
a,O
57-year,O
-,O
old,O
woman,O
",",O
under,O
treatment,O
for,O
angina,I-Entity
with,O
80,O
mg,O
propranolol,I-Entity
daily,O
.,O
Following,I-Entity
these,O
basic,O
sinus,O
cycles,O
",",O
alternating,O
rhythm,O
started,O
with,O
the,O
longer,O
P,I-Entity
-,O
P,I-Entity
interval,O
.,O
In,I-Entity
one,O
recording,O
a,O
short,I-Entity
period,O
of,O
regular,O
sinus,O
rhythm,O
with,O
intermittent,O
2/1,O
S,I-Entity
-,O
A,I-Entity
block,O
was,O
observed,O
.,O
Atropine,I-Entity
1,O
mg,O
given,O
intravenously,O
resulted,O
in,O
shortening,O
of,O
all,O
P,I-Entity
-,O
P,I-Entity
intervals,O
without,O
changing,O
the,O
rhythm,O
.,O
The,I-Entity
abnormal,I-Entity
rhythm,O
disappeared,O
with,O
the,O
withdrawal,O
of,O
propranolol,I-Entity
and,O
when,O
the,O
drug,O
was,O
restarted,O
a,O
2/1,O
S,I-Entity
-,O
A,I-Entity
block,O
was,O
seen,O
.,O
This,I-Entity
was,O
accepted,O
as,O
evidence,O
for,O
propranolol,I-Entity
being,O
the,O
cause,O
of,O
this,O
conduction,O
disorder,I-Entity
.,O
Antitumor,I-Entity
effect,O
",",O
cardiotoxicity,I-Entity
",",O
and,O
nephrotoxicity,I-Entity
of,O
doxorubicin,I-Entity
in,O
the,O
IgM,I-Entity
solid,O
immunocytoma,I-Entity
-,O
bearing,O
LOU,I-Entity
/,O
M,I-Entity
/,O
WSL,I-Entity
rat,O
.,O
Antitumor,I-Entity
activity,O
",",O
cardiotoxicity,I-Entity
",",O
and,O
nephrotoxicity,I-Entity
induced,O
by,O
doxorubicin,I-Entity
were,O
studied,O
in,O
LOU,I-Entity
/,O
M,I-Entity
/,O
WSL,I-Entity
inbred,O
rats,O
each,O
bearing,O
a,O
transplantable,O
solid,O
IgM,I-Entity
immunocytoma,I-Entity
.,O
Animals,I-Entity
with,O
a,O
tumor,I-Entity
(,O
diameter,O
",",O
15.8,O
+,O
/-,O
3.3,O
mm,O
),O
were,O
treated,O
with,O
iv,O
injections,O
of,O
doxorubicin,I-Entity
on,O
5,O
consecutive,O
days,O
",",O
followed,O
by,O
1,O
weekly,O
injection,O
for,O
7,O
weeks,O
(,O
dose,O
range,O
",",O
0.015,O
-,O
4.0,O
Tumor,I-Entity
regression,O
was,O
observed,O
with,O
0.5,O
mg,O
doxorubicin,I-Entity
/,O
kg,O
.,O
Complete,I-Entity
disappearance,I-Entity
of,O
the,O
tumor,I-Entity
was,O
induced,O
with,O
1.0,O
mg,O
doxorubicin,I-Entity
/,O
kg,O
.,O
Histologic,I-Entity
evidence,O
of,O
cardiotoxicity,I-Entity
scored,O
as,O
grade,O
III,I-Entity
was,O
only,O
observed,O
at,O
a,O
dose,O
of,O
1.0,O
mg,O
doxorubicin,I-Entity
/,O
kg,O
.,O
Light,I-Entity
microscopic,O
evidence,O
of,O
renal,O
damage,O
was,O
seen,O
above,O
a,O
dose,O
of,O
0.5,O
mg,O
doxorubicin,I-Entity
/,O
kg,O
",",O
which,O
resulted,O
in,O
albuminuria,I-Entity
and,O
very,O
low,O
serum,O
albumin,O
levels,O
.,O
In,I-Entity
the,O
group,O
that,O
received,O
1.0,O
mg,O
doxorubicin,I-Entity
/,O
kg,O
",",O
the,O
serum,O
albumin,O
level,O
decreased,O
from,O
33.6,O
+,O
/-,O
Ascites,I-Entity
and,O
hydrothorax,O
were,O
observed,O
simultaneously,O
.,O
The,I-Entity
same,O
experiments,O
were,O
performed,O
with,O
non,O
-,O
tumor,I-Entity
-,O
bearing,O
rats,O
",",O
in,O
which,O
no,O
major,O
differences,O
were,O
observed,O
.,O
In,I-Entity
conclusion,O
",",O
antitumor,O
activity,O
",",O
cardiotoxicity,I-Entity
",",O
and,O
nephrotoxicity,I-Entity
were,O
studied,O
simultaneously,O
in,O
the,O
same,O
LOU,I-Entity
/,O
M,I-Entity
/,O
WSL,I-Entity
rat,O
.,O
Albuminuria,I-Entity
due,O
to,O
renal,O
damage,O
led,O
to,O
extremely,O
low,O
serum,O
albumin,O
levels,O
",",O
so,O
ascites,I-Entity
and,O
hydrothorax,O
were,O
not,O
necessarily,O
a,O
consequence,O
of,O
the,O
observed,O
cardiomyopathy,I-Entity
.,O
Intraoperative,I-Entity
bradycardia,I-Entity
and,O
hypotension,I-Entity
associated,O
with,O
timolol,I-Entity
and,O
pilocarpine,I-Entity
eye,O
drops,O
.,O
A,I-Entity
69-yr,I-Entity
-,O
old,O
man,O
",",O
who,O
was,O
concurrently,O
being,O
treated,O
with,O
pilocarpine,I-Entity
nitrate,I-Entity
and,O
timolol,I-Entity
maleate,I-Entity
eye,O
drops,O
",",O
developed,O
a,O
bradycardia,I-Entity
and,O
became,O
hypotensive,I-Entity
during,O
halothane,I-Entity
anaesthesia,O
.,O
Both,I-Entity
timolol,I-Entity
and,O
pilocarpine,I-Entity
were,O
subsequently,O
identified,O
in,O
a,O
24-h,O
collection,O
of,O
urine,I-Entity
.,O
Timolol,I-Entity
(,O
but,O
not,O
pilocarpine,I-Entity
),O
was,O
detected,O
in,O
a,O
sample,O
of,O
plasma,O
removed,O
during,O
surgery,O
;,O
the,O
plasma,O
concentration,O
of,O
timolol,I-Entity
(,O
2.6,O
ng,O
ml-1,O
),O
was,O
consistent,O
with,O
partial,O
beta,O
-,O
adrenoceptor,O
blockade,O
.,O
It,I-Entity
is,O
postulated,O
that,O
this,O
action,O
may,O
have,O
been,O
enhanced,O
during,O
halothane,I-Entity
anaesthesia,O
with,O
resultant,O
bradycardia,I-Entity
and,O
hypotension,I-Entity
.,O
Pilocarpine,I-Entity
may,O
have,O
had,O
a,O
contributory,O
effect,O
.,O
Succinylcholine,I-Entity
apnoea,I-Entity
:,O
attempted,O
reversal,O
with,O
anticholinesterases,O
.,O
Anticholinesterases,I-Entity
were,O
administered,O
in,O
an,O
attempt,O
to,O
antagonize,O
prolonged,O
neuromuscular,O
blockade,O
following,O
the,O
administration,O
of,O
succinylcholine,I-Entity
in,O
a,O
patient,O
later,O
found,O
to,O
be,O
homozygous,O
for,O
atypical,O
plasma,O
cholinesterase,O
.,O
Edrophonium,I-Entity
10,O
mg,O
",",O
given,O
74,I-Entity
min,O
after,O
succinylcholine,I-Entity
",",O
when,O
train,O
-,O
of,O
-,O
four,O
stimulation,O
was,O
characteristic,O
of,O
phase,O
II,I-Entity
block,O
",",O
produced,O
partial,O
antagonism,I-Entity
which,O
was,O
not,O
sustained,O
.,O
Repeated,I-Entity
doses,O
of,O
edrophonium,I-Entity
to,O
70,I-Entity
mg,O
and,O
neostigmine,I-Entity
to,O
2.5,O
mg,O
did,O
not,O
antagonize,O
or,O
augment,O
the,O
block,O
.,O
Spontaneous,I-Entity
respiration,I-Entity
recommenced,O
200,O
min,O
after,O
succinylcholine,I-Entity
administration,O
.,O
It,I-Entity
is,O
concluded,O
that,O
anticholinesterases,O
are,O
only,O
partially,O
effective,O
in,O
restoring,O
neuromuscular,O
function,O
in,O
succinylcholine,I-Entity
apnoea,I-Entity
despite,O
muscle,O
twitch,I-Entity
activity,O
typical,O
of,O
phase,O
II,I-Entity
block,O
.,O
Effect,I-Entity
of,O
doxorubicin,I-Entity
on,O
[,O
omega,I-Entity
-,O
I-131]heptadecanoic,I-Entity
acid,O
myocardial,B-Entity
scintigraphy,I-Entity
and,O
echocardiography,O
in,O
dogs,O
.,O
The,I-Entity
effects,O
of,O
serial,O
treatment,O
with,O
doxorubicin,I-Entity
on,O
dynamic,O
myocardial,B-Entity
scintigraphy,I-Entity
with,O
[,O
omega,I-Entity
-,O
I-131]heptadecanoic,I-Entity
acid,O
(,O
I-131,I-Entity
HA,I-Entity
),O
",",O
and,O
on,O
global,O
left,O
-,O
ventricular,O
function,O
determined,O
echocardiographically,O
",",O
were,O
studied,O
in,O
a,O
group,O
of,O
nine,O
mongrel,I-Entity
dogs,O
.,O
Total,I-Entity
extractable,O
myocardial,B-Entity
lipid,O
was,O
compared,O
postmortem,O
between,O
a,O
group,O
of,O
control,O
dogs,O
and,O
doxorubicin,I-Entity
-,O
treated,O
dogs,O
.,O
A,I-Entity
significant,O
and,O
then,O
progressive,O
fall,O
in,O
global,O
LV,I-Entity
function,O
was,O
observed,O
at,O
a,O
cumulative,O
doxorubicin,I-Entity
dose,O
of,O
4,O
mg,O
/,O
kg,O
.,O
A,I-Entity
significant,O
increase,O
in,O
the,O
myocardial,B-Entity
t1/2,O
of,O
the,O
I-131,I-Entity
HA,I-Entity
was,O
observed,O
only,O
at,O
a,O
higher,O
cumulative,O
dose,O
",",O
10,O
mg,O
/,O
kg,O
.,O
No,I-Entity
significant,O
alteration,I-Entity
in,O
total,O
extractable,O
myocardial,B-Entity
lipids,O
was,O
observed,O
between,O
control,O
dogs,O
and,O
those,O
treated,O
with,O
doxorubicin,I-Entity
.,O
Our,I-Entity
findings,O
suggest,O
that,O
the,O
changes,O
leading,O
to,O
an,O
alteration,I-Entity
of,O
myocardial,B-Entity
dynamic,O
imaging,O
with,O
I-131,I-Entity
HA,I-Entity
are,O
not,O
the,O
initiating,O
factor,O
in,O
doxorubicin,I-Entity
cardiotoxicity,I-Entity
.,O
Hemodynamics,I-Entity
and,O
myocardial,B-Entity
metabolism,O
under,O
deliberate,O
hypotension,I-Entity
.,O
Coronary,I-Entity
blood,O
flow,O
",",O
cardiac,O
work,O
and,O
metabolism,O
were,O
studied,O
in,O
dogs,O
under,O
sodium,I-Entity
nitroprusside,I-Entity
(,O
SNP,I-Entity
),O
and,O
trimetaphan,I-Entity
(,O
TMP,I-Entity
),O
deliberate,O
hypotension,I-Entity
(,O
20%,O
and,O
Regarding,I-Entity
the,O
effects,O
of,O
drug,O
-,O
induced,O
hypotension,I-Entity
on,O
coronary,O
blood,O
flow,O
",",O
aortic,O
and,O
coronary,O
sinus,O
metabolic,O
data,O
(,O
pH,I-Entity
",",O
pO2,I-Entity
",",O
pCO2,I-Entity
),O
we,O
could,O
confirm,O
that,O
nitroprusside,I-Entity
hypotension,I-Entity
could,O
be,O
safely,O
used,O
to,O
30%,O
mean,O
blood,O
pressure,O
decrease,O
from,O
control,O
",",O
trimetaphan,I-Entity
hypotension,I-Entity
to,O
20%,O
mean,O
blood,O
pressure,O
decrease,O
.,O
Cardiac,I-Entity
work,O
was,O
significantly,O
reduced,O
during,O
SNP,I-Entity
hypotension,I-Entity
.,O
Myocardial,I-Entity
O2,I-Entity
consumption,O
and,O
O2,I-Entity
availability,O
were,O
directly,O
dependent,O
on,O
the,O
coronary,O
perfusion,O
.,O
Evidence,I-Entity
for,O
a,O
selective,O
brain,O
noradrenergic,I-Entity
involvement,O
in,O
the,O
locomotor,O
stimulant,O
effects,O
of,O
amphetamine,I-Entity
in,O
the,O
rat,O
.,O
Male,I-Entity
rats,O
received,O
the,O
noradrenaline,I-Entity
neurotoxin,I-Entity
DSP4,I-Entity
(,O
50,O
mg,O
/,O
kg,O
),O
7,O
days,O
prior,O
to,O
injection,O
of,O
D,I-Entity
-,O
amphetamine,I-Entity
(,O
10,O
or,O
40,O
mumol,I-Entity
/,O
kg,O
i.p,O
.,O
),O
.,O
The,I-Entity
hyperactivity,I-Entity
induced,O
by,O
D,I-Entity
-,O
amphetamine,I-Entity
(,O
10,O
mumol,I-Entity
/,O
kg,O
),O
was,O
significantly,O
reduced,O
by,O
DSP4,I-Entity
pretreatment,O
.,O
However,I-Entity
",",O
the,O
increased,O
rearings,O
and,O
the,O
amphetamine,I-Entity
-,O
induced,O
stereotypies,O
were,O
not,O
blocked,O
by,O
pretreatment,O
with,O
DSP4,I-Entity
.,O
The,I-Entity
reduction,O
of,O
amphetamine,I-Entity
hyperactivity,I-Entity
induced,O
by,O
DSP4,I-Entity
was,O
blocked,O
by,O
pretreatment,O
with,O
the,O
noradrenaline,I-Entity
-,O
uptake,O
blocking,I-Entity
agent,O
",",O
desipramine,I-Entity
",",O
which,O
prevents,O
the,O
neurotoxic,I-Entity
action,O
of,O
DSP4,I-Entity
.,O
The,I-Entity
present,O
results,O
suggest,O
a,O
selective,O
involvement,O
of,O
central,O
noradrenergic,I-Entity
neurones,O
in,O
the,O
locomotor,O
stimulant,O
effect,O
of,O
amphetamine,I-Entity
in,O
the,O
rat,O
.,O
Accelerated,I-Entity
junctional,O
rhythms,O
during,O
oral,O
verapamil,I-Entity
therapy,O
.,O
This,I-Entity
study,O
examined,O
the,O
frequency,O
of,O
atrioventricular,B-Entity
(,O
AV,I-Entity
),O
dissociation,I-Entity
and,O
accelerated,O
junctional,O
rhythms,O
in,O
59,I-Entity
patients,O
receiving,O
oral,O
verapamil,I-Entity
.,O
Accelerated,I-Entity
junctional,O
rhythms,O
and,O
AV,I-Entity
dissociation,I-Entity
were,O
frequent,O
in,O
patients,O
with,O
supraventricular,O
tachyarrhythmias,I-Entity
",",O
particularly,O
AV,I-Entity
nodal,O
reentry,O
.,O
Verapamil,I-Entity
administration,O
to,O
these,O
patients,O
led,O
to,O
an,O
asymptomatic,O
increase,O
in,O
activity,O
of,O
these,O
junctional,O
pacemakers,O
.,O
In,I-Entity
patients,O
with,O
various,O
chest,O
pain,I-Entity
syndromes,I-Entity
",",O
verapamil,I-Entity
neither,O
increased,O
the,O
frequency,O
of,O
junctional,O
rhythms,O
nor,O
suppressed,O
their,O
role,O
as,O
escape,O
rhythms,O
under,O
physiologically,O
appropriate,O
circumstances,O
.,O
Treatment,I-Entity
of,O
ovarian,B-Entity
cancer,I-Entity
with,O
a,O
combination,O
of,O
cis,O
-,O
platinum,O
",",O
adriamycin,I-Entity
",",O
cyclophosphamide,I-Entity
and,O
hexamethylmelamine,I-Entity
.,O
During,I-Entity
the,O
last,O
2,O
1/2,O
years,O
",",O
38,O
patients,O
with,O
ovarian,B-Entity
cancer,I-Entity
were,O
treated,O
with,O
a,O
combination,O
of,O
cisplatinum,I-Entity
(,O
CPDD,I-Entity
),O
",",O
50,O
mg,O
/,O
m2,O
",",O
adriamycin,I-Entity
",",O
30,O
mg,O
/,O
m2,O
",",O
cyclophosphamide,I-Entity
",",O
300,O
mg,O
/,O
m2,O
",",O
on,O
day,O
1,O
;,O
and,O
hexamethylmelamine,I-Entity
(,O
HMM,I-Entity
),O
",",O
6,O
mg,O
/,O
kg,O
daily,O
",",O
for,O
14,O
days,O
.,O
14,O
of,O
the,O
38,O
patients,O
were,O
previously,O
treated,O
with,O
chemotherapy,O
",",O
1,O
with,O
radiation,O
",",O
6,O
with,O
both,O
chemotherapy,O
and,O
radiation,O
",",O
and,O
17,O
did,O
not,O
have,O
any,O
treatment,O
before,O
CPDD,I-Entity
combination,O
.,O
Hematologic,I-Entity
toxicity,I-Entity
was,O
moderate,O
and,O
with,O
reversible,O
anemia,I-Entity
developing,O
in,O
71%,O
of,O
patients,O
.,O
Gastrointestinal,I-Entity
side,O
effects,O
from,O
CPDD,I-Entity
were,O
universal,O
.,O
HMM,I-Entity
gastrointestinal,B-Entity
toxicity,I-Entity
necessitated,O
discontinuation,O
of,O
the,O
drug,O
in,O
5,O
patients,O
.,O
Severe,I-Entity
nephrotoxicity,I-Entity
was,O
observed,O
in,O
2,O
patients,O
but,O
was,O
reversible,O
.,O
Nontraumatic,I-Entity
dissecting,O
aneurysm,I-Entity
of,O
the,O
basilar,I-Entity
artery,I-Entity
.,O
A,I-Entity
case,O
of,O
nontraumatic,O
dissecting,O
aneurysm,I-Entity
of,O
the,O
basilar,I-Entity
artery,I-Entity
in,O
association,O
with,O
hypertension,I-Entity
",",O
smoke,I-Entity
",",O
and,O
oral,O
contraceptives,I-Entity
is,O
reported,O
in,O
a,O
young,O
female,O
patient,O
with,O
a,O
locked,O
-,O
in,O
syndrome,I-Entity
.,O
Propylthiouracil,I-Entity
-,O
induced,O
hepatic,B-Entity
damage,O
.,O
Two,I-Entity
cases,O
of,O
propylthiouracil,I-Entity
-,O
induced,O
liver,I-Entity
damage,O
have,O
been,O
observed,O
.,O
The,I-Entity
first,O
case,O
is,O
of,O
an,O
acute,O
type,O
of,O
damage,O
",",O
proven,O
by,O
rechallenge,O
;,O
the,O
second,O
presents,O
a,O
clinical,O
and,O
histologic,O
picture,O
resembling,O
chronic,O
active,O
hepatitis,I-Entity
",",O
with,O
spontaneous,O
remission,O
.,O
Studies,I-Entity
on,O
the,O
bradycardia,I-Entity
induced,O
by,O
bepridil,I-Entity
.,O
Bepridil,I-Entity
",",O
a,O
novel,O
active,O
compound,O
for,O
prophylactic,O
treatment,O
of,O
anginal,I-Entity
attacks,O
",",O
induced,O
persistent,O
bradycardia,I-Entity
and,O
a,O
non,O
-,O
specific,O
anti,O
-,O
tachycardial,I-Entity
effect,O
",",O
the,O
mechanisms,O
of,O
which,O
were,O
investigated,O
in,O
vitro,O
and,O
in,O
vivo,O
.,O
In,I-Entity
vitro,O
perfusion,O
of,O
bepridil,I-Entity
in,O
the,O
life,O
-,O
support,O
medium,O
for,O
isolated,O
sino,O
-,O
atrial,I-Entity
tissue,O
from,O
rabbit,I-Entity
heart,O
",",O
caused,O
a,O
reduction,O
in,O
action,O
potential,O
(,O
AP,I-Entity
),O
spike,O
frequency,O
(,O
recorded,O
by,O
KCl,I-Entity
microelectrodes,O
),O
starting,O
at,O
doses,O
of,O
5,O
X,I-Entity
10(-6,O
),O
M.,I-Entity
Bepridil,I-Entity
at,O
a,O
dose,O
of,O
5,O
X,I-Entity
10(-6,O
),O
In,I-Entity
vivo,O
injection,O
of,O
bepridil,I-Entity
at,O
a,O
dose,O
of,O
5,O
mg,O
/,O
kg,O
(,O
i.v,O
.,O
),O
It,I-Entity
is,O
concluded,O
that,O
bepridil,I-Entity
reduces,O
heart,O
rate,O
by,O
acting,O
directly,O
on,O
the,O
sinus,O
node,O
.,O
This,I-Entity
effect,O
",",O
which,O
results,O
in,O
a,O
flattening,O
of,O
the,O
phase,O
0,O
and,O
phase,O
4,O
slope,O
",",O
together,O
with,O
a,O
longer,O
AP,I-Entity
duration,O
",",O
may,O
be,O
due,O
to,O
an,O
increase,O
in,O
the,O
time,O
constants,O
of,O
slow,O
inward,O
ionic,O
currents,O
(,O
already,O
demonstrated,O
elsewhere,O
),O
",",O
but,O
also,O
to,O
an,O
increased,O
time,O
constant,O
for,O
deactivation,O
of,O
the,O
outward,O
potassium,I-Entity
current,O
(,O
Ip,I-Entity
),O
.,O
Hepatitis,I-Entity
and,O
renal,O
tubular,O
acidosis,I-Entity
after,O
anesthesia,O
with,O
methoxyflurane,I-Entity
.,O
A,I-Entity
69-year,O
-,O
old,O
man,O
operated,O
for,O
acute,O
cholecystitis,I-Entity
under,O
methoxyflurane,I-Entity
anesthesia,O
developed,O
postoperatively,O
a,O
hepatic,B-Entity
insufficiency,I-Entity
syndrome,I-Entity
and,O
renal,O
tubular,O
acidosis,I-Entity
.,O
Massive,I-Entity
bleeding,I-Entity
appeared,O
during,O
surgery,O
which,O
lasted,O
for,O
six,O
hours,O
.,O
Pituitary,I-Entity
response,O
to,O
luteinizing,O
hormone,I-Entity
-,O
releasing,O
hormone,I-Entity
during,O
haloperidol,I-Entity
-,O
induced,O
hyperprolactinemia,I-Entity
.,O
The,I-Entity
effects,O
of,O
a,O
6-hour,O
infusion,O
with,O
haloperidol,I-Entity
on,O
serum,O
prolactin,O
and,O
luteinizing,O
hormone,I-Entity
(,O
LH,I-Entity
),O
Control,I-Entity
patients,O
received,O
infusions,O
of,O
0.9%,O
NaCl,I-Entity
solution,O
.,O
During,I-Entity
the,O
course,O
of,O
haloperidol,I-Entity
infusions,O
",",O
significant,O
hyperprolactinemia,I-Entity
was,O
found,O
",",O
together,O
with,O
an,O
abolished,O
pituitary,O
response,O
to,O
LH,I-Entity
-,O
RH,I-Entity
",",O
as,O
compared,O
with,O
responses,O
of,O
control,O
subjects,O
.,O
Antirifampicin,I-Entity
antibodies,O
in,O
acute,O
rifampicin,I-Entity
-,O
associated,O
renal,O
failure,I-Entity
.,O
5,O
patients,O
with,O
acute,O
renal,O
failure,I-Entity
(,O
3,O
with,O
thrombopenia,I-Entity
and,O
hemolysis,I-Entity
),O
induced,O
by,O
the,O
reintroduction,O
of,O
rifampicin,I-Entity
are,O
described,O
.,O
Antibodies,I-Entity
suggested,O
to,O
be,O
of,O
the,O
IgM,I-Entity
class,O
were,O
detected,O
in,O
all,O
3,O
patients,O
with,O
hematological,O
disorders,I-Entity
.,O
The,I-Entity
pattern,O
of,O
non,O
-,O
specific,O
acute,O
tubular,O
necrosis,I-Entity
found,O
in,O
the,O
2,O
biopsied,O
patients,O
",",O
indistinguishable,O
from,O
that,O
of,O
ischemic,I-Entity
origin,O
",",O
raised,O
the,O
possibility,O
of,O
a,O
vascular,O
-,O
mediated,O
damage,O
.,O
Cardiovascular,I-Entity
effects,O
of,O
hypotension,I-Entity
induced,O
by,O
adenosine,I-Entity
triphosphate,I-Entity
and,O
sodium,I-Entity
nitroprusside,I-Entity
on,O
dogs,O
with,O
denervated,O
hearts,O
.,O
Adenosine,I-Entity
triphosphate,I-Entity
(,O
ATP,I-Entity
),O
and,O
sodium,I-Entity
nitroprusside,I-Entity
(,O
SNP,I-Entity
),O
are,O
administered,O
to,O
patients,O
to,O
induce,O
and,O
control,O
hypotension,I-Entity
during,O
anesthesia,O
.,O
SNP,I-Entity
is,O
authorized,O
for,O
clinical,O
use,O
in,O
USA,I-Entity
and,O
UK,I-Entity
",",O
and,O
ATP,I-Entity
is,O
clinically,O
used,O
in,O
other,O
countries,O
such,O
as,O
Japan,I-Entity
.,O
ATP,I-Entity
(,O
10,O
dogs,O
),O
or,O
SNP,I-Entity
(,O
10,O
dogs,O
),O
was,O
administered,O
to,O
reduce,O
mean,O
arterial,O
pressure,O
by,O
30%,O
to,O
70%,O
of,O
control,O
.,O
Before,I-Entity
",",O
during,O
and,O
after,O
induced,O
hypotension,I-Entity
",",O
we,O
measured,O
major,O
cardiovascular,O
parameters,O
.,O
Hypotension,I-Entity
induced,O
by,O
ATP,I-Entity
was,O
accompanied,O
by,O
significant,O
decreases,O
in,O
mean,O
pulmonary,O
arterial,O
pressure,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
central,O
venous,O
pressure,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
left,O
ventricular,O
end,O
-,O
diastolic,I-Entity
pressure,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
total,O
peripheral,O
resistance,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
rate,O
pressure,O
product,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
total,O
body,O
oxygen,I-Entity
consumption,O
(,O
p,O
less,O
than,O
0.05,O
),O
",",O
and,O
heart,O
rate,O
(,O
p,O
less,O
than,O
0.001,O
),O
;,O
all,O
these,O
variables,O
returned,O
normal,O
within,O
30,O
min,O
after,O
ATP,I-Entity
was,O
stopped,O
.,O
During,I-Entity
hypotension,I-Entity
produced,O
by,O
SNP,I-Entity
similar,O
decreases,O
were,O
observed,O
in,O
mean,O
pulmonary,O
arterial,O
pressure,O
(,O
p,O
less,O
than,O
0.01,O
),O
",",O
central,O
venous,O
pressure,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
left,O
ventricular,O
end,O
-,O
diastolic,I-Entity
pressure,O
(,O
p,O
less,O
than,O
0.01,O
),O
",",O
total,O
peripheral,O
resistance,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
rate,O
pressure,O
product,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
and,O
oxygen,I-Entity
content,O
difference,O
between,O
arterial,O
and,O
mixed,O
venous,O
blood,O
(,O
p,O
less,O
than,O
0.05,O
),O
",",O
while,O
heart,O
rate,O
(,O
p,O
less,O
than,O
0.001,O
),O
and,O
cardiac,O
output,O
(,O
p,O
less,O
than,O
0.05,O
),O
were,O
increased,O
.,O
Recoveries,I-Entity
of,O
heart,O
rate,O
and,O
left,O
ventricular,O
end,O
-,O
diastolic,I-Entity
pressure,O
were,O
not,O
shown,O
within,O
60,O
min,O
after,O
SNP,I-Entity
had,O
been,O
stopped,O
.,O
Both,I-Entity
ATP,I-Entity
and,O
SNP,I-Entity
should,O
act,O
on,O
the,O
pacemaker,O
tissue,O
of,O
the,O
heart,O
.,O
Comparative,I-Entity
study,O
:,O
Endografine,I-Entity
(,O
diatrizoate,I-Entity
),O
",",O
Vasurix,I-Entity
polyvidone,I-Entity
(,O
acetrizoate,I-Entity
),O
",",O
Dimer,I-Entity
-,O
X,I-Entity
(,O
iocarmate,I-Entity
),O
and,O
Hexabrix,I-Entity
(,O
ioxaglate,I-Entity
),O
in,O
hysterosalpingography,I-Entity
.,O
Side,I-Entity
effects,O
of,O
hysterosalpingography,I-Entity
with,O
Dimer,I-Entity
-,O
X,I-Entity
",",O
Hexabrix,I-Entity
",",O
Vasurix,I-Entity
polyvidone,I-Entity
and,O
Endografine,I-Entity
in,O
142,I-Entity
consecutive,O
patients,O
",",O
receiving,O
one,O
of,O
the,O
four,O
tested,O
media,O
were,O
evaluated,O
from,O
replies,O
to,O
postal,O
questionnaires,O
.,O
The,I-Entity
Dimer,I-Entity
-,O
X,I-Entity
group,O
had,O
a,O
higher,O
incidence,O
of,O
nausea,I-Entity
and,O
dizziness,I-Entity
.,O
The,I-Entity
Endografine,I-Entity
group,O
had,O
a,O
higher,O
incidence,O
of,O
abdominal,O
pain,I-Entity
.,O
Hexabrix,I-Entity
and,O
Vasurix,I-Entity
polyvidone,I-Entity
are,O
considered,O
the,O
best,O
contrast,O
media,O
for,O
hysterosalpingography,I-Entity
and,O
perhaps,O
because,O
of,O
its,O
low,O
toxicity,I-Entity
Hexabrix,I-Entity
should,O
be,O
preferred,O
.,O
Post,I-Entity
-,O
suxamethonium,I-Entity
pains,I-Entity
in,O
Nigerian,I-Entity
surgical,O
patients,O
.,O
Contrary,I-Entity
to,O
an,O
earlier,O
report,O
by,O
Coxon,I-Entity
",",O
scoline,I-Entity
pain,I-Entity
occurs,O
in,O
African,I-Entity
negroes,I-Entity
.,O
About,I-Entity
62%,O
of,O
the,O
out,O
-,O
patients,O
developed,O
scoline,I-Entity
pain,I-Entity
as,O
compared,O
with,O
about,O
26%,O
among,O
the,O
in,O
-,O
patients,O
.,O
The,I-Entity
abolition,O
of,O
muscle,O
fasciculations,I-Entity
(,O
by,O
0.075mg,I-Entity
/,O
kg,O
dose,O
of,O
Fazadinium,I-Entity
),O
did,O
not,O
influence,O
the,O
occurrence,O
of,O
scoline,I-Entity
pain,I-Entity
.,O
Neither,I-Entity
the,O
type,O
of,O
induction,O
agent,O
(,O
Althesin,I-Entity
or,O
Thiopentone,I-Entity
),O
nor,O
the,O
salt,O
preparation,O
of,O
suxamethonium,I-Entity
used,O
(,O
chloride,I-Entity
or,O
bromide,I-Entity
),O
",",O
affected,O
the,O
incidence,O
of,O
scoline,I-Entity
pain,I-Entity
.,O
Medial,I-Entity
changes,O
in,O
arterial,O
spasm,I-Entity
induced,O
by,O
L,I-Entity
-,O
norepinephrine,I-Entity
.,O
In,I-Entity
the,O
media,O
of,O
the,O
saphenous,I-Entity
artery,I-Entity
and,O
its,O
distal,O
branch,O
",",O
vasoconstriction,O
induced,O
by,O
L,I-Entity
-,O
norepinephrine,I-Entity
produced,O
many,O
cell,O
-,O
to,O
-,O
cell,O
hernias,I-Entity
within,O
15,O
minutes,O
.,O
The,I-Entity
experimental,O
data,O
are,O
discussed,O
in,O
relation,O
to,O
medial,O
changes,O
observed,O
in,O
other,O
instances,O
of,O
arterial,O
spasm,I-Entity
.,O
Abnormalities,I-Entity
of,O
the,O
pupil,O
and,O
visual,O
-,O
evoked,O
potential,O
in,O
quinine,I-Entity
amblyopia,I-Entity
.,O
Total,I-Entity
blindness,I-Entity
with,O
a,O
transient,O
tonic,I-Entity
pupillary,I-Entity
response,O
",",O
denervation,O
supersensitivity,I-Entity
",",O
and,O
abnormal,I-Entity
visual,O
-,O
evoked,O
potentials,O
developed,O
in,O
a,O
54-year,O
-,O
old,O
man,O
after,O
the,O
use,O
of,O
quinine,I-Entity
sulfate,O
for,O
leg,O
cramps,I-Entity
.,O
A,I-Entity
transient,O
tonic,I-Entity
pupillary,I-Entity
response,O
",",O
denervation,O
supersensitivity,I-Entity
",",O
and,O
abnormal,I-Entity
visual,O
-,O
evoked,O
potentials,O
in,O
quinine,I-Entity
toxicity,I-Entity
",",O
to,O
our,O
knowledge,O
",",O
have,O
not,O
been,O
previously,O
reported,O
.,O
Suxamethonium,I-Entity
-,O
induced,O
jaw,O
stiffness,I-Entity
and,O
myalgia,I-Entity
associated,O
with,O
atypical,O
cholinesterase,O
:,O
case,O
report,O
.,O
An,I-Entity
11-year,O
-,O
old,O
boy,O
was,O
given,O
halothane,I-Entity
",",O
nitrous,I-Entity
oxide,I-Entity
and,O
oxygen,I-Entity
",",O
pancuronium,I-Entity
0.4,O
mg,O
and,O
suxamethonium,I-Entity
100,O
mg,O
for,O
induction,O
of,O
anaesthesia,O
.,O
In,I-Entity
response,O
to,O
this,O
a,O
marked,O
jaw,O
stiffness,I-Entity
occurred,O
which,O
lasted,O
for,O
two,O
minutes,O
and,O
the,O
anaesthesia,O
were,O
terminated,O
.,O
Four,I-Entity
hours,O
of,O
apnoea,I-Entity
ensued,O
and,O
he,O
suffered,O
generalized,O
severe,O
myalgia,I-Entity
lasting,O
for,O
one,O
week,O
.,O
He,I-Entity
was,O
found,O
to,O
have,O
atypical,O
plasma,O
cholinesterase,O
with,O
a,O
dibucaine,I-Entity
number,O
of,O
12,O
",",O
indicating,O
homozygocity,O
.,O
The,I-Entity
case,O
shows,O
that,O
prolonged,O
jaw,O
rigidity,I-Entity
and,O
myalgia,I-Entity
may,O
occur,O
after,O
suxamethonium,I-Entity
in,O
patients,O
with,O
atypical,O
cholinesterase,O
despite,O
pretreatment,O
with,O
pancuronium,I-Entity
.,O
Indomethacin,I-Entity
-,O
induced,O
hyperkalemia,I-Entity
in,O
three,O
patients,O
with,O
gouty,I-Entity
arthritis,I-Entity
.,O
We,I-Entity
describe,O
three,O
patients,O
in,O
whom,O
severe,O
",",O
life,O
-,O
threatening,I-Entity
hyperkalemia,I-Entity
and,O
renal,O
insufficiency,I-Entity
developed,O
after,O
treatment,O
of,O
acute,O
gouty,I-Entity
arthritis,I-Entity
with,O
indomethacin,I-Entity
.,O
This,I-Entity
complication,O
may,O
result,O
from,O
an,O
inhibition,O
of,O
prostaglandin,I-Entity
synthesis,O
and,O
consequent,O
hyporeninemic,I-Entity
hypoaidosteronism,I-Entity
.,O
Careful,I-Entity
attention,O
to,O
renal,O
function,O
and,O
potassium,I-Entity
balance,O
in,O
patients,O
receiving,O
indomethacin,I-Entity
or,O
other,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
agents,O
",",O
particularly,O
in,O
those,O
patients,O
with,O
diabetes,I-Entity
mellitus,I-Entity
or,O
preexisting,O
renal,O
disease,I-Entity
",",O
will,O
help,O
prevent,O
this,O
potentially,O
serious,O
complication,O
.,O
Etomidate,I-Entity
:,O
a,O
foreshortened,O
clinical,O
trial,O
.,O
A,I-Entity
clinical,O
evaluation,O
of,O
etomidate,I-Entity
for,O
outpatient,I-Entity
cystoscopy,I-Entity
was,O
embarked,O
upon,O
.,O
Unpremedicated,I-Entity
patients,O
were,O
given,O
fentanyl,I-Entity
1,O
microgram,O
/,O
kg,O
followed,O
by,O
etomidate,I-Entity
0.3,O
mg,O
/,O
kg,O
.,O
Anaesthesia,I-Entity
was,O
maintained,O
with,O
intermittent,O
etomidate,I-Entity
in,O
2,O
-,O
4,O
mg,O
doses,O
.,O
Venous,I-Entity
pain,I-Entity
occurred,O
in,O
68%,O
of,O
patients,O
and,O
50%,O
had,O
redness,I-Entity
",",O
pain,I-Entity
or,O
swelling,I-Entity
related,O
to,O
the,O
injection,O
site,O
",",O
in,O
some,O
cases,O
lasting,O
up,O
to,O
three,O
weeks,O
after,O
anaesthesia,O
.,O
Skeletal,I-Entity
movements,O
occurred,O
in,O
50%,O
of,O
patients,O
;,O
30%,O
experienced,O
respiratory,O
upset,I-Entity
",",O
one,O
sufficiently,O
severe,O
to,O
necessitate,O
abandoning,O
the,O
technique,O
.,O
Nausea,I-Entity
and,O
vomiting,I-Entity
occurred,O
in,O
40%,O
and,O
25%,O
had,O
disturbing,I-Entity
emergence,O
psychoses,I-Entity
.,O
Levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
are,O
improved,O
by,O
fluoxetine,I-Entity
.,O
We,I-Entity
evaluated,O
the,O
severity,O
of,O
motor,O
disability,I-Entity
and,O
dyskinesias,I-Entity
in,O
seven,O
levodopa,I-Entity
-,O
responsive,O
patients,O
with,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
after,O
an,O
acute,O
challenge,O
with,O
the,O
mixed,O
dopamine,I-Entity
agonist,I-Entity
",",O
apomorphine,I-Entity
",",O
before,O
and,O
after,O
the,O
administration,O
of,O
fluoxetine,I-Entity
(,O
20,O
mg,O
twice,O
per,O
day,O
),O
for,O
11,O
+,O
/-,O
After,I-Entity
fluoxetine,I-Entity
treatment,O
",",O
there,O
was,O
a,O
significant,O
47%,O
improvement,O
(,O
p,O
<,O
0.05,O
),O
of,O
apomorphine,I-Entity
-,O
induced,O
dyskinesias,I-Entity
without,O
modification,O
of,O
parkinsonian,I-Entity
motor,O
disability,I-Entity
.,O
The,I-Entity
dyskinesias,I-Entity
were,O
reduced,O
predominantly,O
in,O
the,O
lower,O
limbs,O
during,O
the,O
onset,O
and,O
disappearance,I-Entity
of,O
dystonic,I-Entity
dyskinesias,I-Entity
(,O
onset-,O
and,O
end,O
-,O
of,O
-,O
dose,O
dyskinesias,I-Entity
),O
and,O
in,O
the,O
upper,O
limbs,O
during,O
choreic,O
mid,O
-,O
dose,O
dyskinesias,I-Entity
.,O
The,I-Entity
results,O
suggest,O
that,O
increased,O
brain,O
serotoninergic,I-Entity
transmission,O
with,O
fluoxetine,I-Entity
may,O
reduce,O
levodopa-,I-Entity
or,O
dopamine,I-Entity
agonist,I-Entity
-,O
induced,O
dyskinesias,I-Entity
without,O
aggravating,O
parkinsonian,I-Entity
motor,O
disability,I-Entity
.,O
A,I-Entity
large,O
population,O
-,O
based,O
follow,O
-,O
up,O
study,O
of,O
trimethoprim,I-Entity
-,O
sulfamethoxazole,I-Entity
",",O
trimethoprim,I-Entity
",",O
and,O
cephalexin,I-Entity
for,O
uncommon,O
serious,O
drug,O
toxicity,I-Entity
.,O
We,I-Entity
conducted,O
a,O
population,O
-,O
based,O
45-day,O
follow,O
-,O
up,O
study,O
of,O
"232,390",O
people,O
who,O
were,O
prescribed,O
trimethoprim,I-Entity
-,O
sulfamethoxazole,I-Entity
(,O
TMP,I-Entity
-,O
SMZ,I-Entity
),O
",",O
"266,951",O
prescribed,O
trimethoprim,I-Entity
alone,O
",",O
and,O
"196,397",O
prescribed,O
cephalexin,I-Entity
",",O
to,O
estimate,O
the,O
risk,O
of,O
serious,O
liver,I-Entity
",",O
blood,O
",",O
skin,O
",",O
and,O
renal,O
disorders,I-Entity
resulting,O
in,O
referral,O
or,O
hospitalization,O
associated,O
with,O
these,O
drugs,O
.,O
The,I-Entity
risk,O
of,O
clinically,O
important,O
idiopathic,I-Entity
liver,I-Entity
disease,I-Entity
was,O
similar,O
for,O
persons,O
prescribed,O
TMP,I-Entity
-,O
SMZ,I-Entity
(,O
"5.2/100,000",O
),O
and,O
those,O
prescribed,O
trimethoprim,I-Entity
alone,O
(,O
"3.8/100,000",O
),O
.,O
The,I-Entity
risk,O
for,O
those,O
prescribed,O
cephalexin,I-Entity
was,O
somewhat,O
lower,O
(,O
"2.0/100,000",O
),O
.,O
Only,I-Entity
five,O
patients,O
experienced,O
blood,O
disorders,I-Entity
",",O
one,O
of,O
whom,O
was,O
exposed,O
to,O
TMP,I-Entity
-,O
SMZ,I-Entity
;,O
of,O
seven,O
with,O
erythema,I-Entity
multiforme,I-Entity
and,O
Stevens,I-Entity
-,O
Johnson,I-Entity
syndrome,I-Entity
",",O
four,O
were,O
exposed,O
to,O
TMP,I-Entity
-,O
SMZ,I-Entity
.,O
The,I-Entity
one,O
case,O
of,O
toxic,I-Entity
epidermal,O
necrolysis,I-Entity
occurred,O
in,O
a,O
patient,O
who,O
took,O
cephalexin,I-Entity
.,O
Finally,I-Entity
",",O
only,O
five,O
cases,O
of,O
acute,O
parenchymal,O
renal,O
disease,I-Entity
occurred,O
",",O
none,O
likely,O
to,O
be,O
caused,O
by,O
a,O
study,O
drug,O
.,O
Clinical,I-Entity
safety,O
of,O
lidocaine,I-Entity
in,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
myocardial,B-Entity
infarction,I-Entity
.,O
STUDY,I-Entity
OBJECTIVE,I-Entity
:,O
To,I-Entity
evaluate,O
the,O
safety,O
of,O
lidocaine,I-Entity
in,O
the,O
setting,O
of,O
cocaine,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
(,O
MI,I-Entity
),O
.,O
Patients,I-Entity
with,O
cocaine,I-Entity
-,O
associated,O
MI,I-Entity
who,O
received,O
lidocaine,I-Entity
in,O
the,O
emergency,O
department,O
.,O
Of,I-Entity
29,O
patients,O
who,O
received,O
lidocaine,I-Entity
in,O
the,O
setting,O
of,O
cocaine,I-Entity
-,O
associated,O
MI,I-Entity
",",O
no,O
patient,O
died,O
;,O
exhibited,O
bradydysrhythmias,I-Entity
",",O
ventricular,O
tachycardia,I-Entity
",",O
or,O
ventricular,O
fibrillation,I-Entity
;,O
or,O
experienced,O
seizures,I-Entity
after,O
administration,O
of,O
lidocaine,I-Entity
(,O
95%,O
confidence,O
interval,O
",",O
0%,O
to,O
11%,O
),O
.,O
CONCLUSION,I-Entity
:,O
Despite,I-Entity
theoretical,O
concerns,O
that,O
lidocaine,I-Entity
may,O
enhance,O
cocaine,I-Entity
toxicity,I-Entity
",",O
the,O
use,O
of,O
lidocaine,I-Entity
in,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
MI,I-Entity
was,O
not,O
associated,O
with,O
significant,O
cardiovascular,O
or,O
central,O
nervous,I-Entity
system,O
toxicity,I-Entity
.,O
Paclitaxel,I-Entity
3-hour,O
infusion,O
given,O
alone,O
and,O
combined,O
with,O
carboplatin,I-Entity
:,O
preliminary,O
results,O
of,O
dose,O
-,O
escalation,O
trials,O
.,O
Paclitaxel,I-Entity
(,O
Taxol,I-Entity
;,O
Bristol,I-Entity
-,O
Myers,I-Entity
Squibb,I-Entity
Company,I-Entity
",",O
Princeton,I-Entity
",",O
NJ,I-Entity
),O
by,O
3-hour,O
infusion,O
was,O
combined,O
with,O
carboplatin,I-Entity
in,O
a,O
phase,O
I,I-Entity
/,O
II,I-Entity
study,O
directed,O
to,O
patients,O
with,O
non,O
-,O
small,O
cell,O
lung,O
cancer,I-Entity
.,O
Carboplatin,I-Entity
was,O
given,O
at,O
a,O
fixed,O
target,O
area,O
under,O
the,O
concentration,O
-,O
time,O
curve,O
of,O
6.0,O
by,O
the,O
Calvert,I-Entity
formula,O
",",O
whereas,O
paclitaxel,I-Entity
was,O
escalated,O
in,O
patient,O
cohorts,O
from,O
150,I-Entity
mg,O
/,O
m2,O
(,O
dose,O
level,O
I,I-Entity
),O
to,O
175,I-Entity
",",O
200,O
",",O
225,I-Entity
",",O
and,O
250,O
mg,O
/,O
m2,O
.,O
The,I-Entity
225,I-Entity
mg,O
/,O
m2,O
level,O
was,O
expanded,O
for,O
the,O
phase,O
II,I-Entity
study,O
since,O
the,O
highest,O
level,O
achieved,O
(,O
250,O
mg,O
/,O
m2,O
),O
required,O
modification,O
because,O
of,O
nonhematologic,O
toxicities,I-Entity
(,O
arthralgia,I-Entity
and,O
sensory,O
neuropathy,I-Entity
),O
.,O
Toxicities,I-Entity
were,O
compared,O
with,O
a,O
cohort,O
of,O
patients,O
in,O
a,O
phase,O
I,I-Entity
trial,O
of,O
paclitaxel,I-Entity
alone,O
at,O
identical,O
dose,O
levels,O
.,O
Carboplatin,I-Entity
did,O
not,O
appear,O
to,O
add,O
to,O
the,O
hematologic,O
toxicities,I-Entity
observed,O
",",O
and,O
the,O
paclitaxel,I-Entity
/,O
carboplatin,I-Entity
combination,O
could,O
be,O
dosed,O
every,O
3,O
weeks,O
.,O
The,I-Entity
dose,O
-,O
dependent,O
effect,O
of,O
misoprostol,I-Entity
on,O
indomethacin,I-Entity
-,O
induced,O
renal,O
dysfunction,I-Entity
in,O
well,O
compensated,O
cirrhosis,I-Entity
.,O
Misoprostol,I-Entity
(,O
200,O
micrograms,O
),O
has,O
been,O
shown,O
to,O
acutely,O
counteract,O
the,O
indomethacin,I-Entity
-,O
induced,O
renal,O
dysfunction,I-Entity
in,O
well,O
compensated,O
cirrhotic,I-Entity
patients,O
.,O
The,I-Entity
aim,O
of,O
this,O
study,O
was,O
to,O
determine,O
if,O
the,O
prophylactic,O
value,O
of,O
misoprostol,I-Entity
was,O
dose,O
-,O
dependent,O
.,O
Parameters,I-Entity
of,O
renal,O
hemodynamics,O
and,O
tubular,O
sodium,I-Entity
and,O
water,O
handling,O
were,O
assessed,O
by,O
clearance,O
techniques,O
in,O
26,O
well,O
compensated,O
cirrhotic,I-Entity
patients,O
before,O
and,O
after,O
an,O
oral,O
combination,O
of,O
50,O
mg,O
of,O
indomethacin,I-Entity
and,O
various,O
doses,O
of,O
misoprostol,I-Entity
.,O
The,I-Entity
200-micrograms,O
dose,O
was,O
able,O
to,O
totally,O
abolish,O
the,O
deleterious,I-Entity
renal,O
effects,O
of,O
indomethacin,I-Entity
",",O
whereas,O
the,O
800-micrograms,O
dose,O
resulted,O
in,O
significant,O
worsening,O
of,O
renal,O
hemodynamics,O
and,O
sodium,I-Entity
retention,O
.,O
These,I-Entity
results,O
suggest,O
that,O
the,O
renal,O
protective,O
effects,O
of,O
misoprostol,I-Entity
is,O
dose,O
-,O
dependent,O
.,O
However,I-Entity
",",O
until,O
this,O
apparent,O
ability,O
of,O
200,O
micrograms,O
of,O
misoprostol,I-Entity
to,O
prevent,O
the,O
adverse,O
effects,O
of,O
indomethacin,I-Entity
on,O
renal,O
function,O
is,O
confirmed,O
with,O
chronic,O
frequent,O
dosing,O
",",O
it,O
would,O
be,O
prudent,O
to,O
avoid,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
therapy,O
in,O
patients,O
with,O
cirrhosis,I-Entity
.,O
Increased,I-Entity
frequency,O
and,O
severity,O
of,O
angio,O
-,O
oedema,I-Entity
related,O
to,O
long,O
-,O
term,O
therapy,O
with,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
inhibitor,O
in,O
two,O
patients,O
.,O
Adverse,I-Entity
reactions,O
to,O
drugs,O
are,O
well,O
recognized,O
as,O
a,O
cause,O
of,O
acute,O
or,O
chronic,O
urticaria,I-Entity
",",O
and,O
angio,O
-,O
oedema,I-Entity
.,O
Angiotensin,I-Entity
-,O
converting,O
enzyme,O
(,O
ACE,I-Entity
),O
inhibitors,O
",",O
used,O
to,O
treat,O
hypertension,I-Entity
and,O
congestive,B-Entity
heart,O
failure,I-Entity
",",O
were,O
introduced,O
in,O
Europe,I-Entity
in,O
the,O
middle,O
of,O
the,O
eighties,O
",",O
and,O
the,O
use,O
of,O
these,O
drugs,O
has,O
increased,O
progressively,O
.,O
Soon,I-Entity
after,O
the,O
introduction,O
of,O
ACE,I-Entity
inhibitors,O
",",O
acute,O
bouts,O
of,O
angio,O
-,O
oedema,I-Entity
were,O
reported,O
in,O
association,O
with,O
the,O
use,O
of,O
these,O
drugs,O
.,O
We,I-Entity
wish,O
to,O
draw,O
attention,O
to,O
the,O
possibility,O
of,O
adverse,O
reactions,O
to,O
ACE,I-Entity
inhibitors,O
after,O
long,O
-,O
term,O
use,O
and,O
in,O
patients,O
with,O
pre,O
-,O
existing,O
angio,O
-,O
oedema,I-Entity
.,O
Myoclonus,I-Entity
associated,O
with,O
lorazepam,I-Entity
therapy,O
in,O
very,O
-,O
low,O
-,O
birth,O
-,O
weight,O
infants,O
.,O
Lorazepam,I-Entity
is,O
being,O
used,O
with,O
increasing,O
frequency,O
as,O
a,O
sedative,O
in,O
the,O
newborn,O
and,O
the,O
young,O
infant,O
.,O
Concern,I-Entity
has,O
been,O
raised,O
with,O
regard,O
to,O
the,O
safety,O
of,O
lorazepam,I-Entity
in,O
this,O
age,O
group,O
",",O
especially,O
in,O
very,O
-,O
low,O
-,O
birth,O
-,O
weight,O
(,O
VLBW,I-Entity
;,O
<,O
"1,500",O
g,O
),O
infants,O
.,O
Three,I-Entity
young,O
infants,O
",",O
all,O
of,O
birth,O
weight,O
<,O
"1,500",O
g,O
",",O
experienced,O
myoclonus,I-Entity
following,O
the,O
intravenous,O
administration,O
of,O
lorazepam,I-Entity
.,O
The,I-Entity
potential,O
neurotoxic,I-Entity
effects,O
of,O
the,O
drug,O
(,O
and,O
its,O
vehicle,O
),O
in,O
this,O
population,O
are,O
discussed,O
.,O
Injectable,I-Entity
lorazepam,I-Entity
should,O
be,O
used,O
with,O
caution,O
in,O
VLBW,I-Entity
infants,O
.,O
right,O
ventricular,O
pacing,O
during,O
cardiopulmonary,O
resuscitation,O
of,O
pediatric,O
patients,O
with,O
acute,O
cardiomyopathy,I-Entity
.,O
We,I-Entity
describe,O
the,O
cardiopulmonary,O
resuscitation,O
efforts,O
on,O
five,O
patients,O
who,O
presented,O
in,O
acute,O
circulatory,O
failure,I-Entity
from,O
myocardial,B-Entity
dysfunction,I-Entity
.,O
Three,I-Entity
patients,O
had,O
acute,O
viral,O
myocarditis,I-Entity
",",O
one,O
had,O
a,O
carbamazepine,I-Entity
-,O
induced,O
acute,O
eosinophilic,I-Entity
myocarditis,I-Entity
",",O
and,O
one,O
had,O
cardiac,O
hemosiderosis,I-Entity
resulting,O
in,O
acute,O
cardiogenic,I-Entity
shock,I-Entity
.,O
An,I-Entity
introducer,O
sheath,O
",",O
a,O
pacemaker,O
",",O
and,O
sterile,O
pacing,O
wires,I-Entity
were,O
made,O
readily,O
available,O
for,O
the,O
patients,O
",",O
should,O
the,O
need,O
arise,O
to,O
terminate,O
resistant,O
cardiac,O
dysrhythmias,I-Entity
.,O
All,I-Entity
patients,O
developed,O
cardiocirculatory,O
arrest,I-Entity
associated,O
with,O
extreme,O
hypotension,I-Entity
and,O
dysrhythmias,I-Entity
within,O
the,O
first,O
48,I-Entity
hours,O
of,O
their,O
admission,O
to,O
the,O
pediatric,O
intensive,O
care,O
unit,O
(,O
PICU,I-Entity
),O
.,O
These,I-Entity
patients,O
had,O
a,O
second,O
event,O
of,O
cardiac,O
arrest,I-Entity
",",O
resulting,O
in,O
death,I-Entity
",",O
within,O
10,O
to,O
60,O
minutes,O
.,O
We,I-Entity
conclude,O
that,O
cardiac,O
pacing,O
during,O
resuscitative,O
efforts,O
in,O
pediatric,O
patients,O
suffering,O
from,O
acute,O
myocardial,B-Entity
dysfunction,I-Entity
may,O
not,O
have,O
long,O
-,O
term,O
value,O
in,O
and,O
of,O
itself,O
;,O
however,O
",",O
if,O
temporary,O
hemodynamic,O
stability,O
is,O
achieved,O
by,O
this,O
procedure,O
",",O
it,O
may,O
provide,O
additional,O
time,O
needed,O
to,O
institute,O
other,O
therapeutic,O
modalities,O
.,O
Efficacy,I-Entity
and,O
safety,O
of,O
granisetron,I-Entity
",",O
a,O
selective,O
5-hydroxytryptamine-3,I-Entity
receptor,O
antagonist,O
",",O
in,O
the,O
prevention,O
of,O
nausea,I-Entity
and,O
vomiting,I-Entity
induced,O
by,O
high,O
-,O
dose,O
cisplatin,I-Entity
.,O
PURPOSE,I-Entity
:,O
To,I-Entity
assess,O
the,O
antiemetic,O
effects,O
and,O
safety,O
profile,O
of,O
four,O
different,O
doses,O
of,O
granisetron,I-Entity
(,O
Kytril,I-Entity
;,O
SmithKline,I-Entity
Beecham,I-Entity
Pharmaceuticals,I-Entity
",",O
Philadelphia,I-Entity
",",O
PA,I-Entity
),O
when,O
administered,O
as,O
a,O
single,O
intravenous,O
(,O
IV,I-Entity
),O
dose,O
for,O
prophylaxis,O
of,O
cisplatin,I-Entity
-,O
induced,O
nausea,I-Entity
and,O
vomiting,I-Entity
.,O
One,I-Entity
hundred,O
eighty,O
-,O
four,O
chemotherapy,O
-,O
naive,O
patients,O
receiving,O
high,O
-,O
dose,O
cisplatin,I-Entity
(,O
81,I-Entity
to,O
120,I-Entity
mg,O
/,O
m2,O
),O
were,O
randomized,O
to,O
receive,O
one,O
of,O
four,O
granisetron,I-Entity
doses,O
(,O
5,O
",",O
10,O
",",O
20,O
",",O
or,O
40,O
micrograms,O
/,O
kg,O
),O
administered,O
before,O
chemotherapy,O
.,O
Patients,I-Entity
were,O
observed,O
on,O
an,O
inpatient,O
basis,O
for,O
18,O
to,O
24,O
hours,O
",",O
and,O
vital,O
signs,O
",",O
nausea,I-Entity
",",O
vomiting,I-Entity
",",O
retching,I-Entity
",",O
and,O
appetite,O
were,O
assessed,O
.,O
After,I-Entity
granisetron,I-Entity
doses,O
of,O
5,O
",",O
10,O
",",O
20,O
",",O
and,O
40,O
micrograms,O
/,O
kg,O
",",O
a,O
major,O
response,O
(,O
<,O
or,O
=,O
two,O
vomiting,I-Entity
or,O
retching,I-Entity
episodes,O
",",O
and,O
no,O
antiemetic,O
rescue,O
),O
was,O
recorded,O
in,O
23%,O
",",O
57%,O
",",O
58%,O
",",O
and,O
60%,O
of,O
patients,O
",",O
respectively,O
",",O
and,O
a,O
complete,O
response,O
(,O
no,O
vomiting,I-Entity
or,O
retching,I-Entity
",",O
and,O
no,O
antiemetic,O
rescue,O
),O
in,O
18%,O
",",O
41%,O
",",O
40%,O
",",O
and,O
47%,O
of,O
patients,O
",",O
respectively,O
.,O
There,I-Entity
was,O
a,O
statistically,O
longer,O
time,O
to,O
first,O
episode,O
of,O
nausea,I-Entity
(,O
P,I-Entity
=,O
.0015,O
),O
and,O
vomiting,I-Entity
(,O
P,I-Entity
=,O
.0001,O
),O
",",O
and,O
fewer,O
patients,O
were,O
administered,O
additional,O
antiemetic,O
medication,O
in,O
the,O
10-micrograms,O
/,O
kg,O
dosing,O
groups,O
than,O
in,O
the,O
5-micrograms,O
/,O
kg,O
dosing,O
group,O
.,O
As,I-Entity
granisetron,I-Entity
dose,O
increased,O
",",O
appetite,O
return,O
increased,O
(,O
P,I-Entity
=,O
.040,O
),O
.,O
Headache,I-Entity
was,O
the,O
most,O
frequently,O
reported,O
adverse,O
event,O
(,O
20%,O
),O
.,O
A,I-Entity
single,O
10-,O
",",O
20-,I-Entity
",",O
or,O
40-micrograms,O
/,O
kg,O
dose,O
of,O
granisetron,I-Entity
was,O
effective,O
in,O
controlling,O
vomiting,I-Entity
in,O
57%,O
to,O
60%,O
of,O
patients,O
who,O
received,O
cisplatin,I-Entity
at,O
doses,O
greater,O
than,O
81,I-Entity
mg,O
/,O
m2,O
and,O
totally,O
prevented,O
vomiting,I-Entity
in,O
40%,O
to,O
47%,O
of,O
patients,O
.,O
Granisetron,I-Entity
was,O
well,O
tolerated,O
at,O
all,O
doses,O
.,O
Adverse,I-Entity
interaction,O
between,O
clonidine,I-Entity
and,O
verapamil,I-Entity
.,O
OBJECTIVE,I-Entity
:,O
To,I-Entity
report,O
two,O
cases,O
of,O
a,O
possible,O
adverse,O
interaction,O
between,O
clonidine,I-Entity
and,O
verapamil,I-Entity
resulting,O
in,O
atrioventricular,B-Entity
(,O
AV,I-Entity
),O
block,O
in,O
both,O
patients,O
and,O
severe,O
hypotension,I-Entity
in,O
one,O
patient,O
.,O
A,I-Entity
54-year,O
-,O
old,O
woman,O
with,O
hyperaldosteronism,I-Entity
was,O
treated,O
with,O
verapamil,I-Entity
480,O
mg,O
/,O
d,O
and,O
spironolactone,I-Entity
100,O
mg,O
/,O
d,O
.,O
After,I-Entity
the,O
addition,O
of,O
a,O
minimal,O
dose,O
of,O
clonidine,I-Entity
(,O
0.15,O
mg,O
bid,O
),O
",",O
she,O
developed,O
complete,O
AV,I-Entity
block,O
and,O
severe,O
hypotension,I-Entity
",",O
which,O
resolved,O
upon,O
cessation,O
of,O
all,O
medications,O
.,O
A,I-Entity
65-year,O
-,O
old,O
woman,O
was,O
treated,O
with,O
extended,O
-,O
release,O
verapamil,I-Entity
240,I-Entity
mg,O
/,O
d,O
.,O
After,I-Entity
the,O
addition,O
of,O
clonidine,I-Entity
0.15,O
mg,O
bid,O
she,O
developed,O
complete,O
AV,I-Entity
block,O
",",O
which,O
resolved,O
after,O
all,O
therapy,O
was,O
stopped,O
.,O
DISCUSSION,I-Entity
:,O
An,I-Entity
adverse,O
interaction,O
between,O
clonidine,I-Entity
and,O
verapamil,I-Entity
has,O
not,O
been,O
reported,O
previously,O
.,O
Caution,I-Entity
is,O
recommended,O
in,O
combining,O
clonidine,I-Entity
and,O
verapamil,I-Entity
therapy,O
",",O
even,O
in,O
patients,O
who,O
do,O
not,O
have,O
sinus,O
or,O
AV,I-Entity
node,O
dysfunction,I-Entity
.,O
Pharmacological,I-Entity
studies,O
on,O
a,O
new,O
dihydrothienopyridine,I-Entity
calcium,I-Entity
antagonist,O
",",O
S-312-d,I-Entity
.,O
S-312,I-Entity
",",O
S-312-d,I-Entity
",",O
but,O
not,O
S-312-l,I-Entity
",",O
L,I-Entity
-,O
type,O
calcium,I-Entity
channel,O
antagonists,O
",",O
showed,O
anticonvulsant,O
effects,O
on,O
the,O
audiogenic,I-Entity
tonic,I-Entity
convulsions,I-Entity
in,O
DBA/2,O
mice,O
;,O
and,O
their,O
ED50,I-Entity
values,O
were,O
18.4,O
(,O
12.8,O
-,O
27.1,O
),O
mg,O
/,O
kg,O
",",O
p.o,O
.,O
and,O
15.0,O
(,O
10.2,O
-,O
23.7,O
),O
mg,O
/,O
kg,O
",",O
p.o,O
.,O
",",O
respectively,O
",",O
while,O
that,O
of,O
flunarizine,I-Entity
was,O
34.0,O
(,O
26.0,O
-,O
44.8,O
Although,I-Entity
moderate,O
anticonvulsant,O
effects,O
of,O
S-312-d,I-Entity
in,O
higher,O
doses,O
were,O
observed,O
against,O
the,O
clonic,I-Entity
convulsions,I-Entity
induced,O
by,O
pentylenetetrazole,I-Entity
(,O
85,O
mg,O
/,O
kg,O
",",O
s.c,O
.,O
),O
or,O
bemegride,I-Entity
(,O
40,O
mg,O
/,O
kg,O
",",O
s.c,O
.,O
),O
",",O
no,O
effects,O
were,O
observed,O
in,O
convulsions,I-Entity
induced,O
by,O
N,I-Entity
-,O
methyl,I-Entity
-,O
D,I-Entity
-,O
aspartate,I-Entity
",",O
picrotoxin,I-Entity
",",O
or,O
electroshock,O
in,O
Slc,I-Entity
:,O
ddY,I-Entity
mice,O
.,O
S-312-d,I-Entity
may,O
be,O
useful,O
in,O
the,O
therapy,O
of,O
certain,O
types,O
of,O
human,O
epilepsy,I-Entity
.,O
Transmural,I-Entity
myocardial,B-Entity
infarction,I-Entity
with,O
sumatriptan,I-Entity
.,O
For,I-Entity
sumatriptan,I-Entity
",",O
tightness,I-Entity
in,O
the,O
chest,O
caused,O
by,O
an,O
unknown,O
mechanism,O
has,O
been,O
reported,O
in,O
3,O
-,O
5%,O
of,O
users,O
.,O
We,I-Entity
describe,O
a,O
47-year,O
-,O
old,O
woman,O
with,O
an,O
acute,O
myocardial,B-Entity
infarction,I-Entity
after,O
administration,O
of,O
sumatriptan,I-Entity
6,O
mg,O
subcutaneously,O
for,O
cluster,O
headache,I-Entity
.,O
The,I-Entity
patient,O
had,O
no,O
history,O
of,O
underlying,O
ischaemic,I-Entity
heart,O
disease,I-Entity
or,O
Prinzmetal,I-Entity
's,I-Entity
angina,I-Entity
.,O
Flumazenil,I-Entity
induces,O
seizures,I-Entity
and,O
death,I-Entity
in,O
mixed,O
cocaine,I-Entity
-,O
diazepam,I-Entity
intoxications,O
.,O
Administration,I-Entity
of,O
the,O
benzodiazepine,I-Entity
antagonist,O
flumazenil,I-Entity
may,O
unmask,O
seizures,I-Entity
in,O
mixed,O
cocaine,I-Entity
-,O
benzodiazepine,I-Entity
intoxication,O
.,O
Male,I-Entity
Sprague,I-Entity
-,O
Dawley,I-Entity
rats,O
received,O
100,O
mg,O
/,O
kg,O
cocaine,I-Entity
IP,I-Entity
alone,O
",",O
5,O
mg,O
/,O
kg,O
diazepam,I-Entity
alone,O
",",O
or,O
a,O
combination,O
of,O
diazepam,I-Entity
and,O
cocaine,I-Entity
.,O
Three,I-Entity
minutes,O
later,O
",",O
groups,O
were,O
challenged,O
with,O
vehicle,O
or,O
flumazenil,I-Entity
5,O
or,O
10,O
mg,O
/,O
kg,O
IP,I-Entity
.,O
Animal,I-Entity
behavior,O
",",O
seizures,I-Entity
(,O
time,O
to,O
and,O
incidence,O
),O
",",O
death,I-Entity
(,O
time,O
to,O
and,O
incidence,O
),O
",",O
and,O
cortical,O
EEG,I-Entity
tracings,I-Entity
were,O
recorded,O
.,O
Administration,I-Entity
of,O
flumazenil,I-Entity
to,O
animals,O
after,O
they,O
had,O
received,O
a,O
combination,O
dose,O
of,O
cocaine,I-Entity
and,O
diazepam,I-Entity
.,O
In,I-Entity
group,O
1,O
",",O
animals,O
received,O
cocaine,I-Entity
followed,O
by,O
vehicle,O
.,O
This,I-Entity
resulted,O
in,O
100%,O
developing,O
seizures,I-Entity
and,O
death,I-Entity
.,O
Group,I-Entity
2,O
received,O
diazepam,I-Entity
alone,O
followed,O
by,O
vehicle,O
.,O
Group,I-Entity
3,O
received,O
diazepam,I-Entity
followed,O
by,O
5,O
mg,O
/,O
kg,O
flumazenil,I-Entity
.,O
Animals,I-Entity
became,O
somnolent,I-Entity
after,O
diazepam,I-Entity
and,O
then,O
active,O
after,O
flumazenil,I-Entity
administration,O
.,O
In,I-Entity
group,O
4,O
",",O
a,O
combination,O
of,O
cocaine,I-Entity
and,O
diazepam,I-Entity
was,O
administered,O
simultaneously,O
.,O
This,I-Entity
resulted,O
in,O
no,O
overt,O
or,O
EEG,I-Entity
-,O
detectable,O
seizures,I-Entity
and,O
a,O
50%,O
incidence,O
of,O
death,I-Entity
.,O
Group,I-Entity
5,O
received,O
a,O
similar,O
combination,O
of,O
cocaine,I-Entity
and,O
diazepam,I-Entity
",",O
followed,O
later,O
by,O
5,O
mg,O
/,O
kg,O
flumazenil,I-Entity
.,O
This,I-Entity
resulted,O
in,O
an,O
increased,O
incidence,O
of,O
seizures,I-Entity
",",O
90%,O
(,O
P,I-Entity
<,O
.01,O
),O
",",O
and,O
death,I-Entity
",",O
100%,O
Group,I-Entity
6,O
received,O
cocaine,I-Entity
and,O
diazepam,I-Entity
followed,O
by,O
10,O
mg,O
/,O
kg,O
flumazenil,I-Entity
.,O
This,I-Entity
also,O
resulted,O
in,O
an,O
increased,O
incidence,O
of,O
seizures,I-Entity
",",O
90%,O
CONCLUSION,I-Entity
:,O
Flumazenil,I-Entity
can,O
unmask,O
seizures,I-Entity
and,O
increase,O
the,O
incidence,O
of,O
death,I-Entity
in,O
a,O
model,O
of,O
combined,O
cocaine,I-Entity
-,O
diazepam,I-Entity
intoxications,O
.,O
Mechanisms,I-Entity
for,O
protective,O
effects,O
of,O
free,O
radical,O
scavengers,O
on,O
gentamicin,I-Entity
-,O
mediated,O
nephropathy,I-Entity
in,O
rats,O
.,O
Studies,I-Entity
were,O
performed,O
to,O
examine,O
the,O
mechanisms,O
for,O
the,O
protective,O
effects,O
of,O
free,O
radical,O
scavengers,O
on,O
gentamicin,I-Entity
(,O
GM)-mediated,I-Entity
nephropathy,I-Entity
.,O
Administration,I-Entity
of,O
GM,I-Entity
at,O
40,O
mg,O
/,O
kg,O
sc,O
for,O
13,O
days,O
to,O
rats,O
induced,O
a,O
significant,O
reduction,O
in,O
renal,O
blood,O
flow,O
(,O
RBF,I-Entity
),O
and,O
inulin,O
clearance,O
(,O
CIn,I-Entity
),O
as,O
well,O
as,O
marked,O
tubular,O
damage,O
.,O
A,I-Entity
significant,O
reduction,O
in,O
urinary,O
guanosine,I-Entity
"3',5'-cyclic",I-Entity
monophosphate,I-Entity
(,O
cGMP,I-Entity
),O
excretion,O
and,O
a,O
significant,O
increase,O
in,O
renal,O
cortical,O
renin,O
and,O
endothelin-1,I-Entity
contents,O
were,O
also,O
observed,O
in,O
GM,I-Entity
-,O
mediated,O
nephropathy,I-Entity
.,O
Superoxide,I-Entity
dismutase,O
(,O
SOD,I-Entity
),O
or,O
dimethylthiourea,I-Entity
(,O
DMTU,I-Entity
),O
significantly,O
lessened,O
the,O
GM,I-Entity
-,O
induced,O
decrement,O
in,O
CIn,I-Entity
.,O
The,I-Entity
SOD,I-Entity
-,O
induced,O
increase,O
in,O
glomerular,O
filtration,O
rate,O
was,O
associated,O
with,O
a,O
marked,O
improvement,O
in,O
RBF,I-Entity
",",O
an,O
increase,O
in,O
urinary,O
cGMP,I-Entity
excretion,O
",",O
and,O
a,O
decrease,O
in,O
renal,O
renin,O
and,O
endothelin-1,I-Entity
content,O
.,O
SOD,I-Entity
did,O
not,O
attenuate,O
the,O
tubular,O
damage,O
.,O
In,I-Entity
contrast,O
",",O
DMTU,I-Entity
significantly,O
reduced,O
the,O
tubular,O
damage,O
and,O
lipid,O
peroxidation,O
",",O
but,O
it,O
did,O
not,O
affect,O
renal,O
hemodynamics,O
and,O
vasoactive,O
substances,O
.,O
Neither,I-Entity
SOD,I-Entity
nor,O
DMTU,I-Entity
affected,O
the,O
renal,O
cortical,O
GM,I-Entity
content,O
in,O
GM,I-Entity
-,O
treated,O
rats,O
.,O
These,I-Entity
results,O
suggest,O
that,O
1,O
),O
both,O
SOD,I-Entity
and,O
DMTU,I-Entity
have,O
protective,O
effects,O
on,O
GM,I-Entity
-,O
mediated,O
nephropathy,I-Entity
",",O
2,O
),O
the,O
mechanisms,O
for,O
the,O
protective,O
effects,O
differ,O
for,O
SOD,I-Entity
and,O
DMTU,I-Entity
",",O
and,O
3,O
),O
superoxide,I-Entity
anions,O
play,O
a,O
critical,O
role,O
in,O
GM,I-Entity
-,O
induced,O
renal,O
vasoconstriction,O
.,O
Assessment,I-Entity
of,O
cardiomyocyte,O
DNA,I-Entity
synthesis,O
during,O
hypertrophy,I-Entity
in,O
adult,O
mice,O
.,O
The,I-Entity
ability,O
of,O
cardiomyocytes,O
to,O
synthesize,O
DNA,I-Entity
in,O
response,O
to,O
experimentally,O
induced,O
cardiac,O
hypertrophy,I-Entity
was,O
assessed,O
in,O
adult,O
mice,O
.,O
Isoproterenol,I-Entity
delivered,O
by,O
osmotic,O
minipump,O
implantation,O
in,O
adult,O
C3Heb,I-Entity
/,O
FeJ,I-Entity
mice,O
resulted,O
in,O
a,O
46%,O
increase,O
in,O
heart,O
weight,O
and,O
a,O
19.3%,O
increase,O
in,O
cardiomyocyte,O
area,O
.,O
No,I-Entity
DNA,I-Entity
synthesis,O
",",O
as,O
assessed,O
by,O
autoradiographic,O
analysis,O
of,O
isolated,O
cardiomyocytes,O
",",O
was,O
observed,O
in,O
control,O
or,O
hypertrophic,I-Entity
hearts,O
.,O
To,I-Entity
determine,O
whether,O
the,O
capacity,O
for,O
reactive,O
DNA,I-Entity
synthesis,O
was,O
also,O
subject,O
to,O
genetic,O
regulation,O
",",O
cardiac,O
hypertrophy,I-Entity
was,O
induced,O
in,O
the,O
strains,O
of,O
mice,O
comprising,O
the,O
extremes,O
of,O
the,O
nuclear,O
number,O
survey,O
.,O
These,I-Entity
data,O
indicate,O
that,O
adult,O
mouse,O
atrial,I-Entity
and,O
ventricular,O
cardiomyocytes,O
do,O
not,O
synthesize,O
DNA,I-Entity
in,O
response,O
to,O
isoproterenol,I-Entity
-,O
induced,O
cardiac,O
hypertrophy,I-Entity
.,O
Central,I-Entity
cardiovascular,O
effects,O
of,O
AVP,I-Entity
and,O
ANP,I-Entity
in,O
normotensive,I-Entity
and,O
spontaneously,O
hypertensive,I-Entity
rats,O
.,O
The,I-Entity
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
compare,O
influence,O
of,O
central,O
arginine,I-Entity
vasopressin,I-Entity
(,O
AVP,I-Entity
),O
and,O
of,O
atrial,I-Entity
natriuretic,O
peptide,I-Entity
(,O
ANP,I-Entity
),O
on,O
control,O
of,O
arterial,O
blood,O
pressure,O
(,O
MAP,I-Entity
),O
and,O
heart,O
rate,O
(,O
HR,I-Entity
),O
in,O
normotensive,I-Entity
(,O
WKY,I-Entity
),O
and,O
spontaneously,O
hypertensive,I-Entity
(,O
SHR,I-Entity
),O
rats,O
.,O
injections,O
of,O
either,O
vehicle,O
or,O
1,O
",",O
10,O
and,O
50,O
ng,O
of,O
AVP,I-Entity
and,O
25,O
",",O
125,I-Entity
and,O
500,O
ng,O
of,O
ANP,I-Entity
.,O
Sensitivity,I-Entity
of,O
cardiac,O
component,O
of,O
baroreflex,I-Entity
(,O
CCB,I-Entity
),O
",",O
expressed,O
as,O
a,O
slope,O
of,O
the,O
regression,O
line,O
was,O
determined,O
from,O
relationships,O
between,O
systolic,O
arterial,O
pressure,O
(,O
SAP,I-Entity
),O
and,O
HR,I-Entity
period,O
(,O
HRp,I-Entity
),O
during,O
phenylephrine,I-Entity
(,O
Phe)-induced,I-Entity
hypertension,I-Entity
and,O
sodium,I-Entity
nitroprusside,I-Entity
(,O
SN)-induced,I-Entity
hypotension,I-Entity
.,O
CCB,I-Entity
was,O
measured,O
before,O
and,O
after,O
administration,O
of,O
either,O
vehicle,O
",",O
AVP,I-Entity
",",O
ANP,I-Entity
",",O
or,O
both,O
peptides,I-Entity
together,O
.,O
Increases,I-Entity
of,O
MAP,I-Entity
occurred,O
after,O
LV,I-Entity
administration,O
of,O
1,O
",",O
10,O
and,O
50,O
ng,O
of,O
AVP,I-Entity
in,O
WKY,I-Entity
and,O
of,O
10,O
and,O
50,O
ng,O
in,O
SHR,I-Entity
.,O
ANP,I-Entity
did,O
not,O
cause,O
significant,O
changes,O
in,O
MAP,I-Entity
in,O
both,O
strains,O
as,O
compared,O
to,O
vehicle,O
",",O
but,O
it,O
abolished,O
AVP,I-Entity
-,O
induced,O
MAP,I-Entity
increase,O
in,O
WKY,I-Entity
and,O
SHR,I-Entity
.,O
CCB,I-Entity
was,O
reduced,O
in,O
WKY,I-Entity
and,O
SHR,I-Entity
after,O
LV,I-Entity
administration,O
of,O
AVP,I-Entity
during,O
SN,I-Entity
-,O
induced,O
hypotension,I-Entity
.,O
In,I-Entity
SHR,I-Entity
but,O
not,O
in,O
WKY,I-Entity
administration,O
of,O
ANP,I-Entity
",",O
AVP,I-Entity
and,O
ANP,I-Entity
+,O
AVP,I-Entity
decreased,O
CCB,I-Entity
during,O
Phe,I-Entity
-,O
induced,O
MAP,I-Entity
elevation,O
.,O
The,I-Entity
results,O
indicate,O
that,O
centrally,O
applied,O
AVP,I-Entity
and,O
ANP,I-Entity
exert,I-Entity
differential,O
effects,O
on,O
blood,O
pressure,O
and,O
baroreflex,I-Entity
control,O
of,O
heart,O
rate,O
in,O
WKY,I-Entity
and,O
SHR,I-Entity
and,O
suggest,O
interaction,O
of,O
these,O
two,O
peptides,I-Entity
in,O
blood,O
pressure,O
regulation,O
at,O
the,O
level,O
of,O
central,O
nervous,I-Entity
system,O
.,O
Cutaneous,I-Entity
exposure,O
to,O
warfarin,I-Entity
-,O
like,O
anticoagulant,O
causing,O
an,O
intracerebral,O
hemorrhage,I-Entity
:,O
a,O
case,O
report,O
.,O
A,I-Entity
case,O
of,O
intercerebral,O
hematoma,I-Entity
due,O
to,O
warfarin,I-Entity
-,O
induced,O
coagulopathy,I-Entity
is,O
presented,O
.,O
The,I-Entity
39-year,O
-,O
old,O
woman,O
had,O
spread,O
a,O
warfarin,I-Entity
-,O
type,O
rat,O
poison,I-Entity
around,O
her,O
house,O
weekly,O
using,O
her,O
bare,O
hands,O
",",O
with,O
no,O
washing,O
post,O
application,O
.,O
Percutaneous,I-Entity
absorption,O
of,O
warfarin,I-Entity
causing,O
coagulopathy,I-Entity
",",O
reported,O
three,O
times,O
in,O
the,O
past,O
",",O
is,O
a,O
significant,O
risk,O
if,O
protective,O
measures,O
",",O
such,O
as,O
gloves,O
",",O
are,O
not,O
used,O
.,O
An,I-Entity
adverse,O
drug,O
interaction,O
with,O
piroxicam,I-Entity
",",O
which,O
she,O
took,O
occasionally,O
",",O
may,O
have,O
exacerbated,O
the,O
coagulopathy,I-Entity
.,O
Pediatric,I-Entity
heart,O
transplantation,O
without,O
chronic,O
maintenance,O
steroids,I-Entity
.,O
Indications,I-Entity
for,O
transplantation,O
were,O
idiopathic,I-Entity
cardiomyopathy,I-Entity
(,O
52%,O
),O
",",O
congenital,O
heart,O
disease,I-Entity
(,O
35%,O
),O
with,O
and,O
without,O
prior,O
repair,O
(,O
71%,O
and,O
29%,O
",",O
respectively,O
),O
",",O
hypertrophic,I-Entity
cardiomyopathy,I-Entity
(,O
5%,O
),O
",",O
valvular,O
heart,O
disease,I-Entity
(,O
3%,O
),O
",",O
and,O
doxorubicin,I-Entity
cardiomyopathy,I-Entity
(,O
5%,O
),O
.,O
Patients,I-Entity
were,O
managed,O
with,O
cyclosporine,I-Entity
and,O
azathioprine,I-Entity
.,O
Steroids,I-Entity
were,O
given,O
to,O
39%,O
of,O
patients,O
for,O
refractory,O
rejection,I-Entity
",",O
but,O
weaning,O
was,O
always,O
attempted,O
and,O
generally,O
successful,O
(,O
64%,O
),O
.,O
Five,I-Entity
patients,O
(,O
14%,O
),O
received,O
maintenance,O
steroids,I-Entity
.,O
There,I-Entity
have,O
been,O
no,O
deaths,I-Entity
related,O
to,O
rejection,I-Entity
or,O
infection,I-Entity
.,O
Freedom,I-Entity
from,O
serious,O
infections,I-Entity
was,O
83%,O
at,O
1,O
month,O
and,O
65%,O
at,O
1,O
year,O
.,O
Cytomegalovirus,I-Entity
infections,I-Entity
were,O
treated,O
successfully,O
with,O
ganciclovir,I-Entity
in,O
11,O
patients,O
.,O
Twenty,I-Entity
-,O
one,O
patients,O
(,O
60%,O
),O
have,O
undergone,O
annual,O
catheterizations,O
and,O
no,O
sign,O
of,O
graft,O
atherosclerosis,I-Entity
has,O
been,O
observed,O
.,O
Seizures,I-Entity
occurred,O
in,O
five,O
patients,O
(,O
14%,O
),O
and,O
hypertension,I-Entity
was,O
treated,O
in,O
10,O
patients,O
(,O
28%,O
),O
.,O
No,I-Entity
patient,O
was,O
disabled,I-Entity
and,O
no,O
lymphoproliferative,O
disorder,I-Entity
was,O
observed.(ABSTRACT,O
TRUNCATED,I-Entity
AT,I-Entity
250,O
WORDS,I-Entity
),O
Delirium,I-Entity
during,O
fluoxetine,I-Entity
treatment,O
.,O
Only,I-Entity
a,O
few,O
reports,O
exist,O
",",O
however,O
",",O
on,O
the,O
relationship,O
between,O
the,O
serum,O
concentrations,O
of,O
selective,O
serotonin,I-Entity
reuptake,O
inhibitors,O
(,O
SSRIs,I-Entity
),O
and,O
their,O
toxic,I-Entity
effects,O
.,O
In,I-Entity
some,O
cases,O
",",O
a,O
high,O
serum,O
concentration,O
of,O
citalopram,I-Entity
(,O
>,O
600,O
nmol,I-Entity
/,O
L,I-Entity
),O
in,O
elderly,O
patients,O
has,O
been,O
associated,O
with,O
increased,O
somnolence,I-Entity
and,O
movement,O
difficulties,O
.,O
Widespread,I-Entity
cognitive,O
disorders,I-Entity
",",O
such,O
as,O
delirium,I-Entity
",",O
have,O
not,O
been,O
previously,O
linked,O
with,O
high,O
blood,O
levels,O
of,O
SSRIs,I-Entity
.,O
In,I-Entity
this,O
report,O
",",O
we,O
describe,O
a,O
patient,O
with,O
acute,O
hyperkinetic,I-Entity
delirium,I-Entity
connected,O
with,O
a,O
high,O
serum,O
total,O
fluoxetine,I-Entity
(,O
fluoxetine,I-Entity
plus,O
desmethylfluoxetine,I-Entity
),O
concentration,O
.,O
Pulmonary,I-Entity
edema,I-Entity
and,O
shock,I-Entity
after,O
high,O
-,O
dose,O
aracytine,I-Entity
-,O
C,I-Entity
for,O
lymphoma,I-Entity
;,O
possible,O
role,O
of,O
TNF,I-Entity
-,O
alpha,O
and,O
PAF,I-Entity
.,O
Four,I-Entity
out,O
of,O
23,O
consecutive,O
patients,O
treated,O
with,O
high,O
-,O
dose,O
Ara,I-Entity
-,O
C,I-Entity
for,O
lymphomas,I-Entity
in,O
our,O
institution,O
developed,O
a,O
strikingly,O
similar,O
syndrome,I-Entity
during,O
the,O
perfusion,O
.,O
It,I-Entity
was,O
characterized,O
by,O
the,O
onset,O
of,O
fever,I-Entity
",",O
diarrhea,I-Entity
",",O
shock,I-Entity
",",O
pulmonary,O
edema,I-Entity
",",O
acute,O
renal,O
failure,I-Entity
",",O
metabolic,O
acidosis,I-Entity
",",O
weight,O
gain,O
and,O
leukocytosis,I-Entity
.,O
Thorough,I-Entity
bacteriological,O
screening,O
failed,O
to,O
provide,O
evidence,O
of,O
infection,I-Entity
.,O
Sequential,I-Entity
biological,O
assays,O
of,O
IL-1,I-Entity
",",O
IL-2,I-Entity
",",O
TNF,I-Entity
and,O
PAF,I-Entity
were,O
performed,O
during,O
Ara,I-Entity
-,O
C,I-Entity
infusion,O
to,O
ten,O
patients,O
",",O
including,O
the,O
four,O
who,O
developed,O
the,O
syndrome,I-Entity
.,O
As,I-Entity
TNF,I-Entity
and,O
PAF,I-Entity
are,O
thought,O
to,O
be,O
involved,O
in,O
the,O
development,O
of,O
septic,I-Entity
shock,I-Entity
and,O
adult,O
respiratory,O
distress,I-Entity
syndrome,I-Entity
",",O
we,O
hypothesize,O
that,O
high,O
-,O
dose,O
Ara,I-Entity
-,O
C,I-Entity
may,O
be,O
associated,O
with,O
cytokine,I-Entity
release,O
.,O
Protective,I-Entity
effect,O
of,O
clentiazem,I-Entity
against,O
epinephrine,I-Entity
-,O
induced,O
cardiac,O
injury,I-Entity
in,O
rats,O
.,O
We,I-Entity
investigated,O
the,O
effects,O
of,O
clentiazem,I-Entity
",",O
a,O
"1,5-benzothiazepine",O
calcium,I-Entity
antagonist,O
",",O
on,O
epinephrine,I-Entity
-,O
induced,O
cardiomyopathy,I-Entity
in,O
rats,O
.,O
With,I-Entity
2-week,O
chronic,O
epinephrine,I-Entity
infusion,O
",",O
16,O
of,O
30,O
rats,O
died,O
within,O
4,O
days,O
",",O
and,O
severe,O
ischemic,I-Entity
lesions,O
and,O
fibrosis,I-Entity
of,O
the,O
left,O
ventricles,O
were,O
observed,O
.,O
In,I-Entity
epinephrine,I-Entity
-,O
treated,O
rats,O
",",O
left,O
atrial,I-Entity
and,O
left,O
ventricular,O
papillary,I-Entity
muscle,O
contractile,O
responses,O
to,O
isoproterenol,I-Entity
were,O
reduced,O
",",O
but,O
responses,O
to,O
calcium,I-Entity
were,O
normal,O
or,O
enhanced,O
compared,O
to,O
controls,O
.,O
Treatment,I-Entity
with,O
clentiazem,I-Entity
prevented,O
epinephrine,I-Entity
-,O
induced,O
death,I-Entity
(,O
P,I-Entity
<,O
.05,O
),O
",",O
and,O
attenuated,O
the,O
ventricular,O
ischemic,I-Entity
lesions,O
and,O
fibrosis,I-Entity
",",O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
.,O
Left,I-Entity
atrial,I-Entity
and,O
left,O
ventricular,O
papillary,I-Entity
muscle,O
contractile,O
responses,O
to,O
isoproterenol,I-Entity
were,O
reduced,O
compared,O
to,O
controls,O
in,O
groups,O
treated,O
with,O
clentiazem,I-Entity
alone,O
",",O
but,O
combined,O
with,O
epinephrine,I-Entity
",",O
clentiazem,I-Entity
restored,O
left,O
atrial,I-Entity
responses,O
and,O
enhanced,O
left,O
ventricular,O
papillary,I-Entity
responses,O
to,O
isoproterenol,I-Entity
.,O
On,I-Entity
the,O
other,O
hand,O
clentiazem,I-Entity
did,O
not,O
prevent,O
epinephrine,I-Entity
-,O
induced,O
down,O
-,O
regulation,O
of,O
alpha,O
and,O
beta,O
adrenoceptors,O
.,O
Interestingly,I-Entity
",",O
clentiazem,I-Entity
",",O
infused,O
alone,O
",",O
resulted,O
in,O
decreased,O
adrenergic,O
receptor,O
densities,O
in,O
the,O
left,O
ventricle,O
.,O
Clentiazem,I-Entity
also,O
did,O
not,O
prevent,O
the,O
enhanced,O
responses,O
to,O
calcium,I-Entity
seen,O
in,O
the,O
epinephrine,I-Entity
-,O
treated,O
animals,O
",",O
although,O
the,O
high,O
dose,O
of,O
clentiazem,I-Entity
partially,O
attenuated,O
the,O
maximal,O
response,O
to,O
calcium,I-Entity
compared,O
to,O
epinephrine,I-Entity
-,O
treated,O
animals,O
.,O
In,I-Entity
conclusion,O
",",O
clentiazem,I-Entity
attenuated,O
epinephrine,I-Entity
-,O
induced,O
cardiac,O
injury,I-Entity
",",O
possibly,O
through,O
its,O
effect,O
on,O
the,O
adrenergic,O
pathway,O
.,O
Cocaine,I-Entity
induced,O
myocardial,B-Entity
ischemia,I-Entity
.,O
We,I-Entity
report,O
a,O
case,O
of,O
myocardial,B-Entity
ischemia,I-Entity
induced,O
by,O
cocaine,I-Entity
.,O
The,I-Entity
ischemia,I-Entity
probably,O
induced,O
by,O
coronary,O
artery,I-Entity
spasm,I-Entity
was,O
reversed,O
by,O
nitroglycerin,I-Entity
and,O
calcium,I-Entity
blocking,I-Entity
agents,O
.,O
Doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
monitored,O
by,O
ECG,I-Entity
in,O
freely,O
moving,O
mice,O
.,O
In,I-Entity
laboratory,O
animals,O
",",O
histology,O
is,O
most,O
commonly,O
used,O
to,O
study,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
With,I-Entity
this,O
model,O
we,O
investigated,O
the,O
effect,O
of,O
chronic,O
doxorubicin,I-Entity
administration,O
on,O
the,O
ECG,I-Entity
of,O
freely,O
moving,O
BALB,I-Entity
/,O
c,O
mice,O
and,O
the,O
efficacy,O
of,O
ICRF-187,I-Entity
as,O
a,O
protective,O
agent,O
.,O
11.8,O
ms,O
in,O
week,O
10,O
(,O
7,O
weekly,O
doses,O
of,O
4,O
mg,O
/,O
kg,O
doxorubicin,I-Entity
given,O
i.v,O
.,O
After,I-Entity
sacrifice,O
the,O
hearts,O
of,O
doxorubicin,I-Entity
-,O
treated,O
animals,O
were,O
enlarged,O
and,O
the,O
atria,O
were,O
hypertrophic,I-Entity
.,O
As,I-Entity
this,O
schedule,O
exerted,O
more,O
toxicity,I-Entity
than,O
needed,O
to,O
investigate,O
protective,O
agents,O
",",O
the,O
protection,O
of,O
ICRF-187,I-Entity
was,O
determined,O
using,O
a,O
dose,O
schedule,O
with,O
lower,O
general,O
toxicity,I-Entity
(,O
6,O
weekly,O
doses,O
of,O
4,O
mg,O
/,O
kg,O
doxorubicin,I-Entity
given,O
i.v,O
.,O
On,I-Entity
this,O
schedule,O
",",O
the,O
animals,O
',O
hearts,O
appeared,O
normal,O
after,O
sacrifice,O
and,O
ICRF-187,I-Entity
(,O
50,O
mg,O
/,O
kg,O
given,O
i.p,O
.,O
1,O
h,O
before,O
doxorubicin,I-Entity
),O
provided,O
almost,O
full,O
protection,O
.,O
The,I-Entity
results,O
indicate,O
that,O
this,O
new,O
model,O
is,O
very,O
sensitive,I-Entity
and,O
enables,O
monitoring,O
of,O
the,O
development,O
of,O
cardiotoxicity,I-Entity
with,O
time,O
.,O
These,I-Entity
findings,O
result,O
in,O
a,O
model,O
that,O
allows,O
the,O
testing,O
of,O
protectors,O
against,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
as,O
demonstrated,O
by,O
the,O
protection,O
provided,O
by,O
ICRF-187,I-Entity
.,O
Epinephrine,I-Entity
dysrhythmogenicity,I-Entity
is,O
not,O
enhanced,O
by,O
subtoxic,I-Entity
bupivacaine,I-Entity
in,O
dogs,O
.,O
Since,I-Entity
bupivacaine,I-Entity
and,O
epinephrine,I-Entity
may,O
both,O
precipitate,O
dysrhythmias,I-Entity
",",O
circulating,O
bupivacaine,I-Entity
during,O
regional,O
anesthesia,O
could,O
potentiate,O
dysrhythmogenic,I-Entity
effects,O
of,O
epinephrine,I-Entity
.,O
We,I-Entity
therefore,O
examined,O
whether,O
bupivacaine,I-Entity
alters,I-Entity
the,O
dysrhythmogenicity,I-Entity
of,O
subsequent,O
administration,O
of,O
epinephrine,I-Entity
in,O
conscious,O
",",O
healthy,O
dogs,O
and,O
in,O
anesthetized,O
dogs,O
with,O
myocardial,B-Entity
infarction,I-Entity
.,O
Forty,I-Entity
-,O
one,O
conscious,O
dogs,O
received,O
10,O
micrograms.kg-1.min-1,O
epinephrine,I-Entity
.,O
Seventeen,I-Entity
animals,O
responded,O
with,O
ventricular,O
tachycardia,I-Entity
(,O
VT,I-Entity
),O
within,O
3,O
min,O
.,O
After,I-Entity
3,O
h,O
",",O
these,O
responders,O
randomly,O
received,O
1,O
or,O
2,O
mg,O
/,O
kg,O
bupivacaine,I-Entity
or,O
saline,O
over,O
5,O
min,O
",",O
followed,O
by,O
10,O
micrograms.kg-1.min-1,O
epinephrine,I-Entity
.,O
In,I-Entity
the,O
bupivacaine,I-Entity
groups,O
",",O
epinephrine,I-Entity
caused,O
fewer,O
prodysrhythmic,O
effects,O
than,O
without,O
bupivacaine,I-Entity
.,O
VT,I-Entity
appeared,O
in,O
fewer,O
dogs,O
and,O
at,O
a,O
later,O
time,O
",",O
and,O
there,O
were,O
more,O
sinoatrial,O
beats,O
and,O
less,O
ectopies,I-Entity
.,O
Epinephrine,I-Entity
shortened,O
QT,I-Entity
less,O
after,O
bupivacaine,I-Entity
than,O
in,O
control,O
animals,O
.,O
One,I-Entity
day,O
after,O
experimental,O
myocardial,B-Entity
infarction,I-Entity
",",O
six,O
additional,O
halothane,I-Entity
-,O
anesthetized,O
dogs,O
received,O
4,O
micrograms.kg-1.min-1,O
epinephrine,I-Entity
until,O
VT,I-Entity
appeared,O
.,O
After,I-Entity
45,I-Entity
min,O
",",O
1,O
mg,O
/,O
kg,O
bupivacaine,I-Entity
was,O
injected,O
over,O
5,O
min,O
",",O
again,O
followed,O
by,O
4,O
micrograms.kg-1.min-1,O
epinephrine,I-Entity
.,O
In,I-Entity
these,O
dogs,O
",",O
the,O
prodysrhythmic,O
response,O
to,O
epinephrine,I-Entity
was,O
also,O
mitigated,O
by,O
preceding,O
bupivacaine,I-Entity
.,O
Bupivacaine,I-Entity
antagonizes,I-Entity
epinephrine,I-Entity
dysrhythmogenicity,I-Entity
in,O
conscious,O
dogs,O
susceptible,O
to,O
VT,I-Entity
and,O
in,O
anesthetized,O
dogs,O
with,O
spontaneous,O
postinfarct,I-Entity
dysrhythmias,I-Entity
.,O
There,I-Entity
is,O
no,O
evidence,O
that,O
systemic,O
subtoxic,I-Entity
bupivacaine,I-Entity
administration,O
enhances,O
the,O
dysrhythmogenicity,I-Entity
of,O
subsequent,O
epinephrine,I-Entity
.,O
Milk,I-Entity
-,O
alkali,I-Entity
syndrome,I-Entity
induced,O
by,O
"1,25(OH)2D",O
in,O
a,O
patient,O
with,O
hypoparathyroidism,I-Entity
.,O
Milk,I-Entity
-,O
alkali,I-Entity
syndrome,I-Entity
was,O
first,O
described,O
70,I-Entity
years,O
ago,O
in,O
the,O
context,O
of,O
the,O
treatment,O
of,O
peptic,I-Entity
ulcer,I-Entity
disease,I-Entity
with,O
large,O
amounts,O
of,O
calcium,I-Entity
and,O
alkali,I-Entity
.,O
Although,I-Entity
with,O
current,O
ulcer,I-Entity
therapy,O
(,O
H-2,I-Entity
blockers,O
",",O
omeprazole,I-Entity
",",O
and,O
sucralfate,I-Entity
),O
",",O
the,O
frequency,O
of,O
milk,O
-,O
alkali,I-Entity
syndrome,I-Entity
has,O
decreased,O
significantly,O
",",O
the,O
classic,O
triad,I-Entity
of,O
hypercalcemia,I-Entity
",",O
alkalosis,I-Entity
",",O
and,O
renal,O
impairment,I-Entity
remains,O
the,O
hallmark,O
of,O
the,O
syndrome,I-Entity
.,O
Milk,I-Entity
-,O
alkali,I-Entity
syndrome,I-Entity
can,O
present,O
serious,O
and,O
occasionally,O
life,O
-,O
threatening,I-Entity
illness,I-Entity
unless,O
diagnosed,O
and,O
treated,O
appropriately,O
.,O
This,I-Entity
article,O
presents,O
a,O
patient,O
with,O
hypoparathyroidism,I-Entity
who,O
was,O
treated,O
with,O
calcium,I-Entity
carbonate,I-Entity
and,O
calcitriol,I-Entity
resulting,O
in,O
two,O
admissions,O
to,O
the,O
hospital,O
for,O
milk,O
-,O
alkali,I-Entity
syndrome,I-Entity
.,O
The,I-Entity
patient,O
was,O
successfully,O
treated,O
with,O
intravenous,O
pamidronate,I-Entity
on,O
his,O
first,O
admission,O
and,O
with,O
hydrocortisone,I-Entity
on,O
the,O
second,O
.,O
This,I-Entity
illustrates,O
intravenous,O
pamidronate,I-Entity
as,O
a,O
valuable,O
therapeutic,O
tool,O
when,O
milk,O
-,O
alkali,I-Entity
syndrome,I-Entity
presents,O
as,O
hypercalcemic,B-Entity
emergency,O
.,O
Encephalopathy,I-Entity
during,O
amitriptyline,I-Entity
therapy,O
:,O
are,O
neuroleptic,O
malignant,I-Entity
syndrome,I-Entity
and,O
serotonin,I-Entity
syndrome,I-Entity
spectrum,O
disorders,I-Entity
?,O
This,I-Entity
report,O
describes,O
a,O
case,O
of,O
encephalopathy,I-Entity
developed,O
in,O
the,O
course,O
of,O
amitriptyline,I-Entity
therapy,O
",",O
during,O
a,O
remission,O
of,O
unipolar,O
depression,I-Entity
.,O
This,I-Entity
patient,O
could,O
have,O
been,O
diagnosed,O
as,O
having,O
either,O
neuroleptic,O
malignant,I-Entity
syndrome,I-Entity
(,O
NMS,I-Entity
),O
or,O
serotonin,I-Entity
syndrome,I-Entity
(,O
SS,I-Entity
),O
.,O
The,I-Entity
major,O
determinant,O
of,O
the,O
symptoms,O
may,O
have,O
been,O
dopamine,I-Entity
/,O
serotonin,I-Entity
imbalance,I-Entity
in,O
the,O
central,O
nervous,I-Entity
system,O
.,O
The,I-Entity
NMS,I-Entity
-,O
like,O
encephalopathy,I-Entity
that,O
develops,O
in,O
association,O
with,O
the,O
use,O
of,O
antidepressants,I-Entity
indicates,O
that,O
NMS,I-Entity
and,O
SS,I-Entity
are,O
spectrum,O
disorders,I-Entity
induced,O
by,O
drugs,O
with,O
both,O
antidopaminergic,O
and,O
serotonergic,I-Entity
effects,O
.,O
Genetic,I-Entity
separation,O
of,O
tumor,I-Entity
growth,O
and,O
hemorrhagic,I-Entity
phenotypes,O
in,O
an,O
estrogen,I-Entity
-,O
induced,O
tumor,I-Entity
.,O
Chronic,I-Entity
administration,O
of,O
estrogen,I-Entity
to,O
the,O
Fischer,I-Entity
344,O
(,O
F344,I-Entity
),O
rat,O
induces,O
growth,O
of,O
large,O
",",O
hemorrhagic,I-Entity
pituitary,O
tumors,I-Entity
.,O
Ten,I-Entity
weeks,O
of,O
diethylstilbestrol,I-Entity
(,O
DES,I-Entity
),O
treatment,O
caused,O
female,O
F344,I-Entity
rat,O
pituitaries,O
to,O
grow,O
to,O
an,O
average,O
of,O
109.2,O
+,O
/-,O
1.4,O
mg,O
for,O
untreated,O
rats,O
",",O
and,O
to,O
become,O
highly,O
hemorrhagic,I-Entity
.,O
The,I-Entity
same,O
DES,I-Entity
treatment,O
produced,O
no,O
significant,O
growth,O
(,O
8.9,O
+,O
/-,O
An,I-Entity
F1,I-Entity
hybrid,O
of,O
F344,I-Entity
and,O
BN,I-Entity
exhibited,O
significant,O
pituitary,O
growth,O
after,O
10,O
weeks,O
of,O
DES,I-Entity
treatment,O
with,O
an,O
average,O
mass,O
of,O
26.3,O
+,O
/-,O
Surprisingly,I-Entity
",",O
the,O
F1,I-Entity
hybrid,O
tumors,I-Entity
were,O
not,O
hemorrhagic,I-Entity
and,O
had,O
hemoglobin,O
content,O
and,O
outward,O
appearance,O
identical,O
to,O
that,O
of,O
BN,I-Entity
.,O
However,I-Entity
",",O
while,O
DES,I-Entity
-,O
induced,O
pituitary,O
growth,O
exhibited,O
quantitative,O
",",O
additive,O
inheritance,O
",",O
the,O
hemorrhagic,I-Entity
phenotype,O
exhibited,O
recessive,O
",",O
epistatic,O
inheritance,O
.,O
Only,I-Entity
5,O
of,O
the,O
160,I-Entity
F2,I-Entity
pituitaries,O
exhibited,O
the,O
hemorrhagic,I-Entity
phenotype,O
;,O
36,O
of,O
the,O
160,I-Entity
F2,I-Entity
pituitaries,O
were,O
in,O
the,O
F344,I-Entity
range,O
of,O
mass,O
",",O
but,O
31,O
of,O
these,O
were,O
not,O
hemorrhagic,I-Entity
",",O
indicating,O
that,O
the,O
hemorrhagic,I-Entity
phenotype,O
is,O
not,O
merely,O
a,O
consequence,O
of,O
extensive,O
growth,O
.,O
The,I-Entity
hemorrhagic,I-Entity
F2,I-Entity
pituitaries,O
were,O
all,O
among,O
the,O
most,O
massive,O
",",O
indicating,O
that,O
some,O
of,O
the,O
genes,O
regulate,O
both,O
phenotypes,O
.,O
Increased,I-Entity
expression,O
of,O
neuronal,O
nitric,I-Entity
oxide,I-Entity
synthase,O
in,O
bladder,I-Entity
afferent,O
pathways,O
following,O
chronic,O
bladder,I-Entity
irritation,I-Entity
.,O
Immunocytochemical,I-Entity
techniques,O
were,O
used,O
to,O
examine,O
alterations,I-Entity
in,O
the,O
expression,O
of,O
neuronal,O
nitric,I-Entity
oxide,I-Entity
synthase,O
(,O
NOS,I-Entity
),O
in,O
bladder,I-Entity
pathways,O
following,O
acute,O
and,O
chronic,O
irritation,I-Entity
of,O
the,O
urinary,O
tract,O
of,O
the,O
rat,O
.,O
Chemical,I-Entity
cystitis,I-Entity
was,O
induced,O
by,O
cyclophosphamide,I-Entity
(,O
CYP,I-Entity
),O
which,O
is,O
metabolized,O
to,O
acrolein,I-Entity
",",O
an,O
irritant,I-Entity
eliminated,O
in,O
the,O
urine,I-Entity
.,O
Injection,I-Entity
of,O
CYP,I-Entity
(,O
n,O
=,O
10,O
",",O
75,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
Fos,I-Entity
-,O
IR,I-Entity
in,O
the,O
spinal,O
cord,O
was,O
not,O
changed,O
in,O
rats,O
receiving,O
chronic,O
CYP,I-Entity
treatment,O
(,O
In,I-Entity
control,O
animals,O
and,O
in,O
animals,O
treated,O
acutely,O
with,O
CYP,I-Entity
",",O
only,O
small,O
numbers,O
of,O
NOS,I-Entity
-,O
IR,I-Entity
cells,O
(,O
0.5,O
-,O
0.7,O
cell,O
profiles,O
/,O
sections,O
),O
were,O
detected,O
in,O
the,O
L6-S1,I-Entity
dorsal,O
root,O
ganglia,I-Entity
(,O
DRG,I-Entity
),O
.,O
Chronic,I-Entity
CYP,I-Entity
administration,O
significantly,O
(,O
P,I-Entity
<,O
or,O
=,O
.002,O
),O
increased,O
bladder,I-Entity
weight,O
by,O
60%,O
and,O
increased,O
(,O
7-,I-Entity
to,O
11-fold,O
),O
the,O
numbers,O
of,O
NOS,I-Entity
-,O
immunoreactive,O
(,O
IR,I-Entity
),O
afferent,O
neurons,O
in,O
the,O
L6-S1,I-Entity
DRG,I-Entity
.,O
Bladder,I-Entity
afferent,O
cells,O
in,O
the,O
L6-S1,I-Entity
DRG,I-Entity
labeled,O
by,O
Fluorogold,I-Entity
(,O
40,O
microliters,O
),O
injected,O
into,O
the,O
bladder,I-Entity
wall,O
did,O
not,O
exhibit,O
NOS,I-Entity
-,O
IR,I-Entity
in,O
control,O
animals,O
;,O
however,O
",",O
following,O
chronic,O
CYP,I-Entity
administration,O
",",O
a,O
significant,O
percentage,O
of,O
bladder,I-Entity
afferent,O
neurons,O
were,O
NOS,I-Entity
-,O
IR,I-Entity
:,O
Effects,I-Entity
of,O
a,O
new,O
calcium,I-Entity
antagonist,O
",",O
CD-832,I-Entity
",",O
on,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
ischemia,I-Entity
in,O
dogs,O
with,O
partial,O
coronary,O
stenosis,I-Entity
.,O
Effects,I-Entity
of,O
CD-832,I-Entity
on,O
isoproterenol,I-Entity
(,O
ISO)-induced,I-Entity
myocardial,B-Entity
ischemia,I-Entity
were,O
studied,O
in,O
dogs,O
with,O
partial,O
coronary,O
stenosis,I-Entity
of,O
the,O
left,O
circumflex,O
coronary,O
artery,I-Entity
and,O
findings,O
were,O
compared,O
with,O
those,O
for,O
nifedipine,I-Entity
or,O
diltiazem,I-Entity
.,O
In,I-Entity
the,O
presence,O
of,O
coronary,O
artery,I-Entity
stenosis,I-Entity
",",O
3-min,O
periods,O
of,O
intracoronary,O
ISO,I-Entity
infusion,O
(,O
10,O
ng,O
/,O
kg,O
/,O
min,O
),O
increased,O
heart,O
rate,O
and,O
maximal,O
rate,O
of,O
left,O
ventricular,O
pressure,O
rise,O
",",O
which,O
resulted,O
in,O
a,O
decrease,O
in,O
percentage,O
segmental,O
shortening,O
and,O
ST,I-Entity
-,O
segment,O
elevation,O
of,O
the,O
epicardial,O
electrocardiogram,O
.,O
After,I-Entity
the,O
control,O
ISO,I-Entity
infusion,O
with,O
stenosis,I-Entity
was,O
performed,O
",",O
equihypotensive,O
doses,O
of,O
CD-832,I-Entity
(,O
3,O
and,O
10,O
micrograms,O
/,O
kg,O
/,O
min,O
",",O
n,O
=,O
7,O
),O
",",O
nifedipine,I-Entity
(,O
1,O
and,O
3,O
micrograms,O
/,O
kg,O
/,O
min,O
",",O
n,O
=,O
9,O
),O
or,O
diltiazem,I-Entity
(,O
10,O
and,O
30,O
micrograms,O
/,O
kg,O
/,O
min,O
",",O
n,O
=,O
7,O
),O
were,O
infused,O
5,O
min,O
before,O
and,O
during,O
the,O
second,O
and,O
third,O
ISO,I-Entity
infusion,O
.,O
Both,I-Entity
CD-832,I-Entity
and,O
diltiazem,I-Entity
",",O
but,O
not,O
nifedipine,I-Entity
",",O
significantly,O
reduced,O
the,O
increase,O
in,O
heart,O
rate,O
induced,O
by,O
ISO,I-Entity
infusion,O
.,O
In,I-Entity
contrast,O
to,O
nifedipine,I-Entity
",",O
CD-832,I-Entity
(,O
10,O
micrograms,O
/,O
<,O
.01,O
),O
at,O
3,O
min,O
after,O
ISO,I-Entity
infusion,O
with,O
stenosis,I-Entity
.,O
Diltiazem,I-Entity
(,O
30,O
micrograms,O
/,O
kg,O
/,O
min,O
),O
also,O
prevented,O
the,O
decrease,O
in,O
percentage,O
segmental,O
shortening,O
from,O
34,O
+,O
/-,O
.01,O
),O
at,O
3,O
min,O
after,O
ISO,I-Entity
infusion,O
with,O
stenosis,I-Entity
.,O
These,I-Entity
data,O
show,O
that,O
CD-832,I-Entity
improves,O
myocardial,B-Entity
ischemia,I-Entity
during,O
ISO,I-Entity
infusion,O
with,O
stenosis,I-Entity
and,O
suggest,O
that,O
the,O
negative,O
chronotropic,O
property,O
of,O
CD-832,I-Entity
plays,O
a,O
major,O
role,O
in,O
the,O
beneficial,O
effects,O
of,O
CD-832,I-Entity
.,O
The,I-Entity
effect,O
of,O
recombinant,O
human,O
insulin,I-Entity
-,O
like,O
growth,O
factor,O
-,O
I,I-Entity
on,O
chronic,O
puromycin,I-Entity
aminonucleoside,I-Entity
nephropathy,I-Entity
in,O
rats,O
.,O
We,I-Entity
recently,O
demonstrated,O
that,O
recombinant,O
hGH,I-Entity
exacerbates,O
renal,O
functional,O
and,O
structural,O
injury,I-Entity
in,O
chronic,O
puromycin,I-Entity
aminonucleoside,I-Entity
(,O
PAN,I-Entity
),O
nephropathy,I-Entity
",",O
an,O
experimental,O
model,O
of,O
glomerular,O
disease,I-Entity
.,O
IGF,I-Entity
-,O
I,I-Entity
is,O
a,O
safer,O
alternative,O
for,O
the,O
treatment,O
of,O
growth,O
failure,I-Entity
in,O
rats,O
with,O
chronic,O
PAN,I-Entity
nephropathy,I-Entity
.,O
The,I-Entity
glomerulopathy,I-Entity
was,O
induced,O
by,O
seven,O
serial,O
injections,O
of,O
PAN,I-Entity
over,O
12,O
wk,O
.,O
rhIGF,I-Entity
-,O
I,I-Entity
improved,O
weight,O
gain,O
by,O
14%,O
(,O
p,O
<,O
0.05,O
),O
",",O
without,O
altering,O
hematocrit,O
or,O
blood,O
pressure,O
in,O
rats,O
with,O
renal,O
disease,I-Entity
.,O
I,I-Entity
treatment,O
in,O
rats,O
with,O
chronic,O
PAN,I-Entity
nephropathy,I-Entity
.,O
0.06,O
mL,I-Entity
/,O
min/100,O
g,O
of,O
body,O
weight,O
in,O
untreated,O
PAN,I-Entity
nephropathy,I-Entity
animals,O
",",O
p,O
The,I-Entity
improvement,O
in,O
GFR,I-Entity
was,O
not,O
associated,O
with,O
enhanced,O
glomerular,O
hypertrophy,I-Entity
or,O
increased,O
segmental,O
glomerulosclerosis,I-Entity
",",O
tubulointerstitial,O
injury,I-Entity
",",O
or,O
renal,O
cortical,O
malondialdehyde,I-Entity
content,O
.,O
In,I-Entity
rats,O
with,O
PAN,I-Entity
nephropathy,I-Entity
",",O
administration,O
of,O
rhIGF,I-Entity
-,O
I,I-Entity
increased,O
IGF,I-Entity
-,O
I,I-Entity
and,O
GH,I-Entity
receptor,O
gene,O
expression,O
",",O
without,O
altering,O
the,O
steady,O
state,O
level,O
of,O
IGF,I-Entity
-,O
I,I-Entity
receptor,O
mRNA,I-Entity
.,O
In,I-Entity
normal,O
rats,O
with,O
intact,O
kidneys,I-Entity
",",O
rhIGF,I-Entity
-,O
I,I-Entity
administration,O
(,O
n,O
=,O
4,O
),O
did,O
not,O
alter,O
weight,O
gain,O
",",O
blood,O
pressure,O
",",O
proteinuria,I-Entity
",",O
GFR,I-Entity
",",O
glomerular,O
planar,O
area,O
",",O
renal,O
cortical,O
malondialdehyde,I-Entity
content,O
",",O
or,O
glomerular,O
or,O
tubulointerstitial,O
damage,O
",",O
compared,O
with,O
untreated,O
animals,O
(,O
n,O
=,O
4,O
),O
.,O
We,I-Entity
conclude,O
that,O
:,O
1,O
),O
administration,O
of,O
rhIGF,I-Entity
-,O
I,I-Entity
improves,O
growth,O
and,O
GFR,I-Entity
in,O
rats,O
with,O
chronic,O
PAN,I-Entity
nephropathy,I-Entity
and,O
2,O
),O
unlike,O
rhGH,I-Entity
",",O
long,O
-,O
term,O
use,O
of,O
rhIGF,I-Entity
-,O
I,I-Entity
does,O
not,O
worsen,O
renal,O
functional,O
and,O
structural,O
injury,I-Entity
in,O
this,O
disease,I-Entity
model,O
.,O
Nefiracetam,I-Entity
(,O
DM-9384,I-Entity
),O
reverses,O
apomorphine,I-Entity
-,O
induced,O
amnesia,I-Entity
of,O
a,O
passive,O
avoidance,I-Entity
response,O
:,O
Nefiracetam,I-Entity
is,O
a,O
novel,O
pyrrolidone,I-Entity
derivative,O
which,O
attenuates,O
scopolamine,I-Entity
-,O
induced,O
learning,O
and,O
post,O
-,O
training,O
consolidation,O
deficits,I-Entity
.,O
Given,I-Entity
that,O
apomorphine,I-Entity
inhibits,O
passive,O
avoidance,I-Entity
retention,O
when,O
given,O
during,O
training,O
or,O
in,O
a,O
defined,O
10,O
-,O
12h,O
post,O
-,O
training,O
period,O
",",O
we,O
evaluated,O
the,O
ability,O
of,O
nefiracetam,I-Entity
to,O
attenuate,O
amnesia,I-Entity
induced,O
by,O
dopaminergic,O
agonism,I-Entity
.,O
A,I-Entity
step,O
-,O
down,O
passive,O
avoidance,I-Entity
paradigm,O
was,O
employed,O
and,O
nefiracetam,I-Entity
(,O
3,O
mg,O
/,O
kg,O
),O
and,O
apomorphine,I-Entity
(,O
0.5,O
mg,O
/,O
kg,O
),O
were,O
given,O
alone,O
or,O
in,O
combination,O
during,O
training,O
and,O
at,O
the,O
10,O
-,O
12h,O
post,O
-,O
training,O
period,O
of,O
consolidation,O
.,O
Co,I-Entity
-,O
administration,O
of,O
nefiracetam,I-Entity
and,O
apomorphine,I-Entity
during,O
training,O
or,O
10h,I-Entity
thereafter,O
produced,O
no,O
significant,O
anti,O
-,O
amnesic,I-Entity
effect,O
.,O
However,I-Entity
",",O
administration,O
of,O
nefiracetam,I-Entity
during,O
training,O
completely,O
reversed,O
the,O
amnesia,I-Entity
induced,O
by,O
apomorphine,I-Entity
at,O
the,O
10h,I-Entity
post,O
-,O
training,O
time,O
and,O
the,O
converse,O
was,O
also,O
true,O
.,O
These,I-Entity
effects,O
were,O
not,O
mediated,O
by,O
a,O
dopaminergic,O
mechanism,O
as,O
nefiracetam,I-Entity
",",O
at,O
millimolar,I-Entity
concentrations,O
",",O
failed,O
to,O
displace,O
either,O
[,O
3H]SCH,I-Entity
23390,I-Entity
or,O
[,O
3H]spiperone,I-Entity
binding,O
from,O
D1,I-Entity
or,O
D2,I-Entity
dopamine,I-Entity
receptor,O
subtypes,O
",",O
respectively,O
.,O
It,I-Entity
is,O
suggested,O
that,O
nefiracetam,I-Entity
augments,O
molecular,O
processes,O
in,O
the,O
early,O
stages,O
of,O
events,O
which,O
ultimately,O
lead,O
to,O
consolidation,O
of,O
memory,O
.,O
Human,I-Entity
corticotropin,I-Entity
-,O
releasing,O
hormone,I-Entity
and,O
thyrotropin,I-Entity
-,O
releasing,O
hormone,I-Entity
modulate,O
the,O
hypercapnic,I-Entity
ventilatory,O
response,O
in,O
humans,O
.,O
Human,I-Entity
corticotropin,I-Entity
-,O
releasing,O
hormone,I-Entity
(,O
hCRH,I-Entity
),O
and,O
thyrotropin,I-Entity
-,O
releasing,O
hormone,I-Entity
(,O
TRH,I-Entity
),O
are,O
known,O
to,O
stimulate,O
ventilation,O
after,O
i.v,O
.,O
Two,I-Entity
subsequent,O
CO2-rebreathing,I-Entity
tests,O
were,O
performed,O
in,O
healthy,O
young,O
volunteers,O
.,O
During,I-Entity
the,O
first,O
test,O
0.9%,O
NaCl,I-Entity
was,O
given,O
i.v,O
.,O
Nine,I-Entity
subjects,O
received,O
0.9%,O
NaCl,I-Entity
i.v,O
.,O
The,I-Entity
CO2-response,I-Entity
curves,O
for,O
the,O
two,O
tests,O
were,O
compared,O
within,O
the,O
same,O
subject,O
.,O
In,I-Entity
the,O
hCRH,I-Entity
group,O
a,O
marked,O
parallel,I-Entity
shift,O
of,O
the,O
CO2-response,I-Entity
curve,O
to,O
the,O
left,O
was,O
observed,O
after,O
hCRH,I-Entity
(,O
P,I-Entity
<,O
0.01,O
),O
.,O
hCRH,I-Entity
and,O
TRH,I-Entity
caused,O
a,O
reduction,O
in,O
the,O
CO2,I-Entity
threshold,O
.,O
The,I-Entity
CO2-response,I-Entity
curves,O
in,O
the,O
control,O
group,O
were,O
nearly,O
identical,O
.,O
The,I-Entity
results,O
indicate,O
an,O
additive,O
effect,O
of,O
both,O
releasing,O
hormones,O
on,O
the,O
hypercapnic,I-Entity
ventilatory,O
response,O
in,O
humans,O
",",O
presumably,O
independent,O
of,O
central,O
chemosensitivity,I-Entity
.,O
Lamivudine,I-Entity
is,O
effective,O
in,O
suppressing,O
hepatitis,I-Entity
B,I-Entity
virus,O
DNA,I-Entity
in,O
Chinese,I-Entity
hepatitis,I-Entity
B,I-Entity
surface,O
antigen,O
carriers,O
:,O
a,O
placebo,O
-,O
controlled,O
trial,O
.,O
Lamivudine,I-Entity
is,O
a,O
novel,O
"2',3'-dideoxy",I-Entity
cytosine,I-Entity
analogue,O
that,O
has,O
potent,O
inhibitory,O
effects,O
on,O
hepatitis,I-Entity
B,I-Entity
virus,O
replication,O
in,O
vitro,O
and,O
in,O
vivo,O
.,O
We,I-Entity
performed,O
a,O
single,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
study,O
to,O
assess,O
its,O
effectiveness,O
and,O
safety,O
in,O
Chinese,I-Entity
hepatitis,I-Entity
B,I-Entity
surface,O
antigen,O
(,O
HBsAg,I-Entity
),O
carriers,O
.,O
Forty,I-Entity
-,O
two,O
Chinese,I-Entity
HBsAg,I-Entity
carriers,O
were,O
randomized,O
to,O
receive,O
placebo,O
(,O
6,O
patients,O
),O
or,O
lamivudine,I-Entity
orally,O
in,O
dosages,O
of,O
25,O
mg,O
",",O
100,O
mg,O
",",O
or,O
300,O
mg,O
daily,O
(,O
12,O
patients,O
for,O
each,O
dosage,O
),O
.,O
All,I-Entity
36,O
patients,O
receiving,O
lamivudine,I-Entity
had,O
a,O
decrease,O
in,O
hepatitis,I-Entity
B,I-Entity
virus,O
(,O
HBV,I-Entity
),O
DNA,I-Entity
values,O
of,O
>,O
90%,O
(,O
P,I-Entity
<,O
.001,O
compared,O
with,O
placebo,O
),O
.,O
Although,I-Entity
25,O
mg,O
of,O
lamivudine,I-Entity
was,O
slightly,O
less,O
effective,O
than,O
100,O
mg,O
(,O
P,I-Entity
=,O
.011,O
),O
and,O
300,O
mg,O
(,O
P,I-Entity
=,O
.005,I-Entity
),O
",",O
it,O
still,O
induced,O
94%,O
suppression,O
of,O
HBV,I-Entity
DNA,I-Entity
after,O
the,O
fourth,O
week,O
of,O
therapy,O
.,O
There,I-Entity
was,O
no,O
change,O
in,O
the,O
hepatitis,I-Entity
B,I-Entity
e,O
antigen,O
status,O
or,O
in,O
aminotransferase,O
levels,O
.,O
In,I-Entity
conclusion,O
",",O
a,O
4-week,O
course,O
of,O
lamivudine,I-Entity
was,O
safe,O
and,O
effective,O
in,O
suppression,O
of,O
HBV,I-Entity
DNA,I-Entity
in,O
Chinese,I-Entity
HBsAg,I-Entity
carriers,O
.,O
Studies,I-Entity
with,O
long,O
-,O
term,O
lamivudine,I-Entity
administration,O
should,O
be,O
performed,O
to,O
determine,O
if,O
prolonged,O
suppression,O
of,O
HBV,I-Entity
DNA,I-Entity
can,O
be,O
achieved,O
.,O
Population,I-Entity
-,O
based,O
study,O
of,O
risk,O
of,O
venous,O
thromboembolism,I-Entity
associated,O
with,O
various,O
oral,O
contraceptives,I-Entity
.,O
BACKGROUND,I-Entity
:,O
Four,I-Entity
studies,O
published,O
since,O
December,I-Entity
",",O
1995,O
",",O
reported,O
that,O
the,O
incidence,O
of,O
venous,O
thromboembolism,I-Entity
(,O
VTE,I-Entity
),O
was,O
higher,O
in,O
women,O
who,O
used,O
oral,O
contraceptives,I-Entity
(,O
OCs,I-Entity
),O
containing,O
the,O
third,O
-,O
generation,O
progestagens,I-Entity
gestodene,I-Entity
or,O
desogestrel,I-Entity
than,O
in,O
users,O
of,O
OCs,I-Entity
containing,O
second,O
-,O
generation,O
progestagens,I-Entity
.,O
The,I-Entity
aim,O
of,O
our,O
study,O
was,O
to,O
re,O
-,O
examine,O
the,O
association,O
between,O
risk,O
of,O
VTE,I-Entity
and,O
OC,I-Entity
use,O
with,O
a,O
different,O
study,O
design,O
and,O
analysis,O
to,O
avoid,O
some,O
of,O
the,O
bias,O
and,O
confounding,I-Entity
of,O
the,O
earlier,O
studies,O
.,O
All,I-Entity
women,O
who,O
had,O
a,O
recorded,O
diagnosis,O
of,O
deep,O
-,O
vein,O
thrombosis,I-Entity
",",O
venous,O
thrombosis,I-Entity
not,O
otherwise,O
specified,O
",",O
or,O
pulmonary,O
embolus,I-Entity
during,O
the,O
study,O
period,O
",",O
and,O
who,O
had,O
been,O
treated,O
with,O
an,O
anticoagulant,O
were,O
identified,O
as,O
potential,O
cases,O
of,O
VTE,I-Entity
.,O
We,I-Entity
did,O
a,O
cohort,O
analysis,O
to,O
estimate,O
and,O
compare,O
incidence,O
of,O
VTE,I-Entity
in,O
users,O
of,O
the,O
main,O
OC,I-Entity
preparations,O
",",O
and,O
a,O
nested,O
case,O
-,O
control,O
study,O
to,O
calculate,O
the,O
odds,O
ratios,O
of,O
VTE,I-Entity
associated,O
with,O
use,O
of,O
different,O
types,O
of,O
OC,I-Entity
",",O
after,O
adjustment,O
for,O
potential,O
confounding,I-Entity
factors,O
.,O
In,I-Entity
the,O
case,O
-,O
control,O
study,O
",",O
we,O
matched,O
cases,O
to,O
controls,O
by,O
exact,O
year,O
of,O
birth,O
",",O
practice,O
",",O
and,O
current,O
use,O
of,O
OCs,I-Entity
.,O
We,I-Entity
used,O
a,O
multiple,O
logistic,O
regression,O
model,O
that,O
included,O
body,O
-,O
mass,O
index,O
",",O
number,O
of,O
cycles,O
",",O
change,O
in,O
type,O
of,O
OC,I-Entity
prescribed,O
within,O
3,O
months,O
of,O
the,O
event,O
",",O
previous,O
pregnancy,I-Entity
",",O
and,O
concurrent,O
disease,I-Entity
.,O
FINDINGS,I-Entity
:,O
85,O
women,O
met,O
the,O
inclusion,O
criteria,O
for,O
VTE,I-Entity
",",O
two,O
of,O
whom,O
were,O
users,O
of,O
progestagen,I-Entity
-,O
only,O
OCs,I-Entity
.,O
Of,I-Entity
the,O
83,I-Entity
cases,O
of,O
VTE,I-Entity
associated,O
with,O
use,O
of,O
combined,O
OCs,I-Entity
",",O
43,O
were,O
recorded,O
as,O
deep,O
-,O
vein,O
thrombosis,I-Entity
",",O
35,O
as,O
pulmonary,O
thrombosis,I-Entity
",",O
and,O
five,O
as,O
venous,O
thrombosis,I-Entity
not,O
otherwise,O
specified,O
.,O
The,I-Entity
crude,O
rate,O
of,O
VTE,I-Entity
per,O
"10,000",I-Entity
woman,O
-,O
years,O
was,O
4.10,O
in,O
current,O
users,O
of,O
any,O
OC,I-Entity
",",O
3.10,O
in,O
users,O
of,O
second,O
-,O
generation,O
OCs,I-Entity
",",O
and,O
4.96,O
in,O
users,O
of,O
third,O
-,O
generation,O
preparations,O
.,O
After,I-Entity
adjustment,O
for,O
age,O
",",O
the,O
rate,O
ratio,O
of,O
VTE,I-Entity
in,O
users,O
of,O
third,O
-,O
generation,O
relative,O
to,O
second,O
-,O
generation,O
OCs,I-Entity
was,O
1.68,O
(,O
95%,O
CI,I-Entity
1.04,O
-,O
2.75,O
),O
.,O
Logistic,I-Entity
regression,O
showed,O
no,O
significant,O
difference,O
in,O
the,O
risk,O
of,O
VTE,I-Entity
between,O
users,O
of,O
third,O
-,O
generation,O
and,O
second,O
-,O
generation,O
OCs,I-Entity
.,O
Among,I-Entity
users,O
of,O
third,O
-,O
generation,O
progestagens,I-Entity
",",O
the,O
risk,O
of,O
VTE,I-Entity
was,O
higher,O
in,O
users,O
of,O
desogestrel,I-Entity
with,O
20,O
g,O
ethinyloestradiol,I-Entity
than,O
in,O
users,O
of,O
gestodene,I-Entity
or,O
desogestrel,I-Entity
with,O
30,O
g,O
ethinyloestradiol,I-Entity
.,O
With,I-Entity
all,O
second,O
-,O
generation,O
OCs,I-Entity
as,O
the,O
reference,O
",",O
the,O
odds,O
ratios,O
for,O
VTE,I-Entity
were,O
3.49,O
(,O
1.21,O
-,O
10.12,O
),O
for,O
desogestrel,I-Entity
plus,O
20,O
g,O
ethinyloestradiol,I-Entity
and,O
1.18,O
(,O
0.66,O
-,O
2.17,O
),O
for,O
the,O
other,O
third,O
-,O
generation,O
progestagens,I-Entity
.,O
The,I-Entity
previously,O
reported,O
increase,O
in,O
odds,O
ratio,O
associated,O
with,O
third,O
-,O
generation,O
OCs,I-Entity
when,O
compared,O
with,O
second,O
-,O
generation,O
products,O
is,O
likely,O
to,O
have,O
been,O
the,O
result,O
of,O
residual,O
confounding,I-Entity
by,O
age,O
.,O
The,I-Entity
increased,O
odds,O
ratio,O
associated,O
with,O
products,O
containing,O
20,O
micrograms,O
ethinyloestradiol,I-Entity
and,O
desogestrel,I-Entity
compared,O
with,O
the,O
30,O
micrograms,O
product,O
is,O
biologically,O
implausible,O
",",O
and,O
is,O
likely,O
to,O
be,O
the,O
result,O
of,O
preferential,O
prescribing,O
and,O
",",O
thus,O
",",O
confounding,I-Entity
.,O
MK-801,I-Entity
augments,O
pilocarpine,I-Entity
-,O
induced,O
electrographic,O
seizure,I-Entity
but,O
protects,O
against,O
brain,O
damage,O
in,O
rats,O
The,I-Entity
authors,O
examined,O
the,O
anticonvulsant,O
effects,O
of,O
MK-801,I-Entity
on,O
the,O
pilocarpine,I-Entity
-,O
induced,O
seizure,I-Entity
model,O
.,O
Intraperitoneal,I-Entity
injection,O
of,O
pilocarpine,I-Entity
(,O
400,O
mg,O
/,O
kg,O
),O
induced,O
tonic,I-Entity
and,O
clonic,I-Entity
seizure,I-Entity
.,O
Scopolamine,I-Entity
(,O
10,O
mg,O
/,O
kg,O
),O
and,O
pentobarbital,I-Entity
(,O
5,O
mg,O
/,O
kg,O
),O
prevented,O
development,O
of,O
pilocarpine,I-Entity
-,O
induced,O
behavioral,O
seizure,I-Entity
but,O
MK-801,I-Entity
(,O
0.5,O
mg,O
/,O
kg,O
),O
did,O
not,O
.,O
An,I-Entity
electrical,O
seizure,I-Entity
measured,O
with,O
hippocampal,O
EEG,I-Entity
appeared,O
in,O
the,O
pilocarpine,I-Entity
-,O
treated,O
group,O
.,O
Scopolamine,I-Entity
and,O
pentobarbital,I-Entity
blocked,O
the,O
pilocarpine,I-Entity
-,O
induced,O
electrographic,O
seizure,I-Entity
",",O
MK-801,I-Entity
treatment,O
augmented,O
the,O
electrographic,O
seizure,I-Entity
induced,O
by,O
pilocarpine,I-Entity
.,O
Brain,I-Entity
damage,O
was,O
assessed,O
by,O
examining,O
the,O
hippocampus,O
microscopically,O
.,O
Pilocarpine,I-Entity
produced,O
neuronal,O
death,I-Entity
in,O
the,O
hippocampus,O
",",O
which,O
showed,O
pyknotic,I-Entity
changes,O
.,O
Pentobarbital,I-Entity
",",O
scopolamine,I-Entity
and,O
MK-801,I-Entity
protected,O
the,O
brain,O
damage,O
by,O
pilocarpine,I-Entity
",",O
though,O
in,O
the,O
MK-801-treated,I-Entity
group,O
",",O
the,O
pyramidal,O
cells,O
of,O
hippocampus,O
appeared,O
darker,O
than,O
normal,O
.,O
These,I-Entity
results,O
indicate,O
that,O
status,O
epilepticus,I-Entity
induced,O
by,O
pilocarpine,I-Entity
is,O
initiated,O
by,O
cholinergic,O
overstimulation,O
and,O
propagated,O
by,O
glutamatergic,O
transmission,O
",",O
the,O
elevation,O
of,O
which,O
may,O
cause,O
brain,O
damage,O
through,O
an,O
excitatory,O
NMDA,I-Entity
receptor,O
-,O
mediated,O
mechanism,O
.,O
Paclitaxel,I-Entity
",",O
5-fluorouracil,I-Entity
",",O
and,O
folinic,O
acid,O
in,O
metastatic,O
breast,O
cancer,I-Entity
:,O
5-Fluorouracil,I-Entity
plus,O
folinic,O
acid,O
and,O
paclitaxel,I-Entity
(,O
Taxol,I-Entity
;,O
Bristol,I-Entity
-,O
Myers,I-Entity
Squibb,I-Entity
Company,I-Entity
",",O
Princeton,I-Entity
",",O
NJ,I-Entity
),O
are,O
effective,O
salvage,O
therapies,O
for,O
metastatic,O
breast,O
cancer,I-Entity
patients,O
.,O
Paclitaxel,I-Entity
and,O
5-fluorouracil,I-Entity
have,O
additive,O
cytotoxicity,O
in,O
MCF-7,O
cell,O
lines,O
.,O
We,I-Entity
performed,O
a,O
phase,O
II,I-Entity
trial,O
of,O
paclitaxel,I-Entity
175,I-Entity
mg,O
/,O
m2,O
over,O
3,O
hours,O
on,O
day,O
I,I-Entity
followed,O
by,O
folinic,O
acid,O
300,O
mg,O
over,O
1,O
hour,O
before,O
5-fluorouracil,I-Entity
350,I-Entity
mg,O
/,O
m2,O
on,O
days,O
1,O
to,O
3,O
every,O
28,O
days,O
(,O
TFL,I-Entity
),O
in,O
women,O
with,O
metastatic,O
breast,O
cancer,I-Entity
.,O
Analysis,I-Entity
is,O
reported,O
on,O
37,I-Entity
patients,O
with,O
a,O
minimum,O
of,O
6,O
months,O
follow,O
-,O
up,O
who,O
received,O
a,O
total,O
of,O
192,I-Entity
cycles,O
of,O
TFL,I-Entity
:,O
nine,O
cycles,O
(,O
5%,O
),O
were,O
associated,O
with,O
grade,O
3/4,O
neutropenia,I-Entity
requiring,O
hospitalization,O
;,O
seven,O
(,O
4%,O
),O
cycles,O
in,O
two,O
patients,O
required,O
granulocyte,O
colony,O
-,O
stimulating,O
factor,O
due,O
to,O
neutropenia,I-Entity
;,O
no,O
patient,O
required,O
platelet,O
transfusions,O
.,O
Grade,I-Entity
3/4,O
nonhematologic,O
toxicities,I-Entity
were,O
uncommon,O
.,O
Of,I-Entity
the,O
19,O
evaluable,O
patients,O
with,O
prior,O
doxorubicin,I-Entity
exposure,O
",",O
11,O
(,O
58%,O
),O
responded,O
compared,O
with,O
nine,O
of,O
15,O
(,O
60%,O
),O
without,O
prior,O
doxorubicin,I-Entity
.,O
Plasma,I-Entity
paclitaxel,I-Entity
concentrations,O
were,O
measured,O
at,O
the,O
completion,O
of,O
paclitaxel,I-Entity
infusion,O
and,O
at,O
24,O
hours,O
in,O
19,O
patients,O
.,O
TFL,I-Entity
is,O
an,O
active,O
",",O
well,O
-,O
tolerated,O
regimen,I-Entity
in,O
metastatic,O
breast,O
cancer,I-Entity
.,O
Efficacy,I-Entity
and,O
proarrhythmia,I-Entity
with,O
the,O
use,O
of,O
d,O
",",O
l,O
-,O
sotalol,I-Entity
for,O
sustained,O
ventricular,O
tachyarrhythmias,I-Entity
.,O
This,I-Entity
study,O
prospectively,O
evaluated,O
the,O
clinical,O
efficacy,O
",",O
the,O
incidence,O
of,O
torsades,I-Entity
de,O
pointes,I-Entity
",",O
and,O
the,O
presumable,O
risk,O
factors,O
for,O
torsades,I-Entity
de,O
pointes,I-Entity
in,O
patients,O
treated,O
with,O
d,O
",",O
l,O
-,O
sotalol,I-Entity
for,O
sustained,O
ventricular,O
tachyarrhythmias,I-Entity
.,O
Eighty,I-Entity
-,O
one,O
consecutive,O
patients,O
(,O
54,I-Entity
with,O
coronary,O
artery,I-Entity
disease,I-Entity
",",O
and,O
20,O
with,O
dilated,O
cardiomyopathy,I-Entity
),O
with,O
inducible,O
sustained,O
ventricular,O
tachycardia,I-Entity
or,O
ventricular,O
fibrillation,I-Entity
received,O
oral,O
d,O
",",O
l,O
-,O
sotalol,I-Entity
to,O
prevent,O
induction,O
of,O
the,O
ventricular,O
tachyarrhythmia,I-Entity
.,O
During,I-Entity
oral,O
loading,O
with,O
d,O
",",O
l,O
-,O
sotalol,I-Entity
",",O
continuous,O
electrocardiographic,O
(,O
ECG,I-Entity
),O
monitoring,O
was,O
performed,O
.,O
Those,I-Entity
patients,O
in,O
whom,O
d,O
",",O
l,O
-,O
sotalol,I-Entity
prevented,O
induction,O
of,O
ventricular,O
tachycardia,I-Entity
or,O
ventricular,O
fibrillation,I-Entity
were,O
discharged,O
with,O
the,O
drug,O
and,O
followed,O
up,O
on,O
an,O
outpatient,I-Entity
basis,O
for,O
21,O
+,O
/-,O
Induction,I-Entity
of,O
the,O
ventricular,O
tachyarrhythmia,I-Entity
was,O
prevented,O
by,O
oral,O
d,O
",",O
l,O
-,O
sotalol,I-Entity
in,O
35,O
(,O
43%,O
),O
patients,O
;,O
the,O
ventricular,O
tachyarrhythmia,I-Entity
remained,O
inducible,O
in,O
40,O
(,O
49%,O
),O
patients,O
;,O
and,O
two,O
(,O
2.5%,O
),O
patients,O
did,O
not,O
tolerate,O
even,O
40,O
mg,O
of,O
d,O
",",O
l,O
-,O
sotalol,I-Entity
once,O
daily,O
.,O
Four,I-Entity
(,O
5%,O
),O
patients,O
had,O
from,O
torsades,I-Entity
de,O
pointes,I-Entity
during,O
the,O
initial,O
oral,O
treatment,O
with,O
d,O
",",O
l,O
-,O
sotalol,I-Entity
.,O
Neither,I-Entity
ECG,I-Entity
[,O
sinus,O
-,O
cycle,O
length,O
(,O
SCL,I-Entity
),O
",",O
QT,I-Entity
or,O
QTc,I-Entity
interval,O
",",O
or,O
U,I-Entity
wave,O
],O
nor,O
clinical,O
parameters,O
identified,O
patients,O
at,O
risk,O
for,O
torsades,I-Entity
de,O
pointes,I-Entity
.,O
However,I-Entity
",",O
the,O
oral,O
dose,O
of,O
d,O
",",O
l,O
-,O
sotalol,I-Entity
was,O
significantly,O
lower,O
in,O
patients,O
with,O
torsades,I-Entity
de,O
pointes,I-Entity
(,O
200,O
+,O
/-,O
Risk,I-Entity
factors,O
associated,O
with,O
the,O
development,O
of,O
torsades,I-Entity
de,O
pointes,I-Entity
were,O
the,O
appearance,O
of,O
an,O
U,I-Entity
wave,O
(,O
p,O
=,O
0.049,O
),O
",",O
female,O
gender,O
(,O
p,O
=,O
0.015,O
),O
",",O
and,O
significant,O
dose,O
-,O
corrected,O
changes,O
of,O
SCL,I-Entity
",",O
QT,I-Entity
interval,O
",",O
and,O
QTc,I-Entity
interval,O
(,O
During,I-Entity
follow,O
-,O
up,O
",",O
seven,O
(,O
20%,O
),O
patients,O
had,O
a,O
nonfatal,O
ventricular,O
tachycardia,I-Entity
recurrence,O
",",O
and,O
two,O
(,O
6%,O
),O
One,I-Entity
female,O
patient,O
with,O
stable,O
cardiac,O
disease,I-Entity
had,O
recurrent,O
torsades,I-Entity
de,O
pointes,I-Entity
after,O
2,O
years,O
of,O
successful,O
treatment,O
with,O
d,O
",",O
l,O
-,O
sotalol,I-Entity
.,O
Torsades,I-Entity
de,O
pointes,I-Entity
occurred,O
early,O
during,O
treatment,O
even,O
with,O
low,O
doses,O
of,O
oral,O
d,O
",",O
l,O
-,O
sotalol,I-Entity
.,O
Pronounced,I-Entity
changes,O
in,O
the,O
surface,O
ECG,I-Entity
(,O
cycle,O
length,O
",",O
QT,I-Entity
",",O
and,O
QTc,I-Entity
),O
in,O
relation,O
to,O
the,O
dose,O
of,O
oral,O
d,O
",",O
l,O
-,O
sotalol,I-Entity
might,O
identify,O
a,O
subgroup,O
of,O
patients,O
with,O
an,O
increased,O
risk,O
for,O
torsades,I-Entity
de,O
pointes,I-Entity
.,O
Other,I-Entity
ECG,I-Entity
parameters,O
before,O
the,O
application,O
of,O
d,O
",",O
l,O
-,O
sotalol,I-Entity
did,O
not,O
identify,O
patients,O
at,O
increased,O
risk,O
for,O
torsades,I-Entity
de,O
pointes,I-Entity
.,O
Recurrence,I-Entity
rates,O
of,O
ventricular,O
tachyarrhythmias,I-Entity
are,O
high,O
despite,O
complete,O
suppression,O
of,O
the,O
arrhythmia,I-Entity
during,O
programmed,O
stimulation,O
.,O
Therefore,I-Entity
programmed,O
electrical,O
stimulation,O
in,O
the,O
case,O
of,O
d,O
",",O
l,O
-,O
sotalol,I-Entity
seems,O
to,O
be,O
of,O
limited,O
prognostic,O
value,O
.,O
Chronic,I-Entity
hyperprolactinemia,I-Entity
and,O
changes,O
in,O
dopamine,I-Entity
neurons,O
.,O
The,I-Entity
purpose,O
of,O
this,O
study,O
was,O
to,O
induce,O
hyperprolactinemia,I-Entity
in,O
rats,O
for,O
extended,O
periods,O
of,O
time,O
and,O
examine,O
its,O
effects,O
on,O
dopaminergic,O
systems,O
in,O
the,O
brain,O
.,O
Hyperprolactinemia,I-Entity
was,O
induced,O
by,O
treatment,O
with,O
haloperidol,I-Entity
",",O
a,O
dopamine,I-Entity
receptor,O
antagonist,O
",",O
and,O
Palkovits,I-Entity
',O
microdissection,O
technique,O
in,O
combination,O
with,O
high,O
-,O
performance,O
liquid,O
chromatography,O
was,O
used,O
to,O
measure,O
neurotransmitter,O
concentrations,O
in,O
several,O
areas,O
of,O
the,O
brain,O
.,O
After,I-Entity
6,O
months,O
of,O
hyperprolactinemia,I-Entity
",",O
dopamine,I-Entity
(,O
DA,I-Entity
),O
concentrations,O
in,O
the,O
median,O
eminence,I-Entity
(,O
ME,I-Entity
),O
increased,O
by,O
84%,O
over,O
the,O
control,O
group,O
.,O
Nine,I-Entity
months,O
of,O
hyperprolactinemia,I-Entity
produced,O
a,O
50%,O
increase,O
in,O
DA,I-Entity
concentrations,O
in,O
the,O
ME,I-Entity
over,O
the,O
control,O
group,O
.,O
However,I-Entity
",",O
DA,I-Entity
response,O
was,O
lost,O
if,O
a,O
9-month,O
long,O
haloperidol,I-Entity
-,O
induced,O
hyperprolactinemia,I-Entity
was,O
followed,O
by,O
a,O
1,O
1/2,O
month,O
-,O
long,O
extremely,O
high,O
increase,O
in,O
serum,O
PRL,I-Entity
levels,O
produced,O
by,O
implantation,O
of,O
MMQ,I-Entity
cells,O
under,O
the,O
kidney,O
capsule,O
.,O
There,I-Entity
was,O
no,O
change,O
in,O
the,O
levels,O
of,O
DA,I-Entity
",",O
norepinephrine,I-Entity
(,O
NE,I-Entity
),O
",",O
serotonin,I-Entity
(,O
5-HT,I-Entity
),O
",",O
or,O
their,O
metabolites,O
in,O
the,O
arcuate,O
nucleus,O
(,O
AN,I-Entity
),O
",",O
medial,O
preoptic,O
area,O
(,O
MPA,I-Entity
),O
",",O
caudate,O
putamen,I-Entity
(,O
CP,I-Entity
),O
",",O
substantia,I-Entity
nigra,I-Entity
(,O
SN,I-Entity
),O
",",O
and,O
zona,I-Entity
incerta,I-Entity
(,O
ZI,I-Entity
),O
",",O
except,O
for,O
a,O
decrease,O
in,O
5-hydroxyindoleacetic,I-Entity
acid,O
(,O
5-HIAA,I-Entity
),O
in,O
the,O
AN,I-Entity
after,O
6-months,O
of,O
hyperprolactinemia,I-Entity
and,O
an,O
increase,O
in,O
DA,I-Entity
concentrations,O
in,O
the,O
AN,I-Entity
after,O
9-months,O
of,O
hyperprolactinemia,I-Entity
.,O
These,I-Entity
results,O
demonstrate,O
that,O
hyperprolactinemia,I-Entity
specifically,O
affects,O
TIDA,I-Entity
neurons,O
and,O
these,O
effects,O
vary,O
",",O
depending,O
on,O
the,O
duration,O
and,O
intensity,O
of,O
hyperprolactinemia,I-Entity
.,O
The,I-Entity
age,O
-,O
related,O
decrease,O
in,O
hypothalamic,O
dopamine,I-Entity
function,O
may,O
be,O
associated,O
with,O
increases,O
in,O
PRL,I-Entity
secretion,O
.,O
Treatment,I-Entity
-,O
related,O
disseminated,O
necrotizing,I-Entity
leukoencephalopathy,I-Entity
with,O
characteristic,O
contrast,O
enhancement,O
of,O
the,O
white,O
matter,O
.,O
This,I-Entity
report,O
describes,O
unique,O
contrast,O
enhancement,O
of,O
the,O
white,O
matter,O
on,O
T1-weighted,I-Entity
magnetic,O
resonance,O
images,O
of,O
two,O
patients,O
with,O
disseminated,O
necrotizing,I-Entity
leukoencephalopathy,I-Entity
",",O
which,O
developed,O
from,O
acute,O
lymphoblastic,B-Entity
leukemia,I-Entity
treated,O
with,O
high,O
-,O
dose,O
methotrexate,I-Entity
.,O
Necropsy,I-Entity
of,O
the,O
first,O
case,O
revealed,O
loss,I-Entity
of,O
myelination,I-Entity
and,O
necrosis,I-Entity
of,O
the,O
white,O
matter,O
.,O
Possible,I-Entity
mechanisms,O
causing,O
such,O
a,O
leukoencephalopathy,I-Entity
are,O
discussed,O
.,O
Thrombotic,I-Entity
complications,O
in,O
acute,O
promyelocytic,O
leukemia,I-Entity
during,O
all,O
-,O
trans,O
-,O
retinoic,I-Entity
acid,O
therapy,O
.,O
A,I-Entity
case,O
of,O
acute,O
renal,O
failure,I-Entity
",",O
due,O
to,O
occlusion,I-Entity
of,O
renal,O
vessels,O
in,O
a,O
patient,O
with,O
acute,O
promyelocytic,O
leukemia,I-Entity
(,O
APL,I-Entity
),O
treated,O
with,O
all,O
-,O
trans,O
-,O
retinoic,I-Entity
acid,O
(,O
ATRA,I-Entity
),O
and,O
tranexamic,I-Entity
acid,O
has,O
been,O
described,O
recently,O
.,O
We,I-Entity
report,O
a,O
case,O
of,O
acute,O
renal,O
failure,I-Entity
in,O
an,O
APL,I-Entity
patient,O
treated,O
with,O
ATRA,I-Entity
alone,O
.,O
This,I-Entity
case,O
further,O
supports,O
the,O
concern,O
about,O
thromboembolic,I-Entity
complications,O
associated,O
with,O
ATRA,I-Entity
therapy,O
in,O
APL,I-Entity
patients,O
.,O
The,I-Entity
patients,O
",",O
a,O
43-year,O
-,O
old,O
man,O
",",O
presented,O
all,O
the,O
signs,O
and,O
symptoms,O
of,O
APL,I-Entity
and,O
was,O
included,O
in,O
a,O
treatment,O
protocol,O
with,O
ATRA,I-Entity
.,O
After,I-Entity
10,O
days,O
of,O
treatment,O
",",O
he,O
developed,O
acute,O
renal,O
failure,I-Entity
that,O
was,O
completely,O
reversible,O
after,O
complete,O
remission,O
of,O
APL,I-Entity
was,O
achieved,O
and,O
therapy,O
discontinued,O
.,O
We,I-Entity
conclude,O
that,O
ATRA,I-Entity
is,O
a,O
valid,O
therapeutic,O
choice,O
for,O
patients,O
with,O
APL,I-Entity
",",O
although,O
the,O
procoagulant,O
tendency,O
is,O
not,O
completely,O
corrected,O
.,O
Thrombotic,I-Entity
events,O
",",O
however,O
",",O
could,O
be,O
avoided,O
by,O
using,O
low,O
-,O
dose,O
heparin,I-Entity
.,O
Pupillary,I-Entity
changes,O
associated,O
with,O
the,O
development,O
of,O
stimulant,O
-,O
induced,O
mania,I-Entity
:,O
a,O
case,O
report,O
.,O
A,I-Entity
30-year,O
-,O
old,O
cocaine,I-Entity
-,O
dependent,O
man,O
who,O
was,O
a,O
subject,O
in,O
a,O
study,O
evaluating,O
the,O
anticraving,O
efficacy,O
of,O
the,O
stimulant,O
medication,O
diethylpropion,I-Entity
(,O
DEP,I-Entity
),O
became,O
manic,I-Entity
during,O
his,O
second,O
week,O
on,O
the,O
study,O
drug,O
.,O
Pupillometric,I-Entity
changes,O
while,O
on,O
DEP,I-Entity
",",O
especially,O
changes,O
in,O
the,O
total,O
power,O
of,O
pupillary,I-Entity
oscillation,I-Entity
",",O
were,O
dramatically,O
different,O
than,O
those,O
observed,O
in,O
the,O
eight,O
other,O
study,O
subjects,O
who,O
did,O
not,O
become,O
manic,I-Entity
.,O
The,I-Entity
large,O
changes,O
in,O
total,O
power,O
of,O
pupillary,I-Entity
oscillation,I-Entity
occurred,O
a,O
few,O
days,O
before,O
the,O
patient,O
became,O
fully,O
manic,I-Entity
.,O
Such,I-Entity
medication,O
-,O
associated,O
changes,O
in,O
the,O
total,O
power,O
of,O
pupillary,I-Entity
oscillation,I-Entity
might,O
be,O
of,O
utility,O
in,O
identifying,O
persons,O
at,O
risk,O
for,O
manic,I-Entity
-,O
like,O
adverse,O
effects,O
during,O
the,O
medical,O
use,O
of,O
psychomotor,B-Entity
stimulants,O
or,O
sympathomimetic,O
agents,O
.,O
OBJECTIVE,I-Entity
:,O
We,I-Entity
wanted,O
to,O
test,O
whether,O
assessment,O
of,O
both,O
a,O
central,O
pain,I-Entity
-,O
related,O
signal,O
(,O
chemo,O
-,O
somatosensory,O
evoked,O
potential,O
",",O
CSSEP,I-Entity
),O
and,O
a,O
concomitantly,O
recorded,O
peripheral,O
signal,O
(,O
negative,O
mucosal,O
potential,O
",",O
NMP,I-Entity
),O
allows,O
for,O
separation,O
of,O
central,O
and,O
peripheral,O
effects,O
of,O
NSAIDs,I-Entity
.,O
For,I-Entity
this,O
purpose,O
",",O
experimental,O
conditions,O
were,O
created,O
in,O
which,O
NSAIDs,I-Entity
had,O
previously,O
been,O
observed,O
to,O
produce,O
effects,O
on,O
phasic,O
and,O
tonic,I-Entity
pain,I-Entity
by,O
either,O
central,O
or,O
peripheral,O
mechanisms,O
.,O
According,I-Entity
to,O
a,O
double,O
-,O
blind,O
",",O
randomised,O
",",O
controlled,O
",",O
threefold,O
cross,O
-,O
over,O
design,O
",",O
18,O
healthy,O
subjects,O
(,O
11,O
males,O
",",O
7,O
females,O
;,O
mean,O
age,O
26,O
years,O
),O
received,O
either,O
placebo,O
",",O
400,O
mg,O
ibuprofen,I-Entity
",",O
or,O
800,O
mg,O
ibuprofen,I-Entity
.,O
Phasic,I-Entity
pain,I-Entity
was,O
applied,O
by,O
means,O
of,O
short,I-Entity
pulses,O
of,O
CO2,I-Entity
to,O
the,O
nasal,O
mucosa,O
(,O
stimulus,O
duration,O
500,O
ms,O
",",O
interval,O
approximately,O
60,O
s,O
),O
",",O
and,O
tonic,I-Entity
pain,I-Entity
was,O
induced,O
in,O
the,O
nasal,O
cavity,O
by,O
means,O
of,O
dry,O
air,O
of,O
controlled,O
temperature,O
",",O
humidity,O
and,O
flow,O
rate,O
(,O
22,O
degrees,O
C,I-Entity
",",O
0%,O
relative,O
humidity,O
",",O
145,I-Entity
ml.s-1,O
),O
.,O
Both,I-Entity
CSSEPs,I-Entity
as,O
central,O
and,O
NMPs,I-Entity
as,O
peripheral,O
correlates,O
of,O
pain,I-Entity
were,O
obtained,O
in,O
response,O
to,O
the,O
CO2,I-Entity
stimuli,O
.,O
Additionally,I-Entity
",",O
the,O
subjects,O
rated,O
the,O
intensity,O
of,O
both,O
phasic,O
and,O
tonic,I-Entity
pain,I-Entity
by,O
means,O
of,O
visual,O
analogue,O
scales,O
.,O
As,I-Entity
described,O
earlier,O
",",O
administration,O
of,O
ibuprofen,I-Entity
was,O
followed,O
by,O
a,O
decrease,O
in,O
tonic,I-Entity
pain,I-Entity
but,O
-,O
relative,O
to,O
placebo,O
-,O
an,O
increase,O
in,O
correlates,O
of,O
phasic,O
pain,I-Entity
",",O
indicating,O
a,O
specific,O
effect,O
of,O
ibuprofen,I-Entity
on,O
the,O
interaction,O
between,O
the,O
pain,I-Entity
stimuli,O
under,O
these,O
special,O
experimental,O
conditions,O
.,O
The,I-Entity
major,O
advantage,O
of,O
this,O
pain,I-Entity
model,O
is,O
the,O
possibility,O
of,O
obtaining,O
peripheral,O
pain,I-Entity
-,O
related,O
activity,O
directly,O
using,O
a,O
non,O
-,O
invasive,O
technique,O
in,O
humans,O
.,O
Acute,I-Entity
severe,O
depression,I-Entity
following,O
peri,O
-,O
operative,O
ondansetron,I-Entity
.,O
A,I-Entity
41-year,O
-,O
old,O
woman,O
with,O
a,O
strong,O
history,O
of,O
postoperative,O
nausea,I-Entity
and,O
vomiting,I-Entity
presented,O
for,O
abdominal,O
hysterectomy,O
3,O
months,O
after,O
a,O
previous,O
anaesthetic,O
where,O
ondansetron,I-Entity
prophylaxis,O
had,O
been,O
used,O
.,O
She,I-Entity
had,O
developed,O
a,O
severe,O
acute,O
major,O
depression,I-Entity
disorder,I-Entity
almost,O
immediately,O
thereafter,O
",",O
possibly,O
related,O
to,O
the,O
use,O
of,O
a,O
serotonin,I-Entity
antagonist,O
.,O
Nine,I-Entity
years,O
before,O
she,O
had,O
experienced,O
a,O
self,O
-,O
limited,O
puerperal,O
depressive,I-Entity
episode,O
.,O
Anaesthesia,I-Entity
with,O
a,O
propofol,I-Entity
infusion,O
and,O
avoidance,I-Entity
of,O
serotonin,I-Entity
antagonists,O
provided,O
a,O
nausea,I-Entity
-,O
free,O
postoperative,O
course,O
without,O
exacerbation,O
of,O
the,O
depression,I-Entity
disorder,I-Entity
.,O
Hypertensive,I-Entity
response,O
during,O
dobutamine,I-Entity
stress,I-Entity
echocardiography,O
.,O
Among,I-Entity
"3,129",O
dobutamine,I-Entity
stress,I-Entity
echocardiographic,O
studies,O
",",O
a,O
hypertensive,I-Entity
response,O
",",O
defined,O
as,O
systolic,O
blood,O
pressure,O
(,O
BP,I-Entity
),O
>,O
or,O
=,O
220,I-Entity
mm,O
Hg,I-Entity
and/or,O
diastolic,I-Entity
BP,I-Entity
>,O
or,O
=,O
110,I-Entity
mm,O
Hg,I-Entity
",",O
occurred,O
in,O
30,O
patients,O
(,O
1%,O
),O
.,O
Patients,I-Entity
with,O
this,O
response,O
more,O
often,O
had,O
a,O
history,O
of,O
hypertension,I-Entity
and,O
had,O
higher,O
resting,O
systolic,O
and,O
diastolic,I-Entity
BP,I-Entity
before,O
dobutamine,I-Entity
infusion,O
.,O
Continuously,I-Entity
nebulized,O
albuterol,I-Entity
in,O
severe,O
exacerbations,O
of,O
asthma,I-Entity
in,O
adults,O
:,O
a,O
case,O
-,O
controlled,O
study,O
.,O
A,I-Entity
retrospective,O
",",O
case,O
-,O
controlled,O
analysis,O
comparing,O
patients,O
admitted,O
to,O
a,O
medical,O
intensive,O
care,O
unit,O
with,O
severe,O
exacerbations,O
of,O
asthma,I-Entity
who,O
received,O
continuously,O
nebulized,O
albuterol,I-Entity
(,O
CNA,I-Entity
),O
versus,O
intermittent,O
albuterol,I-Entity
(,O
INA,I-Entity
),O
treatments,O
is,O
reported,O
.,O
Forty,I-Entity
matched,O
pairs,O
of,O
patients,O
with,O
asthma,I-Entity
are,O
compared,O
.,O
The,I-Entity
incidence,O
of,O
cardiac,O
dysrhythmias,I-Entity
was,O
similar,O
between,O
groups,O
.,O
Symptomatic,I-Entity
hypokalemia,I-Entity
did,O
not,O
occur,O
.,O
Hyperosmolar,I-Entity
nonketotic,O
coma,I-Entity
precipitated,O
by,O
lithium,I-Entity
-,O
induced,O
nephrogenic,I-Entity
diabetes,I-Entity
insipidus,I-Entity
.,O
A,I-Entity
45-year,O
-,O
old,O
man,O
",",O
with,O
a,O
10-year,O
history,O
of,O
manic,I-Entity
depression,I-Entity
treated,O
with,O
lithium,I-Entity
",",O
was,O
admitted,O
with,O
hyperosmolar,I-Entity
",",O
nonketotic,O
coma,I-Entity
.,O
He,I-Entity
gave,O
a,O
five,O
-,O
year,O
history,O
of,O
polyuria,I-Entity
and,O
polydipsia,I-Entity
",",O
during,O
which,O
time,O
urinalysis,O
had,O
been,O
negative,O
for,O
glucose,O
.,O
After,I-Entity
recovery,O
from,O
hyperglycaemia,I-Entity
",",O
he,O
remained,O
polyuric,I-Entity
despite,O
normal,O
blood,O
glucose,O
concentrations,O
;,O
water,O
deprivation,I-Entity
testing,O
indicated,O
nephrogenic,I-Entity
diabetes,I-Entity
insipidus,I-Entity
",",O
likely,O
to,O
be,O
lithium,I-Entity
-,O
induced,O
.,O
We,I-Entity
hypothesize,O
that,O
when,O
this,O
man,O
developed,O
type,O
2,O
diabetes,I-Entity
",",O
chronic,O
polyuria,I-Entity
due,O
to,O
nephrogenic,I-Entity
diabetes,I-Entity
insipidus,I-Entity
was,O
sufficient,O
to,O
precipitate,O
hyperosmolar,I-Entity
dehydration,I-Entity
.,O
Effects,I-Entity
of,O
the,O
intracoronary,O
infusion,O
of,O
cocaine,I-Entity
on,O
left,O
ventricular,O
systolic,O
and,O
diastolic,I-Entity
function,O
in,O
humans,O
.,O
In,I-Entity
dogs,O
",",O
a,O
large,O
amount,O
of,O
intravenous,O
cocaine,I-Entity
causes,O
a,O
profound,O
deterioration,O
of,O
left,O
ventricular,O
(,O
LV,I-Entity
),O
systolic,O
function,O
and,O
an,O
increase,O
in,O
LV,I-Entity
end,O
-,O
diastolic,I-Entity
pressure,O
.,O
This,I-Entity
study,O
was,O
done,O
to,O
assess,O
the,O
influence,O
of,O
a,O
high,O
intracoronary,O
cocaine,I-Entity
concentration,O
on,O
LV,I-Entity
systolic,O
and,O
diastolic,I-Entity
function,O
in,O
humans,O
.,O
METHODS,I-Entity
AND,I-Entity
RESULTS,I-Entity
:,O
In,I-Entity
20,O
patients,O
(,O
14,O
men,O
and,O
6,O
women,O
aged,O
39,O
to,O
72,O
years,O
),O
referred,O
for,O
cardiac,O
catheterization,O
for,O
the,O
evaluation,O
of,O
chest,O
pain,I-Entity
",",O
we,O
measured,O
heart,O
rate,O
",",O
systemic,O
arterial,O
pressure,O
",",O
LV,I-Entity
pressure,O
and,O
its,O
first,O
derivative,O
(,O
dP,I-Entity
/,O
dt,O
),O
",",O
and,O
LV,I-Entity
volumes,O
and,O
ejection,O
fraction,O
before,O
and,O
during,O
the,O
final,O
2,O
to,O
3,O
minutes,O
of,O
a,O
15-minute,O
intracoronary,O
infusion,O
of,O
saline,O
(,O
n=10,O
",",O
control,O
subjects,O
),O
or,O
cocaine,I-Entity
hydrochloride,I-Entity
1,O
mg,O
/,O
min,O
(,O
n=10,O
),O
.,O
With,I-Entity
cocaine,I-Entity
",",O
the,O
drug,O
concentration,O
in,O
blood,O
obtained,O
from,O
the,O
coronary,O
sinus,O
was,O
3.0+/-0.4,O
(,O
mean+/-SD,O
),O
/,O
L,I-Entity
",",O
similar,O
in,O
magnitude,O
to,O
the,O
blood,O
cocaine,I-Entity
concentration,O
reported,O
in,O
abusers,O
dying,O
of,O
cocaine,I-Entity
intoxication,O
.,O
Cocaine,I-Entity
induced,O
no,O
significant,O
change,O
in,O
heart,O
rate,O
",",O
LV,I-Entity
dP,I-Entity
/,O
dt,O
(,O
positive,O
or,O
negative,O
),O
",",O
or,O
LV,I-Entity
end,O
-,O
diastolic,I-Entity
volume,O
",",O
but,O
it,O
caused,O
an,O
increase,O
in,O
systolic,O
and,O
mean,O
arterial,O
pressures,O
",",O
LV,I-Entity
end,O
-,O
diastolic,I-Entity
pressure,O
",",O
and,O
LV,I-Entity
end,O
-,O
systolic,O
volume,O
",",O
as,O
well,O
as,O
a,O
decrease,O
in,O
LV,I-Entity
ejection,O
fraction,O
.,O
In,I-Entity
humans,O
",",O
the,O
intracoronary,O
infusion,O
of,O
cocaine,I-Entity
sufficient,O
in,O
amount,O
to,O
achieve,O
a,O
high,O
drug,O
concentration,O
in,O
coronary,O
sinus,O
blood,O
causes,O
a,O
deterioration,O
of,O
LV,I-Entity
systolic,O
and,O
diastolic,I-Entity
performance,O
.,O
Heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
",",O
paradoxical,I-Entity
thromboembolism,I-Entity
",",O
and,O
other,O
side,O
effects,O
of,O
heparin,I-Entity
therapy,O
.,O
Although,I-Entity
several,O
new,O
anticoagulant,O
drugs,O
are,O
in,O
development,O
",",O
heparin,I-Entity
remains,O
the,O
drug,O
of,O
choice,O
for,O
most,O
anticoagulation,O
needs,O
.,O
The,I-Entity
clinical,O
effects,O
of,O
heparin,I-Entity
are,O
meritorious,O
",",O
but,O
side,O
effects,O
do,O
exist,O
.,O
Important,I-Entity
untoward,O
effects,O
of,O
heparin,I-Entity
therapy,O
including,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
",",O
heparin,I-Entity
-,O
associated,O
osteoporosis,I-Entity
",",O
eosinophilia,I-Entity
",",O
skin,O
reactions,O
",",O
allergic,I-Entity
reactions,O
other,O
than,O
thrombocytopenia,I-Entity
and,O
alopecia,I-Entity
will,O
be,O
discussed,O
in,O
this,O
article,O
.,O
Nonopaque,I-Entity
crystal,O
deposition,O
causing,O
ureteric,B-Entity
obstruction,I-Entity
in,O
patients,O
with,O
HIV,I-Entity
undergoing,O
indinavir,I-Entity
therapy,O
.,O
We,I-Entity
describe,O
the,O
unique,O
CT,I-Entity
features,O
of,O
ureteric,B-Entity
calculi,I-Entity
in,O
six,O
HIV,I-Entity
-,O
infected,I-Entity
patients,O
receiving,O
indinavir,I-Entity
",",O
the,O
most,O
commonly,O
used,O
HIV,I-Entity
protease,O
inhibitor,O
",",O
which,O
is,O
associated,O
with,O
an,O
increased,O
incidence,O
of,O
urolithiasis,I-Entity
.,O
CONCLUSION,I-Entity
:,O
Ureteric,I-Entity
obstruction,I-Entity
caused,O
by,O
precipitated,O
indinavir,I-Entity
crystals,O
may,O
be,O
difficult,O
to,O
diagnose,O
with,O
unenhanced,O
CT,I-Entity
.,O
contrast,O
material,O
to,O
enable,O
diagnosis,O
of,O
ureteric,B-Entity
stones,O
or,O
obstruction,I-Entity
in,O
patients,O
with,O
HIV,I-Entity
infection,I-Entity
who,O
receive,O
indinavir,I-Entity
therapy,O
.,O
Ischemic,I-Entity
colitis,I-Entity
and,O
sumatriptan,I-Entity
use,O
.,O
Sumatriptan,I-Entity
succinate,I-Entity
",",O
a,O
serotonin-1,I-Entity
(,O
5-hydroxytryptamine-1,I-Entity
),O
receptor,O
agonist,I-Entity
",",O
is,O
an,O
antimigraine,I-Entity
drug,O
that,O
is,O
reported,O
to,O
act,O
by,O
selectively,O
constricting,I-Entity
intracranial,B-Entity
arteries,O
.,O
Cases,I-Entity
have,O
been,O
published,O
of,O
coronary,O
vasospasm,I-Entity
",",O
myocardial,B-Entity
ischemia,I-Entity
",",O
and,O
myocardial,B-Entity
infarction,I-Entity
occurring,O
after,O
sumatriptan,I-Entity
use,O
.,O
We,I-Entity
report,O
on,O
the,O
development,O
of,O
8,O
serious,O
cases,O
of,O
ischemic,I-Entity
colitis,I-Entity
in,O
patients,O
with,O
migraine,I-Entity
treated,O
with,O
sumatriptan,I-Entity
.,O
51,I-Entity
patients,O
with,O
medically,O
refractory,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
underwent,O
stereotactic,O
posteromedial,O
pallidotomy,O
between,O
August,I-Entity
1993,O
and,O
February,I-Entity
1997,O
for,O
treatment,O
of,O
bradykinesia,I-Entity
",",O
rigidity,I-Entity
",",O
and,O
L,I-Entity
-,O
DOPA,I-Entity
-,O
induced,O
dyskinesias,I-Entity
.,O
Clinical,I-Entity
assessment,O
as,O
well,O
as,O
blinded,O
ratings,O
of,O
Unified,I-Entity
Parkinson,I-Entity
's,I-Entity
Disease,I-Entity
Rating,I-Entity
Scale,I-Entity
(,O
UPDRS,I-Entity
),O
85,O
percent,O
of,O
patients,O
with,O
dyskinesias,I-Entity
were,O
relieved,O
of,O
symptoms,O
",",O
regardless,O
of,O
whether,O
the,O
pallidotomies,O
were,O
performed,O
with,O
the,O
Gamma,I-Entity
Knife,I-Entity
or,O
radiofrequency,I-Entity
methods,O
.,O
About,I-Entity
2/3,O
of,O
the,O
patients,O
in,O
both,O
Gamma,I-Entity
Knife,I-Entity
and,O
radiofrequency,I-Entity
groups,O
showed,O
improvements,O
in,O
bradykinesia,I-Entity
and,O
rigidity,I-Entity
",",O
although,O
when,O
considered,O
as,O
a,O
group,O
neither,O
the,O
Gamma,I-Entity
Knife,I-Entity
nor,O
the,O
radiofrequency,I-Entity
group,O
showed,O
statistically,O
significant,O
improvements,O
in,O
UPDRS,I-Entity
scores,O
.,O
One,I-Entity
patient,O
in,O
the,O
Gamma,I-Entity
Knife,I-Entity
group,O
(,O
3.4%,O
),O
developed,O
a,O
homonymous,I-Entity
hemianopsia,I-Entity
9,O
months,O
following,O
treatment,O
and,O
5,O
patients,O
(,O
27.7%,O
),O
in,O
the,O
radiofrequency,I-Entity
group,O
became,O
transiently,O
confused,I-Entity
postoperatively,O
.,O
Gamma,I-Entity
Knife,I-Entity
pallidotomy,O
is,O
as,O
effective,O
as,O
radiofrequency,I-Entity
pallidotomy,O
in,O
controlling,O
certain,O
of,O
the,O
symptoms,O
of,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
.,O
It,I-Entity
may,O
be,O
the,O
only,O
practical,O
technique,O
available,O
in,O
certain,O
patients,O
",",O
such,O
as,O
those,O
who,O
take,O
anticoagulants,O
",",O
have,O
bleeding,I-Entity
diatheses,I-Entity
or,O
serious,O
systemic,O
medical,O
illnesses,I-Entity
.,O
Neuroleptic,I-Entity
malignant,I-Entity
syndrome,I-Entity
and,O
methylphenidate,I-Entity
.,O
A,I-Entity
1-year,O
-,O
old,O
female,O
presented,O
with,O
neuroleptic,O
malignant,I-Entity
syndrome,I-Entity
probably,O
caused,O
by,O
methylphenidate,I-Entity
.,O
She,I-Entity
had,O
defects,O
in,O
the,O
supratentorial,O
brain,O
including,O
the,O
basal,O
ganglia,I-Entity
and,O
the,O
striatum,O
(,O
multicystic,B-Entity
encephalomalacia,I-Entity
),O
due,O
to,O
severe,O
perinatal,O
hypoxic,I-Entity
-,O
ischemic,I-Entity
encephalopathy,I-Entity
",",O
which,O
was,O
considered,O
to,O
be,O
a,O
possible,O
predisposing,O
factor,O
causing,O
neuroleptic,O
malignant,I-Entity
syndrome,I-Entity
.,O
However,I-Entity
",",O
methylphenidate,I-Entity
is,O
a,O
dopamine,I-Entity
agonist,I-Entity
via,O
the,O
inhibition,O
of,O
uptake,O
of,O
dopamine,I-Entity
",",O
and,O
therefore,O
dopaminergic,O
systems,O
in,O
the,O
brainstem,O
(,O
mainly,O
the,O
midbrain,O
),O
and,O
the,O
spinal,O
cord,O
were,O
unlikely,O
to,O
participate,O
in,O
the,O
onset,O
of,O
this,O
syndrome,I-Entity
.,O
A,I-Entity
relative,O
gamma,I-Entity
-,O
aminobutyric,I-Entity
acid,O
-,O
ergic,O
deficiency,I-Entity
might,O
occur,O
because,O
diazepam,I-Entity
",",O
a,O
gamma,I-Entity
-,O
aminobutyric,I-Entity
acid,O
-,O
mimetic,I-Entity
agent,O
",",O
was,O
strikingly,O
effective,O
.,O
This,I-Entity
is,O
the,O
first,O
reported,O
patient,O
with,O
neuroleptic,O
malignant,I-Entity
syndrome,I-Entity
probably,O
caused,O
by,O
methylphenidate,I-Entity
.,O
Differential,I-Entity
effects,O
of,O
17alpha,I-Entity
-,O
ethinylestradiol,I-Entity
on,O
the,O
neutral,O
and,O
acidic,O
pathways,O
of,O
bile,I-Entity
salt,O
synthesis,O
in,O
the,O
rat,O
.,O
Effects,I-Entity
of,O
17alpha,I-Entity
-,O
ethinylestradiol,I-Entity
(,O
EE,I-Entity
),O
on,O
the,O
neutral,O
and,O
acidic,O
biosynthetic,O
pathways,O
of,O
bile,I-Entity
salt,O
(,O
BS,I-Entity
),O
synthesis,O
were,O
evaluated,O
in,O
rats,O
with,O
an,O
intact,O
enterohepatic,I-Entity
circulation,O
and,O
in,O
rats,O
with,O
long,O
-,O
term,O
bile,I-Entity
diversion,O
to,O
induce,O
BS,I-Entity
synthesis,O
.,O
For,I-Entity
this,O
purpose,O
",",O
bile,I-Entity
salt,O
pool,O
composition,I-Entity
",",O
synthesis,O
of,O
individual,O
BS,I-Entity
in,O
vivo,O
",",O
hepatic,B-Entity
activities,O
",",O
and,O
expression,O
levels,O
of,O
cholesterol,I-Entity
7alpha,I-Entity
-,O
hydroxylase,O
(,O
CYP7A,I-Entity
),O
",",O
and,O
sterol,I-Entity
27-hydroxylase,I-Entity
(,O
CYP27,I-Entity
),O
",",O
as,O
well,O
as,O
of,O
other,O
enzymes,O
involved,O
in,O
BS,I-Entity
synthesis,O
",",O
were,O
analyzed,O
in,O
rats,O
treated,O
with,O
EE,I-Entity
(,O
5,O
mg,O
/,O
kg,O
",",O
3,O
days,O
),O
or,O
its,O
vehicle,O
.,O
BS,I-Entity
pool,O
size,O
was,O
decreased,O
by,O
27%,O
but,O
total,O
BS,I-Entity
synthesis,O
was,O
not,O
affected,O
by,O
EE,I-Entity
in,O
intact,O
rats,O
.,O
Synthesis,I-Entity
of,O
cholate,I-Entity
was,O
reduced,O
by,O
68%,O
in,O
EE,I-Entity
-,O
treated,O
rats,O
",",O
while,O
that,O
of,O
chenodeoxycholate,I-Entity
was,O
increased,O
by,O
60%,O
.,O
The,I-Entity
recently,O
identified,O
Delta22-isomer,I-Entity
of,O
beta,O
-,O
muricholate,I-Entity
contributed,O
for,O
5.4%,O
and,O
18.3,O
%,O
(,O
P,I-Entity
<,O
0.01,O
),O
to,O
the,O
pool,O
in,O
control,O
and,O
EE,I-Entity
-,O
treated,O
rats,O
",",O
respectively,O
",",O
but,O
could,O
not,O
be,O
detected,O
in,O
bile,I-Entity
after,O
exhaustion,I-Entity
of,O
the,O
pool,O
.,O
A,I-Entity
clear,O
reduction,O
of,O
BS,I-Entity
synthesis,O
was,O
found,O
in,O
bile,I-Entity
-,O
diverted,O
rats,O
treated,O
with,O
EE,I-Entity
",",O
yet,O
biliary,O
BS,I-Entity
composition,I-Entity
was,O
only,O
minimally,O
affected,O
.,O
Activity,I-Entity
of,O
CYP7A,I-Entity
was,O
decreased,O
by,O
EE,I-Entity
in,O
both,O
intact,O
and,O
bile,I-Entity
-,O
diverted,O
rats,O
",",O
whereas,O
the,O
activity,O
of,O
the,O
CYP27,I-Entity
was,O
not,O
affected,O
.,O
Hepatic,I-Entity
mRNA,I-Entity
levels,O
of,O
CYP7A,I-Entity
were,O
significantly,O
reduced,O
by,O
EE,I-Entity
in,O
bile,I-Entity
-,O
diverted,O
rats,O
only,O
;,O
CYP27,I-Entity
mRNA,I-Entity
levels,O
were,O
not,O
affected,O
by,O
EE,I-Entity
.,O
In,I-Entity
addition,O
",",O
mRNA,I-Entity
levels,O
of,O
sterol,I-Entity
12alpha,I-Entity
-,O
hydroxylase,O
and,O
lithocholate,I-Entity
6beta,I-Entity
-,O
hydroxylase,O
were,O
increased,O
by,O
bile,I-Entity
diversion,O
and,O
suppressed,O
by,O
EE,I-Entity
.,O
This,I-Entity
study,O
shows,O
that,O
17alpha,I-Entity
-,O
ethinylestradiol,I-Entity
(,O
EE)-induced,I-Entity
intrahepatic,B-Entity
cholestasis,I-Entity
in,O
rats,O
is,O
associated,O
with,O
selective,O
inhibition,O
of,O
the,O
neutral,O
pathway,O
of,O
bile,I-Entity
salt,O
(,O
BS,I-Entity
),O
synthesis,O
.,O
Simultaneous,I-Entity
impairment,I-Entity
of,O
other,O
enzymes,O
in,O
the,O
BS,I-Entity
biosynthetic,O
pathways,O
may,O
contribute,O
to,O
overall,O
effects,O
of,O
EE,I-Entity
on,O
BS,I-Entity
synthesis,O
.,O
Glibenclamide,I-Entity
-,O
sensitive,I-Entity
hypotension,I-Entity
produced,O
by,O
helodermin,I-Entity
assessed,O
in,O
the,O
rat,O
.,O
The,I-Entity
effects,O
of,O
helodermin,I-Entity
",",O
a,O
basic,O
35-amino,I-Entity
acid,O
peptide,I-Entity
isolated,O
from,O
the,O
venom,I-Entity
of,O
a,O
lizard,I-Entity
salivary,O
gland,O
",",O
on,O
arterial,O
blood,O
pressure,O
and,O
heart,O
rate,O
were,O
examined,O
in,O
the,O
rat,O
",",O
focusing,O
on,O
the,O
possibility,O
that,O
activation,O
of,O
ATP,I-Entity
sensitive,I-Entity
K+,I-Entity
(,O
K(ATP,I-Entity
),O
),O
channels,O
is,O
involved,O
in,O
the,O
responses,O
.,O
Helodermin,I-Entity
produced,O
hypotension,I-Entity
in,O
a,O
dose,O
-,O
dependent,O
manner,O
with,O
approximately,O
similar,O
potency,O
and,O
duration,O
to,O
VIP,I-Entity
.,O
Hypotension,I-Entity
induced,O
by,O
both,O
peptides,I-Entity
was,O
significantly,O
attenuated,O
by,O
glibenclamide,I-Entity
",",O
which,O
abolished,O
a,O
levcromakalim,I-Entity
-,O
produced,O
decrease,O
in,O
arterial,O
blood,O
pressure,O
.,O
Oxyhemoglobin,I-Entity
did,O
not,O
affect,O
helodermin,I-Entity
-,O
induced,O
hypotension,I-Entity
",",O
whereas,O
it,O
shortened,O
the,O
duration,O
of,O
acetylcholine,I-Entity
(,O
ACh)-produced,I-Entity
hypotension,I-Entity
.,O
These,I-Entity
findings,O
suggest,O
that,O
helodermin,I-Entity
-,O
produced,O
hypotension,I-Entity
is,O
partly,O
attributable,O
to,O
the,O
activation,O
of,O
glibenclamide,I-Entity
-,O
sensitive,I-Entity
K+,I-Entity
channels,O
(,O
K(ATP,I-Entity
),O
channels,O
),O
",",O
which,O
presumably,O
exist,O
on,O
arterial,O
smooth,O
muscle,O
cells,O
.,O
EDRF,I-Entity
(,O
endothelium,O
-,O
derived,O
relaxing,O
factor)/nitric,O
oxide,I-Entity
does,O
not,O
seem,O
to,O
play,O
an,O
important,O
role,O
in,O
the,O
peptide,I-Entity
-,O
produced,O
hypotension,I-Entity
.,O
Long,I-Entity
-,O
term,O
efficacy,O
and,O
adverse,O
event,O
of,O
nifedipine,I-Entity
sustained,O
-,O
release,O
tablets,O
for,O
cyclosporin,I-Entity
A,I-Entity
-,O
induced,O
hypertension,I-Entity
in,O
patients,O
with,O
psoriasis,I-Entity
.,O
Thirteen,I-Entity
psoriatic,O
patients,O
with,O
hypertension,I-Entity
during,O
the,O
course,O
of,O
cyclosporin,I-Entity
A,I-Entity
therapy,O
were,O
treated,O
for,O
25,O
months,O
with,O
a,O
calcium,I-Entity
channel,O
blocker,O
",",O
sustained,O
-,O
release,O
nifedipine,I-Entity
",",O
to,O
study,O
the,O
clinical,O
antihypertensive,O
effects,O
and,O
adverse,O
events,O
during,O
treatment,O
with,O
both,O
drugs,O
.,O
Seven,I-Entity
of,O
the,O
13,O
patients,O
had,O
exhibited,O
a,O
subclinical,O
hypertensive,I-Entity
state,O
before,O
cyclosporin,I-Entity
A,I-Entity
therapy,O
.,O
Both,I-Entity
systolic,O
and,O
diastolic,I-Entity
blood,O
pressures,O
of,O
these,O
13,O
patients,O
were,O
decreased,O
significantly,O
after,O
4,O
weeks,O
of,O
nifedipine,I-Entity
therapy,O
",",O
and,O
blood,O
pressure,O
was,O
maintained,O
within,O
the,O
normal,O
range,O
thereafter,O
for,O
25,O
months,O
.,O
The,I-Entity
adverse,O
events,O
during,O
combined,O
therapy,O
with,O
cyclosporin,I-Entity
A,I-Entity
and,O
nifedipine,I-Entity
included,O
an,O
increase,O
in,O
blood,O
urea,I-Entity
nitrogen,I-Entity
levels,O
in,O
9,O
of,O
the,O
13,O
patients,O
and,O
development,O
of,O
gingival,I-Entity
hyperplasia,I-Entity
in,O
2,O
of,O
the,O
13,O
patients,O
.,O
Our,I-Entity
findings,O
indicate,O
that,O
sustained,O
-,O
release,O
nifedipine,I-Entity
is,O
useful,O
for,O
hypertensive,I-Entity
psoriatic,O
patients,O
under,O
long,O
-,O
term,O
treatment,O
with,O
cyclosporin,I-Entity
A,I-Entity
",",O
but,O
that,O
these,O
patients,O
should,O
be,O
monitored,O
for,O
gingival,I-Entity
hyperplasia,I-Entity
.,O
Torsade,I-Entity
de,O
pointes,I-Entity
ventricular,O
tachycardia,I-Entity
during,O
low,O
dose,O
intermittent,O
dobutamine,I-Entity
treatment,O
in,O
a,O
patient,O
with,O
dilated,O
cardiomyopathy,I-Entity
and,O
congestive,B-Entity
heart,O
failure,I-Entity
.,O
The,I-Entity
authors,O
describe,O
the,O
case,O
of,O
a,O
56-year,O
-,O
old,O
woman,O
with,O
chronic,O
",",O
severe,O
heart,O
failure,I-Entity
secondary,O
to,O
dilated,O
cardiomyopathy,I-Entity
and,O
absence,O
of,O
significant,O
ventricular,O
arrhythmias,I-Entity
who,O
developed,O
QT,I-Entity
prolongation,O
and,O
torsade,I-Entity
de,O
pointes,I-Entity
ventricular,O
tachycardia,I-Entity
during,O
one,O
cycle,O
of,O
intermittent,O
low,O
dose,O
(,O
2.5,O
mcg,O
/,O
kg,O
per,O
min,O
),O
dobutamine,I-Entity
.,O
This,I-Entity
report,O
of,O
torsade,I-Entity
de,O
pointes,I-Entity
ventricular,O
tachycardia,I-Entity
during,O
intermittent,O
dobutamine,I-Entity
supports,O
the,O
hypothesis,O
that,O
unpredictable,I-Entity
fatal,O
arrhythmias,I-Entity
may,O
occur,O
even,O
with,O
low,O
doses,O
and,O
in,O
patients,O
with,O
no,O
history,O
of,O
significant,O
rhythm,O
disturbances,I-Entity
.,O
The,I-Entity
mechanisms,O
of,O
proarrhythmic,B-Entity
effects,O
of,O
Dubutamine,I-Entity
are,O
discussed,O
.,O
Positive,I-Entity
skin,O
tests,O
in,O
late,O
reactions,O
to,O
radiographic,O
contrast,O
media,O
.,O
In,I-Entity
the,O
last,O
few,O
years,O
delayed,O
reactions,O
several,O
hours,O
after,O
the,O
injection,O
of,O
radiographic,O
and,O
contrast,O
materials,O
(,O
PRC,I-Entity
),O
have,O
been,O
described,O
with,O
increasing,O
frequency,O
.,O
The,I-Entity
authors,O
report,O
two,O
observations,O
on,O
patients,O
with,O
delayed,O
reactions,O
in,O
whom,O
intradermoreactions,O
(,O
IDR,I-Entity
),O
and,O
patch,O
tests,O
to,O
a,O
series,O
of,O
ionic,O
and,O
non,O
ionic,O
PRC,I-Entity
were,O
studied,O
.,O
After,I-Entity
angiography,O
by,O
the,O
venous,O
route,O
in,O
patient,O
n,O
degree,O
1,O
a,O
biphasic,O
reaction,I-Entity
with,O
an,O
immediate,O
reaction,I-Entity
(,O
dyspnea,I-Entity
",",O
loss,I-Entity
of,O
consciousness,O
),O
and,O
delayed,O
macro,O
-,O
papular,I-Entity
rash,I-Entity
appeared,O
",",O
whilst,O
patient,O
n,O
degree,O
2,O
developed,O
a,O
generalised,O
sensation,O
of,O
heat,O
",",O
persistent,O
pain,I-Entity
at,O
the,O
site,O
of,O
injection,O
immediately,O
and,O
a,O
generalised,O
macro,O
-,O
papular,I-Entity
reaction,I-Entity
after,O
24,O
hours,O
.,O
The,I-Entity
skin,O
tests,O
revealed,O
positive,O
delayed,O
reactions,O
of,O
24,O
hours,O
and,O
48,I-Entity
hours,O
by,O
IDR,I-Entity
and,O
patch,O
tests,O
to,O
only,O
some,O
PRC,I-Entity
with,O
common,O
chains,O
in,O
their,O
structures,O
.,O
The,I-Entity
positive,O
skin,O
tests,O
are,O
in,O
favour,O
of,O
immunological,O
reactions,O
and,O
may,O
help,O
in,O
diagnosis,O
of,O
allergy,I-Entity
in,O
the,O
patients,O
.,O
Risk,I-Entity
of,O
transient,O
hyperammonemic,I-Entity
encephalopathy,I-Entity
in,O
cancer,I-Entity
patients,O
who,O
received,O
continuous,O
infusion,O
of,O
5-fluorouracil,I-Entity
with,O
the,O
complication,O
of,O
dehydration,I-Entity
and,O
infection,I-Entity
.,O
From,I-Entity
1986,O
to,O
1998,O
",",O
29,O
cancer,I-Entity
patients,O
who,O
had,O
32,O
episodes,O
of,O
transient,O
hyperammonemic,I-Entity
encephalopathy,I-Entity
related,O
to,O
continuous,O
infusion,O
of,O
5-fluorouracil,I-Entity
(,O
5-FU,I-Entity
),O
were,O
identified,O
.,O
None,I-Entity
of,O
the,O
patients,O
had,O
decompensated,O
liver,I-Entity
disease,I-Entity
.,O
Onset,I-Entity
of,O
hyperammonemic,I-Entity
encephalopathy,I-Entity
varied,O
from,O
0.5,O
to,O
5,O
days,O
(,O
mean,O
:,O
2.6,O
+,O
/-,O
Plasma,I-Entity
ammonium,I-Entity
level,O
ranged,O
from,O
248,O
to,O
2387,O
microg%,O
(,O
mean,O
:,O
626,O
+,O
/-,O
Among,I-Entity
the,O
32,O
episodes,O
",",O
26,O
(,O
81%,O
),O
had,O
various,O
degrees,O
of,O
azotemia,I-Entity
",",O
18,O
(,O
56%,O
),O
occurred,O
during,O
bacterial,O
infections,I-Entity
and,O
14,O
(,O
44%,O
),O
without,O
infection,I-Entity
occurred,O
during,O
periods,O
of,O
dehydration,I-Entity
.,O
Higher,I-Entity
plasma,O
ammonium,I-Entity
levels,O
and,O
more,O
rapid,O
onset,O
of,O
hyperammonemia,I-Entity
were,O
seen,O
in,O
18,O
patients,O
with,O
bacterial,O
infections,I-Entity
(,O
p=0.003,O
and,O
0.0006,I-Entity
",",O
respectively,O
),O
and,O
in,O
nine,O
patients,O
receiving,O
high,O
daily,O
doses,O
(,O
2600,O
or,O
1800,O
mg,O
/,O
m2,O
),O
of,O
5-FU,I-Entity
(,O
p=0.0001,O
and,O
In,I-Entity
25,O
out,O
of,O
32,O
episodes,O
(,O
78%,O
),O
",",O
plasma,O
ammonium,I-Entity
levels,O
and,O
mental,O
status,O
returned,O
to,O
normal,O
within,O
2,O
days,O
after,O
adequate,O
management,O
.,O
In,I-Entity
conclusion,O
",",O
hyperammonemic,I-Entity
encephalopathy,I-Entity
can,O
occur,O
in,O
patients,O
receiving,O
continuous,O
infusion,O
of,O
5-FU,I-Entity
.,O
Azotemia,I-Entity
",",O
body,O
fluid,O
insufficiency,I-Entity
and,O
bacterial,O
infections,I-Entity
were,O
frequently,O
found,O
in,O
these,O
patients,O
.,O
It,I-Entity
is,O
therefore,O
important,O
to,O
recognize,O
this,O
condition,O
in,O
patients,O
receiving,O
continuous,O
infusion,O
of,O
5-FU,I-Entity
.,O
The,I-Entity
effects,O
of,O
quinine,I-Entity
and,O
4-aminopyridine,I-Entity
on,O
conditioned,O
place,O
preference,O
and,O
changes,O
in,O
motor,O
activity,O
induced,O
by,O
morphine,I-Entity
in,O
rats,O
The,I-Entity
effects,O
of,O
two,O
unselective,O
potassium,I-Entity
(,O
K(+)-,I-Entity
),O
channel,O
blockers,O
",",O
quinine,I-Entity
(,O
12.5,O
",",O
25,O
and,O
50,O
mg,O
/,O
kg,O
),O
and,O
4-aminopyridine,I-Entity
(,O
1,O
and,O
2,O
mg,O
/,O
kg,O
),O
",",O
on,O
conditioned,O
place,O
preference,O
and,O
biphasic,O
changes,O
in,O
motor,O
activity,O
induced,O
by,O
morphine,I-Entity
(,O
10,O
mg,O
/,O
kg,O
),O
were,O
tested,O
in,O
Wistar,I-Entity
rats,O
.,O
Quinine,I-Entity
is,O
known,O
to,O
block,O
voltage-,O
",",O
calcium-,I-Entity
and,O
ATP,I-Entity
-,O
sensitive,I-Entity
K(+)-channels,I-Entity
while,O
4-aminopyridine,I-Entity
is,O
known,O
to,O
block,O
voltage,O
-,O
sensitive,I-Entity
K(+)-channels,I-Entity
.,O
In,I-Entity
the,O
counterbalanced,O
method,O
",",O
quinine,I-Entity
attenuated,O
morphine,I-Entity
-,O
induced,O
place,O
preference,O
",",O
whereas,O
4-aminopyridine,I-Entity
was,O
ineffective,O
.,O
In,I-Entity
the,O
motor,O
activity,O
test,O
measured,O
with,O
an,O
Animex,I-Entity
-,O
activity,O
meter,O
neither,O
of,O
the,O
K(+)-channel,I-Entity
blockers,O
affected,O
morphine,I-Entity
-,O
induced,O
hypoactivity,O
",",O
but,O
both,O
K(+)-channel,I-Entity
blockers,O
prevented,O
morphine,I-Entity
-,O
induced,O
secondary,O
hyperactivity,I-Entity
.,O
These,I-Entity
results,O
suggest,O
the,O
involvement,O
of,O
quinine,I-Entity
-,O
sensitive,I-Entity
but,O
not,O
4-aminopyridine,I-Entity
-,O
sensitive,I-Entity
K(+)-channels,I-Entity
in,O
morphine,I-Entity
reward,O
.,O
It,I-Entity
is,O
also,O
suggested,O
that,O
the,O
blockade,O
of,O
K(+)-channels,I-Entity
sensitive,I-Entity
to,O
these,O
blockers,O
is,O
not,O
sufficient,O
to,O
prevent,O
morphine,I-Entity
-,O
induced,O
hypoactivity,O
whereas,O
morphine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
seems,O
to,O
be,O
connected,O
to,O
both,O
quinine-,I-Entity
and,O
4-aminopyridine,I-Entity
-,O
sensitive,I-Entity
K(+)-channels,I-Entity
.,O
Nociceptin,I-Entity
/,O
orphanin,I-Entity
FQ,I-Entity
and,O
nocistatin,I-Entity
on,O
learning,O
and,O
memory,O
impairment,I-Entity
induced,O
by,O
scopolamine,I-Entity
in,O
mice,O
Nociceptin,I-Entity
",",O
also,O
known,O
as,O
orphanin,I-Entity
FQ,I-Entity
",",O
is,O
an,O
endogenous,O
ligand,O
for,O
the,O
orphan,I-Entity
opioid,O
receptor,O
-,O
like,O
receptor,O
1,O
(,O
ORL1,I-Entity
),O
and,O
involves,O
in,O
various,O
functions,O
in,O
the,O
central,O
nervous,I-Entity
system,O
(,O
CNS,I-Entity
),O
.,O
On,I-Entity
the,O
other,O
hand,O
",",O
nocistatin,I-Entity
is,O
recently,O
isolated,O
from,O
the,O
same,O
precursor,O
as,O
nociceptin,I-Entity
and,O
blocks,O
nociceptin,I-Entity
-,O
induced,O
allodynia,I-Entity
and,O
hyperalgesia,I-Entity
.,O
The,I-Entity
present,O
study,O
was,O
designed,O
to,O
investigate,O
whether,O
nociceptin,I-Entity
/,O
orphanin,I-Entity
FQ,I-Entity
and,O
nocistatin,I-Entity
could,O
modulate,O
impairment,I-Entity
of,O
learning,O
and,O
memory,O
induced,O
by,O
scopolamine,I-Entity
",",O
a,O
muscarinic,O
cholinergic,O
receptor,O
antagonist,O
",",O
using,O
spontaneous,O
alternation,I-Entity
of,O
Y,I-Entity
-,O
maze,O
and,O
step,O
-,O
down,O
type,O
passive,O
avoidance,I-Entity
tasks,O
in,O
mice,O
.,O
While,I-Entity
nocistatin,I-Entity
(,O
0.5,O
-,O
5.0,O
nmol,I-Entity
mouse-1,O
",",O
i.c.v,O
.,O
),O
administered,O
30,O
min,O
before,O
spontaneous,O
alternation,I-Entity
performance,O
or,O
the,O
training,O
session,O
of,O
the,O
passive,O
avoidance,I-Entity
task,O
",",O
had,O
no,O
effect,O
on,O
spontaneous,O
alternation,I-Entity
or,O
passive,O
avoidance,I-Entity
behaviours,O
",",O
a,O
lower,O
per,O
cent,O
alternation,I-Entity
and,O
shorter,O
median,O
step,O
-,O
down,O
latency,O
in,O
the,O
retention,O
test,O
were,O
obtained,O
in,O
nociceptin,I-Entity
(,O
1.5,O
and/or,O
5.0,O
nmol,I-Entity
mouse-1,O
",",O
Administration,I-Entity
of,O
nocistatin,I-Entity
(,O
1.5,O
and/or,O
5.0,O
nmol,I-Entity
mouse-1,O
",",O
i.c.v,O
.,O
),O
30,O
min,O
before,O
spontaneous,O
alternation,I-Entity
performance,O
or,O
the,O
training,O
session,O
of,O
the,O
passive,O
avoidance,I-Entity
task,O
",",O
attenuated,O
the,O
scopolamine,I-Entity
-,O
induced,O
impairment,I-Entity
of,O
spontaneous,O
alternation,I-Entity
and,O
passive,O
avoidance,I-Entity
behaviours,O
.,O
These,I-Entity
results,O
indicated,O
that,O
nocistatin,I-Entity
",",O
a,O
new,O
biologically,O
active,O
peptide,I-Entity
",",O
ameliorates,O
impairments,I-Entity
of,O
spontaneous,O
alternation,I-Entity
and,O
passive,O
avoidance,I-Entity
induced,O
by,O
scopolamine,I-Entity
",",O
and,O
suggested,O
that,O
these,O
peptides,I-Entity
play,O
opposite,O
roles,O
in,O
learning,O
and,O
memory,O
.,O
Meloxicam,I-Entity
-,O
induced,O
liver,I-Entity
toxicity,I-Entity
.,O
We,I-Entity
report,O
the,O
case,O
of,O
a,O
female,O
patient,O
with,O
rheumatoid,O
arthritis,I-Entity
who,O
developed,O
acute,O
cytolytic,O
hepatitis,I-Entity
due,O
to,O
meloxicam,I-Entity
.,O
Recently,I-Entity
introduced,O
in,O
Belgium,I-Entity
",",O
meloxicam,I-Entity
is,O
the,O
first,O
nonsteroidal,O
antiinflammatory,O
drug,O
with,O
selective,O
action,O
on,O
the,O
inducible,O
form,O
of,O
cyclooxygenase,O
2,O
.,O
The,I-Entity
acute,O
cytolytic,O
hepatitis,I-Entity
occurred,O
rapidly,O
after,O
meloxicam,I-Entity
administration,O
and,O
was,O
associated,O
with,O
the,O
development,O
of,O
antinuclear,O
antibodies,O
suggesting,O
a,O
hypersensitivity,I-Entity
mechanism,O
.,O
This,I-Entity
first,O
case,O
of,O
meloxicam,I-Entity
related,O
liver,I-Entity
toxicity,I-Entity
demonstrates,O
the,O
potential,O
of,O
this,O
drug,O
to,O
induce,O
hepatic,B-Entity
damage,O
.,O
Induction,I-Entity
of,O
apoptosis,O
by,O
remoxipride,I-Entity
metabolites,O
in,O
HL60,I-Entity
and,O
CD34+/CD19-,I-Entity
human,O
bone,O
marrow,O
progenitor,O
cells,O
:,O
potential,O
relevance,O
to,O
remoxipride,I-Entity
-,O
induced,O
aplastic,B-Entity
anemia,I-Entity
.,O
The,I-Entity
antipsychotic,O
agent,O
",",O
remoxipride,I-Entity
[,O
(,O
S)-(-)-3-bromo,I-Entity
-,O
"N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz",B-Entity
amide,O
],O
has,O
been,O
associated,O
with,O
acquired,O
aplastic,B-Entity
anemia,I-Entity
.,O
We,I-Entity
have,O
examined,O
the,O
ability,O
of,O
remoxipride,I-Entity
",",O
three,O
pyrrolidine,I-Entity
ring,O
metabolites,O
and,O
five,O
aromatic,I-Entity
ring,O
metabolites,O
of,O
the,O
parent,O
compound,O
to,O
induce,O
apoptosis,O
in,O
HL60,I-Entity
cells,O
and,O
human,O
bone,O
marrow,O
progenitor,O
(,O
HBMP,I-Entity
),O
cells,O
.,O
Apoptosis,I-Entity
was,O
assessed,O
by,O
fluorescence,I-Entity
microscopy,O
in,O
Hoechst,I-Entity
33342-,I-Entity
and,O
propidium,I-Entity
iodide,I-Entity
stained,O
cell,O
samples,O
.,O
The,I-Entity
catechol,I-Entity
and,O
hydroquinone,I-Entity
metabolites,O
",",O
NCQ436,I-Entity
and,O
NCQ344,I-Entity
",",O
induced,O
apoptosis,O
in,O
HL60,I-Entity
and,O
HBMP,I-Entity
cells,O
in,O
a,O
time-,O
and,O
concentration,O
dependent,O
manner,O
",",O
while,O
the,O
phenols,I-Entity
",",O
NCR181,I-Entity
",",O
FLA873,I-Entity
",",O
and,O
FLA797,I-Entity
",",O
and,O
the,O
derivatives,O
formed,O
by,O
oxidation,I-Entity
of,O
the,O
pyrrolidine,I-Entity
ring,O
",",O
FLA838,I-Entity
",",O
NCM001,I-Entity
",",O
and,O
NCL118,I-Entity
",",O
had,O
no,O
effect,O
.,O
No,I-Entity
necrosis,I-Entity
was,O
observed,O
in,O
cells,O
treated,O
with,O
NCQ436,I-Entity
but,O
NCQ344,I-Entity
had,O
a,O
biphasic,O
effect,O
in,O
both,O
cell,O
types,O
",",O
inducing,O
apoptosis,O
at,O
lower,O
concentrations,O
and,O
necrosis,I-Entity
at,O
higher,O
concentrations,O
.,O
These,I-Entity
data,O
show,O
that,O
the,O
catechol,I-Entity
and,O
hydroquinone,I-Entity
metabolites,O
of,O
remoxipride,I-Entity
have,O
direct,O
toxic,I-Entity
effects,O
in,O
HL60,I-Entity
and,O
HBMP,I-Entity
cells,O
",",O
leading,O
to,O
apoptosis,O
",",O
while,O
the,O
phenol,I-Entity
metabolites,O
were,O
inactive,O
.,O
Similarly,I-Entity
",",O
benzene,I-Entity
-,O
derived,O
catechol,I-Entity
and,O
hydroquinone,I-Entity
",",O
but,O
not,O
phenol,I-Entity
",",O
induce,O
apoptosis,O
in,O
HBMP,I-Entity
cells,O
We,I-Entity
propose,O
that,O
remoxipride,I-Entity
and,O
benzene,I-Entity
may,O
induce,O
aplastic,B-Entity
anemia,I-Entity
via,O
production,O
of,O
similar,O
reactive,O
metabolites,O
and,O
that,O
the,O
ability,O
of,O
NCQ436,I-Entity
and,O
NCQ344,I-Entity
to,O
induce,O
apoptosis,O
in,O
HBMP,I-Entity
cells,O
may,O
contribute,O
to,O
the,O
mechanism,O
underlying,O
acquired,O
aplastic,B-Entity
anemia,I-Entity
that,O
has,O
been,O
associated,O
with,O
remoxipride,I-Entity
.,O
Synthesis,I-Entity
and,O
preliminary,O
pharmacological,O
investigations,O
of,O
"1-(1,2-dihydro-2-acenaphthylenyl)piperazine",I-Entity
derivatives,O
as,O
potential,O
atypical,O
antipsychotic,O
agents,O
in,O
mice,O
.,O
The,I-Entity
synthesis,O
and,O
preliminary,O
pharmacological,O
evaluation,O
of,O
a,O
series,O
of,O
potential,O
atypical,O
antipsychotic,O
agents,O
based,O
on,O
the,O
structure,O
of,O
"1-(1,2-dihydro-2-acenaphthylenyl)piperazine",I-Entity
(,O
7,O
),O
is,O
described,O
.,O
Compound,I-Entity
7e,O
",",O
"5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy",B-Entity
dro-1H-,I-Entity
indol-2-one,I-Entity
",",O
from,O
this,O
series,O
showed,O
significant,O
affinities,I-Entity
at,O
the,O
5-HT1A,I-Entity
and,O
5-HT2A,I-Entity
receptors,O
and,O
moderate,O
affinity,I-Entity
at,O
the,O
D2,I-Entity
receptor,O
.,O
7e,O
exhibits,O
a,O
high,O
reversal,O
of,O
catalepsy,I-Entity
induced,O
by,O
haloperidol,I-Entity
indicating,O
its,O
atypical,O
antipsychotic,O
nature,O
.,O
Sub,I-Entity
-,O
chronic,O
inhibition,O
of,O
nitric,I-Entity
-,O
oxide,I-Entity
synthesis,O
modifies,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
and,O
the,O
number,O
of,O
NADPH,I-Entity
-,O
diaphorase,O
neurons,O
in,O
mice,O
.,O
NG,I-Entity
-,O
nitro,I-Entity
-,O
L,I-Entity
-,O
arginine,I-Entity
(,O
L,I-Entity
-,O
NOARG,I-Entity
),O
",",O
an,O
inhibitor,O
of,O
nitric,I-Entity
-,O
oxide,I-Entity
synthase,O
(,O
NOS,I-Entity
),O
",",O
induces,O
catalepsy,I-Entity
in,O
mice,O
.,O
This,I-Entity
effect,O
undergoes,O
rapid,O
tolerance,O
",",O
showing,O
a,O
significant,O
decrease,O
after,O
2,O
days,O
of,O
sub,O
-,O
chronic,O
L,I-Entity
-,O
NOARG,I-Entity
treatment,O
.,O
Nitric,I-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
has,O
been,O
shown,O
to,O
influence,O
dopaminergic,O
neurotransmission,O
in,O
the,O
striatum,O
.,O
Neuroleptic,I-Entity
drugs,O
such,O
as,O
haloperidol,I-Entity
",",O
which,O
block,O
dopamine,I-Entity
receptors,O
",",O
also,O
cause,O
catalepsy,I-Entity
in,O
rodents,O
.,O
To,I-Entity
investigate,O
the,O
effects,O
of,O
subchronic,O
L,I-Entity
-,O
NOARG,I-Entity
treatment,O
in,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
and,O
the,O
number,O
of,O
NOS,I-Entity
neurons,O
in,O
areas,O
related,O
to,O
motor,O
control,O
.,O
Male,I-Entity
albino,O
Swiss,I-Entity
mice,O
were,O
treated,O
sub,O
-,O
chronically,O
(,O
twice,O
a,O
day,O
for,O
4,O
days,O
),O
with,O
L,I-Entity
-,O
NOARG,I-Entity
(,O
40,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
or,O
haloperidol,I-Entity
(,O
1,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
.,O
Catalepsy,I-Entity
was,O
evaluated,O
at,O
the,O
beginning,O
and,O
the,O
end,O
of,O
the,O
treatments,O
.,O
Reduced,I-Entity
nicotinamide,I-Entity
adenine,I-Entity
dinucleotide,I-Entity
phosphate,I-Entity
-,O
diaphorase,O
(,O
NADPH,I-Entity
-,O
d,O
),O
L,I-Entity
-,O
NOARG,I-Entity
sub,O
-,O
chronic,O
administration,O
produced,O
tolerance,O
of,O
L,I-Entity
-,O
NOARG,I-Entity
and,O
of,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
.,O
It,I-Entity
also,O
induced,O
an,O
increase,O
in,O
the,O
number,O
of,O
NADPH,I-Entity
-,O
d,O
-,O
positive,O
cells,O
in,O
the,O
dorsal,O
part,O
of,O
the,O
caudate,O
and,O
accumbens,O
nuclei,O
compared,O
with,O
haloperidol,I-Entity
and,O
in,O
the,O
pedunculopontine,I-Entity
tegmental,I-Entity
nucleus,O
compared,O
with,O
saline,O
.,O
In,I-Entity
contrast,O
",",O
there,O
was,O
a,O
decrease,O
in,O
NADPH,I-Entity
-,O
d,O
neuron,O
number,O
in,O
the,O
substantia,I-Entity
nigra,I-Entity
",",O
pars,O
compacta,O
in,O
both,O
haloperidol,I-Entity
-,O
treated,O
and,O
L,I-Entity
-,O
NOARG,I-Entity
-,O
treated,O
animals,O
.,O
CONCLUSIONS,I-Entity
:,O
The,I-Entity
results,O
give,O
further,O
support,O
to,O
the,O
hypothesis,O
that,O
NO,I-Entity
plays,O
a,O
role,O
in,O
motor,O
behavior,O
control,O
and,O
suggest,O
that,O
it,O
may,O
take,O
part,O
in,O
the,O
synaptic,O
changes,O
produced,O
by,O
antipsychotic,O
treatment,O
.,O
Prolonged,I-Entity
left,O
ventricular,O
dysfunction,I-Entity
occurs,O
in,O
patients,O
with,O
coronary,O
artery,I-Entity
disease,I-Entity
after,O
both,O
dobutamine,I-Entity
and,O
exercise,O
induced,O
myocardial,B-Entity
ischaemia,I-Entity
.,O
OBJECTIVE,I-Entity
:,O
To,I-Entity
determine,O
whether,O
pharmacological,O
stress,I-Entity
leads,O
to,O
prolonged,O
but,O
reversible,O
left,O
ventricular,O
dysfunction,I-Entity
in,O
patients,O
with,O
coronary,O
artery,I-Entity
disease,I-Entity
",",O
similar,O
to,O
that,O
seen,O
after,O
exercise,O
.,O
A,I-Entity
randomised,O
crossover,O
study,O
of,O
recovery,O
time,O
of,O
systolic,O
and,O
diastolic,I-Entity
left,O
ventricular,O
function,O
after,O
exercise,O
and,O
dobutamine,I-Entity
induced,O
ischaemia,I-Entity
.,O
SUBJECTS,I-Entity
:,O
10,O
patients,O
with,O
stable,O
angina,I-Entity
",",O
angiographically,O
proven,O
coronary,O
artery,I-Entity
disease,I-Entity
",",O
and,O
normal,O
left,O
ventricular,O
function,O
.,O
INTERVENTIONS,I-Entity
:,O
Treadmill,I-Entity
exercise,O
and,O
dobutamine,I-Entity
stress,I-Entity
were,O
performed,O
on,O
different,O
days,O
.,O
There,I-Entity
was,O
no,O
difference,O
in,O
the,O
maximum,O
double,O
product,O
(,O
p,O
=,O
0.53,O
),O
or,O
ST,I-Entity
depression,I-Entity
(,O
p,O
=,O
0.63,O
),O
with,O
either,O
form,O
of,O
stress,I-Entity
.,O
After,I-Entity
exercise,O
",",O
ejection,O
fraction,O
was,O
reduced,O
at,O
15,O
and,O
30,O
minutes,O
compared,O
with,O
baseline,O
(,O
mean,O
(,O
SEM,I-Entity
),O
",",O
-5.6,O
(,O
1.5)%,O
",",O
p,O
<,O
0.05,O
;,O
and,O
-6.1,O
(,O
2.2)%,O
",",O
p,O
<,O
0,O
.,O
01,O
),O
",",O
and,O
at,O
30,O
and,O
45,I-Entity
minutes,O
after,O
dobutamine,I-Entity
(,O
-10.8,O
(,O
1.8)%,O
and,O
-5,O
.,O
Regional,I-Entity
analysis,O
showed,O
a,O
reduction,O
in,O
the,O
worst,O
affected,O
segment,O
15,O
and,O
30,O
minutes,O
after,O
exercise,O
(,O
-27.9,O
(,O
7.2)%,O
and,O
-28.6,O
(,O
5.7)%,O
",",O
both,O
p,O
<,O
0.01,O
),O
",",O
and,O
at,O
30,O
minutes,O
after,O
dobutamine,I-Entity
In,I-Entity
patients,O
with,O
coronary,O
artery,I-Entity
disease,I-Entity
",",O
dobutamine,I-Entity
induced,O
ischaemia,I-Entity
results,O
in,O
prolonged,O
reversible,O
left,O
ventricular,O
dysfunction,I-Entity
",",O
presumed,O
to,O
be,O
myocardial,B-Entity
stunning,I-Entity
",",O
similar,O
to,O
that,O
seen,O
after,O
exercise,O
.,O
Dobutamine,I-Entity
induced,O
ischaemia,I-Entity
could,O
therefore,O
be,O
used,O
to,O
study,O
the,O
pathophysiology,O
of,O
this,O
phenomenon,O
further,O
in,O
patients,O
with,O
coronary,O
artery,I-Entity
disease,I-Entity
.,O
Anorexigens,I-Entity
and,O
pulmonary,O
hypertension,I-Entity
in,O
the,O
United,I-Entity
States,I-Entity
:,O
results,O
from,O
the,O
surveillance,O
of,O
North,I-Entity
American,I-Entity
pulmonary,O
hypertension,I-Entity
.,O
BACKGROUND,I-Entity
:,O
The,I-Entity
use,O
of,O
appetite,O
suppressants,I-Entity
in,O
Europe,I-Entity
has,O
been,O
associated,O
with,O
the,O
development,O
of,O
primary,O
pulmonary,O
hypertension,I-Entity
(,O
PPH,I-Entity
),O
.,O
Recently,I-Entity
",",O
fenfluramine,I-Entity
appetite,O
suppressants,I-Entity
became,O
widely,O
used,O
in,O
the,O
United,I-Entity
States,I-Entity
but,O
were,O
withdrawn,O
in,O
September,I-Entity
1997,O
because,O
of,O
concerns,O
over,O
adverse,O
effects,O
.,O
:,O
We,I-Entity
conducted,O
a,O
prospective,O
surveillance,O
study,O
on,O
patients,O
diagnosed,O
with,O
pulmonary,O
hypertension,I-Entity
at,O
12,O
large,O
referral,O
centers,O
in,O
North,I-Entity
America,I-Entity
.,O
Data,I-Entity
collected,O
on,O
patients,O
seen,O
from,O
September,I-Entity
1,O
",",O
1996,O
",",O
to,O
December,I-Entity
31,O
",",O
1997,O
",",O
included,O
the,O
cause,O
of,O
the,O
pulmonary,O
hypertension,I-Entity
and,O
its,O
severity,O
.,O
Patients,I-Entity
with,O
no,O
identifiable,O
cause,O
of,O
pulmonary,O
hypertension,I-Entity
were,O
classed,O
as,O
PPH,I-Entity
.,O
A,I-Entity
history,O
of,O
drug,O
exposure,O
also,O
was,O
taken,O
with,O
special,O
attention,O
on,O
the,O
use,O
of,O
antidepressants,I-Entity
",",O
anorexigens,I-Entity
",",O
and,O
amphetamines,I-Entity
.,O
Five,I-Entity
hundred,O
seventy,O
-,O
nine,O
patients,O
were,O
studied,O
",",O
205,I-Entity
with,O
PPH,I-Entity
and,O
374,O
with,O
pulmonary,O
hypertension,I-Entity
from,O
other,O
causes,O
(,O
secondary,O
pulmonary,O
hypertension,I-Entity
[,O
SPH,I-Entity
],O
),O
.,O
However,I-Entity
",",O
of,O
the,O
medications,O
surveyed,O
",",O
only,O
the,O
fenfluramines,I-Entity
had,O
a,O
significant,O
preferential,O
association,O
with,O
PPH,I-Entity
as,O
compared,O
with,O
SPH,I-Entity
(,O
adjusted,O
odds,O
ratio,O
for,O
use,O
>,O
6,O
months,O
",",O
7.5,O
;,O
95%,O
confidence,O
interval,O
",",O
1.7,O
to,O
32.4,O
),O
.,O
The,I-Entity
magnitude,O
of,O
the,O
association,O
with,O
PPH,I-Entity
",",O
the,O
increase,O
of,O
association,O
with,O
increasing,O
duration,O
of,O
use,O
",",O
and,O
the,O
specificity,O
for,O
fenfluramines,I-Entity
are,O
consistent,O
with,O
previous,O
studies,O
indicating,O
that,O
fenfluramines,I-Entity
are,O
causally,O
related,O
to,O
PPH,I-Entity
.,O
The,I-Entity
high,O
prevalence,O
of,O
anorexigen,I-Entity
use,O
in,O
patients,O
with,O
SPH,I-Entity
also,O
raises,O
the,O
possibility,O
that,O
these,O
drugs,O
precipitate,O
pulmonary,O
hypertension,I-Entity
in,O
patients,O
with,O
underlying,O
conditions,O
associated,O
with,O
SPH,I-Entity
.,O
Clinical,I-Entity
aspects,O
of,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
and,O
thrombosis,I-Entity
and,O
other,O
side,O
effects,O
of,O
heparin,I-Entity
therapy,O
.,O
Heparin,I-Entity
",",O
first,O
used,O
to,O
prevent,O
the,O
clotting,I-Entity
of,O
blood,O
in,O
vitro,O
",",O
has,O
been,O
clinically,O
used,O
to,O
treat,O
thrombosis,I-Entity
for,O
more,O
than,O
50,O
years,O
.,O
Although,I-Entity
several,O
new,O
anticoagulant,O
drugs,O
are,O
in,O
development,O
",",O
heparin,I-Entity
remains,O
the,O
anticoagulant,O
of,O
choice,O
to,O
treat,O
acute,O
thrombotic,I-Entity
episodes,O
.,O
The,I-Entity
clinical,O
effects,O
of,O
heparin,I-Entity
are,O
meritorious,O
",",O
but,O
side,O
effects,O
do,O
exist,O
.,O
Bleeding,I-Entity
is,O
the,O
primary,O
untoward,O
effect,O
of,O
heparin,I-Entity
.,O
Major,I-Entity
bleeding,I-Entity
is,O
of,O
primary,O
concern,O
in,O
patients,O
receiving,O
heparin,I-Entity
therapy,O
.,O
However,I-Entity
",",O
additional,O
important,O
untoward,O
effects,O
of,O
heparin,I-Entity
therapy,O
include,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
",",O
heparin,I-Entity
-,O
associated,O
osteoporosis,I-Entity
",",O
eosinophilia,I-Entity
",",O
skin,O
reactions,O
",",O
allergic,I-Entity
reactions,O
other,O
than,O
thrombocytopenia,I-Entity
",",O
alopecia,I-Entity
",",O
transaminasemia,I-Entity
",",O
hyperkalemia,I-Entity
",",O
hypoaldosteronism,I-Entity
",",O
and,O
priapism,I-Entity
.,O
These,I-Entity
side,O
effects,O
are,O
relatively,O
rare,O
in,O
a,O
given,O
individual,O
",",O
but,O
given,O
the,O
extremely,O
widespread,O
use,O
of,O
heparin,I-Entity
",",O
some,O
are,O
quite,O
common,O
",",O
particularly,O
HITT,I-Entity
and,O
osteoporosis,I-Entity
.,O
Although,I-Entity
reasonable,O
incidences,O
of,O
many,O
of,O
these,O
side,O
effects,O
can,O
be,O
"""""""""",O
softly,O
"""""""""",O
deduced,O
from,O
current,O
reports,O
dealing,O
with,O
unfractionated,O
heparin,I-Entity
",",O
at,O
present,O
the,O
incidences,O
of,O
these,O
side,O
effects,O
with,O
newer,O
low,O
molecular,O
weight,O
heparins,I-Entity
appear,O
to,O
be,O
much,O
less,O
common,O
.,O
A,I-Entity
case,O
of,O
bilateral,O
optic,O
neuropathy,I-Entity
in,O
a,O
patient,O
on,O
tacrolimus,I-Entity
(,O
FK506,I-Entity
),O
therapy,O
after,O
liver,I-Entity
transplantation,O
.,O
PURPOSE,I-Entity
:,O
To,I-Entity
report,O
a,O
case,O
of,O
bilateral,O
optic,O
neuropathy,I-Entity
in,O
a,O
patient,O
receiving,O
tacrolimus,I-Entity
(,O
FK,I-Entity
506,I-Entity
",",O
Prograf,I-Entity
;,O
Fujisawa,I-Entity
USA,I-Entity
",",O
Inc,I-Entity
",",O
Deerfield,I-Entity
",",O
Illinois,I-Entity
),O
for,O
immunosuppression,O
after,O
orthotropic,O
liver,I-Entity
transplantation,O
.,O
In,I-Entity
a,O
58-year,O
-,O
old,O
man,O
receiving,O
tacrolimus,I-Entity
after,O
orthotropic,O
liver,I-Entity
transplantation,O
",",O
serial,O
neuro,I-Entity
-,O
ophthalmologic,O
examinations,O
and,O
laboratory,O
studies,O
were,O
performed,O
.,O
The,I-Entity
patient,O
had,O
episodic,O
deterioration,O
of,O
vision,O
in,O
both,O
eyes,O
",",O
with,O
clinical,O
features,O
resembling,O
ischemic,I-Entity
optic,O
neuropathies,I-Entity
.,O
Deterioration,I-Entity
of,O
vision,O
occurred,O
despite,O
discontinuation,O
of,O
the,O
tacrolimus,I-Entity
.,O
Tacrolimus,I-Entity
and,O
other,O
immunosuppressive,O
agents,O
may,O
be,O
associated,O
with,O
optic,O
nerve,O
toxicity,I-Entity
.,O
Hypercalcemia,I-Entity
",",O
arrhythmia,I-Entity
",",O
and,O
mood,O
stabilizers,O
.,O
Recent,I-Entity
findings,O
in,O
a,O
bipolar,I-Entity
patient,O
receiving,O
maintenance,O
lithium,I-Entity
therapy,O
who,O
developed,O
hypercalcemia,I-Entity
and,O
severe,O
bradyarrhythmia,I-Entity
prompted,O
the,O
authors,O
to,O
conduct,O
a,O
retrospective,O
study,O
of,O
bipolar,I-Entity
patients,O
with,O
lithium,I-Entity
-,O
associated,O
hypercalcemia,I-Entity
.,O
A,I-Entity
printout,O
of,O
all,O
cases,O
of,O
hypercalcemia,I-Entity
that,O
presented,O
during,O
a,O
1-year,O
period,O
was,O
generated,O
.,O
After,I-Entity
eliminating,O
spurious,I-Entity
hypercalcemias,I-Entity
or,O
those,O
associated,O
with,O
intravenous,O
fluids,O
",",O
the,O
authors,O
identified,O
18,O
non,O
-,O
lithium,I-Entity
-,O
treated,O
patients,O
with,O
hypercalcemias,I-Entity
related,O
to,O
malignancies,I-Entity
and,O
other,O
medical,O
conditions,O
(,O
group,O
A,I-Entity
),O
and,O
12,O
patients,O
with,O
lithium,I-Entity
-,O
associated,O
hypercalcemia,I-Entity
(,O
group,O
B,I-Entity
),O
.,O
Thus,I-Entity
",",O
two,O
control,O
groups,O
were,O
generated,O
:,O
group,O
C1,I-Entity
",",O
which,O
included,O
age-,O
and,O
sex,O
-,O
comparable,O
lithium,I-Entity
-,O
treated,O
bipolar,I-Entity
normocalcemic,O
patients,O
",",O
and,O
group,O
C2,I-Entity
",",O
which,O
included,O
bipolar,I-Entity
normocalcemic,O
patients,O
treated,O
with,O
anticonvulsant,O
mood,O
stabilizers,O
.,O
Patients,I-Entity
with,O
hypercalcemia,I-Entity
resulting,O
from,O
medical,O
diseases,I-Entity
and,O
bipolar,I-Entity
patients,O
with,O
lithium,I-Entity
-,O
associated,O
hypercalcemia,I-Entity
had,O
significantly,O
higher,O
frequencies,O
of,O
conduction,O
defects,O
.,O
Attenuation,I-Entity
of,O
nephrotoxicity,I-Entity
by,O
a,O
novel,O
lipid,O
nanosphere,O
(,O
NS-718,I-Entity
),O
incorporating,O
amphotericin,I-Entity
B.,I-Entity
NS-718,I-Entity
",",O
a,O
lipid,O
nanosphere,O
incorporating,O
amphotericin,I-Entity
B,I-Entity
",",O
is,O
effective,O
against,O
pathogenic,O
fungi,O
and,O
has,O
low,O
toxicity,I-Entity
.,O
We,I-Entity
compared,O
the,O
toxicity,I-Entity
of,O
NS-718,I-Entity
with,O
that,O
of,O
Fungizone,I-Entity
(,O
amphotericin,I-Entity
B,I-Entity
-,O
sodium,I-Entity
deoxycholate,I-Entity
;,O
D,I-Entity
-,O
AmB,I-Entity
),O
in,O
vitro,O
using,O
renal,O
cell,O
cultures,O
and,O
in,O
vivo,O
by,O
biochemical,O
analysis,O
",",O
histopathological,O
study,O
of,O
the,O
kidney,O
and,O
pharmacokinetic,O
study,O
of,O
amphotericin,I-Entity
B,I-Entity
following,O
intravenous,O
infusion,O
of,O
the,O
formulation,O
in,O
rats,O
.,O
Incubation,I-Entity
with,O
NS-718,I-Entity
resulted,O
in,O
significantly,O
less,O
damage,O
of,O
cultured,O
human,O
renal,O
proximal,O
tubular,O
epithelial,O
cells,O
compared,O
with,O
D,I-Entity
-,O
AmB.,I-Entity
Serum,I-Entity
blood,O
urea,I-Entity
and,O
creatinine,I-Entity
concentrations,O
increased,O
significantly,O
in,O
rats,O
given,O
an,O
iv,O
infusion,O
of,O
D,I-Entity
-,O
AmB,I-Entity
3,O
mg,O
/,O
kg,O
but,O
not,O
in,O
those,O
given,O
the,O
same,O
dose,O
of,O
NS-718,I-Entity
.,O
Histopathological,I-Entity
examination,O
of,O
the,O
kidney,O
showed,O
tubular,O
necrosis,I-Entity
in,O
D,I-Entity
-,O
AmB,I-Entity
-,O
treated,O
rats,O
but,O
no,O
change,O
in,O
NS-718-treated,I-Entity
rats,O
.,O
Amphotericin,I-Entity
B,I-Entity
concentrations,O
in,O
the,O
kidney,O
in,O
NS-718-treated,I-Entity
rats,O
were,O
higher,O
than,O
those,O
in,O
D,I-Entity
-,O
AmB,I-Entity
-,O
treated,O
rats,O
.,O
Our,I-Entity
in,O
vitro,O
and,O
in,O
vivo,O
results,O
suggest,O
that,O
incorporation,O
of,O
amphotericin,I-Entity
B,I-Entity
into,O
lipid,O
nanospheres,O
of,O
NS-718,I-Entity
attenuates,O
the,O
nephrotoxicity,I-Entity
of,O
amphotericin,I-Entity
B.,I-Entity
Patterns,I-Entity
of,O
sulfadiazine,I-Entity
acute,O
nephrotoxicity,I-Entity
.,O
Sulfadiazine,I-Entity
acute,O
nephrotoxicity,I-Entity
is,O
reviving,O
specially,O
because,O
of,O
its,O
use,O
in,O
toxoplasmosis,I-Entity
in,O
HIV,I-Entity
-,O
positive,O
patients,O
.,O
Under,I-Entity
treatment,O
with,O
sulfadiazine,I-Entity
they,O
developed,O
oliguria,I-Entity
",",O
abdominal,O
pain,I-Entity
",",O
renal,O
failure,I-Entity
and,O
showed,O
multiple,O
radiolucent,I-Entity
renal,O
calculi,I-Entity
in,O
echography,O
.,O
A,I-Entity
nephrostomy,I-Entity
tube,O
had,O
to,O
be,O
placed,O
in,O
one,O
of,O
the,O
patients,O
for,O
ureteral,O
lithiasis,I-Entity
in,O
a,O
single,O
functional,O
kidney,O
.,O
Treatment,I-Entity
with,O
sulfadiazine,I-Entity
requires,O
exquisite,O
control,O
of,O
renal,O
function,O
",",O
an,O
increase,O
in,O
water,O
ingestion,O
and,O
possibly,O
the,O
alcalinization,O
of,O
the,O
urine,I-Entity
.,O
Downbeat,I-Entity
nystagmus,I-Entity
associated,O
with,O
intravenous,O
patient,O
-,O
controlled,O
administration,O
of,O
morphine,I-Entity
.,O
This,I-Entity
case,O
documents,O
a,O
patient,O
who,O
developed,O
dizziness,I-Entity
with,O
downbeating,O
nystagmus,I-Entity
while,O
receiving,O
a,O
relatively,O
large,O
dose,O
of,O
IV,I-Entity
patient,O
-,O
controlled,O
analgesia,O
morphine,I-Entity
.,O
Although,I-Entity
there,O
have,O
been,O
case,O
reports,O
of,O
epidural,O
morphine,I-Entity
with,O
these,O
symptoms,O
and,O
signs,O
",",O
this,O
has,O
not,O
been,O
previously,O
documented,O
with,O
IV,I-Entity
or,O
patient,O
-,O
controlled,O
analgesia,O
morphine,I-Entity
.,O
Hemodynamic,I-Entity
and,O
antiadrenergic,O
effects,O
of,O
dronedarone,I-Entity
and,O
amiodarone,I-Entity
in,O
animals,O
with,O
a,O
healed,O
myocardial,B-Entity
infarction,I-Entity
.,O
The,I-Entity
hemodynamic,O
and,O
antiadrenergic,O
effects,O
of,O
dronedarone,I-Entity
",",O
a,O
noniodinated,O
compound,O
structurally,O
related,O
to,O
amiodarone,I-Entity
",",O
were,O
compared,O
with,O
those,O
of,O
amiodarone,I-Entity
after,O
prolonged,O
oral,O
administration,O
",",O
both,O
at,O
rest,O
and,O
during,O
sympathetic,O
stimulation,O
in,O
conscious,O
dogs,O
with,O
a,O
healed,O
myocardial,B-Entity
infarction,I-Entity
.,O
All,I-Entity
dogs,O
(,O
n,O
=,O
6,O
),O
randomly,O
received,O
orally,O
dronedarone,I-Entity
(,O
10,O
and,O
30,O
mg,O
/,O
kg,O
),O
",",O
amiodarone,I-Entity
(,O
10,O
and,O
30,O
mg,O
/,O
kg,O
),O
",",O
and,O
placebo,O
twice,O
daily,O
for,O
7,O
days,O
",",O
with,O
a,O
3-week,O
washout,I-Entity
between,O
consecutive,O
treatments,O
.,O
Heart,I-Entity
rate,O
(,O
HR,I-Entity
),O
",",O
mean,O
arterial,O
pressure,O
(,O
MBP,I-Entity
),O
",",O
positive,O
rate,O
of,O
increase,O
of,O
left,O
ventricular,O
pressure,O
(,O
+,O
LVdP,I-Entity
/,O
dt,O
),O
",",O
echocardiographically,O
assessed,O
left,O
ventricular,O
ejection,O
fraction,O
(,O
LVEF,I-Entity
),O
",",O
and,O
fractional,O
shortening,O
(,O
FS,I-Entity
),O
",",O
as,O
well,O
as,O
chronotropic,O
response,O
to,O
isoproterenol,I-Entity
and,O
exercise,O
-,O
induced,O
sympathetic,O
stimulation,O
were,O
evaluated,O
under,O
baseline,O
and,O
posttreatment,O
conditions,O
.,O
Resting,I-Entity
values,O
of,O
LVEF,I-Entity
",",O
FS,I-Entity
",",O
+,O
LVdP,I-Entity
/,O
dt,O
",",O
and,O
MBP,I-Entity
remained,O
unchanged,O
whatever,O
the,O
drug,O
and,O
the,O
dosing,O
regimen,I-Entity
",",O
whereas,O
resting,O
HR,I-Entity
was,O
significantly,O
and,O
dose,O
-,O
dependently,O
lowered,O
after,O
dronedarone,I-Entity
and,O
to,O
a,O
lesser,O
extent,O
after,O
amiodarone,I-Entity
.,O
Both,I-Entity
dronedarone,I-Entity
and,O
amiodarone,I-Entity
significantly,O
reduced,O
the,O
exercise,O
-,O
induced,O
tachycardia,I-Entity
and,O
",",O
at,O
the,O
highest,O
dose,O
",",O
decreased,O
the,O
isoproterenol,I-Entity
-,O
induced,O
tachycardia,I-Entity
.,O
Thus,I-Entity
",",O
dronedarone,I-Entity
and,O
amiodarone,I-Entity
displayed,O
a,O
similar,O
level,O
of,O
antiadrenergic,O
effect,O
and,O
did,O
not,O
impair,I-Entity
the,O
resting,O
left,O
ventricular,O
function,O
.,O
Consequently,I-Entity
",",O
dronedarone,I-Entity
might,O
be,O
particularly,O
suitable,O
for,O
the,O
treatment,O
and,O
prevention,O
of,O
various,O
clinical,O
arrhythmias,I-Entity
",",O
without,O
compromising,I-Entity
the,O
left,O
ventricular,O
function,O
.,O
Phase,I-Entity
2,O
trial,O
of,O
liposomal,O
doxorubicin,I-Entity
(,O
40,O
mg,O
/,O
m(2,O
),O
),O
in,O
platinum,O
/,O
paclitaxel,I-Entity
-,O
refractory,O
ovarian,B-Entity
and,O
fallopian,I-Entity
tube,O
cancers,I-Entity
and,O
primary,O
carcinoma,I-Entity
of,O
the,O
peritoneum,I-Entity
.,O
Several,I-Entity
studies,O
have,O
demonstrated,O
liposomal,O
doxorubicin,I-Entity
(,O
Doxil,I-Entity
),O
to,O
be,O
an,O
active,O
antineoplastic,O
agent,O
in,O
platinum,O
-,O
resistant,O
ovarian,B-Entity
cancer,I-Entity
",",O
with,O
dose,O
limiting,O
toxicity,I-Entity
of,O
the,O
standard,O
dosing,O
regimen,I-Entity
(,O
50,O
mg,O
/,O
m(2,O
),O
q,O
4,O
weeks,O
),O
being,O
severe,O
erythrodysesthesia,I-Entity
(,O
"""""""""",O
hand,O
-,O
foot,O
syndrome,I-Entity
"""""""""",O
),O
and,O
stomatitis,I-Entity
.,O
We,I-Entity
wished,O
to,O
develop,O
a,O
more,O
tolerable,O
liposomal,O
doxorubicin,I-Entity
treatment,O
regimen,I-Entity
and,O
document,O
its,O
level,O
of,O
activity,O
in,O
a,O
well,O
-,O
defined,O
patient,O
population,O
with,O
platinum,O
/,O
paclitaxel,I-Entity
-,O
refractory,O
disease,I-Entity
.,O
Patients,I-Entity
with,O
ovarian,B-Entity
or,O
fallopian,I-Entity
tube,O
cancers,I-Entity
or,O
primary,O
peritoneal,O
carcinoma,I-Entity
with,O
platinum,O
/,O
paclitaxel,I-Entity
-,O
refractory,O
disease,I-Entity
(,O
stable,O
or,O
progressive,O
disease,I-Entity
following,O
treatment,O
with,O
these,O
agents,O
or,O
previous,O
objective,O
response,O
<3,O
months,O
in,O
duration,O
),O
were,O
treated,O
with,O
liposomal,O
doxorubicin,I-Entity
at,O
a,O
dose,O
of,O
40,O
mg,O
/,O
m(2,O
),O
q,O
4,O
weeks,O
.,O
Six,I-Entity
(,O
12%,O
),O
and,O
4,O
(,O
8%,O
),O
patients,O
experienced,O
grade,O
2,O
hand,O
-,O
foot,O
syndrome,I-Entity
and,O
stomatitis,I-Entity
",",O
respectively,O
(,O
no,O
episodes,O
of,O
grade,O
3,O
),O
.,O
One,I-Entity
patient,O
developed,O
grade,O
3,O
diarrhea,I-Entity
requiring,O
hospitalization,O
for,O
hydration,O
.,O
The,I-Entity
median,O
number,O
of,O
courses,O
of,O
liposomal,O
doxorubicin,I-Entity
administered,O
on,O
this,O
protocol,O
was,O
2,O
(,O
range,O
:,O
1,O
-,O
12,O
),O
.,O
This,I-Entity
modified,O
liposomal,O
doxorubicin,I-Entity
regimen,I-Entity
results,O
in,O
less,O
toxicity,I-Entity
(,O
stomatitis,I-Entity
",",O
hand,O
-,O
foot,O
syndrome,I-Entity
),O
than,O
the,O
standard,O
FDA,I-Entity
-,O
approved,O
dose,O
schedule,O
.,O
Definite,I-Entity
",",O
although,O
limited,O
",",O
antineoplastic,O
activity,O
is,O
observed,O
in,O
patients,O
with,O
well,O
-,O
defined,O
platinum-,I-Entity
and,O
paclitaxel,I-Entity
-,O
refractory,O
ovarian,B-Entity
cancer,I-Entity
.,O
Efficacy,I-Entity
of,O
olanzapine,I-Entity
in,O
acute,O
bipolar,I-Entity
mania,I-Entity
:,O
a,O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
study,O
.,O
The,I-Entity
Olanzipine,I-Entity
HGGW,I-Entity
Study,I-Entity
Group,I-Entity
.,O
We,I-Entity
compared,O
the,O
efficacy,O
and,O
safety,O
of,O
olanzapine,I-Entity
vs,O
placebo,O
for,O
the,O
treatment,O
of,O
acute,O
bipolar,I-Entity
mania,I-Entity
.,O
A,I-Entity
total,O
of,O
115,I-Entity
patients,O
with,O
a,O
DSM,I-Entity
-,O
IV,I-Entity
diagnosis,O
of,O
bipolar,I-Entity
disorder,I-Entity
",",O
manic,I-Entity
or,O
mixed,O
",",O
were,O
randomized,O
to,O
olanzapine,I-Entity
",",O
5,O
to,O
20,O
mg,O
/,O
d,O
(,O
n,O
=,O
55,I-Entity
),O
",",O
or,O
placebo,O
(,O
n,O
=,O
60,O
),O
.,O
The,I-Entity
primary,O
efficacy,O
measure,O
was,O
the,O
Young,I-Entity
-,O
Mania,I-Entity
Rating,I-Entity
Scale,I-Entity
(,O
Y,I-Entity
-,O
MRS,I-Entity
),O
total,O
score,O
.,O
Safety,I-Entity
was,O
assessed,O
using,O
adverse,O
events,O
",",O
Extrapyramidal,I-Entity
Symptom,I-Entity
(,O
EPS,I-Entity
),O
rating,O
scales,O
",",O
laboratory,O
values,O
",",O
electrocardiograms,O
",",O
vital,O
signs,O
",",O
and,O
weight,O
change,O
.,O
Olanzapine,I-Entity
-,O
treated,O
patients,O
demonstrated,O
a,O
statistically,O
significant,O
greater,O
mean,O
(,O
+,O
/-,O
Olanzapine,I-Entity
-,O
treated,O
patients,O
demonstrated,O
a,O
higher,O
rate,O
of,O
response,O
(,O
65%,O
vs,O
43%,O
",",O
respectively,O
;,O
P,I-Entity
=,O
.02,O
),O
and,O
euthymia,I-Entity
(,O
There,I-Entity
were,O
no,O
statistically,O
significant,O
differences,O
in,O
EPSs,I-Entity
between,O
groups,O
.,O
However,I-Entity
",",O
olanzapine,I-Entity
-,O
treated,O
patients,O
had,O
a,O
statistically,O
significant,O
greater,O
mean,O
(,O
+,O
/-,O
SD,I-Entity
),O
weight,O
gain,O
than,O
placebo,O
-,O
treated,O
patients,O
(,O
2.1,O
+,O
/-,O
2.3,O
kg,O
",",O
respectively,O
),O
and,O
also,O
experienced,O
more,O
treatment,O
-,O
emergent,I-Entity
somnolence,I-Entity
(,O
21,O
patients,O
[,O
38.2%,O
],O
vs,O
5,O
[,O
8.3%,O
],O
",",O
respectively,O
),O
.,O
CONCLUSION,I-Entity
:,O
Olanzapine,I-Entity
demonstrated,O
greater,O
efficacy,O
than,O
placebo,O
in,O
the,O
treatment,O
of,O
acute,O
bipolar,I-Entity
mania,I-Entity
and,O
was,O
generally,O
well,O
tolerated,O
.,O
The,I-Entity
effect,O
of,O
pupil,O
dilation,B-Entity
with,O
tropicamide,I-Entity
on,O
vision,O
and,O
driving,O
simulator,O
performance,O
.,O
To,I-Entity
assess,O
the,O
effect,O
of,O
pupil,O
dilation,B-Entity
on,O
vision,O
and,O
driving,O
ability,O
.,O
METHODS,I-Entity
:,O
A,I-Entity
series,O
of,O
tests,O
on,O
various,O
parameters,O
of,O
visual,O
function,O
and,O
driving,O
simulator,O
performance,O
were,O
performed,O
on,O
12,O
healthy,O
drivers,O
",",O
before,O
and,O
after,O
pupil,O
dilation,B-Entity
using,O
guttae,I-Entity
tropicamide,I-Entity
1%,O
.,O
RESULTS,I-Entity
:,O
Pupillary,I-Entity
dilation,B-Entity
resulted,O
in,O
a,O
statistically,O
significant,O
deterioration,O
in,O
CT,I-Entity
and,O
HCVA,I-Entity
only,O
.,O
Pupillary,I-Entity
dilation,B-Entity
may,O
lead,O
to,O
a,O
decrease,O
in,O
vision,O
and,O
daylight,O
driving,O
performance,O
in,O
young,O
people,O
.,O
A,I-Entity
case,O
of,O
isotretinoin,I-Entity
embryopathy,I-Entity
with,O
bilateral,O
anotia,I-Entity
and,O
Taussig,I-Entity
-,O
Bing,I-Entity
malformation,I-Entity
.,O
We,I-Entity
report,O
a,O
newborn,O
infant,O
with,O
multiple,O
congenital,O
anomalies,I-Entity
(,O
anotia,I-Entity
and,O
Taussig,I-Entity
-,O
Bing,I-Entity
malformation,I-Entity
),O
due,O
to,O
exposure,O
to,O
isotretinoin,I-Entity
within,O
the,O
first,O
trimester,O
.,O
In,I-Entity
this,O
paper,O
we,O
aim,O
to,O
draw,O
to,O
the,O
fact,O
that,O
caution,O
is,O
needed,O
when,O
prescribing,O
vitamin,B-Entity
A,I-Entity
-,O
containing,O
drugs,O
to,O
women,O
of,O
childbearing,I-Entity
years,O
.,O
Effect,I-Entity
of,O
methoxamine,I-Entity
on,O
maximum,O
urethral,O
pressure,O
in,O
women,O
with,O
genuine,O
stress,I-Entity
incontinence,I-Entity
:,O
a,O
placebo,O
-,O
controlled,O
",",O
double,O
-,O
blind,O
crossover,O
study,O
.,O
The,I-Entity
aim,O
of,O
the,O
study,O
was,O
to,O
evaluate,O
the,O
potential,O
role,O
for,O
a,O
selective,O
alpha1-adrenoceptor,O
agonist,I-Entity
in,O
the,O
treatment,O
of,O
urinary,O
stress,I-Entity
incontinence,I-Entity
.,O
Half,I-Entity
log,O
incremental,O
doses,O
of,O
intravenous,O
methoxamine,I-Entity
or,O
placebo,O
(,O
saline,O
),O
were,O
administered,O
to,O
a,O
group,O
of,O
women,O
with,O
genuine,O
stress,I-Entity
incontinence,I-Entity
while,O
measuring,O
maximum,O
urethral,O
pressure,O
(,O
MUP,I-Entity
),O
",",O
blood,O
pressure,O
",",O
heart,O
rate,O
",",O
and,O
symptomatic,O
side,O
effects,O
.,O
Methoxamine,I-Entity
evoked,O
non,O
-,O
significant,O
increases,O
in,O
MUP,I-Entity
and,O
diastolic,I-Entity
blood,O
pressure,O
but,O
caused,O
a,O
significant,O
rise,O
in,O
systolic,O
blood,O
pressure,O
and,O
significant,O
fall,O
in,O
heart,O
rate,O
at,O
maximum,O
dosage,O
.,O
Systemic,I-Entity
side,O
effects,O
including,O
piloerection,I-Entity
",",O
headache,I-Entity
",",O
and,O
cold,I-Entity
extremities,O
were,O
experienced,O
in,O
all,O
subjects,O
.,O
The,I-Entity
results,O
indicate,O
that,O
the,O
clinical,O
usefulness,O
of,O
direct,O
",",O
peripherally,O
acting,O
sub,O
-,O
type,O
-,O
selective,O
alpha1-adrenoceptor,O
agonists,I-Entity
in,O
the,O
medical,O
treatment,O
of,O
stress,I-Entity
incontinence,I-Entity
may,O
be,O
limited,O
by,O
associated,O
piloerection,I-Entity
and,O
cardiovascular,O
side,O
effects,O
.,O
Toleration,I-Entity
of,O
high,O
doses,O
of,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
inhibitors,O
in,O
patients,O
with,O
chronic,O
heart,O
failure,I-Entity
:,O
results,O
from,O
the,O
ATLAS,I-Entity
trial,O
.,O
The,I-Entity
Assessment,I-Entity
of,O
Treatment,I-Entity
with,O
Lisinopril,I-Entity
and,O
Survival,I-Entity
.,O
BACKGROUND,I-Entity
:,O
Treatment,I-Entity
with,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
(,O
ACE,I-Entity
),O
inhibitors,O
reduces,O
mortality,O
and,O
morbidity,O
in,O
patients,O
with,O
chronic,O
heart,O
failure,I-Entity
(,O
CHF,I-Entity
),O
",",O
but,O
most,O
affected,O
patients,O
are,O
not,O
receiving,O
these,O
agents,O
or,O
are,O
being,O
treated,O
with,O
doses,O
lower,O
than,O
those,O
found,O
to,O
be,O
efficacious,O
in,O
trials,O
",",O
primarily,O
because,O
of,O
concerns,O
about,O
the,O
safety,O
and,O
tolerability,O
of,O
these,O
agents,O
",",O
especially,O
at,O
the,O
recommended,O
doses,O
.,O
The,I-Entity
present,O
study,O
examines,O
the,O
safety,O
and,O
tolerability,O
of,O
high-,O
compared,O
with,O
low,O
-,O
dose,O
lisinopril,I-Entity
in,O
CHF,I-Entity
.,O
The,I-Entity
Assessment,I-Entity
of,O
Lisinopril,I-Entity
and,O
Survival,I-Entity
study,O
was,O
a,O
multicenter,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
trial,O
in,O
which,O
patients,O
with,O
or,O
without,O
previous,O
ACE,I-Entity
inhibitor,O
treatment,O
were,O
stabilized,O
receiving,O
medium,O
-,O
dose,O
lisinopril,I-Entity
(,O
12.5,O
or,O
15.0,O
mg,O
once,O
daily,O
[,O
OD,I-Entity
],O
),O
for,O
2,O
to,O
4,O
weeks,O
and,O
then,O
randomized,O
to,O
high-,O
(,O
35.0,O
or,O
32.5,O
mg,O
OD,I-Entity
),O
or,O
low,O
-,O
dose,O
(,O
5.0,O
or,O
2.5,O
mg,O
OD,I-Entity
),O
groups,O
.,O
Patients,I-Entity
with,O
New,I-Entity
York,I-Entity
Heart,I-Entity
Association,I-Entity
classes,O
II,I-Entity
to,O
IV,I-Entity
CHF,I-Entity
and,O
left,O
ventricular,O
ejection,O
fractions,I-Entity
of,O
no,O
greater,O
than,O
0.30,O
(,O
n,O
=,O
3164,I-Entity
),O
were,O
randomized,O
and,O
followed,O
up,O
for,O
a,O
median,O
of,O
46,I-Entity
months,O
.,O
We,I-Entity
examined,O
the,O
occurrence,O
of,O
adverse,O
events,O
and,O
the,O
need,O
for,O
discontinuation,O
and,O
dose,O
reduction,O
during,O
treatment,O
",",O
with,O
a,O
focus,O
on,O
hypotension,I-Entity
and,O
renal,O
dysfunction,I-Entity
.,O
Of,I-Entity
405,O
patients,O
not,O
previously,O
receiving,O
an,O
ACE,I-Entity
inhibitor,O
",",O
doses,O
in,O
only,O
4.2%,O
could,O
not,O
be,O
titrated,O
to,O
the,O
medium,O
doses,O
required,O
for,O
randomization,O
because,O
of,O
symptoms,O
possibly,O
related,O
to,O
hypotension,I-Entity
(,O
2.0%,O
),O
or,O
because,O
of,O
renal,O
dysfunction,I-Entity
or,O
hyperkalemia,I-Entity
(,O
2.3%,O
),O
.,O
Subgroups,I-Entity
presumed,O
to,O
be,O
at,O
higher,O
risk,O
for,O
ACE,I-Entity
inhibitor,O
intolerance,O
(,O
blood,O
pressure,O
",",O
<,O
creatinine,I-Entity
",",O
>,O
or,O
=,O
132.6,O
micromol,I-Entity
/,O
L,I-Entity
[,O
>,O
or,O
=,O
1.5,O
mg,O
/,O
dL,I-Entity
],O
;,O
age,O
",",O
>,O
or,O
=,O
70,I-Entity
years,O
;,O
and,O
patients,O
with,O
diabetes,I-Entity
),O
generally,O
tolerated,O
the,O
high,O
-,O
dose,O
strategy,O
.,O
These,I-Entity
findings,O
demonstrate,O
that,O
ACE,I-Entity
inhibitor,O
therapy,O
in,O
most,O
patients,O
with,O
CHF,I-Entity
can,O
be,O
successfully,O
titrated,O
to,O
and,O
maintained,O
at,O
high,O
doses,O
",",O
and,O
that,O
more,O
aggressive,I-Entity
use,O
of,O
these,O
agents,O
is,O
warranted,O
.,O
Cocaine,I-Entity
",",O
ethanol,I-Entity
",",O
and,O
cocaethylene,I-Entity
cardiotoxity,I-Entity
in,O
an,O
animal,O
model,O
of,O
cocaine,I-Entity
and,O
ethanol,I-Entity
abuse,I-Entity
.,O
Simultaneous,I-Entity
abuse,I-Entity
of,O
cocaine,I-Entity
and,O
ethanol,I-Entity
affects,O
12,O
million,O
Americans,I-Entity
annually,O
.,O
Their,I-Entity
combined,O
cardiac,O
toxicity,I-Entity
may,O
be,O
due,O
to,O
independent,O
effects,O
of,O
each,O
drug,O
;,O
however,O
",",O
they,O
may,O
also,O
be,O
due,O
to,O
cocaethylene,I-Entity
(,O
CE,I-Entity
),O
",",O
a,O
cocaine,I-Entity
metabolite,O
formed,O
only,O
in,O
the,O
presence,O
of,O
ethanol,I-Entity
.,O
The,I-Entity
purpose,O
of,O
this,O
study,O
was,O
to,O
delineate,O
the,O
role,O
of,O
CE,I-Entity
in,O
the,O
combined,O
cardiotoxicity,I-Entity
of,O
cocaine,I-Entity
and,O
ethanol,I-Entity
in,O
a,O
model,O
simulating,O
their,O
abuse,I-Entity
.,O
Twenty,I-Entity
-,O
three,O
dogs,O
were,O
randomized,O
to,O
receive,O
either,O
1,O
),O
three,O
intravenous,O
(,O
IV,I-Entity
),O
boluses,I-Entity
of,O
cocaine,I-Entity
7.5,O
mg,O
/,O
kg,O
with,O
ethanol,I-Entity
(,O
1,O
g,O
/,O
kg,O
),O
as,O
an,O
IV,I-Entity
infusion,O
(,O
C+E,I-Entity
",",O
n,O
=,O
8),O
",",O
2,O
),O
three,O
cocaine,I-Entity
boluses,I-Entity
only,O
(,O
C,I-Entity
",",O
n,O
=,O
6,O
),O
",",O
3,O
),O
ethanol,I-Entity
infusion,O
only,O
(,O
E,I-Entity
",",O
n,O
=,O
5,O
),O
",",O
or,O
4,O
),O
placebo,O
boluses,I-Entity
and,O
infusion,O
(,O
n,O
=,O
4,O
),O
.,O
Two,I-Entity
of,O
eight,O
dogs,O
in,O
the,O
C+E,I-Entity
group,O
experienced,O
cardiovascular,O
collapse,I-Entity
.,O
The,I-Entity
most,O
dramatic,O
hemodynamic,O
changes,O
occurred,O
after,O
each,O
cocaine,I-Entity
bolus,O
in,O
the,O
C+E,I-Entity
and,O
C,I-Entity
only,O
groups,O
;,O
however,O
",",O
persistent,O
hemodynamic,O
changes,O
occurred,O
in,O
the,O
C+E,I-Entity
group,O
.,O
Peak,I-Entity
CE,I-Entity
levels,O
were,O
associated,O
with,O
a,O
45%,O
(,O
SD,I-Entity
+,O
/-,O
22%,O
to,O
69%,O
),O
decrease,O
in,O
cardiac,O
output,O
(,O
p,O
<,O
0.05,O
),O
",",O
a,O
56%,O
(,O
SD,I-Entity
+,O
/-,O
Ventricular,I-Entity
arrhythmias,I-Entity
were,O
primarily,O
observed,O
in,O
the,O
C+E,I-Entity
group,O
",",O
in,O
which,O
four,O
of,O
eight,O
dogs,O
experienced,O
ventricular,O
tachycardia,I-Entity
.,O
Cocaine,I-Entity
and,O
ethanol,I-Entity
in,O
combination,O
were,O
more,O
toxic,I-Entity
than,O
either,O
substance,O
alone,O
.,O
Co,I-Entity
-,O
administration,O
resulted,O
in,O
prolonged,O
cardiac,O
toxicity,I-Entity
and,O
was,O
dysrhythmogenic,I-Entity
.,O
Peak,I-Entity
serum,O
cocaethylene,I-Entity
concentrations,O
were,O
associated,O
with,O
prolonged,O
myocardial,B-Entity
depression,I-Entity
.,O
Worsening,I-Entity
of,O
Parkinsonism,I-Entity
after,O
the,O
use,O
of,O
veralipride,I-Entity
for,O
treatment,O
of,O
menopause,I-Entity
:,O
case,O
report,O
.,O
We,I-Entity
describe,O
a,O
female,O
patient,O
with,O
stable,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
who,O
has,O
shown,O
a,O
marked,O
worsening,O
of,O
her,O
motor,O
functions,O
following,O
therapy,O
of,O
menopause,I-Entity
related,O
symptoms,O
with,O
veralipride,I-Entity
",",O
as,O
well,O
as,O
the,O
improvement,O
of,O
her,O
symptoms,O
back,O
to,O
baseline,O
after,O
discontinuation,O
of,O
the,O
drug,O
.,O
We,I-Entity
emphasize,O
the,O
anti,O
-,O
dopaminergic,O
effect,O
of,O
veralipride,I-Entity
.,O
Viracept,I-Entity
and,O
irregular,O
heartbeat,O
warning,O
.,O
A,I-Entity
group,O
of,O
doctors,O
in,O
Boston,I-Entity
warn,O
that,O
the,O
protease,O
inhibitor,O
Viracept,I-Entity
may,O
cause,O
an,O
irregular,O
heart,O
beat,O
",",O
known,O
as,O
bradycardia,I-Entity
",",O
in,O
people,O
with,O
HIV,I-Entity
.,O
Bradycardia,I-Entity
occurred,O
in,O
a,O
45-year,O
-,O
old,O
male,O
patient,O
who,O
was,O
Viracept,I-Entity
in,O
combination,O
with,O
other,O
anti,O
-,O
HIV,I-Entity
drugs,O
.,O
Frequency,I-Entity
of,O
appearance,O
of,O
myeloperoxidase,O
-,O
antineutrophil,I-Entity
cytoplasmic,O
antibody,O
(,O
MPO,I-Entity
-,O
ANCA,I-Entity
),O
in,O
Graves,I-Entity
',O
disease,I-Entity
patients,O
treated,O
with,O
propylthiouracil,I-Entity
and,O
the,O
relationship,O
between,O
MPO,I-Entity
-,O
ANCA,I-Entity
and,O
clinical,O
manifestations,O
.,O
OBJECTIVE,I-Entity
:,O
Myeloperoxidase,I-Entity
antineutrophil,I-Entity
cytoplasmic,O
antibody,O
(,O
MPO,I-Entity
-,O
ANCA)-positive,I-Entity
vasculitis,I-Entity
has,O
been,O
reported,O
in,O
patients,O
with,O
Graves,I-Entity
',O
disease,I-Entity
who,O
were,O
treated,O
with,O
propylthiouracil,I-Entity
(,O
PTU,I-Entity
),O
.,O
The,I-Entity
appearance,O
of,O
MPO,I-Entity
-,O
ANCA,I-Entity
in,O
these,O
cases,O
was,O
suspected,O
of,O
being,O
related,O
to,O
PTU,I-Entity
because,O
the,O
titres,O
of,O
MPO,I-Entity
-,O
ANCA,I-Entity
decreased,O
when,O
PTU,I-Entity
was,O
stopped,O
.,O
Nevertheless,I-Entity
",",O
there,O
have,O
been,O
no,O
studies,O
on,O
the,O
temporal,O
relationship,O
between,O
the,O
appearance,O
of,O
MPO,I-Entity
-,O
ANCA,I-Entity
and,O
vasculitis,I-Entity
during,O
PTU,I-Entity
therapy,O
",",O
or,O
on,O
the,O
incidence,O
of,O
MPO,I-Entity
-,O
ANCA,I-Entity
in,O
untreated,O
Graves,I-Entity
',O
disease,I-Entity
patients,O
.,O
Therefore,I-Entity
",",O
we,O
sought,O
to,O
address,O
these,O
parameters,O
in,O
patients,O
with,O
Graves,I-Entity
',O
disease,I-Entity
.,O
We,I-Entity
investigated,O
102,I-Entity
untreated,O
patients,O
with,O
hyperthyroidism,I-Entity
due,O
to,O
Graves,I-Entity
',O
disease,I-Entity
for,O
the,O
presence,O
of,O
MPO,I-Entity
-,O
ANCA,I-Entity
",",O
and,O
for,O
the,O
development,O
vasculitis,I-Entity
after,O
starting,O
PTU,I-Entity
therapy,O
.,O
Twenty,I-Entity
-,O
nine,O
of,O
them,O
were,O
later,O
excluded,O
because,O
of,O
adverse,O
effects,O
of,O
PTU,I-Entity
or,O
because,O
the,O
observation,O
period,O
was,O
less,O
than,O
3,O
months,O
.,O
Before,I-Entity
treatment,O
",",O
the,O
MPO,I-Entity
-,O
ANCA,I-Entity
titres,O
of,O
all,O
102,I-Entity
untreated,O
Graves,I-Entity
',O
disease,I-Entity
patients,O
were,O
within,O
the,O
reference,O
range,O
(,O
below,O
10,O
U,I-Entity
/,O
ml,O
),O
.,O
Three,I-Entity
(,O
4.1%,O
),O
of,O
the,O
73,O
patients,O
were,O
positive,O
for,O
MPO,I-Entity
-,O
ANCA,I-Entity
at,O
13,O
",",O
16,O
and,O
17,O
months,O
",",O
respectively,O
",",O
after,O
the,O
start,O
of,O
PTU,I-Entity
therapy,O
.,O
In,I-Entity
two,O
of,O
them,O
",",O
the,O
MPO,I-Entity
-,O
ANCA,I-Entity
titres,O
transiently,O
increased,O
to,O
12.8,O
and,O
15.0,O
U,I-Entity
/,O
ml,O
",",O
respectively,O
",",O
despite,O
continued,O
PTU,I-Entity
therapy,O
",",O
but,O
no,O
vasculitic,I-Entity
disorders,I-Entity
developed,O
.,O
In,I-Entity
the,O
third,O
patient,O
",",O
the,O
MPO,I-Entity
-,O
ANCA,I-Entity
titre,O
increased,O
to,O
204,I-Entity
U,I-Entity
/,O
ml,O
and,O
she,O
developed,O
a,O
higher,O
fever,I-Entity
",",O
oral,O
ulcers,I-Entity
and,O
polyarthralgia,I-Entity
",",O
but,O
the,O
symptoms,O
resolved,O
2,O
weeks,O
after,O
stopping,O
PTU,I-Entity
therapy,O
",",O
and,O
the,O
MPO,I-Entity
-,O
ANCA,I-Entity
titre,O
decreased,O
to,O
20.7,O
U,I-Entity
/,O
ml,O
by,O
4,O
months,O
after,O
discontinuing,O
PTU,I-Entity
.,O
PTU,I-Entity
therapy,O
may,O
be,O
related,O
to,O
the,O
appearance,O
of,O
MPO,I-Entity
-,O
ANCA,I-Entity
",",O
but,O
MPO,I-Entity
-,O
ANCA,I-Entity
does,O
not,O
appear,O
to,O
be,O
closely,O
related,O
to,O
vasculitis,I-Entity
.,O
Prevalence,I-Entity
of,O
heart,O
disease,I-Entity
in,O
asymptomatic,O
chronic,O
cocaine,I-Entity
users,O
.,O
To,I-Entity
determine,O
the,O
prevalence,O
of,O
heart,O
disease,I-Entity
in,O
outpatient,I-Entity
young,O
asymptomatic,O
chronic,O
cocaine,I-Entity
users,O
",",O
35,O
cocaine,I-Entity
users,O
and,O
32,O
age,O
-,O
matched,O
controls,O
underwent,O
resting,O
and,O
exercise,O
electrocardiography,O
(,O
ECG,I-Entity
),O
and,O
Doppler,I-Entity
echocardiography,O
.,O
Findings,I-Entity
consistent,O
with,O
coronary,O
artery,I-Entity
disease,I-Entity
were,O
detected,O
in,O
12,O
(,O
34%,O
),O
patients,O
and,O
3,O
(,O
9%,O
),O
controls,O
(,O
p,O
=,O
0.01,O
),O
.,O
Finally,I-Entity
",",O
resting,O
and,O
peak,O
exercise,O
abnormal,I-Entity
left,O
ventricular,O
filling,O
was,O
detected,O
in,O
38,O
and,O
35%,O
of,O
patients,O
as,O
compared,O
to,O
19,O
and,O
9%,O
of,O
controls,O
",",O
respectively,O
(,O
p,O
=,O
0.11,O
and,O
0.02,O
",",O
respectively,O
),O
.,O
We,I-Entity
conclude,O
that,O
coronary,O
artery,I-Entity
or,O
myocardial,B-Entity
disease,I-Entity
is,O
common,O
(,O
38%,O
),O
in,O
young,O
asymptomatic,O
chronic,O
cocaine,I-Entity
users,O
.,O
Cardioprotective,I-Entity
effects,O
of,O
Picrorrhiza,I-Entity
kurroa,I-Entity
against,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
stress,I-Entity
in,O
rats,O
.,O
The,I-Entity
cardioprotective,O
effect,O
of,O
the,O
ethanol,I-Entity
extract,O
of,O
Picrorrhiza,I-Entity
kurroa,I-Entity
rhizomes,O
and,O
roots,O
(,O
PK,I-Entity
),O
on,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
in,O
rats,O
with,O
respect,O
to,O
lipid,O
metabolism,O
in,O
serum,O
and,O
heart,O
tissue,O
has,O
been,O
investigated,O
.,O
day(-1,O
),O
for,O
15,O
days,O
),O
significantly,O
prevented,O
the,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
and,O
maintained,O
the,O
rats,O
at,O
near,O
normal,O
status,O
.,O
Phase,I-Entity
2,O
early,O
afterdepolarization,O
as,O
a,O
trigger,O
of,O
polymorphic,I-Entity
ventricular,O
tachycardia,I-Entity
in,O
acquired,O
long,O
-,O
QT,I-Entity
syndrome,I-Entity
:,O
direct,O
evidence,O
from,O
intracellular,O
recordings,O
in,O
the,O
intact,O
left,O
ventricular,O
wall,O
.,O
This,I-Entity
study,O
examined,O
the,O
role,O
of,O
phase,O
2,O
early,O
afterdepolarization,O
(,O
EAD,I-Entity
),O
in,O
producing,O
a,O
trigger,O
to,O
initiate,O
torsade,I-Entity
de,O
pointes,I-Entity
(,O
TdP,I-Entity
),O
with,O
QT,I-Entity
prolongation,O
induced,O
by,O
dl,O
-,O
sotalol,I-Entity
and,O
azimilide,I-Entity
.,O
The,I-Entity
contribution,O
of,O
transmural,O
dispersion,I-Entity
of,O
repolarization,O
(,O
TDR,I-Entity
),O
to,O
transmural,O
propagation,O
of,O
EAD,I-Entity
and,O
the,O
maintenance,O
of,O
TdP,I-Entity
was,O
also,O
evaluated,O
.,O
-,O
Sotalol,I-Entity
preferentially,O
prolonged,O
action,O
potential,O
duration,O
(,O
APD,I-Entity
),O
in,O
M,I-Entity
cells,O
dose,O
-,O
dependently,O
(,O
1,O
to,O
100,O
micromol,I-Entity
/,O
L,I-Entity
),O
",",O
leading,O
to,O
QT,I-Entity
prolongation,O
and,O
an,O
increase,O
in,O
TDR,I-Entity
.,O
Azimilide,I-Entity
",",O
however,O
",",O
significantly,O
prolonged,O
APD,I-Entity
and,O
QT,I-Entity
interval,O
at,O
concentrations,O
from,O
0.1,O
to,O
10,O
Unlike,I-Entity
dl,O
-,O
sotalol,I-Entity
",",O
azimilide,I-Entity
(,O
>,O
3,O
micromol,I-Entity
/,O
L,I-Entity
),O
increased,O
epicardial,O
APD,I-Entity
markedly,O
",",O
causing,O
a,O
diminished,O
TDR,I-Entity
.,O
Although,I-Entity
both,O
dl,O
-,O
sotalol,I-Entity
and,O
azimilide,I-Entity
rarely,O
induced,O
EADs,I-Entity
in,O
canine,O
left,O
ventricles,O
",",O
they,O
produced,O
frequent,O
EADs,I-Entity
in,O
rabbits,I-Entity
",",O
in,O
which,O
more,O
pronounced,O
QT,I-Entity
prolongation,O
was,O
seen,O
.,O
An,I-Entity
increase,O
in,O
TDR,I-Entity
by,O
dl,O
-,O
sotalol,I-Entity
facilitated,O
transmural,O
propagation,O
of,O
EADs,I-Entity
that,O
initiated,O
multiple,O
episodes,O
of,O
spontaneous,O
TdP,I-Entity
in,O
3,O
of,O
6,O
rabbit,I-Entity
left,O
ventricles,O
.,O
Of,I-Entity
note,O
",",O
although,O
azimilide,I-Entity
(,O
3,O
to,O
10,O
micromol,I-Entity
/,O
L,I-Entity
),O
increased,O
APD,I-Entity
more,O
than,O
dl,O
-,O
sotalol,I-Entity
",",O
its,O
EADs,I-Entity
often,O
failed,O
to,O
propagate,O
transmurally,O
",",O
probably,O
because,O
of,O
a,O
diminished,O
TDR,I-Entity
.,O
This,I-Entity
study,O
provides,O
the,O
first,O
direct,O
evidence,O
from,O
intracellular,O
action,O
potential,O
recordings,O
that,O
phase,O
2,O
EAD,I-Entity
can,O
be,O
generated,O
from,O
intact,O
ventricular,O
wall,O
and,O
produce,O
a,O
trigger,O
to,O
initiate,O
the,O
onset,O
of,O
TdP,I-Entity
under,O
QT,I-Entity
prolongation,O
.,O
Prenatal,I-Entity
cocaine,I-Entity
exposure,O
and,O
cranial,O
sonographic,O
findings,O
in,O
preterm,I-Entity
infants,O
.,O
Prenatal,I-Entity
cocaine,I-Entity
exposure,O
has,O
been,O
linked,O
with,O
subependymal,O
hemorrhage,I-Entity
and,O
the,O
formation,O
of,O
cysts,I-Entity
that,O
are,O
detectable,O
on,O
cranial,O
sonography,O
in,O
neonates,O
born,O
at,O
term,O
.,O
We,I-Entity
sought,O
to,O
determine,O
if,O
prenatal,O
cocaine,I-Entity
exposure,O
increases,O
the,O
incidence,O
of,O
subependymal,O
cysts,I-Entity
in,O
preterm,I-Entity
infants,O
.,O
METHODS,I-Entity
:,O
We,I-Entity
retrospectively,O
reviewed,O
the,O
medical,O
records,I-Entity
and,O
cranial,O
sonograms,O
obtained,O
during,O
a,O
1-year,O
period,O
on,O
122,I-Entity
premature,I-Entity
(,O
<,O
36,O
weeks,O
of,O
gestation,O
),O
infants,O
.,O
Infants,I-Entity
were,O
categorized,O
into,O
1,O
of,O
2,O
groups,O
:,O
those,O
exposed,O
to,O
cocaine,I-Entity
and,O
those,O
not,O
exposed,O
to,O
cocaine,I-Entity
.,O
Infants,I-Entity
were,O
assigned,O
to,O
the,O
cocaine,I-Entity
-,O
exposed,O
group,O
if,O
there,O
was,O
a,O
maternal,O
history,O
of,O
cocaine,I-Entity
abuse,I-Entity
during,O
pregnancy,I-Entity
or,O
if,O
maternal,O
or,O
neonatal,O
urine,I-Entity
toxicology,I-Entity
results,O
were,O
positive,O
at,O
the,O
time,O
of,O
delivery,O
.,O
The,I-Entity
incidence,O
of,O
subependymal,O
cysts,I-Entity
in,O
the,O
117,I-Entity
remaining,O
infants,O
was,O
14%,O
(,O
16,O
of,O
117,I-Entity
),O
.,O
The,I-Entity
incidence,O
of,O
subependymal,O
cysts,I-Entity
in,O
infants,O
exposed,O
to,O
cocaine,I-Entity
prenatally,O
was,O
44%,O
(,O
8,O
of,O
18,O
),O
compared,O
with,O
8%,O
(,O
8,O
of,O
99,I-Entity
),O
in,O
the,O
unexposed,O
group,O
(,O
p,O
We,I-Entity
found,O
an,O
increased,O
incidence,O
of,O
subependymal,O
cyst,O
formation,O
in,O
preterm,I-Entity
infants,O
who,O
were,O
exposed,O
to,O
cocaine,I-Entity
prenatally,O
.,O
Thalidomide,I-Entity
neuropathy,I-Entity
in,O
patients,O
treated,O
for,O
metastatic,O
prostate,O
cancer,I-Entity
.,O
We,I-Entity
prospectively,O
evaluated,O
thalidomide,I-Entity
-,O
induced,O
neuropathy,I-Entity
using,O
electrodiagnostic,O
studies,O
.,O
Sixty,I-Entity
-,O
seven,O
men,O
with,O
metastatic,O
androgen,I-Entity
-,O
independent,O
prostate,O
cancer,I-Entity
in,O
an,O
open,O
-,O
label,O
trial,O
of,O
oral,O
thalidomide,I-Entity
underwent,O
neurologic,O
examinations,O
and,O
nerve,O
conduction,O
studies,O
(,O
NCS,I-Entity
),O
prior,O
to,O
and,O
at,O
3-month,O
intervals,O
during,O
treatment,O
.,O
Thalidomide,I-Entity
was,O
discontinued,O
in,O
55,I-Entity
patients,O
for,O
lack,O
of,O
therapeutic,O
response,O
.,O
Of,I-Entity
67,I-Entity
patients,O
initially,O
enrolled,O
",",O
24,O
remained,O
on,O
thalidomide,I-Entity
for,O
3,O
months,O
",",O
8,O
remained,O
at,O
6,O
months,O
",",O
and,O
3,O
remained,O
at,O
9,O
months,O
.,O
Six,I-Entity
patients,O
developed,O
neuropathy,I-Entity
.,O
Neuropathy,I-Entity
may,O
thus,O
be,O
a,O
common,O
complication,O
of,O
thalidomide,I-Entity
in,O
older,O
patients,O
.,O
The,I-Entity
SNAP,I-Entity
index,O
can,O
be,O
used,O
to,O
monitor,O
peripheral,O
neuropathy,I-Entity
",",O
but,O
not,O
for,O
early,O
detection,O
.,O
Overexpression,I-Entity
of,O
copper,I-Entity
/,O
zinc,I-Entity
-,O
superoxide,I-Entity
dismutase,O
protects,O
from,O
kanamycin,I-Entity
-,O
induced,O
hearing,O
loss,I-Entity
.,O
The,I-Entity
participation,O
of,O
reactive,O
oxygen,I-Entity
species,O
in,O
aminoglycoside,I-Entity
-,O
induced,O
ototoxicity,I-Entity
has,O
been,O
deduced,O
from,O
observations,O
that,O
aminoglycoside,I-Entity
-,O
iron,I-Entity
complexes,O
catalyze,O
the,O
formation,O
of,O
superoxide,I-Entity
radicals,I-Entity
in,O
vitro,O
and,O
that,O
antioxidants,O
attenuate,O
ototoxicity,I-Entity
in,O
vivo,O
.,O
We,I-Entity
therefore,O
hypothesized,O
that,O
overexpression,I-Entity
of,O
Cu,I-Entity
/,O
Zn,I-Entity
-,O
superoxide,I-Entity
dismutase,O
(,O
h,O
-,O
SOD1,I-Entity
),O
should,O
protect,O
transgenic,O
mice,O
from,O
ototoxicity,I-Entity
.,O
Transgenic,I-Entity
and,O
nontransgenic,O
littermates,O
received,O
kanamycin,I-Entity
(,O
400,O
mg,O
/,O
kg,O
body,O
weight,O
/,O
day,O
),O
for,O
10,O
days,O
beginning,O
on,O
day,O
10,O
after,O
birth,O
.,O
In,I-Entity
nontransgenic,O
animals,O
",",O
the,O
threshold,O
in,O
the,O
kanamycin,I-Entity
-,O
treated,O
group,O
was,O
45,I-Entity
-,O
50,O
dB,I-Entity
higher,O
than,O
in,O
saline,O
-,O
injected,O
controls,O
.,O
In,I-Entity
the,O
transgenic,O
group,O
",",O
kanamycin,I-Entity
increased,O
the,O
threshold,O
by,O
only,O
15,O
dB,I-Entity
over,O
the,O
respective,O
controls,O
.,O
The,I-Entity
protection,O
by,O
overexpression,I-Entity
of,O
superoxide,I-Entity
dismutase,O
supports,O
the,O
hypothesis,O
that,O
oxidant,O
stress,I-Entity
plays,O
a,O
significant,O
role,O
in,O
aminoglycoside,I-Entity
-,O
induced,O
ototoxicity,I-Entity
.,O
Prednisone,I-Entity
induces,O
anxiety,I-Entity
and,O
glial,O
cerebral,O
changes,O
in,O
rats,O
.,O
OBJECTIVE,I-Entity
:,O
To,I-Entity
assess,O
whether,O
prednisone,I-Entity
(,O
PDN,I-Entity
),O
produces,O
anxiety,I-Entity
and/or,O
cerebral,O
glial,O
changes,O
in,O
rats,O
.,O
The,I-Entity
moderate,O
-,O
dose,O
group,O
received,O
5,O
mg,O
/,O
kg,O
/,O
day,O
PDN,I-Entity
released,O
from,O
a,O
subcutaneous,O
implant,O
.,O
In,I-Entity
the,O
high,O
-,O
dose,O
group,O
",",O
implants,O
containing,O
PDN,I-Entity
equivalent,O
to,O
60,O
mg,O
/,O
kg,O
/,O
day,O
were,O
applied,O
.,O
In,I-Entity
the,O
control,O
group,O
implants,O
contained,O
no,O
PDN,I-Entity
.,O
Anxiety,I-Entity
was,O
assessed,O
using,O
an,O
open,O
field,O
and,O
elevated,O
plus,O
-,O
maze,O
devices,O
.,O
Anxiety,I-Entity
was,O
documented,O
in,O
both,O
groups,O
of,O
PDN,I-Entity
treated,O
rats,O
compared,O
with,O
controls,O
.,O
The,I-Entity
magnitude,O
of,O
transformation,O
of,O
the,O
microglia,O
assessed,O
by,O
the,O
number,O
of,O
intersections,O
was,O
significantly,O
higher,O
in,O
the,O
PDN,I-Entity
groups,O
than,O
in,O
controls,O
in,O
the,O
prefrontal,O
cortex,O
(,O
moderate,O
-,O
dose,O
",",O
24.1,O
;,O
high,O
-,O
dose,O
",",O
23.6,O
;,O
controls,O
18.7,O
;,O
The,I-Entity
number,O
of,O
stained,O
microglia,O
cells,O
was,O
significantly,O
higher,O
in,O
the,O
PDN,I-Entity
treated,O
groups,O
in,O
the,O
prefrontal,O
cortex,O
than,O
in,O
controls,O
(,O
moderate,O
-,O
dose,O
",",O
29.1,O
;,O
high,O
-,O
dose,O
",",O
28.4,O
;,O
control,O
",",O
17.7,O
cells,O
per,O
field,O
;,O
p,O
<,O
0.01,O
),O
.,O
CONCLUSION,I-Entity
:,O
Subacute,I-Entity
exposure,O
to,O
PDN,I-Entity
induced,O
anxiety,I-Entity
and,O
reactivity,O
of,O
microglia,O
.,O
The,I-Entity
relevance,O
of,O
these,O
features,O
for,O
patients,O
using,O
PDN,I-Entity
remains,O
to,O
be,O
elucidated,O
.,O
Phase,I-Entity
II,I-Entity
study,O
of,O
carboplatin,I-Entity
and,O
liposomal,O
doxorubicin,I-Entity
in,O
patients,O
with,O
recurrent,O
squamous,I-Entity
cell,O
carcinoma,I-Entity
of,O
the,O
cervix,O
.,O
The,I-Entity
activity,O
of,O
the,O
combination,O
of,O
carboplatin,I-Entity
and,O
liposomal,O
doxorubicin,I-Entity
was,O
tested,O
in,O
a,O
Phase,I-Entity
II,I-Entity
study,O
of,O
patients,O
with,O
recurrent,O
cervical,O
carcinoma,I-Entity
.,O
METHODS,I-Entity
:,O
The,I-Entity
combination,O
of,O
carboplatin,I-Entity
(,O
area,O
under,O
the,O
concentration,O
curve,O
[,O
AUC,I-Entity
],O
",",O
5,O
),O
and,O
liposomal,O
doxorubicin,I-Entity
(,O
Doxil,I-Entity
;,O
starting,O
dose,O
",",O
40,O
mg,O
/,O
m(2,O
),O
),O
was,O
administered,O
intravenously,O
every,O
28,O
days,O
to,O
37,I-Entity
patients,O
with,O
recurrent,O
squamous,I-Entity
cell,O
cervical,O
carcinoma,I-Entity
to,O
determine,O
antitumor,O
activity,O
and,O
toxicity,I-Entity
profile,O
.,O
Twenty,I-Entity
-,O
nine,O
patients,O
were,O
assessable,O
for,O
response,O
",",O
and,O
35,O
patients,O
were,O
assessable,O
for,O
toxicity,I-Entity
.,O
The,I-Entity
main,O
toxic,I-Entity
effect,O
was,O
myelosuppression,I-Entity
",",O
with,O
Grade,I-Entity
3,O
and,O
4,O
neutropenia,I-Entity
in,O
16,O
patients,O
",",O
anemia,I-Entity
in,O
12,O
patients,O
",",O
thrombocytopenia,I-Entity
in,O
11,O
patients,O
",",O
and,O
neutropenic,O
fever,I-Entity
in,O
3,O
patients,O
.,O
Four,I-Entity
patients,O
had,O
five,O
infusion,O
-,O
related,O
reactions,O
during,O
the,O
infusion,O
of,O
liposomal,O
doxorubicin,I-Entity
",",O
leading,O
to,O
treatment,O
discontinuation,O
in,O
three,O
patients,O
.,O
Grade,I-Entity
>,O
or,O
=,O
2,O
nonhematologic,O
toxicity,I-Entity
included,O
nausea,I-Entity
in,O
17,O
patients,O
",",O
emesis,I-Entity
in,O
14,O
patients,O
",",O
fatigue,I-Entity
in,O
9,O
patients,O
",",O
mucositis,I-Entity
and/or,O
stomatitis,I-Entity
in,O
8,O
patients,O
",",O
constipation,I-Entity
in,O
6,O
patients,O
",",O
weight,O
loss,I-Entity
in,O
5,O
patients,O
",",O
hand,O
-,O
foot,O
syndrome,I-Entity
in,O
2,O
patients,O
",",O
and,O
skin,O
reactions,O
in,O
3,O
patients,O
.,O
The,I-Entity
combination,O
of,O
carboplatin,I-Entity
and,O
liposomal,O
doxorubicin,I-Entity
has,O
modest,O
activity,O
in,O
patients,O
with,O
recurrent,O
cervical,O
carcinoma,I-Entity
.,O
Antimicrobial,I-Entity
-,O
induced,O
mania,I-Entity
(,O
antibiomania,I-Entity
),O
:,O
a,O
review,O
of,O
spontaneous,O
reports,O
.,O
The,I-Entity
authors,O
reviewed,O
reported,O
cases,O
of,O
antibiotic,O
-,O
induced,O
manic,I-Entity
episodes,O
by,O
means,O
of,O
a,O
MEDLINE,I-Entity
and,O
PsychLit,I-Entity
search,O
for,O
reports,O
of,O
antibiotic,O
-,O
induced,O
mania,I-Entity
.,O
Twenty,I-Entity
-,O
one,O
reports,O
of,O
antimicrobial,O
-,O
induced,O
mania,I-Entity
were,O
found,O
in,O
the,O
literature,O
.,O
There,I-Entity
were,O
6,O
cases,O
implicating,O
clarithromycin,I-Entity
",",O
13,O
implicating,O
isoniazid,I-Entity
",",O
and,O
1,O
case,O
each,O
implicating,O
erythromycin,I-Entity
and,O
amoxicillin,I-Entity
.,O
Of,I-Entity
these,O
",",O
clarithromycin,I-Entity
was,O
implicated,O
in,O
23,O
(,O
27.6%,O
),O
cases,O
",",O
ciprofloxacin,I-Entity
in,O
12,O
(,O
14.4%,O
),O
cases,O
",",O
and,O
ofloxacin,I-Entity
in,O
10,O
(,O
12%,O
),O
cases,O
.,O
Cotrimoxazole,I-Entity
",",O
metronidazole,I-Entity
",",O
and,O
erythromycin,I-Entity
were,O
involved,O
in,O
15,O
reported,O
manic,I-Entity
episodes,O
.,O
Cases,I-Entity
reported,O
by,O
the,O
FDA,I-Entity
showed,O
clarithromycin,I-Entity
and,O
ciprofloxacin,I-Entity
to,O
be,O
the,O
most,O
frequently,O
associated,O
with,O
the,O
development,O
of,O
mania,I-Entity
.,O
Patients,I-Entity
have,O
an,O
increased,O
risk,O
of,O
developing,O
mania,I-Entity
while,O
being,O
treated,O
with,O
antimicrobials,O
.,O
Further,I-Entity
research,O
clearly,O
is,O
required,O
to,O
determine,O
the,O
incidence,O
of,O
antimicrobial,O
-,O
induced,O
mania,I-Entity
",",O
the,O
relative,O
risk,O
factors,O
of,O
developing,O
an,O
antimicrobial,O
-,O
induced,O
manic,I-Entity
episode,O
among,O
various,O
demographic,O
populations,O
",",O
and,O
the,O
incidence,O
of,O
patients,O
who,O
continue,O
to,O
have,O
persistent,O
affective,O
disorders,I-Entity
once,O
the,O
initial,O
episode,O
",",O
which,O
occurs,O
while,O
the,O
patient,O
is,O
taking,O
antibiotics,O
",",O
subsides,O
.,O
The,I-Entity
authors,O
elected,O
to,O
name,O
this,O
syndrome,I-Entity
"""""""""",O
antibiomania,I-Entity
.,O
"""""""""",O
Levodopa,I-Entity
-,O
induced,O
ocular,O
dyskinesias,I-Entity
in,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
.,O
Levodopa,I-Entity
-,O
induced,O
ocular,O
dyskinesias,I-Entity
are,O
very,O
uncommon,O
.,O
Usually,I-Entity
they,O
occur,O
simultaneously,O
with,O
limb,O
peak,O
-,O
dose,O
choreatic,O
dyskinesias,I-Entity
.,O
We,I-Entity
report,O
on,O
a,O
patient,O
with,O
leftward,O
and,O
upward,O
deviations,I-Entity
of,O
gaze,O
during,O
the,O
peak,O
effect,O
of,O
levodopa,I-Entity
",",O
and,O
hypothesize,O
that,O
a,O
severe,O
dopaminergic,O
denervation,O
in,O
the,O
caudate,O
nucleus,O
is,O
needed,O
for,O
the,O
appearance,O
of,O
these,O
levodopa,I-Entity
-,O
induce,O
ocular,O
dyskinesias,I-Entity
.,O
A,I-Entity
comparison,O
of,O
glyceryl,I-Entity
trinitrate,I-Entity
with,O
diclofenac,I-Entity
for,O
the,O
treatment,O
of,O
primary,O
dysmenorrhea,I-Entity
:,O
an,O
open,O
",",O
randomized,O
",",O
cross,O
-,O
over,O
trial,O
.,O
Primary,I-Entity
dysmenorrhea,I-Entity
is,O
a,O
syndrome,I-Entity
characterized,O
by,O
painful,O
uterine,B-Entity
contractility,O
caused,O
by,O
a,O
hypersecretion,I-Entity
of,O
endometrial,O
prostaglandins,I-Entity
;,O
non,O
-,O
steroidal,I-Entity
anti,O
-,O
inflammatory,O
drugs,O
are,O
the,O
first,O
choice,O
for,O
its,O
treatment,O
.,O
However,I-Entity
",",O
in,O
vivo,O
and,O
in,O
vitro,O
studies,O
have,O
demonstrated,O
that,O
myometrial,O
cells,O
are,O
also,O
targets,O
of,O
the,O
relaxant,O
effects,O
of,O
nitric,I-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
.,O
The,I-Entity
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
determine,O
the,O
efficacy,O
of,O
glyceryl,I-Entity
trinitrate,I-Entity
(,O
GTN,I-Entity
),O
",",O
an,O
NO,I-Entity
donor,O
",",O
in,O
the,O
resolution,O
of,O
primary,O
dysmenorrhea,I-Entity
in,O
comparison,O
with,O
diclofenac,I-Entity
(,O
DCF,I-Entity
),O
.,O
A,I-Entity
total,O
of,O
24,O
patients,O
with,O
the,O
diagnosis,O
of,O
severe,O
primary,O
dysmenorrhea,I-Entity
were,O
studied,O
during,O
two,O
consecutive,O
menstrual,O
cycles,O
.,O
cross,O
-,O
over,O
",",O
controlled,O
design,O
",",O
patients,O
were,O
randomized,O
to,O
receive,O
either,O
DCF,I-Entity
per,O
os,O
or,O
GTN,I-Entity
patches,O
the,O
first,O
days,O
of,O
menses,I-Entity
",",O
when,O
menstrual,O
cramps,I-Entity
became,O
unendurable,O
.,O
Patients,I-Entity
received,O
up,O
to,O
3,O
doses,O
/,O
day,O
of,O
50,O
mg,O
DCF,I-Entity
or,O
2.5,O
mg/24,O
h,O
transdermal,O
GTN,I-Entity
for,O
the,O
first,O
3,O
days,O
of,O
the,O
cycle,O
",",O
according,O
to,O
their,O
needs,O
.,O
The,I-Entity
difference,O
in,O
pain,I-Entity
intensity,O
score,O
(,O
DPI,I-Entity
),O
was,O
the,O
main,O
outcome,O
variable,O
.,O
Both,I-Entity
treatments,O
significantly,O
reduced,O
DPI,I-Entity
by,O
the,O
30th,O
minute,O
(,O
GTN,I-Entity
",",O
-12.8,O
DCF,I-Entity
",",O
-18.9,O
However,I-Entity
",",O
DCF,I-Entity
continued,O
to,O
be,O
effective,O
in,O
reducing,O
pelvic,O
pain,I-Entity
for,O
two,O
hours,O
",",O
whereas,O
GTN,I-Entity
scores,O
remained,O
more,O
or,O
less,O
stable,O
after,O
30,O
min,O
and,O
significantly,O
higher,O
than,O
those,O
for,O
DFC,I-Entity
(,O
after,O
one,O
hour,O
:,O
GTN,I-Entity
",",O
-12.8,O
16.6,O
and,O
after,O
two,O
hours,O
:,O
GTN,I-Entity
",",O
-23.7,O
Low,I-Entity
back,O
pain,I-Entity
was,O
also,O
relieved,O
by,O
both,O
drugs,O
.,O
Headache,I-Entity
was,O
significantly,O
increased,O
by,O
GTN,I-Entity
but,O
not,O
by,O
DCF,I-Entity
.,O
Eight,I-Entity
patients,O
stopped,O
using,O
GTN,I-Entity
because,O
headache,I-Entity
--,O
attributed,O
to,O
its,O
use,O
--,O
became,O
intolerable,O
.,O
These,I-Entity
findings,O
indicate,O
that,O
GTN,I-Entity
has,O
a,O
reduced,O
efficacy,O
and,O
tolerability,O
by,O
comparison,O
with,O
DCF,I-Entity
in,O
the,O
treatment,O
of,O
primary,O
dysmenorrhea,I-Entity
.,O
Temocapril,I-Entity
",",O
a,O
long,O
-,O
acting,O
non,O
-,O
SH,I-Entity
group,O
angiotensin,I-Entity
converting,O
enzyme,O
inhibitor,O
",",O
modulates,O
glomerular,O
injury,I-Entity
in,O
chronic,O
puromycin,I-Entity
aminonucleoside,I-Entity
nephrosis,I-Entity
.,O
The,I-Entity
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
determine,O
whether,O
chronic,O
administration,O
of,O
temocapril,I-Entity
",",O
a,O
long,O
-,O
acting,O
non,O
-,O
SH,I-Entity
group,O
angiotensin,I-Entity
converting,O
enzyme,O
(,O
ACE,I-Entity
),O
inhibitor,O
",",O
reduced,O
proteinuria,I-Entity
",",O
inhibited,O
glomerular,O
hypertrophy,I-Entity
and,O
prevented,O
glomerulosclerosis,I-Entity
in,O
chronic,O
puromycin,I-Entity
aminonucleoside,I-Entity
(,O
PAN,I-Entity
),O
-,O
induced,O
nephrotic,I-Entity
rats,O
.,O
Nephrosis,I-Entity
was,O
induced,O
by,O
injection,O
of,O
PAN,I-Entity
(,O
15mg/100,I-Entity
g,O
body,O
weight,O
),O
in,O
male,O
Sprague,I-Entity
-,O
Dawley,I-Entity
(,O
SD,I-Entity
),O
rats,O
.,O
Four,I-Entity
groups,O
were,O
used,O
",",O
i,O
),O
the,O
PAN,I-Entity
group,O
(,O
14,O
),O
",",O
ii,O
),O
PAN,I-Entity
/,O
temocapril,I-Entity
(,O
13,O
),O
",",O
iii,O
),O
temocapril,I-Entity
(,O
14,O
),O
and,O
iv,O
),O
untreated,O
controls,O
(,O
15,O
),O
.,O
Temocapril,I-Entity
(,O
8,O
mg,O
/,O
kg,O
/,O
day,O
),O
was,O
administered,O
to,O
the,O
rats,O
which,O
were,O
killed,O
at,O
weeks,O
4,O
",",O
14,O
or,O
20,O
.,O
Systolic,I-Entity
BP,I-Entity
in,O
the,O
PAN,I-Entity
group,O
was,O
significantly,O
high,O
at,O
4,O
",",O
14,O
and,O
20,O
weeks,O
",",O
but,O
was,O
normal,O
in,O
the,O
PAN,I-Entity
/,O
temocapril,I-Entity
group,O
.,O
Urinary,I-Entity
protein,O
excretion,O
in,O
the,O
PAN,I-Entity
group,O
increased,O
significantly,O
",",O
peaking,O
at,O
8,O
days,O
",",O
then,O
decreased,O
at,O
4,O
weeks,O
",",O
but,O
rose,O
again,O
significantly,O
at,O
14,O
and,O
20,O
weeks,O
.,O
Temocapril,I-Entity
did,O
not,O
attenuate,O
proteinuria,I-Entity
at,O
8,O
days,O
",",O
but,O
it,O
did,O
markedly,O
lower,O
it,O
from,O
weeks,O
4,O
to,O
20,O
.,O
The,I-Entity
glomerulosclerosis,I-Entity
index,O
(,O
GSI,I-Entity
),O
was,O
6.21,O
%,O
at,O
4,O
weeks,O
and,O
respectively,O
25.35,O
%,O
and,O
30.49,O
%,O
at,O
14,O
and,O
20,O
weeks,O
in,O
the,O
PAN,I-Entity
group,O
.,O
The,I-Entity
ratio,O
of,O
glomerular,O
tuft,O
area,O
to,O
the,O
area,O
of,O
Bowman,I-Entity
's,I-Entity
capsules,O
(,O
GT,I-Entity
/,O
BC,I-Entity
),O
in,O
the,O
PAN,I-Entity
group,O
was,O
significantly,O
increased,O
",",O
but,O
it,O
was,O
significantly,O
lower,O
in,O
the,O
PAN,I-Entity
/,O
temocapril,I-Entity
group,O
.,O
It,I-Entity
appears,O
that,O
temocapril,I-Entity
was,O
effective,O
in,O
retarding,I-Entity
renal,O
progression,O
and,O
protected,O
renal,O
function,O
in,O
PAN,I-Entity
neprotic,I-Entity
rats,O
.,O
Pulmonary,I-Entity
hypertension,I-Entity
after,O
ibuprofen,I-Entity
prophylaxis,O
in,O
very,O
preterm,I-Entity
infants,O
.,O
We,I-Entity
report,O
three,O
cases,O
of,O
severe,O
hypoxaemia,I-Entity
after,O
ibuprofen,I-Entity
administration,O
during,O
a,O
randomised,O
controlled,O
trial,O
of,O
prophylactic,O
treatment,O
of,O
patent,O
ductus,O
arteriosus,I-Entity
with,O
ibuprofen,I-Entity
in,O
premature,I-Entity
infants,O
born,O
at,O
less,O
than,O
28,O
weeks,O
of,O
gestation,O
.,O
Hypoxaemia,I-Entity
resolved,O
quickly,O
on,O
inhaled,O
nitric,I-Entity
oxide,I-Entity
therapy,O
.,O
We,I-Entity
suggest,O
that,O
investigators,O
involved,O
in,O
similar,O
trials,O
pay,O
close,O
attention,O
to,O
pulmonary,O
pressure,O
if,O
hypoxaemia,I-Entity
occurs,O
after,O
prophylactic,O
administration,O
of,O
ibuprofen,I-Entity
.,O
Hyponatremia,I-Entity
and,O
syndrome,I-Entity
of,O
inappropriate,O
anti,O
-,O
diuretic,I-Entity
hormone,I-Entity
reported,O
with,O
the,O
use,O
of,O
Vincristine,I-Entity
:,O
an,O
over,O
-,O
representation,O
of,O
Asians,I-Entity
?,O
This,I-Entity
retrospective,O
study,O
used,O
a,O
pharmaceutical,O
company,O
's,I-Entity
global,O
safety,O
database,O
to,O
determine,O
the,O
reporting,O
rate,O
of,O
hyponatremia,I-Entity
and/or,O
syndrome,I-Entity
of,O
inappropriate,O
secretion,O
of,O
anti,O
-,O
diuretic,I-Entity
hormone,I-Entity
(,O
SIADH,I-Entity
),O
among,O
vincristine,I-Entity
-,O
treated,O
patients,O
and,O
to,O
explore,O
the,O
possibility,O
of,O
at,O
-,O
risk,O
population,O
subgroups,O
.,O
METHOD,I-Entity
:,O
We,I-Entity
searched,O
the,O
Eli,I-Entity
Lilly,I-Entity
and,O
Company,I-Entity
's,I-Entity
computerized,O
adverse,O
event,O
database,O
for,O
all,O
reported,O
cases,O
of,O
hyponatremia,I-Entity
and/or,O
SIADH,I-Entity
as,O
of,O
1,O
November,I-Entity
1999,O
that,O
had,O
been,O
reported,O
during,O
the,O
use,O
of,O
vincristine,I-Entity
.,O
A,I-Entity
total,O
of,O
76,I-Entity
cases,O
of,O
hyponatremia,I-Entity
and/or,O
SIADH,I-Entity
associated,O
with,O
vincristine,I-Entity
use,O
were,O
identified,O
.,O
Approximately,I-Entity
75%,O
of,O
the,O
patients,O
were,O
receiving,O
treatment,O
for,O
leukemia,I-Entity
or,O
lymphoma,I-Entity
.,O
CONCLUSION,I-Entity
:,O
Our,I-Entity
data,O
suggest,O
that,O
Asian,I-Entity
patients,O
may,O
be,O
at,O
increased,O
risk,O
of,O
hyponatremia,I-Entity
and/or,O
SIADH,I-Entity
associated,O
with,O
vincristine,I-Entity
use,O
.,O
Although,I-Entity
the,O
overall,O
reported,O
rate,O
of,O
SIADH,I-Entity
associated,O
with,O
vincristine,I-Entity
is,O
very,O
low,O
",",O
physicians,O
caring,I-Entity
for,O
Asian,I-Entity
oncology,O
patients,O
should,O
be,O
aware,O
of,O
this,O
potential,O
serious,O
but,O
reversible,O
adverse,O
event,O
.,O
Delayed,I-Entity
toxicity,I-Entity
of,O
cyclophosphamide,I-Entity
on,O
the,O
bladder,I-Entity
of,O
DBA/2,O
and,O
C57BL/6,I-Entity
female,O
mouse,O
.,O
The,I-Entity
present,O
study,O
describes,O
the,O
delayed,O
development,O
of,O
a,O
severe,O
bladder,I-Entity
pathology,O
in,O
a,O
susceptible,O
strain,O
of,O
mice,O
(,O
DBA/2,O
),O
but,O
not,O
in,O
a,O
resistant,O
strain,O
(,O
C57BL/6,I-Entity
),O
when,O
both,O
were,O
treated,O
with,O
a,O
single,O
300,O
mg,O
/,O
kg,O
dose,O
of,O
cyclophosphamide,I-Entity
(,O
CY,I-Entity
),O
.,O
Inbred,I-Entity
DBA/2,O
and,O
C57BL/6,I-Entity
female,O
mice,O
were,O
injected,O
with,O
CY,I-Entity
",",O
and,O
the,O
effect,O
of,O
the,O
drug,O
on,O
the,O
bladder,I-Entity
was,O
assessed,O
during,O
100,O
days,O
by,O
light,O
microscopy,O
using,O
different,O
staining,I-Entity
procedures,O
",",O
and,O
after,O
30,O
days,O
by,O
conventional,O
electron,O
microscopy,O
.,O
Early,I-Entity
CY,I-Entity
toxicity,I-Entity
caused,O
a,O
typical,O
haemorrhagic,I-Entity
cystitis,I-Entity
in,O
both,O
strains,O
that,O
was,O
completely,O
repaired,O
in,O
about,O
7,O
-,O
10,O
days,O
.,O
After,I-Entity
30,O
days,O
of,O
CY,I-Entity
injection,O
ulcerous,I-Entity
and,O
non,O
-,O
ulcerous,I-Entity
forms,O
of,O
chronic,O
cystitis,I-Entity
appeared,O
in,O
86%,O
of,O
DBA/2,O
mice,O
but,O
only,O
in,O
4%,O
of,O
C57BL/6,I-Entity
mice,O
.,O
Delayed,I-Entity
cystitis,I-Entity
was,O
characterized,O
by,O
infiltration,I-Entity
and,O
transepithelial,O
passage,O
into,O
the,O
lumen,O
of,O
inflammatory,O
cells,O
and,O
by,O
frequent,O
exfoliation,O
of,O
the,O
urothelium,I-Entity
.,O
Delayed,I-Entity
cystitis,I-Entity
still,O
persisted,O
in,O
DBA/2,O
mice,O
100,O
days,O
after,O
treatment,O
.,O
These,I-Entity
results,O
indicate,O
that,O
delayed,O
toxicity,I-Entity
of,O
CY,I-Entity
in,O
female,O
DBA/2,O
mice,O
causes,O
a,O
bladder,I-Entity
pathology,O
that,O
is,O
not,O
observed,O
in,O
C57BL/6,I-Entity
mice,O
.,O
This,I-Entity
pathology,O
resembles,O
interstitial,O
cystitis,I-Entity
in,O
humans,O
and,O
could,O
perhaps,O
be,O
used,O
as,O
an,O
animal,O
model,O
for,O
studies,O
on,O
the,O
disease,I-Entity
.,O
High,I-Entity
-,O
dose,O
5-fluorouracil,I-Entity
/,O
folinic,O
acid,O
in,O
combination,O
with,O
three,O
-,O
weekly,O
mitomycin,I-Entity
C,I-Entity
in,O
the,O
treatment,O
of,O
advanced,O
gastric,O
cancer,I-Entity
.,O
BACKGROUND,I-Entity
:,O
The,I-Entity
24-hour,O
continuous,O
infusion,O
of,O
5-fluorouracil,I-Entity
(,O
5-FU,I-Entity
),O
and,O
folinic,O
acid,O
(,O
FA,I-Entity
),O
as,O
part,O
of,O
several,O
new,O
multidrug,O
chemotherapy,O
regimens,I-Entity
in,O
advanced,O
gastric,O
cancer,I-Entity
(,O
AGC,I-Entity
),O
has,O
shown,O
to,O
be,O
effective,O
",",O
with,O
low,O
toxicity,I-Entity
.,O
In,I-Entity
a,O
previous,O
phase,O
II,I-Entity
study,O
with,O
3-weekly,O
bolus,O
5-FU,I-Entity
",",O
FA,I-Entity
and,O
mitomycin,I-Entity
C,I-Entity
(,O
MMC,I-Entity
),O
we,O
found,O
a,O
low,O
toxicity,I-Entity
rate,O
and,O
response,O
rates,O
comparable,O
to,O
those,O
of,O
regimens,I-Entity
such,O
as,O
ELF,I-Entity
",",O
FAM,I-Entity
or,O
FAMTX,I-Entity
",",O
and,O
a,O
promising,O
median,O
overall,O
survival,O
.,O
In,I-Entity
order,O
to,O
improve,O
this,O
MMC,I-Entity
-,O
dependent,O
schedule,O
we,O
initiated,O
a,O
phase,O
II,I-Entity
study,O
with,O
high,O
-,O
dose,O
5-FU,I-Entity
/,O
FA,I-Entity
and,O
3-weekly,O
bolus,O
MMC,I-Entity
.,O
From,I-Entity
February,I-Entity
",",O
1998,O
to,O
September,I-Entity
",",O
2000,O
we,O
recruited,O
33,O
patients,O
with,O
AGC,I-Entity
to,O
receive,O
weekly,O
24-hour,O
5-FU,I-Entity
"2,600",O
mg,O
/,O
m(2,O
),O
preceded,O
by,O
2-hour,O
FA,I-Entity
500,O
mg,O
/,O
m(2,O
),O
for,O
6,O
weeks,O
",",O
followed,O
by,O
a,O
2-week,O
rest,O
period,O
.,O
MMC,I-Entity
10,O
mg,O
/,O
m(2,O
),O
was,O
added,O
in,O
3-weekly,O
intervals,O
.,O
18,O
patients,O
had,O
a,O
primary,O
AGC,I-Entity
",",O
and,O
15,O
showed,O
a,O
relapsed,O
AGC,I-Entity
.,O
The,I-Entity
worst,O
toxicities,I-Entity
(,O
%,O
),O
observed,O
were,O
(,O
CTC,I-Entity
-,O
NCI,I-Entity
1/2/3,O
),O
:,O
leukopenia,I-Entity
45.5/18.2/6.1,O
",",O
thrombocytopenia,I-Entity
33.3/9.1/6.1,O
",",O
vomitus,I-Entity
24.2/9.1/0,O
",",O
diarrhea,I-Entity
36.4/6.1/3.0,O
",",O
stomatitis,I-Entity
18.2/9.1/0,O
",",O
hand,O
-,O
foot,O
syndrome,I-Entity
12.1/0/0,O
.,O
Two,I-Entity
patients,O
developed,O
hemolytic,I-Entity
-,O
uremic,I-Entity
syndrome,I-Entity
(,O
HUS,I-Entity
),O
.,O
High,I-Entity
-,O
dose,O
5-FU,I-Entity
/,O
FA,I-Entity
/,O
MMC,I-Entity
is,O
an,O
effective,O
and,O
well,O
-,O
tolerated,O
outpatient,I-Entity
regimen,I-Entity
for,O
AGC,I-Entity
(,O
objective,O
response,O
rate,O
54.6%,O
),O
.,O
It,I-Entity
may,O
serve,O
as,O
an,O
alternative,O
to,O
cisplatin,I-Entity
-,O
containing,O
regimens,I-Entity
;,O
however,O
",",O
it,O
has,O
to,O
be,O
considered,O
that,O
possibly,O
HUS,I-Entity
may,O
occur,O
.,O
Persistent,I-Entity
sterile,O
leukocyturia,I-Entity
is,O
associated,O
with,O
impaired,I-Entity
renal,O
function,O
in,O
human,O
immunodeficiency,I-Entity
virus,O
type,O
1-infected,I-Entity
children,O
treated,O
with,O
indinavir,I-Entity
.,O
BACKGROUND,I-Entity
:,O
Prolonged,I-Entity
administration,O
of,O
indinavir,I-Entity
is,O
associated,O
with,O
the,O
occurrence,O
of,O
a,O
variety,O
of,O
renal,O
complications,O
in,O
adults,O
.,O
A,I-Entity
prospective,O
study,O
to,O
monitor,O
indinavir,I-Entity
-,O
related,O
nephrotoxicity,I-Entity
in,O
a,O
cohort,O
of,O
30,O
human,O
immunodeficiency,I-Entity
virus,O
type,O
1-infected,I-Entity
children,O
treated,O
with,O
indinavir,I-Entity
.,O
METHODS,I-Entity
:,O
Urinary,I-Entity
pH,I-Entity
",",O
albumin,O
",",O
creatinine,I-Entity
",",O
the,O
presence,O
of,O
erythrocytes,O
",",O
leukocytes,O
",",O
bacteria,O
and,O
crystals,O
",",O
and,O
culture,O
were,O
analyzed,O
every,O
3,O
months,O
for,O
96,I-Entity
weeks,O
.,O
Serum,I-Entity
creatinine,I-Entity
levels,O
were,O
routinely,O
determined,O
at,O
the,O
same,O
time,O
points,O
.,O
Steady,I-Entity
-,O
state,O
pharmacokinetics,O
of,O
indinavir,I-Entity
were,O
done,O
at,O
week,O
4,O
after,O
the,O
initiation,O
of,O
indinavir,I-Entity
.,O
The,I-Entity
cumulative,O
incidence,O
of,O
persistent,O
sterile,O
leukocyturia,I-Entity
(,O
>,O
or,O
=,O
75,O
cells/,O
micro,O
L,I-Entity
in,O
at,O
least,O
2,O
consecutive,O
visits,O
),O
after,O
96,I-Entity
weeks,O
was,O
53%,O
.,O
Persistent,I-Entity
sterile,O
leukocyturia,I-Entity
was,O
frequently,O
associated,O
with,O
a,O
mild,O
increase,O
in,O
the,O
urine,I-Entity
albumin,O
/,O
creatinine,I-Entity
ratio,O
and,O
by,O
microscopic,O
hematuria,I-Entity
.,O
The,I-Entity
cumulative,O
incidence,O
of,O
serum,O
creatinine,I-Entity
levels,O
>,O
50%,O
above,O
normal,O
was,O
33%,O
after,O
96,I-Entity
weeks,O
.,O
Children,I-Entity
with,O
persistent,O
sterile,O
leukocyturia,I-Entity
more,O
frequently,O
had,O
serum,O
creatinine,I-Entity
levels,O
of,O
50%,O
above,O
normal,O
than,O
those,O
children,O
without,O
persistent,O
sterile,O
leukocyturia,I-Entity
.,O
In,I-Entity
children,O
younger,O
than,O
5.6,O
years,O
",",O
persistent,O
sterile,O
leukocyturia,I-Entity
was,O
significantly,O
more,O
frequent,O
than,O
in,O
older,O
children,O
.,O
A,I-Entity
higher,O
cumulative,O
incidence,O
of,O
persistent,O
leukocyturia,I-Entity
was,O
found,O
in,O
children,O
with,O
an,O
area,O
under,O
the,O
curve,O
>,O
19,O
mg,O
/,O
L,I-Entity
x,O
h,O
or,O
a,O
peak,O
serum,O
level,O
of,O
indinavir,I-Entity
>,O
12,O
mg,O
In,I-Entity
4,O
children,O
",",O
indinavir,I-Entity
was,O
discontinued,O
because,O
of,O
nephrotoxicity,I-Entity
.,O
Subsequently,I-Entity
",",O
the,O
serum,O
creatinine,I-Entity
levels,O
decreased,O
",",O
the,O
urine,I-Entity
albumin,O
/,O
creatinine,I-Entity
ratios,O
returned,O
to,O
zero,O
",",O
and,O
the,O
leukocyturia,I-Entity
disappeared,O
within,O
3,O
months,O
.,O
Children,I-Entity
treated,O
with,O
indinavir,I-Entity
have,O
a,O
high,O
cumulative,O
incidence,O
of,O
persistent,O
sterile,O
leukocyturia,I-Entity
.,O
Children,I-Entity
with,O
persistent,O
sterile,O
leukocyturia,I-Entity
more,O
frequently,O
had,O
an,O
increase,O
in,O
serum,O
creatinine,I-Entity
levels,O
of,O
>,O
50%,O
above,O
normal,O
.,O
The,I-Entity
impairment,I-Entity
of,O
the,O
renal,O
function,O
in,O
these,O
children,O
occurred,O
in,O
the,O
absence,O
of,O
clinical,O
symptoms,O
of,O
nephrolithiasis,I-Entity
.,O
Indinavir,I-Entity
-,O
associated,O
nephrotoxicity,I-Entity
must,O
be,O
monitored,O
closely,O
",",O
especially,O
in,O
children,O
with,O
risk,O
factors,O
such,O
as,O
persistent,O
sterile,O
leukocyturia,I-Entity
",",O
age,O
<,O
5.6,O
years,O
",",O
an,O
area,O
under,O
the,O
curve,O
of,O
indinavir,I-Entity
>,O
19,O
mg,O
/,O
L,I-Entity
x,O
h,O
",",O
and,O
a,O
C(max,I-Entity
),O
Utility,I-Entity
of,O
troponin,I-Entity
I,I-Entity
in,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
chest,O
pain,I-Entity
.,O
Baseline,I-Entity
electrocardiogram,O
abnormalities,I-Entity
and,O
market,O
elevations,O
not,O
associated,O
with,O
myocardial,B-Entity
necrosis,I-Entity
make,O
accurate,O
diagnosis,O
of,O
myocardial,B-Entity
infarction,I-Entity
(,O
MI,I-Entity
),O
difficult,O
in,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
chest,O
pain,I-Entity
.,O
OBJECTIVE,I-Entity
:,O
To,I-Entity
assess,O
outcomes,O
based,O
on,O
troponin,I-Entity
positivity,I-Entity
in,O
patients,O
with,O
cocaine,I-Entity
chest,O
pain,I-Entity
admitted,O
for,O
exclusion,O
of,O
MI,I-Entity
.,O
Outcomes,I-Entity
were,O
examined,O
in,O
patients,O
admitted,O
for,O
possible,O
MI,I-Entity
after,O
cocaine,I-Entity
use,O
.,O
All,I-Entity
patients,O
underwent,O
a,O
rapid,O
rule,O
-,O
in,O
protocol,O
that,O
included,O
serial,O
sampling,O
of,O
creatine,I-Entity
kinase,O
(,O
CK,I-Entity
),O
",",O
CK,I-Entity
-,O
MB,I-Entity
",",O
and,O
cardiac,O
troponin,I-Entity
I,I-Entity
(,O
cTnI,I-Entity
),O
over,O
eight,O
hours,O
.,O
Outcomes,I-Entity
included,O
CK,I-Entity
-,O
MB,I-Entity
MI,I-Entity
(,O
CK,I-Entity
-,O
MB,I-Entity
>,O
or=,O
4,O
",",O
cardiac,O
death,I-Entity
",",O
and,O
significant,O
coronary,O
disease,I-Entity
(,O
>,O
or=50%,O
),O
.,O
Of,I-Entity
the,O
246,O
admitted,O
patients,O
",",O
34,O
(,O
14%,O
),O
met,O
CK,I-Entity
-,O
MB,I-Entity
criteria,O
for,O
MI,I-Entity
and,O
38,O
(,O
16%,O
),O
Three,I-Entity
of,O
the,O
four,O
patients,O
without,O
significant,O
disease,I-Entity
who,O
had,O
cTnI,I-Entity
elevations,O
met,O
CK,I-Entity
-,O
MB,I-Entity
criteria,O
for,O
MI,I-Entity
",",O
and,O
the,O
other,O
had,O
a,O
peak,O
CK,I-Entity
-,O
MB,I-Entity
level,O
of,O
13,O
ng,O
/,O
mL.,I-Entity
Sensitivities,I-Entity
",",O
specificities,O
",",O
and,O
positive,O
and,O
negative,O
likelihood,O
ratios,O
for,O
predicting,O
cardiac,O
death,I-Entity
or,O
significant,O
disease,I-Entity
were,O
high,O
for,O
both,O
CK,I-Entity
-,O
MB,I-Entity
MI,I-Entity
and,O
cTnI,I-Entity
and,O
were,O
not,O
significantly,O
different,O
.,O
CONCLUSIONS,I-Entity
:,O
Most,I-Entity
patients,O
with,O
cTnI,I-Entity
elevations,O
meet,O
CK,I-Entity
-,O
MB,I-Entity
criteria,O
for,O
MI,I-Entity
",",O
as,O
well,O
as,O
have,O
a,O
high,O
incidence,O
of,O
underlying,O
significant,O
disease,I-Entity
.,O
Troponin,I-Entity
appears,O
to,O
have,O
an,O
equivalent,O
diagnostic,O
accuracy,O
compared,O
with,O
CK,I-Entity
-,O
MB,I-Entity
for,O
diagnosing,O
necrosis,I-Entity
in,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
chest,O
pain,I-Entity
and,O
suspected,O
MI,I-Entity
.,O
Acute,I-Entity
interstitial,O
nephritis,I-Entity
due,O
to,O
nicergoline,I-Entity
(,O
Sermion,I-Entity
),O
.,O
We,I-Entity
report,O
a,O
case,O
of,O
acute,O
interstitial,O
nephritis,I-Entity
(,O
AIN,I-Entity
),O
due,O
to,O
nicergoline,I-Entity
(,O
Sermion,I-Entity
),O
.,O
A,I-Entity
50-year,O
-,O
old,O
patient,O
admitted,O
to,O
our,O
hospital,O
for,O
fever,I-Entity
and,O
acute,O
renal,O
failure,I-Entity
.,O
Before,I-Entity
admission,O
",",O
he,O
had,O
been,O
taking,O
nicergoline,I-Entity
and,O
bendazac,I-Entity
lysine,I-Entity
due,O
to,O
retinal,B-Entity
vein,O
occlusion,I-Entity
at,O
ophthalmologic,O
department,O
.,O
Thereafter,I-Entity
",",O
he,O
experienced,O
intermittent,O
fever,I-Entity
and,O
skin,O
rash,I-Entity
.,O
On,I-Entity
admission,O
",",O
clinical,O
symptoms,O
(,O
i.e.,O
arthralgia,I-Entity
and,O
fever,I-Entity
),O
and,O
laboratory,O
findings,O
(,O
i.e.,O
eosinophilia,I-Entity
and,O
renal,O
failure,I-Entity
),O
suggested,O
AIN,I-Entity
",",O
and,O
which,O
was,O
confirmed,O
by,O
pathologic,O
findings,O
on,O
renal,O
biopsy,O
.,O
A,I-Entity
lymphocyte,O
transformation,O
test,O
demonstrated,O
a,O
positive,O
result,O
against,O
nicergoline,I-Entity
.,O
Treatment,I-Entity
was,O
consisted,O
of,O
withdrawal,O
of,O
nicergoline,I-Entity
and,O
intravenous,O
methylprednisolone,I-Entity
",",O
and,O
his,O
renal,O
function,O
was,O
completely,O
recovered,O
.,O
To,I-Entity
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
report,O
of,O
nicergoline,I-Entity
-,O
associated,O
AIN,I-Entity
.,O
Neuroleptic,I-Entity
malignant,I-Entity
syndrome,I-Entity
complicated,O
by,O
massive,O
intestinal,O
bleeding,I-Entity
in,O
a,O
patient,O
with,O
chronic,O
renal,O
failure,I-Entity
.,O
A,I-Entity
patient,O
with,O
chronic,O
renal,O
failure,I-Entity
(,O
CRF,I-Entity
),O
developed,O
neuroleptic,O
malignant,I-Entity
syndrome,I-Entity
(,O
NMS,I-Entity
),O
after,O
administration,O
of,O
risperidone,I-Entity
and,O
levomepromazine,I-Entity
.,O
In,I-Entity
addition,O
to,O
the,O
typical,O
symptoms,O
of,O
NMS,I-Entity
",",O
massive,O
intestinal,O
bleeding,I-Entity
was,O
observed,O
during,O
the,O
episode,O
.,O
This,I-Entity
report,O
suggests,O
that,O
NMS,I-Entity
in,O
a,O
patient,O
with,O
CRF,I-Entity
may,O
be,O
complicated,O
by,O
intestinal,O
bleeding,I-Entity
and,O
needs,O
special,O
caution,O
for,O
this,O
complication,O
.,O
Adrenaline,I-Entity
-,O
induced,O
hypertension,I-Entity
was,O
used,O
to,O
destroy,O
the,O
BBB,I-Entity
",",O
which,O
was,O
evaluated,O
using,O
triphenyltetrazolium,I-Entity
(,O
TTC,I-Entity
),O
staining,I-Entity
of,O
the,O
brain,O
slices,O
just,O
after,O
giving,O
adrenaline,I-Entity
for,O
30,O
s.,O
In,I-Entity
normal,O
rats,O
",",O
the,O
whole,O
brain,O
sections,O
exhibited,O
complete,O
staining,I-Entity
with,O
TTC,I-Entity
.,O
After,I-Entity
adrenaline,I-Entity
infusion,O
for,O
30,O
s,O
",",O
there,O
were,O
large,O
unstained,O
areas,O
in,O
the,O
left,O
brain,O
in,O
right,O
-,O
pawed,O
animals,O
",",O
and,O
vice,O
versa,O
in,O
left,O
-,O
pawed,O
animals,O
.,O
Similar,I-Entity
results,O
were,O
obtained,O
in,O
seizure,I-Entity
-,O
induced,O
breakdown,I-Entity
of,O
BBB,I-Entity
.,O
Carvedilol,I-Entity
protects,O
against,O
doxorubicin,I-Entity
-,O
induced,O
mitochondrial,O
cardiomyopathy,I-Entity
.,O
Several,I-Entity
cytopathic,O
mechanisms,O
have,O
been,O
suggested,O
to,O
mediate,O
the,O
dose,O
-,O
limiting,O
cumulative,O
and,O
irreversible,O
cardiomyopathy,I-Entity
caused,O
by,O
doxorubicin,I-Entity
.,O
Recent,I-Entity
evidence,O
indicates,O
that,O
oxidative,O
stress,I-Entity
and,O
mitochondrial,O
dysfunction,I-Entity
are,O
key,O
factors,O
in,O
the,O
pathogenic,O
process,O
.,O
The,I-Entity
objective,O
of,O
this,O
investigation,O
was,O
to,O
test,O
the,O
hypothesis,O
that,O
carvedilol,I-Entity
",",O
a,O
nonselective,O
beta,O
-,O
adrenergic,O
receptor,O
antagonist,O
with,O
potent,O
antioxidant,O
properties,O
",",O
protects,O
against,O
the,O
cardiac,O
and,O
hepatic,B-Entity
mitochondrial,O
bioenergetic,O
dysfunction,I-Entity
associated,O
with,O
subchronic,O
doxorubicin,I-Entity
toxicity,I-Entity
.,O
Heart,I-Entity
and,O
liver,I-Entity
mitochondria,O
were,O
isolated,O
from,O
rats,O
treated,O
for,O
7,O
weeks,O
with,O
doxorubicin,I-Entity
(,O
2,O
mg,O
/,O
kg,O
sc,O
/,O
week,O
),O
",",O
carvedilol,I-Entity
(,O
1,O
mg,O
/,O
kg,O
ip,O
/,O
week,O
),O
",",O
or,O
the,O
combination,O
of,O
the,O
two,O
drugs,O
.,O
Heart,I-Entity
mitochondria,O
isolated,O
from,O
doxorubicin,I-Entity
-,O
treated,O
rats,O
exhibited,O
depressed,I-Entity
rates,O
for,O
state,O
3,O
respiration,I-Entity
(,O
336,O
+,O
/-,O
Mitochondrial,I-Entity
calcium,I-Entity
-,O
loading,O
capacity,O
and,O
the,O
activity,O
of,O
NADH,I-Entity
-,O
dehydrogenase,O
were,O
also,O
suppressed,O
in,O
cardiac,O
mitochondria,O
from,O
doxorubicin,I-Entity
-,O
treated,O
rats,O
.,O
Doxorubicin,I-Entity
treatment,O
also,O
caused,O
a,O
decrease,O
in,O
RCR,I-Entity
for,O
liver,I-Entity
mitochondria,O
(,O
3.9,O
+,O
/-,O
Coadministration,I-Entity
of,O
carvedilol,I-Entity
decreased,O
the,O
extent,O
of,O
cellular,O
vacuolization,O
in,O
cardiac,O
myocytes,I-Entity
and,O
prevented,O
the,O
inhibitory,O
effect,O
of,O
doxorubicin,I-Entity
on,O
mitochondrial,O
respiration,I-Entity
in,O
both,O
heart,O
and,O
liver,I-Entity
.,O
Carvedilol,I-Entity
also,O
prevented,O
the,O
decrease,O
in,O
mitochondrial,O
Ca(2,I-Entity
+,O
),O
loading,O
capacity,O
and,O
the,O
inhibition,O
of,O
the,O
respiratory,O
complexes,O
of,O
heart,O
mitochondria,O
caused,O
by,O
doxorubicin,I-Entity
.,O
Carvedilol,I-Entity
by,O
itself,O
did,O
not,O
affect,O
any,O
of,O
the,O
parameters,O
measured,O
for,O
heart,O
or,O
liver,I-Entity
mitochondria,O
.,O
It,I-Entity
is,O
concluded,O
that,O
this,O
protection,O
by,O
carvedilol,I-Entity
against,O
both,O
the,O
structural,O
and,O
functional,O
cardiac,O
tissue,O
damage,O
may,O
afford,O
significant,O
clinical,O
advantage,O
in,O
minimizing,O
the,O
dose,O
-,O
limiting,O
mitochondrial,O
dysfunction,I-Entity
and,O
cardiomyopathy,I-Entity
that,O
accompanies,O
long,O
-,O
term,O
doxorubicin,I-Entity
therapy,O
in,O
cancer,I-Entity
patients,O
.,O
Cocaine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
is,O
more,O
influenced,O
by,O
adenosine,I-Entity
receptor,O
agonists,I-Entity
than,O
amphetamine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
.,O
The,I-Entity
influence,O
of,O
adenosine,I-Entity
receptor,O
agonists,I-Entity
and,O
antagonists,O
on,O
cocaine,I-Entity
-,O
and,O
amphetamine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
was,O
examined,O
in,O
mice,O
.,O
All,I-Entity
adenosine,I-Entity
receptor,O
agonists,I-Entity
significantly,O
decreased,O
the,O
locomotor,O
activity,O
in,O
mice,O
",",O
and,O
the,O
effects,O
were,O
dose,O
-,O
dependent,O
.,O
It,I-Entity
seems,O
that,O
adenosine,I-Entity
A1,I-Entity
and,O
A2,I-Entity
receptors,O
might,O
be,O
involved,O
in,O
this,O
reaction,I-Entity
.,O
Moreover,I-Entity
",",O
all,O
adenosine,I-Entity
receptor,O
agonists,I-Entity
:,O
2-p-(2-carboxyethyl)phenethylamino-5'-N,B-Entity
-,O
ethylcarboxamidoadenosine,I-Entity
(,O
CGS,I-Entity
21680,I-Entity
),O
",",O
A2A,I-Entity
receptor,O
agonist,I-Entity
",",O
N6-cyclopentyladenosine,B-Entity
(,O
CPA,I-Entity
),O
",",O
A1,I-Entity
receptor,O
agonist,I-Entity
",",O
and,O
5'-N,I-Entity
-,O
ethylcarboxamidoadenosine,I-Entity
(,O
NECA,I-Entity
),O
",",O
A2/A1,I-Entity
receptor,O
agonist,I-Entity
significantly,O
and,O
dose,O
-,O
dependently,O
decreased,O
cocaine,I-Entity
-,O
induced,O
locomotor,O
activity,O
.,O
CPA,I-Entity
reduced,O
cocaine,I-Entity
action,O
at,O
the,O
doses,O
which,O
",",O
given,O
alone,O
",",O
did,O
not,O
influence,O
motility,O
",",O
while,O
CGS,I-Entity
21680,I-Entity
and,O
NECA,I-Entity
decreased,O
the,O
action,O
of,O
cocaine,I-Entity
at,O
the,O
doses,O
which,O
",",O
given,O
alone,O
",",O
decreased,O
locomotor,O
activity,O
in,O
animals,O
.,O
These,I-Entity
results,O
suggest,O
the,O
involvement,O
of,O
both,O
adenosine,I-Entity
receptors,O
in,O
the,O
action,O
of,O
cocaine,I-Entity
although,O
agonists,I-Entity
of,O
A1,I-Entity
receptors,O
seem,O
to,O
have,O
stronger,O
influence,O
on,O
it,O
.,O
The,I-Entity
selective,O
blockade,O
of,O
A2,I-Entity
adenosine,I-Entity
receptor,O
by,O
DMPX,I-Entity
(,O
"3,7-dimethyl-1-propargylxanthine",O
),O
significantly,O
enhanced,O
cocaine,I-Entity
-,O
induced,O
locomotor,O
activity,O
of,O
animals,O
.,O
Caffeine,I-Entity
had,O
similar,O
action,O
but,O
the,O
effect,O
was,O
not,O
significant,O
.,O
CPT,I-Entity
(,O
8-cyclopentyltheophylline)--A1,B-Entity
receptor,O
antagonist,O
",",O
did,O
not,O
show,O
any,O
influence,O
in,O
this,O
test,O
.,O
Similarly,I-Entity
",",O
all,O
adenosine,I-Entity
receptor,O
agonists,I-Entity
decreased,O
amphetamine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
",",O
but,O
at,O
the,O
higher,O
doses,O
than,O
those,O
which,O
were,O
active,O
in,O
cocaine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
.,O
The,I-Entity
selective,O
blockade,O
of,O
A2,I-Entity
adenosine,I-Entity
receptors,O
(,O
DMPX,I-Entity
),O
and,O
non,O
-,O
selective,O
blockade,O
of,O
adenosine,I-Entity
receptors,O
(,O
caffeine,I-Entity
),O
significantly,O
increased,O
the,O
action,O
of,O
amphetamine,I-Entity
in,O
the,O
locomotor,O
activity,O
test,O
.,O
Our,I-Entity
results,O
have,O
shown,O
that,O
all,O
adenosine,I-Entity
receptor,O
agonists,I-Entity
(,O
A1,I-Entity
and,O
A2,I-Entity
),O
reduce,O
cocaine-,I-Entity
and,O
amphetamine,I-Entity
-,O
induced,O
locomotor,O
activity,O
and,O
indicate,O
that,O
cocaine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
is,O
more,O
influenced,O
by,O
adenosine,I-Entity
receptor,O
agonists,I-Entity
(,O
particularly,O
A1,I-Entity
receptors,O
),O
than,O
amphetamine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
.,O
Amiodarone,I-Entity
and,O
the,O
risk,O
of,O
bradyarrhythmia,I-Entity
requiring,O
permanent,O
pacemaker,O
in,O
elderly,O
patients,O
with,O
atrial,I-Entity
fibrillation,I-Entity
and,O
prior,O
myocardial,B-Entity
infarction,I-Entity
.,O
OBJECTIVES,I-Entity
:,O
The,I-Entity
aim,O
of,O
this,O
study,O
was,O
to,O
determine,O
whether,O
the,O
use,O
of,O
amiodarone,I-Entity
in,O
patients,O
with,O
atrial,I-Entity
fibrillation,I-Entity
(,O
AF,I-Entity
),O
increases,O
the,O
risk,O
of,O
bradyarrhythmia,I-Entity
requiring,O
a,O
permanent,O
pacemaker,O
.,O
Reports,I-Entity
of,O
severe,O
bradyarrhythmia,I-Entity
during,O
amiodarone,I-Entity
therapy,O
are,O
infrequent,O
and,O
limited,O
to,O
studies,O
assessing,O
the,O
therapy,O
's,I-Entity
use,O
in,O
the,O
management,O
of,O
patients,O
with,O
ventricular,O
arrhythmias,I-Entity
.,O
METHODS,I-Entity
:,O
A,I-Entity
study,O
cohort,O
of,O
"8,770",O
patients,O
age,O
>,O
or,O
=,O
65,O
years,O
with,O
a,O
new,O
diagnosis,O
of,O
AF,I-Entity
was,O
identified,O
from,O
a,O
provincewide,O
database,O
of,O
Quebec,I-Entity
residents,O
with,O
a,O
myocardial,B-Entity
infarction,I-Entity
(,O
MI,I-Entity
),O
between,O
1991,O
and,O
1999,O
.,O
Using,I-Entity
a,O
nested,O
case,O
-,O
control,O
design,O
",",O
477,I-Entity
cases,O
of,O
bradyarrhythmia,I-Entity
requiring,O
a,O
permanent,O
pacemaker,O
were,O
matched,O
(,O
1:4,O
),O
to,O
"1,908",O
controls,O
.,O
Multivariable,I-Entity
logistic,O
regression,O
was,O
used,O
to,O
estimate,O
the,O
odds,O
ratio,O
(,O
OR,I-Entity
),O
of,O
pacemaker,O
insertion,O
associated,O
with,O
amiodarone,I-Entity
use,O
",",O
controlling,O
for,O
baseline,O
risk,O
factors,O
and,O
exposure,O
to,O
sotalol,I-Entity
",",O
Class,I-Entity
I,I-Entity
antiarrhythmic,O
agents,O
",",O
beta,O
-,O
blockers,O
",",O
calcium,I-Entity
channel,O
blockers,O
",",O
and,O
digoxin,I-Entity
.,O
RESULTS,I-Entity
:,O
amiodarone,I-Entity
use,O
was,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
pacemaker,O
insertion,O
(,O
OR,I-Entity
:,O
2.14,O
",",O
95%,O
confidence,O
interval,O
[,O
CI,I-Entity
],O
:,O
1.30,O
to,O
3.54,O
),O
.,O
Digoxin,I-Entity
was,O
the,O
only,O
other,O
medication,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
pacemaker,O
insertion,O
(,O
OR,I-Entity
:,O
1.78,O
",",O
95%,O
CI,I-Entity
:,O
1.37,O
to,O
2.31,O
),O
.,O
This,I-Entity
study,O
suggests,O
that,O
the,O
use,O
of,O
amiodarone,I-Entity
in,O
elderly,O
patients,O
with,O
AF,I-Entity
and,O
a,O
previous,O
MI,I-Entity
increases,O
the,O
risk,O
of,O
bradyarrhythmia,I-Entity
requiring,O
a,O
permanent,O
pacemaker,O
.,O
The,I-Entity
finding,O
of,O
an,O
augmented,O
risk,O
of,O
pacemaker,O
insertion,O
in,O
elderly,O
women,O
receiving,O
amiodarone,I-Entity
requires,O
further,O
investigation,O
.,O
Indomethacin,I-Entity
-,O
induced,O
morphologic,O
changes,O
in,O
the,O
rat,O
urinary,O
bladder,I-Entity
epithelium,I-Entity
.,O
OBJECTIVES,I-Entity
:,O
To,I-Entity
evaluate,O
the,O
morphologic,O
changes,O
in,O
rat,O
urothelium,I-Entity
induced,O
by,O
indomethacin,I-Entity
.,O
Nonsteroidal,I-Entity
anti,O
-,O
inflammatory,O
drug,O
-,O
induced,O
cystitis,I-Entity
is,O
a,O
poorly,O
recognized,O
and,O
under,O
-,O
reported,O
condition,O
.,O
In,I-Entity
addition,O
to,O
tiaprofenic,I-Entity
acid,O
",",O
indomethacin,I-Entity
has,O
been,O
reported,O
to,O
be,O
associated,O
with,O
this,O
condition,O
.,O
Three,I-Entity
groups,O
were,O
established,O
:,O
a,O
control,O
group,O
(,O
n,O
=,O
10,O
),O
",",O
a,O
high,O
-,O
dose,O
group,O
(,O
n,O
=,O
10,O
),O
",",O
treated,O
with,O
one,O
intraperitoneal,O
injection,O
of,O
indomethacin,I-Entity
20,O
mg,O
/,O
kg,O
",",O
and,O
a,O
therapeutic,O
dose,O
group,O
(,O
n,O
=,O
10,O
),O
in,O
which,O
oral,O
indomethacin,I-Entity
was,O
administered,O
3.25,O
mg,O
/,O
kg,O
body,O
weight,O
daily,O
for,O
3,O
weeks,O
.,O
When,I-Entity
compared,O
with,O
the,O
control,O
group,O
",",O
both,O
indomethacin,I-Entity
groups,O
revealed,O
statistically,O
increased,O
numbers,O
of,O
mast,O
cells,O
in,O
the,O
mucosa,O
(,O
P,I-Entity
<,O
0.0001,O
),O
and,O
penetration,O
of,O
lanthanum,I-Entity
nitrate,I-Entity
through,O
intercellular,O
areas,O
of,O
the,O
epithelium,I-Entity
.,O
Indomethacin,I-Entity
resulted,O
in,O
histopathologic,O
findings,O
typical,O
of,O
interstitial,O
cystitis,I-Entity
",",O
such,O
as,O
leaky,I-Entity
bladder,I-Entity
epithelium,I-Entity
and,O
mucosal,O
mastocytosis,I-Entity
.,O
The,I-Entity
true,O
incidence,O
of,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drug,O
-,O
induced,O
cystitis,I-Entity
in,O
humans,O
must,O
be,O
clarified,O
by,O
prospective,O
clinical,O
trials,O
.,O
An,I-Entity
open,O
-,O
label,O
phase,O
II,I-Entity
study,O
of,O
low,O
-,O
dose,O
thalidomide,I-Entity
in,O
androgen,I-Entity
-,O
independent,O
prostate,O
cancer,I-Entity
.,O
The,I-Entity
antiangiogenic,O
effects,O
of,O
thalidomide,I-Entity
have,O
been,O
assessed,O
in,O
clinical,O
trials,O
in,O
patients,O
with,O
various,O
solid,O
and,O
haematological,O
malignancies,I-Entity
.,O
Thalidomide,I-Entity
blocks,O
the,O
activity,O
of,O
angiogenic,O
agents,O
including,O
bFGF,I-Entity
",",O
VEGF,I-Entity
and,O
IL-6,I-Entity
.,O
We,I-Entity
undertook,O
an,O
open,O
-,O
label,O
study,O
using,O
thalidomide,I-Entity
100,O
mg,O
once,O
daily,O
for,O
up,O
to,O
6,O
months,O
in,O
20,O
men,O
with,O
androgen,I-Entity
-,O
independent,O
prostate,O
cancer,I-Entity
.,O
Patients,I-Entity
underwent,O
regular,O
measurement,O
of,O
prostate,O
-,O
specific,O
antigen,O
(,O
PSA,I-Entity
),O
",",O
urea,I-Entity
and,O
electrolytes,O
",",O
serum,O
bFGF,I-Entity
and,O
VEGF,I-Entity
.,O
Adverse,I-Entity
effects,O
included,O
constipation,I-Entity
",",O
morning,O
drowsiness,O
",",O
dizziness,I-Entity
and,O
rash,I-Entity
",",O
and,O
resulted,O
in,O
withdrawal,O
from,O
the,O
study,O
by,O
three,O
men,O
.,O
Evidence,I-Entity
of,O
peripheral,O
sensory,O
neuropathy,I-Entity
was,O
found,O
in,O
nine,O
of,O
13,O
men,O
before,O
treatment,O
.,O
In,I-Entity
the,O
seven,O
men,O
who,O
completed,O
six,O
months,O
on,O
thalidomide,I-Entity
",",O
subclinical,O
evidence,O
of,O
peripheral,O
neuropathy,I-Entity
was,O
found,O
in,O
four,O
before,O
treatment,O
",",O
but,O
in,O
all,O
seven,O
at,O
repeat,O
testing,O
.,O
The,I-Entity
findings,O
indicate,O
that,O
thalidomide,I-Entity
may,O
be,O
an,O
option,O
for,O
patients,O
who,O
have,O
failed,O
other,O
forms,O
of,O
therapy,O
",",O
provided,O
close,O
follow,O
-,O
up,O
is,O
maintained,O
for,O
development,O
of,O
peripheral,O
neuropathy,I-Entity
.,O
Central,I-Entity
nervous,I-Entity
system,O
toxicity,I-Entity
following,O
the,O
administration,O
of,O
levobupivacaine,I-Entity
for,O
lumbar,O
plexus,O
block,O
:,O
Central,I-Entity
nervous,I-Entity
system,O
and,O
cardiac,O
toxicity,I-Entity
following,O
the,O
administration,O
of,O
local,O
anesthetics,O
is,O
a,O
recognized,O
complication,O
of,O
regional,O
anesthesia,O
.,O
Levobupivacaine,I-Entity
",",O
the,O
pure,O
S(-,I-Entity
),O
enantiomer,O
of,O
bupivacaine,I-Entity
",",O
was,O
developed,O
to,O
improve,O
the,O
cardiac,O
safety,O
profile,O
of,O
bupivacaine,I-Entity
.,O
We,I-Entity
describe,O
2,O
cases,O
of,O
grand,O
mal,O
seizures,I-Entity
following,O
accidental,O
intravascular,O
injection,O
of,O
levobupivacaine,I-Entity
.,O
Immediately,I-Entity
after,O
the,O
administration,O
of,O
levobupivacaine,I-Entity
0.5%,O
with,O
epinephrine,I-Entity
2.5,O
microgram,O
/,O
mL,I-Entity
",",O
the,O
patients,O
developed,O
grand,O
mal,O
seizures,I-Entity
",",O
despite,O
negative,O
aspiration,I-Entity
for,O
blood,O
and,O
no,O
clinical,O
signs,O
of,O
intravenous,O
epinephrine,I-Entity
administration,O
.,O
The,I-Entity
seizures,I-Entity
were,O
successfully,O
treated,O
with,O
sodium,I-Entity
thiopental,I-Entity
in,O
addition,O
to,O
succinylcholine,I-Entity
in,O
1,O
patient,O
.,O
Neither,I-Entity
patient,O
developed,O
signs,O
of,O
cardiovascular,O
toxicity,I-Entity
.,O
Both,I-Entity
patients,O
were,O
treated,O
preoperatively,O
with,O
beta,O
-,O
adrenergic,O
antagonist,O
medications,O
",",O
which,O
may,O
have,O
masked,O
the,O
cardiovascular,O
signs,O
of,O
the,O
unintentional,O
intravascular,O
administration,O
of,O
levobupivacaine,I-Entity
with,O
epinephrine,I-Entity
.,O
Although,I-Entity
levobupivacaine,I-Entity
may,O
have,O
a,O
safer,O
cardiac,O
toxicity,I-Entity
profile,O
than,O
racemic,O
bupivacaine,I-Entity
",",O
if,O
adequate,O
amounts,O
of,O
levobupivacaine,I-Entity
reach,O
the,O
circulation,O
",",O
it,O
will,O
result,O
in,O
convulsions,I-Entity
.,O
Plasma,I-Entity
concentrations,O
sufficient,O
to,O
result,O
in,O
central,O
nervous,I-Entity
system,O
toxicity,I-Entity
did,O
not,O
produce,O
manifestations,O
of,O
cardiac,O
toxicity,I-Entity
in,O
these,O
2,O
patients,O
.,O
Anaesthetic,I-Entity
complications,O
associated,O
with,O
myotonia,I-Entity
congenita,I-Entity
:,O
case,O
study,O
and,O
comparison,O
with,O
other,O
myotonic,O
disorders,I-Entity
.,O
Myotonia,I-Entity
congenita,I-Entity
(,O
MC,I-Entity
),O
is,O
caused,O
by,O
a,O
defect,I-Entity
in,O
the,O
skeletal,O
muscle,O
chloride,I-Entity
channel,O
function,O
",",O
which,O
may,O
cause,O
sustained,O
membrane,O
depolarisation,I-Entity
.,O
We,I-Entity
describe,O
a,O
previously,O
healthy,O
32-year,O
-,O
old,O
woman,O
who,O
developed,O
a,O
life,O
-,O
threatening,I-Entity
muscle,O
spasm,I-Entity
and,O
secondary,O
ventilation,O
difficulties,O
following,O
a,O
preoperative,O
injection,O
of,O
suxamethonium,I-Entity
.,O
The,I-Entity
muscle,O
spasms,I-Entity
disappeared,O
spontaneously,O
and,O
the,O
surgery,O
proceeded,O
without,O
further,O
problems,O
.,O
When,I-Entity
subsequently,O
questioned,O
",",O
she,O
reported,O
minor,O
symptoms,O
suggesting,O
a,O
myotonic,O
condition,O
.,O
Myotonia,I-Entity
was,O
found,O
on,O
clinical,O
examination,O
and,O
EMG,I-Entity
.,O
The,I-Entity
diagnosis,O
MC,I-Entity
was,O
confirmed,O
genetically,O
.,O
We,I-Entity
give,O
a,O
brief,O
overview,O
of,O
ion,O
channel,O
disorders,I-Entity
including,O
malignant,I-Entity
hyperthermia,I-Entity
and,O
their,O
anaesthetic,O
considerations,O
.,O
Respiratory,I-Entity
pattern,O
in,O
a,O
rat,O
model,O
of,O
epilepsy,I-Entity
.,O
Apnea,I-Entity
is,O
known,O
to,O
occur,O
during,O
seizures,I-Entity
",",O
but,O
systematic,O
studies,O
of,O
ictal,O
respiratory,O
changes,O
in,O
adults,O
are,O
few,O
.,O
Here,I-Entity
we,O
sought,O
to,O
generate,O
information,O
with,O
regard,O
to,O
the,O
interictal,O
period,O
in,O
animals,O
with,O
pilocarpine,I-Entity
-,O
induced,O
epilepsy,I-Entity
.,O
METHODS,I-Entity
:,O
Twelve,I-Entity
rats,O
(,O
six,O
chronically,O
epileptic,I-Entity
animals,O
and,O
six,O
controls,O
),O
were,O
anesthetized,O
",",O
given,O
tracheotomies,O
",",O
and,O
subjected,O
to,O
hyperventilation,I-Entity
or,O
hypoventilation,I-Entity
conditions,O
.,O
The,I-Entity
hyperventilation,I-Entity
maneuver,O
caused,O
a,O
decrease,O
in,O
spontaneous,O
ventilation,O
in,O
pilocarpine,I-Entity
-,O
treated,O
and,O
control,O
rats,O
.,O
Although,I-Entity
VE,I-Entity
had,O
a,O
similar,O
decrease,O
in,O
both,O
groups,O
",",O
in,O
the,O
epileptic,I-Entity
group,O
",",O
the,O
decrease,O
in,O
VE,I-Entity
was,O
due,O
to,O
a,O
significant,O
(,O
p,O
<,O
0.05,O
),O
increase,O
in,O
TE,I-Entity
peak,O
in,O
relation,O
to,O
that,O
of,O
the,O
control,O
animals,O
.,O
In,I-Entity
the,O
epileptic,I-Entity
group,O
",",O
the,O
increase,O
in,O
VE,I-Entity
was,O
mediated,O
by,O
a,O
significant,O
(,O
p,O
<,O
0.05,O
),O
decrease,O
in,O
TE,I-Entity
peak,O
compared,O
with,O
the,O
control,O
group,O
.,O
CONCLUSIONS,I-Entity
:,O
The,I-Entity
data,O
indicate,O
that,O
pilocarpine,I-Entity
-,O
treated,O
animals,O
have,O
an,O
altered,O
ability,O
to,O
react,O
to,O
(,O
or,O
compensate,O
for,O
),O
blood,O
gas,O
changes,O
with,O
changes,O
in,O
ventilation,O
and,O
suggest,O
that,O
it,O
is,O
centrally,O
determined,O
.,O
We,I-Entity
speculate,O
on,O
the,O
possible,O
relation,O
of,O
the,O
current,O
findings,O
on,O
treating,O
different,O
epilepsy,I-Entity
-,O
associated,O
conditions,O
.,O
Increased,I-Entity
serum,O
soluble,O
Fas,I-Entity
in,O
patients,O
with,O
acute,O
liver,I-Entity
failure,I-Entity
due,O
to,O
paracetamol,I-Entity
overdose,I-Entity
.,O
Experimental,I-Entity
studies,O
have,O
suggested,O
that,O
apoptosis,O
via,O
the,O
Fas,I-Entity
/,O
Fas,I-Entity
Ligand,I-Entity
signaling,O
system,O
may,O
play,O
an,O
important,O
role,O
in,O
the,O
development,O
of,O
acute,O
liver,I-Entity
failure,I-Entity
.,O
The,I-Entity
aim,O
of,O
the,O
study,O
was,O
to,O
investigate,O
the,O
soluble,O
form,O
of,O
Fas,I-Entity
in,O
patients,O
with,O
acute,O
liver,I-Entity
failure,I-Entity
.,O
METHODOLOGY,I-Entity
:,O
Serum,I-Entity
levels,O
of,O
sFas,I-Entity
(,O
soluble,O
Fas,I-Entity
),O
were,O
measured,O
by,O
ELISA,I-Entity
in,O
24,O
patients,O
with,O
acute,O
liver,I-Entity
failure,I-Entity
and,O
10,O
normal,O
control,O
subjects,O
.,O
Serum,I-Entity
levels,O
of,O
tumor,I-Entity
necrosis,I-Entity
factor,O
-,O
alpha,O
and,O
interferon,I-Entity
-,O
gamma,I-Entity
were,O
also,O
determined,O
by,O
ELISA,I-Entity
.,O
Serum,I-Entity
sFas,I-Entity
was,O
significantly,O
increased,O
in,O
patients,O
with,O
acute,O
liver,I-Entity
failure,I-Entity
(,O
median,O
",",O
26.8,O
U,I-Entity
/,O
mL,I-Entity
;,O
range,O
",",O
6.9,O
-,O
52.7,O
U,I-Entity
/,O
mL,I-Entity
),O
compared,O
to,O
the,O
normal,O
controls,O
(,O
median,O
",",O
8.6,O
U,I-Entity
/,O
mL,I-Entity
;,O
range,O
",",O
6.5,O
-,O
12.0,O
U,I-Entity
/,O
mL,I-Entity
",",O
P,I-Entity
<,O
0.0001,O
),O
.,O
Levels,I-Entity
were,O
significantly,O
greater,O
in,O
patients,O
with,O
acute,O
liver,I-Entity
failure,I-Entity
due,O
to,O
paracetamol,I-Entity
overdose,I-Entity
(,O
median,O
",",O
28.7,O
U,I-Entity
/,O
mL,I-Entity
;,O
range,O
",",O
12.8,O
-,O
52.7,O
U,I-Entity
/,O
mL,I-Entity
",",O
n,O
=,O
17,O
),O
than,O
those,O
due,O
to,O
non,O
-,O
A,I-Entity
to,O
E,I-Entity
hepatitis,I-Entity
(,O
median,O
",",O
12.5,O
U,I-Entity
/,O
mL,I-Entity
;,O
range,O
",",O
6.9,O
-,O
46.0,O
U,I-Entity
/,O
mL,I-Entity
",",O
A,I-Entity
significant,O
correlation,O
was,O
observed,O
between,O
serum,O
sFas,I-Entity
levels,O
and,O
aspartate,I-Entity
aminotransferase,O
(,O
r,O
=,O
0.613,O
",",O
P,I-Entity
<,O
0.01,O
),O
.,O
The,I-Entity
increased,O
concentration,O
of,O
sFas,I-Entity
in,O
serum,O
of,O
patients,O
with,O
acute,O
liver,I-Entity
failure,I-Entity
may,O
reflect,O
activation,O
of,O
Fas,I-Entity
-,O
mediated,O
apoptosis,O
in,O
the,O
liver,I-Entity
and,O
this,O
together,O
with,O
increased,O
tumor,I-Entity
necrosis,I-Entity
factor,O
-,O
alpha,O
may,O
be,O
an,O
important,O
factor,O
in,O
liver,I-Entity
cell,O
loss,I-Entity
.,O
Bilateral,I-Entity
subthalamic,O
nucleus,O
stimulation,O
for,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
.,O
High,I-Entity
frequency,O
stimulation,O
of,O
the,O
subthalamic,O
nucleus,O
(,O
STN,I-Entity
),O
is,O
known,O
to,O
ameliorate,O
the,O
signs,O
and,O
symptoms,O
of,O
advanced,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
.,O
METHOD,I-Entity
:,O
Twenty,I-Entity
-,O
three,O
patients,O
suffering,O
from,O
severe,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
(,O
Stages,I-Entity
III,I-Entity
-,O
V,I-Entity
on,O
Hoehn,I-Entity
and,O
Yahr,I-Entity
scale,O
),O
and,O
",",O
particularly,O
bradykinesia,I-Entity
",",O
rigidity,I-Entity
",",O
and,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
underwent,O
bilateral,O
implantation,O
of,O
electrodes,O
in,O
the,O
STN,I-Entity
.,O
Preoperative,I-Entity
and,O
postoperative,O
assessments,O
of,O
these,O
patients,O
at,O
1,O
",",O
3,O
",",O
6,O
and,O
12,O
months,O
follow,O
-,O
up,O
",",O
in,O
"""""""""",O
on,O
"""""""""",O
and,O
"""""""""",O
off,O
"""""""""",O
drug,O
conditions,O
",",O
was,O
carried,O
out,O
using,O
Unified,I-Entity
Parkinson,I-Entity
's,I-Entity
Disease,I-Entity
Rating,I-Entity
Scale,I-Entity
",",O
Hoehn,I-Entity
and,O
Yahr,I-Entity
staging,O
",",O
England,I-Entity
activities,O
of,O
daily,O
living,O
score,O
and,O
video,O
recordings,O
.,O
(,O
Unified,I-Entity
Parkinson,I-Entity
's,I-Entity
Disease,I-Entity
Rating,I-Entity
Scale,I-Entity
parts,O
II,I-Entity
and,O
III,I-Entity
),O
off,O
medication,O
improved,O
by,O
62%,O
and,O
61%,O
respectively,O
(,O
p<0.0005,O
),O
.,O
The,I-Entity
subscores,O
for,O
the,O
akinesia,I-Entity
",",O
rigidity,I-Entity
",",O
tremor,I-Entity
and,O
gait,O
also,O
improved,O
.,O
The,I-Entity
average,O
levodopa,I-Entity
dose,O
decreased,O
from,O
813,I-Entity
mg,O
to,O
359,I-Entity
mg,O
.,O
Bilateral,I-Entity
subthalamic,O
nucleus,O
stimulation,O
is,O
an,O
effective,O
treatment,O
for,O
advanced,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
.,O
It,I-Entity
reduces,O
the,O
severity,O
of,O
"""""""""",O
off,O
"""""""""",O
phase,O
symptoms,O
",",O
improves,O
the,O
axial,O
symptoms,O
and,O
reduces,O
levodopa,I-Entity
requirements,O
.,O
The,I-Entity
reduction,O
in,O
the,O
levodopa,I-Entity
dose,O
is,O
useful,O
in,O
controlling,O
drug,O
-,O
induced,O
dyskinesias,I-Entity
.,O
Ocular,I-Entity
motility,O
changes,O
after,O
subtenon,O
carboplatin,I-Entity
chemotherapy,O
for,O
retinoblastoma,I-Entity
.,O
Focal,I-Entity
subtenon,O
carboplatin,I-Entity
injections,O
have,O
recently,O
been,O
used,O
as,O
a,O
presumably,O
toxicity,I-Entity
-,O
free,O
adjunct,O
to,O
systemic,O
chemotherapy,O
for,O
intraocular,O
retinoblastoma,I-Entity
.,O
OBJECTIVE,I-Entity
:,O
To,I-Entity
report,O
our,O
clinical,O
experience,O
with,O
abnormal,I-Entity
ocular,O
motility,O
in,O
patients,O
treated,O
with,O
subtenon,O
carboplatin,I-Entity
chemotherapy,O
.,O
:,O
We,I-Entity
noted,O
abnormal,I-Entity
ocular,O
motility,O
in,O
10,O
consecutive,O
patients,O
with,O
retinoblastoma,I-Entity
who,O
had,O
received,O
subtenon,O
carboplatin,I-Entity
.,O
During,I-Entity
ocular,O
manipulation,O
under,O
general,O
anesthesia,O
",",O
we,O
assessed,O
their,O
eyes,O
by,O
forced,O
duction,I-Entity
testing,O
",",O
comparing,O
ocular,O
motility,O
after,O
tumor,I-Entity
control,O
with,O
ocular,O
motility,O
at,O
diagnosis,O
.,O
Limitation,I-Entity
of,O
ocular,O
motility,O
was,O
detected,O
in,O
all,O
12,O
eyes,O
of,O
10,O
patients,O
treated,O
for,O
intraocular,O
retinoblastoma,I-Entity
with,O
1,O
to,O
6,O
injections,O
of,O
subtenon,O
carboplatin,I-Entity
as,O
part,O
of,O
multimodality,O
therapy,O
.,O
Histopathological,I-Entity
examination,O
revealed,O
many,O
lipophages,O
in,O
the,O
periorbital,O
fat,I-Entity
surrounding,O
the,O
optic,O
nerve,O
in,O
1,O
eye,O
",",O
indicative,O
of,O
phagocytosis,I-Entity
of,O
previously,O
existing,O
fat,I-Entity
cells,O
and,O
suggesting,O
prior,O
fat,I-Entity
necrosis,I-Entity
.,O
The,I-Entity
enucleations,O
were,O
technically,O
difficult,O
and,O
hazardous,O
for,O
globe,O
rupture,I-Entity
because,O
of,O
extensive,O
orbital,O
soft,O
tissue,O
adhesions,O
.,O
Subtenon,I-Entity
carboplatin,I-Entity
chemotherapy,O
is,O
associated,O
with,O
significant,O
fibrosis,I-Entity
of,O
orbital,O
soft,O
tissues,O
",",O
leading,O
to,O
mechanical,O
restriction,O
of,O
eye,O
movements,O
and,O
making,O
subsequent,O
enucleation,O
difficult,O
.,O
Subtenon,I-Entity
carboplatin,I-Entity
is,O
not,O
free,O
of,O
toxicity,I-Entity
",",O
and,O
its,O
use,O
is,O
best,O
restricted,O
to,O
specific,O
indications,O
.,O
Ethambutol,I-Entity
and,O
optic,O
neuropathy,I-Entity
.,O
PURPOSE,I-Entity
:,O
To,I-Entity
demonstrate,O
the,O
association,O
between,O
ethambutol,I-Entity
and,O
optic,O
neuropathy,I-Entity
.,O
METHOD,I-Entity
:,O
Thirteen,I-Entity
patients,O
who,O
developed,O
optic,O
neuropathy,I-Entity
after,O
being,O
treated,O
with,O
ethambutol,I-Entity
for,O
tuberculosis,I-Entity
of,O
the,O
lung,O
or,O
lymph,I-Entity
node,O
at,O
Siriraj,I-Entity
Hospital,I-Entity
between,O
1997,O
and,O
2001,O
were,O
retrospectively,O
reviewed,O
.,O
RESULTS,I-Entity
:,O
All,I-Entity
patients,O
had,O
optic,O
neuropathy,I-Entity
between,O
1,O
to,O
6,O
months,O
(,O
mean,O
=,O
2.9,O
months,O
),O
after,O
starting,O
ethambutol,I-Entity
therapy,O
at,O
a,O
dosage,O
ranging,O
from,O
13,O
to,O
20,O
mg,O
/,O
kg,O
/,O
day,O
(,O
mean,O
=,O
17,O
mg,O
/,O
kg,O
/,O
day,O
),O
.,O
Of,I-Entity
6,O
patients,O
with,O
irreversible,O
visual,O
impairment,I-Entity
",",O
4,O
patients,O
had,O
diabetes,I-Entity
mellitus,I-Entity
",",O
glaucoma,I-Entity
and,O
a,O
history,O
of,O
heavy,O
smoking,I-Entity
.,O
CONCLUSION,I-Entity
:,O
Early,I-Entity
recognition,O
of,O
optic,O
neuropathy,I-Entity
should,O
be,O
considered,O
in,O
patients,O
with,O
ethambutol,I-Entity
therapy,O
.,O
A,I-Entity
low,O
dose,O
and,O
prompt,O
discontinuation,O
of,O
the,O
drug,O
is,O
recommended,O
particularly,O
in,O
individuals,O
with,O
diabetes,I-Entity
mellitus,I-Entity
",",O
glaucoma,I-Entity
or,O
who,O
are,O
heavy,O
smokers,I-Entity
.,O
Treatment,I-Entity
of,O
compensatory,O
gustatory,O
hyperhidrosis,I-Entity
with,O
topical,O
glycopyrrolate,I-Entity
.,O
Gustatory,I-Entity
hyperhidrosis,I-Entity
is,O
facial,O
sweating,I-Entity
usually,O
associated,O
with,O
the,O
eating,O
of,O
hot,O
spicy,I-Entity
food,O
or,O
even,O
smelling,O
this,O
food,O
.,O
Current,I-Entity
options,O
of,O
treatment,O
include,O
oral,O
anticholinergic,O
drugs,O
",",O
the,O
topical,O
application,O
of,O
anticholinergics,O
or,O
aluminum,I-Entity
chloride,I-Entity
",",O
and,O
the,O
injection,O
of,O
botulinum,I-Entity
toxin,I-Entity
.,O
Thirteen,I-Entity
patients,O
have,O
been,O
treated,O
to,O
date,O
with,O
1.5%,O
or,O
2%,O
topical,O
glycopyrrolate,I-Entity
.,O
All,I-Entity
patients,O
had,O
gustatory,O
hyperhidrosis,I-Entity
",",O
which,O
interfered,I-Entity
with,O
their,O
social,O
activities,O
",",O
after,O
transthroacic,O
endoscopic,O
sympathectomy,O
",",O
and,O
which,O
was,O
associated,O
with,O
compensatory,O
focal,O
hyperhidrosis,I-Entity
.,O
After,I-Entity
applying,O
topical,O
glycopyrrolate,I-Entity
",",O
the,O
subjective,O
effect,O
was,O
excellent,O
(,O
no,O
sweating,I-Entity
after,O
eating,O
hot,O
spicy,I-Entity
food,O
),O
in,O
10,O
patients,O
(,O
77%,O
),O
",",O
and,O
fair,O
(,O
clearly,O
reduced,O
sweating,I-Entity
),O
in,O
3,O
patients,O
(,O
23%,O
),O
.,O
Adverse,I-Entity
effects,O
included,O
a,O
mildly,O
dry,O
mouth,O
and,O
a,O
sore,I-Entity
throat,I-Entity
in,O
2,O
patients,O
(,O
2%,O
glycopyrrolate,I-Entity
),O
",",O
a,O
light,O
headache,I-Entity
in,O
1,O
patient,O
(,O
1.5%,O
glycopyrrolate,I-Entity
),O
.,O
The,I-Entity
topical,O
application,O
of,O
a,O
glycopyrrolate,I-Entity
pad,O
appeared,O
to,O
be,O
safe,O
",",O
efficacious,O
",",O
well,O
tolerated,O
",",O
and,O
a,O
convenient,O
method,O
of,O
treatment,O
for,O
moderate,O
to,O
severe,O
symptoms,O
of,O
gustatory,O
hyperhidrosis,I-Entity
in,O
post,O
transthoracic,O
endoscopic,O
sympathectomy,O
or,O
sympathicotomy,O
patients,O
",",O
with,O
few,O
side,O
effects,O
.,O
Pharmacological,I-Entity
characteristics,O
and,O
side,O
effects,O
of,O
a,O
new,O
galenic,O
formulation,O
of,O
propofol,I-Entity
without,O
soyabean,I-Entity
oil,O
.,O
We,I-Entity
compared,O
the,O
pharmacokinetics,O
",",O
pharmacodynamics,O
and,O
safety,O
profile,O
of,O
a,O
new,O
galenic,O
formulation,O
of,O
propofol,I-Entity
(,O
AM149,I-Entity
1%,O
),O
",",O
which,O
does,O
not,O
contain,O
soyabean,I-Entity
oil,O
",",O
with,O
a,O
standard,O
formulation,O
of,O
propofol,I-Entity
(,O
Disoprivan,I-Entity
1%,O
),O
.,O
In,I-Entity
a,O
randomised,O
",",O
double,O
-,O
blind,O
",",O
cross,O
-,O
over,O
study,O
",",O
30,O
healthy,O
volunteers,O
received,O
a,O
single,O
intravenous,O
bolus,O
injection,O
of,O
2.5,O
mg.kg-1,O
propofol,I-Entity
.,O
Plasma,I-Entity
propofol,I-Entity
levels,O
were,O
measured,O
for,O
48,I-Entity
h,O
following,O
drug,O
administration,O
and,O
evaluated,O
according,O
to,O
a,O
three,O
-,O
compartment,O
model,O
.,O
The,I-Entity
pharmacodynamic,O
parameters,O
assessed,O
included,O
induction,O
and,O
emergence,O
times,O
",",O
respiratory,O
and,O
cardiovascular,O
effects,O
",",O
and,O
pain,I-Entity
on,O
injection,O
.,O
Owing,I-Entity
to,O
a,O
high,O
incidence,O
of,O
thrombophlebitis,I-Entity
",",O
the,O
study,O
was,O
terminated,O
prematurely,O
and,O
only,O
the,O
data,O
of,O
the,O
two,O
parallel,I-Entity
treatment,O
groups,O
(,O
15,O
patients,O
in,O
each,O
group,O
),O
were,O
analysed,O
.,O
Pain,I-Entity
on,O
injection,O
(,O
80,O
vs.,O
20%,O
",",O
p,O
<,O
0.01,O
),O
and,O
thrombophlebitis,I-Entity
(,O
93.3,O
vs.,O
6.6%,O
",",O
p,O
<,O
0.001,O
),O
occurred,O
more,O
frequently,O
with,O
AM149,I-Entity
than,O
with,O
Disoprivan,I-Entity
.,O
Although,I-Entity
both,O
formulations,O
had,O
similar,O
pharmacokinetic,O
and,O
pharmacodynamic,O
profiles,O
the,O
new,O
formulation,O
is,O
not,O
suitable,O
for,O
clinical,O
use,O
due,O
to,O
the,O
high,O
incidence,O
of,O
thrombophlebitis,I-Entity
produced,O
.,O
Vinorelbine,I-Entity
-,O
related,O
cardiac,O
events,O
:,O
a,O
meta,O
-,O
analysis,O
of,O
randomized,O
clinical,O
trials,O
.,O
Several,I-Entity
cases,O
of,O
cardiac,O
adverse,O
reactions,O
related,O
to,O
vinorelbine,I-Entity
(,O
VNR,I-Entity
),O
have,O
been,O
reported,O
in,O
the,O
literature,O
.,O
In,I-Entity
order,O
to,O
quantify,O
the,O
incidence,O
of,O
these,O
cardiac,O
events,O
",",O
we,O
performed,O
a,O
meta,O
-,O
analysis,O
of,O
clinical,O
trials,O
comparing,O
VNR,I-Entity
with,O
other,O
chemotherapeutic,O
agents,O
in,O
the,O
treatment,O
of,O
various,O
malignancies,I-Entity
.,O
Randomized,I-Entity
clinical,O
trials,O
comparing,O
VNR,I-Entity
with,O
other,O
drugs,O
in,O
the,O
treatment,O
of,O
cancer,I-Entity
were,O
searched,O
in,O
Medline,I-Entity
",",O
Embase,I-Entity
",",O
Evidence,I-Entity
-,O
based,O
Medicine,I-Entity
Reviews,I-Entity
databases,O
and,O
the,O
Cochrane,I-Entity
library,O
from,O
1987,O
to,O
2002,O
.,O
We,I-Entity
found,O
19,O
trials,O
",",O
involving,O
2441,I-Entity
patients,O
treated,O
by,O
VNR,I-Entity
and,O
2050,I-Entity
control,O
patients,O
.,O
The,I-Entity
incidence,O
of,O
cardiac,O
events,O
with,O
VNR,I-Entity
was,O
1.19%,O
[,O
95%,O
confidence,O
interval,O
(,O
CI,I-Entity
),O
(,O
0.75,O
;,O
1.67,O
),O
],O
.,O
There,I-Entity
was,O
no,O
difference,O
in,O
the,O
risk,O
of,O
cardiac,O
events,O
between,O
VNR,I-Entity
and,O
other,O
drugs,O
[,O
odds,O
ratio,O
:,O
0.92,O
",",O
95%,O
CI,I-Entity
(,O
0.54,O
;,O
1.55,O
),O
],O
.,O
The,I-Entity
risk,O
of,O
VNR,I-Entity
cardiac,O
events,O
was,O
similar,O
to,O
vindesine,I-Entity
(,O
VDS,I-Entity
),O
and,O
other,O
cardiotoxic,I-Entity
drugs,O
[,O
fluorouracil,I-Entity
",",O
anthracyclines,I-Entity
",",O
gemcitabine,I-Entity
(,O
GEM,I-Entity
),O
em,O
leader,O
],O
.,O
Even,I-Entity
if,O
it,O
did,O
not,O
reach,O
statistical,O
significance,O
because,O
of,O
a,O
few,O
number,O
of,O
cases,O
",",O
the,O
risk,O
was,O
lower,O
in,O
trials,O
excluding,O
patients,O
with,O
cardiac,O
history,O
",",O
and,O
seemed,O
to,O
be,O
higher,O
in,O
trials,O
including,O
patients,O
with,O
pre,O
-,O
existing,O
cardiac,O
diseases,I-Entity
.,O
Vinorelbine,I-Entity
-,O
related,O
cardiac,O
events,O
concern,O
about,O
1%,O
of,O
treated,O
patients,O
in,O
clinical,O
trials,O
.,O
However,I-Entity
",",O
the,O
risk,O
associated,O
with,O
VNR,I-Entity
seems,O
to,O
be,O
similar,O
to,O
that,O
of,O
other,O
chemotherapeutic,O
agents,O
in,O
the,O
same,O
indications,O
.,O
MRI,I-Entity
findings,O
of,O
hypoxic,I-Entity
cortical,O
laminar,O
necrosis,I-Entity
in,O
a,O
child,O
with,O
hemolytic,I-Entity
anemia,I-Entity
crisis,I-Entity
.,O
We,I-Entity
present,O
magnetic,O
resonance,O
imaging,O
findings,O
of,O
a,O
5-year,O
-,O
old,O
girl,O
who,O
had,O
a,O
rapidly,O
installing,O
hemolytic,I-Entity
anemia,I-Entity
crisis,I-Entity
induced,O
by,O
trimethoprim,I-Entity
-,O
sulfomethoxazole,I-Entity
",",O
resulting,O
in,O
cerebral,O
anoxia,I-Entity
leading,O
to,O
permanent,O
damage,O
.,O
Magnetic,I-Entity
Resonance,I-Entity
imaging,O
revealed,O
cortical,O
laminar,O
necrosis,I-Entity
in,O
arterial,O
border,O
zones,O
in,O
both,O
cerebral,O
hemispheres,O
",",O
ischemic,I-Entity
changes,O
in,O
subcortical,O
white,O
matter,O
of,O
left,O
cerebral,O
hemisphere,O
",",O
and,O
in,O
the,O
left,O
putamen,I-Entity
.,O
Although,I-Entity
cortical,O
laminar,O
necrosis,I-Entity
is,O
a,O
classic,O
entity,O
in,O
adulthood,O
related,O
to,O
conditions,O
of,O
energy,O
depletions,O
",",O
there,O
are,O
few,O
reports,O
available,O
in,O
children,O
.,O
The,I-Entity
natural,O
history,O
of,O
Vigabatrin,I-Entity
associated,O
visual,O
field,O
defects,O
in,O
patients,O
electing,O
to,O
continue,O
their,O
medication,O
.,O
PURPOSE,I-Entity
:,O
To,I-Entity
determine,O
the,O
natural,O
history,O
of,O
visual,O
field,O
defects,O
in,O
a,O
group,O
of,O
patients,O
known,O
to,O
have,O
Vigabatrin,I-Entity
-,O
associated,O
changes,O
who,O
elected,O
to,O
continue,O
the,O
medication,O
because,O
of,O
good,O
seizure,I-Entity
control,O
.,O
All,I-Entity
patients,O
taking,O
Vigabatrin,I-Entity
alone,O
or,O
in,O
combination,O
with,O
other,O
antiepileptic,O
drugs,O
for,O
at,O
least,O
5,O
years,O
(,O
range,O
5,O
-,O
12,O
years,O
),O
were,O
entered,O
into,O
a,O
visual,O
surveillance,O
programme,O
.,O
Following,I-Entity
already,O
published,O
methodology,O
(,O
Eye,I-Entity
2002,O
;,O
16;567,O
-,O
571,O
),O
monocular,O
mean,O
radial,O
degrees,O
(,O
MRDs,I-Entity
),O
to,O
the,O
I/4e,I-Entity
isopter,I-Entity
on,O
Goldmann,I-Entity
perimetry,O
was,O
calculated,O
for,O
the,O
right,O
eye,O
at,O
the,O
time,O
of,O
discovery,O
of,O
a,O
visual,O
field,O
defect,I-Entity
and,O
again,O
after,O
not,O
less,O
than,O
18,O
months,O
follow,O
-,O
up,O
.,O
Only,I-Entity
one,O
patient,O
demonstrated,O
a,O
deterioration,O
in,O
visual,O
field,O
during,O
the,O
study,O
period,O
and,O
discontinued,O
treatment,O
.,O
Established,I-Entity
visual,O
field,O
defects,O
presumed,O
to,O
be,O
due,O
to,O
Vigabatrin,I-Entity
therapy,O
did,O
not,O
usually,O
progress,O
in,O
spite,O
of,O
continuing,O
use,O
of,O
the,O
medication,O
.,O
These,I-Entity
data,O
give,O
support,O
to,O
the,O
hypothesis,O
that,O
the,O
pathogenesis,O
of,O
Vigabatrin,I-Entity
-,O
associated,O
visual,O
field,O
defects,O
may,O
be,O
an,O
idiosyncratic,O
adverse,O
drug,O
reaction,I-Entity
rather,O
than,O
dose,O
-,O
dependent,O
toxicity,I-Entity
.,O
Induction,I-Entity
of,O
rosaceiform,I-Entity
dermatitis,I-Entity
during,O
treatment,O
of,O
facial,O
inflammatory,O
dermatoses,I-Entity
with,O
tacrolimus,I-Entity
ointment,O
.,O
Tacrolimus,I-Entity
ointment,O
is,O
increasingly,O
used,O
for,O
anti,O
-,O
inflammatory,O
treatment,O
of,O
sensitive,I-Entity
areas,O
such,O
as,O
the,O
face,O
",",O
and,O
recent,O
observations,O
indicate,O
that,O
the,O
treatment,O
is,O
effective,O
in,O
steroid,I-Entity
-,O
aggravated,I-Entity
rosacea,I-Entity
and,O
perioral,O
dermatitis,I-Entity
.,O
We,I-Entity
report,O
on,O
rosaceiform,I-Entity
dermatitis,I-Entity
as,O
a,O
complication,O
of,O
treatment,O
with,O
tacrolimus,I-Entity
ointment,O
.,O
Six,I-Entity
adult,O
patients,O
with,O
inflammatory,O
facial,O
dermatoses,I-Entity
were,O
treated,O
with,O
tacrolimus,I-Entity
ointment,O
because,O
of,O
the,O
ineffectiveness,O
of,O
standard,O
treatments,O
.,O
Within,I-Entity
2,O
to,O
3,O
weeks,O
of,O
initially,O
effective,O
and,O
well,O
-,O
tolerated,O
treatment,O
",",O
3,O
patients,O
with,O
a,O
history,O
of,O
rosacea,I-Entity
and,O
1,O
with,O
a,O
history,O
of,O
acne,I-Entity
experienced,O
sudden,I-Entity
worsening,O
with,O
pustular,O
rosaceiform,I-Entity
lesions,O
.,O
In,I-Entity
1,O
patient,O
with,O
eyelid,O
eczema,I-Entity
",",O
rosaceiform,I-Entity
periocular,O
dermatitis,I-Entity
gradually,O
appeared,O
after,O
3,O
weeks,O
of,O
treatment,O
.,O
In,I-Entity
1,O
patient,O
with,O
atopic,O
dermatitis,I-Entity
",",O
telangiectatic,O
and,O
papular,I-Entity
rosacea,I-Entity
insidiously,I-Entity
appeared,O
after,O
5,O
months,O
of,O
treatment,O
.,O
Our,I-Entity
observations,O
suggest,O
that,O
the,O
spectrum,O
of,O
rosaceiform,I-Entity
dermatitis,I-Entity
as,O
a,O
complication,O
of,O
treatment,O
with,O
tacrolimus,I-Entity
ointment,O
is,O
heterogeneous,O
.,O
A,I-Entity
variety,O
of,O
factors,O
",",O
such,O
as,O
vasoactive,O
properties,O
of,O
tacrolimus,I-Entity
",",O
proliferation,O
of,O
Demodex,I-Entity
due,O
to,O
local,O
immunosuppression,O
",",O
and,O
the,O
occlusive,I-Entity
properties,O
of,O
the,O
ointment,O
",",O
may,O
be,O
involved,O
in,O
the,O
observed,O
phenomena,O
.,O
Structural,I-Entity
abnormalities,I-Entity
in,O
the,O
brains,O
of,O
human,O
subjects,O
who,O
use,O
methamphetamine,I-Entity
.,O
We,I-Entity
visualize,O
",",O
for,O
the,O
first,O
time,O
",",O
the,O
profile,O
of,O
structural,O
deficits,I-Entity
in,O
the,O
human,O
brain,O
associated,O
with,O
chronic,O
methamphetamine,I-Entity
(,O
MA,I-Entity
),O
abuse,I-Entity
.,O
Studies,I-Entity
of,O
human,O
subjects,O
who,O
have,O
used,O
MA,I-Entity
chronically,O
have,O
revealed,O
deficits,I-Entity
in,O
dopaminergic,O
and,O
serotonergic,I-Entity
systems,O
and,O
cerebral,O
metabolic,O
abnormalities,I-Entity
.,O
Using,I-Entity
magnetic,O
resonance,O
imaging,O
(,O
MRI,I-Entity
),O
and,O
new,O
computational,O
brain,O
-,O
mapping,O
techniques,O
",",O
we,O
determined,O
the,O
pattern,O
of,O
structural,O
brain,O
alterations,I-Entity
associated,O
with,O
chronic,O
MA,I-Entity
abuse,I-Entity
in,O
human,O
subjects,O
and,O
related,O
these,O
deficits,I-Entity
to,O
cognitive,O
impairment,I-Entity
.,O
We,I-Entity
used,O
high,O
-,O
resolution,O
MRI,I-Entity
and,O
surface,O
-,O
based,O
computational,O
image,O
analyses,O
to,O
map,O
regional,O
abnormalities,I-Entity
in,O
the,O
cortex,O
",",O
hippocampus,O
",",O
white,O
matter,O
",",O
and,O
ventricles,O
in,O
22,O
human,O
subjects,O
who,O
used,O
MA,I-Entity
and,O
21,O
age,O
-,O
matched,O
",",O
healthy,O
controls,O
.,O
Cortical,I-Entity
maps,O
revealed,O
severe,O
gray,O
-,O
matter,O
deficits,I-Entity
in,O
the,O
cingulate,O
",",O
limbic,O
",",O
and,O
paralimbic,O
cortices,I-Entity
of,O
MA,I-Entity
abusers,O
(,O
averaging,O
11.3%,O
below,O
control,O
;,O
On,I-Entity
average,O
",",O
MA,I-Entity
abusers,O
had,O
7.8%,O
smaller,O
hippocampal,O
volumes,O
than,O
control,O
subjects,O
(,O
p,O
<,O
0.01,O
;,O
left,O
",",O
p,O
=,O
0.01,O
;,O
right,O
",",O
p,O
<,O
0.05,O
),O
and,O
significant,O
white,O
-,O
matter,O
hypertrophy,I-Entity
(,O
7.0%,O
;,O
MRI,I-Entity
-,O
based,O
maps,O
suggest,O
that,O
chronic,O
methamphetamine,I-Entity
abuse,I-Entity
causes,O
a,O
selective,O
pattern,O
of,O
cerebral,O
deterioration,O
that,O
contributes,O
to,O
impaired,I-Entity
memory,O
performance,O
.,O
MA,I-Entity
may,O
selectively,O
damage,O
the,O
medial,O
temporal,O
lobe,O
and,O
",",O
consistent,O
with,O
metabolic,O
studies,O
",",O
the,O
cingulate,O
-,O
limbic,O
cortex,O
",",O
inducing,O
neuroadaptation,I-Entity
",",O
neuropil,I-Entity
reduction,O
",",O
or,O
cell,O
death,I-Entity
.,O
Prominent,I-Entity
white,O
-,O
matter,O
hypertrophy,I-Entity
may,O
result,O
from,O
altered,O
myelination,I-Entity
and,O
adaptive,O
glial,O
changes,O
",",O
including,O
gliosis,I-Entity
secondary,O
to,O
neuronal,O
damage,O
.,O
These,I-Entity
brain,O
substrates,O
may,O
help,O
account,O
for,O
the,O
symptoms,O
of,O
MA,I-Entity
abuse,I-Entity
",",O
providing,O
therapeutic,O
targets,O
for,O
drug,O
-,O
induced,O
brain,O
injury,I-Entity
.,O
Disruption,I-Entity
of,O
hepatic,B-Entity
lipid,O
homeostasis,I-Entity
in,O
mice,O
after,O
amiodarone,I-Entity
treatment,O
is,O
associated,O
with,O
peroxisome,I-Entity
proliferator,O
-,O
activated,O
receptor,O
-,O
alpha,O
target,O
gene,O
activation,O
.,O
Amiodarone,I-Entity
",",O
an,O
efficacious,O
and,O
widely,O
used,O
antiarrhythmic,O
agent,O
",",O
has,O
been,O
reported,O
to,O
cause,O
hepatotoxicity,I-Entity
in,O
some,O
patients,O
.,O
To,I-Entity
gain,O
insight,O
into,O
the,O
mechanism,O
of,O
this,O
unwanted,O
effect,O
",",O
mice,O
were,O
administered,O
various,O
doses,O
of,O
amiodarone,I-Entity
and,O
examined,O
for,O
changes,O
in,O
hepatic,B-Entity
histology,O
and,O
gene,O
regulation,O
.,O
Amiodarone,I-Entity
induced,O
hepatomegaly,I-Entity
",",O
hepatocyte,O
microvesicular,I-Entity
lipid,O
accumulation,O
",",O
and,O
a,O
significant,O
decrease,O
in,O
serum,O
triglycerides,I-Entity
and,O
glucose,O
.,O
Northern,I-Entity
blot,O
analysis,O
of,O
hepatic,B-Entity
RNA,I-Entity
revealed,O
a,O
dose,O
-,O
dependent,O
increase,O
in,O
the,O
expression,O
of,O
a,O
number,O
of,O
genes,O
critical,O
for,O
fatty,B-Entity
acid,O
oxidation,I-Entity
",",O
lipoprotein,O
assembly,O
",",O
and,O
lipid,O
transport,O
.,O
The,I-Entity
absence,O
of,O
induction,O
of,O
these,O
genes,O
as,O
well,O
as,O
hepatomegaly,I-Entity
in,O
PPARalpha,I-Entity
knockout,O
[,O
PPARalpha-/-,I-Entity
],O
mice,O
indicated,O
that,O
the,O
effects,O
of,O
amiodarone,I-Entity
were,O
dependent,O
upon,O
the,O
presence,O
of,O
a,O
functional,O
PPARalpha,I-Entity
gene,O
.,O
Compared,I-Entity
to,O
wild,O
-,O
type,O
mice,O
",",O
treatment,O
of,O
PPARalpha-/-,I-Entity
mice,O
with,O
amiodarone,I-Entity
resulted,O
in,O
an,O
increased,O
rate,O
and,O
extent,O
of,O
total,O
body,O
weight,O
loss,I-Entity
.,O
The,I-Entity
inability,I-Entity
of,O
amiodarone,I-Entity
to,O
directly,O
activate,O
either,O
human,O
or,O
mouse,O
PPARalpha,I-Entity
transiently,O
expressed,O
in,O
human,O
HepG2,I-Entity
hepatoma,I-Entity
cells,O
indicates,O
that,O
the,O
effects,O
of,O
amiodarone,I-Entity
on,O
the,O
function,O
of,O
this,O
receptor,O
were,O
indirect,O
.,O
Based,I-Entity
upon,O
these,O
results,O
",",O
we,O
conclude,O
that,O
amiodarone,I-Entity
disrupts,I-Entity
hepatic,B-Entity
lipid,O
homeostasis,I-Entity
and,O
that,O
the,O
increased,O
expression,O
of,O
PPARalpha,I-Entity
target,O
genes,O
is,O
secondary,O
to,O
this,O
toxic,I-Entity
effect,O
.,O
These,I-Entity
results,O
provide,O
important,O
new,O
mechanistic,O
information,O
regarding,O
the,O
hepatotoxic,I-Entity
effects,O
of,O
amiodarone,I-Entity
and,O
indicate,O
that,O
PPARalpha,I-Entity
protects,O
against,O
amiodarone,I-Entity
-,O
induced,O
hepatotoxicity,I-Entity
.,O
Safety,I-Entity
and,O
compliance,O
with,O
once,O
-,O
daily,O
niacin,I-Entity
extended,O
-,O
release,O
/,O
lovastatin,I-Entity
as,O
initial,O
therapy,O
in,O
the,O
Impact,I-Entity
of,O
Medical,I-Entity
Subspecialty,I-Entity
on,O
Patient,I-Entity
Compliance,I-Entity
to,O
Treatment,I-Entity
(,O
IMPACT,I-Entity
),O
study,O
.,O
Niacin,I-Entity
extended,O
-,O
release,O
/,O
lovastatin,I-Entity
is,O
a,O
new,O
combination,O
product,O
approved,O
for,O
treatment,O
of,O
primary,O
hypercholesterolemia,I-Entity
and,O
mixed,O
dyslipidemia,I-Entity
.,O
This,I-Entity
open,O
-,O
labeled,O
",",O
multicenter,O
study,O
evaluated,O
the,O
safety,O
of,O
bedtime,O
niacin,I-Entity
extended,O
-,O
release,O
/,O
lovastatin,I-Entity
when,O
dosed,O
as,O
initial,O
therapy,O
and,O
patient,O
compliance,O
to,O
treatment,O
in,O
various,O
clinical,O
practice,O
settings,O
.,O
A,I-Entity
total,O
of,O
"4,499",O
patients,O
with,O
dyslipidemia,I-Entity
requiring,O
drug,O
intervention,O
was,O
enrolled,O
at,O
"1,081",O
sites,O
.,O
Patients,I-Entity
were,O
treated,O
with,O
1,O
tablet,O
(,O
500,O
mg,O
of,O
niacin,I-Entity
extended,O
-,O
release/20,O
mg,O
of,O
lovastatin,I-Entity
),O
once,O
nightly,O
for,O
4,O
weeks,O
and,O
then,O
2,O
tablets,O
for,O
8,O
weeks,O
.,O
Patients,I-Entity
also,O
received,O
dietary,O
counseling,O
",",O
educational,O
materials,O
",",O
and,O
reminders,O
to,O
call,O
a,O
toll,O
-,O
free,O
number,O
that,O
provided,O
further,O
education,O
about,O
dyslipidemia,I-Entity
and,O
niacin,I-Entity
extended,O
-,O
release,O
/,O
lovastatin,I-Entity
.,O
Primary,I-Entity
end,O
points,O
were,O
study,O
compliance,O
",",O
increases,O
in,O
liver,I-Entity
transaminases,O
to,O
>,O
3,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
",",O
and,O
clinical,O
myopathy,I-Entity
.,O
Compliance,I-Entity
to,O
niacin,I-Entity
extended,O
-,O
release,O
/,O
lovastatin,I-Entity
was,O
77%,O
",",O
with,O
"3,245",O
patients,O
completing,O
the,O
study,O
.,O
Flushing,I-Entity
was,O
the,O
most,O
common,O
adverse,O
event,O
",",O
reported,O
by,O
18%,O
of,O
patients,O
and,O
leading,O
to,O
discontinuation,O
by,O
6%,O
.,O
Incidence,I-Entity
of,O
increased,O
aspartate,I-Entity
aminotransferase,O
and/or,O
alanine,I-Entity
aminotransferase,O
>,O
3,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
was,O
<,O
0.3%,O
.,O
An,I-Entity
increase,O
of,O
creatine,I-Entity
phosphokinase,O
to,O
>,O
5,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
occurred,O
in,O
0.24%,O
of,O
patients,O
",",O
and,O
no,O
cases,O
of,O
drug,O
-,O
induced,O
myopathy,I-Entity
were,O
observed,O
.,O
Niacin,I-Entity
extended,O
-,O
release,O
/,O
lovastatin,I-Entity
"1,000/40",I-Entity
mg,O
",",O
dosed,O
as,O
initial,O
therapy,O
",",O
was,O
associated,O
with,O
good,O
compliance,O
and,O
safety,O
and,O
had,O
very,O
low,O
incidences,O
of,O
increased,O
liver,I-Entity
and,O
muscle,O
enzymes,O
.,O
Protective,I-Entity
effect,O
of,O
Terminalia,I-Entity
chebula,I-Entity
against,O
experimental,O
myocardial,B-Entity
injury,I-Entity
induced,O
by,O
isoproterenol,I-Entity
.,O
Cardioprotective,I-Entity
effect,O
of,O
ethanolic,I-Entity
extract,O
of,O
Terminalia,I-Entity
chebula,I-Entity
fruits,I-Entity
(,O
500,O
mg,O
/,O
kg,O
body,O
wt,O
),O
was,O
examined,O
in,O
isoproterenol,I-Entity
(,O
200,O
mg,O
/,O
kg,O
body,O
wt,O
),O
induced,O
myocardial,B-Entity
damage,O
in,O
rats,O
.,O
In,I-Entity
isoproterenol,I-Entity
administered,O
rats,O
",",O
the,O
level,O
of,O
lipid,O
peroxides,I-Entity
increased,O
significantly,O
in,O
the,O
serum,O
and,O
heart,O
.,O
Histopathological,I-Entity
examination,O
was,O
carried,O
out,O
to,O
confirm,O
the,O
myocardial,B-Entity
necrosis,I-Entity
.,O
T.,I-Entity
chebula,I-Entity
extract,O
pretreatment,O
was,O
found,O
to,O
ameliorate,O
the,O
effect,O
of,O
isoproterenol,I-Entity
on,O
lipid,O
peroxide,I-Entity
formation,O
and,O
retained,O
the,O
activities,O
of,O
the,O
diagnostic,O
marker,O
enzymes,O
.,O
A,I-Entity
case,O
of,O
postoperative,O
anxiety,I-Entity
due,O
to,O
low,O
dose,O
droperidol,I-Entity
used,O
with,O
patient,O
-,O
controlled,O
analgesia,O
.,O
Postoperatively,I-Entity
",",O
she,O
was,O
given,O
a,O
patient,O
-,O
controlled,O
analgesia,O
device,O
delivering,O
boluses,I-Entity
of,O
diamorphine,I-Entity
0.5,O
mg,O
and,O
droperidol,I-Entity
0.025,O
mg,O
.,O
The,I-Entity
diagnosis,O
of,O
droperidol,I-Entity
-,O
induced,O
psychological,O
disturbance,I-Entity
was,O
not,O
made,O
straight,O
away,O
although,O
on,O
subsequent,O
close,O
questioning,O
the,O
patient,O
gave,O
a,O
very,O
clear,O
history,O
.,O
After,I-Entity
she,O
had,O
received,O
a,O
total,O
of,O
only,O
0.9,O
mg,O
droperidol,I-Entity
",",O
a,O
syringe,O
containing,O
diamorphine,I-Entity
only,O
was,O
substituted,O
and,O
her,O
unease,I-Entity
resolved,O
completely,O
.,O
Accurate,I-Entity
patient,O
history,O
contributes,O
to,O
differentiating,O
diabetes,I-Entity
insipidus,I-Entity
:,O
a,O
case,O
study,O
.,O
The,I-Entity
case,O
discussed,O
herein,O
initially,O
appeared,O
to,O
be,O
neurogenic,I-Entity
diabetes,I-Entity
insipidus,I-Entity
(,O
DI,I-Entity
),O
secondary,O
to,O
a,O
traumatic,I-Entity
brain,O
injury,I-Entity
.,O
The,I-Entity
nursing,O
staff,O
",",O
by,O
reviewing,O
the,O
patient,O
's,I-Entity
health,O
history,O
with,O
his,O
family,O
",",O
discovered,O
a,O
history,O
of,O
polydipsia,I-Entity
and,O
long,O
-,O
standing,O
lithium,I-Entity
use,O
.,O
Lithium,I-Entity
is,O
implicated,O
in,O
drug,O
-,O
induced,O
nephrogenic,I-Entity
DI,I-Entity
",",O
and,O
because,O
the,O
patient,O
had,O
not,O
received,O
lithium,I-Entity
since,O
being,O
admitted,O
to,O
the,O
hospital,O
",",O
his,O
treatment,O
changed,O
to,O
focus,O
on,O
nephrogenic,I-Entity
DI,I-Entity
.,O
By,I-Entity
combining,O
information,O
from,O
the,O
patient,O
history,O
",",O
the,O
physical,O
examination,O
",",O
and,O
radiologic,O
and,O
laboratory,O
studies,O
",",O
the,O
critical,O
care,O
team,O
demonstrated,O
that,O
the,O
patient,O
had,O
been,O
self,O
-,O
treating,O
his,O
lithium,I-Entity
-,O
induced,O
nephrogenic,I-Entity
DI,I-Entity
and,O
developed,O
neurogenic,I-Entity
DI,I-Entity
secondary,O
to,O
brain,O
trauma,I-Entity
.,O
Thus,I-Entity
successful,O
treatment,O
required,O
that,O
nephrogenic,I-Entity
and,O
neurogenic,I-Entity
DI,I-Entity
be,O
treated,O
concomitantly,O
.,O
Factors,I-Entity
contributing,O
to,O
ribavirin,I-Entity
-,O
induced,O
anemia,I-Entity
.,O
Interferon,I-Entity
and,O
ribavirin,I-Entity
combination,O
therapy,O
for,O
chronic,O
hepatitis,I-Entity
C,I-Entity
produces,O
hemolytic,I-Entity
anemia,I-Entity
.,O
This,I-Entity
study,O
was,O
conducted,O
to,O
identify,O
the,O
factors,O
contributing,O
to,O
ribavirin,I-Entity
-,O
induced,O
anemia,I-Entity
.,O
METHODS,I-Entity
:,O
Eighty,I-Entity
-,O
eight,O
patients,O
with,O
chronic,O
hepatitis,I-Entity
C,I-Entity
who,O
received,O
interferon,I-Entity
-,O
alpha-2b,B-Entity
at,O
a,O
dose,O
of,O
6,O
MU,I-Entity
administered,O
intramuscularly,O
for,O
24,O
weeks,O
in,O
combination,O
with,O
ribavirin,I-Entity
administered,O
orally,O
at,O
a,O
dose,O
of,O
600,O
mg,O
or,O
800,O
mg,O
participated,O
in,O
the,O
study,O
.,O
A,I-Entity
hemoglobin,O
concentration,O
of,O
<,O
10,O
g,O
/,O
dL,I-Entity
was,O
defined,O
as,O
ribavirin,I-Entity
-,O
induced,O
anemia,I-Entity
.,O
Ribavirin,I-Entity
-,O
induced,O
anemia,I-Entity
occurred,O
in,O
18,O
(,O
20.5%,O
),O
patients,O
during,O
treatment,O
.,O
A,I-Entity
2,O
g,O
/,O
dL,I-Entity
decrease,O
in,O
hemoglobin,O
concentrations,O
in,O
patients,O
with,O
anemia,I-Entity
was,O
observed,O
at,O
week,O
2,O
after,O
the,O
start,O
of,O
treatment,O
.,O
A,I-Entity
significant,O
relationship,O
was,O
observed,O
between,O
the,O
rate,O
of,O
reduction,O
of,O
hemoglobin,O
concentrations,O
at,O
week,O
2,O
and,O
the,O
severity,O
of,O
anemia,I-Entity
(,O
P,I-Entity
<,O
0.01,O
),O
.,O
Such,I-Entity
factors,O
as,O
sex,O
(,O
female,O
),O
",",O
age,O
(,O
>,O
or,O
=,O
60,O
years,O
old,O
),O
",",O
and,O
the,O
ribavirin,I-Entity
dose,O
by,O
body,O
weight,O
(,O
12,O
mg,O
/,O
kg,O
or,O
more,O
),O
were,O
significant,O
by,O
univariate,O
analysis,O
.,O
Careful,I-Entity
administration,O
is,O
necessary,O
in,O
patients,O
>,O
or,O
=,O
60,O
years,O
old,O
",",O
in,O
female,O
patients,O
",",O
and,O
in,O
patients,O
receiving,O
a,O
ribavirin,I-Entity
dose,O
of,O
12,O
mg,O
/,O
kg,O
or,O
more,O
.,O
Oxidative,I-Entity
damage,O
precedes,O
nitrative,O
damage,O
in,O
adriamycin,I-Entity
-,O
induced,O
cardiac,O
mitochondrial,O
injury,I-Entity
.,O
The,I-Entity
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
determine,O
if,O
elevated,O
reactive,O
oxygen,I-Entity
(,O
ROS)/nitrogen,I-Entity
species,O
(,O
RNS,I-Entity
),O
reported,O
to,O
be,O
present,O
in,O
adriamycin,I-Entity
(,O
ADR)-induced,I-Entity
cardiotoxicity,I-Entity
actually,O
resulted,O
in,O
cardiomyocyte,O
B6C3,I-Entity
mice,O
were,O
treated,O
with,O
a,O
single,O
dose,O
of,O
20,O
mg,O
/,O
kg,O
ADR,I-Entity
.,O
Ultrastructural,I-Entity
damage,O
and,O
levels,O
of,O
4-hydroxy-2-nonenal,I-Entity
(,O
4HNE)-protein,I-Entity
adducts,O
and,O
3-nitrotyrosine,I-Entity
(,O
3NT,I-Entity
),O
were,O
analyzed,O
.,O
Analysis,I-Entity
of,O
4HNE,I-Entity
protein,O
adducts,O
by,O
immunogold,O
electron,O
microscopy,O
showed,O
appearance,O
of,O
4HNE,I-Entity
protein,O
adducts,O
in,O
mitochondria,O
as,O
early,O
as,O
3,O
hours,O
",",O
with,O
a,O
peak,O
at,O
6,O
hours,O
and,O
subsequent,O
decline,O
at,O
24,O
hours,O
.,O
3NT,I-Entity
levels,O
were,O
significantly,O
increased,O
in,O
all,O
subcellular,O
compartments,O
at,O
6,O
hours,O
and,O
subsequently,O
declined,O
at,O
24,O
hours,O
.,O
Our,I-Entity
data,O
showed,O
ADR,I-Entity
induced,O
4HNE,I-Entity
-,O
protein,O
adducts,O
in,O
mitochondria,O
at,O
the,O
same,O
time,O
point,O
as,O
when,O
mitochondrial,O
injury,I-Entity
initially,O
appeared,O
.,O
These,I-Entity
results,O
document,O
for,O
the,O
first,O
time,O
in,O
vivo,O
that,O
mitochondrial,O
oxidative,O
damage,O
precedes,O
nitrative,O
damage,O
.,O
The,I-Entity
progressive,O
nature,O
of,O
mitochondrial,O
injury,I-Entity
suggests,O
that,O
mitochondria,O
",",O
not,O
other,O
subcellular,O
organelles,O
",",O
are,O
the,O
major,O
site,O
of,O
intracellular,O
injury,I-Entity
.,O
Sotalol,I-Entity
-,O
induced,O
coronary,O
spasm,I-Entity
in,O
a,O
patient,O
with,O
dilated,O
cardiomyopathy,I-Entity
associated,O
with,O
sustained,O
ventricular,O
tachycardia,I-Entity
.,O
A,I-Entity
54-year,O
-,O
old,O
man,O
with,O
severe,O
left,O
ventricular,O
dysfunction,I-Entity
due,O
to,O
dilated,O
cardiomyopathy,I-Entity
was,O
referred,O
to,O
our,O
hospital,O
for,O
symptomatic,O
incessant,O
sustained,O
ventricular,O
tachycardia,I-Entity
(,O
VT,I-Entity
),O
.,O
After,I-Entity
the,O
administration,O
of,O
nifekalant,I-Entity
hydrochloride,I-Entity
",",O
sustained,O
VT,I-Entity
was,O
terminated,O
.,O
An,I-Entity
alternate,O
class,O
III,I-Entity
agent,O
",",O
sotalol,I-Entity
",",O
was,O
also,O
effective,O
for,O
the,O
prevention,O
of,O
VT,I-Entity
.,O
However,I-Entity
",",O
one,O
month,O
after,O
switching,O
over,O
nifekalant,I-Entity
to,O
sotalol,I-Entity
",",O
a,O
short,I-Entity
duration,O
of,O
ST,I-Entity
elevation,O
was,O
documented,O
in,O
ECG,I-Entity
monitoring,O
at,O
almost,O
the,O
same,O
time,O
for,O
three,O
consecutive,O
days,O
.,O
ST,I-Entity
elevation,O
with,O
chest,O
discomfort,I-Entity
disappeared,O
since,O
he,O
began,O
taking,O
long,O
-,O
acting,O
diltiazem,I-Entity
.,O
Coronary,I-Entity
vasospasm,I-Entity
may,O
be,O
induced,O
by,O
the,O
non,O
-,O
selective,O
beta,O
-,O
blocking,I-Entity
properties,O
of,O
sotalol,I-Entity
.,O
Effects,I-Entity
of,O
the,O
antidepressant,I-Entity
trazodone,I-Entity
",",O
a,O
5-HT,I-Entity
2A/2C,I-Entity
receptor,O
antagonist,O
",",O
on,O
dopamine,I-Entity
-,O
dependent,O
behaviors,O
in,O
rats,O
.,O
RATIONALE,I-Entity
:,O
5-Hydroxytryptamine,I-Entity
",",O
via,O
stimulation,O
of,O
5-HT,I-Entity
2C,I-Entity
receptors,O
",",O
exerts,I-Entity
a,O
tonic,I-Entity
inhibitory,O
influence,O
on,O
dopaminergic,O
neurotransmission,O
",",O
whereas,O
activation,O
of,O
5-HT,I-Entity
2A,I-Entity
receptors,O
enhances,O
stimulated,O
DAergic,I-Entity
neurotransmission,O
.,O
The,I-Entity
antidepressant,I-Entity
trazodone,I-Entity
is,O
a,O
5-HT,I-Entity
2A/2C,I-Entity
receptor,O
antagonist,O
.,O
OBJECTIVES,I-Entity
:,O
To,I-Entity
evaluate,O
the,O
effect,O
of,O
trazodone,I-Entity
treatment,O
on,O
behaviors,O
dependent,O
on,O
the,O
functional,O
status,O
of,O
the,O
nigrostriatal,O
DAergic,I-Entity
system,O
.,O
The,I-Entity
effect,O
of,O
pretreatment,O
with,O
trazodone,I-Entity
on,O
dexamphetamine-,I-Entity
and,O
apomorphine,I-Entity
-,O
induced,O
oral,O
stereotypies,O
",",O
on,O
catalepsy,I-Entity
induced,O
by,O
haloperidol,I-Entity
and,O
apomorphine,I-Entity
(,O
0.05,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
",",O
on,O
ergometrine,I-Entity
-,O
induced,O
wet,O
dog,O
shake,O
(,O
WDS,I-Entity
),O
behavior,O
and,O
fluoxetine,I-Entity
-,O
induced,O
penile,I-Entity
erections,I-Entity
was,O
studied,O
in,O
rats,O
.,O
We,I-Entity
also,O
investigated,O
whether,O
trazodone,I-Entity
induces,O
catalepsy,I-Entity
in,O
rats,O
.,O
Trazodone,I-Entity
at,O
2.5,O
-,O
20,O
mg,O
did,O
not,O
induce,O
catalepsy,I-Entity
",",O
and,O
did,O
not,O
antagonize,O
apomorphine,I-Entity
(,O
1.5,O
and,O
3,O
mg,O
/,O
kg,O
),O
stereotypy,O
and,O
apomorphine,I-Entity
(,O
0.05,O
mg,O
/,O
kg)-induced,O
catalepsy,I-Entity
.,O
trazodone,I-Entity
enhanced,O
dexamphetamine,I-Entity
stereotypy,O
",",O
and,O
antagonized,I-Entity
haloperidol,I-Entity
catalepsy,I-Entity
",",O
ergometrine,I-Entity
-,O
induced,O
WDS,I-Entity
behavior,O
and,O
fluoxetine,I-Entity
-,O
induced,O
penile,I-Entity
erections,I-Entity
.,O
Trazodone,I-Entity
at,O
30,O
",",O
40,O
and,O
50,O
mg,O
induced,O
catalepsy,I-Entity
and,O
antagonized,I-Entity
apomorphine,I-Entity
and,O
dexamphetamine,I-Entity
stereotypies,O
.,O
Our,I-Entity
results,O
indicate,O
that,O
trazodone,I-Entity
at,O
2.5,O
-,O
20,O
mg,O
/,O
kg,O
does,O
not,O
block,O
pre-,O
and,O
postsynaptic,O
striatal,O
D2,I-Entity
DA,I-Entity
receptors,O
",",O
while,O
at,O
30,O
",",O
40,O
and,O
50,O
mg,O
/,O
kg,O
it,O
blocks,O
postsynaptic,O
striatal,O
D2,I-Entity
DA,I-Entity
receptors,O
.,O
Furthermore,I-Entity
",",O
at,O
5,O
",",O
10,O
and,O
20,O
mg,O
/,O
kg,O
",",O
trazodone,I-Entity
blocks,O
5-HT,I-Entity
2A,I-Entity
and,O
5-HT,I-Entity
2C,I-Entity
receptors,O
.,O
We,I-Entity
suggest,O
that,O
trazodone,I-Entity
(,O
5,O
",",O
10,O
and,O
20,O
mg,O
/,O
kg,O
),O
",",O
by,O
blocking,I-Entity
the,O
5-HT,I-Entity
2C,I-Entity
receptors,O
",",O
releases,O
the,O
nigrostriatal,O
DAergic,I-Entity
neurons,O
from,O
tonic,I-Entity
inhibition,O
caused,O
by,O
5-HT,I-Entity
",",O
and,O
thereby,O
potentiates,O
dexamphetamine,I-Entity
stereotypy,O
and,O
antagonizes,I-Entity
haloperidol,I-Entity
catalepsy,I-Entity
.,O
Swallowing,I-Entity
abnormalities,I-Entity
and,O
dyskinesia,I-Entity
in,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
.,O
Gastrointestinal,I-Entity
abnormalities,I-Entity
in,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
have,O
been,O
known,O
for,O
almost,O
two,O
centuries,O
",",O
but,O
many,O
aspects,O
concerning,O
their,O
pathophysiology,O
have,O
not,O
been,O
completely,O
clarified,O
.,O
The,I-Entity
aim,O
of,O
this,O
study,O
was,O
to,O
characterize,O
the,O
oropharyngeal,O
dynamics,O
in,O
PD,I-Entity
patients,O
with,O
and,O
without,O
levodopa,I-Entity
-,O
induced,O
dyskinesia,I-Entity
.,O
Fifteen,I-Entity
dyskinetic,I-Entity
",",O
12,O
nondyskinetic,O
patients,O
",",O
and,O
a,O
control,O
group,O
were,O
included,O
.,O
Patients,I-Entity
were,O
asked,O
about,O
dysphagia,I-Entity
and,O
evaluated,O
with,O
the,O
Unified,I-Entity
Parkinson,I-Entity
's,I-Entity
Disease,I-Entity
Rating,I-Entity
Scale,I-Entity
Parts,I-Entity
II,I-Entity
and,O
III,I-Entity
and,O
the,O
Hoehn,I-Entity
and,O
Yahr,I-Entity
scale,O
.,O
Deglutition,I-Entity
was,O
assessed,O
using,O
modified,O
barium,I-Entity
swallow,O
with,O
videofluoroscopy,I-Entity
.,O
Nondyskinetic,I-Entity
patients,O
",",O
but,O
not,O
the,O
dyskinetic,I-Entity
ones,O
",",O
showed,O
less,O
oropharyngeal,O
swallowing,O
efficiency,O
(,O
OPSE,I-Entity
),O
for,O
liquid,O
food,O
than,O
controls,O
(,O
Dunnett,I-Entity
",",O
P,I-Entity
=,O
0.02,O
),O
.,O
Dyskinetic,I-Entity
patients,O
tended,O
to,O
have,O
a,O
greater,O
OPSE,I-Entity
than,O
nondyskinetic,O
(,O
Dunnett,I-Entity
",",O
P,I-Entity
=,O
0.06,O
),O
.,O
Patients,I-Entity
who,O
were,O
using,O
a,O
higher,O
dose,O
of,O
levodopa,I-Entity
had,O
a,O
greater,O
OPSE,I-Entity
and,O
a,O
trend,O
toward,O
a,O
smaller,O
oral,O
transit,O
time,O
(,O
Pearson,I-Entity
's,I-Entity
correlation,O
",",O
P,I-Entity
=,O
0.01,O
and,O
0.08,O
",",O
respectively,O
),O
.,O
Neither,I-Entity
the,O
report,O
of,O
dysphagia,I-Entity
nor,O
any,O
of,O
the,O
PD,I-Entity
severity,O
parameters,O
correlated,O
to,O
the,O
videofluoroscopic,O
variables,O
.,O
In,I-Entity
the,O
current,O
study,O
",",O
dyskinetic,I-Entity
patients,O
performed,O
better,O
in,O
swallowing,O
function,O
",",O
which,O
could,O
be,O
explained,O
on,O
the,O
basis,O
of,O
a,O
greater,O
levodopa,I-Entity
dose,O
.,O
Our,I-Entity
results,O
suggest,O
a,O
role,O
for,O
levodopa,I-Entity
in,O
the,O
oral,O
phase,O
of,O
deglutition,I-Entity
and,O
confirm,O
that,O
dysphagia,I-Entity
is,O
not,O
a,O
good,O
predictor,O
of,O
deglutition,I-Entity
alterations,I-Entity
in,O
PD,I-Entity
.,O
Inhibition,I-Entity
of,O
nuclear,O
factor,O
-,O
kappaB,I-Entity
activation,O
attenuates,O
tubulointerstitial,O
nephritis,I-Entity
induced,O
by,O
gentamicin,I-Entity
.,O
:,O
Animals,I-Entity
treated,O
with,O
gentamicin,I-Entity
can,O
show,O
residual,O
areas,O
of,O
interstitial,O
fibrosis,I-Entity
in,O
the,O
renal,O
cortex,O
.,O
kinases,O
and,O
macrophages,O
in,O
the,O
renal,O
cortex,O
and,O
structural,O
and,O
functional,O
renal,O
changes,O
of,O
rats,O
treated,O
with,O
gentamicin,I-Entity
or,O
gentamicin,I-Entity
+,O
pyrrolidine,I-Entity
dithiocarbamate,I-Entity
(,O
PDTC,I-Entity
),O
",",O
an,O
NF,I-Entity
-,O
kappaB,I-Entity
inhibitor,O
.,O
METHODS,I-Entity
:,O
38,O
female,O
Wistar,I-Entity
rats,O
were,O
injected,O
with,O
gentamicin,I-Entity
",",O
40,O
mg,O
/,O
kg,O
",",O
twice,O
a,O
day,O
for,O
9,O
days,O
",",O
38,O
with,O
gentamicin,I-Entity
+,O
PDTC,I-Entity
",",O
and,O
28,O
with,O
0.15,O
M,I-Entity
NaCl,I-Entity
solution,O
.,O
Gentamicin,I-Entity
-,O
treated,O
rats,O
presented,O
a,O
transitory,O
increase,O
in,O
plasma,O
creatinine,I-Entity
levels,O
.,O
Increased,I-Entity
ED-1,I-Entity
",",O
MAP,I-Entity
kinases,O
and,O
NF,I-Entity
-,O
kappaB,I-Entity
staining,I-Entity
were,O
also,O
observed,O
in,O
the,O
renal,O
cortex,O
from,O
all,O
gentamicin,I-Entity
-,O
treated,O
rats,O
compared,O
to,O
control,O
(,O
p,O
<,O
0.05,O
),O
.,O
The,I-Entity
animals,O
killed,O
on,O
day,O
30,O
also,O
presented,O
fibrosis,I-Entity
in,O
the,O
renal,O
cortex,O
despite,O
the,O
recovery,O
of,O
renal,O
function,O
.,O
Treatment,I-Entity
with,O
PDTC,I-Entity
reduced,O
the,O
functional,O
and,O
structural,O
changes,O
induced,O
by,O
gentamicin,I-Entity
.,O
These,I-Entity
data,O
show,O
that,O
inhibition,O
of,O
NF,I-Entity
-,O
kappaB,I-Entity
activation,O
attenuates,O
tubulointerstitial,O
nephritis,I-Entity
induced,O
by,O
gentamicin,I-Entity
.,O
Glucose,I-Entity
metabolism,O
in,O
patients,O
with,O
schizophrenia,I-Entity
treated,O
with,O
atypical,O
antipsychotic,O
agents,O
:,O
a,O
frequently,O
sampled,O
intravenous,O
glucose,O
tolerance,O
test,O
and,O
minimal,O
model,O
analysis,O
.,O
While,I-Entity
the,O
incidence,O
of,O
new,O
-,O
onset,O
diabetes,I-Entity
mellitus,I-Entity
may,O
be,O
increasing,O
in,O
patients,O
with,O
schizophrenia,I-Entity
treated,O
with,O
certain,O
atypical,O
antipsychotic,O
agents,O
",",O
it,O
remains,O
unclear,O
whether,O
atypical,O
agents,O
are,O
directly,O
affecting,O
glucose,O
metabolism,O
or,O
simply,O
increasing,O
known,O
risk,O
factors,O
for,O
diabetes,I-Entity
.,O
OBJECTIVE,I-Entity
:,O
To,I-Entity
study,O
the,O
2,O
drugs,O
most,O
clearly,O
implicated,O
(,O
clozapine,I-Entity
and,O
olanzapine,I-Entity
),O
and,O
risperidone,I-Entity
using,O
a,O
frequently,O
sampled,O
intravenous,O
glucose,O
tolerance,O
test,O
.,O
A,I-Entity
cross,O
-,O
sectional,O
design,O
in,O
stable,O
",",O
treated,O
patients,O
with,O
schizophrenia,I-Entity
evaluated,O
using,O
a,O
frequently,O
sampled,O
intravenous,O
glucose,O
tolerance,O
test,O
and,O
the,O
Bergman,I-Entity
minimal,O
model,O
analysis,O
.,O
Patients,I-Entity
Fifty,I-Entity
subjects,O
signed,O
informed,O
consent,O
and,O
41,O
underwent,O
the,O
frequently,O
sampled,O
intravenous,O
glucose,O
tolerance,O
test,O
.,O
Thirty,I-Entity
-,O
six,O
nonobese,I-Entity
subjects,O
with,O
schizophrenia,I-Entity
or,O
schizoaffective,I-Entity
disorder,I-Entity
",",O
matched,O
by,O
body,O
mass,O
index,O
and,O
treated,O
with,O
either,O
clozapine,I-Entity
",",O
olanzapine,I-Entity
",",O
or,O
risperidone,I-Entity
",",O
were,O
included,O
in,O
the,O
analysis,O
.,O
Fasting,I-Entity
plasma,O
glucose,O
and,O
fasting,O
serum,O
insulin,I-Entity
levels,O
",",O
insulin,I-Entity
sensitivity,O
index,O
",",O
homeostasis,I-Entity
model,O
assessment,O
of,O
insulin,I-Entity
resistance,O
",",O
and,O
glucose,O
effectiveness,O
.,O
28.9,O
months,O
(,O
clozapine,I-Entity
),O
",",O
29.5,O
+,O
/-,O
17.5,O
months,O
(,O
olanzapine,I-Entity
),O
",",O
and,O
40.9,O
+,O
/-,O
33.7,O
(,O
risperidone,I-Entity
),O
.,O
Fasting,I-Entity
serum,O
insulin,I-Entity
concentrations,O
differed,O
among,O
groups,O
(,O
F(33,I-Entity
),O
=,O
3.35,O
;,O
P,I-Entity
=,O
.047,O
),O
(,O
clozapine,I-Entity
>,O
olanzapine,I-Entity
>,O
risperidone,I-Entity
),O
with,O
significant,O
differences,O
between,O
clozapine,I-Entity
and,O
risperidone,I-Entity
(,O
t(33,O
),O
=,O
2.32,O
;,O
P,I-Entity
=,O
.03,O
),O
and,O
olanzapine,I-Entity
and,O
risperidone,I-Entity
(,O
t(33,O
),O
=,O
2.15,O
;,O
P,I-Entity
=,O
.04,O
),O
.,O
There,I-Entity
was,O
a,O
significant,O
difference,O
in,O
insulin,I-Entity
sensitivity,O
index,O
among,O
groups,O
(,O
F(33,I-Entity
),O
=,O
10.66,O
;,O
P<.001,I-Entity
),O
(,O
clozapine,I-Entity
<,O
olanzapine,I-Entity
<,O
risperidone,I-Entity
),O
",",O
with,O
subjects,O
who,O
received,O
clozapine,I-Entity
and,O
olanzapine,I-Entity
exhibiting,O
significant,O
insulin,I-Entity
resistance,O
compared,O
with,O
subjects,O
who,O
were,O
treated,O
with,O
risperidone,I-Entity
(,O
clozapine,I-Entity
vs,O
risperidone,I-Entity
",",O
t(33,O
),O
=,O
-4.29,O
;,O
P<.001,I-Entity
;,O
olanzapine,I-Entity
vs,O
risperidone,I-Entity
",",O
t(33,O
),O
=,O
-3.62,O
;,O
P,I-Entity
=,O
.001,O
[,O
P<.001,I-Entity
],O
),O
.,O
The,I-Entity
homeostasis,I-Entity
model,O
assessment,O
of,O
insulin,I-Entity
resistance,O
also,O
differed,O
significantly,O
among,O
groups,O
(,O
F(33,I-Entity
),O
=,O
4.92,O
;,O
P,I-Entity
=,O
.01,O
),O
(,O
clozapine,I-Entity
>,O
olanzapine,I-Entity
>,O
risperidone,I-Entity
),O
(,O
clozapine,I-Entity
vs,O
risperidone,I-Entity
",",O
t(33,O
),O
=,O
2.94,O
;,O
P,I-Entity
=,O
.006,I-Entity
;,O
olanzapine,I-Entity
vs,O
risperidone,I-Entity
",",O
t(33,O
),O
=,O
2.42,O
;,O
P,I-Entity
=,O
.02,O
),O
.,O
There,I-Entity
was,O
a,O
significant,O
difference,O
among,O
groups,O
in,O
glucose,O
effectiveness,O
(,O
F(30,I-Entity
),O
=,O
4.18,O
;,O
P,I-Entity
=,O
.02,O
),O
(,O
clozapine,I-Entity
<,O
olanzapine,I-Entity
<,O
risperidone,I-Entity
),O
with,O
significant,O
differences,O
between,O
clozapine,I-Entity
and,O
risperidone,I-Entity
(,O
t(30,I-Entity
),O
=,O
-2.59,O
;,O
P,I-Entity
=,O
.02,O
),O
and,O
olanzapine,I-Entity
and,O
risperidone,I-Entity
(,O
t(30,I-Entity
),O
=,O
-2.34,O
",",O
P,I-Entity
=,O
.03,O
),O
.,O
Both,I-Entity
nonobese,I-Entity
clozapine-,I-Entity
and,O
olanzapine,I-Entity
-,O
treated,O
groups,O
displayed,O
significant,O
insulin,I-Entity
resistance,O
and,O
impairment,I-Entity
of,O
glucose,O
effectiveness,O
compared,O
with,O
risperidone,I-Entity
-,O
treated,O
subjects,O
.,O
Patients,I-Entity
taking,O
clozapine,I-Entity
and,O
olanzapine,I-Entity
must,O
be,O
examined,O
for,O
insulin,I-Entity
resistance,O
and,O
its,O
consequences,O
.,O
Focal,I-Entity
cerebral,O
ischemia,I-Entity
in,O
rats,O
:,O
effect,O
of,O
phenylephrine,I-Entity
-,O
induced,O
hypertension,I-Entity
during,O
reperfusion,O
.,O
After,I-Entity
180,I-Entity
min,O
of,O
temporary,O
middle,O
cerebral,O
artery,I-Entity
occlusion,I-Entity
in,O
spontaneously,O
hypertensive,I-Entity
rats,O
",",O
the,O
effect,O
of,O
phenylephrine,I-Entity
-,O
induced,O
hypertension,I-Entity
on,O
ischemic,I-Entity
brain,O
injury,I-Entity
and,O
blood,O
-,O
brain,O
barrier,O
permeability,O
was,O
determined,O
.,O
Blood,I-Entity
pressure,O
was,O
manipulated,O
by,O
one,O
of,O
the,O
following,O
schedules,O
during,O
120,I-Entity
min,O
of,O
reperfusion,O
:,O
Control,I-Entity
",",O
normotensive,I-Entity
reperfusion,O
;,O
90/hypertension,I-Entity
(,O
90/HTN,I-Entity
),O
",",O
blood,O
pressure,O
was,O
increased,O
by,O
35,O
mm,O
Hg,I-Entity
during,O
the,O
initial,O
90,I-Entity
min,O
of,O
reperfusion,O
only,O
;,O
15/hypertension,O
(,O
15/HTN,I-Entity
),O
",",O
normotensive,I-Entity
reperfusion,O
for,O
30,O
min,O
followed,O
by,O
15,O
min,O
of,O
hypertension,I-Entity
and,O
75,O
min,O
of,O
normotension,I-Entity
.,O
Part,I-Entity
A,I-Entity
",",O
for,O
eight,O
rats,O
in,O
each,O
group,O
brain,O
injury,I-Entity
was,O
evaluated,O
by,O
staining,I-Entity
tissue,O
using,O
"2,3,5-triphenyltetrazolium",I-Entity
chloride,I-Entity
and,O
edema,I-Entity
was,O
evaluated,O
by,O
microgravimetry,O
.,O
Brain,I-Entity
injury,I-Entity
(,O
percentage,O
of,O
the,O
ischemic,I-Entity
hemisphere,O
),O
was,O
less,O
in,O
the,O
15/HTN,I-Entity
group,O
(,O
16,O
+,O
/-,O
SD,I-Entity
),O
versus,O
the,O
90/HTN,I-Entity
group,O
(,O
30,O
+,O
/-,O
Specific,I-Entity
gravity,O
was,O
greater,O
in,O
the,O
15/HTN,I-Entity
group,O
(,O
1.043,O
+,O
/-,O
0.002,O
),O
versus,O
the,O
90/HTN,I-Entity
(,O
1.036,O
+,O
/-,O
0.003,O
),O
and,O
control,O
(,O
1.037,O
+,O
/-,O
Evans,I-Entity
Blue,I-Entity
(,O
mug,O
g-1,O
of,O
brain,O
tissue,O
),O
was,O
greater,O
in,O
the,O
90/HTN,I-Entity
group,O
(,O
24.4,O
+,O
/-,O
4.1,O
),O
",",O
which,O
was,O
in,O
turn,O
greater,O
than,O
the,O
15/HTN,I-Entity
group,O
(,O
7.3,O
+,O
/-,O
This,I-Entity
study,O
supports,O
a,O
hypothesis,O
that,O
during,O
reperfusion,O
",",O
a,O
short,I-Entity
interval,O
of,O
hypertension,I-Entity
decreases,O
brain,O
injury,I-Entity
and,O
edema,I-Entity
;,O
and,O
that,O
sustained,O
hypertension,I-Entity
increases,O
the,O
risk,O
of,O
vasogenic,O
edema,I-Entity
.,O
People,I-Entity
aged,O
over,O
75,O
in,O
atrial,I-Entity
fibrillation,I-Entity
on,O
warfarin,I-Entity
:,O
the,O
rate,O
of,O
major,O
hemorrhage,I-Entity
and,O
stroke,O
in,O
more,O
than,O
500,O
patient,O
-,O
years,O
of,O
follow,O
-,O
up,O
.,O
OBJECTIVES,I-Entity
:,O
To,I-Entity
determine,O
the,O
incidence,O
of,O
major,O
hemorrhage,I-Entity
and,O
stroke,O
in,O
people,O
aged,O
76,I-Entity
and,O
older,O
with,O
atrial,I-Entity
fibrillation,I-Entity
on,O
adjusted,O
-,O
dose,O
warfarin,I-Entity
who,O
had,O
been,O
recently,O
been,O
admitted,O
to,O
hospital,O
.,O
Two,I-Entity
hundred,O
thirty,O
-,O
five,O
patients,O
aged,O
76,I-Entity
and,O
older,O
admitted,O
to,O
a,O
major,O
healthcare,O
network,O
between,O
July,I-Entity
1,O
",",O
2001,O
",",O
and,O
June,I-Entity
30,O
",",O
2002,O
",",O
with,O
atrial,I-Entity
fibrillation,I-Entity
on,O
warfarin,I-Entity
were,O
enrolled,O
.,O
Information,I-Entity
regarding,O
major,O
bleeding,I-Entity
episodes,O
",",O
strokes,O
",",O
and,O
warfarin,I-Entity
use,O
was,O
obtained,O
from,O
patients,O
",",O
relatives,O
",",O
primary,O
physicians,O
",",O
and,O
medical,O
records,I-Entity
.,O
Total,I-Entity
follow,O
-,O
up,O
on,O
warfarin,I-Entity
was,O
530,O
years,O
(,O
mean,O
28,O
months,O
),O
.,O
There,I-Entity
were,O
53,I-Entity
major,O
hemorrhages,I-Entity
",",O
for,O
an,O
annual,O
rate,O
of,O
10.0%,O
",",O
including,O
24,O
(,O
45.3%,O
),O
life,O
-,O
threatening,I-Entity
and,O
five,O
(,O
9.4%,O
),O
fatal,O
bleeds,I-Entity
.,O
The,I-Entity
annual,O
stroke,O
rate,O
after,O
initiation,O
of,O
warfarin,I-Entity
was,O
2.6%,O
.,O
The,I-Entity
rate,O
of,O
major,O
hemorrhage,I-Entity
was,O
high,O
in,O
this,O
old,O
",",O
frail,I-Entity
group,O
",",O
but,O
excluding,O
fatalities,O
",",O
resulted,O
in,O
no,O
long,O
-,O
term,O
sequelae,O
",",O
and,O
the,O
stroke,O
rate,O
on,O
warfarin,I-Entity
was,O
low,O
",",O
demonstrating,O
how,O
effective,O
warfarin,I-Entity
treatment,O
is,O
.,O
Safety,I-Entity
of,O
celecoxib,I-Entity
in,O
patients,O
with,O
adverse,O
skin,O
reactions,O
to,O
acetaminophen,I-Entity
(,O
paracetamol,I-Entity
),O
and,O
nimesulide,I-Entity
associated,O
or,O
not,O
with,O
common,O
non,O
-,O
steroidal,I-Entity
anti,O
-,O
inflammatory,O
drugs,O
.,O
BACKGROUND,I-Entity
:,O
Acetaminophen,I-Entity
(,O
paracetamol,I-Entity
--,O
P,I-Entity
),O
and,O
Nimesulide,I-Entity
(,O
N,I-Entity
),O
are,O
widely,O
used,O
analgesic,O
-,O
antipyretic,O
/,O
anti,O
-,O
inflammatory,O
drugs,O
.,O
The,I-Entity
rate,O
of,O
adverse,O
hypersensitivity,I-Entity
reactions,O
to,O
these,O
agents,O
is,O
generally,O
low,O
.,O
Celecoxib,I-Entity
(,O
CE,I-Entity
),O
is,O
a,O
novel,O
drug,O
",",O
with,O
high,O
selectivity,O
and,O
affinity,I-Entity
for,O
COX-2,I-Entity
enzyme,O
.,O
We,I-Entity
evaluated,O
the,O
tolerability,O
of,O
CE,I-Entity
in,O
a,O
group,O
of,O
patients,O
with,O
documented,O
history,O
of,O
adverse,O
cutaneous,O
reactions,O
to,O
P,I-Entity
and,O
N,I-Entity
associated,O
or,O
not,O
to,O
classic,O
NSAIDs,I-Entity
.,O
:,O
We,I-Entity
studied,O
9,O
patients,O
with,O
hypersensitivity,I-Entity
to,O
P,I-Entity
and,O
N,I-Entity
with,O
or,O
without,O
associated,O
reactions,O
to,O
classic,O
NSAIDs,I-Entity
.,O
The,I-Entity
diagnosis,O
of,O
P,I-Entity
and,O
N,I-Entity
-,O
induced,O
skin,O
reactions,O
was,O
based,O
in,O
vivo,O
challenge,O
.,O
After,I-Entity
three,O
days,O
",",O
a,O
cumulative,O
dosage,O
of,O
200,O
mg,O
of,O
CE,I-Entity
in,O
refracted,O
doses,O
were,O
given,O
.,O
The,I-Entity
challenge,O
was,O
considered,O
positive,O
if,O
one,O
or,O
more,O
of,O
the,O
following,O
appeared,O
:,O
erythema,I-Entity
",",O
rush,O
or,O
urticaria,I-Entity
-,O
angioedema,I-Entity
.,O
No,I-Entity
reaction,I-Entity
was,O
observed,O
with,O
placebo,O
and,O
eight,O
patients,O
(,O
88.8%,O
),O
tolerated,O
CE,I-Entity
.,O
Only,I-Entity
one,O
patient,O
developed,O
a,O
moderate,O
angioedema,I-Entity
of,O
the,O
lips,O
.,O
CONCLUSION,I-Entity
:,O
Only,I-Entity
one,O
hypersensitivity,I-Entity
reaction,I-Entity
to,O
CE,I-Entity
was,O
documented,O
among,O
9,O
P,I-Entity
and,O
N,I-Entity
-,O
highly,O
NSAIDs,I-Entity
intolerant,O
patients,O
.,O
Thus,I-Entity
",",O
we,O
conclude,O
that,O
CE,I-Entity
is,O
a,O
reasonably,O
safe,O
alternative,O
to,O
be,O
used,O
in,O
subjects,O
who,O
do,O
not,O
tolerate,O
P,I-Entity
and,O
N.,I-Entity
Case,I-Entity
-,O
control,O
study,O
of,O
regular,O
analgesic,O
and,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
use,O
and,O
end,O
-,O
stage,O
renal,O
disease,I-Entity
.,O
Studies,I-Entity
on,O
the,O
association,O
between,O
the,O
long,O
-,O
term,O
use,O
of,O
aspirin,I-Entity
and,O
other,O
analgesic,O
and,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drugs,O
(,O
NSAIDs,I-Entity
),O
and,O
end,O
-,O
stage,O
renal,O
disease,I-Entity
(,O
ESRD,I-Entity
),O
have,O
given,O
conflicting,O
results,O
.,O
In,I-Entity
order,O
to,O
examine,O
this,O
association,O
",",O
a,O
case,O
-,O
control,O
study,O
with,O
incident,I-Entity
cases,O
of,O
ESRD,I-Entity
was,O
carried,O
out,O
.,O
METHODS,I-Entity
:,O
The,I-Entity
cases,O
were,O
all,O
patients,O
entering,O
the,O
local,O
dialysis,O
program,O
because,O
of,O
ESRD,I-Entity
in,O
the,O
study,O
area,O
between,O
June,I-Entity
1,O
",",O
1995,O
and,O
November,I-Entity
30,O
",",O
1997,O
.,O
They,I-Entity
were,O
classified,O
according,O
to,O
the,O
underlying,O
disease,I-Entity
",",O
which,O
had,O
presumably,O
led,O
them,O
to,O
ESRD,I-Entity
.,O
For,I-Entity
specific,O
groups,O
of,O
drugs,O
",",O
the,O
risks,O
were,O
1.56,O
(,O
1.05,O
-,O
2.30,O
),O
for,O
aspirin,I-Entity
",",O
1.03,O
(,O
0.60,O
-,O
1.76,O
),O
for,O
pyrazolones,I-Entity
",",O
0.80,O
(,O
0.39,O
-,O
1.63,O
),O
for,O
paracetamol,I-Entity
",",O
and,O
0.94,O
(,O
0.57,O
-,O
1.56,O
),O
for,O
nonaspirin,I-Entity
NSAIDs,I-Entity
.,O
The,I-Entity
risk,O
of,O
ESRD,I-Entity
associated,O
with,O
aspirin,I-Entity
was,O
related,O
to,O
the,O
cumulated,O
dose,O
and,O
duration,O
of,O
use,O
",",O
and,O
it,O
was,O
particularly,O
high,O
among,O
the,O
subset,O
of,O
patients,O
with,O
vascular,O
nephropathy,I-Entity
as,O
underlying,O
disease,I-Entity
[,O
2.35,O
(,O
1.17,O
-,O
4.72,O
),O
],O
.,O
CONCLUSION,I-Entity
:,O
Our,I-Entity
data,O
indicate,O
that,O
long,O
-,O
term,O
use,O
of,O
nonaspirin,I-Entity
analgesic,O
drugs,O
and,O
NSAIDs,I-Entity
is,O
not,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
ESRD,I-Entity
.,O
However,I-Entity
",",O
the,O
chronic,O
use,O
of,O
aspirin,I-Entity
may,O
increase,O
the,O
risk,O
of,O
ESRD,I-Entity
.,O
Two,I-Entity
cases,O
of,O
amisulpride,I-Entity
overdose,I-Entity
:,O
a,O
cause,O
for,O
prolonged,O
QT,I-Entity
syndrome,I-Entity
.,O
Two,I-Entity
cases,O
of,O
deliberate,O
self,O
-,O
poisoning,I-Entity
with,O
5,O
g,O
and,O
3.6,O
g,O
of,O
amisulpride,I-Entity
",",O
respectively,O
",",O
are,O
reported,O
.,O
In,I-Entity
both,O
cases,O
",",O
QT,I-Entity
prolongation,O
and,O
hypocalcaemia,I-Entity
were,O
noted,O
.,O
The,I-Entity
QT,I-Entity
prolongation,O
appeared,O
to,O
respond,O
to,O
administration,O
of,O
i.v,O
.,O
calcium,I-Entity
gluconate,I-Entity
.,O
Growth,I-Entity
-,O
associated,O
protein,O
43,O
expression,O
in,O
hippocampal,O
molecular,O
layer,O
of,O
chronic,O
epileptic,I-Entity
rats,O
treated,O
with,O
cycloheximide,I-Entity
.,O
GAP43,I-Entity
has,O
been,O
thought,O
to,O
be,O
linked,O
with,O
mossy,I-Entity
fiber,O
sprouting,O
(,O
MFS,I-Entity
),O
in,O
various,O
experimental,O
models,O
of,O
epilepsy,I-Entity
.,O
To,I-Entity
investigate,O
how,O
GAP43,I-Entity
expression,O
(,O
GAP43-ir,I-Entity
),O
correlates,O
with,O
MFS,I-Entity
",",O
we,O
assessed,O
the,O
intensity,O
(,O
densitometry,O
),O
and,O
extension,O
(,O
width,O
),O
of,O
GAP43-ir,I-Entity
in,O
the,O
inner,O
molecular,O
layer,O
of,O
the,O
dentate,O
gyrus,I-Entity
(,O
IML,I-Entity
),O
of,O
rats,O
subject,O
to,O
status,O
epilepticus,I-Entity
induced,O
by,O
pilocarpine,I-Entity
(,O
Pilo,I-Entity
),O
",",O
previously,O
injected,O
or,O
not,O
with,O
cycloheximide,I-Entity
(,O
CHX,I-Entity
),O
",",O
which,O
has,O
been,O
shown,O
to,O
inhibit,O
MFS,I-Entity
.,O
CHX,I-Entity
was,O
injected,O
before,O
the,O
Pilo,I-Entity
injection,O
in,O
adult,O
Wistar,I-Entity
rats,O
.,O
The,I-Entity
Pilo,I-Entity
group,O
was,O
injected,O
with,O
the,O
same,O
drugs,O
",",O
except,O
for,O
CHX,I-Entity
.,O
RESULTS,I-Entity
:,O
Densitometry,I-Entity
showed,O
no,O
significant,O
difference,O
regarding,O
GAP43-ir,I-Entity
in,O
the,O
IML,I-Entity
between,O
Pilo,I-Entity
",",O
CHX+Pilo,I-Entity
",",O
and,O
control,O
groups,O
.,O
However,I-Entity
",",O
the,O
results,O
of,O
the,O
width,O
of,O
the,O
GAP43-ir,I-Entity
band,O
in,O
the,O
IML,I-Entity
showed,O
that,O
CHX+Pilo,I-Entity
and,O
control,O
animals,O
had,O
a,O
significantly,O
larger,O
band,O
(,O
p,O
=,O
0.03,O
),O
as,O
compared,O
with,O
that,O
in,O
the,O
Pilo,I-Entity
group,O
.,O
Our,I-Entity
current,O
finding,O
that,O
animals,O
in,O
the,O
CHX+Pilo,I-Entity
group,O
have,O
a,O
GAP43-ir,I-Entity
band,O
in,O
the,O
IML,I-Entity
",",O
similar,O
to,O
that,O
of,O
controls,O
",",O
reinforces,O
prior,O
data,O
on,O
the,O
blockade,O
of,O
MFS,I-Entity
in,O
these,O
animals,O
.,O
The,I-Entity
change,O
in,O
GAP43-ir,I-Entity
present,O
in,O
Pilo,I-Entity
-,O
treated,O
animals,O
was,O
a,O
thinning,O
of,O
the,O
band,O
to,O
a,O
very,O
narrow,O
layer,O
just,O
above,O
the,O
granule,O
cell,O
layer,O
that,O
is,O
likely,O
to,O
be,O
associated,O
with,O
the,O
loss,I-Entity
of,O
hilar,I-Entity
cell,O
projections,O
that,O
express,O
GAP-43,I-Entity
.,O
Nicotine,I-Entity
antagonizes,I-Entity
caffeine-,I-Entity
but,O
not,O
pentylenetetrazole,I-Entity
-,O
induced,O
anxiogenic,O
effect,O
in,O
mice,O
.,O
Nicotine,I-Entity
and,O
caffeine,I-Entity
are,O
widely,O
consumed,O
licit,O
psychoactive,I-Entity
drugs,O
worldwide,O
.,O
Although,I-Entity
some,O
studies,O
in,O
experimental,O
animals,O
indicate,O
clear,O
pharmacological,O
interactions,O
between,O
them,O
",",O
no,O
studies,O
have,O
shown,O
a,O
specific,O
interaction,O
on,O
anxiety,I-Entity
responses,O
.,O
The,I-Entity
present,O
study,O
investigates,O
the,O
effects,O
of,O
nicotine,I-Entity
on,O
anxiety,I-Entity
induced,O
by,O
caffeine,I-Entity
and,O
another,O
anxiogenic,O
drug,O
",",O
pentylenetetrazole,I-Entity
",",O
in,O
mice,O
.,O
test,O
was,O
used,O
to,O
evaluate,O
the,O
effects,O
of,O
drugs,O
on,O
anxiety,I-Entity
.,O
Adult,I-Entity
male,O
Swiss,I-Entity
Webster,I-Entity
mice,O
(,O
25,O
-,O
32,O
g,O
),O
were,O
given,O
nicotine,I-Entity
(,O
0.05,O
-,O
0.25,O
mg,O
/,O
kg,O
s.c,O
.,O
),O
or,O
saline,O
10,O
min,O
before,O
caffeine,I-Entity
(,O
70,I-Entity
mg,O
/,O
kg,O
i.p,O
.,O
),O
or,O
pentylenetetrazole,I-Entity
(,O
15,O
and,O
30,O
mg,O
Nicotine,I-Entity
(,O
0.05,O
-,O
0.25,O
mg,O
/,O
kg,O
),O
itself,O
did,O
not,O
produce,O
any,O
significant,O
effect,O
in,O
the,O
EPM,I-Entity
test,O
",",O
whereas,O
caffeine,I-Entity
(,O
70,I-Entity
mg,O
/,O
kg,O
),O
and,O
pentylenetetrazole,I-Entity
(,O
30,O
mg,O
/,O
kg,O
),O
produced,O
an,O
anxiogenic,O
effect,O
",",O
apparent,O
with,O
decreases,O
in,O
open,O
-,O
arm,O
time,O
and,O
entry,O
.,O
Nicotine,I-Entity
(,O
0.25,O
mg,O
/,O
kg,O
),O
pretreatment,O
blocked,O
the,O
caffeine-,I-Entity
but,O
not,O
pentylenetetrazole,I-Entity
-,O
induced,O
anxiety,I-Entity
.,O
Our,I-Entity
results,O
suggest,O
that,O
the,O
antagonistic,O
effect,O
of,O
nicotine,I-Entity
on,O
caffeine,I-Entity
-,O
induced,O
anxiety,I-Entity
is,O
specific,O
to,O
caffeine,I-Entity
",",O
instead,O
of,O
a,O
non,O
-,O
specific,O
anxiolytic,O
effect,O
.,O
Thus,I-Entity
",",O
it,O
may,O
extend,O
the,O
current,O
findings,O
on,O
the,O
interaction,O
between,O
nicotine,I-Entity
and,O
caffeine,I-Entity
.,O
Hormone,I-Entity
therapy,O
(,O
HT,I-Entity
),O
is,O
widely,O
used,O
for,O
controlling,O
menopausal,O
symptoms,O
.,O
It,I-Entity
has,O
also,O
been,O
used,O
for,O
the,O
management,O
and,O
prevention,O
of,O
cardiovascular,O
disease,I-Entity
",",O
osteoporosis,I-Entity
and,O
dementia,I-Entity
in,O
older,O
women,O
but,O
the,O
evidence,O
supporting,O
its,O
use,O
for,O
these,O
indications,O
is,O
largely,O
observational,O
.,O
To,I-Entity
assess,O
the,O
effect,O
of,O
long,O
-,O
term,O
HT,I-Entity
on,O
mortality,O
",",O
heart,O
disease,I-Entity
",",O
venous,O
thromboembolism,I-Entity
",",O
stroke,O
",",O
transient,O
ischaemic,I-Entity
attacks,O
",",O
breast,O
cancer,I-Entity
",",O
colorectal,B-Entity
cancer,I-Entity
",",O
ovarian,B-Entity
cancer,I-Entity
",",O
endometrial,O
cancer,I-Entity
",",O
gallbladder,O
disease,I-Entity
",",O
cognitive,O
function,O
",",O
dementia,I-Entity
",",O
fractures,I-Entity
and,O
quality,O
of,O
life,O
.,O
SELECTION,I-Entity
CRITERIA,I-Entity
:,O
Randomised,I-Entity
double,O
-,O
blind,O
trials,O
of,O
HT,I-Entity
(,O
oestrogens,I-Entity
with,O
or,O
without,O
progestogens,I-Entity
),O
versus,O
placebo,O
",",O
taken,O
for,O
at,O
least,O
one,O
year,O
by,O
perimenopausal,O
or,O
postmenopausal,O
women,O
.,O
In,I-Entity
relatively,O
healthy,O
women,O
",",O
combined,O
continuous,O
HT,I-Entity
significantly,O
increased,O
the,O
risk,O
of,O
venous,O
thromboembolism,I-Entity
or,O
coronary,O
event,O
(,O
after,O
one,O
year,O
's,I-Entity
use,O
),O
",",O
stroke,O
(,O
after,O
3,O
years,O
),O
",",O
breast,O
cancer,I-Entity
(,O
after,O
5,O
years,O
),O
and,O
gallbladder,O
disease,I-Entity
.,O
Long,I-Entity
-,O
term,O
oestrogen,I-Entity
-,O
only,O
HT,I-Entity
also,O
significantly,O
increased,O
the,O
risk,O
of,O
stroke,O
and,O
gallbladder,O
disease,I-Entity
.,O
Overall,I-Entity
",",O
the,O
only,O
statistically,O
significant,O
benefits,O
of,O
HT,I-Entity
were,O
a,O
decreased,O
incidence,O
of,O
fractures,I-Entity
and,O
colon,O
cancer,I-Entity
with,O
long,O
-,O
term,O
use,O
.,O
Among,I-Entity
relatively,O
healthy,O
women,O
over,O
65,O
years,O
taking,O
continuous,O
combined,O
HT,I-Entity
",",O
there,O
was,O
a,O
statistically,O
significant,O
increase,O
in,O
the,O
incidence,O
of,O
dementia,I-Entity
.,O
Among,I-Entity
women,O
with,O
cardiovascular,O
disease,I-Entity
",",O
long,O
-,O
term,O
use,O
of,O
combined,O
continuous,O
HT,I-Entity
significantly,O
increased,O
the,O
risk,O
of,O
venous,O
thromboembolism,I-Entity
.,O
However,I-Entity
",",O
one,O
trial,O
analysed,O
subgroups,O
of,O
2839,I-Entity
relatively,O
healthy,O
50,O
to,O
59,I-Entity
year,O
-,O
old,O
women,O
taking,O
combined,O
continuous,O
HT,I-Entity
and,O
1637,O
taking,O
oestrogen,I-Entity
-,O
only,O
HT,I-Entity
",",O
versus,O
similar,O
-,O
sized,O
placebo,O
groups,O
.,O
The,I-Entity
only,O
significantly,O
increased,O
risk,O
reported,O
was,O
for,O
venous,O
thromboembolism,I-Entity
in,O
women,O
taking,O
combined,O
continuous,O
HT,I-Entity
;,O
their,O
absolute,O
risk,O
remained,O
very,O
low,O
.,O
HT,I-Entity
is,O
not,O
indicated,O
for,O
the,O
routine,O
management,O
of,O
chronic,O
disease,I-Entity
.,O
Drug,I-Entity
-,O
induced,O
liver,I-Entity
injury,I-Entity
:,O
an,O
analysis,O
of,O
461,O
incidences,O
submitted,O
to,O
the,O
Spanish,I-Entity
registry,O
over,O
a,O
10-year,O
period,O
.,O
Progress,I-Entity
in,O
the,O
understanding,O
of,O
susceptibility,O
factors,O
to,O
drug,O
-,O
induced,O
liver,I-Entity
injury,I-Entity
(,O
DILI,I-Entity
),O
and,O
outcome,O
predictability,O
are,O
hampered,O
by,O
the,O
lack,O
of,O
systematic,O
programs,O
to,O
detect,O
bona,I-Entity
fide,O
cases,O
.,O
A,I-Entity
cooperative,O
network,O
was,O
created,O
in,O
1994,O
in,O
Spain,I-Entity
to,O
identify,O
all,O
suspicions,O
of,O
DILI,I-Entity
following,O
a,O
prospective,O
structured,O
report,O
form,O
.,O
The,I-Entity
liver,I-Entity
damage,O
was,O
characterized,O
according,O
to,O
hepatocellular,O
",",O
cholestatic,I-Entity
",",O
and,O
mixed,O
laboratory,O
criteria,O
and,O
to,O
histologic,O
criteria,O
when,O
available,O
.,O
Since,I-Entity
April,I-Entity
1994,O
to,O
August,I-Entity
2004,O
",",O
461,O
out,O
of,O
570,O
submitted,O
cases,O
",",O
involving,O
505,I-Entity
drugs,O
",",O
were,O
deemed,O
to,O
be,O
related,O
to,O
DILI,I-Entity
.,O
The,I-Entity
antiinfective,O
group,O
of,O
drugs,O
was,O
the,O
more,O
frequently,O
incriminated,I-Entity
",",O
amoxicillin,I-Entity
-,O
clavulanate,I-Entity
accounting,O
for,O
the,O
12.8%,O
of,O
the,O
whole,O
series,O
.,O
Indeed,I-Entity
",",O
the,O
incidence,O
of,O
liver,I-Entity
transplantation,O
and,O
death,I-Entity
in,O
this,O
group,O
was,O
11.7%,O
if,O
patients,O
had,O
jaundice,I-Entity
at,O
presentation,O
",",O
whereas,O
the,O
corresponding,O
figure,O
was,O
3.8%,O
in,O
nonjaundiced,O
patients,O
(,O
P,I-Entity
<,O
.04,O
),O
.,O
Factors,I-Entity
associated,O
with,O
the,O
development,O
of,O
fulminant,O
hepatic,B-Entity
failure,I-Entity
were,O
female,O
sex,O
(,O
OR,I-Entity
=,O
25,O
;,O
95%,O
CI,I-Entity
:,O
4.1,O
-,O
151,I-Entity
;,O
P,I-Entity
95%,O
CI,I-Entity
:,O
1.6,O
-,O
37,I-Entity
;,O
P,I-Entity
<,O
.009,O
),O
",",O
and,O
higher,O
baseline,O
plasma,O
bilirubin,I-Entity
value,O
(,O
OR,I-Entity
=,O
1.15,O
;,O
95%,O
CI,I-Entity
:,O
1.09,O
-,O
1.22,O
;,O
P,I-Entity
Patients,I-Entity
with,O
drug,O
-,O
induced,O
hepatocellular,O
jaundice,I-Entity
have,O
11.7%,O
chance,O
of,O
progressing,O
to,O
death,I-Entity
or,O
transplantation,O
.,O
Amoxicillin,I-Entity
-,O
clavulanate,I-Entity
stands,O
out,O
as,O
the,O
most,O
common,O
drug,O
related,O
to,O
DILI,I-Entity
.,O
Morphological,I-Entity
evaluation,O
of,O
the,O
effect,O
of,O
d,O
-,O
ribose,I-Entity
on,O
adriamycin,I-Entity
-,O
evoked,O
cardiotoxicity,I-Entity
in,O
rats,O
.,O
The,I-Entity
influence,O
of,O
d,O
-,O
ribose,I-Entity
on,O
adriamycin,I-Entity
-,O
induced,O
myocardiopathy,I-Entity
in,O
rats,O
was,O
studied,O
.,O
Adriamycin,I-Entity
in,O
the,O
cumulative,O
dose,O
of,O
25,O
mg,O
/,O
kg,O
evoked,O
fully,O
developed,O
cardiac,O
toxicity,I-Entity
.,O
D,I-Entity
-,O
ribose,I-Entity
in,O
the,O
multiple,O
doses,O
of,O
200,O
mg,O
/,O
kg,O
did,O
not,O
influence,O
ADR,I-Entity
cardiotoxicity,I-Entity
.,O
In,I-Entity
vivo,O
evidences,O
suggesting,O
the,O
role,O
of,O
oxidative,O
stress,I-Entity
in,O
pathogenesis,O
of,O
vancomycin,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
:,O
protection,O
by,O
erdosteine,O
.,O
The,I-Entity
aims,O
of,O
this,O
study,O
were,O
to,O
examine,O
vancomycin,I-Entity
(,O
VCM)-induced,I-Entity
oxidative,O
stress,I-Entity
that,O
promotes,O
production,O
of,O
reactive,O
oxygen,I-Entity
species,O
(,O
ROS,I-Entity
),O
and,O
to,O
investigate,O
the,O
role,O
of,O
erdosteine,O
",",O
an,O
expectorant,O
agent,O
",",O
which,O
has,O
also,O
antioxidant,O
properties,O
",",O
on,O
kidney,O
tissue,O
against,O
the,O
possible,O
VCM,I-Entity
-,O
induced,O
renal,O
impairment,I-Entity
in,O
rats,O
.,O
Rats,I-Entity
were,O
divided,O
into,O
three,O
groups,O
:,O
sham,I-Entity
",",O
VCM,I-Entity
and,O
VCM,I-Entity
plus,O
erdosteine,O
.,O
VCM,I-Entity
was,O
administrated,O
intraperitoneally,O
(,O
i.p,O
.,O
),O
Erdosteine,I-Entity
was,O
administered,O
orally,O
.,O
VCM,I-Entity
administration,O
to,O
control,O
rats,O
significantly,O
increased,O
renal,O
malondialdehyde,I-Entity
(,O
MDA,I-Entity
),O
and,O
urinary,O
(,O
NAG,I-Entity
",",O
a,O
marker,O
of,O
renal,O
tubular,O
injury,I-Entity
),O
excretion,O
but,O
decreased,O
superoxide,I-Entity
dismutase,O
(,O
SOD,I-Entity
),O
and,O
catalase,O
(,O
CAT,I-Entity
),O
activities,O
.,O
Erdosteine,I-Entity
administration,O
with,O
VCM,I-Entity
injections,O
caused,O
significantly,O
decreased,O
renal,O
MDA,I-Entity
and,O
urinary,O
NAG,I-Entity
excretion,O
",",O
and,O
increased,O
SOD,I-Entity
activity,O
",",O
but,O
not,O
CAT,I-Entity
activity,O
in,O
renal,O
tissue,O
when,O
compared,O
with,O
VCM,I-Entity
alone,O
.,O
Erdosteine,I-Entity
showed,O
histopathological,O
protection,O
against,O
VCM,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
.,O
There,I-Entity
were,O
a,O
significant,O
dilatation,O
of,O
tubular,O
lumens,O
",",O
extensive,O
epithelial,O
cell,O
vacuolization,O
",",O
atrophy,I-Entity
",",O
desquamation,I-Entity
",",O
and,O
necrosis,I-Entity
in,O
VCM,I-Entity
-,O
treated,O
rats,O
more,O
than,O
those,O
of,O
the,O
control,O
and,O
the,O
erdosteine,O
groups,O
.,O
Erdosteine,I-Entity
caused,O
a,O
marked,O
reduction,O
in,O
the,O
extent,O
of,O
tubular,O
damage,O
.,O
It,I-Entity
is,O
concluded,O
that,O
oxidative,O
tubular,O
damage,O
plays,O
an,O
important,O
role,O
in,O
the,O
VCM,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
and,O
the,O
modulation,O
of,O
oxidative,O
stress,I-Entity
with,O
erdosteine,O
reduces,O
the,O
VCM,I-Entity
-,O
induced,O
kidney,O
damage,O
both,O
at,O
the,O
biochemical,O
and,O
histological,O
levels,O
.,O
Does,I-Entity
domperidone,I-Entity
potentiate,O
mirtazapine,I-Entity
-,O
associated,O
restless,O
legs,O
syndrome,I-Entity
?,O
There,I-Entity
is,O
now,O
evidence,O
to,O
suggest,O
a,O
central,O
role,O
for,O
the,O
dopaminergic,O
system,O
in,O
restless,O
legs,O
syndrome,I-Entity
(,O
RLS,I-Entity
),O
.,O
For,I-Entity
example,O
",",O
the,O
symptoms,O
of,O
RLS,I-Entity
can,O
be,O
dramatically,O
improved,O
by,O
levodopa,I-Entity
and,O
dopamine,I-Entity
agonists,I-Entity
",",O
whereas,O
central,O
dopamine,I-Entity
D2,I-Entity
receptor,O
antagonists,O
can,O
induce,O
or,O
aggravate,O
RLS,I-Entity
symptoms,O
.,O
To,I-Entity
our,O
knowledge,O
",",O
there,O
is,O
no,O
previous,O
report,O
regarding,O
whether,O
domperidone,I-Entity
",",O
a,O
peripheral,O
dopamine,I-Entity
D2,I-Entity
receptor,O
antagonist,O
",",O
can,O
also,O
induce,O
or,O
aggravate,O
symptoms,O
of,O
RLS,I-Entity
.,O
Mirtazapine,I-Entity
",",O
the,O
first,O
noradrenergic,I-Entity
and,O
specific,O
serotonergic,I-Entity
antidepressant,I-Entity
(,O
NaSSA,I-Entity
),O
",",O
has,O
been,O
associated,O
with,O
RLS,I-Entity
in,O
several,O
recent,O
publications,O
.,O
The,I-Entity
authors,O
report,O
here,O
a,O
depressed,I-Entity
patient,O
comorbid,O
with,O
postprandial,O
dyspepsia,I-Entity
who,O
developed,O
RLS,I-Entity
after,O
mirtazapine,I-Entity
had,O
been,O
added,O
to,O
his,O
domperidone,I-Entity
therapy,O
.,O
Our,I-Entity
patient,O
started,O
to,O
have,O
symptoms,O
of,O
RLS,I-Entity
only,O
after,O
he,O
had,O
been,O
treated,O
with,O
mirtazapine,I-Entity
",",O
and,O
his,O
RLS,I-Entity
symptoms,O
resolved,O
completely,O
upon,O
discontinuation,O
of,O
his,O
mirtazapine,I-Entity
.,O
Such,I-Entity
a,O
temporal,O
relationship,O
between,O
the,O
use,O
of,O
mirtazapine,I-Entity
and,O
the,O
symptoms,O
of,O
RLS,I-Entity
in,O
our,O
patient,O
did,O
not,O
support,O
a,O
potentiating,O
effect,O
of,O
domperione,I-Entity
on,O
mirtazapine,I-Entity
-,O
associated,O
RLS,I-Entity
.,O
However,I-Entity
",",O
physicians,O
should,O
be,O
aware,O
of,O
the,O
possibility,O
that,O
mirtazapine,I-Entity
can,O
be,O
associated,O
with,O
RLS,I-Entity
in,O
some,O
individuals,O
",",O
especially,O
those,O
receiving,O
concomitant,I-Entity
dopamine,I-Entity
D2,I-Entity
receptor,O
antagonists,O
.,O
Antiandrogenic,I-Entity
therapy,O
can,O
cause,O
coronary,O
arterial,O
disease,I-Entity
.,O
AIM,I-Entity
:,O
To,I-Entity
study,O
the,O
change,O
of,O
lipid,O
metabolism,O
by,O
antiandrogen,O
therapy,O
in,O
patients,O
with,O
prostate,O
cancer,I-Entity
.,O
We,I-Entity
studied,O
with,O
a,O
2.5,O
years,O
follow,O
-,O
up,O
the,O
changes,O
in,O
plasma,O
cholesterols,I-Entity
(,O
C,I-Entity
),O
",",O
triglycerides,I-Entity
(,O
TG,I-Entity
),O
",",O
lipoproteins,O
(,O
LP,I-Entity
),O
",",O
and,O
apolipoproteins,O
(,O
Apo,I-Entity
),O
fi,I-Entity
les,O
in,O
24,O
patients,O
of,O
mean,O
age,O
60,O
years,O
with,O
low,O
risk,O
prostate,O
cancer,I-Entity
(,O
stage,O
:,O
T1cN0M0,I-Entity
",",O
Gleason,I-Entity
score,O
:,O
2,O
-,O
5,O
),O
during,O
treatment,O
with,O
cyproterone,I-Entity
acetate,I-Entity
(,O
CPA,I-Entity
),O
without,O
surgical,O
management,O
or,O
radiation,O
therapy,O
.,O
Significant,I-Entity
decreases,O
of,O
HDL,I-Entity
-,O
C,I-Entity
",",O
Apo,I-Entity
A,I-Entity
-,O
I,I-Entity
and,O
Apo,I-Entity
A,I-Entity
-,O
II,I-Entity
and,O
an,O
increase,O
of,O
triglyceride,I-Entity
levels,O
in,O
VLDL,I-Entity
were,O
induced,O
by,O
CPA,I-Entity
.,O
After,I-Entity
a,O
period,O
of,O
2.5,O
years,O
on,O
CPA,I-Entity
treatment,O
",",O
four,O
patients,O
out,O
of,O
twenty,O
-,O
four,O
were,O
found,O
to,O
be,O
affected,O
by,O
coronary,O
heart,O
disease,I-Entity
.,O
Ischaemic,I-Entity
coronary,O
arteriosclerosis,I-Entity
with,O
an,O
incidence,O
rate,O
of,O
16.6%,O
as,O
caused,O
by,O
prolonged,O
CPA,I-Entity
therapy,O
is,O
mediated,O
through,O
changes,O
in,O
HDL,I-Entity
cholesterol,I-Entity
",",O
Apo,I-Entity
A,I-Entity
-,O
I,I-Entity
and,O
Apo,I-Entity
pro,O
fi,I-Entity
les,O
",",O
other,O
than,O
the,O
well,O
-,O
known,O
hyperglyceridemic,I-Entity
effect,O
caused,O
by,O
estrogen,I-Entity
.,O
5-Fluorouracil,I-Entity
cardiotoxicity,I-Entity
induced,O
by,O
alpha,O
-,O
fluoro,I-Entity
-,O
beta,O
-,O
alanine,I-Entity
.,O
Cardiotoxicity,I-Entity
is,O
a,O
rare,O
complication,O
occurring,O
during,O
5-fluorouracil,I-Entity
(,O
5-FU,I-Entity
),O
treatment,O
for,O
malignancies,I-Entity
.,O
We,I-Entity
herein,O
report,O
the,O
case,O
of,O
a,O
70-year,O
-,O
old,O
man,O
with,O
5-FU,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
",",O
in,O
whom,O
a,O
high,O
serum,O
level,O
of,O
alpha,O
-,O
fluoro,I-Entity
-,O
beta,O
-,O
alanine,I-Entity
(,O
FBAL,I-Entity
),O
was,O
observed,O
.,O
The,I-Entity
patient,O
",",O
who,O
had,O
unresectable,O
colon,O
cancer,I-Entity
metastases,O
to,O
the,O
liver,I-Entity
and,O
lung,O
",",O
was,O
referred,O
to,O
us,O
for,O
chemotherapy,O
from,O
an,O
affiliated,O
hospital,O
;,O
he,O
had,O
no,O
cardiac,O
history,O
.,O
After,I-Entity
admission,O
",",O
the,O
patient,O
received,O
a,O
continuous,O
intravenous,O
infusion,O
of,O
5-FU,I-Entity
(,O
1000,O
mg,O
/,O
day,O
),O
",",O
during,O
which,O
precordial,O
pain,I-Entity
with,O
right,O
bundle,O
branch,O
block,O
occurred,O
concomitantly,O
with,O
a,O
high,O
serum,O
FBAL,I-Entity
concentration,O
of,O
1955,O
ng,O
/,O
ml,O
.,O
Both,I-Entity
the,O
precordial,O
pain,I-Entity
and,O
the,O
electrocardiographic,O
changes,O
disappeared,O
spontaneously,O
after,O
the,O
discontinuation,O
of,O
5-FU,I-Entity
.,O
As,I-Entity
the,O
precordial,O
pain,I-Entity
in,O
this,O
patient,O
was,O
considered,O
to,O
have,O
been,O
due,O
to,O
5-FU,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
",",O
the,O
administration,O
of,O
5-FU,I-Entity
was,O
abandoned,O
.,O
Instead,I-Entity
",",O
oral,O
administration,O
of,O
S-1,I-Entity
(,O
a,O
derivative,O
of,O
5-FU,I-Entity
),O
",",O
at,O
200,O
mg,O
/,O
day,O
twice,O
a,O
week,O
",",O
was,O
instituted,O
",",O
because,O
S-1,I-Entity
has,O
a,O
strong,O
inhibitory,O
effect,O
on,O
dihydropyrimidine,I-Entity
dehydrogenase,O
",",O
which,O
catalyzes,O
the,O
degradative,O
of,O
5-FU,I-Entity
into,O
FBAL,I-Entity
.,O
The,I-Entity
serum,O
FBAL,I-Entity
concentration,O
subsequently,O
decreased,O
to,O
352,O
ng,O
/,O
ml,O
",",O
the,O
same,O
as,O
the,O
value,O
measured,O
on,O
the,O
first,O
day,O
of,O
S-1,I-Entity
administration,O
.,O
Thereafter,I-Entity
",",O
no,O
cardiac,O
symptoms,O
were,O
observed,O
.,O
The,I-Entity
experience,O
of,O
this,O
case,O
",",O
together,O
with,O
a,O
review,O
of,O
the,O
literature,O
",",O
suggests,O
that,O
FBAL,I-Entity
is,O
related,O
to,O
5-FU,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
S-1,I-Entity
may,O
be,O
administered,O
safely,O
to,O
patients,O
with,O
5-FU,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
The,I-Entity
influence,O
of,O
the,O
time,O
interval,O
between,O
monoHER,I-Entity
and,O
doxorubicin,I-Entity
administration,O
on,O
the,O
protection,O
against,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
in,O
mice,O
.,O
Despite,I-Entity
its,O
well,O
-,O
known,O
cardiotoxicity,I-Entity
",",O
the,O
anthracyclin,I-Entity
doxorubicin,I-Entity
(,O
DOX,I-Entity
),O
continues,O
to,O
be,O
an,O
effective,O
and,O
widely,O
used,O
chemotherapeutic,O
agent,O
.,O
DOX,I-Entity
-,O
induced,O
cardiac,O
damage,O
presumably,O
results,O
from,O
the,O
formation,O
of,O
free,O
radicals,I-Entity
by,O
DOX,I-Entity
.,O
Reactive,I-Entity
oxygen,I-Entity
species,O
particularly,O
affect,O
the,O
cardiac,O
myocytes,I-Entity
because,O
these,O
cells,O
seem,O
to,O
have,O
a,O
relatively,O
poor,O
antioxidant,O
defense,I-Entity
system,O
.,O
The,I-Entity
semisynthetic,O
flavonoid,O
monohydroxyethylrutoside,I-Entity
(,O
monoHER,I-Entity
),O
showed,O
cardioprotection,O
against,O
DOX,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
through,O
its,O
radical,O
scavenging,O
and,O
iron,I-Entity
chelating,O
properties,O
.,O
Because,I-Entity
of,O
the,O
relatively,O
short,I-Entity
final,O
half,O
-,O
life,O
of,O
monoHER,I-Entity
(,O
about,O
30,O
min,O
),O
",",O
it,O
is,O
expected,O
that,O
the,O
time,O
interval,O
between,O
monoHER,I-Entity
and,O
DOX,I-Entity
might,O
be,O
of,O
influence,O
on,O
the,O
cardioprotective,O
effect,O
of,O
monoHER,I-Entity
.,O
Six,I-Entity
groups,O
of,O
6,O
BALB,I-Entity
/,O
c,O
mice,O
were,O
treated,O
with,O
saline,O
",",O
DOX,I-Entity
alone,O
or,O
DOX,I-Entity
(,O
4,O
mg,O
/,O
kg,O
i.v,O
.,O
),O
preceded,O
by,O
monoHER,I-Entity
(,O
500,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
with,O
an,O
interval,O
of,O
10,O
",",O
30,O
",",O
60,O
or,O
120,I-Entity
min,O
.,O
Their,I-Entity
cardiac,O
tissues,O
were,O
processed,O
for,O
light,O
microscopy,O
",",O
after,O
which,O
cardiomyocyte,O
damage,O
was,O
evaluated,O
according,O
to,O
Billingham,I-Entity
(,O
in,O
Cancer,I-Entity
Treat,I-Entity
Rep,I-Entity
62(6):865,O
-,O
872,O
",",O
1978,O
),O
.,O
Microscopic,I-Entity
evaluation,O
revealed,O
that,O
treatment,O
with,O
DOX,I-Entity
alone,O
induced,O
significant,O
cardiac,O
damage,O
in,O
comparison,O
to,O
the,O
saline,O
control,O
group,O
(,O
P<0.001,I-Entity
),O
.,O
The,I-Entity
number,O
of,O
damaged,O
cardiomyocytes,O
was,O
9.6-fold,O
(,O
95%,O
CI,I-Entity
4.4,O
-,O
21.0,O
),O
higher,O
in,O
mice,O
treated,O
with,O
DOX,I-Entity
alone,O
than,O
that,O
in,O
animals,O
of,O
the,O
control,O
group,O
.,O
The,I-Entity
ratio,O
of,O
aberrant,I-Entity
cardiomyocytes,O
in,O
mice,O
treated,O
with,O
DOX,I-Entity
preceded,O
by,O
monoHER,I-Entity
and,O
those,O
in,O
mice,O
treated,O
with,O
saline,O
ranged,O
from,O
1.6,O
to,O
2.8,O
(,O
mean,O
2.2,O
",",O
95%,O
CI,I-Entity
1.2,O
-,O
4.1,O
",",O
P=0.019,I-Entity
),O
.,O
The,I-Entity
mean,O
protective,O
effect,O
by,O
adding,O
monoHER,I-Entity
before,O
DOX,I-Entity
led,O
to,O
a,O
significant,O
4.4-fold,O
reduction,O
(,O
P<0.001,I-Entity
",",O
95%,O
CI,I-Entity
2.3,O
-,O
8.2,O
),O
of,O
abnormal,I-Entity
cardiomyocytes,O
.,O
This,I-Entity
protective,O
effect,O
did,O
not,O
depend,O
on,O
the,O
time,O
interval,O
between,O
monoHER,I-Entity
and,O
DOX,I-Entity
administration,O
(,O
P=0.345,I-Entity
),O
.,O
CONCLUSION,I-Entity
:,O
The,I-Entity
results,O
indicate,O
that,O
in,O
an,O
outpatient,I-Entity
clinical,O
setting,O
monoHER,I-Entity
may,O
be,O
administered,O
shortly,O
before,O
DOX,I-Entity
.,O
Clinical,I-Entity
evaluation,O
of,O
adverse,O
effects,O
during,O
bepridil,I-Entity
administration,O
for,O
atrial,I-Entity
fibrillation,I-Entity
and,O
flutter,I-Entity
.,O
Bepridil,I-Entity
hydrochloride,I-Entity
(,O
Bpd,I-Entity
),O
has,O
attracted,O
attention,O
as,O
an,O
effective,O
drug,O
for,O
atrial,I-Entity
fibrillation,I-Entity
(,O
AF,I-Entity
),O
and,O
atrial,I-Entity
flutter,I-Entity
(,O
AFL,I-Entity
),O
.,O
However,I-Entity
",",O
serious,O
adverse,O
effects,O
",",O
including,O
torsade,I-Entity
de,O
pointes,I-Entity
(,O
Tdp,I-Entity
),O
",",O
have,O
been,O
reported,O
.,O
Adverse,I-Entity
effects,O
of,O
Bpd,I-Entity
requiring,O
discontinuation,O
of,O
treatment,O
were,O
evaluated,O
.,O
Bpd,I-Entity
was,O
administered,O
to,O
459,I-Entity
patients,O
(,O
361,O
males,O
",",O
63+/-12,O
years,O
old,O
),O
comprising,O
378,I-Entity
AF,I-Entity
and,O
81,I-Entity
AFL,I-Entity
cases,O
.,O
There,I-Entity
was,O
marked,O
QT,I-Entity
prolongation,O
greater,O
than,O
0.55,O
s,O
in,O
13,O
patients,O
",",O
bradycardia,I-Entity
less,O
than,O
40,O
beats,O
/,O
min,O
in,O
6,O
patients,O
",",O
dizziness,I-Entity
and,O
general,O
fatigue,I-Entity
in,O
1,O
patient,O
each,O
.,O
In,I-Entity
4,O
of,O
13,O
patients,O
with,O
QT,I-Entity
prolongation,O
",",O
Tdp,I-Entity
occurred,O
.,O
The,I-Entity
major,O
triggering,O
factors,O
of,O
Tdp,I-Entity
were,O
hypokalemia,I-Entity
and,O
sudden,I-Entity
decrease,O
in,O
heart,O
rate,O
.,O
There,I-Entity
were,O
no,O
differences,O
in,O
the,O
clinical,O
backgrounds,O
of,O
the,O
patients,O
with,O
and,O
without,O
Tdp,I-Entity
other,O
than,O
LAD,I-Entity
and,O
age,O
",",O
which,O
were,O
larger,O
and,O
older,O
in,O
the,O
patients,O
with,O
Tdp,I-Entity
.,O
CONCLUSION,I-Entity
:,O
Careful,I-Entity
observation,O
of,O
serum,O
potassium,I-Entity
concentration,O
and,O
the,O
ECG,I-Entity
should,O
always,O
be,O
done,O
during,O
Bpd,I-Entity
administration,O
",",O
particularly,O
in,O
elderly,O
patients,O
.,O
Enhanced,I-Entity
isoproterenol,I-Entity
-,O
induced,O
cardiac,O
hypertrophy,I-Entity
in,O
transgenic,O
rats,O
with,O
low,O
brain,O
angiotensinogen,O
.,O
We,I-Entity
have,O
previously,O
shown,O
that,O
a,O
permanent,O
deficiency,I-Entity
in,O
the,O
brain,O
renin,O
-,O
angiotensin,I-Entity
system,O
(,O
RAS,I-Entity
),O
may,O
increase,O
the,O
sensitivity,O
of,O
the,O
baroreflex,I-Entity
control,O
of,O
heart,O
rate,O
.,O
agonist,I-Entity
isoproterenol,I-Entity
(,O
Iso,I-Entity
),O
.,O
In,I-Entity
isolated,O
hearts,O
",",O
Iso,I-Entity
induced,O
a,O
significantly,O
greater,O
increase,O
in,O
left,O
ventricular,O
(,O
LV,I-Entity
),O
pressure,O
and,O
maximal,O
contraction,I-Entity
(,O
+,O
dP,I-Entity
/,O
dt(max,O
),O
),O
in,O
the,O
TGR,I-Entity
than,O
in,O
the,O
Sprague,I-Entity
-,O
Dawley,I-Entity
(,O
SD,I-Entity
),O
rats,O
.,O
LV,I-Entity
hypertrophy,I-Entity
induced,O
by,O
Iso,I-Entity
treatment,O
was,O
significantly,O
higher,O
in,O
TGR,I-Entity
than,O
in,O
SD,I-Entity
rats,O
(,O
in,O
g,O
LV,I-Entity
wt/100,O
The,I-Entity
greater,O
LV,I-Entity
hypertrophy,I-Entity
in,O
TGR,I-Entity
rats,O
was,O
associated,O
with,O
more,O
pronounced,O
downregulation,O
of,O
beta,O
-,O
AR,I-Entity
and,O
upregulation,O
of,O
LV,I-Entity
beta,O
-,O
AR,I-Entity
kinase-1,O
mRNA,I-Entity
levels,O
compared,O
with,O
those,O
in,O
SD,I-Entity
rats,O
.,O
The,I-Entity
decrease,O
in,O
the,O
heart,O
rate,O
(,O
HR,I-Entity
),O
induced,O
by,O
the,O
beta,O
-,O
AR,I-Entity
antagonist,O
metoprolol,I-Entity
in,O
conscious,O
rats,O
was,O
significantly,O
attenuated,O
in,O
TGR,I-Entity
compared,O
with,O
SD,I-Entity
rats,O
(,O
-9.9,O
1.5%,O
),O
",",O
whereas,O
the,O
effect,O
of,O
parasympathetic,I-Entity
blockade,O
by,O
atropine,I-Entity
on,O
HR,I-Entity
was,O
similar,O
in,O
both,O
strains,O
.,O
These,I-Entity
results,O
indicate,O
that,O
TGR,I-Entity
are,O
more,O
sensitive,I-Entity
to,O
beta,O
-,O
AR,I-Entity
agonist,I-Entity
-,O
induced,O
cardiac,O
inotropic,O
response,O
and,O
hypertrophy,I-Entity
",",O
possibly,O
due,O
to,O
chronically,O
low,O
sympathetic,O
outflow,O
directed,O
to,O
the,O
heart,O
.,O
Drug,I-Entity
-,O
induced,O
long,O
QT,I-Entity
syndrome,I-Entity
in,O
injection,O
drug,O
users,O
receiving,O
methadone,I-Entity
:,O
high,O
frequency,O
in,O
hospitalized,O
patients,O
and,O
risk,O
factors,O
.,O
Drug,I-Entity
-,O
induced,O
long,O
QT,I-Entity
syndrome,I-Entity
is,O
a,O
serious,O
adverse,O
drug,O
reaction,I-Entity
.,O
Methadone,I-Entity
prolongs,O
the,O
QT,I-Entity
interval,O
in,O
vitro,O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
.,O
In,I-Entity
the,O
inpatient,O
setting,O
",",O
the,O
frequency,O
of,O
QT,I-Entity
interval,O
prolongation,O
with,O
methadone,I-Entity
treatment,O
",",O
its,O
dose,O
dependence,O
",",O
and,O
the,O
importance,O
of,O
cofactors,O
such,O
as,O
drug,O
-,O
drug,O
interactions,O
remain,O
unknown,O
.,O
:,O
We,I-Entity
performed,O
a,O
systematic,O
",",O
retrospective,O
study,O
comparing,O
active,O
or,O
former,O
intravenous,O
drug,O
users,O
receiving,O
methadone,I-Entity
and,O
those,O
not,O
receiving,O
methadone,I-Entity
among,O
all,O
patients,O
hospitalized,O
over,O
a,O
5-year,O
period,O
in,O
a,O
tertiary,O
care,O
hospital,O
.,O
A,I-Entity
total,O
of,O
167,I-Entity
patients,O
receiving,O
methadone,I-Entity
fulfilled,O
the,O
inclusion,O
criteria,O
and,O
were,O
compared,O
with,O
a,O
control,O
group,O
of,O
80,O
injection,O
drug,O
users,O
not,O
receiving,O
methadone,I-Entity
.,O
In,I-Entity
addition,O
to,O
methadone,I-Entity
dose,O
",",O
15,O
demographic,O
",",O
biological,O
",",O
and,O
pharmacological,O
variables,O
were,O
considered,O
as,O
potential,O
risk,O
factors,O
for,O
QT,I-Entity
prolongation,O
.,O
Among,I-Entity
167,I-Entity
methadone,I-Entity
maintenance,O
patients,O
",",O
the,O
prevalence,O
of,O
QTc,I-Entity
prolongation,O
to,O
0.50,O
second((1/2,O
),O
),O
or,O
longer,O
was,O
16.2%,O
compared,O
with,O
0%,O
in,O
80,O
control,O
subjects,O
.,O
Six,I-Entity
patients,O
(,O
3.6%,O
),O
in,O
the,O
methadone,I-Entity
group,O
presented,O
torsades,I-Entity
de,O
pointes,I-Entity
.,O
QTc,I-Entity
length,O
was,O
weakly,O
but,O
significantly,O
associated,O
with,O
methadone,I-Entity
daily,O
dose,O
(,O
Spearman,I-Entity
rank,O
correlation,O
coefficient,O
",",O
0.20,O
;,O
P<.01,I-Entity
),O
.,O
Multivariate,I-Entity
regression,O
analysis,O
allowed,O
attribution,O
of,O
31.8%,O
of,O
QTc,I-Entity
variability,O
to,O
methadone,I-Entity
dose,O
",",O
cytochrome,O
P-450,I-Entity
3A4,I-Entity
drug,O
-,O
drug,O
interactions,O
",",O
hypokalemia,I-Entity
",",O
and,O
altered,O
liver,I-Entity
function,O
.,O
QT,I-Entity
interval,O
prolongation,O
in,O
methadone,I-Entity
maintenance,O
patients,O
hospitalized,O
in,O
a,O
tertiary,O
care,O
center,O
is,O
a,O
frequent,O
finding,O
.,O
Methadone,I-Entity
dose,O
",",O
presence,O
of,O
cytochrome,O
P-450,I-Entity
3A4,I-Entity
inhibitors,O
",",O
potassium,I-Entity
level,O
",",O
and,O
liver,I-Entity
function,O
contribute,O
to,O
QT,I-Entity
prolongation,O
.,O
Long,I-Entity
QT,I-Entity
syndrome,I-Entity
can,O
occur,O
with,O
low,O
doses,O
of,O
methadone,I-Entity
.,O
Mechanisms,I-Entity
of,O
hypertension,I-Entity
induced,O
by,O
nitric,I-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
deficiency,I-Entity
:,O
focus,O
on,O
venous,O
function,O
.,O
Loss,I-Entity
of,O
endothelial,O
cell,O
-,O
derived,O
nitric,I-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
in,O
hypertension,I-Entity
is,O
a,O
hallmark,O
of,O
arterial,O
dysfunction,I-Entity
.,O
Experimental,I-Entity
hypertension,I-Entity
created,O
by,O
the,O
removal,O
of,O
NO,I-Entity
",",O
however,O
",",O
involves,O
mechanisms,O
in,O
addition,O
to,O
decreased,O
arterial,O
vasodilator,O
activity,O
.,O
We,I-Entity
hypothesized,O
that,O
increased,O
venous,O
smooth,O
muscle,O
(,O
venomotor,I-Entity
),O
tone,O
plays,O
a,O
role,O
in,O
Nomega,I-Entity
-,O
nitro,I-Entity
-,O
L,I-Entity
-,O
arginine,I-Entity
(,O
LNNA,I-Entity
),O
hypertension,I-Entity
through,O
these,O
mechanisms,O
.,O
Rats,I-Entity
were,O
treated,O
with,O
the,O
NO,I-Entity
synthase,O
inhibitor,O
LNNA,I-Entity
(,O
0.5,O
g,O
/,O
L,I-Entity
in,O
drinking,I-Entity
water,O
),O
for,O
2,O
weeks,O
.,O
5,O
mm,O
Hg,I-Entity
in,O
LNNA,I-Entity
rats,O
(,O
P<0.05,I-Entity
),O
.,O
Maximal,I-Entity
contraction,I-Entity
to,O
norepinephrine,I-Entity
was,O
modestly,O
reduced,O
in,O
arteries,O
from,O
LNNA,I-Entity
compared,O
with,O
control,O
rats,O
whereas,O
the,O
maximum,O
contraction,I-Entity
to,O
ET-1,I-Entity
was,O
significantly,O
reduced,O
(,O
54%,O
control,O
),O
.,O
Maximum,I-Entity
contraction,I-Entity
of,O
vena,O
cava,O
to,O
norepinephrine,I-Entity
(,O
37%,O
control,O
),O
also,O
was,O
reduced,O
but,O
no,O
change,O
in,O
response,O
to,O
ET-1,I-Entity
was,O
observed,O
.,O
Mean,I-Entity
circulatory,O
filling,O
pressure,O
",",O
an,O
in,O
vivo,O
measure,O
of,O
venomotor,I-Entity
tone,O
",",O
was,O
not,O
elevated,O
in,O
LNNA,I-Entity
hypertension,I-Entity
at,O
1,O
or,O
2,O
weeks,O
after,O
LNNA,I-Entity
.,O
The,I-Entity
superoxide,I-Entity
scavenger,O
tempol,O
(,O
30,O
",",O
100,O
",",O
and,O
300,O
micromol,I-Entity
kg(-1,O
),O
",",O
IV,I-Entity
),O
did,O
not,O
change,O
arterial,O
pressure,O
in,O
control,O
rats,O
but,O
caused,O
a,O
dose,O
-,O
dependent,O
decrease,O
in,O
LNNA,I-Entity
rats,O
(,O
-18,O
+,O
/-,O
Similarly,I-Entity
",",O
ganglionic,O
blockade,O
with,O
hexamethonium,I-Entity
caused,O
a,O
significantly,O
greater,O
fall,O
in,O
LNNA,I-Entity
hypertensive,I-Entity
rats,O
(,O
76,I-Entity
+,O
/-,O
Carotid,I-Entity
arteries,O
",",O
vena,O
cava,O
",",O
and,O
sympathetic,O
ganglia,I-Entity
from,O
LNNA,I-Entity
rats,O
had,O
higher,O
basal,O
levels,O
of,O
superoxide,I-Entity
compared,O
with,O
those,O
from,O
control,O
rats,O
.,O
These,I-Entity
data,O
suggest,O
that,O
while,O
NO,I-Entity
deficiency,I-Entity
increases,O
oxidative,O
stress,I-Entity
and,O
sympathetic,O
activity,O
in,O
both,O
arterial,O
and,O
venous,O
vessels,O
",",O
the,O
impact,O
on,O
veins,O
does,O
not,O
make,O
a,O
major,O
contribution,O
to,O
this,O
form,O
of,O
hypertension,I-Entity
.,O
Association,I-Entity
of,O
DRD2,I-Entity
polymorphisms,I-Entity
and,O
chlorpromazine,I-Entity
-,O
induced,O
extrapyramidal,O
syndrome,I-Entity
in,O
Chinese,I-Entity
schizophrenic,I-Entity
patients,O
.,O
Extrapyramidal,I-Entity
syndrome,I-Entity
(,O
EPS,I-Entity
),O
is,O
most,O
commonly,O
affected,O
by,O
typical,O
antipsychotic,O
drugs,O
that,O
have,O
a,O
high,O
affinity,I-Entity
with,O
the,O
D2,I-Entity
receptor,O
.,O
Recently,I-Entity
",",O
many,O
research,O
groups,O
have,O
reported,O
on,O
the,O
positive,O
relationship,O
between,O
the,O
genetic,O
variations,O
in,O
the,O
DRD2,I-Entity
gene,O
and,O
the,O
therapeutic,O
response,O
in,O
schizophrenia,I-Entity
patients,O
as,O
a,O
result,O
of,O
the,O
role,O
of,O
variations,O
in,O
the,O
receptor,O
in,O
modulating,O
receptor,O
expression,O
.,O
In,I-Entity
this,O
study,O
",",O
we,O
evaluate,O
the,O
role,O
DRD2,I-Entity
plays,O
in,O
chlorpromazine,I-Entity
-,O
induced,O
EPS,I-Entity
in,O
schizophrenic,I-Entity
patients,O
.,O
:,O
We,I-Entity
identified,O
seven,O
SNP(single,I-Entity
nucleotide,I-Entity
polymorphism,I-Entity
),O
(,O
-141Cins,O
>,O
del,I-Entity
",",O
TaqIB,I-Entity
",",O
TaqID,I-Entity
",",O
Ser311Cys,I-Entity
",",O
rs6275,I-Entity
",",O
rs6277,I-Entity
and,O
TaqIA,I-Entity
),O
in,O
the,O
DRD2,I-Entity
gene,O
in,O
146,I-Entity
schizophrenic,I-Entity
inpatients,O
(,O
59,I-Entity
with,O
EPS,I-Entity
and,O
87,I-Entity
without,O
EPS,I-Entity
according,O
to,O
the,O
Simpson,I-Entity
-,O
Angus,I-Entity
Scale,I-Entity
),O
treated,O
with,O
chlorpromazine,I-Entity
after,O
8,O
weeks,O
.,O
CONCLUSION,I-Entity
:,O
Our,I-Entity
results,O
did,O
not,O
lend,O
strong,O
support,O
to,O
the,O
view,O
that,O
the,O
genetic,O
variation,O
of,O
the,O
DRD2,I-Entity
gene,O
plays,O
a,O
major,O
role,O
in,O
the,O
individually,O
variable,O
adverse,O
effect,O
induced,O
by,O
chlorpromazine,I-Entity
",",O
at,O
least,O
in,O
Chinese,I-Entity
patients,O
with,O
schizophrenia,I-Entity
.,O
Our,I-Entity
results,O
confirmed,O
a,O
previous,O
study,O
on,O
the,O
relationship,O
between,O
DRD2,I-Entity
and,O
EPS,I-Entity
in,O
Caucasians,I-Entity
.,O
Physical,I-Entity
training,O
decreases,O
susceptibility,O
to,O
subsequent,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
in,O
the,O
rat,O
.,O
Regular,I-Entity
motor,O
activity,O
has,O
many,O
benefits,O
for,O
mental,O
and,O
physical,O
condition,O
but,O
its,O
implications,O
for,O
epilepsy,I-Entity
are,O
still,O
controversial,O
.,O
In,I-Entity
order,O
to,O
elucidate,O
this,O
problem,O
",",O
we,O
have,O
studied,O
the,O
effect,O
of,O
long,O
-,O
term,O
physical,O
activity,O
on,O
susceptibility,O
to,O
subsequent,O
seizures,I-Entity
.,O
Thereafter,I-Entity
",",O
seizures,I-Entity
were,O
induced,O
by,O
pilocarpine,I-Entity
injections,O
in,O
trained,O
and,O
non,O
-,O
trained,O
control,O
groups,O
.,O
During,I-Entity
the,O
acute,O
period,O
of,O
status,O
epilepticus,I-Entity
",",O
we,O
measured,O
:,O
(,O
1,O
),O
the,O
latency,O
of,O
the,O
first,O
motor,O
sign,O
",",O
(,O
2,O
),O
the,O
intensity,O
of,O
seizures,I-Entity
",",O
(,O
3,O
),O
the,O
time,O
when,O
it,O
occurred,O
within,O
the,O
6-h,I-Entity
observation,O
period,O
",",O
and,O
(,O
4,O
),O
the,O
time,O
when,O
the,O
acute,O
period,O
ended,O
.,O
All,I-Entity
these,O
behavioral,O
parameters,O
showed,O
statistically,O
significant,O
changes,O
suggesting,O
that,O
regular,O
physical,O
exercises,O
decrease,O
susceptibility,O
to,O
subsequently,O
induced,O
seizures,I-Entity
and,O
ameliorate,O
the,O
course,O
of,O
experimentally,O
induced,O
status,O
epilepticus,I-Entity
.,O
Tonic,I-Entity
dopaminergic,O
stimulation,O
impairs,I-Entity
associative,O
learning,O
in,O
healthy,O
subjects,O
.,O
Endogenous,I-Entity
dopamine,I-Entity
plays,O
a,O
central,O
role,O
in,O
salience,O
coding,O
during,O
associative,O
learning,O
.,O
Administration,I-Entity
of,O
the,O
dopamine,I-Entity
precursor,O
levodopa,I-Entity
enhances,O
learning,O
in,O
healthy,O
subjects,O
and,O
stroke,O
patients,O
.,O
Because,I-Entity
levodopa,I-Entity
increases,O
both,O
phasic,O
and,O
tonic,I-Entity
dopaminergic,O
neurotransmission,O
",",O
the,O
critical,O
mechanism,O
mediating,O
the,O
enhancement,O
of,O
learning,O
is,O
unresolved,O
.,O
Subjects,I-Entity
received,O
the,O
tonically,O
stimulating,O
dopamine,I-Entity
-,O
receptor,O
agonist,I-Entity
pergolide,I-Entity
(,O
0.1,O
mg,O
),O
vs,O
placebo,O
120,I-Entity
min,O
before,O
training,O
on,O
each,O
training,O
day,O
.,O
The,I-Entity
dopamine,I-Entity
agonist,I-Entity
significantly,O
impaired,I-Entity
novel,O
word,O
learning,O
compared,O
to,O
placebo,O
.,O
Subjects,I-Entity
treated,O
with,O
pergolide,I-Entity
also,O
showed,O
restricted,O
emotional,I-Entity
responses,O
compared,O
to,O
the,O
PLACEBO,I-Entity
group,O
.,O
The,I-Entity
extent,O
of,O
',O
flattened,O
',O
affect,O
with,O
pergolide,I-Entity
was,O
related,O
to,O
the,O
degree,O
of,O
learning,O
inhibition,O
.,O
These,I-Entity
findings,O
suggest,O
that,O
tonic,I-Entity
occupation,O
of,O
dopamine,I-Entity
receptors,O
impairs,I-Entity
learning,O
by,O
competition,O
with,O
phasic,O
dopamine,I-Entity
signals,O
.,O
Thus,I-Entity
",",O
phasic,O
signaling,O
seems,O
to,O
be,O
the,O
critical,O
mechanism,O
by,O
which,O
dopamine,I-Entity
enhances,O
associative,O
learning,O
in,O
healthy,O
subjects,O
and,O
stroke,O
patients,O
.,O
Minocycline,I-Entity
-,O
induced,O
vasculitis,I-Entity
fulfilling,O
the,O
criteria,O
of,O
polyarteritis,I-Entity
nodosa,I-Entity
.,O
A,I-Entity
47-year,O
-,O
old,O
man,O
who,O
had,O
been,O
taking,O
minocycline,I-Entity
for,O
palmoplantar,I-Entity
pustulosis,I-Entity
developed,O
fever,I-Entity
",",O
myalgias,I-Entity
",",O
polyneuropathy,I-Entity
",",O
and,O
testicular,O
pain,I-Entity
",",O
with,O
elevated,O
C,I-Entity
-,O
reactive,O
protein,O
(,O
CRP,I-Entity
),O
.,O
These,I-Entity
manifestations,O
met,O
the,O
American,I-Entity
College,I-Entity
of,O
Rheumatology,I-Entity
1990,O
criteria,O
for,O
the,O
classification,O
of,O
polyarteritis,I-Entity
nodosa,I-Entity
.,O
Stopping,I-Entity
minocycline,I-Entity
led,O
to,O
amelioration,O
of,O
symptoms,O
and,O
normalization,O
of,O
CRP,I-Entity
level,O
.,O
To,I-Entity
our,O
knowledge,O
",",O
this,O
is,O
the,O
second,O
case,O
of,O
minocycline,I-Entity
-,O
induced,O
vasculitis,I-Entity
satisfying,O
the,O
criteria,O
.,O
Differential,I-Entity
diagnosis,O
for,O
drug,O
-,O
induced,O
disease,I-Entity
is,O
invaluable,O
even,O
for,O
patients,O
with,O
classical,O
polyarteritis,I-Entity
nodosa,I-Entity
.,O
Intramuscular,I-Entity
hepatitis,I-Entity
B,I-Entity
immune,O
globulin,I-Entity
combined,O
with,O
lamivudine,I-Entity
in,O
prevention,O
of,O
hepatitis,I-Entity
B,I-Entity
recurrence,O
after,O
liver,I-Entity
transplantation,O
.,O
BACKGROUND,I-Entity
:,O
Combined,I-Entity
hepatitis,I-Entity
B,I-Entity
immune,O
globulin,I-Entity
(,O
HBIg,I-Entity
),O
and,O
lamivudine,I-Entity
in,O
prophylaxis,O
of,O
the,O
recurrence,O
of,O
hepatitis,I-Entity
B,I-Entity
after,O
liver,I-Entity
transplantation,O
has,O
significantly,O
improved,O
the,O
survival,O
of,O
HBsAg,I-Entity
positive,O
patients,O
.,O
This,I-Entity
study,O
was,O
undertaken,O
to,O
evaluate,O
the,O
outcomes,O
of,O
liver,I-Entity
transplantation,O
for,O
patients,O
with,O
hepatitis,I-Entity
B,I-Entity
virus,O
(,O
HBV,I-Entity
),O
.,O
A,I-Entity
retrospective,O
chart,O
analysis,O
and,O
a,O
review,O
of,O
the,O
organ,O
transplant,O
database,O
identified,O
51,I-Entity
patients,O
(,O
43,O
men,O
and,O
8,O
women,O
),O
transplanted,O
for,O
benign,O
HBV,I-Entity
-,O
related,O
cirrhotic,I-Entity
diseases,I-Entity
between,O
June,I-Entity
2002,O
and,O
December,I-Entity
2004,O
who,O
had,O
survived,O
more,O
than,O
3,O
months,O
.,O
A,I-Entity
daily,O
oral,O
dose,O
of,O
100,O
mg,O
lamivudine,I-Entity
for,O
2,O
weeks,O
before,O
transplantation,O
for,O
10,O
patients,O
enabled,O
57.1%,O
(,O
4/7,O
),O
and,O
62.5%,O
(,O
5/8,O
),O
of,O
HBV,I-Entity
-,O
DNA,I-Entity
and,O
HBeAg,I-Entity
positive,O
patients,O
respectively,O
to,O
convert,O
to,O
be,O
negative,O
.,O
Lamivudine,I-Entity
combined,O
with,O
intramuscular,O
HBIg,I-Entity
can,O
effectively,O
prevent,O
allograft,O
from,O
the,O
recurrence,O
of,O
HBV,I-Entity
after,O
liver,I-Entity
transplantation,O
.,O
Anticonvulsant,I-Entity
effect,O
of,O
eslicarbazepine,I-Entity
acetate,I-Entity
(,O
BIA,I-Entity
2,O
-,O
093,O
),O
on,O
seizures,I-Entity
induced,O
by,O
microperfusion,O
of,O
picrotoxin,I-Entity
in,O
the,O
hippocampus,O
of,O
freely,O
moving,O
rats,O
.,O
Eslicarbazepine,I-Entity
acetate,I-Entity
(,O
BIA,I-Entity
2,O
-,O
093,O
",",O
"S-(-)-10-acetoxy-10,11-dihydro-5H",B-Entity
-,O
dibenzo,I-Entity
/,O
b,O
",",O
f,O
/,O
azepine-5-carboxamide,I-Entity
),O
is,O
a,O
novel,O
antiepileptic,O
drug,O
",",O
now,O
in,O
Phase,I-Entity
III,I-Entity
clinical,O
trials,O
",",O
designed,O
with,O
the,O
aim,O
of,O
improving,O
efficacy,O
and,O
safety,O
in,O
comparison,O
with,O
the,O
structurally,O
related,O
drugs,O
carbamazepine,I-Entity
(,O
CBZ,I-Entity
),O
and,O
oxcarbazepine,I-Entity
(,O
OXC,I-Entity
),O
.,O
We,I-Entity
have,O
studied,O
the,O
effects,O
of,O
oral,O
treatment,O
with,O
eslicarbazepine,I-Entity
acetate,I-Entity
on,O
a,O
whole,O
-,O
animal,O
model,O
in,O
which,O
partial,O
seizures,I-Entity
can,O
be,O
elicited,O
repeatedly,O
on,O
different,O
days,O
without,O
changes,O
in,O
threshold,O
or,O
seizure,I-Entity
patterns,O
.,O
In,I-Entity
the,O
animals,O
treated,O
with,O
threshold,O
doses,O
of,O
picrotoxin,I-Entity
",",O
the,O
average,O
number,O
of,O
seizures,I-Entity
was,O
2.3+/-1.2,O
",",O
and,O
average,O
seizure,I-Entity
duration,O
was,O
39.5+/-8.4s,O
.,O
Pre,I-Entity
-,O
treatment,O
with,O
a,O
dose,O
of,O
30,O
mg,O
/,O
kg,O
2h,I-Entity
before,O
picrotoxin,I-Entity
microperfusion,O
prevented,O
seizures,I-Entity
in,O
the,O
75%,O
of,O
the,O
rats,O
.,O
Lower,I-Entity
doses,O
(,O
3,O
and,O
10mg,I-Entity
/,O
kg,O
),O
did,O
not,O
suppress,O
seizures,I-Entity
",",O
however,O
",",O
after,O
administration,O
of,O
10mg,I-Entity
/,O
kg,O
",",O
significant,O
reductions,O
in,O
seizures,I-Entity
duration,O
(,O
24.3+/-6.8s,O
),O
and,O
seizure,I-Entity
number,O
(,O
1.6+/-0.34,O
),O
were,O
found,O
.,O
No,I-Entity
adverse,O
effects,O
of,O
eslicarbazepine,I-Entity
acetate,I-Entity
were,O
observed,O
in,O
the,O
behavioral,O
/,O
EEG,I-Entity
patterns,O
studied,O
",",O
including,O
sleep,O
/,O
wakefulness,O
cycle,O
",",O
at,O
the,O
doses,O
studied,O
.,O
Acute,I-Entity
renal,O
failure,I-Entity
associated,O
with,O
prolonged,O
intake,O
of,O
slimming,O
pills,O
containing,O
anthraquinones,I-Entity
.,O
Chinese,I-Entity
herbal,O
medicine,O
preparations,O
are,O
widely,O
available,O
and,O
often,O
regarded,O
by,O
the,O
public,O
as,O
natural,O
and,O
safe,O
remedies,O
for,O
a,O
variety,O
of,O
medical,O
conditions,O
.,O
Nephropathy,I-Entity
caused,O
by,O
Chinese,I-Entity
herbs,O
has,O
previously,O
been,O
reported,O
",",O
usually,O
involving,O
the,O
use,O
of,O
aristolochic,O
acids,O
.,O
We,I-Entity
report,O
a,O
23-year,O
-,O
old,O
woman,O
who,O
developed,O
acute,O
renal,O
failure,I-Entity
following,O
prolonged,O
use,O
of,O
a,O
proprietary,O
Chinese,I-Entity
herbal,O
slimming,O
pill,O
that,O
contained,O
anthraquinone,I-Entity
derivatives,O
",",O
extracted,O
from,O
Rhizoma,I-Entity
Rhei,I-Entity
(,O
rhubarb,I-Entity
),O
.,O
The,I-Entity
renal,O
injury,I-Entity
was,O
probably,O
aggravated,I-Entity
by,O
the,O
concomitant,I-Entity
intake,O
of,O
a,O
non,O
-,O
steroidal,I-Entity
anti,O
-,O
inflammatory,O
drug,O
",",O
diclofenac,I-Entity
.,O
Renal,I-Entity
pathology,O
was,O
that,O
of,O
hypocellular,O
interstitial,O
fibrosis,I-Entity
.,O
Spontaneous,I-Entity
renal,O
recovery,O
occurred,O
upon,O
cessation,O
of,O
the,O
slimming,O
pills,O
",",O
but,O
mild,O
interstitial,O
fibrosis,I-Entity
and,O
tubular,O
atrophy,I-Entity
was,O
still,O
evident,O
histologically,O
4,O
months,O
later,O
.,O
Although,I-Entity
a,O
causal,O
relationship,O
between,O
the,O
use,O
of,O
an,O
anthraquinone,I-Entity
-,O
containing,O
herbal,O
agent,O
and,O
renal,O
injury,I-Entity
remains,O
to,O
be,O
proven,O
",",O
phytotherapy,O
-,O
associated,O
interstitial,O
nephropathy,I-Entity
should,O
be,O
considered,O
in,O
patients,O
who,O
present,O
with,O
unexplained,O
renal,O
failure,I-Entity
.,O
Chloroacetaldehyde,I-Entity
as,O
a,O
sulfhydryl,I-Entity
reagent,O
:,O
the,O
role,O
of,O
critical,O
thiol,I-Entity
groups,O
in,O
ifosfamide,I-Entity
nephropathy,I-Entity
.,O
Chloroacetaldehyde,I-Entity
(,O
CAA,I-Entity
),O
is,O
a,O
metabolite,O
of,O
the,O
alkylating,B-Entity
agent,O
ifosfamide,I-Entity
(,O
IFO,I-Entity
),O
and,O
putatively,O
responsible,O
for,O
renal,O
damage,O
following,O
anti,O
-,O
tumor,I-Entity
therapy,O
with,O
IFO,I-Entity
.,O
Depletion,I-Entity
of,O
sulfhydryl,I-Entity
(,O
SH,I-Entity
),O
In,I-Entity
this,O
work,O
the,O
effect,O
of,O
CAA,I-Entity
on,O
human,O
proximal,O
tubule,O
cells,O
in,O
primary,O
culture,O
(,O
hRPTEC,I-Entity
),O
was,O
investigated,O
.,O
Toxicity,I-Entity
of,O
CAA,I-Entity
was,O
determined,O
by,O
protein,O
content,O
",",O
cell,O
number,O
",",O
LDH,I-Entity
release,O
",",O
trypan,O
blue,I-Entity
exclusion,O
assay,O
and,O
caspase-3,I-Entity
activity,O
.,O
Free,I-Entity
thiols,I-Entity
were,O
measured,O
by,O
the,O
method,O
of,O
Ellman,I-Entity
.,O
CAA,I-Entity
reduced,O
hRPTEC,I-Entity
cell,O
number,O
and,O
protein,O
",",O
induced,O
a,O
loss,I-Entity
in,O
free,O
intracellular,O
thiols,I-Entity
and,O
an,O
increase,O
in,O
necrosis,I-Entity
markers,O
.,O
CAA,I-Entity
but,O
not,O
acrolein,I-Entity
inhibited,O
the,O
cysteine,I-Entity
B.,I-Entity
Caspase,I-Entity
activation,O
by,O
cisplatin,I-Entity
was,O
inhibited,O
by,O
CAA,I-Entity
.,O
In,I-Entity
cells,O
stained,O
with,O
fluorescent,O
dyes,I-Entity
targeting,O
lysosomes,O
",",O
CAA,I-Entity
induced,O
an,O
increase,O
in,O
lysosomal,O
size,O
and,O
lysosomal,O
leakage,I-Entity
.,O
The,I-Entity
effects,O
of,O
CAA,I-Entity
on,O
cysteine,I-Entity
protease,O
activities,O
and,O
thiols,I-Entity
could,O
be,O
reproduced,O
in,O
cell,O
lysate,I-Entity
.,O
Acidification,I-Entity
",",O
which,O
slowed,O
the,O
reaction,I-Entity
of,O
CAA,I-Entity
with,O
thiol,I-Entity
donors,O
",",O
could,O
also,O
attenuate,O
effects,O
of,O
CAA,I-Entity
on,O
necrosis,I-Entity
markers,O
",",O
thiol,I-Entity
depletion,O
and,O
cysteine,I-Entity
protease,O
inhibition,O
in,O
living,O
cells,O
.,O
Thus,I-Entity
",",O
CAA,I-Entity
directly,O
reacts,O
with,O
cellular,O
protein,O
and,O
non,O
-,O
protein,O
thiols,I-Entity
",",O
mediating,O
its,O
toxicity,I-Entity
on,O
hRPTEC,I-Entity
.,O
Therefore,I-Entity
",",O
urinary,O
acidification,I-Entity
could,O
be,O
an,O
option,O
to,O
prevent,O
IFO,I-Entity
nephropathy,I-Entity
in,O
patients,O
.,O
Stereological,I-Entity
methods,O
reveal,O
the,O
robust,O
size,O
and,O
stability,O
of,O
ectopic,I-Entity
hilar,I-Entity
granule,O
cells,O
after,O
pilocarpine,I-Entity
-,O
induced,O
status,O
epilepticus,I-Entity
in,O
the,O
adult,O
rat,O
.,O
Following,I-Entity
status,O
epilepticus,I-Entity
in,O
the,O
rat,O
",",O
dentate,O
granule,O
cell,O
neurogenesis,I-Entity
increases,O
greatly,O
",",O
and,O
many,O
of,O
the,O
new,O
neurons,O
appear,O
to,O
develop,O
ectopically,O
",",O
in,O
the,O
hilar,I-Entity
region,O
of,O
the,O
hippocampal,O
formation,O
.,O
It,I-Entity
has,O
been,O
suggested,O
that,O
the,O
ectopic,I-Entity
hilar,I-Entity
granule,O
cells,O
could,O
contribute,O
to,O
the,O
spontaneous,O
seizures,I-Entity
that,O
ultimately,O
develop,O
after,O
status,O
epilepticus,I-Entity
.,O
To,I-Entity
quantify,O
this,O
population,O
",",O
the,O
total,O
number,O
of,O
ectopic,I-Entity
hilar,I-Entity
granule,O
cells,O
was,O
estimated,O
using,O
unbiased,O
stereology,O
at,O
different,O
times,O
after,O
pilocarpine,I-Entity
-,O
induced,O
status,O
epilepticus,I-Entity
.,O
The,I-Entity
results,O
indicate,O
that,O
the,O
size,O
of,O
the,O
hilar,I-Entity
ectopic,I-Entity
granule,O
cell,O
population,O
after,O
status,O
epilepticus,I-Entity
is,O
substantial,O
",",O
and,O
stable,O
over,O
time,O
.,O
Interestingly,I-Entity
",",O
the,O
size,O
of,O
the,O
population,O
appears,O
to,O
be,O
correlated,O
with,O
the,O
frequency,O
of,O
behavioral,O
seizures,I-Entity
",",O
because,O
animals,O
with,O
more,O
ectopic,I-Entity
granule,O
cells,O
in,O
the,O
hilus,I-Entity
have,O
more,O
frequent,O
behavioral,O
seizures,I-Entity
.,O
The,I-Entity
results,O
provide,O
new,O
insight,O
into,O
the,O
potential,O
role,O
of,O
ectopic,I-Entity
hilar,I-Entity
granule,O
cells,O
in,O
the,O
pilocarpine,I-Entity
model,O
of,O
temporal,O
lobe,O
epilepsy,I-Entity
.,O
A,I-Entity
prospective,O
",",O
open,O
-,O
label,O
trial,O
of,O
galantamine,I-Entity
in,O
autistic,I-Entity
disorder,I-Entity
.,O
Post,I-Entity
-,O
mortem,O
studies,O
have,O
reported,O
abnormalities,I-Entity
of,O
the,O
cholinergic,O
system,O
in,O
autism,I-Entity
.,O
The,I-Entity
purpose,O
of,O
this,O
study,O
was,O
to,O
assess,O
the,O
use,O
of,O
galantamine,I-Entity
",",O
an,O
acetylcholinesterase,O
inhibitor,O
and,O
nicotinic,O
receptor,O
modulator,O
",",O
in,O
the,O
treatment,O
of,O
interfering,I-Entity
behaviors,O
in,O
children,O
with,O
autism,I-Entity
.,O
Thirteen,I-Entity
medication,O
-,O
free,O
children,O
with,O
autism,I-Entity
(,O
mean,O
age,O
",",O
8.8,O
+,O
/-,O
3.5,O
years,O
),O
participated,O
in,O
a,O
12-week,O
",",O
open,O
-,O
label,O
trial,O
of,O
galantamine,I-Entity
.,O
Patients,I-Entity
showed,O
a,O
significant,O
reduction,O
in,O
parent,O
-,O
rated,O
irritability,I-Entity
and,O
social,O
withdrawal,O
on,O
the,O
ABC,I-Entity
as,O
well,O
as,O
significant,O
improvements,O
in,O
emotional,I-Entity
lability,O
and,O
inattention,O
on,O
the,O
Conners,I-Entity
',O
Parent,I-Entity
Rating,I-Entity
Scale,I-Entity
--,O
Revised,I-Entity
.,O
Overall,I-Entity
",",O
galantamine,I-Entity
was,O
well,O
-,O
tolerated,O
",",O
with,O
no,O
significant,O
adverse,O
effects,O
apart,O
from,O
headaches,I-Entity
in,O
one,O
patient,O
.,O
In,I-Entity
this,O
open,O
trial,O
",",O
galantamine,I-Entity
was,O
well,O
-,O
tolerated,O
and,O
appeared,O
to,O
be,O
beneficial,O
for,O
the,O
treatment,O
of,O
interfering,I-Entity
behaviors,O
in,O
children,O
with,O
autism,I-Entity
",",O
particularly,O
aggression,I-Entity
",",O
behavioral,O
dyscontrol,I-Entity
",",O
and,O
inattention,O
.,O
Randomized,I-Entity
comparison,O
of,O
olanzapine,I-Entity
versus,O
risperidone,I-Entity
for,O
the,O
treatment,O
of,O
first,O
-,O
episode,O
schizophrenia,I-Entity
:,O
4-month,O
outcomes,O
.,O
OBJECTIVE,I-Entity
:,O
The,I-Entity
authors,O
compared,O
4-month,O
treatment,O
outcomes,O
for,O
olanzapine,I-Entity
versus,O
risperidone,I-Entity
in,O
patients,O
with,O
first,O
-,O
episode,O
schizophrenia,I-Entity
spectrum,O
disorders,I-Entity
.,O
One,I-Entity
hundred,O
twelve,O
subjects,O
(,O
70%,O
male,O
;,O
mean,O
age=23.3,O
years,O
[,O
SD,I-Entity
=,O
5.1,O
],O
),O
with,O
first,O
-,O
episode,O
schizophrenia,I-Entity
(,O
75%,O
),O
",",O
schizophreniform,I-Entity
disorder,I-Entity
(,O
17%,O
),O
",",O
or,O
schizoaffective,I-Entity
disorder,I-Entity
(,O
8%,O
),O
were,O
randomly,O
assigned,O
to,O
treatment,O
with,O
olanzapine,I-Entity
(,O
2.5,O
-,O
20,O
mg,O
/,O
day,O
),O
or,O
risperidone,I-Entity
(,O
1,O
-,O
6,O
mg,O
/,O
day,O
),O
.,O
Response,I-Entity
rates,O
did,O
not,O
significantly,O
differ,O
between,O
olanzapine,I-Entity
(,O
43.7%,O
",",O
95%,O
CI=28.8%-58.6%,I-Entity
),O
and,O
risperidone,I-Entity
(,O
54.3%,O
",",O
95%,O
CI=39.9%-68.7%,I-Entity
),O
.,O
Among,I-Entity
those,O
responding,O
to,O
treatment,O
",",O
more,O
subjects,O
in,O
the,O
olanzapine,I-Entity
group,O
(,O
40.9%,O
",",O
95%,O
CI=16.8%-65.0%,I-Entity
),O
than,O
in,O
the,O
risperidone,I-Entity
group,O
(,O
18.9%,O
",",O
95%,O
CI=0%-39.2%,I-Entity
),O
had,O
subsequent,O
ratings,O
not,O
meeting,O
response,O
criteria,O
.,O
Negative,I-Entity
symptom,O
outcomes,O
and,O
measures,O
of,O
parkinsonism,I-Entity
and,O
akathisia,I-Entity
did,O
not,O
differ,O
between,O
medications,O
.,O
Extrapyramidal,I-Entity
symptom,O
severity,O
scores,O
were,O
1.4,O
(,O
95%,O
CI=1.2,I-Entity
-,O
1.6,O
),O
with,O
risperidone,I-Entity
and,O
1.2,O
(,O
95%,O
CI=1.0,I-Entity
-,O
1.4,O
),O
with,O
olanzapine,I-Entity
.,O
Significantly,I-Entity
more,O
weight,O
gain,O
occurred,O
with,O
olanzapine,I-Entity
than,O
with,O
risperidone,I-Entity
:,O
the,O
increase,O
in,O
weight,O
at,O
4,O
months,O
relative,O
to,O
baseline,O
weight,O
was,O
17.3%,O
(,O
95%,O
CI=14.2%-20.5%,I-Entity
),O
with,O
olanzapine,I-Entity
and,O
11.3%,O
(,O
95%,O
CI=8.4%-14.3%,I-Entity
),O
with,O
risperidone,I-Entity
.,O
Body,I-Entity
mass,O
index,O
at,O
baseline,O
and,O
at,O
4,O
months,O
was,O
24.3,O
(,O
95%,O
CI=22.8,O
-,O
25.7,O
),O
versus,O
28.2,O
(,O
95%,O
CI=26.7,O
-,O
29.7,O
),O
with,O
olanzapine,I-Entity
and,O
23.9,O
(,O
95%,O
CI=22.5,O
-,O
25.3,O
),O
versus,O
26.7,O
(,O
95%,O
CI=25.2,O
-,O
28.2,O
),O
with,O
risperidone,I-Entity
.,O
CONCLUSIONS,I-Entity
:,O
Clinical,I-Entity
outcomes,O
with,O
risperidone,I-Entity
were,O
equal,O
to,O
those,O
with,O
olanzapine,I-Entity
",",O
and,O
response,O
may,O
be,O
more,O
stable,O
.,O
Olanzapine,I-Entity
may,O
have,O
an,O
advantage,O
for,O
motor,O
side,O
effects,O
.,O
Both,I-Entity
medications,O
caused,O
substantial,O
rapid,O
weight,O
gain,O
",",O
but,O
weight,O
gain,O
was,O
greater,O
with,O
olanzapine,I-Entity
.,O
Early,I-Entity
paracentral,O
visual,O
field,O
loss,I-Entity
in,O
patients,O
taking,O
hydroxychloroquine,I-Entity
.,O
OBJECTIVE,I-Entity
:,O
To,I-Entity
review,O
the,O
natural,O
history,O
and,O
ocular,O
and,O
systemic,O
adverse,O
effects,O
of,O
patients,O
taking,O
hydroxychloroquine,I-Entity
sulfate,O
who,O
attended,O
an,O
ophthalmic,O
screening,O
program,O
.,O
RESULTS,I-Entity
:,O
Records,I-Entity
of,O
262,O
patients,O
who,O
were,O
taking,O
hydroxychloroquine,I-Entity
and,O
screened,O
in,O
the,O
Department,I-Entity
of,O
Ophthalmology,I-Entity
were,O
reviewed,O
.,O
Thirty,I-Entity
-,O
five,O
patients,O
(,O
13.4%,O
),O
had,O
visual,O
field,O
abnormalities,I-Entity
",",O
which,O
were,O
attributed,O
to,O
hydroxychloroquine,I-Entity
treatment,O
in,O
4,O
patients,O
(,O
1.5%,O
),O
.,O
The,I-Entity
current,O
study,O
used,O
a,O
protocol,O
of,O
visual,O
acuity,O
and,O
color,O
vision,O
assessment,O
",",O
funduscopy,O
",",O
and,O
Humphrey,I-Entity
10,O
-,O
2,O
visual,O
field,O
testing,O
and,O
shows,O
that,O
visual,O
field,O
defects,O
appeared,O
before,O
any,O
corresponding,O
changes,O
in,O
any,O
other,O
tested,O
clinical,O
parameters,O
;,O
the,O
defects,O
were,O
reproducible,O
and,O
the,O
test,O
parameters,O
were,O
reliable,O
.,O
Patients,I-Entity
taking,O
hydroxychloroquine,I-Entity
can,O
demonstrate,O
a,O
toxic,I-Entity
reaction,I-Entity
in,O
the,O
retina,O
despite,O
the,O
absence,O
of,O
known,O
risk,O
factors,O
.,O
Peri,I-Entity
-,O
operative,O
atrioventricular,B-Entity
block,O
as,O
a,O
result,O
of,O
chemotherapy,O
with,O
epirubicin,I-Entity
and,O
paclitaxel,I-Entity
.,O
A,I-Entity
47-year,O
-,O
old,O
woman,O
presented,O
for,O
mastectomy,O
and,O
immediate,O
latissimus,I-Entity
dorsi,O
flap,O
reconstruction,O
having,O
been,O
diagnosed,O
with,O
carcinoma,I-Entity
of,O
the,O
breast,O
6,O
months,O
previously,O
.,O
In,I-Entity
the,O
preceding,O
months,O
she,O
had,O
received,O
neo,I-Entity
-,O
adjuvant,O
chemotherapy,O
with,O
epirubicin,I-Entity
",",O
paclitaxel,I-Entity
(,O
Taxol,I-Entity
),O
and,O
cyclophosphamide,I-Entity
.,O
She,I-Entity
was,O
found,O
to,O
be,O
bradycardic,O
at,O
pre,O
-,O
operative,O
assessment,O
but,O
had,O
no,O
cardiac,O
symptoms,O
.,O
Second,I-Entity
degree,O
Mobitz,I-Entity
type,O
II,I-Entity
atrioventricular,B-Entity
block,O
was,O
diagnosed,O
on,O
electrocardiogram,O
",",O
and,O
temporary,O
transvenous,O
ventricular,O
pacing,O
instituted,O
in,O
the,O
peri,O
-,O
operative,O
period,O
.,O
We,I-Entity
discuss,O
how,O
evidence,O
-,O
based,O
guidelines,O
would,O
not,O
have,O
been,O
helpful,O
in,O
this,O
case,O
",",O
and,O
how,O
chemotherapy,O
can,O
exhibit,O
substantial,O
cardiotoxicity,I-Entity
that,O
may,O
develop,O
over,O
many,O
years,O
.,O
Risks,I-Entity
and,O
benefits,O
of,O
COX-2,I-Entity
inhibitors,O
vs,O
non,O
-,O
selective,O
NSAIDs,I-Entity
:,O
does,O
their,O
cardiovascular,O
risk,O
exceed,O
their,O
gastrointestinal,B-Entity
benefit,O
?,O
The,I-Entity
risk,O
of,O
acute,O
myocardial,B-Entity
infarction,I-Entity
(,O
AMI,I-Entity
),O
with,O
COX-2,I-Entity
inhibitors,O
may,O
offset,O
their,O
gastrointestinal,B-Entity
(,O
GI,I-Entity
),O
benefit,O
compared,O
with,O
non,O
-,O
selective,O
(,O
NS,I-Entity
),O
non,O
-,O
steroidal,I-Entity
anti,O
-,O
inflammatory,O
drugs,O
(,O
NSAIDs,I-Entity
),O
.,O
We,I-Entity
aimed,O
to,O
compare,O
the,O
risks,O
of,O
hospitalization,O
for,O
AMI,I-Entity
and,O
GI,I-Entity
bleeding,I-Entity
among,O
elderly,O
patients,O
using,O
COX-2,I-Entity
inhibitors,O
",",O
NS,I-Entity
-,O
NSAIDs,I-Entity
and,O
acetaminophen,I-Entity
.,O
METHODS,I-Entity
:,O
We,I-Entity
conducted,O
a,O
retrospective,O
cohort,O
study,O
using,O
administrative,O
data,O
of,O
patients,O
>,O
or,O
=,O
65,O
years,O
of,O
age,O
who,O
filled,O
a,O
prescription,O
for,O
NSAID,I-Entity
or,O
acetaminophen,I-Entity
during,O
1999,O
-,O
2002,O
.,O
Person,I-Entity
-,O
years,O
of,O
exposure,O
among,O
non,O
-,O
users,O
of,O
aspirin,I-Entity
were,O
:,O
"75,761",O
to,O
acetaminophen,I-Entity
",",O
"42,671",O
to,O
rofecoxib,I-Entity
"65,860",O
to,O
celecoxib,I-Entity
",",O
and,O
"37,495",O
to,O
NS,I-Entity
-,O
NSAIDs,I-Entity
.,O
Among,I-Entity
users,O
of,O
aspirin,I-Entity
",",O
they,O
were,O
:,O
"14,671",O
to,O
rofecoxib,I-Entity
",",O
"22,875",O
to,O
celecoxib,I-Entity
",",O
"9,832",O
to,O
NS,I-Entity
-,O
NSAIDs,I-Entity
and,O
"38,048",O
to,O
acetaminophen,I-Entity
.,O
Among,I-Entity
non,O
-,O
users,O
of,O
aspirin,I-Entity
",",O
the,O
adjusted,O
hazard,O
ratios,O
(,O
95%,O
confidence,O
interval,O
),O
of,O
hospitalization,O
for,O
AMI,I-Entity
/,O
GI,I-Entity
vs,O
the,O
acetaminophen,I-Entity
(,O
with,O
no,O
aspirin,I-Entity
),O
group,O
were,O
:,O
rofecoxib,I-Entity
1.27,O
(,O
1.13,O
",",O
1.42,O
),O
",",O
celecoxib,I-Entity
0.93,O
(,O
0.83,O
",",O
1.03,O
),O
",",O
naproxen,I-Entity
1.59,O
(,O
1.31,O
",",O
1.93,O
),O
",",O
diclofenac,I-Entity
1.17,O
(,O
0.99,O
",",O
1.38,O
),O
and,O
ibuprofen,I-Entity
1.05,O
(,O
0.74,O
",",O
1.51,O
),O
.,O
Among,I-Entity
users,O
of,O
aspirin,I-Entity
",",O
they,O
were,O
:,O
rofecoxib,I-Entity
1.73,O
(,O
1.52,O
",",O
1.98,O
),O
",",O
celecoxib,I-Entity
1.34,O
(,O
1.19,O
",",O
1.52,O
),O
",",O
ibuprofen,I-Entity
1.51,O
(,O
0.95,O
",",O
2.41,O
),O
",",O
diclofenac,I-Entity
1.69,O
(,O
1.35,O
",",O
2.10,O
),O
",",O
naproxen,I-Entity
1.35,O
(,O
0.97,O
",",O
1.88,O
),O
and,O
acetaminophen,I-Entity
1.29,O
(,O
1.17,O
",",O
1.42,O
),O
.,O
Among,I-Entity
non,O
-,O
users,O
of,O
aspirin,I-Entity
",",O
naproxen,I-Entity
seemed,O
to,O
carry,O
the,O
highest,O
risk,O
for,O
AMI,I-Entity
/,O
GI,I-Entity
bleeding,I-Entity
.,O
The,I-Entity
AMI,I-Entity
/,O
GI,I-Entity
toxicity,I-Entity
of,O
celecoxib,I-Entity
was,O
similar,O
to,O
that,O
of,O
acetaminophen,I-Entity
and,O
seemed,O
to,O
be,O
better,O
than,O
those,O
of,O
rofecoxib,I-Entity
and,O
NS,I-Entity
-,O
NSAIDs,I-Entity
.,O
Among,I-Entity
users,O
of,O
aspirin,I-Entity
",",O
both,O
celecoxib,I-Entity
and,O
naproxen,I-Entity
seemed,O
to,O
be,O
the,O
least,O
toxic,I-Entity
.,O
Quinine,I-Entity
-,O
induced,O
arrhythmia,I-Entity
in,O
a,O
patient,O
with,O
severe,O
malaria,I-Entity
.,O
It,I-Entity
was,O
reported,O
that,O
there,O
was,O
a,O
case,O
of,O
severe,O
malaria,I-Entity
patient,O
with,O
jaundice,I-Entity
who,O
presented,O
with,O
arrhythmia,I-Entity
(,O
premature,I-Entity
ventricular,O
contraction,I-Entity
),O
while,O
getting,O
quinine,I-Entity
infusion,O
was,O
reported,O
.,O
A,I-Entity
man,O
",",O
25,O
years,O
old,O
",",O
was,O
admitted,O
to,O
hospital,O
with,O
high,O
fever,I-Entity
",",O
chill,O
",",O
vomiting,I-Entity
",",O
jaundice,I-Entity
.,O
On,I-Entity
admission,O
",",O
laboratory,O
examination,O
showed,O
Plasmodium,I-Entity
falciparum,I-Entity
(,O
+,O
+,O
+,O
+,O
),O
",",O
total,O
bilirubin,I-Entity
8.25,O
mg,O
/,O
dL,I-Entity
",",O
conjugated,O
bilirubin,I-Entity
4.36,O
mg,O
/,O
dL,I-Entity
",",O
unconjugated,O
bilirubin,I-Entity
3.89,O
mg,O
/,O
dL,I-Entity
",",O
potassium,I-Entity
3.52,O
meq,I-Entity
/,O
L,I-Entity
Patient,I-Entity
was,O
diagnosed,O
as,O
severe,O
malaria,I-Entity
with,O
jaundice,I-Entity
and,O
got,O
quinine,I-Entity
infusion,O
in,O
dextrose,I-Entity
5%,O
500,O
mg/8,O
hour,O
.,O
On,I-Entity
the,O
second,O
day,O
the,O
patient,O
had,O
vomitus,I-Entity
",",O
diarrhea,I-Entity
",",O
tinnitus,I-Entity
",",O
loss,I-Entity
of,O
hearing,O
.,O
After,I-Entity
30,O
hours,O
of,O
quinine,I-Entity
infusion,O
the,O
patient,O
felt,O
palpitation,O
and,O
electrocardiography,O
(,O
ECG,I-Entity
),O
recording,O
showed,O
premature,I-Entity
ventricular,O
contraction,I-Entity
(,O
PVC,I-Entity
),O
>,O
5,O
x,O
/,O
minute,O
",",O
trigemini,I-Entity
",",O
constant,O
type,O
--,O
sinoatrial,O
block,O
",",O
positive,O
U,I-Entity
wave,O
.,O
He,I-Entity
was,O
treated,O
with,O
lidocaine,I-Entity
50,O
mg,O
intravenously,O
followed,O
by,O
infusion,O
1500,I-Entity
mg,O
in,O
dextrose,I-Entity
5%/24,O
hour,O
and,O
potassium,I-Entity
aspartate,I-Entity
tablet,O
.,O
Quinine,I-Entity
infusion,O
was,O
discontinued,O
and,O
changed,O
with,O
sulfate,O
quinine,I-Entity
tablets,O
.,O
Three,I-Entity
hours,O
later,O
the,O
patient,O
felt,O
better,O
",",O
the,O
frequency,O
of,O
PVC,I-Entity
reduced,O
to,O
4,O
-,O
5,O
x,O
/,O
minute,O
and,O
on,O
the,O
third,O
day,O
ECG,I-Entity
was,O
normal,O
",",O
potassium,I-Entity
level,O
was,O
3.34,O
meq,I-Entity
/,O
L.,I-Entity
Quinine,I-Entity
",",O
like,O
quinidine,I-Entity
",",O
is,O
a,O
chincona,I-Entity
alkaloid,O
that,O
has,O
anti,O
-,O
arrhythmic,I-Entity
property,O
",",O
although,O
it,O
also,O
pro,O
-,O
arrhythmic,I-Entity
that,O
can,O
cause,O
various,O
arrhythmias,I-Entity
",",O
including,O
severe,O
arrhythmia,I-Entity
such,O
as,O
multiple,O
PVC,I-Entity
.,O
Administration,I-Entity
of,O
parenteral,O
quinine,I-Entity
must,O
be,O
done,O
carefully,O
and,O
with,O
good,O
observation,O
because,O
of,O
its,O
pro,O
-,O
arrhythmic,I-Entity
effect,O
",",O
especially,O
in,O
older,O
patients,O
who,O
have,O
heart,O
diseases,I-Entity
or,O
patients,O
with,O
electrolyte,O
disorder,I-Entity
(,O
hypokalemia,I-Entity
),O
which,O
frequently,O
occurs,O
due,O
to,O
vomiting,I-Entity
and,O
or,O
diarrhea,I-Entity
in,O
malaria,I-Entity
cases,O
.,O
Penicillamine,I-Entity
-,O
related,O
lichenoid,I-Entity
dermatitis,I-Entity
and,O
utility,O
of,O
zinc,I-Entity
acetate,I-Entity
in,O
a,O
Wilson,I-Entity
disease,I-Entity
patient,O
with,O
hepatic,B-Entity
presentation,O
",",O
anxiety,I-Entity
and,O
SPECT,I-Entity
abnormalities,I-Entity
.,O
Wilson,I-Entity
's,I-Entity
disease,I-Entity
is,O
an,O
autosomal,O
recessive,O
disorder,I-Entity
of,O
hepatic,B-Entity
copper,I-Entity
metabolism,O
with,O
consequent,O
copper,I-Entity
accumulation,O
and,O
toxicity,I-Entity
in,O
many,O
tissues,O
and,O
consequent,O
hepatic,B-Entity
",",O
neurologic,O
and,O
psychiatric,I-Entity
disorders,I-Entity
.,O
We,I-Entity
report,O
a,O
case,O
of,O
Wilson,I-Entity
's,I-Entity
disease,I-Entity
with,O
chronic,O
liver,I-Entity
disease,I-Entity
;,O
moreover,O
",",O
in,O
our,O
patient,O
",",O
presenting,O
also,O
with,O
high,O
levels,O
of,O
state,O
anxiety,I-Entity
without,O
depression,I-Entity
",",O
99mTc,I-Entity
-,O
ECD,I-Entity
-,O
SPECT,I-Entity
showed,O
cortical,O
hypoperfusion,I-Entity
in,O
frontal,O
lobes,O
",",O
more,O
marked,O
on,O
the,O
left,O
frontal,O
lobe,O
.,O
During,I-Entity
the,O
follow,O
-,O
up,O
of,O
our,O
patient,O
",",O
penicillamine,I-Entity
was,O
interrupted,I-Entity
after,O
the,O
appearance,O
of,O
a,O
lichenoid,I-Entity
dermatitis,I-Entity
",",O
and,O
zinc,I-Entity
acetate,I-Entity
permitted,O
to,O
continue,O
the,O
successful,O
treatment,O
of,O
the,O
patient,O
without,O
side,O
-,O
effects,O
.,O
In,I-Entity
our,O
case,O
the,O
therapy,O
with,O
zinc,I-Entity
acetate,I-Entity
represented,O
an,O
effective,O
treatment,O
for,O
a,O
Wilson,I-Entity
's,I-Entity
disease,I-Entity
patient,O
in,O
which,O
penicillamine,I-Entity
-,O
related,O
side,O
effects,O
appeared,O
.,O
The,I-Entity
safety,O
of,O
the,O
zinc,I-Entity
acetate,I-Entity
allowed,O
us,O
to,O
avoid,O
other,O
potentially,O
toxic,I-Entity
chelating,O
drugs,O
;,O
this,O
observation,O
is,O
in,O
line,O
with,O
the,O
growing,O
evidence,O
on,O
the,O
efficacy,O
of,O
the,O
drug,O
in,O
the,O
treatment,O
of,O
Wilson,I-Entity
's,I-Entity
disease,I-Entity
.,O
Since,I-Entity
most,O
of,O
Wilson,I-Entity
's,I-Entity
disease,I-Entity
penicillamine,I-Entity
-,O
treated,O
patients,O
do,O
not,O
seem,O
to,O
develop,O
this,O
skin,O
lesion,I-Entity
",",O
it,O
could,O
be,O
conceivable,O
that,O
a,O
specific,O
genetic,O
factor,O
is,O
involved,O
in,O
drug,O
response,O
.,O
Further,I-Entity
studies,O
are,O
needed,O
for,O
a,O
better,O
clarification,O
of,O
Wilson,I-Entity
's,I-Entity
disease,I-Entity
therapy,O
",",O
and,O
in,O
particular,O
to,O
differentiate,O
specific,O
therapies,O
for,O
different,O
Wilson,I-Entity
's,I-Entity
disease,I-Entity
phenotypes,O
.,O
A,I-Entity
dramatic,O
drop,O
in,O
blood,O
pressure,O
following,O
prehospital,O
GTN,I-Entity
administration,O
.,O
A,I-Entity
male,O
in,O
his,O
sixties,O
with,O
no,O
history,O
of,O
cardiac,O
chest,O
pain,I-Entity
awoke,O
with,O
chest,O
pain,I-Entity
following,O
an,O
afternoon,O
sleep,O
.,O
The,I-Entity
patient,O
's,I-Entity
observations,O
were,O
within,O
normal,O
limits,O
",",O
he,O
was,O
administered,O
oxygen,I-Entity
via,O
a,O
face,O
mask,O
and,O
glyceryl,I-Entity
trinitrate,I-Entity
(,O
GTN,I-Entity
),O
.,O
Several,I-Entity
minutes,O
after,O
the,O
GTN,I-Entity
the,O
patient,O
experienced,O
a,O
sudden,I-Entity
drop,O
in,O
blood,O
pressure,O
and,O
heart,O
rate,O
",",O
this,O
was,O
rectified,O
by,O
atropine,I-Entity
sulphate,I-Entity
and,O
a,O
fluid,O
challenge,O
.,O
Prehospital,I-Entity
care,O
providers,O
who,O
are,O
managing,O
any,O
patient,O
with,O
a,O
syncopal,I-Entity
episode,O
that,O
fails,O
to,O
recover,O
within,O
a,O
reasonable,O
time,O
frame,O
should,O
consider,O
the,O
Bezold,I-Entity
-,O
Jarisch,I-Entity
reflex,O
as,O
the,O
cause,O
and,O
manage,O
the,O
patient,O
accordingly,O
.,O
Acute,I-Entity
encephalopathy,I-Entity
and,O
cerebral,O
vasospasm,I-Entity
after,O
multiagent,O
chemotherapy,O
including,O
PEG,I-Entity
-,O
asparaginase,I-Entity
and,O
intrathecal,O
cytarabine,I-Entity
for,O
the,O
treatment,O
of,O
acute,O
lymphoblastic,B-Entity
leukemia,I-Entity
.,O
A,I-Entity
7-year,O
-,O
old,O
girl,O
with,O
an,O
unusual,O
reaction,I-Entity
to,O
induction,O
chemotherapy,O
for,O
precursor,O
B,I-Entity
-,O
cell,O
acute,O
lymphoblastic,B-Entity
leukemia,I-Entity
(,O
ALL,I-Entity
),O
is,O
described,O
.,O
The,I-Entity
patient,O
developed,O
acute,O
encephalopathy,I-Entity
evidenced,O
by,O
behavioral,O
changes,O
",",O
aphasia,I-Entity
",",O
incontinence,I-Entity
",",O
visual,O
hallucinations,I-Entity
",",O
and,O
right,O
-,O
sided,O
weakness,I-Entity
with,O
diffuse,O
cerebral,O
vasospasm,I-Entity
on,O
magnetic,O
resonance,O
angiography,O
after,O
the,O
administration,O
of,O
intrathecal,O
cytarabine,I-Entity
.,O
Vincristine,I-Entity
",",O
dexamethasone,I-Entity
",",O
and,O
polyethylene,I-Entity
glycol,I-Entity
-,O
asparaginase,I-Entity
were,O
also,O
administered,O
before,O
the,O
episode,O
as,O
part,O
of,O
induction,O
therapy,O
.,O
Comparison,I-Entity
of,O
valsartan,I-Entity
/,O
hydrochlorothiazide,I-Entity
combination,O
therapy,O
at,O
doses,O
up,O
to,O
320/25,O
mg,O
versus,O
monotherapy,O
:,O
a,O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
study,O
followed,O
by,O
long,O
-,O
term,O
combination,O
therapy,O
in,O
hypertensive,I-Entity
adults,O
.,O
One,I-Entity
third,O
of,O
patients,O
treated,O
for,O
hypertension,I-Entity
attain,O
adequate,O
blood,O
pressure,O
(,O
BP,I-Entity
),O
control,O
",",O
and,O
multidrug,O
regimens,I-Entity
are,O
often,O
required,O
.,O
Given,I-Entity
the,O
lifelong,O
nature,O
of,O
hypertension,I-Entity
",",O
there,O
is,O
a,O
need,O
to,O
evaluate,O
the,O
long,O
-,O
term,O
efficacy,O
and,O
tolerability,O
of,O
higher,O
doses,O
of,O
combination,O
anti,O
-,O
hypertensive,I-Entity
therapies,O
.,O
This,I-Entity
study,O
investigated,O
the,O
efficacy,O
and,O
tolerability,O
of,O
valsartan,I-Entity
(,O
VAL,I-Entity
),O
or,O
hydrochlorothiazide,I-Entity
(,O
HCTZ)-monotherapy,I-Entity
and,O
higher,O
-,O
dose,O
combinations,O
in,O
patients,O
with,O
essential,O
hypertension,I-Entity
.,O
Patients,I-Entity
with,O
essential,O
hypertension,I-Entity
(,O
mean,O
sitting,O
diastolic,I-Entity
BP,I-Entity
[,O
MSDBP,I-Entity
],O
",",O
>,O
or,O
=,O
95,O
mm,O
Hg,I-Entity
and,O
<,O
110,I-Entity
mm,O
Hg,I-Entity
),O
were,O
randomized,O
to,O
1,O
of,O
8,O
treatment,O
groups,O
:,O
VAL,I-Entity
160,I-Entity
or,O
320,I-Entity
mg,O
;,O
HCTZ,I-Entity
12.5,O
or,O
25,O
mg,O
;,O
VAL,I-Entity
/,O
HCTZ,I-Entity
160/12.5,O
",",O
320/12.5,O
",",O
or,O
320/25,O
mg,O
;,O
or,O
placebo,O
.,O
VAL,I-Entity
/,O
HCTZ,I-Entity
320/12.5,O
and,O
320/25,O
mg,O
were,O
further,O
investigated,O
in,O
a,O
54-week,O
",",O
open,O
-,O
label,O
extension,O
.,O
All,I-Entity
active,O
treatments,O
were,O
associated,O
with,O
significantly,O
reduced,O
MSSBP,I-Entity
and,O
MSDBP,I-Entity
during,O
the,O
core,O
8-week,O
study,O
",",O
with,O
each,O
monotherapy,O
significantly,O
contributing,O
to,O
the,O
overall,O
effect,O
of,O
combination,O
therapy,O
(,O
VAL,I-Entity
and,O
HCTZ,I-Entity
",",O
P,I-Entity
The,I-Entity
mean,O
reduction,O
in,O
MSSBP,I-Entity
/,O
MSDBP,I-Entity
with,O
VAL,I-Entity
/,O
HCTZ,I-Entity
320/25,O
mg,O
was,O
24.7/16.6,O
mm,O
Hg,I-Entity
",",O
compared,O
with,O
5.9/7.0,O
mm,O
Hg,I-Entity
with,O
placebo,O
.,O
The,I-Entity
reduction,O
in,O
MSSBP,I-Entity
was,O
significantly,O
greater,O
with,O
VAL,I-Entity
/,O
HCTZ,I-Entity
320/25,O
mg,O
compared,O
with,O
VAL,I-Entity
/,O
HCTZ,I-Entity
160/12.5,O
mg,O
(,O
P,I-Entity
<,O
0.002,O
),O
.,O
The,I-Entity
incidence,O
of,O
hypokalemia,I-Entity
was,O
lower,O
with,O
VAL,I-Entity
/,O
HCTZ,I-Entity
combinations,O
(,O
1.8%-6.1%,O
),O
than,O
with,O
HCTZ,I-Entity
monotherapies,O
(,O
7.1%-13.3%,O
),O
.,O
The,I-Entity
efficacy,O
and,O
tolerability,O
of,O
VAL,I-Entity
/,O
HCTZ,I-Entity
combinations,O
were,O
maintained,O
during,O
the,O
extension,O
(,O
797,I-Entity
patients,O
),O
.,O
In,I-Entity
this,O
study,O
population,O
",",O
combination,O
therapies,O
with,O
VAL,I-Entity
/,O
HCTZ,I-Entity
were,O
associated,O
with,O
significantly,O
greater,O
BP,I-Entity
reductions,O
compared,O
with,O
either,O
monotherapy,O
",",O
were,O
well,O
tolerated,O
",",O
and,O
were,O
associated,O
with,O
less,O
hypokalemia,I-Entity
than,O
HCTZ,I-Entity
alone,O
.,O
Succimer,I-Entity
chelation,O
improves,O
learning,O
",",O
attention,O
",",O
and,O
arousal,I-Entity
regulation,O
in,O
lead,O
-,O
exposed,O
rats,O
but,O
produces,O
lasting,O
cognitive,O
impairment,I-Entity
in,O
the,O
absence,O
of,O
lead,O
exposure,O
.,O
BACKGROUND,I-Entity
:,O
There,I-Entity
is,O
growing,O
pressure,O
for,O
clinicians,O
to,O
prescribe,O
chelation,O
therapy,O
at,O
only,O
slightly,O
elevated,O
blood,O
lead,O
levels,O
.,O
However,I-Entity
",",O
very,O
few,O
studies,O
have,O
evaluated,O
whether,O
chelation,O
improves,O
cognitive,O
outcomes,O
in,O
Pb,I-Entity
-,O
exposed,O
children,O
",",O
or,O
whether,O
these,O
agents,O
have,O
adverse,O
effects,O
that,O
may,O
affect,O
brain,O
development,O
in,O
the,O
absence,O
of,O
Pb,I-Entity
exposure,O
.,O
The,I-Entity
present,O
study,O
was,O
designed,O
to,O
answer,O
these,O
questions,O
",",O
using,O
a,O
rodent,I-Entity
model,O
of,O
early,O
childhood,O
Pb,I-Entity
exposure,O
and,O
treatment,O
with,O
succimer,I-Entity
",",O
a,O
widely,O
used,O
chelating,O
agent,O
for,O
the,O
treatment,O
of,O
Pb,I-Entity
poisoning,I-Entity
.,O
Pb,I-Entity
exposure,O
produced,O
lasting,O
impairments,I-Entity
in,O
learning,O
",",O
attention,O
",",O
inhibitory,O
control,O
",",O
and,O
arousal,I-Entity
regulation,O
",",O
paralleling,O
the,O
areas,O
of,O
dysfunction,I-Entity
seen,O
in,O
Pb,I-Entity
-,O
exposed,O
children,O
.,O
Succimer,I-Entity
treatment,O
of,O
the,O
Pb,I-Entity
-,O
exposed,O
rats,O
significantly,O
improved,O
learning,O
",",O
attention,O
",",O
and,O
arousal,I-Entity
regulation,O
",",O
although,O
the,O
efficacy,O
of,O
the,O
treatment,O
varied,O
as,O
a,O
function,O
of,O
the,O
Pb,I-Entity
exposure,O
level,O
and,O
the,O
specific,O
functional,O
deficit,I-Entity
.,O
In,I-Entity
contrast,O
",",O
succimer,I-Entity
treatment,O
of,O
rats,O
not,O
previously,O
exposed,O
to,O
Pb,I-Entity
produced,O
lasting,O
and,O
pervasive,O
cognitive,O
and,O
affective,O
dysfunction,I-Entity
comparable,O
in,O
magnitude,O
to,O
that,O
produced,O
by,O
the,O
higher,O
Pb,I-Entity
exposure,O
regimen,I-Entity
.,O
These,I-Entity
are,O
the,O
first,O
data,O
",",O
to,O
our,O
knowledge,O
",",O
to,O
show,O
that,O
treatment,O
with,O
any,O
chelating,O
agent,O
can,O
alleviate,O
cognitive,O
deficits,I-Entity
due,O
to,O
Pb,I-Entity
exposure,O
.,O
These,I-Entity
findings,O
suggest,O
that,O
it,O
may,O
be,O
possible,O
to,O
identify,O
a,O
succimer,I-Entity
treatment,O
protocol,O
that,O
improves,O
cognitive,O
outcomes,O
in,O
Pb,I-Entity
-,O
exposed,O
children,O
.,O
However,I-Entity
",",O
they,O
also,O
suggest,O
that,O
succimer,I-Entity
treatment,O
should,O
be,O
strongly,O
discouraged,O
for,O
children,O
who,O
do,O
not,O
have,O
elevated,O
tissue,O
levels,O
of,O
Pb,I-Entity
or,O
other,O
heavy,O
metals,O
.,O
Caffeine,I-Entity
challenge,O
test,O
in,O
panic,I-Entity
disorder,I-Entity
and,O
depression,I-Entity
with,O
panic,I-Entity
attacks,O
.,O
Our,I-Entity
aim,O
was,O
to,O
observe,O
if,O
patients,O
with,O
panic,I-Entity
disorder,I-Entity
(,O
PD,I-Entity
),O
and,O
patients,O
with,O
major,O
depression,I-Entity
with,O
panic,I-Entity
attacks,O
(,O
MDP,I-Entity
),O
(,O
Diagnostic,I-Entity
and,O
Statistical,I-Entity
Manual,I-Entity
of,O
Mental,I-Entity
Disorders,I-Entity
",",O
Fourth,I-Entity
Edition,I-Entity
criteria,O
),O
respond,O
in,O
a,O
similar,O
way,O
to,O
the,O
induction,O
of,O
panic,I-Entity
attacks,O
by,O
an,O
oral,O
caffeine,I-Entity
challenge,O
test,O
.,O
We,I-Entity
randomly,O
selected,O
29,O
patients,O
with,O
PD,I-Entity
",",O
27,O
with,O
MDP,I-Entity
",",O
25,O
with,O
major,O
depression,I-Entity
without,O
panic,I-Entity
attacks,O
(,O
MD,I-Entity
),O
",",O
and,O
28,O
healthy,O
volunteers,O
.,O
In,I-Entity
a,O
randomized,O
double,O
-,O
blind,O
experiment,O
performed,O
in,O
2,O
occasions,O
7,O
days,O
apart,O
",",O
480,O
mg,O
caffeine,I-Entity
and,O
a,O
caffeine,I-Entity
-,O
free,O
(,O
placebo,O
),O
solution,O
were,O
administered,O
in,O
a,O
coffee,O
form,O
and,O
anxiety,I-Entity
scales,O
were,O
applied,O
before,O
and,O
after,O
each,O
test,O
.,O
A,I-Entity
total,O
of,O
58.6%,O
(,O
n,O
=,O
17,O
),O
of,O
patients,O
with,O
PD,I-Entity
",",O
44.4%,O
(,O
n,O
=,O
12,O
),O
of,O
patients,O
with,O
MDP,I-Entity
",",O
12.0%,O
(,O
n,O
=,O
3,O
),O
of,O
patients,O
with,O
MD,I-Entity
",",O
and,O
7.1%,O
(,O
n=,O
2,O
),O
of,O
control,O
subjects,O
had,O
a,O
panic,I-Entity
attack,O
after,O
the,O
480-mg,O
caffeine,I-Entity
challenge,O
test,O
(,O
chi(2)(3,I-Entity
),O
=,O
16.22,O
",",O
P,I-Entity
=,O
.001,O
),O
.,O
The,I-Entity
patients,O
with,O
PD,I-Entity
and,O
MDP,I-Entity
were,O
more,O
sensitive,I-Entity
to,O
caffeine,I-Entity
than,O
were,O
patients,O
with,O
MD,I-Entity
and,O
healthy,O
volunteers,O
.,O
No,I-Entity
panic,I-Entity
attack,O
was,O
observed,O
after,O
the,O
caffeine,I-Entity
-,O
free,O
solution,O
intake,O
.,O
The,I-Entity
patients,O
with,O
MD,I-Entity
had,O
a,O
lower,O
heart,O
rate,O
response,O
to,O
the,O
test,O
than,O
all,O
the,O
other,O
groups,O
(,O
2-way,O
analysis,O
of,O
variance,O
",",O
group,O
by,O
time,O
interaction,O
with,O
Greenhouse,I-Entity
-,O
Geisser,I-Entity
correction,O
:,O
"F(3,762",I-Entity
),O
=,O
2.85,O
",",O
P,I-Entity
=,O
.026,O
),O
.,O
Our,I-Entity
data,O
suggest,O
that,O
there,O
is,O
an,O
association,O
between,O
panic,I-Entity
attacks,O
",",O
no,O
matter,O
if,O
associated,O
with,O
PD,I-Entity
or,O
MDP,I-Entity
",",O
and,O
hyperreactivity,I-Entity
to,O
an,O
oral,O
caffeine,I-Entity
challenge,O
test,O
.,O
Mitral,I-Entity
annuloplasty,O
as,O
a,O
ventricular,O
restoration,O
method,O
for,O
the,O
failing,O
left,O
ventricle,O
:,O
a,O
pilot,O
study,O
.,O
Undersized,I-Entity
mitral,O
annuloplasty,O
(,O
MAP,I-Entity
),O
is,O
effective,O
in,O
patients,O
with,O
dilated,O
cardiomyopathy,I-Entity
and,O
functional,O
mitral,O
regurgitation,O
(,O
MR,I-Entity
),O
since,O
",",O
as,O
well,O
as,O
addressing,O
the,O
MR,I-Entity
",",O
the,O
MAP,I-Entity
may,O
also,O
reshape,O
the,O
dilated,O
left,O
ventricular,O
(,O
LV,I-Entity
),O
base,O
.,O
However,I-Entity
",",O
the,O
direct,O
benefits,O
of,O
this,O
possible,O
reshaping,O
on,O
LV,I-Entity
function,O
in,O
the,O
absence,O
of,O
underlying,O
MR,I-Entity
remain,O
incompletely,O
understood,O
.,O
The,I-Entity
study,O
aim,O
was,O
to,O
identify,O
these,O
benefits,O
in,O
a,O
canine,O
model,O
of,O
acute,O
heart,O
failure,I-Entity
.,O
Acute,I-Entity
heart,O
failure,I-Entity
was,O
induced,O
by,O
propranolol,I-Entity
and,O
volume,O
loading,O
after,O
weaning,O
from,O
cardiopulmonary,O
bypass,O
;,O
an,O
absence,O
of,O
MR,I-Entity
was,O
confirmed,O
by,O
echocardiography,O
.,O
Data,I-Entity
were,O
acquired,O
at,O
baseline,O
",",O
after,O
induction,O
of,O
acute,O
heart,O
failure,I-Entity
",",O
and,O
after,O
MAP,I-Entity
.,O
:,O
The,I-Entity
data,O
acquired,O
suggest,O
that,O
isolated,O
MAP,I-Entity
may,O
have,O
certain,O
benefits,O
on,O
LV,I-Entity
dimension,O
/,O
function,O
in,O
acute,O
heart,O
failure,I-Entity
",",O
even,O
in,O
the,O
absence,O
of,O
MR,I-Entity
.,O
However,I-Entity
",",O
further,O
investigations,O
are,O
warranted,O
in,O
a,O
model,O
of,O
chronic,O
heart,O
failure,I-Entity
.,O
Piperacillin,I-Entity
/,O
tazobactam,I-Entity
-,O
induced,O
seizure,I-Entity
rapidly,O
reversed,O
by,O
high,O
flux,O
hemodialysis,O
in,O
a,O
patient,O
on,O
peritoneal,O
dialysis,O
.,O
Despite,I-Entity
popular,O
use,O
of,O
piperacillin,I-Entity
",",O
the,O
dire,I-Entity
neurotoxicity,I-Entity
associated,O
with,O
piperacillin,I-Entity
still,O
goes,O
unrecognized,O
",",O
leading,O
to,O
a,O
delay,O
in,O
appropriate,O
management,O
.,O
We,I-Entity
report,O
a,O
57-year,O
-,O
old,O
woman,O
with,O
end,O
-,O
stage,O
renal,O
disease,I-Entity
receiving,O
continuous,O
ambulatory,O
peritoneal,O
dialysis,O
(,O
CAPD,I-Entity
),O
",",O
who,O
developed,O
slurred,I-Entity
speech,O
",",O
tremor,I-Entity
",",O
bizarre,I-Entity
behavior,O
",",O
progressive,O
mental,O
confusion,I-Entity
",",O
and,O
2,O
episodes,O
of,O
generalized,O
tonic,I-Entity
-,O
clonic,I-Entity
seizure,I-Entity
(,O
GTCS,I-Entity
),O
after,O
5,O
doses,O
of,O
piperacillin,I-Entity
/,O
tazobactam,I-Entity
(,O
2,O
g/250,O
mg,O
),O
were,O
given,O
for,O
bronchiectasis,I-Entity
with,O
secondary,O
infection,I-Entity
.,O
The,I-Entity
laboratory,O
data,O
revealed,O
normal,O
plasma,O
electrolyte,O
and,O
ammonia,O
levels,O
but,O
leukocytosis,I-Entity
.,O
Neurologic,I-Entity
examinations,O
showed,O
dysarthria,I-Entity
and,O
bilateral,O
Babinski,I-Entity
sign,O
.,O
Despite,I-Entity
the,O
use,O
of,O
antiepileptic,O
agents,O
",",O
another,O
GTCS,I-Entity
episode,O
recurred,O
after,O
the,O
sixth,O
dose,O
of,O
piperacillin,I-Entity
/,O
tazobactam,I-Entity
.,O
Brain,I-Entity
magnetic,O
resonance,O
imaging,O
did,O
not,O
demonstrate,O
acute,O
infarction,I-Entity
and,O
organic,O
brain,O
lesions,O
.,O
Piperacillin,I-Entity
-,O
induced,O
encephalopathy,I-Entity
should,O
be,O
considered,O
in,O
any,O
uremic,I-Entity
patients,O
with,O
unexplained,O
neurological,O
manifestations,O
.,O
CAPD,I-Entity
is,O
inefficient,I-Entity
in,O
removing,O
piperacillin,I-Entity
",",O
whereas,O
hemodialysis,O
can,O
rapidly,O
terminate,O
the,O
piperacillin,I-Entity
-,O
induced,O
encephalopathy,I-Entity
.,O
Frequency,I-Entity
of,O
transient,O
ipsilateral,O
vocal,O
cord,O
paralysis,I-Entity
in,O
patients,O
undergoing,O
carotid,O
endarterectomy,O
under,O
local,O
anesthesia,O
.,O
Temporary,I-Entity
ipsilateral,O
vocal,O
nerve,O
palsies,I-Entity
due,O
to,O
local,O
anesthetics,O
have,O
been,O
described,O
",",O
however,O
.,O
Such,I-Entity
complications,O
are,O
most,O
important,O
in,O
situations,O
where,O
there,O
is,O
a,O
pre,O
-,O
existing,O
contralateral,O
paralysis,I-Entity
.,O
Anesthesia,I-Entity
was,O
performed,O
by,O
injecting,O
20,O
to,O
40,O
mL,I-Entity
of,O
a,O
mixture,O
of,O
long,O
-,O
acting,O
(,O
ropivacaine,I-Entity
),O
and,O
short,I-Entity
-,O
acting,O
(,O
prilocaine,I-Entity
),O
anesthetic,O
.,O
Twelve,I-Entity
patients,O
(,O
43%,O
),O
were,O
found,O
to,O
have,O
intraoperative,O
ipsilateral,O
vocal,O
cord,O
paralysis,I-Entity
.,O
There,I-Entity
were,O
no,O
significant,O
differences,O
in,O
operating,O
time,O
or,O
volume,O
or,O
frequency,O
of,O
anesthetic,O
administration,O
in,O
patients,O
with,O
temporary,O
vocal,O
cord,O
paralysis,I-Entity
compared,O
with,O
those,O
without,O
.,O
CONCLUSION,I-Entity
:,O
Local,I-Entity
anesthesia,O
led,O
to,O
temporary,O
ipsilateral,O
vocal,O
cord,O
paralysis,I-Entity
in,O
almost,O
half,O
of,O
these,O
patients,O
.,O
Because,I-Entity
pre,O
-,O
existing,O
paralysis,I-Entity
is,O
of,O
a,O
relevant,O
frequency,O
(,O
up,O
to,O
3%,O
),O
",",O
a,O
preoperative,O
evaluation,O
of,O
vocal,O
cord,O
function,O
before,O
carotid,O
endarterectomy,O
under,O
local,O
anesthesia,O
is,O
recommended,O
to,O
avoid,O
intraoperative,O
bilateral,O
paralysis,I-Entity
.,O
In,I-Entity
patients,O
with,O
preoperative,O
contralateral,O
vocal,O
cord,O
paralysis,I-Entity
",",O
surgery,O
under,O
general,O
anesthesia,O
should,O
be,O
considered,O
.,O
Neuroprotective,I-Entity
effects,O
of,O
melatonin,I-Entity
upon,O
the,O
offspring,O
cerebellar,O
cortex,O
in,O
the,O
rat,O
model,O
of,O
BCNU,I-Entity
-,O
induced,O
cortical,O
dysplasia,I-Entity
.,O
Cortical,I-Entity
dysplasia,I-Entity
is,O
a,O
malformation,I-Entity
characterized,O
by,O
defects,O
in,O
proliferation,O
",",O
migration,O
and,O
maturation,O
.,O
This,I-Entity
study,O
was,O
designed,O
to,O
evaluate,O
the,O
alterations,I-Entity
in,O
offspring,O
rat,O
cerebellum,O
induced,O
by,O
maternal,O
exposure,O
to,O
"carmustine-[1,3-bis",I-Entity
(,O
2-chloroethyl)-1-nitrosoure,B-Entity
],O
(,O
BCNU,I-Entity
),O
and,O
to,O
investigate,O
the,O
effects,O
of,O
exogenous,O
melatonin,I-Entity
upon,O
cerebellar,O
BCNU,I-Entity
-,O
induced,O
cortical,O
dysplasia,I-Entity
",",O
using,O
histological,O
and,O
biochemical,O
analyses,O
.,O
Pregnant,I-Entity
Wistar,I-Entity
rats,O
were,O
assigned,O
to,O
five,O
groups,O
:,O
intact,O
-,O
control,O
",",O
saline,O
-,O
control,O
",",O
melatonin,I-Entity
-,O
treated,O
",",O
BCNU,I-Entity
-,O
exposed,O
and,O
BCNU,I-Entity
-,O
exposed,O
plus,O
melatonin,I-Entity
.,O
Rats,I-Entity
were,O
exposed,O
to,O
BCNU,I-Entity
on,O
embryonic,O
day,O
15,O
and,O
melatonin,I-Entity
was,O
given,O
until,O
delivery,O
.,O
Immuno,I-Entity
/,O
histochemistry,O
and,O
electron,O
microscopy,O
were,O
carried,O
out,O
on,O
the,O
offspring,O
cerebellum,O
",",O
and,O
levels,O
of,O
malondialdehyde,I-Entity
and,O
superoxide,I-Entity
dismutase,O
were,O
determined,O
.,O
Histopathologically,I-Entity
",",O
typical,O
findings,O
were,O
observed,O
in,O
the,O
cerebella,I-Entity
from,O
the,O
control,O
groups,O
",",O
but,O
the,O
findings,O
consistent,O
with,O
early,O
embryonic,O
development,O
were,O
noted,O
in,O
BCNU,I-Entity
-,O
exposed,O
cortical,O
dysplasia,I-Entity
group,O
.,O
There,I-Entity
was,O
a,O
marked,O
increase,O
in,O
the,O
number,O
of,O
TUNEL,I-Entity
positive,O
cells,O
and,O
nestin,O
positive,O
cells,O
in,O
BCNU,I-Entity
-,O
exposed,O
group,O
",",O
but,O
a,O
decreased,O
immunoreactivity,O
to,O
glial,O
fibrillary,O
acidic,O
protein,O
",",O
synaptophysin,I-Entity
and,O
transforming,O
growth,O
factor,O
beta1,O
was,O
observed,O
",",O
indicating,O
a,O
delayed,O
maturation,O
",",O
and,O
melatonin,I-Entity
significantly,O
reversed,O
these,O
changes,O
.,O
Malondialdehyde,I-Entity
level,O
in,O
BCNU,I-Entity
-,O
exposed,O
group,O
was,O
higher,O
than,O
those,O
in,O
control,O
groups,O
and,O
melatonin,I-Entity
decreased,O
malondialdehyde,I-Entity
levels,O
in,O
BCNU,I-Entity
group,O
(,O
P<0.01,I-Entity
),O
",",O
while,O
there,O
were,O
no,O
significant,O
differences,O
in,O
the,O
superoxide,I-Entity
dismutase,O
levels,O
between,O
these,O
groups,O
.,O
These,I-Entity
data,O
suggest,O
that,O
exposure,O
of,O
animals,O
to,O
BCNU,I-Entity
during,O
pregnancy,I-Entity
leads,O
to,O
delayed,O
maturation,O
of,O
offspring,O
cerebellum,O
and,O
melatonin,I-Entity
protects,O
the,O
cerebellum,O
against,O
the,O
effects,O
of,O
BCNU,I-Entity
.,O
Myo,I-Entity
-,O
inositol-1-phosphate,I-Entity
(,O
MIP,I-Entity
),O
Lithium,I-Entity
and,O
valproate,I-Entity
are,O
the,O
prototypic,O
mood,O
stabilizers,O
and,O
have,O
diverse,O
structures,O
and,O
targets,O
.,O
Both,I-Entity
drugs,O
influence,O
inositol,I-Entity
metabolism,O
.,O
Lithium,I-Entity
inhibits,O
IMPase,I-Entity
and,O
valproate,I-Entity
inhibits,O
MIP,I-Entity
synthase,O
.,O
This,I-Entity
study,O
shows,O
that,O
MIP,I-Entity
synthase,O
inhibition,O
does,O
not,O
replicate,O
or,O
augment,O
the,O
effects,O
of,O
lithium,I-Entity
in,O
the,O
inositol,I-Entity
sensitive,I-Entity
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
model,O
.,O
This,I-Entity
lack,O
of,O
effects,O
may,O
stem,O
from,O
the,O
low,O
contribution,O
of,O
de,O
-,O
novo,O
synthesis,O
to,O
cellular,O
inositol,I-Entity
supply,O
or,O
to,O
the,O
inhibition,O
of,O
the,O
de,O
-,O
novo,O
synthesis,O
by,O
lithium,I-Entity
itself,O
.,O
Non,I-Entity
-,O
steroidal,I-Entity
anti,O
-,O
inflammatory,O
drugs,O
-,O
associated,O
acute,O
interstitial,O
nephritis,I-Entity
with,O
granular,O
tubular,O
basement,O
membrane,O
deposits,O
.,O
Acute,I-Entity
tubulo,O
-,O
interstitial,O
nephritis,I-Entity
(,O
ATIN,I-Entity
),O
is,O
an,O
important,O
cause,O
of,O
acute,O
renal,O
failure,I-Entity
resulting,O
from,O
a,O
variety,O
of,O
insults,I-Entity
",",O
including,O
immune,O
complex,O
-,O
mediated,O
tubulo,O
-,O
interstitial,O
injury,I-Entity
",",O
but,O
drugs,O
such,O
as,O
non,O
-,O
steroidal,I-Entity
anti,O
-,O
inflammatory,O
drugs,O
(,O
NSAIDs,I-Entity
),O
are,O
a,O
far,O
more,O
frequent,O
cause,O
.,O
Overall,I-Entity
",",O
as,O
an,O
entity,O
",",O
ATIN,I-Entity
remains,O
under,O
-,O
diagnosed,O
",",O
as,O
symptoms,O
resolve,O
spontaneously,O
if,O
the,O
medication,O
is,O
stopped,O
.,O
We,I-Entity
report,O
on,O
a,O
14-year,O
-,O
old,O
boy,O
who,O
developed,O
acute,O
renal,O
failure,I-Entity
2,O
weeks,O
after,O
aortic,O
valve,O
surgery,O
.,O
He,I-Entity
was,O
put,O
on,O
aspirin,I-Entity
following,O
surgery,O
and,O
took,O
ibuprofen,I-Entity
for,O
fever,I-Entity
for,O
nearly,O
a,O
week,O
prior,O
to,O
presentation,O
.,O
He,I-Entity
then,O
presented,O
to,O
the,O
emergency,O
department,O
feeling,O
quite,O
ill,O
and,O
was,O
found,O
to,O
have,O
a,O
blood,O
urea,I-Entity
nitrogen,I-Entity
(,O
BUN,I-Entity
),O
concentration,O
of,O
of,O
147,I-Entity
mg,O
/,O
dl,O
",",O
creatinine,I-Entity
of,O
15.3,O
mg,O
/,O
dl,O
and,O
serum,O
potassium,I-Entity
of,O
8.7,O
mEq,I-Entity
/,O
l,O
.,O
A,I-Entity
kidney,O
biopsy,O
showed,O
inflammatory,O
infiltrate,O
consistent,O
with,O
ATIN,I-Entity
.,O
He,I-Entity
needed,O
dialysis,O
for,O
2,O
weeks,O
and,O
was,O
treated,O
successfully,O
with,O
steroids,I-Entity
for,O
6,O
months,O
.,O
His,I-Entity
renal,O
recovery,O
and,O
disappearance,I-Entity
of,O
proteinuria,I-Entity
took,O
a,O
year,O
.,O
In,I-Entity
conclusion,O
",",O
this,O
is,O
a,O
first,O
report,O
of,O
NSAIDs,I-Entity
-,O
associated,O
ATIN,I-Entity
",",O
showing,O
deposits,O
of,O
granular,O
immune,O
complex,O
present,O
only,O
in,O
the,O
TBM,I-Entity
and,O
not,O
in,O
the,O
glomeruli,O
.,O
Rifampicin,I-Entity
-,O
associated,O
segmental,O
necrotizing,I-Entity
glomerulonephritis,I-Entity
in,O
staphylococcal,O
endocarditis,I-Entity
.,O
necrotising,I-Entity
glomerulonephritis,I-Entity
has,O
been,O
reported,O
as,O
complication,O
of,O
rifampicin,I-Entity
therapy,O
in,O
patients,O
receiving,O
treatment,O
for,O
tuberculosis,I-Entity
.,O
Changing,I-Entity
epidemiology,O
of,O
infections,I-Entity
such,O
as,O
infective,I-Entity
endocarditis,I-Entity
(,O
IE,I-Entity
),O
has,O
led,O
to,O
an,O
increase,O
in,O
the,O
use,O
of,O
rifampicin,I-Entity
for,O
Staphylococcal,I-Entity
infections,I-Entity
.,O
We,I-Entity
describe,O
a,O
case,O
of,O
a,O
patient,O
with,O
Staphylococcal,I-Entity
IE,I-Entity
who,O
developed,O
acute,O
renal,O
failure,I-Entity
secondary,O
to,O
a,O
segmental,O
necrotising,I-Entity
glomerulonephritis,I-Entity
while,O
being,O
treated,O
with,O
rifampicin,I-Entity
",",O
and,O
review,O
the,O
literature,O
regarding,O
this,O
complication,O
of,O
rifampicin,I-Entity
therapy,O
.,O
Rate,I-Entity
of,O
YMDD,I-Entity
motif,O
mutants,O
in,O
lamivudine,I-Entity
-,O
untreated,O
Iranian,I-Entity
patients,O
with,O
chronic,O
hepatitis,I-Entity
B,I-Entity
virus,O
infection,I-Entity
.,O
Lamivudine,I-Entity
is,O
used,O
for,O
the,O
treatment,O
of,O
chronic,O
hepatitis,I-Entity
B,I-Entity
patients,O
.,O
Recent,I-Entity
studies,O
show,O
that,O
the,O
YMDD,I-Entity
motif,O
mutants,O
(,O
resistant,O
hepatitis,I-Entity
B,I-Entity
virus,O
),O
occur,O
as,O
natural,O
genome,O
variability,O
in,O
lamivudine,I-Entity
-,O
untreated,O
chronic,O
hepatitis,I-Entity
B,I-Entity
patients,O
.,O
In,I-Entity
this,O
study,O
we,O
aimed,O
to,O
determine,O
the,O
rate,O
of,O
YMDD,I-Entity
motif,O
mutants,O
in,O
lamivudine,I-Entity
-,O
untreated,O
chronic,O
hepatitis,I-Entity
B,I-Entity
patients,O
in,O
Iran,I-Entity
.,O
A,I-Entity
total,O
of,O
77,I-Entity
chronic,O
hepatitis,I-Entity
B,I-Entity
patients,O
who,O
had,O
not,O
been,O
treated,O
with,O
lamivudine,I-Entity
were,O
included,O
in,O
the,O
study,O
.,O
All,I-Entity
patients,O
were,O
also,O
tested,O
for,O
liver,I-Entity
enzymes,O
",",O
anti,O
-,O
HCV,I-Entity
",",O
HBeAg,I-Entity
",",O
and,O
anti,O
-,O
HBe,I-Entity
.,O
HBeAg,I-Entity
was,O
positive,O
in,O
40%,O
and,O
anti,O
-,O
HBe,I-Entity
in,O
60%,O
of,O
the,O
patients,O
.,O
YMDD,I-Entity
motif,O
mutants,O
were,O
not,O
detected,O
in,O
any,O
of,O
the,O
patients,O
despite,O
the,O
liver,I-Entity
enzyme,O
levels,O
and,O
the,O
presence,O
of,O
HBeAg,I-Entity
or,O
anti,O
-,O
HBe,I-Entity
.,O
CONCLUSION,I-Entity
:,O
Although,I-Entity
the,O
natural,O
occurrence,O
of,O
YMDD,I-Entity
motif,O
mutants,O
in,O
lamivudine,I-Entity
-,O
untreated,O
patients,O
with,O
chronic,O
hepatitis,I-Entity
B,I-Entity
has,O
been,O
reported,O
",",O
these,O
mutants,O
were,O
not,O
detected,O
in,O
Iranian,I-Entity
lamivudine,I-Entity
-,O
untreated,O
chronic,O
hepatitis,I-Entity
B,I-Entity
patients,O
.,O
Branch,I-Entity
retinal,B-Entity
vein,O
occlusion,I-Entity
and,O
fluoxetine,I-Entity
.,O
A,I-Entity
case,O
of,O
branch,O
retinal,B-Entity
vein,O
occlusion,I-Entity
associated,O
with,O
fluoxetine,I-Entity
-,O
induced,O
secondary,O
hypertension,I-Entity
is,O
described,O
.,O
Although,I-Entity
an,O
infrequent,O
complication,O
of,O
selective,O
serotonin,I-Entity
reuptake,O
inhibitor,O
therapy,O
",",O
it,O
is,O
important,O
that,O
ophthalmologists,O
are,O
aware,O
that,O
these,O
agents,O
can,O
cause,O
hypertension,I-Entity
because,O
this,O
class,O
of,O
drugs,O
is,O
widely,O
prescribed,O
.,O
The,I-Entity
differential,O
effects,O
of,O
bupivacaine,I-Entity
and,O
lidocaine,I-Entity
on,O
prostaglandin,I-Entity
E2,I-Entity
release,O
",",O
cyclooxygenase,O
gene,O
expression,O
and,O
pain,I-Entity
in,O
a,O
clinical,O
pain,I-Entity
model,O
.,O
In,I-Entity
addition,O
to,O
blocking,I-Entity
nociceptive,B-Entity
input,O
from,O
surgical,O
sites,O
",",O
long,O
-,O
acting,O
local,O
anesthetics,O
might,O
directly,O
modulate,O
inflammation,I-Entity
.,O
In,I-Entity
the,O
present,O
study,O
",",O
we,O
describe,O
the,O
proinflammatory,O
effects,O
of,O
bupivacaine,I-Entity
on,O
local,O
prostaglandin,I-Entity
E2,I-Entity
(,O
PGE2,I-Entity
),O
production,O
and,O
cyclooxygenase,O
(,O
COX,I-Entity
),O
gene,O
expression,O
that,O
increases,O
postoperative,O
pain,I-Entity
in,O
human,O
subjects,O
.,O
METHODS,I-Entity
:,O
Subjects,I-Entity
(,O
n,O
=,O
114,I-Entity
),O
undergoing,O
extraction,O
of,O
impacted,O
third,O
molars,O
received,O
either,O
2%,O
lidocaine,I-Entity
or,O
0.5%,O
bupivacaine,I-Entity
before,O
surgery,O
and,O
either,O
rofecoxib,I-Entity
50,O
mg,O
or,O
placebo,O
orally,O
90,I-Entity
min,O
before,O
surgery,O
and,O
for,O
the,O
following,O
48,I-Entity
h.,O
Oral,I-Entity
mucosal,O
biopsies,O
were,O
taken,O
before,O
surgery,O
and,O
48,I-Entity
h,O
after,O
surgery,O
.,O
After,I-Entity
extraction,O
",",O
a,O
microdialysis,O
probe,O
was,O
placed,O
at,O
the,O
surgical,O
site,O
for,O
PGE2,I-Entity
and,O
thromboxane,I-Entity
B2,I-Entity
(,O
TXB2,I-Entity
),O
measurements,O
.,O
The,I-Entity
bupivacaine,I-Entity
/,O
rofecoxib,I-Entity
group,O
reported,O
significantly,O
less,O
pain,I-Entity
",",O
as,O
assessed,O
by,O
a,O
visual,O
analog,O
scale,O
",",O
compared,O
with,O
the,O
other,O
three,O
treatment,O
groups,O
over,O
the,O
first,O
4,O
h.,O
However,I-Entity
",",O
the,O
bupivacaine,I-Entity
/,O
placebo,O
group,O
reported,O
significantly,O
more,O
pain,I-Entity
at,O
24,O
h,O
and,O
PGE2,I-Entity
levels,O
during,O
the,O
first,O
4,O
h,O
were,O
significantly,O
higher,O
than,O
the,O
other,O
three,O
treatment,O
groups,O
.,O
Moreover,I-Entity
",",O
bupivacaine,I-Entity
significantly,O
increased,O
COX-2,I-Entity
gene,O
expression,O
at,O
48,I-Entity
h,O
as,O
compared,O
with,O
the,O
lidocaine,I-Entity
/,O
placebo,O
group,O
.,O
Thromboxane,I-Entity
levels,O
were,O
not,O
significantly,O
affected,O
by,O
any,O
of,O
the,O
treatments,O
",",O
indicating,O
that,O
the,O
effects,O
seen,O
were,O
attributable,O
to,O
inhibition,O
of,O
COX-2,I-Entity
",",O
but,O
not,O
COX-1,I-Entity
.,O
These,I-Entity
results,O
suggest,O
that,O
bupivacaine,I-Entity
stimulates,O
COX-2,I-Entity
gene,O
expression,O
after,O
tissue,O
injury,I-Entity
",",O
which,O
is,O
associated,O
with,O
higher,O
PGE2,I-Entity
production,O
and,O
pain,I-Entity
after,O
the,O
local,O
anesthetic,O
effect,O
dissipates,O
.,O
p75NTR,I-Entity
expression,O
in,O
rat,O
urinary,O
bladder,I-Entity
sensory,O
neurons,O
and,O
spinal,O
cord,O
with,O
cyclophosphamide,I-Entity
-,O
induced,O
cystitis,I-Entity
.,O
Previous,I-Entity
studies,O
have,O
examined,O
the,O
expression,O
and,O
regulation,O
of,O
tyrosine,I-Entity
kinase,O
receptors,O
(,O
Trks,I-Entity
),O
in,O
micturition,O
reflexes,I-Entity
with,O
urinary,O
bladder,I-Entity
inflammation,I-Entity
.,O
The,I-Entity
present,O
studies,O
examine,O
the,O
expression,O
and,O
regulation,O
of,O
another,O
receptor,O
known,O
to,O
bind,O
NGF,I-Entity
",",O
p75(NTR,I-Entity
),O
",",O
after,O
various,O
durations,O
of,O
bladder,I-Entity
inflammation,I-Entity
induced,O
by,O
cyclophosphamide,I-Entity
(,O
CYP,I-Entity
),O
.,O
CYP,I-Entity
-,O
induced,O
cystitis,I-Entity
increased,O
(,O
P,I-Entity
<,O
or,O
=,O
0.001,O
),O
The,I-Entity
number,O
of,O
p75(NTR)-immunoreactive,I-Entity
(,O
-IR,O
),O
cells,O
in,O
the,O
lumbosacral,O
dorsal,O
root,O
ganglia,I-Entity
(,O
DRG,I-Entity
),O
also,O
increased,O
(,O
P,I-Entity
<,O
or,O
=,O
0.05,O
),O
with,O
CYP,I-Entity
-,O
induced,O
cystitis,I-Entity
(,O
acute,O
",",O
intermediate,O
",",O
and,O
chronic,O
),O
.,O
Quantitative,I-Entity
",",O
real,O
-,O
time,O
polymerase,O
chain,O
reaction,I-Entity
also,O
demonstrated,O
significant,O
increases,O
(,O
P,I-Entity
<,O
or,O
=,O
0.01,O
),O
in,O
p75(NTR,I-Entity
),O
mRNA,I-Entity
in,O
DRG,I-Entity
with,O
intermediate,O
and,O
chronic,O
CYP,I-Entity
-,O
induced,O
cystitis,I-Entity
.,O
In,I-Entity
bladder,I-Entity
afferent,O
cells,O
in,O
DRG,I-Entity
",",O
p75(NTR)-IR,I-Entity
was,O
also,O
increased,O
(,O
P,I-Entity
<,O
or,O
=,O
0.01,O
),O
with,O
cystitis,I-Entity
.,O
These,I-Entity
studies,O
demonstrate,O
that,O
p75(NTR,I-Entity
),O
expression,O
in,O
micturition,O
reflexes,I-Entity
is,O
present,O
constitutively,I-Entity
and,O
modified,O
by,O
bladder,I-Entity
inflammation,I-Entity
.,O
Azathioprine,I-Entity
-,O
induced,O
suicidal,I-Entity
erythrocyte,O
death,I-Entity
.,O
Azathioprine,I-Entity
is,O
widely,O
used,O
as,O
an,O
immunosuppressive,O
drug,O
.,O
The,I-Entity
side,O
effects,O
of,O
azathioprine,I-Entity
include,O
anemia,I-Entity
",",O
which,O
has,O
been,O
attributed,O
to,O
bone,O
marrow,O
suppression,O
.,O
Alternatively,I-Entity
",",O
anemia,I-Entity
could,O
result,O
from,O
accelerated,O
suicidal,I-Entity
erythrocyte,O
death,I-Entity
or,O
eryptosis,O
",",O
which,O
is,O
characterized,O
by,O
exposure,O
of,O
phosphatidylserine,I-Entity
(,O
PS,I-Entity
),O
at,O
the,O
erythrocyte,O
surface,O
and,O
by,O
cell,O
shrinkage,I-Entity
.,O
METHODS,I-Entity
:,O
The,I-Entity
present,O
experiments,O
explored,O
whether,O
azathioprine,I-Entity
influences,O
eryptosis,O
.,O
According,I-Entity
to,O
annexin,I-Entity
V,I-Entity
binding,O
",",O
erythrocytes,O
from,O
patients,O
indeed,O
showed,O
a,O
significant,O
increase,O
of,O
PS,I-Entity
exposure,O
within,O
1,O
week,O
of,O
treatment,O
with,O
azathioprine,I-Entity
.,O
In,I-Entity
a,O
second,O
series,O
",",O
cytosolic,O
Ca2,I-Entity
+,O
activity,O
(,O
Fluo3,I-Entity
fluorescence,I-Entity
),O
",",O
cell,O
volume,O
(,O
forward,O
scatter,O
),O
",",O
and,O
PS,I-Entity
-,O
exposure,O
(,O
annexin,I-Entity
V,I-Entity
binding,O
),O
were,O
determined,O
by,O
FACS,I-Entity
analysis,O
in,O
erythrocytes,O
from,O
healthy,O
volunteers,O
.,O
Exposure,I-Entity
to,O
azathioprine,I-Entity
(,O
>,O
or,O
=,O
2,O
microg,O
/,O
mL,I-Entity
),O
for,O
48,I-Entity
hours,O
increased,O
cytosolic,O
Ca2,I-Entity
+,O
activity,O
and,O
annexin,I-Entity
V,I-Entity
binding,O
and,O
decreased,O
forward,O
scatter,O
.,O
The,I-Entity
effect,O
of,O
azathioprine,I-Entity
on,O
both,O
annexin,I-Entity
V,I-Entity
binding,O
and,O
forward,O
scatter,O
was,O
significantly,O
blunted,O
in,O
the,O
nominal,O
absence,O
of,O
extracellular,O
Ca2,I-Entity
+,O
.,O
Azathioprine,I-Entity
triggers,O
suicidal,I-Entity
erythrocyte,O
death,I-Entity
",",O
an,O
effect,O
presumably,O
contributing,O
to,O
azathioprine,I-Entity
-,O
induced,O
anemia,I-Entity
.,O
BACKGROUND,I-Entity
:,O
Spinal,I-Entity
anaesthesia,O
is,O
widely,O
employed,O
in,O
clinical,O
practice,O
but,O
has,O
the,O
main,O
drawback,O
of,O
post,O
-,O
spinal,O
block,O
hypotension,I-Entity
.,O
In,I-Entity
the,O
lateral,O
position,O
with,O
operative,O
side,O
down,O
",",O
patients,O
recived,O
10,O
mg,O
(,O
2mls,I-Entity
),O
of,O
0.5%,O
hyperbaric,O
bupivacaine,I-Entity
through,O
a,O
25-gauge,O
spinal,O
needle,O
.,O
Blood,I-Entity
pressure,O
",",O
heart,O
rate,O
",",O
respiratory,O
rate,O
and,O
oxygen,I-Entity
saturation,O
were,O
monitored,O
over,O
1,O
hour,O
.,O
RESULTS,I-Entity
:,O
Three,I-Entity
patients,O
(,O
8.1%,O
),O
in,O
the,O
unilateral,O
group,O
and,O
5,O
(,O
13.5%,O
),O
in,O
the,O
conventional,O
group,O
developed,O
hypotension,I-Entity
",",O
P=,I-Entity
0.71,O
.,O
Four,I-Entity
(,O
10.8%,O
),O
patients,O
in,O
the,O
conventional,O
group,O
and,O
1,O
(,O
2.7%,O
),O
in,O
the,O
unilateral,O
group,O
",",O
P=,I-Entity
0.17,O
required,O
epinephrine,I-Entity
infusion,O
to,O
treat,O
hypotension,I-Entity
.,O
The,I-Entity
mean,O
respiratory,O
rate,O
and,O
oxygen,I-Entity
saturations,O
in,O
the,O
two,O
groups,O
were,O
similar,O
.,O
Also,I-Entity
",",O
the,O
type,O
of,O
spinal,O
block,O
instituted,O
affected,O
neither,O
the,O
respiratory,O
rate,O
nor,O
the,O
arterial,O
oxygen,I-Entity
saturation,O
.,O
Spectrum,I-Entity
of,O
adverse,O
events,O
after,O
generic,O
HAART,I-Entity
in,O
southern,O
Indian,I-Entity
HIV,I-Entity
-,O
infected,I-Entity
patients,O
.,O
To,I-Entity
determine,O
the,O
incidence,O
of,O
clinically,O
significant,O
adverse,O
events,O
after,O
long,O
-,O
term,O
",",O
fixed,O
-,O
dose,O
",",O
generic,O
highly,O
active,O
antiretroviral,O
therapy,O
(,O
HAART,I-Entity
),O
use,O
among,O
HIV,I-Entity
-,O
infected,I-Entity
individuals,O
in,O
South,I-Entity
India,I-Entity
",",O
we,O
examined,O
the,O
experiences,O
of,O
3154,I-Entity
HIV,I-Entity
-,O
infected,I-Entity
individuals,O
who,O
received,O
a,O
minimum,O
of,O
3,O
months,O
of,O
generic,O
HAART,I-Entity
between,O
February,I-Entity
1996,O
and,O
December,I-Entity
2006,O
at,O
a,O
tertiary,O
HIV,I-Entity
care,O
referral,O
center,O
in,O
South,I-Entity
India,I-Entity
.,O
The,I-Entity
most,O
common,O
regimens,I-Entity
were,O
3TC,I-Entity
+,O
d4,O
T,I-Entity
+,O
nevirapine,I-Entity
(,O
NVP,I-Entity
),O
(,O
54.8%,O
),O
",",O
zidovudine,I-Entity
(,O
AZT,I-Entity
),O
+,O
3TC,I-Entity
+,O
NVP,I-Entity
(,O
14.5%,O
),O
",",O
3TC,I-Entity
+,O
d4,O
T,I-Entity
+,O
efavirenz,I-Entity
(,O
EFV,I-Entity
),O
(,O
20.1%,O
),O
",",O
and,O
AZT,I-Entity
+,O
3TC,I-Entity
+,O
EFV,I-Entity
(,O
5.4%,O
),O
.,O
The,I-Entity
most,O
common,O
adverse,O
events,O
and,O
median,O
CD4,I-Entity
at,O
time,O
of,O
event,O
were,O
rash,I-Entity
(,O
15.2%,O
;,O
CD4,I-Entity
",",O
285,I-Entity
cells,O
/,O
microL,I-Entity
),O
and,O
peripheral,O
neuropathy,I-Entity
(,O
9.0%,O
and,O
348,O
cells,O
/,O
microL,I-Entity
),O
.,O
Clinically,I-Entity
significant,O
anemia,I-Entity
(,O
hemoglobin,O
<,O
7,O
g,O
/,O
dL,I-Entity
),O
was,O
observed,O
in,O
5.4%,O
of,O
patients,O
(,O
CD4,I-Entity
",",O
165,I-Entity
cells,O
/,O
microL,I-Entity
),O
and,O
hepatitis,I-Entity
(,O
clinical,O
jaundice,I-Entity
with,O
alanine,I-Entity
aminotransferase,O
>,O
5,O
times,O
upper,O
limits,O
of,O
normal,O
),O
in,O
3.5%,O
of,O
patients,O
(,O
CD4,I-Entity
",",O
260,I-Entity
cells,O
/,O
microL,I-Entity
),O
.,O
Women,I-Entity
were,O
significantly,O
more,O
likely,O
to,O
experience,O
lactic,I-Entity
acidosis,I-Entity
",",O
while,O
men,O
were,O
significantly,O
more,O
likely,O
to,O
experience,O
immune,O
reconstitution,O
syndrome,I-Entity
(,O
p,O
<,O
0.05,O
),O
.,O
Among,I-Entity
the,O
patients,O
with,O
1,O
year,O
of,O
follow,O
-,O
up,O
",",O
NVP,I-Entity
therapy,O
was,O
significantly,O
associated,O
with,O
developing,O
rash,I-Entity
and,O
d4,O
T,I-Entity
therapy,O
with,O
developing,O
peripheral,O
neuropathy,I-Entity
(,O
p,O
<,O
0.05,O
),O
.,O
Anemia,I-Entity
and,O
hepatitis,I-Entity
often,O
occur,O
within,O
12,O
weeks,O
of,O
initiating,O
generic,O
HAART,I-Entity
.,O
Frequent,I-Entity
and,O
early,O
monitoring,O
for,O
these,O
toxicities,I-Entity
is,O
warranted,O
in,O
developing,O
countries,O
where,O
generic,O
HAART,I-Entity
is,O
increasingly,O
available,O
.,O
Thalidomide,I-Entity
and,O
sensory,O
neurotoxicity,I-Entity
:,O
a,O
neurophysiological,O
study,O
.,O
Recent,I-Entity
studies,O
confirmed,O
a,O
high,O
incidence,O
of,O
sensory,O
axonal,O
neuropathy,I-Entity
in,O
patients,O
treated,O
with,O
different,O
doses,O
of,O
thalidomide,I-Entity
.,O
The,I-Entity
study,O
's,I-Entity
aims,O
were,O
to,O
measure,O
variations,O
in,O
sural,O
nerve,O
sensory,O
action,O
potential,O
(,O
SAP,I-Entity
),O
amplitude,O
in,O
patients,O
with,O
refractory,O
cutaneous,O
lupus,I-Entity
erythematosus,I-Entity
(,O
CLE,I-Entity
),O
treated,O
with,O
thalidomide,I-Entity
and,O
use,O
these,O
findings,O
to,O
identify,O
the,O
neurotoxic,I-Entity
potential,O
of,O
thalidomide,I-Entity
and,O
the,O
recovery,O
capacity,O
of,O
sensory,O
fibres,I-Entity
after,O
discontinuation,O
of,O
treatment,O
.,O
Clinical,I-Entity
and,O
electrophysiological,O
data,O
in,O
12,O
female,O
patients,O
with,O
CLE,I-Entity
during,O
treatment,O
with,O
thalidomide,I-Entity
and,O
up,O
to,O
47,I-Entity
months,O
after,O
discontinuation,O
of,O
treatment,O
were,O
analysed,O
.,O
Five,I-Entity
patients,O
complained,O
of,O
paresthesias,I-Entity
and,O
leg,O
cramps,I-Entity
.,O
After,I-Entity
thalidomide,I-Entity
treatment,O
",",O
sural,O
SAP,I-Entity
amplitude,O
recovered,O
in,O
3,O
patients,O
.,O
At,I-Entity
detection,O
of,O
reduction,O
in,O
sural,O
nerve,O
SAP,I-Entity
amplitude,O
",",O
the,O
median,O
thalidomide,I-Entity
cumulative,O
dose,O
was,O
21.4,O
g.,O
The,I-Entity
threshold,O
neurotoxic,I-Entity
dosage,O
is,O
lower,O
than,O
previously,O
reported,O
.,O
This,I-Entity
electrophysiological,O
parameter,O
provides,O
information,O
about,O
subclinical,O
neurotoxic,I-Entity
potential,O
of,O
thalidomide,I-Entity
but,O
is,O
not,O
helpful,O
in,O
predicting,O
the,O
appearance,O
of,O
sensory,O
symptoms,O
.,O
Amiodarone,I-Entity
-,O
related,O
pulmonary,O
mass,O
and,O
unique,O
membranous,I-Entity
glomerulonephritis,I-Entity
in,O
a,O
patient,O
with,O
valvular,O
heart,O
disease,I-Entity
:,O
Diagnostic,I-Entity
pitfall,O
and,O
new,O
findings,O
.,O
Amiodarone,I-Entity
is,O
an,O
anti,O
-,O
arrhythmic,I-Entity
drug,O
for,O
life,O
-,O
threatening,I-Entity
tachycardia,I-Entity
",",O
but,O
various,O
adverse,O
effects,O
have,O
been,O
reported,O
.,O
Reported,I-Entity
herein,O
is,O
an,O
autopsy,O
case,O
of,O
valvular,O
heart,O
disease,I-Entity
",",O
in,O
a,O
patient,O
who,O
developed,O
a,O
lung,O
mass,O
(,O
1.5,O
cm,O
in,O
diameter,O
),O
and,O
proteinuria,I-Entity
(,O
2.76,O
g,O
/,O
day,O
),O
after,O
treatment,O
with,O
amiodarone,I-Entity
for,O
a,O
long,O
time,O
.,O
The,I-Entity
lung,O
mass,O
was,O
highly,O
suspected,O
to,O
be,O
lung,O
cancer,I-Entity
on,O
CT,I-Entity
and,O
positron,I-Entity
emission,I-Entity
tomography,O
",",O
but,O
histologically,O
the,O
lesion,I-Entity
was,O
composed,O
of,O
lymphoplasmacytic,O
infiltrates,O
in,O
alveolar,O
walls,O
and,O
intra,O
-,O
alveolar,O
accumulation,O
of,O
foamy,I-Entity
macrophages,O
containing,O
characteristic,O
myelinoid,I-Entity
bodies,O
",",O
indicating,O
that,O
it,O
was,O
an,O
amiodarone,I-Entity
-,O
related,O
lesion,I-Entity
.,O
In,I-Entity
addition,O
",",O
the,O
lung,O
tissue,O
had,O
unevenly,O
distributed,O
hemosiderin,I-Entity
deposition,O
",",O
and,O
abnormally,I-Entity
tortuous,I-Entity
capillaries,O
were,O
seen,O
in,O
the,O
mass,O
and,O
in,O
heavily,O
hemosiderotic,O
lung,O
portions,O
outside,O
the,O
mass,O
.,O
Autoimmune,I-Entity
diseases,I-Entity
",",O
viral,O
hepatitis,I-Entity
",",O
malignant,I-Entity
neoplasms,I-Entity
or,O
other,O
diseases,I-Entity
with,O
a,O
known,O
relationship,O
to,O
membranous,I-Entity
glomerulonephritis,I-Entity
were,O
not,O
found,O
.,O
The,I-Entity
present,O
case,O
highlights,O
the,O
possibility,O
that,O
differential,O
diagnosis,O
between,O
an,O
amiodarone,I-Entity
-,O
related,O
pulmonary,O
lesion,I-Entity
and,O
a,O
neoplasm,I-Entity
can,O
be,O
very,O
difficult,O
radiologically,O
",",O
and,O
suggests,O
that,O
membranous,I-Entity
glomerulonephritis,I-Entity
might,O
be,O
another,O
possible,O
complication,O
of,O
amiodarone,I-Entity
treatment,O
.,O
Risk,I-Entity
of,O
coronary,O
artery,I-Entity
disease,I-Entity
associated,O
with,O
initial,O
sulphonylurea,I-Entity
treatment,O
of,O
patients,O
with,O
type,O
2,O
diabetes,I-Entity
:,O
a,O
matched,O
case,O
-,O
control,O
study,O
.,O
This,I-Entity
study,O
sought,O
to,O
assess,O
the,O
risk,O
of,O
developing,O
coronary,O
artery,I-Entity
disease,I-Entity
(,O
CAD,I-Entity
),O
associated,O
with,O
initial,O
treatment,O
of,O
type,O
2,O
diabetes,I-Entity
with,O
different,O
sulphonylureas,I-Entity
.,O
METHODS,I-Entity
:,O
In,I-Entity
type,O
2,O
diabetic,I-Entity
patients,O
",",O
cases,O
who,O
developed,O
CAD,I-Entity
were,O
compared,O
retrospectively,O
with,O
controls,O
that,O
did,O
not,O
.,O
The,I-Entity
20-year,O
risk,O
of,O
CAD,I-Entity
at,O
diagnosis,O
of,O
diabetes,I-Entity
",",O
using,O
the,O
UKPDS,I-Entity
risk,O
engine,O
",",O
was,O
used,O
to,O
match,O
cases,O
with,O
controls,O
.,O
The,I-Entity
76,I-Entity
cases,O
of,O
CAD,I-Entity
were,O
compared,O
with,O
152,I-Entity
controls,O
.,O
The,I-Entity
hazard,O
of,O
developing,O
CAD,I-Entity
(,O
95%,O
CI,I-Entity
),O
associated,O
with,O
initial,O
treatment,O
increased,O
by,O
2.4-fold,O
(,O
1.3,O
-,O
4.3,O
",",O
P=0.004,I-Entity
),O
with,O
glibenclamide,I-Entity
;,O
2-fold,O
(,O
0.9,O
-,O
4.6,O
",",O
P=0.099,I-Entity
),O
with,O
glipizide,I-Entity
;,O
2.9-fold,O
(,O
1.6,O
-,O
5.1,O
",",O
P=0.000,I-Entity
),O
with,O
either,O
",",O
and,O
was,O
unchanged,O
with,O
metformin,I-Entity
.,O
The,I-Entity
hazard,O
decreased,O
0.3-fold,O
(,O
0.7,O
-,O
1.7,O
",",O
P=0.385,I-Entity
),O
with,O
glimepiride,I-Entity
",",O
0.4-fold,O
(,O
0.7,O
-,O
1.3,O
",",O
P=0.192,I-Entity
),O
with,O
gliclazide,I-Entity
",",O
and,O
0.4-fold,O
(,O
0.7,O
-,O
1.1,O
",",O
P=0.09,I-Entity
),O
with,O
either,O
.,O
CONCLUSIONS,I-Entity
:,O
Initiating,I-Entity
treatment,O
of,O
type,O
2,O
diabetes,I-Entity
with,O
glibenclamide,I-Entity
or,O
glipizide,I-Entity
is,O
associated,O
with,O
increased,O
risk,O
of,O
CAD,I-Entity
in,O
comparison,O
to,O
gliclazide,I-Entity
or,O
glimepiride,I-Entity
.,O
If,I-Entity
confirmed,O
",",O
this,O
may,O
be,O
important,O
because,O
most,O
Indian,I-Entity
patients,O
receive,O
the,O
cheaper,O
older,O
sulphonylureas,I-Entity
",",O
and,O
present,O
guidelines,O
do,O
not,O
distinguish,O
between,O
individual,O
agents,O
.,O
Reduced,I-Entity
progression,O
of,O
adriamycin,I-Entity
nephropathy,I-Entity
in,O
spontaneously,O
hypertensive,I-Entity
rats,O
treated,O
by,O
losartan,I-Entity
.,O
The,I-Entity
aim,O
of,O
the,O
study,O
was,O
to,O
investigate,O
the,O
antihypertensive,O
effects,O
of,O
angiotensin,I-Entity
II,I-Entity
type-1,O
receptor,O
blocker,O
",",O
losartan,I-Entity
",",O
and,O
its,O
potential,O
in,O
slowing,O
down,O
renal,O
disease,I-Entity
progression,O
in,O
spontaneously,O
hypertensive,I-Entity
rats,O
(,O
SHR,I-Entity
),O
with,O
adriamycin,I-Entity
(,O
ADR,I-Entity
),O
nephropathy,I-Entity
.,O
Groups,I-Entity
ADR(6,I-Entity
),O
",",O
ADR+LOS(6,I-Entity
),O
and,O
ADR(12,I-Entity
),O
",",O
and,O
ADR+LOS(12,I-Entity
),O
received,O
ADR,I-Entity
(,O
2,O
mg,O
/,O
kg,O
/,O
b.w,O
.,O
Group,I-Entity
ADR+LOS(6,I-Entity
),O
received,O
losartan,I-Entity
(,O
10,O
mg,O
/,O
kg,O
/,O
b.w./day,O
by,O
gavages,I-Entity
),O
for,O
6,O
weeks,O
and,O
group,O
ADR+LOS(12,I-Entity
),O
for,O
12,O
weeks,O
after,O
second,O
injection,O
of,O
ADR,I-Entity
.,O
Short,I-Entity
-,O
term,O
losartan,I-Entity
treatment,O
",",O
besides,O
antihypertensive,O
effect,O
",",O
improved,O
glomerular,O
filtration,O
rate,O
and,O
ameliorated,O
glomerulosclerosis,I-Entity
resulting,O
in,O
decreased,O
proteinuria,I-Entity
.,O
Prolonged,I-Entity
treatment,O
with,O
losartan,I-Entity
showed,O
further,O
reduction,O
of,O
glomerulosclerosis,I-Entity
associated,O
with,O
reduced,O
progression,O
of,O
tubular,O
atrophy,I-Entity
and,O
interstitial,O
fibrosis,I-Entity
",",O
thus,O
preventing,O
heavy,O
proteinuria,I-Entity
and,O
chronic,O
renal,O
failure,I-Entity
.,O
Losartan,I-Entity
reduced,O
uraemia,I-Entity
and,O
increased,O
urea,I-Entity
clearance,O
in,O
advanced,O
ADR,I-Entity
nephropathy,I-Entity
in,O
SHR,I-Entity
.,O
Histological,I-Entity
examination,O
showed,O
that,O
losartan,I-Entity
could,O
prevent,O
tubular,O
atrophy,I-Entity
",",O
interstitial,O
infiltration,I-Entity
and,O
fibrosis,I-Entity
in,O
ADR,I-Entity
nephropathy,I-Entity
.,O
CONCLUSION,I-Entity
:,O
Losartan,I-Entity
reduces,O
the,O
rate,O
of,O
progression,O
of,O
ADR,I-Entity
-,O
induced,O
focal,O
segmental,O
glomerulosclerosis,I-Entity
to,O
end,O
-,O
stage,O
renal,O
disease,I-Entity
in,O
SHR,I-Entity
.,O
The,I-Entity
risks,O
of,O
aprotinin,O
and,O
tranexamic,I-Entity
acid,O
in,O
cardiac,O
surgery,O
:,O
a,O
one,O
-,O
year,O
follow,O
-,O
up,O
of,O
1188,O
consecutive,O
patients,O
.,O
BACKGROUND,I-Entity
:,O
Our,I-Entity
aim,O
was,O
to,O
investigate,O
postoperative,O
complications,O
and,O
mortality,O
after,O
administration,O
of,O
aprotinin,O
compared,O
to,O
tranexamic,I-Entity
acid,O
in,O
an,O
unselected,O
",",O
consecutive,O
cohort,O
.,O
During,I-Entity
the,O
first,O
5,O
mo,O
",",O
596,I-Entity
patients,O
received,O
aprotinin,O
(,O
Group,I-Entity
A,I-Entity
),O
;,O
in,O
the,O
next,O
5,O
mo,O
",",O
592,I-Entity
patients,O
were,O
treated,O
with,O
tranexamic,I-Entity
acid,O
(,O
Group,I-Entity
T,I-Entity
),O
.,O
Postoperatively,I-Entity
",",O
a,O
significantly,O
higher,O
incidence,O
of,O
seizures,I-Entity
was,O
found,O
in,O
Group,I-Entity
T,I-Entity
(,O
4.6%,O
vs,O
1.2%,O
",",O
P,I-Entity
Persistent,I-Entity
atrial,I-Entity
fibrillation,I-Entity
(,O
7.9%,O
vs,O
2.3%,O
",",O
P,I-Entity
=,O
0.020,O
),O
and,O
renal,O
failure,I-Entity
(,O
9.7%,O
vs,O
1.7%,O
",",O
P,I-Entity
=,O
0.002,O
),O
were,O
also,O
more,O
common,O
in,O
Group,I-Entity
T,I-Entity
",",O
in,O
the,O
primary,O
valve,O
surgery,O
subgroup,O
.,O
On,I-Entity
the,O
contrary,O
",",O
among,O
primary,O
coronary,O
artery,I-Entity
bypass,O
surgery,O
patients,O
",",O
there,O
were,O
more,O
acute,O
myocardial,B-Entity
infarctions,I-Entity
and,O
renal,O
dysfunction,I-Entity
in,O
Group,I-Entity
A,I-Entity
(,O
5.8%,O
vs,O
2.0%,O
",",O
P,I-Entity
=,O
0.027,O
;,O
22.5%,O
vs,O
15.2%,O
",",O
P,I-Entity
=,O
0.036,O
",",O
respectively,O
),O
.,O
Administration,I-Entity
of,O
aprotinin,O
should,O
be,O
avoided,O
in,O
coronary,O
artery,I-Entity
bypass,O
graft,O
and,O
high,O
risk,O
patients,O
",",O
whereas,O
administration,O
of,O
tranexamic,I-Entity
acid,O
is,O
not,O
recommended,O
in,O
valve,O
surgery,O
.,O
The,I-Entity
biological,O
properties,O
of,O
the,O
optical,O
isomers,O
of,O
propranolol,I-Entity
and,O
their,O
effects,O
on,O
cardiac,O
arrhythmias,I-Entity
.,O
1,O
.,O
The,I-Entity
optical,O
isomers,O
of,O
propranolol,I-Entity
have,O
been,O
compared,O
for,O
their,O
beta,O
-,O
blocking,I-Entity
and,O
antiarrhythmic,O
activities.2,O
.,O
In,I-Entity
blocking,I-Entity
the,O
positive,O
inotropic,O
and,O
chronotropic,O
responses,O
to,O
isoprenaline,I-Entity
",",O
(,O
+,O
),O
-propranolol,I-Entity
had,O
less,O
than,O
one,O
hundredth,O
the,O
potency,O
of,O
(,O
-)-propranolol,I-Entity
.,O
At,I-Entity
dose,O
levels,O
of,O
(,O
+,O
),O
-propranolol,I-Entity
which,O
attenuated,O
the,O
responses,O
to,O
isoprenaline,I-Entity
",",O
there,O
was,O
a,O
significant,O
prolongation,O
of,O
the,O
PR,I-Entity
interval,O
of,O
the,O
electrocardiogram.3,O
.,O
The,I-Entity
metabolic,O
responses,O
to,O
isoprenaline,I-Entity
in,O
dogs,O
(,O
an,O
increase,O
in,O
circulating,O
glucose,O
",",O
lactate,I-Entity
and,O
free,O
fatty,B-Entity
acids,O
),O
were,O
all,O
blocked,O
by,O
(,O
-)-propranolol,I-Entity
.,O
-Propranolol,O
had,O
no,O
effect,O
on,O
fatty,B-Entity
acid,O
mobilization,O
but,O
significantly,O
reduced,O
the,O
increments,O
in,O
both,O
lactate,I-Entity
and,O
glucose.4,I-Entity
.,O
Both,I-Entity
isomers,O
of,O
propranolol,I-Entity
possessed,O
similar,O
depressant,I-Entity
potency,O
on,O
isolated,O
atrial,I-Entity
muscle,O
taken,O
from,O
guinea,I-Entity
-,O
pigs.5,O
.,O
The,I-Entity
isomers,O
of,O
propranolol,I-Entity
exhibited,O
similar,O
local,O
anaesthetic,O
potencies,O
on,O
an,O
isolated,O
frog,O
nerve,O
preparation,O
at,O
a,O
level,O
approximately,O
three,O
times,O
that,O
of,O
procaine,I-Entity
.,O
Both,I-Entity
isomers,O
of,O
propranolol,I-Entity
were,O
capable,O
of,O
preventing,O
adrenaline,I-Entity
-,O
induced,O
cardiac,O
arrhythmias,I-Entity
in,O
cats,O
anaesthetized,O
with,O
halothane,I-Entity
",",O
but,O
the,O
mean,O
dose,O
of,O
(,O
-)-propranolol,I-Entity
was,O
0.09+/-0.02,O
mg,O
/,O
kg,O
whereas,O
that,O
of,O
(,O
+,O
),O
-propranolol,I-Entity
was,O
4.2+/-1.2,O
mg,O
/,O
kg,O
.,O
-propranolol,I-Entity
there,O
was,O
a,O
significant,O
prolongation,O
of,O
the,O
PR,I-Entity
interval,O
of,O
the,O
electrocardiogram,O
.,O
Blockade,I-Entity
of,O
arrhythmias,I-Entity
with,O
both,O
isomers,O
was,O
surmountable,O
by,O
increasing,O
the,O
dose,O
of,O
adrenaline.7,I-Entity
.,O
Both,I-Entity
isomers,O
of,O
propranolol,I-Entity
were,O
also,O
capable,O
of,O
reversing,O
ventricular,O
tachycardia,I-Entity
caused,O
by,O
ouabain,I-Entity
in,O
anaesthetized,O
cats,O
and,O
dogs,O
.,O
The,I-Entity
dose,O
of,O
(,O
-)-propranolol,I-Entity
was,O
significantly,O
smaller,O
than,O
that,O
of,O
(,O
+,O
),O
-propranolol,I-Entity
in,O
both,O
species,O
but,O
much,O
higher,O
than,O
that,O
required,O
to,O
produce,O
evidence,O
of,O
beta,O
-,O
blockade.8,O
.,O
Topotecan,I-Entity
in,O
combination,O
with,O
radiotherapy,O
in,O
unresectable,O
glioblastoma,I-Entity
:,O
a,O
phase,O
2,O
study,O
.,O
Improving,I-Entity
glioblastoma,I-Entity
multiforme,I-Entity
(,O
GBM,I-Entity
),O
treatment,O
with,O
radio,O
-,O
chemotherapy,O
remains,O
a,O
challenge,O
.,O
Topotecan,I-Entity
is,O
an,O
attractive,O
option,O
as,O
it,O
exhibits,O
growth,O
inhibition,O
of,O
human,O
glioma,I-Entity
as,O
well,O
as,O
brain,O
penetration,O
.,O
The,I-Entity
present,O
study,O
assessed,O
the,O
combination,O
of,O
radiotherapy,O
(,O
60,O
Gy/30,I-Entity
fractions/40,I-Entity
days,O
),O
and,O
topotecan,I-Entity
(,O
0.9,O
mg,O
/,O
m(2)/day,O
on,O
days,O
1,O
-,O
5,O
on,O
weeks,O
1,O
",",O
3,O
and,O
5,O
),O
in,O
50,O
adults,O
with,O
histologically,O
proven,O
and,O
untreated,O
GBM,I-Entity
.,O
The,I-Entity
incidence,O
of,O
non,O
-,O
hematological,O
toxicities,I-Entity
was,O
low,O
and,O
grade,O
3,O
-,O
4,O
hematological,O
toxicities,I-Entity
were,O
reported,O
in,O
20,O
patients,O
(,O
mainly,O
lymphopenia,I-Entity
and,O
neutropenia,I-Entity
),O
.,O
Topotecan,I-Entity
in,O
combination,O
with,O
radiotherapy,O
was,O
well,O
tolerated,O
.,O
However,I-Entity
",",O
while,O
response,O
and,O
stabilization,O
concerned,O
one,O
-,O
third,O
of,O
the,O
patients,O
",",O
the,O
study,O
did,O
not,O
show,O
increased,O
benefits,O
in,O
terms,O
of,O
survival,O
in,O
patients,O
with,O
unresectable,O
GBM,I-Entity
.,O
Long,I-Entity
-,O
term,O
lithium,I-Entity
therapy,O
leading,O
to,O
hyperparathyroidism,I-Entity
:,O
a,O
case,O
report,O
.,O
This,I-Entity
paper,O
reviews,O
the,O
effect,O
of,O
chronic,O
lithium,I-Entity
therapy,O
on,O
serum,O
calcium,I-Entity
level,O
and,O
parathyroid,I-Entity
glands,O
",",O
its,O
pathogenesis,O
",",O
and,O
treatment,O
options,O
.,O
We,I-Entity
examined,O
the,O
case,O
of,O
a,O
lithium,I-Entity
-,O
treated,O
patient,O
who,O
had,O
recurrent,O
hypercalcemia,I-Entity
to,O
better,O
understand,O
the,O
disease,I-Entity
process,O
.,O
CONCLUSION,I-Entity
:,O
Primary,I-Entity
hyperparathyroidism,I-Entity
is,O
a,O
rare,O
but,O
potentially,O
life,O
-,O
threatening,I-Entity
side,O
effect,O
of,O
long,O
-,O
term,O
lithium,I-Entity
therapy,O
.,O
PRACTICAL,I-Entity
IMPLICATIONS,I-Entity
:,O
As,I-Entity
much,O
as,O
15%,O
of,O
lithium,I-Entity
-,O
treated,O
patients,O
become,O
hypercalcemic,B-Entity
.,O
By,I-Entity
routinely,O
monitoring,O
serum,O
calcium,I-Entity
levels,O
",",O
healthcare,O
providers,O
can,O
improve,O
the,O
quality,O
of,O
life,O
of,O
this,O
patient,O
group,O
.,O
The,I-Entity
purpose,O
of,O
this,O
study,O
was,O
to,O
compare,O
surgical,O
conditions,O
",",O
including,O
the,O
amount,O
of,O
intraoperative,O
bleeding,I-Entity
as,O
well,O
as,O
intraoperative,O
blood,O
pressure,O
",",O
during,O
functional,O
endoscopic,O
sinus,O
surgery,O
(,O
FESS,I-Entity
),O
using,O
flexible,O
reinforced,O
laryngeal,O
mask,O
airway,O
(,O
FRLMA,I-Entity
),O
versus,O
endotracheal,O
tube,O
(,O
ETT,I-Entity
),O
in,O
maintaining,O
controlled,O
hypotension,I-Entity
anesthesia,O
induced,O
by,O
propofol,I-Entity
-,O
remifentanil,I-Entity
total,O
i.v,O
.,O
METHODS,I-Entity
:,O
Sixty,I-Entity
normotensive,I-Entity
American,I-Entity
Society,I-Entity
of,O
Anesthesiologists,I-Entity
I,I-Entity
-,O
II,I-Entity
adult,O
patients,O
undergoing,O
FESS,I-Entity
under,O
controlled,O
hypotension,I-Entity
anesthesia,O
caused,O
by,O
propofol,I-Entity
-,O
remifentanil,I-Entity
-,O
TIVA,I-Entity
were,O
randomly,O
assigned,O
into,O
two,O
groups,O
:,O
group,O
I,I-Entity
",",O
FRLMA,I-Entity
;,O
group,O
II,I-Entity
",",O
ETT,I-Entity
.,O
Hemorrhage,I-Entity
was,O
measured,O
and,O
the,O
visibility,O
of,O
the,O
operative,O
field,O
was,O
evaluated,O
according,O
to,O
a,O
six,O
-,O
point,O
scale,O
.,O
Controlled,I-Entity
hypotension,I-Entity
was,O
achieved,O
within,O
a,O
shorter,O
period,O
using,O
laryngeal,O
mask,O
using,O
lower,O
rates,O
of,O
remifentanil,I-Entity
infusion,O
and,O
lower,O
total,O
dose,O
of,O
remifentanil,I-Entity
.,O
In,I-Entity
summary,O
",",O
our,O
results,O
indicate,O
that,O
airway,O
management,O
using,O
FRLMA,I-Entity
during,O
controlled,O
hypotension,I-Entity
anesthesia,O
provided,O
better,O
surgical,O
conditions,O
in,O
terms,O
of,O
quality,O
of,O
operative,O
field,O
and,O
blood,O
loss,I-Entity
and,O
allowed,O
for,O
convenient,O
induced,O
hypotension,I-Entity
with,O
low,O
doses,O
of,O
remifentanil,I-Entity
during,O
TIVA,I-Entity
in,O
patients,O
undergoing,O
FESS,I-Entity
.,O
Nonalcoholic,I-Entity
fatty,B-Entity
liver,I-Entity
disease,I-Entity
during,O
valproate,I-Entity
therapy,O
.,O
Valproic,I-Entity
acid,O
(,O
VPA,I-Entity
),O
is,O
effective,O
for,O
the,O
treatment,O
of,O
many,O
types,O
of,O
epilepsy,I-Entity
",",O
but,O
its,O
use,O
can,O
be,O
associated,O
with,O
an,O
increase,O
in,O
body,O
weight,O
.,O
We,I-Entity
report,O
a,O
case,O
of,O
nonalcoholic,O
fatty,B-Entity
liver,I-Entity
disease,I-Entity
(,O
NAFLD,I-Entity
),O
arising,O
in,O
a,O
child,O
who,O
developed,O
obesity,I-Entity
during,O
VPA,I-Entity
treatment,O
.,O
Laboratory,I-Entity
data,O
revealed,O
hyperinsulinemia,I-Entity
with,O
insulin,I-Entity
resistance,O
.,O
After,I-Entity
the,O
withdrawal,O
of,O
VPA,I-Entity
therapy,O
",",O
our,O
patient,O
showed,O
a,O
significant,O
weight,O
loss,I-Entity
",",O
a,O
decrease,O
of,O
body,O
mass,O
index,O
",",O
and,O
normalization,O
of,O
metabolic,O
and,O
endocrine,O
parameters,O
;,O
moreover,O
",",O
ultrasound,O
measurements,O
showed,O
a,O
complete,O
normalization,O
.,O
The,I-Entity
present,O
case,O
suggests,O
that,O
obesity,I-Entity
",",O
hyperinsulinemia,I-Entity
",",O
insulin,I-Entity
resistance,O
",",O
and,O
long,O
-,O
term,O
treatment,O
with,O
VPA,I-Entity
may,O
be,O
all,O
associated,O
with,O
the,O
development,O
of,O
NAFLD,I-Entity
;,O
this,O
side,O
effect,O
is,O
reversible,O
after,O
VPA,I-Entity
withdrawal,O
.,O
Carbimazole,I-Entity
induced,O
ANCA,I-Entity
positive,O
vasculitis,I-Entity
.,O
Anti,I-Entity
-,O
thyroid,I-Entity
drugs,O
",",O
like,O
carbimazole,I-Entity
and,O
propylthiouracil,I-Entity
(,O
PTU,I-Entity
),O
are,O
commonly,O
prescribed,O
for,O
the,O
treatment,O
of,O
hyperthyroidism,I-Entity
.,O
One,I-Entity
should,O
be,O
aware,O
of,O
the,O
side,O
effects,O
of,O
antithyroid,I-Entity
medications,O
.,O
Antineutrophil,I-Entity
cytoplasmic,O
antibody,O
(,O
ANCA)--associated,I-Entity
vasculitis,I-Entity
is,O
a,O
potentially,O
life,O
-,O
threatening,I-Entity
adverse,O
effect,O
of,O
antithyroidmedications,O
.,O
We,I-Entity
report,O
a,O
patient,O
with,O
Graves,I-Entity
',O
disease,I-Entity
who,O
developed,O
ANCA,I-Entity
positive,O
carbimazole,I-Entity
induced,O
vasculitis,I-Entity
.,O
The,I-Entity
episode,O
was,O
characterized,O
by,O
a,O
vasculitic,I-Entity
skin,O
rash,I-Entity
associated,O
with,O
large,O
joint,O
arthritis,I-Entity
",",O
pyrexia,I-Entity
and,O
parotiditis,I-Entity
but,O
no,O
renal,O
or,O
pulmonary,O
involvement,O
.,O
He,I-Entity
was,O
referred,O
to,O
us,O
for,O
neurological,O
evaluation,O
because,O
he,O
had,O
difficulty,O
in,O
getting,O
up,O
from,O
squatting,O
position,O
and,O
was,O
suspected,O
to,O
have,O
myositis,I-Entity
.,O
Carbimazole,I-Entity
and,O
methimazole,I-Entity
have,O
a,O
lower,O
incidence,O
of,O
reported,O
ANCA,I-Entity
positive,O
side,O
effects,O
than,O
PUT,I-Entity
.,O
To,I-Entity
the,O
best,O
of,O
our,O
knowledge,O
this,O
is,O
the,O
first,O
ANCA,I-Entity
positive,O
carbimazole,I-Entity
induced,O
vasculitis,I-Entity
case,O
reported,O
from,O
India,I-Entity
.,O
Aspirin,I-Entity
for,O
the,O
primary,O
prevention,O
of,O
cardiovascular,O
events,O
:,O
an,O
update,O
of,O
the,O
evidence,O
for,O
the,O
U.S.,I-Entity
Preventive,I-Entity
Services,I-Entity
Task,I-Entity
Force,I-Entity
.,O
Coronary,I-Entity
heart,O
disease,I-Entity
and,O
cerebrovascular,O
disease,I-Entity
are,O
leading,O
causes,O
of,O
death,I-Entity
in,O
the,O
United,I-Entity
States,I-Entity
.,O
In,I-Entity
2002,O
",",O
the,O
U.S.,I-Entity
Preventive,I-Entity
Services,I-Entity
Task,I-Entity
Force,I-Entity
(,O
USPSTF,I-Entity
),O
strongly,O
recommended,O
that,O
clinicians,O
discuss,O
aspirin,I-Entity
with,O
adults,O
who,O
are,O
at,O
increased,O
risk,O
for,O
coronary,O
heart,O
disease,I-Entity
.,O
PURPOSE,I-Entity
:,O
To,I-Entity
determine,O
the,O
benefits,O
and,O
harms,I-Entity
of,O
taking,O
aspirin,I-Entity
for,O
the,O
primary,O
prevention,O
of,O
myocardial,B-Entity
infarctions,I-Entity
",",O
strokes,O
",",O
and,O
death,I-Entity
.,O
STUDY,I-Entity
SELECTION,I-Entity
:,O
English,I-Entity
-,O
language,O
randomized,O
",",O
controlled,O
trials,O
(,O
RCTs,I-Entity
),O
;,O
case,O
-,O
control,O
studies,O
;,O
meta,O
-,O
analyses,O
;,O
and,O
systematic,O
reviews,O
of,O
aspirin,I-Entity
versus,O
control,O
for,O
the,O
primary,O
prevention,O
of,O
cardiovascular,O
disease,I-Entity
(,O
CVD,I-Entity
),O
were,O
selected,O
to,O
answer,O
the,O
following,O
questions,O
:,O
Does,I-Entity
aspirin,I-Entity
decrease,O
coronary,O
heart,O
events,O
",",O
strokes,O
",",O
death,I-Entity
from,O
coronary,O
heart,O
events,O
or,O
stroke,O
",",O
or,O
all,O
-,O
cause,O
mortality,O
in,O
adults,O
without,O
known,O
CVD,I-Entity
?,O
Does,I-Entity
aspirin,I-Entity
increase,O
gastrointestinal,B-Entity
bleeding,I-Entity
or,O
hemorrhagic,I-Entity
strokes,O
?,O
DATA,I-Entity
SYNTHESIS,I-Entity
:,O
New,I-Entity
evidence,O
from,O
1,O
good,O
-,O
quality,O
RCT,I-Entity
",",O
1,O
good,O
-,O
quality,O
meta,O
-,O
analysis,O
",",O
and,O
2,O
fair,O
-,O
quality,O
subanalyses,O
of,O
RCTs,I-Entity
demonstrates,O
that,O
aspirin,I-Entity
use,O
reduces,O
the,O
number,O
of,O
CVD,I-Entity
events,O
in,O
patients,O
without,O
known,O
CVD,I-Entity
.,O
Men,I-Entity
in,O
these,O
studies,O
experienced,O
fewer,O
myocardial,B-Entity
infarctions,I-Entity
and,O
women,O
experienced,O
fewer,O
ischemic,I-Entity
strokes,O
.,O
Aspirin,I-Entity
does,O
not,O
seem,O
to,O
affect,O
CVD,I-Entity
mortality,O
or,O
all,O
-,O
cause,O
mortality,O
in,O
either,O
men,O
or,O
women,O
.,O
The,I-Entity
use,O
of,O
aspirin,I-Entity
for,O
primary,O
prevention,O
increases,O
the,O
risk,O
for,O
major,O
bleeding,I-Entity
events,O
",",O
primarily,O
gastrointestinal,B-Entity
bleeding,I-Entity
events,O
",",O
in,O
both,O
men,O
and,O
women,O
.,O
Men,I-Entity
have,O
an,O
increased,O
risk,O
for,O
hemorrhagic,I-Entity
strokes,O
with,O
aspirin,I-Entity
use,O
.,O
A,I-Entity
new,O
RCT,I-Entity
and,O
meta,O
-,O
analysis,O
suggest,O
that,O
the,O
risk,O
for,O
hemorrhagic,I-Entity
strokes,O
in,O
women,O
is,O
not,O
statistically,O
significantly,O
increased,O
.,O
New,I-Entity
evidence,O
on,O
aspirin,I-Entity
for,O
the,O
primary,O
prevention,O
of,O
CVD,I-Entity
is,O
limited,O
.,O
The,I-Entity
dose,O
of,O
aspirin,I-Entity
used,O
in,O
the,O
RCTs,I-Entity
varied,O
",",O
which,O
prevented,O
the,O
estimation,O
of,O
the,O
most,O
appropriate,O
dose,O
for,O
primary,O
prevention,O
.,O
Aspirin,I-Entity
reduces,O
the,O
risk,O
for,O
myocardial,B-Entity
infarction,I-Entity
in,O
men,O
and,O
strokes,O
in,O
women,O
.,O
Aspirin,I-Entity
use,O
increases,O
the,O
risk,O
for,O
serious,O
bleeding,I-Entity
events,O
.,O
Reducing,I-Entity
harm,O
associated,O
with,O
anticoagulation,O
:,O
practical,O
considerations,O
of,O
argatroban,I-Entity
therapy,O
in,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
.,O
Argatroban,I-Entity
is,O
a,O
hepatically,O
metabolized,O
",",O
direct,O
thrombin,O
inhibitor,O
used,O
for,O
prophylaxis,O
or,O
treatment,O
of,O
thrombosis,I-Entity
in,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
(,O
HIT,I-Entity
),O
and,O
for,O
patients,O
with,O
or,O
at,O
risk,O
of,O
HIT,I-Entity
undergoing,O
percutaneous,O
coronary,O
intervention,O
(,O
PCI,I-Entity
),O
.,O
The,I-Entity
objective,O
of,O
this,O
review,O
is,O
to,O
summarize,O
practical,O
considerations,O
of,O
argatroban,I-Entity
therapy,O
in,O
HIT,I-Entity
.,O
The,I-Entity
US,I-Entity
FDA,I-Entity
-,O
recommended,O
argatroban,I-Entity
dose,O
in,O
HIT,I-Entity
is,O
2,O
microg,O
/,O
kg,O
/,O
min,O
(,O
reduced,O
in,O
patients,O
with,O
hepatic,B-Entity
impairment,I-Entity
and,O
in,O
paediatric,O
patients,O
),O
",",O
adjusted,O
to,O
achieve,O
activated,O
partial,O
thromboplastin,I-Entity
times,O
(,O
aPTTs,I-Entity
),O
1.5,O
-,O
3,O
times,O
baseline,O
(,O
not,O
>,O
100,O
seconds,O
),O
.,O
Contemporary,I-Entity
experiences,O
indicate,O
that,O
reduced,O
doses,O
are,O
also,O
needed,O
in,O
patients,O
with,O
conditions,O
associated,O
with,O
hepatic,B-Entity
hypoperfusion,I-Entity
",",O
e.g.,O
heart,O
failure,I-Entity
",",O
yet,O
are,O
unnecessary,O
for,O
renal,O
dysfunction,I-Entity
",",O
adult,O
age,O
",",O
sex,O
",",O
race,O
/,O
ethnicity,O
or,O
obesity,I-Entity
.,O
Argatroban,I-Entity
0.5,O
-,O
1.2,O
For,I-Entity
PCI,I-Entity
",",O
argatroban,I-Entity
has,O
not,O
been,O
investigated,O
in,O
hepatically,O
impaired,I-Entity
patients,O
;,O
dose,O
adjustment,O
is,O
unnecessary,O
for,O
adult,O
age,O
",",O
sex,O
",",O
race,O
/,O
ethnicity,O
or,O
obesity,I-Entity
",",O
and,O
lesser,O
doses,O
may,O
be,O
adequate,O
with,O
concurrent,O
glycoprotein,O
IIb,I-Entity
/,O
IIIa,I-Entity
inhibition,O
.,O
Argatroban,I-Entity
prolongs,O
the,O
International,I-Entity
Normalized,I-Entity
Ratio,I-Entity
",",O
and,O
published,O
approaches,O
for,O
monitoring,O
the,O
argatroban,I-Entity
-,O
to,O
-,O
warfarin,I-Entity
transition,O
should,O
be,O
followed,O
.,O
Major,I-Entity
bleeding,I-Entity
with,O
argatroban,I-Entity
is,O
0,O
-,O
10%,O
in,O
the,O
non,O
-,O
interventional,O
setting,O
and,O
0,O
-,O
5.8%,O
periprocedurally,O
.,O
Argatroban,I-Entity
has,O
no,O
specific,O
antidote,O
",",O
and,O
if,O
excessive,O
anticoagulation,O
occurs,O
",",O
argatroban,I-Entity
infusion,O
should,O
be,O
stopped,O
or,O
reduced,O
.,O
Improved,I-Entity
familiarity,O
of,O
healthcare,O
professionals,O
with,O
argatroban,I-Entity
therapy,O
in,O
HIT,I-Entity
",",O
including,O
in,O
special,O
populations,O
and,O
during,O
PCI,I-Entity
",",O
may,O
facilitate,O
reduction,O
of,O
harm,O
associated,O
with,O
HIT,I-Entity
(,O
e.g.,O
fewer,O
thromboses,I-Entity
),O
or,O
its,O
treatment,O
(,O
e.g.,O
fewer,O
argatroban,I-Entity
medication,O
errors,I-Entity
),O
.,O
Rhabdomyolysis,I-Entity
and,O
brain,O
ischemic,I-Entity
stroke,O
in,O
a,O
heroin,I-Entity
-,O
dependent,O
male,O
under,O
methadone,I-Entity
maintenance,O
therapy,O
.,O
OBJECTIVE,I-Entity
:,O
There,I-Entity
are,O
several,O
complications,O
associated,O
with,O
heroin,I-Entity
abuse,I-Entity
",",O
some,O
of,O
which,O
are,O
life,O
-,O
threatening,I-Entity
.,O
Methadone,I-Entity
may,O
aggravate,O
this,O
problem,O
.,O
A,I-Entity
33-year,O
-,O
old,O
man,O
presented,O
with,O
rhabdomyolysis,I-Entity
and,O
cerebral,O
ischemic,I-Entity
stroke,O
after,O
intravenous,O
heroin,I-Entity
.,O
He,I-Entity
had,O
used,O
heroin,I-Entity
since,O
age,O
20,O
",",O
and,O
had,O
used,O
150,I-Entity
mg,O
methadone,I-Entity
daily,O
for,O
6,O
months,O
.,O
He,I-Entity
was,O
found,O
unconsciousness,I-Entity
at,O
home,O
and,O
was,O
sent,O
to,O
our,O
hospital,O
.,O
In,I-Entity
the,O
ICU,I-Entity
",",O
we,O
found,O
rhabdomyolysis,I-Entity
",",O
acute,O
renal,O
failure,I-Entity
and,O
acute,O
respiratory,O
failure,I-Entity
.,O
After,I-Entity
transfer,O
to,O
an,O
internal,O
ward,O
",",O
we,O
noted,O
aphasia,I-Entity
and,O
weakness,I-Entity
of,O
his,O
left,O
limbs,O
.,O
After,I-Entity
MRI,I-Entity
",",O
we,O
found,O
cerebral,O
ischemic,I-Entity
infarction,I-Entity
.,O
Those,I-Entity
using,O
methadone,I-Entity
and,O
heroin,I-Entity
simultaneously,O
may,O
increase,O
risk,O
of,O
rhabdomyolysis,I-Entity
and,O
ischemic,I-Entity
stroke,O
.,O
Patients,I-Entity
under,O
methadone,I-Entity
maintenance,O
therapy,O
should,O
be,O
warned,O
regarding,O
these,O
serious,O
adverse,O
events,O
.,O
Hypotheses,I-Entity
of,O
heroin,I-Entity
-,O
related,O
rhabdomyolysis,I-Entity
and,O
stroke,O
in,O
heroin,I-Entity
abusers,O
are,O
discussed,O
.,O
Increased,I-Entity
vulnerability,O
to,O
6-hydroxydopamine,I-Entity
lesion,I-Entity
and,O
reduced,O
development,O
of,O
dyskinesias,I-Entity
in,O
mice,O
lacking,O
CB1,I-Entity
cannabinoid,I-Entity
receptors,O
.,O
Motor,I-Entity
impairment,I-Entity
",",O
dopamine,I-Entity
(,O
DA,I-Entity
),O
neuronal,O
activity,O
and,O
proenkephalin,I-Entity
(,O
PENK,I-Entity
),O
gene,O
expression,O
in,O
the,O
caudate,O
-,O
putamen,I-Entity
(,O
CPu,I-Entity
),O
were,O
measured,O
in,O
6-OHDA,I-Entity
-,O
lesioned,O
and,O
treated,O
(,O
L,I-Entity
-,O
DOPA+benserazide,I-Entity
),O
A,I-Entity
lesion,I-Entity
induced,O
by,O
6-OHDA,I-Entity
produced,O
more,O
severe,O
motor,O
deterioration,O
in,O
CB1,I-Entity
KO,I-Entity
mice,O
accompanied,O
by,O
more,O
loss,I-Entity
of,O
DA,I-Entity
neurons,O
and,O
increased,O
PENK,I-Entity
gene,O
expression,O
in,O
the,O
CPu,I-Entity
.,O
CB1,I-Entity
KO,I-Entity
mice,O
exhibited,O
higher,O
MDA,I-Entity
levels,O
and,O
iNOS,I-Entity
protein,O
expression,O
in,O
the,O
CPu,I-Entity
and,O
Cg,I-Entity
compared,O
to,O
WT,I-Entity
mice,O
.,O
Treatment,I-Entity
with,O
L,I-Entity
-,O
DOPA+benserazide,I-Entity
(,O
12,O
weeks,O
),O
resulted,O
in,O
less,O
severe,O
dyskinesias,I-Entity
in,O
CB1,I-Entity
KO,I-Entity
than,O
in,O
WT,I-Entity
mice,O
.,O
The,I-Entity
results,O
revealed,O
that,O
the,O
lack,O
of,O
cannabinoid,I-Entity
CB1,I-Entity
receptors,O
increased,O
the,O
severity,O
of,O
motor,O
impairment,I-Entity
and,O
DA,I-Entity
lesion,I-Entity
",",O
and,O
reduced,O
L,I-Entity
-,O
DOPA,I-Entity
-,O
induced,O
dyskinesias,I-Entity
.,O
These,I-Entity
results,O
suggest,O
that,O
activation,O
of,O
CB1,I-Entity
receptors,O
offers,O
neuroprotection,O
against,O
dopaminergic,O
lesion,I-Entity
and,O
the,O
development,O
of,O
L,I-Entity
-,O
DOPA,I-Entity
-,O
induced,O
dyskinesias,I-Entity
.,O
Animal,I-Entity
model,O
of,O
mania,I-Entity
induced,O
by,O
ouabain,I-Entity
:,O
Evidence,I-Entity
of,O
oxidative,O
stress,I-Entity
in,O
submitochondrial,O
particles,O
of,O
the,O
rat,O
brain,O
.,O
The,I-Entity
intracerebroventricular,B-Entity
(,O
ICV,I-Entity
),O
administration,O
of,O
ouabain,I-Entity
(,O
a,O
Na(+)/K(+)-ATPase,I-Entity
inhibitor,O
),O
in,O
rats,O
has,O
been,O
suggested,O
to,O
mimic,O
some,O
symptoms,O
of,O
human,O
bipolar,I-Entity
mania,I-Entity
.,O
Clinical,I-Entity
studies,O
have,O
shown,O
that,O
bipolar,I-Entity
disorder,I-Entity
may,O
be,O
related,O
to,O
mitochondrial,O
dysfunction,I-Entity
.,O
Herein,I-Entity
",",O
we,O
investigated,O
the,O
behavioral,O
and,O
biochemical,O
effects,O
induced,O
by,O
the,O
ICV,I-Entity
administration,O
of,O
ouabain,I-Entity
in,O
rats,O
.,O
To,I-Entity
achieve,O
this,O
aim,O
",",O
the,O
effects,O
of,O
ouabain,I-Entity
injection,O
immediately,O
after,O
and,O
7,O
days,O
following,O
a,O
single,O
ICV,I-Entity
administration,O
(,O
at,O
concentrations,O
of,O
10(-2,O
),O
and,O
10(-3)M,O
),O
on,O
locomotion,O
was,O
measured,O
using,O
the,O
open,O
-,O
field,O
test,O
.,O
Additionally,I-Entity
",",O
thiobarbituric,I-Entity
acid,O
reactive,O
substances,O
(,O
TBARSs,I-Entity
),O
and,O
superoxide,I-Entity
production,O
were,O
measured,O
in,O
submitochondrial,O
particles,O
of,O
the,O
prefrontal,O
cortex,O
",",O
hippocampus,O
",",O
striatum,O
and,O
amygdala,O
.,O
Our,I-Entity
findings,O
demonstrated,O
that,O
ouabain,I-Entity
at,O
10(-2,O
),O
and,O
10(-3)M,O
induced,O
hyperlocomotion,I-Entity
in,O
rats,O
",",O
and,O
this,O
response,O
remained,O
up,O
to,O
7,O
days,O
following,O
a,O
single,O
ICV,I-Entity
injection,O
.,O
In,I-Entity
addition,O
",",O
we,O
observed,O
that,O
the,O
persistent,O
increase,O
in,O
the,O
rat,O
spontaneous,O
locomotion,O
is,O
associated,O
with,O
increased,O
TBARS,I-Entity
levels,O
and,O
superoxide,I-Entity
generation,O
in,O
submitochondrial,O
particles,O
in,O
the,O
prefrontal,O
cortex,O
",",O
striatum,O
and,O
amygdala,O
.,O
In,I-Entity
conclusion,O
",",O
ouabain,I-Entity
-,O
induced,O
mania,I-Entity
-,O
like,O
behavior,O
may,O
provide,O
a,O
useful,O
animal,O
model,O
to,O
test,O
the,O
hypothesis,O
of,O
the,O
involvement,O
of,O
oxidative,O
stress,I-Entity
in,O
bipolar,I-Entity
disorder,I-Entity
.,O
Intraoperative,I-Entity
dialysis,O
during,O
liver,I-Entity
transplantation,O
with,O
citrate,I-Entity
dialysate,I-Entity
.,O
Liver,I-Entity
transplantation,O
for,O
acutely,O
ill,O
patients,O
with,O
fulminant,O
liver,I-Entity
failure,I-Entity
carries,O
high,O
intraoperative,O
and,O
immediate,O
postoperative,O
risks,O
.,O
These,I-Entity
are,O
increased,O
with,O
the,O
presence,O
of,O
concomitant,I-Entity
acute,O
kidney,O
injury,I-Entity
(,O
AKI,I-Entity
),O
and,O
intraoperative,O
dialysis,O
is,O
sometimes,O
required,O
to,O
allow,O
the,O
transplant,O
to,O
proceed,O
.,O
The,I-Entity
derangements,I-Entity
in,O
the,O
procoagulant,O
and,O
anticoagulant,O
pathways,O
during,O
fulminant,O
liver,I-Entity
failure,I-Entity
can,O
lead,O
to,O
difficulties,O
with,O
anticoagulation,O
during,O
dialysis,O
",",O
especially,O
when,O
continued,O
in,O
the,O
operating,O
room,O
.,O
Systemic,I-Entity
anticoagulation,O
is,O
unsafe,O
and,O
regional,O
citrate,I-Entity
anticoagulation,O
in,O
the,O
absence,O
of,O
a,O
functional,O
liver,I-Entity
carries,O
the,O
risk,O
of,O
citrate,I-Entity
toxicity,I-Entity
.,O
Citrate,I-Entity
dialysate,I-Entity
",",O
a,O
new,O
dialysate,I-Entity
with,O
citric,O
acid,O
can,O
be,O
used,O
for,O
anticoagulation,O
in,O
patients,O
who,O
can,O
not,O
tolerate,O
heparin,I-Entity
or,O
regional,O
citrate,I-Entity
.,O
We,I-Entity
report,O
a,O
case,O
of,O
a,O
40-year,O
-,O
old,O
female,O
with,O
acetaminophen,I-Entity
-,O
induced,O
fulminant,O
liver,I-Entity
failure,I-Entity
with,O
associated,O
AKI,I-Entity
who,O
underwent,O
intraoperative,O
dialytic,O
support,O
during,O
liver,I-Entity
transplantation,O
anticoagulated,O
with,O
citrate,I-Entity
dialysate,I-Entity
during,O
the,O
entire,O
procedure,O
.,O
The,I-Entity
patient,O
tolerated,O
the,O
procedure,O
well,O
without,O
any,O
signs,O
of,O
citrate,I-Entity
toxicity,I-Entity
and,O
maintained,O
adequate,O
anticoagulation,O
for,O
patency,O
of,O
the,O
dialysis,O
circuit,O
.,O
Citrate,I-Entity
dialysate,I-Entity
is,O
a,O
safe,O
alternative,O
for,O
intradialytic,O
support,O
of,O
liver,I-Entity
transplantation,O
in,O
fulminant,O
liver,I-Entity
failure,I-Entity
.,O
Delirium,I-Entity
in,O
a,O
patient,O
with,O
toxic,I-Entity
flecainide,I-Entity
plasma,O
concentrations,O
:,O
the,O
role,O
of,O
a,O
pharmacokinetic,O
drug,O
interaction,O
with,O
paroxetine,I-Entity
.,O
OBJECTIVE,I-Entity
:,O
To,I-Entity
describe,O
a,O
case,O
of,O
flecainide,I-Entity
-,O
induced,O
delirium,I-Entity
associated,O
with,O
a,O
pharmacokinetic,O
drug,O
interaction,O
with,O
paroxetine,I-Entity
.,O
A,I-Entity
69-year,O
-,O
old,O
white,O
female,O
presented,O
to,O
the,O
emergency,O
department,O
with,O
a,O
history,O
of,O
confusion,I-Entity
and,O
paranoia,I-Entity
over,O
the,O
past,O
several,O
days,O
.,O
On,I-Entity
admission,O
the,O
patient,O
was,O
taking,O
carvedilol,I-Entity
12,O
mg,O
twice,O
daily,O
",",O
warfarin,I-Entity
2,O
mg,O
/,O
day,O
",",O
folic,I-Entity
acid,O
1,O
mg,O
/,O
day,O
",",O
levothyroxine,I-Entity
100,O
microg,O
/,O
day,O
",",O
pantoprazole,I-Entity
40,O
mg,O
/,O
day,O
",",O
paroxetine,I-Entity
40,O
mg,O
/,O
day,O
",",O
and,O
flecainide,I-Entity
100,O
mg,O
twice,O
daily,O
.,O
Flecainide,I-Entity
had,O
been,O
started,O
2,O
weeks,O
prior,O
for,O
atrial,I-Entity
fibrillation,I-Entity
.,O
Laboratory,I-Entity
test,O
findings,O
on,O
admission,O
were,O
notable,O
only,O
for,O
a,O
flecainide,I-Entity
plasma,O
concentration,O
of,O
1360,O
microg,O
/,O
L,I-Entity
(,O
reference,O
range,O
200,O
-,O
1000,O
),O
.,O
A,I-Entity
metabolic,O
drug,O
interaction,O
between,O
flecainide,I-Entity
and,O
paroxetine,I-Entity
",",O
which,O
the,O
patient,O
had,O
been,O
taking,O
for,O
more,O
than,O
5,O
years,O
",",O
was,O
considered,O
.,O
Paroxetine,I-Entity
was,O
discontinued,O
and,O
the,O
dose,O
of,O
flecainide,I-Entity
was,O
reduced,O
to,O
50,O
mg,O
twice,O
daily,O
.,O
Her,I-Entity
delirium,I-Entity
resolved,O
3,O
days,O
later,O
.,O
DISCUSSION,I-Entity
:,O
Flecainide,I-Entity
and,O
pharmacologically,O
similar,O
agents,O
that,O
interact,O
with,O
sodium,I-Entity
channels,O
may,O
cause,O
delirium,I-Entity
in,O
susceptible,O
patients,O
.,O
A,I-Entity
MEDLINE,I-Entity
search,O
(,O
1966-January,O
2009,O
),O
revealed,O
one,O
in,O
vivo,O
pharmacokinetic,O
study,O
on,O
the,O
interaction,O
between,O
flecainide,I-Entity
",",O
a,O
CYP2D6,I-Entity
substrate,O
",",O
and,O
paroxetine,I-Entity
",",O
a,O
CYP2D6,I-Entity
inhibitor,O
",",O
as,O
well,O
as,O
3,O
case,O
reports,O
of,O
flecainide,I-Entity
-,O
induced,O
delirium,I-Entity
.,O
According,I-Entity
to,O
the,O
Naranjo,I-Entity
probability,O
scale,O
",",O
flecainide,I-Entity
was,O
the,O
probable,O
cause,O
of,O
the,O
patient,O
's,I-Entity
delirium,I-Entity
;,O
the,O
Horn,I-Entity
Drug,I-Entity
Interaction,I-Entity
Probability,I-Entity
Scale,I-Entity
indicates,O
a,O
possible,O
pharmacokinetic,O
drug,O
interaction,O
between,O
flecainide,I-Entity
and,O
paroxetine,I-Entity
.,O
Supratherapeutic,I-Entity
flecainide,I-Entity
plasma,O
concentrations,O
may,O
cause,O
delirium,I-Entity
.,O
Because,I-Entity
toxicity,I-Entity
may,O
occur,O
when,O
flecainide,I-Entity
is,O
prescribed,O
with,O
paroxetine,I-Entity
and,O
other,O
potent,O
CYP2D6,I-Entity
inhibitors,O
",",O
flecainide,I-Entity
plasma,O
concentrations,O
should,O
be,O
monitored,O
closely,O
with,O
commencement,O
of,O
CYP2D6,I-Entity
inhibitors,O
.,O
Efficacy,I-Entity
of,O
everolimus,I-Entity
(,O
RAD001,I-Entity
),O
in,O
patients,O
with,O
advanced,O
NSCLC,I-Entity
previously,O
treated,O
with,O
chemotherapy,O
alone,O
or,O
with,O
chemotherapy,O
and,O
EGFR,I-Entity
inhibitors,O
.,O
BACKGROUND,I-Entity
:,O
Treatment,I-Entity
options,O
are,O
scarce,O
in,O
pretreated,O
advanced,O
non,O
-,O
small,O
-,O
cell,O
lung,O
cancer,I-Entity
(,O
NSCLC,I-Entity
),O
patients,O
.,O
RAD001,I-Entity
",",O
an,O
oral,O
inhibitor,O
of,O
the,O
mammalian,O
target,O
of,O
rapamycin,I-Entity
(,O
mTOR,I-Entity
),O
",",O
has,O
shown,O
phase,O
I,I-Entity
efficacy,O
in,O
NSCLC,I-Entity
.,O
METHODS,I-Entity
:,O
Stage,I-Entity
IIIb,I-Entity
or,O
IV,I-Entity
NSCLC,I-Entity
patients,O
",",O
with,O
two,O
or,O
fewer,O
prior,O
chemotherapy,O
regimens,I-Entity
",",O
one,O
platinum,O
based,O
(,O
stratum,O
1,O
),O
or,O
both,O
chemotherapy,O
and,O
epidermal,O
growth,O
factor,O
receptor,O
tyrosine,I-Entity
kinase,O
inhibitors,O
(,O
stratum,O
2,O
),O
",",O
received,O
RAD001,I-Entity
10,O
mg,O
/,O
day,O
until,O
progression,O
or,O
unacceptable,O
toxicity,I-Entity
.,O
Analyses,I-Entity
of,O
markers,O
associated,O
with,O
the,O
mTOR,I-Entity
pathway,O
were,O
carried,O
out,O
on,O
archival,O
tumor,I-Entity
from,O
a,O
subgroup,O
using,O
immunohistochemistry,O
(,O
IHC,I-Entity
),O
and,O
direct,O
mutation,O
sequencing,O
.,O
Common,I-Entity
>,O
or,O
=,O
grade,O
3,O
events,O
were,O
fatigue,I-Entity
",",O
dyspnea,I-Entity
",",O
stomatitis,I-Entity
",",O
anemia,I-Entity
",",O
and,O
thrombocytopenia,I-Entity
.,O
Pneumonitis,I-Entity
",",O
probably,O
or,O
possibly,O
related,O
",",O
mainly,O
grade,O
1/2,O
",",O
occurred,O
in,O
25%,O
.,O
RAD001,I-Entity
10,O
mg,O
/,O
day,O
was,O
well,O
tolerated,O
",",O
showing,O
modest,O
clinical,O
activity,O
in,O
pretreated,O
NSCLC,I-Entity
.,O
Evaluation,I-Entity
of,O
RAD001,I-Entity
plus,O
standard,O
therapy,O
for,O
metastatic,O
NSCLC,I-Entity
continues,O
.,O
Posttransplant,I-Entity
anemia,I-Entity
:,O
the,O
role,O
of,O
sirolimus,I-Entity
.,O
Posttransplant,I-Entity
anemia,I-Entity
is,O
a,O
common,O
problem,O
that,O
may,O
hinder,O
patients,O
',O
quality,O
of,O
life,O
.,O
A,I-Entity
variety,O
of,O
factors,O
have,O
been,O
identified,O
that,O
increase,O
the,O
risk,O
of,O
posttransplant,O
anemia,I-Entity
",",O
of,O
which,O
the,O
level,O
of,O
renal,O
function,O
is,O
most,O
important,O
.,O
Sirolimus,I-Entity
",",O
a,O
mammalian,O
target,O
of,O
rapamycin,I-Entity
inhibitor,O
",",O
has,O
been,O
implicated,O
as,O
playing,O
a,O
special,O
role,O
in,O
posttransplant,O
anemia,I-Entity
.,O
This,I-Entity
review,O
considers,O
anemia,I-Entity
associated,O
with,O
sirolimus,I-Entity
",",O
including,O
its,O
presentation,O
",",O
mechanisms,O
",",O
and,O
management,O
.,O
Coronary,I-Entity
computerized,O
tomography,O
angiography,O
for,O
rapid,O
discharge,O
of,O
low,O
-,O
risk,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
chest,O
pain,I-Entity
.,O
Most,I-Entity
patients,O
presenting,O
to,O
emergency,O
departments,O
(,O
EDs,I-Entity
),O
with,O
cocaine,I-Entity
-,O
associated,O
chest,O
pain,I-Entity
are,O
admitted,O
for,O
at,O
least,O
12,O
hours,O
and,O
receive,O
a,O
"""""""""",O
rule,O
out,O
acute,O
coronary,O
syndrome,I-Entity
"""""""""",O
protocol,O
",",O
often,O
with,O
noninvasive,O
testing,O
prior,O
to,O
discharge,O
.,O
In,I-Entity
patients,O
without,O
cocaine,I-Entity
use,O
",",O
coronary,O
computerized,O
tomography,O
angiography,O
(,O
CTA,I-Entity
),O
has,O
been,O
shown,O
to,O
be,O
useful,O
for,O
identifying,O
a,O
group,O
of,O
patients,O
at,O
low,O
risk,O
for,O
cardiac,O
events,O
who,O
can,O
be,O
safely,O
discharged,O
.,O
It,I-Entity
is,O
unclear,O
whether,O
a,O
coronary,O
CTA,I-Entity
strategy,O
would,O
be,O
efficacious,O
in,O
cocaine,I-Entity
-,O
associated,O
chest,O
pain,I-Entity
",",O
as,O
coronary,O
vasospasm,I-Entity
may,O
account,O
for,O
some,O
of,O
the,O
ischemia,I-Entity
.,O
We,I-Entity
studied,O
whether,O
a,O
negative,O
coronary,O
CTA,I-Entity
in,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
chest,O
pain,I-Entity
could,O
identify,O
a,O
subset,O
safe,O
for,O
discharge,O
.,O
:,O
We,I-Entity
prospectively,O
evaluated,O
the,O
safety,O
of,O
coronary,O
CTA,I-Entity
for,O
low,O
-,O
risk,O
patients,O
who,O
presented,O
to,O
the,O
ED,I-Entity
with,O
cocaineassociated,I-Entity
chest,O
pain,I-Entity
(,O
self,O
-,O
reported,O
or,O
positive,O
urine,I-Entity
test,O
),O
.,O
Patients,I-Entity
with,O
negative,O
coronary,O
CTA,I-Entity
(,O
maximal,O
stenosis,I-Entity
less,O
than,O
50%,O
),O
were,O
discharged,O
.,O
The,I-Entity
main,O
outcome,O
was,O
30-day,O
cardiovascular,O
death,I-Entity
or,O
myocardial,B-Entity
infarction,I-Entity
.,O
A,I-Entity
total,O
of,O
59,I-Entity
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
chest,O
pain,I-Entity
were,O
evaluated,O
.,O
Six,I-Entity
patients,O
had,O
coronary,O
stenosis,I-Entity
>,O
During,I-Entity
the,O
30-day,O
follow,O
-,O
up,O
period,O
",",O
no,O
patients,O
died,O
of,O
a,O
cardiovascular,O
event,O
(,O
0%,O
;,O
95%,O
CI,I-Entity
",",O
0,O
-,O
6.1%,O
),O
and,O
no,O
patient,O
sustained,O
a,O
nonfatal,O
myocardial,B-Entity
infarction,I-Entity
(,O
0%,O
;,O
95%,O
CI,I-Entity
",",O
0,O
-,O
6.1%,O
),O
.,O
Although,I-Entity
cocaine,I-Entity
-,O
associated,O
myocardial,B-Entity
ischemia,I-Entity
can,O
result,O
from,O
coronary,O
vasoconstriction,O
",",O
patients,O
with,O
cocaine,I-Entity
associated,O
chest,O
pain,I-Entity
",",O
a,O
non,O
-,O
ischemic,I-Entity
ECG,I-Entity
",",O
and,O
a,O
TIMI,I-Entity
risk,O
score,O
Late,I-Entity
fulminant,O
posterior,O
reversible,O
encephalopathy,I-Entity
syndrome,I-Entity
after,O
liver,I-Entity
transplant,O
.,O
Posterior,I-Entity
leukoencephalopathy,I-Entity
due,O
to,O
calcineurin,O
-,O
inhibitor,O
-,O
related,O
neurotoxicity,I-Entity
is,O
a,O
rare,O
but,O
severe,O
complication,O
that,O
results,O
from,O
treatment,O
with,O
immunosuppressive,O
agents,O
(,O
primarily,O
those,O
administered,O
after,O
a,O
liver,I-Entity
or,O
kidney,O
transplant,O
),O
.,O
:,O
We,I-Entity
report,O
the,O
case,O
of,O
a,O
46-year,O
-,O
old,O
woman,O
who,O
received,O
a,O
liver,I-Entity
transplant,O
in,O
our,O
center,O
as,O
treatment,O
for,O
alcoholic,I-Entity
cirrhosis,I-Entity
and,O
in,O
whom,O
either,O
a,O
fulminant,O
course,O
of,O
posterior,O
leukoencephalopathy,I-Entity
or,O
posterior,O
reversible,O
encephalopathy,I-Entity
syndrome,I-Entity
developed,O
110,I-Entity
days,O
after,O
transplant,O
.,O
Switching,I-Entity
the,O
immunosuppressive,O
regimen,I-Entity
from,O
tacrolimus,I-Entity
to,O
cyclosporine,I-Entity
did,O
not,O
improve,O
the,O
clinical,O
situation,O
.,O
Posterior,I-Entity
reversible,O
encephalopathy,I-Entity
syndrome,I-Entity
after,O
liver,I-Entity
transplant,O
is,O
rare,O
.,O
Prolonged,I-Entity
hypothermia,I-Entity
as,O
a,O
bridge,O
to,O
recovery,O
for,O
cerebral,O
edema,I-Entity
and,O
intracranial,B-Entity
hypertension,I-Entity
associated,O
with,O
fulminant,O
hepatic,B-Entity
failure,I-Entity
.,O
BACKGROUND,I-Entity
:,O
To,I-Entity
review,O
evidence,O
-,O
based,O
treatment,O
options,O
in,O
patients,O
with,O
cerebral,O
edema,I-Entity
complicating,O
fulminant,O
hepatic,B-Entity
failure,I-Entity
(,O
FHF,I-Entity
),O
and,O
discuss,O
the,O
potential,O
applications,O
of,O
hypothermia,I-Entity
.,O
METHOD,I-Entity
:,O
Case,I-Entity
-,O
based,O
observations,O
from,O
a,O
medical,O
intensive,O
care,O
unit,O
(,O
MICU,I-Entity
),O
in,O
a,O
tertiary,O
care,O
facility,O
in,O
a,O
27-year,O
-,O
old,O
female,O
with,O
FHF,I-Entity
from,O
acetaminophen,I-Entity
and,O
resultant,O
cerebral,O
edema,I-Entity
.,O
Our,I-Entity
patient,O
was,O
admitted,O
to,O
the,O
MICU,I-Entity
after,O
being,O
found,O
unresponsive,O
with,O
presumed,O
toxicity,I-Entity
from,O
acetaminophen,I-Entity
which,O
was,O
ingested,O
over,O
a,O
2-day,O
period,O
.,O
Initial,I-Entity
evaluation,O
confirmed,O
FHF,I-Entity
from,O
acetaminophen,I-Entity
and,O
cerebral,O
edema,I-Entity
.,O
The,I-Entity
patient,O
was,O
treated,O
with,O
hyperosmolar,I-Entity
therapy,O
",",O
hyperventilation,I-Entity
",",O
sedation,O
",",O
and,O
chemical,O
paralysis,I-Entity
.,O
We,I-Entity
then,O
initiated,O
therapeutic,O
hypothermia,I-Entity
which,O
was,O
continued,O
for,O
5,O
days,O
.,O
At,I-Entity
re,O
-,O
warming,O
",",O
patient,O
had,O
resolution,O
of,O
her,O
cerebral,O
edema,I-Entity
and,O
intracranial,B-Entity
hypertension,I-Entity
.,O
In,I-Entity
patients,O
with,O
FHF,I-Entity
and,O
cerebral,O
edema,I-Entity
from,O
acetaminophen,I-Entity
overdose,I-Entity
",",O
prolonged,O
therapeutic,O
hypothermia,I-Entity
could,O
potentially,O
be,O
used,O
as,O
a,O
life,O
saving,O
therapy,O
and,O
a,O
bridge,O
to,O
hepatic,B-Entity
and,O
neurological,O
recovery,O
.,O
A,I-Entity
clinical,O
trial,O
of,O
hypothermia,I-Entity
in,O
patients,O
with,O
this,O
condition,O
is,O
warranted,O
.,O
Binasal,I-Entity
visual,O
field,O
defects,O
are,O
not,O
specific,O
to,O
vigabatrin,I-Entity
.,O
This,I-Entity
study,O
investigated,O
the,O
visual,O
defects,O
associated,O
with,O
the,O
antiepileptic,O
drug,O
vigabatrin,I-Entity
(,O
VGB,I-Entity
),O
.,O
Two,I-Entity
hundred,O
four,O
people,O
with,O
epilepsy,I-Entity
were,O
grouped,O
on,O
the,O
basis,O
of,O
antiepileptic,O
drug,O
therapy,O
(,O
current,O
",",O
previous,O
",",O
or,O
no,O
exposure,O
to,O
VGB,I-Entity
),O
.,O
Groups,I-Entity
were,O
matched,O
with,O
respect,O
to,O
age,O
",",O
gender,O
",",O
and,O
seizure,I-Entity
frequency,O
.,O
Bilateral,I-Entity
visual,O
field,O
constriction,I-Entity
was,O
observed,O
in,O
59%,O
of,O
patients,O
currently,O
taking,O
VGB,I-Entity
",",O
43%,O
of,O
patients,O
who,O
previously,O
took,O
VGB,I-Entity
",",O
and,O
24%,O
of,O
patients,O
with,O
no,O
exposure,O
to,O
VGB,I-Entity
.,O
Assessment,I-Entity
of,O
retinal,B-Entity
function,O
revealed,O
abnormal,I-Entity
responses,O
in,O
48%,O
of,O
current,O
VGB,I-Entity
users,O
and,O
22%,O
of,O
prior,O
VGB,I-Entity
users,O
",",O
but,O
in,O
none,O
of,O
the,O
patients,O
without,O
previous,O
exposure,O
to,O
VGB,I-Entity
.,O
Bilateral,I-Entity
visual,O
field,O
abnormalities,I-Entity
are,O
common,O
in,O
the,O
treated,O
epilepsy,I-Entity
population,O
",",O
irrespective,O
of,O
drug,O
history,O
.,O
Assessment,I-Entity
by,O
conventional,O
static,O
perimetry,O
may,O
neither,O
be,O
sufficiently,O
sensitive,I-Entity
nor,O
specific,O
to,O
reliably,O
identify,O
retinal,B-Entity
toxicity,I-Entity
associated,O
with,O
VGB,I-Entity
.,O
Smoking,I-Entity
of,O
crack,I-Entity
cocaine,I-Entity
as,O
a,O
risk,O
factor,O
for,O
HIV,I-Entity
infection,I-Entity
among,O
people,O
who,O
use,O
injection,O
drugs,O
.,O
Little,I-Entity
is,O
known,O
about,O
the,O
possible,O
role,O
that,O
smoking,I-Entity
crack,I-Entity
cocaine,I-Entity
has,O
on,O
the,O
incidence,O
of,O
HIV,I-Entity
infection,I-Entity
.,O
Given,I-Entity
the,O
increasing,O
use,O
of,O
crack,I-Entity
cocaine,I-Entity
",",O
we,O
sought,O
to,O
examine,O
whether,O
use,O
of,O
this,O
illicit,O
drug,O
has,O
become,O
a,O
risk,O
factor,O
for,O
HIV,I-Entity
infection,I-Entity
.,O
To,I-Entity
determine,O
whether,O
the,O
risk,O
of,O
HIV,I-Entity
seroconversion,I-Entity
among,O
daily,O
smokers,I-Entity
of,O
crack,I-Entity
cocaine,I-Entity
changed,O
over,O
time,O
",",O
we,O
used,O
Cox,I-Entity
proportional,O
hazards,O
regression,O
and,O
divided,O
the,O
study,O
into,O
3,O
periods,O
:,O
May,I-Entity
1,O
",",O
1996-Nov,O
.,O
30,O
",",O
1999,O
(,O
period,O
1,O
),O
",",O
Dec.,I-Entity
1,O
",",O
1999-Nov,O
.,O
30,O
",",O
2002,O
(,O
period,O
2,O
),O
",",O
and,O
Dec.,I-Entity
1,O
",",O
2002-Dec,O
.,O
30,O
",",O
2005,O
(,O
period,O
3,O
),O
.,O
Of,I-Entity
these,O
",",O
137,O
acquired,O
HIV,I-Entity
infection,I-Entity
during,O
follow,O
-,O
up,O
.,O
The,I-Entity
mean,O
proportion,O
of,O
participants,O
who,O
reported,O
daily,O
smoking,I-Entity
of,O
crack,I-Entity
cocaine,I-Entity
increased,O
from,O
11.6%,O
in,O
period,O
1,O
to,O
39.7%,O
in,O
period,O
3,O
.,O
After,I-Entity
adjusting,O
for,O
potential,O
confounders,O
",",O
we,O
found,O
that,O
the,O
risk,O
of,O
HIV,I-Entity
seroconversion,I-Entity
among,O
participants,O
who,O
were,O
daily,O
smokers,I-Entity
of,O
crack,I-Entity
cocaine,I-Entity
increased,O
over,O
time,O
(,O
period,O
1,O
:,O
hazard,O
ratio,O
[,O
HR,I-Entity
],O
1.03,O
",",O
95%,O
confidence,O
interval,O
[,O
CI,I-Entity
],O
0.57,O
-,O
1.85,O
;,O
period,O
2,O
:,O
HR,I-Entity
1.68,O
",",O
95%,O
INTERPRETATION,I-Entity
:,O
Smoking,I-Entity
of,O
crack,I-Entity
cocaine,I-Entity
was,O
found,O
to,O
be,O
an,O
independent,O
risk,O
factor,O
for,O
HIV,I-Entity
seroconversion,I-Entity
among,O
people,O
who,O
were,O
injection,O
drug,O
users,O
.,O
This,I-Entity
finding,O
points,O
to,O
the,O
urgent,O
need,O
for,O
evidence,O
-,O
based,O
public,O
health,O
initiatives,O
targeted,O
at,O
people,O
who,O
smoke,I-Entity
crack,I-Entity
cocaine,I-Entity
.,O
Fluoxetine,I-Entity
improves,O
the,O
memory,O
deficits,I-Entity
caused,O
by,O
the,O
chemotherapy,O
agent,O
5-fluorouracil,I-Entity
.,O
Cancer,I-Entity
patients,O
who,O
have,O
been,O
treated,O
with,O
systemic,O
adjuvant,O
chemotherapy,O
have,O
described,O
experiencing,O
deteriorations,I-Entity
in,O
cognition,O
.,O
A,I-Entity
widely,O
used,O
chemotherapeutic,O
agent,O
",",O
5-fluorouracil,I-Entity
(,O
5-FU,I-Entity
),O
",",O
readily,O
crosses,O
the,O
blood,O
-,O
brain,O
barrier,O
and,O
so,O
could,O
have,O
a,O
direct,O
effect,O
on,O
brain,O
function,O
.,O
In,I-Entity
contrast,O
reports,O
indicate,O
that,O
hippocampal,O
dependent,O
neurogenesis,I-Entity
and,O
cognition,O
are,O
enhanced,O
by,O
the,O
SSRI,I-Entity
antidepressant,I-Entity
Fluoxetine,I-Entity
.,O
In,I-Entity
this,O
investigation,O
the,O
behavioural,O
effects,O
of,O
chronic,O
(,O
two,O
week,O
),O
treatment,O
with,O
5-FU,I-Entity
and,O
(,O
three,O
weeks,O
),O
with,O
Fluoxetine,I-Entity
either,O
separately,O
or,O
in,O
combination,O
with,O
5-FU,I-Entity
were,O
tested,O
on,O
adult,O
Lister,I-Entity
hooded,O
rats,O
.,O
Behavioural,I-Entity
effects,O
were,O
tested,O
using,O
a,O
context,O
dependent,O
conditioned,O
emotional,I-Entity
response,O
test,O
(,O
CER,I-Entity
),O
which,O
showed,O
that,O
animals,O
treated,O
with,O
5-FU,I-Entity
had,O
a,O
significant,O
reduction,O
in,O
freezing,O
time,O
compared,O
to,O
controls,O
.,O
Animals,I-Entity
treated,O
only,O
with,O
5-FU,I-Entity
showed,O
significant,O
deficits,I-Entity
in,O
their,O
ability,O
to,O
carry,O
out,O
the,O
OLR,I-Entity
task,O
but,O
co,O
administration,O
of,O
Fluoxetine,I-Entity
improved,O
their,O
performance,O
.,O
5-FU,I-Entity
chemotherapy,O
caused,O
a,O
significant,O
reduction,O
in,O
the,O
number,O
of,O
proliferating,O
cells,O
in,O
the,O
sub,O
granular,O
zone,O
of,O
the,O
dentate,O
gyrus,I-Entity
compared,O
to,O
controls,O
.,O
This,I-Entity
reduction,O
was,O
eliminated,O
when,O
Fluoxetine,I-Entity
was,O
co,O
administered,O
with,O
5-FU,I-Entity
.,O
Fluoxetine,I-Entity
on,O
its,O
own,O
had,O
no,O
effect,O
on,O
proliferating,O
cell,O
number,O
or,O
behaviour,O
.,O
These,I-Entity
findings,O
suggest,O
that,O
5-FU,I-Entity
can,O
negatively,O
affect,O
both,O
cell,O
proliferation,O
and,O
hippocampal,O
dependent,O
working,O
memory,O
and,O
that,O
these,O
deficits,I-Entity
can,O
be,O
reversed,O
by,O
the,O
simultaneous,O
administration,O
of,O
the,O
antidepressant,I-Entity
Fluoxetine,I-Entity
.,O
Liver,I-Entity
-,O
specific,O
ablation,O
of,O
integrin,I-Entity
-,O
linked,O
kinase,O
in,O
mice,O
results,O
in,O
enhanced,O
and,O
prolonged,O
cell,O
proliferation,O
and,O
hepatomegaly,I-Entity
after,O
phenobarbital,I-Entity
administration,O
.,O
This,I-Entity
study,O
investigates,O
the,O
role,O
of,O
ILK,I-Entity
in,O
liver,I-Entity
enlargement,I-Entity
induced,O
by,O
phenobarbital,I-Entity
(,O
PB,I-Entity
),O
.,O
liver-/-,I-Entity
mice,O
were,O
given,O
PB,I-Entity
(,O
0.1%,O
in,O
drinking,I-Entity
water,O
),O
for,O
10,O
days,O
.,O
Livers,I-Entity
were,O
harvested,O
on,O
2,O
",",O
5,O
",",O
and,O
10,O
days,O
during,O
PB,I-Entity
administration,O
.,O
There,I-Entity
were,O
slightly,O
increased,O
proliferating,O
cell,O
nuclear,O
antigen,O
-,O
positive,O
cells,O
in,O
the,O
ILK,I-Entity
/,O
liver-/-,I-Entity
animals,O
at,O
day,O
2,O
as,O
compared,O
to,O
WT,I-Entity
after,O
PB,I-Entity
administration,O
.,O
/,O
liver-/-,I-Entity
mice,O
also,O
showed,O
increased,O
expression,O
of,O
key,O
genes,O
involved,O
in,O
hepatocyte,O
proliferation,O
at,O
different,O
time,O
points,O
during,O
PB,I-Entity
administration,O
.,O
Lack,I-Entity
of,O
ILK,I-Entity
in,O
the,O
hepatocytes,O
imparts,O
prolonged,O
proliferative,O
response,O
not,O
only,O
to,O
stimuli,O
related,O
to,O
liver,I-Entity
regeneration,O
but,O
also,O
to,O
xenobiotic,I-Entity
chemical,O
mitogens,O
",",O
such,O
as,O
PB,I-Entity
.,O
Decreased,I-Entity
Expression,I-Entity
of,O
Na,I-Entity
/,O
K,I-Entity
-,O
ATPase,I-Entity
",",O
NHE3,I-Entity
",",O
NBC1,I-Entity
",",O
AQP1,I-Entity
and,O
OAT,I-Entity
in,O
Gentamicin,I-Entity
-,O
induced,O
Nephropathy,I-Entity
.,O
The,I-Entity
present,O
study,O
was,O
aimed,O
to,O
determine,O
whether,O
there,O
is,O
an,O
altered,O
regulation,O
of,O
tubular,O
transporters,O
in,O
gentamicin,I-Entity
-,O
induced,O
nephropathy,I-Entity
.,O
Sprague,I-Entity
-,O
Dawley,I-Entity
male,O
rats,O
(,O
200~250,I-Entity
g,O
),O
were,O
subcutaneously,O
injected,O
with,O
gentamicin,I-Entity
(,O
100,O
mg,O
/,O
kg,O
per,O
day,O
),O
for,O
7,O
days,O
",",O
and,O
the,O
expression,O
of,O
tubular,O
transporters,O
was,O
determined,O
by,O
immunoblotting,O
and,O
immunohistochemistry,O
.,O
Gentamicin,I-Entity
-,O
treated,O
rats,O
exhibited,O
significantly,O
decreased,O
creatinine,I-Entity
clearance,O
along,O
with,O
increased,O
plasma,O
creatinine,I-Entity
levels,O
.,O
Accordingly,I-Entity
",",O
the,O
fractional,O
excretion,O
of,O
sodium,I-Entity
increased,O
.,O
Immunoblotting,I-Entity
and,O
immunohistochemistry,O
revealed,O
decreased,O
expression,O
of,O
Na(+)/K(+)-ATPase,I-Entity
",",O
NHE3,I-Entity
",",O
NBC1,I-Entity
",",O
and,O
AQP1,I-Entity
in,O
the,O
kidney,O
of,O
gentamicin,I-Entity
-,O
treated,O
rats,O
.,O
Gentamicin,I-Entity
-,O
induced,O
nephropathy,I-Entity
may,O
at,O
least,O
in,O
part,O
be,O
causally,O
related,O
with,O
a,O
decreased,O
expression,O
of,O
Na(+)/K(+)-ATPase,I-Entity
",",O
NHE3,I-Entity
",",O
NBC1,I-Entity
",",O
AQP1,I-Entity
and,O
OAT,I-Entity
.,O
Longitudinal,I-Entity
association,O
of,O
alcohol,I-Entity
use,O
with,O
HIV,I-Entity
disease,I-Entity
progression,O
and,O
psychological,O
health,O
of,O
women,O
with,O
HIV,I-Entity
.,O
We,I-Entity
evaluated,O
the,O
association,O
of,O
alcohol,I-Entity
consumption,O
and,O
depression,I-Entity
",",O
and,O
their,O
effects,O
on,O
HIV,I-Entity
disease,I-Entity
progression,O
among,O
women,O
with,O
HIV,I-Entity
.,O
The,I-Entity
participants,O
had,O
physical,O
examination,O
",",O
medical,O
record,O
extraction,O
",",O
and,O
venipuncture,I-Entity
",",O
CD4+T,I-Entity
-,O
cell,O
counts,O
determination,O
",",O
measurement,O
of,O
depression,I-Entity
symptoms,O
(,O
using,O
the,O
self,O
-,O
report,O
Center,I-Entity
for,O
Epidemiological,I-Entity
Studies,I-Entity
-,O
Depression,I-Entity
Scale,I-Entity
),O
",",O
and,O
alcohol,I-Entity
use,O
assessment,O
at,O
enrollment,O
",",O
and,O
semiannually,O
until,O
March,I-Entity
2000,O
.,O
There,I-Entity
was,O
no,O
significant,O
association,O
between,O
level,O
of,O
alcohol,I-Entity
use,O
and,O
CD4,I-Entity
+,O
T,I-Entity
-,O
cell,O
counts,O
.,O
When,I-Entity
participants,O
were,O
stratified,O
by,O
antiretroviral,O
therapy,O
(,O
ART,I-Entity
),O
use,O
",",O
the,O
association,O
between,O
alcohol,I-Entity
and,O
CD4,I-Entity
+,O
T,I-Entity
-,O
cell,O
did,O
not,O
reach,O
statistical,O
significance,O
.,O
The,I-Entity
association,O
between,O
alcohol,I-Entity
consumption,O
and,O
depression,I-Entity
was,O
significant,O
(,O
p<0.001,O
),O
.,O
Depression,I-Entity
had,O
a,O
significant,O
negative,O
effect,O
on,O
CD4,I-Entity
+,O
T,I-Entity
-,O
cell,O
counts,O
over,O
time,O
regardless,O
of,O
ART,I-Entity
use,O
.,O
Our,I-Entity
findings,O
suggest,O
that,O
alcohol,I-Entity
consumption,O
has,O
a,O
direct,O
association,O
with,O
depression,I-Entity
.,O
Moreover,I-Entity
",",O
depression,I-Entity
is,O
associated,O
with,O
HIV,I-Entity
disease,I-Entity
progression,O
.,O
Our,I-Entity
findings,O
have,O
implications,O
for,O
the,O
provision,O
of,O
alcohol,I-Entity
use,O
interventions,O
and,O
psychological,O
resources,O
to,O
improve,O
the,O
health,O
of,O
women,O
with,O
HIV,I-Entity
.,O
Chemokine,I-Entity
CCL2,I-Entity
and,O
its,O
receptor,O
CCR2,I-Entity
are,O
increased,O
in,O
the,O
hippocampus,O
following,O
pilocarpine,I-Entity
-,O
induced,O
status,O
epilepticus,I-Entity
.,O
Neuroinflammation,I-Entity
occurs,O
after,O
seizures,I-Entity
and,O
is,O
implicated,O
in,O
epileptogenesis,O
.,O
CCR2,I-Entity
is,O
a,O
chemokine,I-Entity
receptor,O
for,O
CCL2,I-Entity
and,O
their,O
interaction,O
mediates,O
monocyte,O
infiltration,I-Entity
in,O
the,O
neuroinflammatory,O
cascade,I-Entity
triggered,O
in,O
different,O
brain,O
pathologies,O
.,O
In,I-Entity
this,O
work,O
CCR2,I-Entity
and,O
CCL2,I-Entity
expression,O
were,O
examined,O
following,O
status,O
epilepticus,I-Entity
(,O
SE,I-Entity
),O
induced,O
by,O
pilocarpine,I-Entity
injection,O
.,O
METHODS,I-Entity
:,O
SE,I-Entity
was,O
induced,O
by,O
pilocarpine,I-Entity
injection,O
.,O
Control,I-Entity
rats,O
were,O
injected,O
with,O
saline,O
instead,O
of,O
pilocarpine,I-Entity
.,O
Five,I-Entity
days,O
after,O
SE,I-Entity
",",O
CCR2,I-Entity
staining,I-Entity
in,O
neurons,O
and,O
glial,O
cells,O
was,O
examined,O
using,O
imunohistochemical,O
analyses,O
.,O
Increased,I-Entity
CCR2,I-Entity
was,O
observed,O
in,O
the,O
hippocampus,O
after,O
SE,I-Entity
.,O
Seizures,I-Entity
also,O
resulted,O
in,O
alterations,I-Entity
to,O
the,O
cell,O
types,O
expressing,O
CCR2,I-Entity
.,O
Increased,I-Entity
numbers,O
of,O
neurons,O
that,O
expressed,O
CCR2,I-Entity
was,O
observed,O
following,O
SE,I-Entity
.,O
Microglial,I-Entity
cells,O
were,O
more,O
closely,O
apposed,O
to,O
the,O
CCR2-labeled,I-Entity
cells,O
in,O
SE,I-Entity
rats,O
.,O
In,I-Entity
addition,O
",",O
rats,O
that,O
experienced,O
SE,I-Entity
exhibited,O
CCR2-labeling,I-Entity
in,O
populations,O
of,O
hypertrophied,I-Entity
astrocytes,I-Entity
",",O
especially,O
in,O
CA1,I-Entity
and,O
dentate,O
gyrus,I-Entity
.,O
Examination,I-Entity
of,O
CCL2,I-Entity
expression,O
showed,O
that,O
it,O
was,O
elevated,O
in,O
the,O
hippocampus,O
following,O
SE,I-Entity
.,O
CONCLUSION,I-Entity
:,O
The,I-Entity
data,O
show,O
that,O
CCR2,I-Entity
and,O
CCL2,I-Entity
are,O
up,O
-,O
regulated,O
in,O
the,O
hippocampus,O
after,O
pilocarpine,I-Entity
-,O
induced,O
SE,I-Entity
.,O
Seizures,I-Entity
also,O
result,O
in,O
changes,O
to,O
CCR2,I-Entity
receptor,O
expression,O
in,O
neurons,O
and,O
astrocytes,I-Entity
.,O
These,I-Entity
changes,O
might,O
be,O
involved,O
in,O
detrimental,O
neuroplasticity,I-Entity
and,O
neuroinflammatory,O
changes,O
that,O
occur,O
following,O
seizures,I-Entity
.,O
Metallothionein,I-Entity
induction,O
reduces,O
caspase-3,I-Entity
activity,O
and,O
TNFalpha,I-Entity
levels,O
with,O
preservation,O
of,O
cognitive,O
function,O
and,O
intact,O
hippocampal,O
neurons,O
in,O
carmustine,I-Entity
-,O
treated,O
rats,O
.,O
On,I-Entity
the,O
other,O
hand,O
",",O
induction,O
of,O
metallothionein,I-Entity
(,O
MT,I-Entity
),O
by,O
ZnSO(4,I-Entity
),O
and,O
its,O
role,O
in,O
neuroprotection,O
has,O
been,O
documented,O
.,O
The,I-Entity
present,O
study,O
aimed,O
to,O
explore,O
the,O
effect,O
of,O
MT,I-Entity
induction,O
on,O
carmustine,I-Entity
(,O
BCNU)-induced,I-Entity
hippocampal,O
cognitive,O
dysfunction,I-Entity
in,O
rats,O
.,O
A,I-Entity
total,O
of,O
60,O
male,O
Wistar,I-Entity
albino,O
rats,O
were,O
randomly,O
divided,O
into,O
four,O
groups,O
(,O
15/group,O
),O
:,O
The,I-Entity
control,O
group,O
injected,O
with,O
single,O
doses,O
of,O
normal,O
saline,O
(,O
i.c.v,O
),O
followed,O
24,O
h,O
later,O
by,O
BCNU,I-Entity
solvent,O
(,O
i.v,O
),O
.,O
The,I-Entity
second,O
group,O
administered,O
ZnSO(4,I-Entity
),O
(,O
0.1,O
micromol/10,O
microl,O
normal,O
saline,O
",",O
i.c.v,O
",",O
once,O
),O
then,O
BCNU,I-Entity
solvent,O
(,O
i.v,O
),O
after,O
24,O
h.,O
Third,I-Entity
group,O
received,O
BCNU,I-Entity
(,O
20,O
mg,O
/,O
kg,O
",",O
i.v,O
",",O
once,O
),O
Fourth,I-Entity
group,O
received,O
a,O
single,O
dose,O
of,O
ZnSO(4,I-Entity
),O
(,O
0.1,O
micromol/10,O
microl,O
normal,O
saline,O
",",O
i.c.v,O
),O
then,O
BCNU,I-Entity
(,O
20,O
mg,O
/,O
kg,O
",",O
i.v,O
",",O
once,O
),O
after,O
24,O
h.,O
The,I-Entity
obtained,O
data,O
revealed,O
that,O
BCNU,I-Entity
administration,O
resulted,O
in,O
deterioration,O
of,O
learning,O
and,O
short,I-Entity
-,O
term,O
memory,O
(,O
STM,I-Entity
),O
",",O
as,O
measured,O
by,O
using,O
radial,O
arm,O
water,O
maze,O
",",O
accompanied,O
with,O
decreased,O
hippocampal,O
glutathione,I-Entity
reductase,O
(,O
GR,I-Entity
),O
activity,O
and,O
reduced,O
glutathione,I-Entity
(,O
GSH,I-Entity
),O
content,O
.,O
Also,I-Entity
",",O
BCNU,I-Entity
administration,O
increased,O
serum,O
tumor,I-Entity
necrosis,I-Entity
factor,O
-,O
alpha,O
(,O
TNFalpha,I-Entity
),O
",",O
hippocampal,O
MT,I-Entity
and,O
malondialdehyde,I-Entity
(,O
MDA,I-Entity
),O
contents,O
as,O
well,O
as,O
caspase-3,I-Entity
activity,O
in,O
addition,O
to,O
histological,O
alterations,I-Entity
.,O
ZnSO(4,I-Entity
),O
pretreatment,O
counteracted,O
BCNU,I-Entity
-,O
induced,O
inhibition,O
of,O
GR,I-Entity
and,O
depletion,O
of,O
GSH,I-Entity
and,O
resulted,O
in,O
significant,O
reduction,O
in,O
the,O
levels,O
of,O
MDA,I-Entity
and,O
TNFalpha,I-Entity
as,O
well,O
as,O
the,O
activity,O
of,O
caspase-3,I-Entity
.,O
The,I-Entity
histological,O
features,O
were,O
improved,O
in,O
hippocampus,O
of,O
rats,O
treated,O
with,O
ZnSO(4,I-Entity
),O
+,O
BCNU,I-Entity
compared,O
to,O
only,O
BCNU,I-Entity
-,O
treated,O
animals,O
.,O
In,I-Entity
conclusion,O
",",O
MT,I-Entity
induction,O
halts,O
BCNU,I-Entity
-,O
induced,O
hippocampal,O
toxicity,I-Entity
as,O
it,O
prevented,O
GR,I-Entity
inhibition,O
and,O
GSH,I-Entity
depletion,O
and,O
counteracted,O
the,O
increased,O
levels,O
of,O
TNFalpha,I-Entity
",",O
MDA,I-Entity
and,O
caspase-3,I-Entity
activity,O
with,O
subsequent,O
preservation,O
of,O
cognition,O
.,O
Fatal,I-Entity
carbamazepine,I-Entity
induced,O
fulminant,O
eosinophilic,I-Entity
(,O
hypersensitivity,I-Entity
),O
myocarditis,I-Entity
:,O
emphasis,O
on,O
anatomical,O
and,O
histological,O
characteristics,O
",",O
mechanisms,O
and,O
genetics,O
of,O
drug,O
hypersensitivity,I-Entity
and,O
differential,O
diagnosis,O
.,O
The,I-Entity
most,O
severe,O
adverse,O
reactions,O
to,O
carbamazepine,I-Entity
have,O
been,O
observed,O
in,O
the,O
haemopoietic,O
system,O
",",O
the,O
liver,I-Entity
and,O
the,O
cardiovascular,O
system,O
.,O
A,I-Entity
frequently,O
fatal,O
",",O
although,O
exceptionally,O
rare,O
side,O
effect,O
of,O
carbamazepine,I-Entity
is,O
necrotizing,I-Entity
eosinophilic,I-Entity
(,O
hypersensitivity,I-Entity
),O
myocarditis,I-Entity
.,O
We,I-Entity
report,O
a,O
case,O
of,O
hypersensitivity,I-Entity
myocarditis,I-Entity
secondary,O
to,O
administration,O
of,O
carbamazepine,I-Entity
.,O
Acute,I-Entity
hypersensitivity,I-Entity
myocarditis,I-Entity
was,O
not,O
suspected,O
clinically,O
",",O
and,O
the,O
diagnosis,O
was,O
made,O
post,O
-,O
mortem,O
.,O
Clinically,I-Entity
",",O
death,I-Entity
was,O
due,O
to,O
cardiogenic,I-Entity
shock,I-Entity
.,O
To,I-Entity
best,O
of,O
our,O
knowledge,O
this,O
is,O
the,O
second,O
case,O
of,O
fatal,O
carbamazepine,I-Entity
induced,O
myocarditis,I-Entity
reported,O
in,O
English,I-Entity
literature,O
.,O
Neuropsychiatric,I-Entity
behaviors,O
in,O
the,O
MPTP,I-Entity
marmoset,I-Entity
model,O
of,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
.,O
Neuropsychiatric,I-Entity
symptoms,O
are,O
increasingly,O
recognised,O
as,O
a,O
significant,O
problem,O
in,O
patients,O
with,O
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
.,O
These,I-Entity
symptoms,O
may,O
be,O
due,O
to,O
',O
sensitisation,I-Entity
',O
following,O
repeated,O
levodopa,I-Entity
treatment,O
or,O
a,O
direct,O
effect,O
of,O
dopamine,I-Entity
on,O
the,O
disease,I-Entity
state,O
.,O
The,I-Entity
levodopa,I-Entity
-,O
treated,O
MPTP,I-Entity
-,O
lesioned,O
marmoset,I-Entity
was,O
used,O
as,O
a,O
model,O
of,O
neuropsychiatric,O
symptoms,O
in,O
PD,I-Entity
patients,O
.,O
Here,I-Entity
we,O
compare,O
the,O
time,O
course,O
of,O
levodopa,I-Entity
-,O
induced,O
motor,O
fluctuations,I-Entity
and,O
neuropsychiatric,O
-,O
like,O
behaviors,O
to,O
determine,O
the,O
relationship,O
between,O
duration,O
of,O
treatment,O
and,O
onset,O
of,O
symptoms,O
.,O
Marmosets,I-Entity
were,O
administered,O
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",I-Entity
(,O
2.0,O
mg,O
/,O
kg,O
s.c,O
.,O
),O
for,O
five,O
days,O
",",O
resulting,O
in,O
stable,O
parkinsonism,I-Entity
.,O
Levodopa,I-Entity
(,O
15,O
mg,O
/,O
kg,O
and,O
benserazide,I-Entity
",",O
3.75,O
mg,O
/,O
kg,O
),O
Animals,I-Entity
were,O
evaluated,O
for,O
parkinsonian,I-Entity
disability,I-Entity
",",O
dyskinesia,I-Entity
and,O
on,O
-,O
time,O
(,O
motor,O
fluctuations,I-Entity
),O
and,O
neuropsychiatric,O
-,O
like,O
behaviors,O
on,O
Day,I-Entity
0,O
(,O
prior,O
to,O
levodopa,I-Entity
),O
and,O
on,O
Days,I-Entity
1,O
",",O
7,O
",",O
13,O
",",O
27,O
and,O
30,O
of,O
treatment,O
using,O
post,O
hoc,O
DVD,I-Entity
analysis,O
by,O
a,O
trained,O
rater,O
",",O
blind,O
to,O
the,O
treatment,O
day,O
.,O
The,I-Entity
neuropsychiatric,O
-,O
like,O
behavior,O
rating,O
scale,O
demonstrated,O
high,O
interrater,O
reliability,O
between,O
three,O
trained,O
raters,O
of,O
differing,O
professional,O
backgrounds,O
.,O
As,I-Entity
anticipated,O
",",O
animals,O
exhibited,O
a,O
progressive,O
increase,O
in,O
levodopa,I-Entity
-,O
induced,O
motor,O
fluctuations,I-Entity
",",O
dyskinesia,I-Entity
and,O
wearing,O
-,O
off,O
",",O
that,O
correlated,O
with,O
the,O
duration,O
of,O
levodopa,I-Entity
therapy,O
.,O
In,I-Entity
contrast,O
",",O
levodopa,I-Entity
-,O
induced,O
neuropsychiatric,O
-,O
like,O
behaviors,O
were,O
present,O
on,O
Day,I-Entity
1,O
of,O
levodopa,I-Entity
treatment,O
and,O
their,O
severity,O
did,O
not,O
correlate,O
with,O
duration,O
of,O
treatment,O
.,O
The,I-Entity
data,O
suggest,O
that,O
neuropsychiatric,O
disorders,I-Entity
in,O
PD,I-Entity
are,O
more,O
likely,O
an,O
interaction,O
between,O
levodopa,I-Entity
and,O
the,O
disease,I-Entity
state,O
than,O
a,O
consequence,O
of,O
sensitisation,I-Entity
to,O
repeated,O
dopaminergic,O
therapy,O
.,O
Contrast,I-Entity
medium,O
nephrotoxicity,I-Entity
after,O
renal,O
artery,I-Entity
and,O
coronary,O
angioplasty,O
.,O
Renal,I-Entity
dysfunction,I-Entity
induced,O
by,O
iodinated,O
contrast,O
medium,O
(,O
CM,I-Entity
),O
administration,O
can,O
minimize,O
the,O
benefit,O
of,O
the,O
interventional,O
procedure,O
in,O
patients,O
undergoing,O
renal,O
angioplasty,O
(,O
PTRA,I-Entity
),O
.,O
To,I-Entity
compare,O
the,O
susceptibility,O
to,O
nephrotoxic,I-Entity
effect,O
of,O
CM,I-Entity
in,O
patients,O
undergoing,O
PTRA,I-Entity
with,O
that,O
of,O
patients,O
submitted,O
to,O
percutaneous,O
coronary,O
intervention,O
(,O
PCI,I-Entity
),O
.,O
A,I-Entity
total,O
of,O
33,O
patients,O
successfully,O
treated,O
with,O
PTRA,I-Entity
(,O
PTRA,I-Entity
group,O
",",O
mean,O
age,O
70+/-12,O
years,O
",",O
23,O
female,O
",",O
basal,O
creatinine,I-Entity
1.46+/-0.79,O
",",O
range,O
0.7,O
-,O
4.9,O
mg,O
/,O
dl,O
),O
were,O
compared,O
with,O
33,O
patients,O
undergoing,O
successful,O
PCI,I-Entity
(,O
PCI,I-Entity
group,O
),O
",",O
matched,O
for,O
basal,O
creatinine,I-Entity
(,O
1.44+/-0.6,O
",",O
range,O
0.7,O
-,O
3.4,O
mg,O
/,O
dl,O
),O
",",O
gender,O
",",O
and,O
age,O
.,O
serum,O
creatinine,I-Entity
was,O
measured,O
.,O
RESULTS,I-Entity
:,O
Postprocedural,I-Entity
creatinine,I-Entity
level,O
decreased,O
nonsignificantly,I-Entity
in,O
the,O
PTRA,I-Entity
group,O
(,O
1.46+/-0.8,O
vs.,O
1.34+/-0.5,O
mg,O
/,O
dl,O
",",O
Changes,I-Entity
in,O
serum,O
creatinine,I-Entity
after,O
intervention,O
(,O
after,O
-,O
before,O
),O
were,O
significantly,O
different,O
between,O
the,O
PTRA,I-Entity
and,O
PCI,I-Entity
groups,O
(,O
-0.12+/-0.5,O
vs.,O
0.13+/-0.3,O
",",O
P=0.014,I-Entity
),O
.,O
This,I-Entity
difference,O
was,O
not,O
related,O
to,O
either,O
a,O
different,O
clinical,O
risk,O
profile,O
or,O
to,O
the,O
volume,O
of,O
CM,I-Entity
administered,O
.,O
CONCLUSION,I-Entity
:,O
In,I-Entity
this,O
preliminary,O
study,O
patients,O
submitted,O
to,O
PTRA,I-Entity
showed,O
a,O
lower,O
susceptibility,O
to,O
renal,O
damage,O
induced,O
by,O
CM,I-Entity
administration,O
than,O
PCI,I-Entity
patients,O
.,O
The,I-Entity
effectiveness,O
of,O
PTRA,I-Entity
on,O
renal,O
function,O
seems,O
to,O
be,O
barely,O
influenced,O
by,O
CM,I-Entity
toxicity,I-Entity
.,O
Medical,I-Entity
and,O
psychiatric,I-Entity
outcomes,O
for,O
patients,O
transplanted,O
for,O
acetaminophen,I-Entity
-,O
induced,O
acute,O
liver,I-Entity
failure,I-Entity
:,O
a,O
case,O
-,O
control,O
study,O
.,O
Acetaminophen,I-Entity
-,O
induced,O
hepatotoxicity,I-Entity
is,O
the,O
most,O
common,O
cause,O
of,O
acute,O
liver,I-Entity
failure,I-Entity
(,O
ALF,I-Entity
),O
in,O
the,O
UK,I-Entity
.,O
:,O
We,I-Entity
compared,O
the,O
severity,O
of,O
pretransplant,O
illness,I-Entity
",",O
psychiatric,I-Entity
co,O
-,O
morbidity,O
",",O
medical,O
and,O
psychosocial,I-Entity
outcomes,O
of,O
all,O
patients,O
who,O
had,O
undergone,O
liver,I-Entity
transplantation,O
(,O
LT,I-Entity
),O
emergently,O
between,O
1999,O
-,O
2004,O
for,O
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
(,O
n=36,O
),O
with,O
age-,O
and,O
sex,O
-,O
matched,O
patients,O
undergoing,O
emergent,I-Entity
LT,I-Entity
for,O
non,O
-,O
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
(,O
n=35,O
),O
and,O
elective,O
LT,I-Entity
for,O
chronic,O
liver,I-Entity
disease,I-Entity
(,O
CLD,I-Entity
",",O
n=34,O
),O
.,O
Acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
patients,O
undergoing,O
LT,I-Entity
had,O
a,O
greater,O
severity,O
of,O
pre,O
-,O
LT,I-Entity
illness,I-Entity
reflected,O
by,O
higher,O
Acute,I-Entity
Physiology,I-Entity
and,O
Chronic,I-Entity
Health,I-Entity
Evaluation,I-Entity
II,I-Entity
Twenty,I-Entity
(,O
56%,O
),O
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
patients,O
had,O
a,O
formal,O
psychiatric,I-Entity
diagnosis,O
before,O
LT,I-Entity
(,O
non,O
-,O
acetaminophen,I-Entity
-,O
induced,O
ALF=0/35,I-Entity
",",O
CLD=2/34,I-Entity
;,O
P<0.01,I-Entity
for,O
all,O
),O
and,O
nine,O
(,O
25%,O
),O
had,O
a,O
previous,O
suicide,I-Entity
attempt,O
.,O
During,I-Entity
follow,O
-,O
up,O
(,O
median,O
5,O
years,O
),O
",",O
there,O
were,O
no,O
significant,O
differences,O
in,O
rejection,I-Entity
(,O
acute,O
and,O
chronic,O
),O
",",O
graft,O
failure,I-Entity
or,O
survival,O
between,O
the,O
groups,O
(,O
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
1,O
year,O
87%,O
",",O
5,O
years,O
75%,O
;,O
non,O
-,O
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
88%,O
",",O
78%,O
;,O
CLD,I-Entity
93%,O
",",O
82%,O
:,O
P>0.6,I-Entity
log,O
rank,O
),O
.,O
Two,I-Entity
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
patients,O
reattempted,O
suicide,I-Entity
post,O
-,O
LT,I-Entity
(,O
one,O
died,O
8,O
years,O
post,O
-,O
LT,I-Entity
),O
.,O
Despite,I-Entity
a,O
high,O
prevalence,O
of,O
psychiatric,I-Entity
disturbance,I-Entity
",",O
outcomes,O
for,O
patients,O
transplanted,O
emergently,O
for,O
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
were,O
comparable,O
to,O
those,O
transplanted,O
for,O
non,O
-,O
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
and,O
electively,O
for,O
CLD,I-Entity
.,O
Studies,I-Entity
of,O
synergy,I-Entity
between,O
morphine,I-Entity
and,O
a,O
novel,O
sodium,I-Entity
channel,O
blocker,O
",",O
CNSB002,I-Entity
",",O
in,O
rat,O
models,O
of,O
inflammatory,O
and,O
neuropathic,I-Entity
pain,I-Entity
.,O
This,I-Entity
study,O
determined,O
the,O
antihyperalgesic,O
effect,O
of,O
CNSB002,I-Entity
",",O
a,O
sodium,I-Entity
channel,O
blocker,O
with,O
antioxidant,O
properties,O
given,O
alone,O
and,O
in,O
combinations,O
with,O
morphine,I-Entity
in,O
rat,O
models,O
of,O
inflammatory,O
and,O
neuropathic,I-Entity
pain,I-Entity
.,O
Dose,I-Entity
response,O
curves,O
for,O
nonsedating,O
doses,O
of,O
morphine,I-Entity
and,O
CNSB002,I-Entity
given,O
intraperitoneally,O
alone,O
and,O
together,O
in,O
combinations,O
were,O
constructed,O
for,O
antihyperalgesic,O
effect,O
using,O
paw,O
withdrawal,O
from,O
noxious,I-Entity
heat,O
in,O
two,O
rat,O
pain,I-Entity
models,O
:,O
carrageenan,I-Entity
-,O
induced,O
paw,O
inflammation,I-Entity
and,O
streptozotocin,I-Entity
(,O
STZ)-induced,I-Entity
diabetic,I-Entity
neuropathy,I-Entity
.,O
The,I-Entity
maximum,O
nonsedating,O
doses,O
were,O
:,O
morphine,I-Entity
",",O
3.2,O
mg,O
/,O
kg,O
;,O
CNSB002,I-Entity
10.0,O
mg,O
/,O
kg,O
;,O
5.0,O
mg,O
/,O
kg,O
CNSB002,I-Entity
with,O
morphine,I-Entity
3.2,O
mg,O
/,O
kg,O
in,O
combination,O
.,O
The,I-Entity
doses,O
calculated,O
to,O
cause,O
50%,O
reversal,O
of,O
hyperalgesia,I-Entity
(,O
ED50,I-Entity
),O
were,O
7.54,O
(,O
1.81,O
),O
and,O
4.83,O
(,O
1.54,O
),O
in,O
the,O
carrageenan,I-Entity
model,O
and,O
44.18,O
(,O
1.37,O
),O
and,O
9.14,O
(,O
1.24,O
),O
in,O
the,O
STZ,I-Entity
-,O
induced,O
neuropathy,I-Entity
model,O
for,O
CNSB002,I-Entity
and,O
morphine,I-Entity
",",O
respectively,O
(,O
mg,O
/,O
kg,O
;,O
mean,O
",",O
SEM,I-Entity
),O
.,O
The,I-Entity
ED50,I-Entity
values,O
for,O
morphine,I-Entity
when,O
given,O
in,O
combination,O
with,O
CNSB002,I-Entity
(,O
5,O
mg,O
/,O
kg,O
),O
were,O
less,O
than,O
the,O
maximum,O
nonsedating,O
dose,O
:,O
0.56,O
(,O
1.55,O
),O
in,O
the,O
carrageenan,I-Entity
model,O
and,O
1.37,O
(,O
1.23,O
),O
in,O
the,O
neuropathy,I-Entity
model,O
(,O
mg,O
/,O
kg,O
;,O
mean,O
",",O
SEM,I-Entity
),O
.,O
The,I-Entity
antinociception,O
after,O
morphine,I-Entity
(,O
3.2,O
mg,O
/,O
kg,O
),O
was,O
increased,O
by,O
co,O
-,O
administration,O
with,O
CNSB002,I-Entity
from,O
28.0,O
and,O
31.7%,O
to,O
114.6,O
and,O
56.9%,O
reversal,O
of,O
hyperalgesia,I-Entity
in,O
the,O
inflammatory,O
and,O
neuropathic,I-Entity
models,O
",",O
respectively,O
(,O
P,I-Entity
<,O
0.01,O
;,O
one,O
-,O
way,O
analysis,O
of,O
variance,O
-,O
significantly,O
greater,O
than,O
either,O
drug,O
given,O
alone,O
),O
.,O
The,I-Entity
maximum,O
antihyperalgesic,O
effect,O
achievable,O
with,O
nonsedating,O
doses,O
of,O
morphine,I-Entity
may,O
be,O
increased,O
significantly,O
when,O
the,O
drug,O
is,O
used,O
in,O
combination,O
with,O
CNSB002,I-Entity
.,O
Heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
:,O
a,O
practical,O
review,O
.,O
Heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
(,O
HIT,I-Entity
),O
remains,O
under,O
-,O
recognized,O
despite,O
its,O
potentially,O
devastating,O
outcomes,O
.,O
It,I-Entity
begins,O
when,O
heparin,I-Entity
exposure,O
stimulates,O
the,O
formation,O
of,O
heparin,I-Entity
-,O
platelet,O
factor,O
4,O
antibodies,O
",",O
which,O
in,O
turn,O
triggers,O
the,O
release,O
of,O
procoagulant,O
platelet,O
particles,O
.,O
Thrombosis,I-Entity
and,O
thrombocytopenia,I-Entity
that,O
follow,O
comprise,O
the,O
2,O
hallmark,O
traits,O
of,O
HIT,I-Entity
",",O
with,O
the,O
former,O
largely,O
responsible,O
for,O
significant,O
vascular,O
complications,O
.,O
The,I-Entity
prevalence,O
of,O
HIT,I-Entity
varies,O
among,O
several,O
subgroups,O
",",O
with,O
greater,O
incidence,O
in,O
surgical,O
as,O
compared,O
with,O
medical,O
populations,O
.,O
HIT,I-Entity
must,O
be,O
acknowledged,O
for,O
its,O
intense,O
predilection,O
for,O
thrombosis,I-Entity
and,O
suspected,O
whenever,O
thrombosis,I-Entity
occurs,O
after,O
heparin,I-Entity
exposure,O
.,O
The,I-Entity
treatment,O
of,O
HIT,I-Entity
mandates,O
an,O
immediate,O
cessation,O
of,O
all,O
heparin,I-Entity
exposure,O
and,O
the,O
institution,O
of,O
an,O
antithrombotic,O
therapy,O
",",O
most,O
commonly,O
using,O
a,O
direct,O
thrombin,O
inhibitor,O
.,O
Current,I-Entity
"""""""""",O
diagnostic,O
"""""""""",O
tests,O
",",O
which,O
primarily,O
include,O
functional,O
and,O
antigenic,O
assays,O
",",O
have,O
more,O
of,O
a,O
confirmatory,O
than,O
diagnostic,O
role,O
in,O
the,O
management,O
of,O
HIT,I-Entity
.,O
Special,I-Entity
attention,O
must,O
be,O
paid,O
to,O
cardiac,O
patients,O
who,O
are,O
often,O
exposed,O
to,O
heparin,I-Entity
multiple,O
times,O
during,O
their,O
course,O
of,O
treatment,O
.,O
Direct,I-Entity
thrombin,O
inhibitors,O
are,O
appropriate,O
",",O
evidence,O
-,O
based,O
alternatives,O
to,O
heparin,I-Entity
in,O
patients,O
with,O
a,O
history,O
of,O
HIT,I-Entity
",",O
who,O
need,O
to,O
undergo,O
percutaneous,O
coronary,O
intervention,O
.,O
As,I-Entity
heparin,I-Entity
remains,O
one,O
of,O
the,O
most,O
frequently,O
used,O
medications,O
today,O
with,O
potential,O
for,O
HIT,I-Entity
with,O
every,O
heparin,I-Entity
exposure,O
",",O
a,O
close,O
vigilance,O
of,O
platelet,O
counts,O
must,O
be,O
practiced,O
whenever,O
heparin,I-Entity
is,O
initiated,O
.,O
Abductor,I-Entity
paralysis,I-Entity
after,O
botox,O
injection,O
for,O
adductor,O
spasmodic,O
dysphonia,I-Entity
.,O
Botulinum,I-Entity
toxin,I-Entity
(,O
Botox,I-Entity
),O
injections,O
into,O
the,O
thyroarytenoid,B-Entity
muscles,O
are,O
the,O
current,O
standard,O
of,O
care,O
for,O
adductor,O
spasmodic,O
dysphonia,I-Entity
(,O
ADSD,I-Entity
),O
.,O
Reported,I-Entity
adverse,O
effects,O
include,O
a,O
period,O
of,O
breathiness,I-Entity
",",O
throat,I-Entity
pain,I-Entity
",",O
and,O
difficulty,O
with,O
swallowing,O
liquids,O
.,O
Here,I-Entity
we,O
report,O
multiple,O
cases,O
of,O
bilateral,O
abductor,O
paralysis,I-Entity
following,O
Botox,I-Entity
injections,O
for,O
ADSD,I-Entity
",",O
a,O
complication,O
previously,O
unreported,O
.,O
Patients,I-Entity
that,O
received,O
Botox,I-Entity
injections,O
for,O
spasmodic,O
dysphonia,I-Entity
between,O
January,I-Entity
2000,O
and,O
October,I-Entity
2009,O
were,O
evaluated,O
.,O
Patients,I-Entity
with,O
ADSD,I-Entity
were,O
identified,O
.,O
For,I-Entity
patients,O
with,O
bilateral,O
abductor,O
paralysis,I-Entity
",",O
age,O
",",O
sex,O
",",O
paralytic,I-Entity
Botox,I-Entity
dose,O
",",O
prior,O
Botox,I-Entity
dose,O
",",O
and,O
course,O
following,O
paralysis,I-Entity
were,O
noted,O
.,O
From,I-Entity
a,O
database,O
of,O
452,O
patients,O
receiving,O
Botox,I-Entity
",",O
352,O
patients,O
had,O
been,O
diagnosed,O
with,O
ADSD,I-Entity
.,O
Of,I-Entity
these,O
352,O
patients,O
",",O
eight,O
patients,O
suffered,O
bilateral,O
abductor,O
paralysis,I-Entity
",",O
and,O
two,O
suffered,O
this,O
complication,O
twice,O
.,O
Most,I-Entity
patients,O
had,O
received,O
treatments,O
prior,O
to,O
abductor,O
paralysis,I-Entity
and,O
continued,O
receiving,O
after,O
paralysis,I-Entity
.,O
The,I-Entity
incidence,O
of,O
abductor,O
paralysis,I-Entity
after,O
Botox,I-Entity
injection,O
for,O
ADSD,I-Entity
was,O
0.34%,O
.,O
Bilateral,I-Entity
abductor,O
paralysis,I-Entity
is,O
a,O
rare,O
complication,O
of,O
Botox,I-Entity
injections,O
for,O
ADSD,I-Entity
",",O
causing,O
difficulty,O
with,O
breathing,O
upon,O
exertion,I-Entity
.,O
The,I-Entity
likely,O
mechanism,O
of,O
paralysis,I-Entity
is,O
diffusion,O
of,O
Botox,I-Entity
around,O
the,O
muscular,O
process,O
of,O
the,O
arytenoid,O
to,O
the,O
posterior,O
cricoarytenoid,B-Entity
muscles,O
.,O
The,I-Entity
paralysis,I-Entity
is,O
temporary,O
",",O
and,O
watchful,O
waiting,O
with,O
restriction,O
of,O
activity,O
is,O
the,O
recommended,O
management,O
.,O
Mitochondrial,I-Entity
impairment,I-Entity
contributes,O
to,O
cocaine,I-Entity
-,O
induced,O
cardiac,O
dysfunction,I-Entity
:,O
Prevention,I-Entity
by,O
the,O
targeted,O
antioxidant,O
MitoQ.,I-Entity
The,I-Entity
goal,O
of,O
this,O
study,O
was,O
to,O
assess,O
mitochondrial,O
function,O
and,O
ROS,I-Entity
production,O
in,O
an,O
experimental,O
model,O
of,O
cocaine,I-Entity
-,O
induced,O
cardiac,O
dysfunction,I-Entity
.,O
We,I-Entity
hypothesized,O
that,O
cocaine,I-Entity
abuse,I-Entity
may,O
lead,O
to,O
altered,O
mitochondrial,O
function,O
that,O
in,O
turn,O
may,O
cause,O
left,O
ventricular,O
dysfunction,I-Entity
.,O
Seven,I-Entity
days,O
of,O
cocaine,I-Entity
administration,O
to,O
rats,O
led,O
to,O
an,O
increased,O
oxygen,I-Entity
consumption,O
detected,O
in,O
cardiac,O
fibers,O
",",O
specifically,O
through,O
complex,O
I,I-Entity
and,O
complex,O
III,I-Entity
.,O
In,I-Entity
parallel,I-Entity
there,O
was,O
a,O
decrease,O
in,O
ATP,I-Entity
synthesis,O
",",O
whereas,O
no,O
difference,O
was,O
observed,O
in,O
subsarcolemmal,I-Entity
mitochondria,O
.,O
This,I-Entity
uncoupling,O
effect,O
on,O
oxidative,O
phosphorylation,O
was,O
not,O
detectable,O
after,O
short,I-Entity
-,O
term,O
exposure,O
to,O
cocaine,I-Entity
",",O
suggesting,O
that,O
these,O
mitochondrial,O
abnormalities,I-Entity
were,O
a,O
late,O
rather,O
than,O
a,O
primary,O
event,O
in,O
the,O
pathological,O
response,O
to,O
cocaine,I-Entity
.,O
MitoQ,I-Entity
",",O
a,O
mitochondrial,O
-,O
targeted,O
antioxidant,O
",",O
was,O
shown,O
to,O
completely,O
prevent,O
these,O
mitochondrial,O
abnormalities,I-Entity
as,O
well,O
as,O
cardiac,O
dysfunction,I-Entity
characterized,O
here,O
by,O
a,O
diastolic,I-Entity
dysfunction,I-Entity
studied,O
with,O
a,O
conductance,O
catheter,O
to,O
obtain,O
pressure,O
-,O
volume,O
data,O
.,O
Taken,I-Entity
together,O
",",O
these,O
results,O
extend,O
previous,O
studies,O
and,O
demonstrate,O
that,O
cocaine,I-Entity
-,O
induced,O
cardiac,O
dysfunction,I-Entity
may,O
be,O
due,O
to,O
a,O
mitochondrial,O
defect,I-Entity
.,O
Trimethoprim,I-Entity
-,O
induced,O
immune,O
hemolytic,I-Entity
anemia,I-Entity
in,O
a,O
pediatric,O
oncology,O
patient,O
presenting,O
as,O
an,O
acute,O
hemolytic,I-Entity
transfusion,O
reaction,I-Entity
.,O
A,I-Entity
10-year,O
-,O
old,O
male,O
with,O
acute,O
leukemia,I-Entity
presented,O
with,O
post,O
-,O
chemotherapy,O
anemia,I-Entity
.,O
During,I-Entity
red,O
cell,O
transfusion,O
",",O
he,O
developed,O
hemoglobinuria,I-Entity
.,O
Drug,I-Entity
-,O
induced,O
immune,O
hemolytic,I-Entity
anemia,I-Entity
was,O
suspected,O
because,O
of,O
positive,O
direct,O
antiglobulin,O
test,O
",",O
negative,O
eluate,I-Entity
",",O
and,O
microspherocytes,O
on,O
smear,O
pre-,O
and,O
post,O
-,O
transfusion,O
.,O
Drug,I-Entity
studies,O
using,O
the,O
indirect,O
antiglobulin,O
test,O
were,O
strongly,O
positive,O
with,O
trimethoprim,I-Entity
and,O
trimethoprim,I-Entity
-,O
sulfamethoxazole,I-Entity
but,O
negative,O
with,O
sulfamethoxazole,I-Entity
.,O
Other,I-Entity
causes,O
of,O
anemia,I-Entity
should,O
be,O
considered,O
in,O
patients,O
with,O
worse,O
-,O
than,O
-,O
expected,O
anemia,I-Entity
after,O
chemotherapy,O
.,O
Furthermore,I-Entity
",",O
hemolysis,I-Entity
during,O
transfusion,O
is,O
not,O
always,O
a,O
transfusion,O
reaction,I-Entity
.,O
Blockade,I-Entity
of,O
endothelial,O
-,O
mesenchymal,O
transition,O
by,O
a,O
Smad3,I-Entity
inhibitor,O
delays,O
the,O
early,O
development,O
of,O
streptozotocin,I-Entity
-,O
induced,O
diabetic,I-Entity
nephropathy,I-Entity
.,O
OBJECTIVE,I-Entity
:,O
A,I-Entity
multicenter,O
",",O
controlled,O
trial,O
showed,O
that,O
early,O
blockade,O
of,O
the,O
renin,O
-,O
angiotensin,I-Entity
system,O
in,O
patients,O
with,O
type,O
1,O
diabetes,I-Entity
and,O
normoalbuminuria,I-Entity
did,O
not,O
retard,I-Entity
the,O
progression,O
of,O
nephropathy,I-Entity
",",O
suggesting,O
that,O
other,O
mechanism(s,O
),O
are,O
involved,O
in,O
the,O
pathogenesis,O
of,O
early,O
diabetic,I-Entity
nephropathy,I-Entity
(,O
diabetic,I-Entity
nephropathy,I-Entity
),O
.,O
We,I-Entity
have,O
previously,O
demonstrated,O
that,O
endothelial,O
-,O
mesenchymal,O
-,O
transition,O
(,O
EndoMT,I-Entity
),O
contributes,O
to,O
the,O
early,O
development,O
of,O
renal,O
interstitial,O
fibrosis,I-Entity
independently,O
of,O
microalbuminuria,I-Entity
in,O
mice,O
with,O
streptozotocin,I-Entity
(,O
STZ)-induced,I-Entity
diabetes,I-Entity
.,O
In,I-Entity
the,O
present,O
study,O
",",O
we,O
hypothesized,O
that,O
blocking,I-Entity
EndoMT,I-Entity
reduces,O
the,O
early,O
development,O
of,O
diabetic,I-Entity
nephropathy,I-Entity
.,O
Blocking,I-Entity
studies,O
using,O
receptor,O
for,O
AGE,I-Entity
siRNA,I-Entity
and,O
a,O
specific,O
inhibitor,O
of,O
Smad3,I-Entity
(,O
SIS3,I-Entity
),O
were,O
performed,O
in,O
MMECs,I-Entity
and,O
in,O
STZ,I-Entity
-,O
induced,O
diabetic,I-Entity
nephropathy,I-Entity
in,O
Tie2-Cre;Loxp,I-Entity
-,O
EGFP,I-Entity
mice,O
.,O
/,O
Western,I-Entity
blotting,I-Entity
showed,O
that,O
Smad3,I-Entity
was,O
activated,O
by,O
AGEs,I-Entity
but,O
was,O
inhibited,O
by,O
SIS3,I-Entity
in,O
MMECs,I-Entity
and,O
in,O
STZ,I-Entity
-,O
induced,O
diabetic,I-Entity
nephropathy,I-Entity
.,O
Confocal,I-Entity
microscopy,O
and,O
real,O
-,O
time,O
PCR,I-Entity
further,O
demonstrated,O
that,O
SIS3,I-Entity
abrogated,O
EndoMT,I-Entity
",",O
reduced,O
renal,O
fibrosis,I-Entity
",",O
and,O
retarded,I-Entity
progression,O
of,O
nephropathy,I-Entity
.,O
EndoMT,I-Entity
is,O
a,O
novel,O
pathway,O
leading,O
to,O
early,O
development,O
of,O
diabetic,I-Entity
nephropathy,I-Entity
.,O
Blockade,I-Entity
of,O
EndoMT,I-Entity
by,O
SIS3,I-Entity
may,O
provide,O
a,O
new,O
strategy,O
to,O
retard,I-Entity
the,O
progression,O
of,O
diabetic,I-Entity
nephropathy,I-Entity
and,O
other,O
diabetes,I-Entity
complications,O
.,O
Cytostatic,I-Entity
and,O
anti,O
-,O
angiogenic,O
effects,O
of,O
temsirolimus,I-Entity
in,O
refractory,O
mantle,O
cell,O
lymphoma,I-Entity
.,O
Mantle,I-Entity
cell,O
lymphoma,I-Entity
(,O
MCL,I-Entity
),O
is,O
a,O
rare,O
and,O
aggressive,I-Entity
type,O
of,O
B,I-Entity
-,O
cell,O
non,O
-,O
Hodgkin,I-Entity
's,I-Entity
lymphoma,I-Entity
.,O
However,I-Entity
",",O
a,O
38%,O
remission,O
rate,O
has,O
been,O
recently,O
reported,O
in,O
refractory,O
MCL,I-Entity
treated,O
with,O
temsirolimus,I-Entity
",",O
a,O
mTOR,I-Entity
inhibitor,O
.,O
Here,I-Entity
we,O
had,O
the,O
opportunity,O
to,O
study,O
a,O
case,O
of,O
refractory,O
MCL,I-Entity
who,O
had,O
tumor,I-Entity
regression,O
two,O
months,O
after,O
temsirolimus,I-Entity
treatment,O
",",O
and,O
a,O
progression,O
-,O
free,O
survival,O
of,O
10,O
months,O
.,O
In,I-Entity
this,O
case,O
",",O
lymph,I-Entity
node,O
biopsies,O
were,O
performed,O
before,O
and,O
six,O
months,O
after,O
temsirolimus,I-Entity
therapy,O
.,O
Comparison,I-Entity
of,O
the,O
two,O
biopsies,O
showed,O
that,O
temsirolimus,I-Entity
inhibited,O
tumor,I-Entity
cell,O
proliferation,O
through,O
cell,O
cycle,O
arrest,I-Entity
",",O
but,O
did,O
not,O
induce,O
any,O
change,O
in,O
the,O
number,O
of,O
apoptotic,O
tumor,I-Entity
cells,O
.,O
Apart,I-Entity
from,O
this,O
cytostatic,O
effect,O
",",O
temsirolimus,I-Entity
had,O
an,O
antiangiogenic,O
effect,O
with,O
decrease,O
of,O
tumor,I-Entity
microvessel,O
density,O
and,O
of,O
VEGF,I-Entity
expression,O
.,O
Moreover,I-Entity
",",O
numerous,O
patchy,O
",",O
well,O
-,O
limited,O
fibrotic,I-Entity
areas,O
",",O
compatible,O
with,O
post,O
-,O
necrotic,I-Entity
tissue,O
repair,O
",",O
were,O
found,O
after,O
6-month,O
temsirolimus,I-Entity
therapy,O
.,O
Thus,I-Entity
",",O
temsirolimus,I-Entity
reduced,O
tumor,I-Entity
burden,O
through,O
associated,O
cytostatic,O
and,O
anti,O
-,O
angiogenic,O
effects,O
.,O
This,I-Entity
dual,O
effect,O
of,O
temsirolimus,I-Entity
on,O
tumor,I-Entity
tissue,O
could,O
contribute,O
to,O
its,O
recently,O
reported,O
efficiency,O
in,O
refractory,O
MCL,I-Entity
resistant,O
to,O
conventional,O
chemotherapy,O
.,O
Syncope,I-Entity
caused,O
by,O
hyperkalemia,I-Entity
during,O
use,O
of,O
a,O
combined,O
therapy,O
with,O
the,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
inhibitor,O
and,O
spironolactone,I-Entity
.,O
A,I-Entity
76,I-Entity
year,O
-,O
old,O
woman,O
with,O
a,O
history,O
of,O
coronary,O
artery,I-Entity
bypass,O
grafting,O
and,O
prior,O
myocardial,B-Entity
infarction,I-Entity
was,O
transferred,O
to,O
the,O
emergency,O
room,O
with,O
loss,I-Entity
of,O
consciousness,O
due,O
to,O
marked,O
bradycardia,I-Entity
caused,O
by,O
hyperkalemia,I-Entity
.,O
The,I-Entity
concentration,O
of,O
serum,O
potassium,I-Entity
was,O
high,O
",",O
and,O
normal,O
sinus,O
rhythm,O
was,O
restored,O
after,O
correction,O
of,O
the,O
serum,O
potassium,I-Entity
level,O
.,O
The,I-Entity
cause,O
of,O
hyperkalemia,I-Entity
was,O
considered,O
to,O
be,O
several,O
doses,O
of,O
spiranolactone,I-Entity
",",O
an,O
aldosterone,I-Entity
antagonist,O
",",O
in,O
addition,O
to,O
the,O
long,O
-,O
term,O
intake,O
of,O
ramipril,I-Entity
",",O
an,O
ACE,I-Entity
inhibitor,O
.,O
Clinicians,I-Entity
should,O
be,O
alert,O
to,O
the,O
possibility,O
of,O
hyperkalemia,I-Entity
",",O
especially,O
in,O
elderly,O
patients,O
using,O
ACE,I-Entity
/,O
ARB,I-Entity
in,O
combination,O
with,O
potassium,I-Entity
sparing,O
agents,O
and,O
who,O
have,O
mild,O
renal,O
disturbance,I-Entity
.,O
Diffuse,I-Entity
skeletal,O
pain,I-Entity
after,O
administration,O
of,O
alendronate,I-Entity
.,O
Osteoporosis,I-Entity
is,O
caused,O
by,O
bone,O
resorption,I-Entity
in,O
excess,O
of,O
bone,O
formation,O
",",O
and,O
bisphosphonates,I-Entity
",",O
are,O
used,O
to,O
inhibit,O
bone,O
resorption,I-Entity
.,O
Alendronate,I-Entity
",",O
a,O
biphosphonate,I-Entity
",",O
is,O
effective,O
for,O
both,O
the,O
treatment,O
and,O
prevention,O
of,O
osteoporosis,I-Entity
in,O
postmenopausal,O
women,O
.,O
Musculoskeletal,I-Entity
pain,I-Entity
may,O
be,O
an,O
important,O
side,O
effect,O
in,O
these,O
patients,O
.,O
We,I-Entity
presented,O
a,O
patient,O
admitted,O
to,O
our,O
out,O
-,O
patient,O
clinic,O
with,O
diffuse,O
skeletal,O
pain,I-Entity
after,O
three,O
consecutive,O
administration,O
of,O
alendronate,I-Entity
.,O
We,I-Entity
conclude,O
that,O
patients,O
with,O
osteoporosis,I-Entity
can,O
report,O
pain,I-Entity
",",O
and,O
bisphosphonate,I-Entity
-,O
related,O
pain,I-Entity
should,O
also,O
be,O
considered,O
before,O
ascribing,O
this,O
complaint,O
to,O
osteoporosis,I-Entity
.,O
Cerebrospinal,I-Entity
fluid,O
penetration,O
of,O
high,O
-,O
dose,O
daptomycin,I-Entity
in,O
suspected,O
Staphylococcus,I-Entity
aureus,I-Entity
meningitis,I-Entity
.,O
OBJECTIVE,I-Entity
:,O
To,I-Entity
report,O
a,O
case,O
of,O
methicillin,I-Entity
-,O
sensitive,I-Entity
Staphylococcus,I-Entity
aureus,I-Entity
(,O
MSSA,I-Entity
),O
bacteremia,I-Entity
with,O
suspected,O
MSSA,I-Entity
meningitis,I-Entity
treated,O
with,O
high,O
-,O
dose,O
daptomycin,I-Entity
assessed,O
with,O
concurrent,O
serum,O
and,O
cerebrospinal,O
fluid,O
(,O
CSF,I-Entity
),O
concentrations,O
.,O
A,I-Entity
54-year,O
-,O
old,O
male,O
presented,O
to,O
the,O
emergency,O
department,O
with,O
generalized,O
weakness,I-Entity
and,O
presumed,O
health,O
-,O
care,O
-,O
associated,O
pneumonia,I-Entity
shown,O
on,O
chest,O
radiograph,O
.,O
Treatment,I-Entity
was,O
empirically,O
initiated,O
with,O
vancomycin,I-Entity
",",O
levofloxacin,I-Entity
",",O
and,O
piperacillin,I-Entity
/,O
tazobactam,I-Entity
.,O
Blood,I-Entity
cultures,O
revealed,O
S.,I-Entity
aureus,I-Entity
susceptible,O
to,O
oxacillin,I-Entity
.,O
Empiric,I-Entity
antibiotic,O
treatment,O
was,O
narrowed,O
to,O
nafcillin,I-Entity
on,O
day,O
4,O
.,O
On,I-Entity
day,O
8,O
",",O
the,O
patient,O
developed,O
acute,O
renal,O
failure,I-Entity
(,O
serum,O
creatinine,I-Entity
1.9,O
mg,O
/,O
dL,I-Entity
",",O
increased,O
from,O
1.2,O
mg,O
/,O
dL,I-Entity
the,O
previous,O
day,O
and,O
0.8,O
mg,O
/,O
dL,I-Entity
on,O
admission,O
),O
.,O
The,I-Entity
patient,O
's,I-Entity
Glasgow,I-Entity
Coma,I-Entity
Score,I-Entity
was,O
3,O
",",O
with,O
normal,O
findings,O
shown,O
on,O
computed,O
tomography,O
scan,O
of,O
the,O
head,O
72,O
hours,O
following,O
an,O
episode,O
of,O
cardiac,O
arrest,I-Entity
on,O
day,O
10,O
.,O
The,I-Entity
patient,O
experienced,O
relapsing,O
MSSA,I-Entity
bacteremia,I-Entity
on,O
day,O
9,O
",",O
increasing,O
the,O
suspicion,O
for,O
a,O
central,O
nervous,I-Entity
system,O
(,O
CNS,I-Entity
),O
infection,I-Entity
.,O
Nafcillin,I-Entity
was,O
discontinued,O
and,O
daptomycin,I-Entity
9,O
mg,O
/,O
kg,O
daily,O
was,O
initiated,O
for,O
suspected,O
meningitis,I-Entity
and,O
was,O
continued,O
until,O
the,O
patient,O
's,I-Entity
death,I-Entity
on,O
day,O
16,O
.,O
Daptomycin,I-Entity
serum,O
and,O
CSF,I-Entity
trough,O
concentrations,O
were,O
11.21,O
ug,I-Entity
/,O
mL,I-Entity
and,O
0.52,O
Creatine,I-Entity
kinase,O
levels,O
were,O
normal,O
prior,O
to,O
daptomycin,I-Entity
therapy,O
and,O
were,O
not,O
reassessed,O
.,O
Daptomycin,I-Entity
was,O
initiated,O
in,O
our,O
patient,O
secondary,O
to,O
possible,O
nafcillin,I-Entity
-,O
induced,O
acute,O
interstitial,O
nephritis,I-Entity
and,O
relapsing,O
bacteremia,I-Entity
.,O
High,I-Entity
-,O
dose,O
daptomycin,I-Entity
may,O
be,O
an,O
alternative,O
option,O
for,O
MSSA,I-Entity
bacteremia,I-Entity
with,O
or,O
without,O
a,O
CNS,I-Entity
source,O
in,O
patients,O
who,O
have,O
failed,O
or,O
can,O
not,O
tolerate,O
standard,O
therapy,O
.,O
Further,I-Entity
clinical,O
evaluation,O
in,O
patients,O
with,O
confirmed,O
meningitis,I-Entity
is,O
warranted,O
.,O
The,I-Entity
role,O
of,O
nitric,I-Entity
oxide,I-Entity
in,O
convulsions,I-Entity
induced,O
by,O
lindane,I-Entity
in,O
rats,O
.,O
Lindane,I-Entity
is,O
an,O
organochloride,I-Entity
pesticide,O
and,O
scabicide,I-Entity
.,O
It,I-Entity
evokes,O
convulsions,I-Entity
mainly,O
trough,O
the,O
blockage,I-Entity
of,O
GABA(A,I-Entity
),O
receptors,O
.,O
Nitric,I-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
",",O
gaseous,O
neurotransmitter,O
",",O
has,O
contradictor,O
role,O
in,O
epileptogenesis,O
due,O
to,O
opposite,O
effects,O
of,O
L,I-Entity
-,O
arginine,I-Entity
",",O
precursor,O
of,O
NO,I-Entity
syntheses,O
(,O
NOS,I-Entity
),O
",",O
and,O
L,I-Entity
-,O
NAME,I-Entity
(,O
NOS,I-Entity
inhibitor,O
),O
observed,O
in,O
different,O
epilepsy,I-Entity
models,O
.,O
The,I-Entity
aim,O
of,O
the,O
current,O
study,O
was,O
to,O
determine,O
the,O
effects,O
of,O
NO,I-Entity
on,O
the,O
behavioral,O
and,O
EEG,I-Entity
characteristics,O
of,O
lindane,I-Entity
-,O
induced,O
epilepsy,I-Entity
in,O
male,O
Wistar,I-Entity
albino,O
rats,O
.,O
The,I-Entity
administration,O
of,O
L,I-Entity
-,O
arginine,I-Entity
(,O
600,O
",",O
800,O
and,O
1000,O
mg,O
/,O
in,O
dose,O
-,O
dependent,O
manner,O
significantly,O
increased,O
convulsion,I-Entity
incidence,O
and,O
severity,O
and,O
shortened,O
latency,O
time,O
to,O
first,O
convulsion,I-Entity
elicited,O
by,O
lower,O
lindane,I-Entity
dose,O
(,O
4,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
.,O
On,I-Entity
the,O
contrary,O
",",O
pretreatment,O
with,O
L,I-Entity
-,O
NAME,I-Entity
(,O
500,O
",",O
700,O
and,O
900,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
decreased,O
convulsion,I-Entity
incidence,O
and,O
severity,O
and,O
prolonged,O
latency,O
time,O
to,O
convulsion,I-Entity
following,O
injection,O
with,O
a,O
convulsive,I-Entity
dose,O
of,O
lindane,I-Entity
(,O
8,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
.,O
EEG,I-Entity
analyses,O
showed,O
increase,O
of,O
number,O
and,O
duration,O
of,O
ictal,O
periods,O
in,O
EEG,I-Entity
of,O
rats,O
receiving,O
l,O
-,O
arginine,I-Entity
prior,O
to,O
lindane,I-Entity
and,O
decrease,O
of,O
this,O
number,O
in,O
rats,O
pretreated,O
with,O
L,I-Entity
-,O
NAME,I-Entity
.,O
These,I-Entity
results,O
support,O
the,O
conclusion,O
that,O
NO,I-Entity
plays,O
a,O
role,O
of,O
endogenous,O
convulsant,I-Entity
in,O
rat,O
model,O
of,O
lindane,I-Entity
seizures,I-Entity
.,O
Long,I-Entity
-,O
term,O
oral,O
galactose,I-Entity
treatment,O
prevents,O
cognitive,O
deficits,I-Entity
in,O
male,O
Wistar,I-Entity
rats,O
treated,O
intracerebroventricularly,O
with,O
streptozotocin,I-Entity
.,O
Basic,I-Entity
and,O
clinical,O
research,O
has,O
demonstrated,O
that,O
dementia,I-Entity
of,O
sporadic,O
Alzheimer,I-Entity
's,I-Entity
disease,I-Entity
(,O
sAD,I-Entity
),O
type,O
is,O
associated,O
with,O
dysfunction,I-Entity
of,O
the,O
insulin,I-Entity
-,O
receptor,O
(,O
IR,I-Entity
),O
system,O
followed,O
by,O
decreased,O
glucose,O
transport,O
via,O
glucose,O
transporter,O
GLUT4,I-Entity
and,O
decreased,O
glucose,O
metabolism,O
in,O
brain,O
cells,O
.,O
An,I-Entity
alternative,O
source,O
of,O
energy,O
is,O
d,O
-,O
galactose,I-Entity
(,O
the,O
C-4-epimer,B-Entity
of,O
d,O
-,O
glucose,O
),O
which,O
is,O
transported,O
into,O
the,O
brain,O
by,O
insulin,I-Entity
-,O
independent,O
GLUT3,I-Entity
transporter,O
where,O
it,O
might,O
be,O
metabolized,O
to,O
glucose,O
via,O
the,O
Leloir,I-Entity
pathway,O
.,O
Exclusively,I-Entity
parenteral,O
daily,O
injections,O
of,O
galactose,I-Entity
induce,O
memory,O
deterioration,O
in,O
rodents,O
and,O
are,O
used,O
to,O
generate,O
animal,O
aging,I-Entity
model,O
",",O
but,O
the,O
effects,O
of,O
oral,O
galactose,I-Entity
treatment,O
on,O
cognitive,O
functions,O
have,O
never,O
been,O
tested,O
.,O
We,I-Entity
have,O
investigated,O
the,O
effects,O
of,O
continuous,O
daily,O
oral,O
galactose,I-Entity
(,O
200,O
mg,O
/,O
kg,O
/,O
day,O
),O
treatment,O
on,O
cognitive,O
deficits,I-Entity
in,O
streptozotocin,I-Entity
-,O
induced,O
(,O
STZ,I-Entity
-,O
icv,O
),O
rat,O
model,O
of,O
sAD,I-Entity
",",O
tested,O
by,O
Morris,I-Entity
Water,I-Entity
Maze,I-Entity
and,O
Passive,I-Entity
Avoidance,I-Entity
test,O
",",O
respectively,O
.,O
One,I-Entity
month,O
of,O
oral,O
galactose,I-Entity
treatment,O
initiated,O
immediately,O
after,O
the,O
STZ,I-Entity
-,O
icv,O
administration,O
",",O
successfully,O
prevented,O
development,O
of,O
the,O
STZ,I-Entity
-,O
icv,O
-,O
induced,O
cognitive,O
deficits,I-Entity
.,O
Beneficial,I-Entity
effect,O
of,O
oral,O
galactose,I-Entity
was,O
independent,O
of,O
the,O
rat,O
age,O
and,O
of,O
the,O
galactose,I-Entity
dose,O
ranging,O
from,O
100,O
to,O
300,O
mg,O
Additionally,I-Entity
",",O
oral,O
galactose,I-Entity
administration,O
led,O
to,O
the,O
appearance,O
of,O
galactose,I-Entity
in,O
the,O
blood,O
.,O
The,I-Entity
increase,O
of,O
galactose,I-Entity
concentration,O
in,O
the,O
cerebrospinal,O
fluid,O
was,O
several,O
times,O
lower,O
after,O
oral,O
than,O
after,O
parenteral,O
administration,O
of,O
the,O
same,O
galactose,I-Entity
dose,O
.,O
Oral,I-Entity
galactose,I-Entity
exposure,O
might,O
have,O
beneficial,O
effects,O
on,O
learning,O
and,O
memory,O
ability,O
and,O
could,O
be,O
worth,O
investigating,O
for,O
improvement,O
of,O
cognitive,O
deficits,I-Entity
associated,O
with,O
glucose,O
hypometabolism,I-Entity
in,O
AD,I-Entity
.,O
